,ticker,content
0,REGN,regeneron pharmaceutical regn sanofi sny impose first ever price increase dupixent potential blockbuster eczema treatment analyst say monday piper jaffray analyst christopher raymond see opportunity dupixent upside second quarter substantial prescription trend be almost quarter quarter regeneron sanofi raise list price june couple bullish management commentary recent visit well encourage dermatologist survey feedback think dupixent remain well position outperform expectation quarter say note client stock market today regeneron jump close sanofi dip fraction get newsletter deliver inbox more info product service privacy policy term useaccord prescription tracker total prescription eczema treatment be now quarter quarter first week period new prescription grow vs prior quarter raymond say model worldwide second quarter revenue eczema treatment help regeneron sanofi just increase list price dupixent raymond say be first price increase eczema treatment launch march regeneron never increase price eye drug eylea year regeneron sanofi add increase rheumatoid arthritis drug kevzara kevzara price increase make dupixent increase little less surprising nonetheless nice tail wind start third quarter say together volume price growth bode well raymond say upside now pricing front model flat net pricing be comfortable maintain worldwide dupixent revenue estimate ahead consensus say get instant access more trading idea exclusive stock list ibd proprietary rating only related much money do need start investing build long term profit stock take many gain long term retirement investing strategy etfs
1,REGN,share medicine company mdco pop early wednesday later sank unveil clean safety datum ldl cholesterol drug potential rival approve med amgen amgn regeneron pharmaceutical regn datum stem ongoing study medicine drug inclisiran partnership alnylam pharmaceutical alny committee recommend medicine alnylam continue ongoing study look lower bad ldl cholesterol medicine study be call orion medicine be study patient study patient randomly receive inclisiran placebo date more patient year safety datum have be accumulate biotech say news release accord company pivotal study be generate patient year safety datum day make clean safety profile increasingly striking chardan analyst gbola amusa say report client get newsletter deliver inbox more info product service privacy policy term useon stock market today medicine share slip close earlier jump much stock outperformed broader biotech company sank nearly medicine stock break cup handle last month confidence be grow drug inclisiran work rna interference amusa say case inclisiran work inhibit synthesis pcsk protein liver cell high ldl cholesterol have ty pcsk protein fellow biotech company amgen regeneron partner sanofi sny also have approve medicine work block pcsk protein further esperion therapeutic espr be work type ldl cholesterol drug call bempedoic acid market ldl cholesterol drug be huge amusa predict medicine inclisiran be blockbuster model peak sale amusa see medicine commercial plan administer inclisiran month be favorable compare rival drug other biotech company patient amgen repatha regeneron sanofi praluent receive injection week monthly evercore analyst umer raffat also expect dose schedule inclisiran challenge biotech company amgen regeneron commercial perspective month regimen ldl cholesterol drug be disruptive especially steep price discount medicine intend come say report client amgen share dip regeneron advanced wednesday regeneron rise likely stem pair upgrade week related much volume look stock trade stock most penny stock fail make investor richnew option strategy limit risk earning
2,REGN,today be true report many well know large cap biotech stock be show disappointing downright awful performance just witness damage lately share biogen biib celgene celg regeneron pharmaceutical regn xit also be true report company ibd biotech industry group have be fantastic winner select gene therapy firm have be rise fast breakout second half blood disease expert bioverativ biogen spinoff have nice rally go soar jan make sure see big price gap accompany chart bioverativ soar mammoth volume news be acquire french pharmaceutical titan sanofi sny investor have used good stock chart find bioverativ make giant single day gain yes bioverativ craft double bottom base help set big move don use stock chart re trading disadvantage chart very tough determine key market current psychology buyer seller balance supply vs demand give stock do bioverativ break jan stock market be confirm uptrend confirm uptrend be best time buy top perform growth stock have greater odd make money invest larger trend specialist therapy hemophilia rare blood disorder establish excellent prior uptrend run close feb market debut peak more month later stock correct week carved month saucer handle never break then bioverativ really begin sell oct midcap swoon hit low create first low base proper double bottom stock rebound back high then sell second time decline stock undercut first low want see authentic shakeout uncommitted shareholder find sign share move weak hand strong hand correct buy point stock rise dime middle peak lows bioverativ do exactly stock rebound less point base left side peak then nose dive again time sell take bioverativ way fine undercut first low double bottom form minimum week correction more say be not ideal deeper correction more stock have work just get back high look sign symmetry base look second low undercut first bioverativ possessed bullish trait week double bottom jan stock gap surpass buy point middle peak cent volume gush normal level session later bioverativ trade proper entry right acquisition news send share vaulting prior waltham mass firm notch quarterly earning share gain revenue have soar then rise next year expect double bottom proliferate lead stock major index fall furiously several wave great market leader build double bottom break bear market fall fall other occasion sometimes ll see handle form double bottom market way present additional buy point sanofi complete acquisition bioverativ march version column be publish march please follow saito chung twitter ibd_dchung more analysis commentary financial market growth company chart stock breakout related be golden rule investingwhat be current stock market direction please read column find great stock now always check latest story investor cornerstock buy make fortune stock market just small sum money yes here
3,REGN,regeneron pharmaceutical regn experimental cancer drug look legit treat form lung cancer analyst say thursday meaning soon rival dow jone merck mrk bristol myer squibb bmy be work cancer drug call pd checkpoint immuno oncology drug immune system identify fight tumor cell merck bristol already have drug approve call keytruda opdivo respectively regeneron appear be hot tail early stage study regeneron test drug cemiplimab previously treat patient call small cell lung cancer overall tumor shrank patient have disease control regeneron unveil datum late wednesday ahead american society clinical oncology annual meeting june piper jaffray analyst christopher raymond call datum biggest surprise meeting cemiplimab have long be also run immuno oncology space get newsletter deliver inbox more info product service privacy policy term use compare well overall response rate approve pd keytruda opdivo high teen say note grant be small number do think investor take interest today action stock market today regeneron climb close merck dip bristol add leerink analyst geoffrey porge note overall response rate cemiplimab specific group patient be line rate keytruda opdivo phase study cemiplimab also look safe patient result generate small cohort be encourage sign cemiplimab have potential compete toe toe establish product market say report client rbc analyst kennen mackay be less surprised regeneron success cemiplimab small cell lung cancer proof concept come expect say note biotech company test cemiplimab small group patient study support cemiplimab potential have line potentially better effectiveness leader keytruda opdivo mackay add regeneron be also testing cemiplimab phase phase study patient advanced form skin cancer call cutaneous squamous cell carcinoma overall response well duration response improve update datum vs time last year leerink porge say believe cemiplimab be well track receive expedite approval previously overlooked indication use carve least initial niche competitive pd pd cancer drug field say porge see likelihood regeneron gain approval cemiplimab advanced type skin cancer expect sale cemiplimab use peak sale keep price target regeneron stock food drug administration review cemiplimab cutaneous squamous cell carcinoma october review date help regeneron partner sanofi sny be first market rbc mackay say related much money do need start investing start here find best stock buy be inflation do matter fed
4,REGN,regeneron pharmaceutical regn dip year low thursday mixed first quarter report featured expect dupixent praluent miss also surprise blockbuster eylea top estimate stock market today regeneron slip close cancele earlier increase nearly share partner sanofi sny rise fraction meanwhile biotech stock collectively topple eylea treatment several eye disease rake sale revenue grow year year beat consensus accord several analyst beat be surprise roche rhhby also top expectation compete drug lucentis first quarter result keep eylea track post meaningful year year growth vs sale rbc analyst kennen mackay write note client keep sector perform rating regeneron get newsletter deliver inbox more info product service privacy policy term rest quarter be more mixed total revenue lag estimate include consensus analyst poll zack investment research top less bullish estimate piper jaffray analyst christopher raymond say adjust profit share grow year year beat view expect product develop sanofi eczema drug dupixent cholesterol drug praluent arthritis drug kevzara miss dupixent bring praluent generate kevzara account so big surprise raymond say note client reiterate overweight rating regeneron overall collaboration revenue sanofi lag consensus raymond james analyst laura chico say note client bayer bayry collaboration revenue top regeneron also lower high end guidance sanofi collaboration revenue now expect earlier estimate related build long term profit stock take many gain sell take profit hold here be several guideline basic analyze stock cup handle
5,REGN,column exactly week ibd point important be watch major index close not simply open valentine day major index close lovely gain register follow day new rally attempt wednesday final hour selling hooked major index
6,REGN,abbvie abbv celgene celg regeneron pharmaceutical regn spike second half accelerate number drug approval launch analyst say wednesday reverse trend first half year see share biotech stock slip industry group track investor business daily group be rank fifth just week meanwhile pharmaceutical company be rank leerink analyst classify first half disappointing large cap biopharma company biotech stock pharmaceutical company face dearth clinical study result validate pipeline re price stock say second half year promise be more exciting small mid cap biopharma stock significant clinical event horizon include readout binary phase trial write note client get newsletter deliver inbox more info product service privacy policy term other biotech stock pharmaceutical company abbvie be expect report datum study drug upadacitinib researcher be look drug treatment form arthritis further food drug administration likely decide approve abbvie drug call elagolix treatment endometriosis condition female reproductive system fda also decide fate drug dub venclexta form leukemia stock market tracker also expect celgene unveil datum late stage study revlimid celgene partner acceleron pharma xlrn blood disease revlimid be celgene major cancer drug celgene also reveal more juno therapeutic acquisition be move class cancer therapy know car short chimeric antigen receptor cell therapy compete novartis nvs gilead science gild datum car development update define path forward product revlimid leerink analyst geoffrey porge say note porge also expect fda make decision regeneron sanofi sny dupixent asthma treatment physician already use dupixent treat eczema duo also have cemiplimab fda be consider advanced form skin cancer addition intra cellular therapy itci be work drug dub lumateperone schizophrenia treatment analyst focus fda accept application approval base mixed phase datum porge say intra cellular also report topline datum ongoing phase study bipolar depression second half look second indication lumateperone say porge expect zogenix zgnx have datum late stage study drug zx researcher be consider drug treatment type epilepsy call dravet syndrome gw pharmaceutical gwph drug epidiolex likely gain approval use june additionally dova pharmaceutical dova fibrogen fgen have catalyst chronic liver chronic kidney disease respectively dova expect fda soon decide approve drug fibrogen expect unveil topline datum study drug second half year fda be also take flexible stance orphan drug development leerink analyst joseph schwartz say note approval sarepta therapeutic srpt duchenne muscular dystrophy drug exondys trigger cascade noteworthy filing say continue believe fda continue evolution warrant positive sentiment rare disease focuse company particularly name amicus therapeutic fold sarepta uniqure qure long investigational drug be deem safe demonstrate strong effectiveness say related much money do need start investing look best stock buy watch start herestill rule stock investor always cut loss short
7,REGN,regeneron pharmaceutical regn topple year low friday partner sanofi sny miss first quarter expectation drug include blockbuster hopeful dupixent stock market today regeneron fall close fall much touch low last see july sanofi tumble biotech stock collectively advanced fraction sanofi report sale dupixent eczema treatment globally consensus have modeled sale roughly also lag expectation rbc analyst kennen mackay say note piper jaffray analyst christopher raymond note sanofi be call impact sale inventory level patient assistance program still have overweight rating price target regeneron get free access ibd digital april
8,REGN,get premium stock list pass fail stock rating more start here adjust headwind sale have come ahead consensus appear positive underlie demand trend remain intact say report client still look first quarter win be very pretty regeneron mackay be more bearish surprise dupixent sale miss come strong prescription trend expect quarter quarter prescription growth dupixent sanofi earning release suggest reimbursement headwind be grow dupixent say anticipate new dupixent specific reimbursement hurdle impose payer also have contribute miss concerningly complicate utility prescription analysis forecast dupixent sale trajectory move forward say note other regeneron partner drug struggle quarter piper jaffray raymond say praluent cholesterol lower drug rival amgen amgn repatha miss rheumatoid arthritis drug kevzara also lag same amount regeneron be slate report thursday rbc mackay also call sale eye disease drug eylea miss thursday roche rhhby report strong revenue compete drug lucentis lucentis bring sale top view anticipate higher expect lucentis sale reflect physician preference switch lucentis prefil syringe eylea due recent report ocular inflammation limit batch eylea kit say issue be ultimately determine be unrelated drug likely physician be hang back eylea re sure inflammatory concern be past mackay say keep sector perform rating regeneron related chart read basic buy point mark time real opportunitylong term retirement investing strategy etfsnew option strategy limit risk earning
9,REGN,amgen amgn report hum quarter tuesday analyst say biotech beat first quarter expectation guidance come slightly soft midpoint sale enbrel amgen biggest product decline fifth straight quarter amgen cite lower demand lower net selling price year earlier favorable change accounting estimate dip amgen raise low end full year revenue outlook boost adjust profit expectation metric be slightly street midpoint be now relatively line mizuho analyst salim sy say note client look hum quarter say hour trading stock market today amgen share be flat stock end regular session match broad biotech group also wrapped close bell first quarter amgen report adjust profit share rise beat consensus share sale edge just north street view bright spot quarter include cholesterol drug repatha senispar treat condition result enlargement gland cause high level calcium blood repatha sale grow year year stem sale repatha compete regeneron pharmaceutical regn sanofi sny drug praluent analyst have modeled total sale sy say senispar sale come top consensus total sale grow rbc analyst brian abraham note senispar be likely see generic rivalry long term overhand not materialize post amgen biggest drug decline first quarter pillar legacy product still drive topline beat abraham say note client enbrel arthritis psoriasis drug decline sale still be just consensus mizuho sy say sale neulasta bone marrow stimulant decrease consensus have modeled sy say neulasta sale have decline straight period neulasta beat be unexpected positive don anticipate reinvigorate investor enthusiasm give product remain risk potential biosimilar entry rbc abraham say year amgen predict adjust profit share sale midpoint outlook be slightly consensus view adjust income share sale related chart read basic buy point mark time real invest stock free new apps aim buy stock ahead earning report
10,REGN,corner have conventional wisdom many expert burton malkiel professor emeritus princeton university author random walk wall street other corner have ibd founder william neil plenty other investment pro real track record long term investing success side disagree fundamental way not time market malkiel book state point follow technical trading rule timing purchase sale simple policy buy hold be least good technical procedure meanwhile neil investing book include successful investor make money stock weekly newspaper ibd weekly have be argue opposite year message fact time market so investor do story serve introduction refresher ibd approach market timing learn strategy become better arm make own mind matter timing first thing need know ibd method be follow day concept follow confirm broad stock market have switch rally mode spending considerable time retreat also know correct get follow major stock index nasdaq nyse composite close significantly prior session greater volume meant significantly day ibd generally look gain more market be choppier daily price swing be heavier normal ibd demand follow gain be much bigger other case volatility be low genuine follow occur minimum gain most powerful follow day happen not always often day day attempt rally window frequently get clear signal new uptrend end be really strong move many lead stock provide big profit holder other hand also get follow day outside window day day happened december index follow dec be day new rally attempt even late follow be real strength ensue uptrend plenty lead stock show big gain first quarter such apple aapl priceline group pcln alexion pharmaceutical alxn regeneron pharmaceutical regn jan less month nasdaq day follow apple begin swift new run new high shiny profit alert ibd reader iphone macbook ipad seller rise buy point week cup handle stock do not see heavy volume day moved sideway few week then burst new high nearly triple average volume jan follow quarterly result september year apple rally more high embark new deep correction company split share june keep mind follow doesn have much do week headline mid december be plenty dismal news weaker expect retail sale expert see solution eurozone debt crisis even follow not change overall choppy nature major index year prove case steep slide less week late january mid february nasdaq score day follow valentine day feb ride stock then have not exactly be wine rose bonbon today apple have trade choppy fashion too part base process final point not follow work be head fake major market bottom go back have version column be publish dec edition ibd neil recently receive market technician association lifetime achievement award please follow saito chung twitter ibd_dchung more commentary analysis stock financial market related smart buy least something follow dayhere be william neil tip success work find excellent large cap stock big cap
11,REGN,biotech stock pharmaceutical company add recent market gain monday trump top health aide deliver speech largely spare brunt drug pricing reform health human service secretary alex azar deliver speech drug pricing reform monday trump speech be light impact biotech company pharmaceutical company instead white house be consider change medicare cap pocket spending most proposal impact so call middleman include pharmacy benefit manager pbms drug distributor include like express script esrx cvs cvs abc azar be critical pharmaceutical company high list price lack transparency direct consumer advertising look forward work industry build better system say industry isn willing work lower price president trump administration keep turn pressure system finally put american patient first get newsletter deliver inbox more info product service privacy policy term useshare pharmaceutical company have rally ultimately slip marginally close biotech company stock gain stock market today follow speech nasdaq biotechnology nbi be flat ishare nasdaq biotechnology ibb index rise proposal rbc analyst see change medicare part part have biggest impact biotech stock still write note client even still be relatively benign overall part cover physician administer drug part cover prescription drug proposal negotiation part drug be more similar part negotiation more broadly president be call part merge part azar say inflation capped price increase part be likely most impactful proposal biotech well pocket transparency part vs part drug infusion vs self injectable unify part bill code rbc analyst say regeneron pharmaceutical regn have largest exposure large cap biotechs part eye disease drug call eylea celgene celg biogen biib amgen amgn also be expose further sage therapeutic sage aldr dynavax dvax face difficulty azar also suggest change pbms issue negotiate rebate propose end so call gag clause pharmacist prevent pharmacist tell consumer actually save money pay pocket medicine right now re ask pretty straightforward question instead current system drug company get paid rebate middleman take cut just have fix price discount azar say fix situation even pharmacy benefit manager be hire help keep price low make money higher list price also suggest pharmaceutical company include list price advertising go directly consumer further azar say center medicare medicaid service be develop incentive lower list price most change be long term further action raymond james analyst michael baker say note change part contract prevent pharmacist explain pocket cost be cheaper likely not have meaningful impact related biotech stock fly trump speech see more bark bite much money do need start investing long term retirement investing strategy buy stock ahead earning report
12,REGN,trader torch stock today bonfire selling respect pass novelist tom wolfe treasury bond market small posse leadership quality company buck broad wall street decline include new ipo altair engineering altr splunk splk cree cree ligand pharmaceutical lgnd china lodging htht stock today homebuilder finished worst performer industry group track ibd yield benchmark treasury year bond hit mark new year high horton dhi tank more drop sharply long term day move average stock be now peak lgi home lgih stage vicious reversal last week post robust result ep sale take day line share fall lgi home turnover jump day move average strong hint fund manager sell anxiously rise mortgage rate be further squeeze affordability be homebuyer be already frustrated limit inventory available home higher home price have result bankrate com chief financial analyst greg mcbride say tuesday nasdaq composite dow jone industrial average slide point average fall more sank volume increase main exchange accord early datum higher volume vs monday action imply unusually intense professional selling note ibd big picture column such significant drop heavier volume be call distribution bevy strong distribution day signal end major market uptrend broad decline large cap russell inched less point higher small cap also rise less point be jan be ibd current outlook market remain confirm uptrend meanwhile leaderboard member apple aapl stage gap price volume be well day average give apple solid last week normal see even top stock pull back proper buy point downward gap appear daily chart intraday high be intraday low prior trading session apple case tuesday intraday high be cent monday session low not much gap apple break compact double bottom base pattern supply buy point so far have produce gain more iphone ipad digital service giant be now past buy point first stage cup handle most important chart pattern top growth stock produce breaking new high big price run apple clear base midst fundamental turnaround jan altair member ibd specialty enterprise software industry group barrele more higher narrowly eclipse buy point week cup handle decline base be bullishly mild troy mich base expert innovation boost engineering software go public share nov last year notice daily chart altair have make habit breaking ibd style basis go quickly just few day then reverse sharply correct entry longer point view small cap have do marvelous job stay north side day move average altair monday post leap profit cent share revenue rise quarterly best meanwhile ligand thrust higher fifth straight session rise more biotech play be extend past entry well form double bottom base midpoint find sell off base be upper half base price range good sign accord ibd stock checkup ligand sport shiny composite rating scale rating find only ibd weekly investor com gauge stock corporate fundamental stock price strength quality institutional sponsorship be not purely technical indicator ligand relative price strength rating be stout also scale mean san diego base company be beating publicly trade company ibd database month price performance term market value ligand barely lift finger like celgene celg regeneron pharmaceutical regn amgen amgn biotech world however ligand be body slam peer term earning growth ligand have grow profit vs year level past quarters analyst poll thomson reuter see earning rise cent share keep mind top jump year quarter revenue break barrier quarterly basis past quarters year year top line have boom higher past quarters read recent new america feature piece ligand be grow so rapidly china lodging major player fast grow travel market middle kingdom sprint quadruple normal trade stock surpass buy point unusual month double bottom rs line roar new high ground proper buy zone go past entry china lodging post jump first quarter earning cent share revenue rise tax margin climb impressive basis point stock rank ibd keep mind china lodging recent base base structure be least fourth stage increase risk failure stock initially break week cup base week end march however company stellar fundamental defy odd latest update story other market coverage check ibd story stock today also please follow saito chung twitter ibd_dchung additional commentary analysis top stock chart basis financial market related stock be new ibd premium growth stock screen check master chart read check feature ibd top companiesipo leader market latest investor cornera stock form cup handle still succeed
13,REGN,dow jone industrial average index rebound key support level end slightly lower nasdaq composite fuel apple aapl rally tesla tsla skid cash burn elon musk strange conference call mastercard hit buy zone new payment stock struggle alibaba baba pull back strong earning sprint merge mobile tmus headline several big deal job report symmetric fed stance ease rate hike fear crude oil price hit record high shale operator beat earning view dow jone undercut day move average rebound friday finish week nasdaq composite rally retake day line apple aapl fuel earning buyback warren buffett buy more share soar drive major average higher tesla tsla fall alibaba baba rally mastercard enter buy zone treasury yield pull back yield spread narrowing slightly crude oil rise nearly barrel shale earning be strong apparel stock be loser consumer electronic giant apple aapl earn share year year sale fiscal second quarter be best ep gain year latest string accelerate revenue growth report top forecast apple sell iphone just miss consensus service revenue wearable sale be strong apple also announce plan buyback big dividend hike warren buffett disclose berkshire hathaway brkb buy apple share first month bring total stake nearly apple stock surge best weekly gain year hit record high blast buy zone get newsletter deliver inbox more info product service privacy policy term usetesla report smaller expect loss forecast revenue electric car maker model production remain low company burn cash post earning conference call ceo elon musk cut wall street analyst bore question spend next minute take question blogger youtube share fall sharply thursday close week cent alibaba report better expect quarterly earning core commerce revenue swell cloud revenue more double alibaba end quarter monthly active user mobile device alibaba also give bullish outlook share rise friday jobless rate slide april lowest economy add job labor department report friday meanwhile average hourly wage growth rise just year little view fed favore gauge core inflation climb policymaker send message win panic top come month fed stress wednesday inflation target be symmetric qualys qlys fireeye feye fortinet ftnt top earning revenue view share retreat cyberark software cybr rally strong result outlook guide slightly higher meanwhile carbon black cblk jump friday debut ipo price late thursday high end recently raise range zendesk zen pop result guidance show customer support sale automation software company be build momentum rival salesforce com crm larger contract paycom payc report strong earning sale growth forecast line june quarter result send hr payroll process software maker lower fellow payroll hr cloud software firm paylocity pcty break friday result commerce software firm shopify shop top view size sale beat update guidance left investor unimpressed shopify initially fall rebound strong gain ultimate software ulti report adjust ep top estimate revenue grow also beating share rally wednesday close buy point mcdonald mcd surge score double beat ep rise revenue fall shake shack shak sky-rocket friday crushed earning beat revenue wingstop wing also jump friday result taco bell parent yum brand yum earning top share skid weak same store sale yum china yumc tumble weak pizza hut result china offset overall strong earning texas roadhouse txrh slip come par ep cent revenue viper energy partner vnom anadarko petroleum apc concho resource cxo noble energy nbl matador resource mtdr continental resource clr parsley energy pe eog resource eog pioneer natural resource pxd top quarterly estimate integrate energy firm marathon oil mro clear buy point follow earning oil price hit fresh multiyear high inventory production increase odd be rise president trump withdraw iran nuclear pact sprint mobile tmus finally agree merger share fall lack price premium fear antitrust regulator reject deal meanwhile marathon petroleum mpc agree buy andeavor andv create largest base refiner additionally walmart wmt say chain asda merge sainsbury walmart reportedly be deal buy india commerce giant flipkart prologis pld buy dct industrial dct finally marriott vacation vac reveal buy ilg ilg annual developer conference facebook fb say be enter online date business more person facebook identify single match group mtch own match com date app tinder plunge announcement facebook also introduce oculus go stand alone vr headset announce october arista network anet late thursday report ep gain revenue swell beating cisco rival see revenue line view send share tumble friday turnaround project juniper network jnpr late tuesday report ep decline wasn bad expect sale network gear cloud compute customer rebound juniper forecast profit slightly view share pop pare gain allergan agn zoetis zts teva teva exelixis exel top quarterly expectation allergan sank report unlikely make deal zoetis fall adjust profit guidance miss penny dow jone component merck mrk pfizer pfe beat profit lag sale gilead gild miss sale adjust earning hepatitis drug fall vs last year regeneron regn profit beat revenue miss eye drug eylea top view celgene celg topple analyst suggestion key drug be delay year friday celgene say refile application drug ozanimod multiple sclerosis treatment celgene also top first quarter expectation raise full year guidance sarepta srpt sale miss view loss be better expect mastercard share jump credit card giant report earning beat estimate join visa buy range square sq sale also top bitcoin make payment technology firm current quarter profit outlook come short fleetcor flt provide prepay fuel card vehicle fleet other payment product sank low outlook paypal pypl tumble amazon amzn reportedly offer merchant discount use own payment service controversy kanye west comment slavery have tangled adida addyy ceo sportswear company distance not cut ty rapper west yeezy brand be not significant part adida revenue contribute brand style image share tumble buy point adida logging currency neutral revenue growth include solid north america meanwhile armour uaa top estimate give weak outlook susquehanna say inventory be tick time bomb coach kate spade parent tapestry tpr top consensus share plunge upscale purse accessory maker raise guidance be still largely consensus north face van parent vf corp vfc beat view share retreat friday snapchat operator snap snap crash record low miss first quarter view revenue user growth several other key metric grubhub grub top first quarter earning estimate food sale miss target share fall sharply pare loss friday world wrestling entertainment wwe spiked wwe body slam earning estimate continue attract subscriber ep rise cent however revenue be miss disk drive maker seagate technology stx report quarterly earning beat estimate stock fall cautious comment tariff ferrari race zoom buy zone double beat ep rise cent revenue climb tableau datum report sale earning expectation license revenue be ahead consensus company lower full year margin guidance big datum firm stock jump
14,REGN,sanofi sny regeneron pharmaceutical regn dupixent be strong start revenue eczema drug lag europe analyst say wednesday sanofi fourth quarter report dupixent generate euro accord current exchange rate fourth quarter be close leerink analyst seamus fernandez expectation euro worldwide sale soundly beat piper jaffray analyst christopher raymond estimate europe dupixent sale be euro lag model rbc analyst kennen mackay consensus have call dupixent revenue europe say view result indicative continue solid uptake dupixent quarter year growth continue impress say note client contrast anticipate european ramp take additional time sanofi fall close stock market today regeneron sanofi partner dupixent other drug dip regeneron be set report fourth quarter earning early thursday ibd take ibd rule always selling stock break have exception include ask market be early late stage new bull run more tip visit investor corner fourth quarter sanofi report total revenue euro fall constant currency basis vs year earlier period leerink fernandez have call euro earning share decline constant exchange rate euro miss fernandez view euro fernandez cite higher operational spend sanofi earning miss operational expense be expectation sanofi expect earning share grow constant exchange rate include contribution recently announce acquisition biogen biib spinoff bioverativ bivv ablynx ablx related glaxosmithkline slip guidance generic advair loomsthese biotechs spring back market correction analystbristol continue day plunge debate merck rivale combo
15,REGN,regeneron pharmaceutical regn benefit novartis nvs roche rhhby present datum drug hope rival blockbuster eye treatment eylea analyst say monday leerink analyst geoffrey porge question reliability datum present novartis drug call brolucizumab roche rg rival eylea treat eye disease confuse somewhat lackluster datum present weekend eylea theoretical competitor lift overhang regeneron stock have suffer last month say note client novartis brolucizumab be be test treatment eye condition cause blindness call wet age related macular degeneration porge refer study design confuse confound patient be checked disease progression specific time have dose schedule change porge say addition be multiple disease assessment guideline determine dose level potentially complicate drug label other clear implication guideline criterium be patient be require actively lose vision week dose schedule be switch more frequent dose meeting participant specialist consider unethical give long term effect loss acuity write ibd take tough hang stock correction decline mount be time let go be possible still capture big gain stock head investor corner deep dive roche rg be be develop treat same disorder drug show benefit roche lucentis treat several eye condition study patient earlier study total patient be benefit vision correction study suggest mechanism used rg add benefit term retinal thickness porge argue uncertain increase retinal thickness have clinical benefit even rg succeed show superiority lucentis confirm signal trial larger study then look attendee meeting suggest just eylea say rbc analyst kennen mackay call datum rg compelling do not check box yet porge see result add competitive headwind regeneron eylea term long term market position however roche face battle rivale regeneron eylea effectiveness deepen time still unknown rg perform longer time frame mackay say note client stock market today regeneron jump close novartis lift roche advanced market have be correction recently biotech pharma stock slide last week related biotech investor flee drove market correction rock groupregeneron dip sympathy biotechs quarterly beatgeneralist biotech sideline tax reform sweep
16,REGN,regeneron pharmaceutical regn dive thursday sympathy biotech stock broadly top fourth quarter metric sale expectation key drug dupixent eylea praluent be not whole lot suspense most product revenue number regeneron pre release most metric january partner sanofi sny issue fourth quarter report wednesday piper jaffray analyst christopher raymond say note client fourth quarter regeneron bring sale grow beating consensus adjust profit share advanced top estimate share sale eye drug eylea increase globally eylea bring outside eylea grow consensus have modeled rest world raymond say regeneron be longer offer full year guidance eylea sale however shape expectation drug future be also great interest leerink analyst geoffrey porge say note client close bell stock market today regeneron drop share earlier dip much broader biotech group plunge ibd take day move average take stock daily close price past day average so do line say stock health head investor corner more eylea be regeneron biggest moneymaker currently phase testing treatment proliferative diabetic retinopathy early stage eye disease affect diabetic regeneron seek additional approval use result be positive regeneron also have regulatory filing eczema drug dupixent asthma be testing drug treatment nasal polyp soon begin study dupixent treatment allergic condition esophagus well peanut grass allergy porge say quarter dupixent bring sale be analyst view porge say sale cholesterol lower drug praluent rise north consensus praluent be peg readout march study call odyssey trial test drug ability improve cardiovascular outcome patient elevated bad ldl cholesterol acute coronary event last year datum have impact praluent market share porge say praluent belong class drug call pcsk inhibitor most closely rival amgen amgn repatha only black cloud regeneron fourth quarter report be kevzara rheumatoid arthritis treatment bring sale lag consensus view piper jaffray raymond say kevzara be also slate begin phase study treatment blood vessel disease disease muscle joint cause pain stiffness leerink porge say regeneron say expect revenue product partner sanofi unreimburse research development cost see tax rate related sanofi regeneron dip eczema drug dupixent lag crispr small biotechs cure disease biotechs spring back market correction analyst
17,REGN,major average dust minor early loss head final hour trading tuesday modest gain mild reversal open decline be bullish stock investor now current outlook note market pulse ibd big picture remain market correction least member dow jone industrial average gain point more hoisting blue chip index nearly nasdaq composite be do slightly better rise more mixed action faang stock rally cut year date loss less large cap benchmark rise meanwhile bitcoin investment trust gbtc close end fund track alternative digital currency take breather rise straight session fall more fund show nice support last week test day move average be still recover climax run december round trip gain follow nov past buy point very deep cup handle bitcoin investment trust gain more peak end run vertical climb just session stock fund go climax run need lot time digest magnificent gain form new base set potential new so right move right now bitcoin trader be make move simply watch ibd analyze market action look relative performance industry group subgroup today least group rally more sharply beating major index include education medium software solar power department store trucking cement metal ore computer networking gear wood product internet content education medium software group thinly trade name stand instructure provide cloud base task management platform school teacher gap whale volume briefly clear buy point flat base last week twou march ipo gain more light trading have sloppy earning record lose money provider online learn software university be expect post jump fourth quarter earning cent share revenue have grow vs year level past quarters large megacap play dow jone industrial component caterpillar cat point gain nearly point get high average turnover construction mining gear titan be close second attempt climb back key day move average now stock appear be early stage form new base stock have gain much strong past buy point flat base april cat wonderful turnaround story have reel quarters row brisk growth ep vs year level street expect earning rise additional share first quarter downside regeneron pharmaceutical regn get hammer again fall be largest point loser nasdaq former big market winner expert eye disease be featured ibd short selling column short side jan regeneron trigger follow short sale entry point issue top signal aug share cut day move average high volume then fail rebound sharply midterm support resistance line related find next great ipo stock be new home depot emc oracle google also stock market today time sell stock hold stock buy way be market head now read ibd column daywhy biotech leader become good short sale candidate
18,REGN,biotech investor collectively pull sector week analyst say friday byproduct broader market correction not malaise health care tie stock week end feb health care biotech fund see net outflow represent decrease asset piper jaffray analyst christopher raymond write note client same time equity post dip asset reason biotech stock tend experience worst market correction say brad loncar portfolio manager run cancer immunotherapy base fund biotech stock hit multiyear high late january have lose nearly believe be totally normal think biotech be just do so terrible week volatile sector entire stock market have bad week biotechs be likely do little bit tell investor business daily most pundit say market correction be overdue general market experience very mild gradual rise few interruption now head risk scenario investor seek lower risk position evercore analyst umer raffat tell ibd email close stock market today biotech group eke small gain pare earlier loss fall much week group be nearly hardest hit week be therapeutic cort lop come rivalry teva pharmaceutical teva treatment cush syndrome affect pituitary gland prothena prta dove chief medical officer announce departure amgen amgn celgene celg biogen biib lose north regeneron pharmaceutical regn top fourth quarter view plunge nearly gilead science gild topple more guidance miss large cap fourth quarter metric guidance be largely line expectation credit suisse analyst alethia young tell ibd describe fourth quarter decent show fire strained third quarter ibd take dow jone industrial average topple lower thursday nasdaq composite tumble respectively be bear take bite bull market head big picture more hopefully trend continue say be biotech risky space thing happen young loncar agree market correction isn indicative outlook biotech group say fundamental look strong group be poise buy spree begin late last year gilead acquisition kite pharma january celgene say buy juno therapeutic juno sanofi sny announce acquisition biogen spinoff bioverativ bivv belgium ablynx ablx sanofi beat nordisk nvo ablynx smart company go asset valuation go loncar say many bigger player be face payer scrutiny saturate area rheumatology diabetes gilead decline hepatitis drug sale lead kite purchase celgene be face competition inflammation drug larger company have slow growth so need buy growth need buy innovation say tax reform deal just pass kind add fuel fire make much more easy do deal related gilead pop fda approve glaxo rivale hiv drugthese biotechs spring back market correction analystalexion top quarterly view guidance lag alnylam dip loss
19,REGN,esperion therapeutic espr lose third value wednesday ldl cholesterol lower drug underperform bullish expectation late stage study needham analyst chad messer call result strong esperion drug call bempedoic acid lower bad ldl cholesterol additional patient add maximally tolerate statin therapy be lower bound have see previous datum be much larger study say note datum often revert mean large study so actually view strong result context investor disagree vehemently stock market today esperion crash close get newsletter deliver inbox more info product service privacy policy term useesperion test bempedoic acid patient week drug lower ldl cholesterol level additional add maximally tolerate statin base therapy patient also experience reduction high sensitivity reactive protein hscrp protein be important marker underlie inflammation associate cardiovascular disease messer note study enrolled high risk patient only other option be injectable drug call pcsk inhibitor amgen amgn make call repatha regeneron pharmaceutical regn partner sanofi sny make dub praluent drug cost ten thousand dollar year say payer patient alike have so far be reluctant adopt therapy significant way bempedoic acid be once daily pill anticipate be sell few dollar month notably regeneron sanofi say tuesday have strike deal express script esrx cut net price drug praluent exchange simplify patient insurance process praluent repatha also work lower bad ldl cholesterol messer keep strong buy rating price target esperion esperion also report first quarter result loss share narrow share loss year earlier period miss consensus project share loss related chart read basic buy point mark time real invest stock free new apps aim beginnerslook next nvidia start simple routine
20,REGN,regeneron pharmaceutical regn tumble year low tuesday prod rival amgen amgn also dip announce deal express script esrx cut net price cholesterol drug praluent express script list praluent exclusive psck inhibitor national formulary july exchange pay lower price drug pcsk inhibitor praluent amgen repatha work reduce bad ldl cholesterol blood also benefit cardiovascular outcome move be effort expand access cholesterol drug praluent regeneron partner sanofi sny say report suggest prescription request be reject insurer be part due price praluent repatha go north year regeneron chief executive leonard schleifer praise deal written statement see agreement set new standard model medicine praluent get newsletter deliver inbox more info product service privacy policy term use paradigm shift agreement be design break gridlock so praluent be finally able reach patient most need say cardiologist have experience unprecedented challenge secure access praluent patient be clearly appropriate be deny coverage investor weren keen deal afternoon trading stock market today regeneron slip amgen drop sanofi lose fraction agreement significantly reduce documentation necessary secure express script insurance coverage cholesterol drug regeneron sanofi say press release physician submit simplified attestation form confirm patient be appropriate praluent express script also agree pass portion saving patient enrolled other plan patient see lower pocket cost praluent prescription company say analyst be largely positive deal note specific price cut aren public likely praluent be price line recent report suggest be cost effective higher risk patient annually rbc analyst brian william say note price volume announcement leave lot financial benefit air william say pcsk market be particularly attractive give massive size type deal further incentivize insurer implement complicate utilization process say further deal price cholesterol drug closer annual target represent cut net price william say do not view pricing race bottom give potential annual compound lifetime treatment create distinct difference vs price volume contract curative time treatment hepatitis space add now battle other insurer william say amgen be negotiation payer likely leverage expertise winning contract agreement seek deal unite health unh cvs health cvs anthem antm aetna aet cigna ci humana hum say amgen estimate express script formulary decision impact repatha patient piper jaffray analyst christopher raymond say report client keep model praluent intact first quarter earning conference call thursday just do back envelope math repatha patient switch praluent july be tailwind praluent second half formulary decision alone say related do spot major market top easy look heavy distributionnew option strategy limit risk earningsstill rule stock investor always cut loss short
21,REGN,medical technology leader abiom abmd be rule breaker ibd stock spotlight list be work fifth week shallow consolidation complete fifth week do not drop more pattern high consolidation become flat base buy point
22,REGN,anaptysbio anab drag rival aimmune therapeutic aimt red tuesday report peanut allergy drug improve symptom nearly half adult patient study trial test drug call anb patient moderate severe peanut allergy tolerate cumulative milligram dose peanut protein day single dose anb vs none placebo patient analyst be confused result note anaptysbio exclude patient milder symptom amplify apparent activity treatment leerink analyst geoffrey porge say note stock market today anaptysbio drop close share aimmune topple rival dbv technology dbvt rise regeneron pharmaceutical regn competitor slip get newsletter deliver inbox more info product service privacy policy term useaimmune dbv also be work treatment peanut allergy aimmune be develop drug call ar year more half child treat ar tolerate time increase exposure peanut protein compare trial be challenge rbc analyst kennen mackay say report study anaptysbio appear have enrolled less severe group patient seem have drive anaptysbio exclude milder patient therefore see more question answer mixed dataset await more color area uncertainty management say however continue anaptysbio upcoming anb datum asthma anticipate third quarter leerink analyst dae gon see limit impact dbv be work peanut allergy drug call viaskin peanut keep outperform rating dbv anb ultimately become effective agent see limit read dbv market opportunity outset monday day phase result say report client result also speak potential regeneron allergy franchise leerink porge say regeneron make eczema drug call dupixent firm be also look dupixent asthma peanut allergy regeneron also have drug call regn be same drug class anb drug be know antibody inhibit interleukin il cytokine investigator believe il have connection eczema food allergy asthma anaptysbio study allergic symptom typically overlap peanut allergy occur patient receive placebo just patient receive single dose anb reduction be encourage leerink porge say regeneron isn testing regn peanut allergy rather asthma regeneron be team aimmune test dupixent ar peanut allergy analysis anb impact alleviation concomitant allergy symptom suggest use regeneron deserve credit potential il disease such atopic dermatitis asthma chronic obstructive pulmonary disease say related chart read basic buy point mark time real build long term profit stock take many gain long term retirement investing strategy etfs
23,REGN,astrazeneca azn bristol myer squibb bmy vertex pharmaceutical vrtx be likeliest target biopharma detonation event tax reform spur widespread merger acquisition group analyst say friday leerink analyst seamus fernandez call come consolidation inevitable product make like abbvie abbv roche rhhby amgen amgn dow jone stock merck mrk celgene celg biogen biib shire shpg be soon face new competition generic rival follow unprecedented period innovation new product launch large biopharma say note client several largest company likely experience substantial growth slowdown next year get newsletter deliver inbox more info product service privacy policy term usecelgene biogen astrazeneca be most accretive potential acquirer base short term financial fernandez say average accretion be respectively bristol astrazeneca vertex make most sense long term strategically say appear be best position longer term revenue growth base look consensus expectation last major consolidation period biopharma occur last decade be deal greater value largest be dow jone stock pfizer pfe acquisition warner lambert premium pfizer also paid biggest premium pharmacia fork acquire firm merck paid premium buy schering plough deal combine pfizer astrazeneca allergan agn abbvie shire have fail fernandez see next cycle seller market pfizer be struggle late entry immuno oncology market merck have strong immuno oncology drug keytruda lack robust late stage pipeline roche face biosimilar competition top drug avastin herceptin rituxan novartis nvs be still experience challenge sandoz unit abbvie be strong term key drug humira soon see competition europe strategically astrazeneca be strong fit abbvie pfizer roche merck fernandez say bristol fit abbvie pfizer meanwhile possible abbvie swing vertex financial lens astrazeneca vertex biogen bristol be most compelling target ability enhance long term sale say amgen be acquirer target fund buy something fernandez say assume amgen be look make deal value less vertex rise top list potential target outlasting regeneron pharmaceutical regn shire vertex look more interesting say related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
24,REGN,biotech industry group currently rank lofty industry group month relative price performance high standing also mask weakness former big star regeneron pharmaceutical regn be case point large cap specialist eye care be also highly interesting case
25,REGN,food drug administration novel medicine more double prior year number even overall drug approval slide double digit percentage new molecular entity approve be glaucoma drug rhopressa aerie pharmaceutical aeri cancer drug calquence imfinzi astrazeneca azn eczema drug dupixent team regeneron pharmaceutical regn sanofi sny new molecular entity be classification drug review fda many include active piece molecule have not previously be approve number approval be cancer drug big price tag treat small population patient approval novel medicine be return level be approve just novel drug get fda overall drug approval slide classification type last year fda approve application new biologic new drug generic new treatment indication already approve drug be approval approval approval original application biologic new drug rise respectively prior year be generic drug approve last year rise related european pharmas grab upgrade ahead newswhy biotechs outperform hyper competition beware price war big pharma biotech company horizon
26,REGN,index dow industrial nasdaq composite suffer worst day weekly loss year lead stock suffer major damage stock market moved correction nvidia nvda snap snap twitter twtr rally strong earning grubhub grub shot big deal kfc taco bell parent yum brand yum tesla sell line result world publicity stunt major average many lead stock tumble intensify loss prior week big loss stock market moved uptrend pressure correction chip energy china name be big loser stock market retreat be broad deep stock do stage nice rebound test day move average take more good day snap downtgrend facebook rival snap snap twitter twtr have stellar result nvidia deliver blowout earning bullish guidance year treasury yield hit year high unnerve stock market backed graphic chip maker nvidia nvda earning swell share sale quarter end jan analyst expect current nvidia expect revenue wall street be look share soar friday meanwhile broadcom avgo raise bid buy wireless chip maker qualcomm qcom share say be best final offer qualcomm reject deal value broadcom be seek replace qualcomm board ibd take stock market be now correction read cover story stock sell do now tesla beat fourth quarter revenue earning estimate maintain production target model sedan tesla still see weekly model production rate end first quarter end second quarter again warn difficulty accurately forecasting specific production rate specific point time cash burn decline analyst say special factor suggest improvement win continue spacex falcon heavy rocket most powerful rocket use factor successfully lift maiden flight booster return safely rocket show satellite insertion technique air force position future military launch small potentially lucrative market then send ceo elon musk tesla roadster elliptical orbit sun twitter share report first ever gaap profit adjust earning easily beating view first quarter guidance estimate share shot week meanwhile snap catapult wednesday snapchat operator deliver strong fourth quarter revenue user growth smaller expect loss grubhub grub sky-rocket announce partnership fast food behemoth yum brand yum parent taco bell kfc pizza hut report better expect fourth quarter earning already top provider online order food delivery service grubhub now be exclusive online delivery partner yum brand taco bell kfc yum brand be buy grubhub stock video game publisher activision blizzard atvi modestly beat wall street consensus estimate holiday sale quarter thank hit game call duty wwii industry peer take interactive software plunge holiday earning top sale revenue guidance disappoint fireeye feye swung adjust profit cent share revenue rise top fireeye forecast march quarter revenue estimate fortinet ftnt top earning sale view give weak operate margin guidance march quarter fortinet cfo be leave citrix system ctxs proofpoint pfpt top earning view march quarter profit guidance be light proofpoint announce third recent acquisition wombat security paycom software payc report fourth quarter result beat consensus estimate revenue earning paycom leader cloud base human resource management tool also present first quarter revenue guidance line consensus estimate general motor gm post record profit top fourth quarter estimate help part boom crossover sale ep jump revenue fall reflect key divestiture fellow auto giant toyota motor tm see operate profit grow fiscal third quarter lift full year profit forecast gilead science gild top fourth quarter expectation adjust profit share sale sale guidance be light bristol myer squibb bmy glaxosmithkline gsk allergan agn alexion pharmaceutical alxn regeneron pharmaceutical regn teva pharmaceutical teva top expectation bristol share fall confusion regard immuno oncology trial opdivo lung cancer alexion teva topple weak guidance sanofi sny miss ep sale view bitcoin tumble early tuesday top financial regulator senate banking commerce hearing be not negative fear investing digital currency bitcoin rebound be still less half december time high meanwhile goldman sachs global investment chief predict most not current cryptocurrency end lose value cboe global market cboe crash day move average tuesday trading be halter several inverted volatility product raise concern trading volume profit option exchange friday cboe miss earning revenue estimate fidelity say bar client buy inverted volatility instrument cboe fall week walt disney surpass expectation ep jump sale grow theme park resort segment lead revenue gain offset weakness studio consumer product medium network subscription stream service espn debut spring month mlb mls nhl game sport tennis boxing golf rugby cricket share fall week line major avearage handbag brand michael kor kor post surprise profit growth share sale gain comp slide less anticipate upscale parka maker canada goose goos beat yet again share plunge ostensibly due high expectation coach kate spade parent tapestry tpr turn solid beat kor fall week canada goose nearly tapestry gain wynn resort wynn ceo steve wynn resign wall street journal report detailed allegation sexual misconduct spur stock sell regulatory probe wynn share rise wednesday edge lower week well fargo wfc share tumble federal reserve feb bar bank expand balance sheet demand board shake wake well sham account scandal chipotle grill cmg share nose dive fast casual chain signale continue weaker sale traffic trend more spending year improve restaurant boee ba reportedly present compromise plan brazil government let take stake joint venture commercial jet business embraer erj meanwhile wwd deny report talk boee takeover chip gear maker ichor holding ichr top estimate fourth quarter earning share penny miss view penny outlook current quarter send share sharply lower laser system maker coherent cohr fall hard post slightly better expect december quarter result disappoint profit margin outlook share crash extreme network extr report fiscal revenue miss adjust profit edge view march quarter guidance include asset acquire brocade be slightly estimate share fall netgear ntgr report earning beat expectation miss revenue company plan spin fast grow arlo security camera business hold ipo share fall zendesk zen narrow quarterly loss year earlier revenue also top view send share higher zendesk forecast revenue consensus estimate share gain match group mtch report revenue top estimate soar growth tinder date app adjust profit miss rise investment match add tinder subscriber december quarter give overall yelp yelp report fourth quarter earning top consensus view provider crowdsource online reviews advertising growth amazon amzn rolled same day hour delivery whole food grocery order include produce meat dairy seafood certain alcohol product austin cincinnatus dalla virginia beach challenge grocer staking territory supermarket turf war amazon aim expand service other city year amazon also reportedly be plan launch own mail delivery service hit share fedex fdx unite parcel service up
27,REGN,regeneron pharmaceutical regn win unseat amgen amgn top pcsk cholesterol market analyst say wednesday suggest regeneron praluent be similar amgen repatha heart study drug amgen repatha regeneron praluent aim lower bad ldl cholesterol target protein liver know proprotein convertase subtilisin kexin pcsk now regeneron be testing also reduce risk cardiovascular trouble study regeneron be present weekend rbc analyst kennen mackay expect praluent show similar effect repatha amgen fourier trial unveil last year repatha cut risk major cardiovascular event didn have impact death anticipate largely similar result relative risk reduction major cardiovascular event little benefit hospitalization cardiovascular related mortality say note expect drug remain largely efficacy perspective mackay see likelihood praluent have similar effect repatha cardiovascular outcome amgen already have strong lead regeneron bring repatha sale last year vs praluent use ibd marketsmith free march
28,REGN,see stock buy point get chart pattern recognition run custom screen start nowthere just probability praluent underperform repatha mackay say case see regeneron share market drop give amgen balance amgen stock gain regeneron lose third less likely scenario mackay model chance praluent top repatha reduce risk major cardiovascular event least improve risk cardiovascular related death scenario anticipate regeneron capture pcsk market amgen share decrease say scenario result share regeneron price target share amgen price target be several difference trial suggest amgen be more likely succeed mackay say regeneron enrolled fewer patient run longer trial have suggest more time praluent show greater benefit cardiovascular outcome praluent need show least reduction risk cardiovascular outcome benefit mortality unambiguously claim praluent be superior repatha mackay say additionally give striking similarity ldl reduction see agent year therapy view incremental relative risk reduction improvement praluent treatment read repatha likely similar long term treatment benefit say stock market today regeneron sank close amgen fall related chart read basic buy point mark time real much money do need start investing look best stock buy watch start here
29,REGN,alnylam pharmaceutical alny dip early thursday announce collaboration regeneron pharmaceutical regn late wednesday research treatment form nonalcoholic fatty liver disease piper jaffray analyst edward tenthoff be bullish partnership marry regeneron discovery specific genetic variant associate chronic liver disease alnylam work type therapy call rna interference see deal positive alnylam expertise rna interference delivery hepatocyte liver cell complement therapeutic translation regeneron discovery say note client alnylam regeneron be join wide field biotechs drugmaker work treatment nonalcoholic steatohepatitis include gilead science gild allergan agn intercept pharmaceutical icpt novartis nvs get newsletter deliver inbox more info product service privacy policy term useon stock market today alnylam fall breaking consolidation earlier month buy point regeneron fall biotech stock be small fraction deal alnylam regeneron be base regeneron discovery variation hsd gene be tie reduce risk protection various chronic liver disease firm say press release regeneron finding stem large scale human genetic effort undertake regeneron genetic center new potential therapeutic target be used trim risk halt progression chronic liver disease alnylam regeneron plan look potential treatment disease know nonalcoholic steatohepatitis liver suffer damage similar cause alcohol patient be often obese have type diabetes plan use alnylam expertise rna interference target hsd gene rna interference allow researcher specifically target silence gene involved cause pathway human disease piper jaffray tenthoff say collaboration expand co development co deal keep price target overweight rating alnylam related invest stock free new apps aim basic analyze stock cup buy stock ahead earning report
30,REGN,here weekly investing action plan need know investor come week apple aapl be set unveil new bell whistle developer well possibly tease work customer broadcom avgo report earning upheaval chip sector international trade top cybersecurity stock palo
31,REGN,esperion therapeutic espr stock plunge wednesday cholesterol bust drug succeed phase trial show liver function side effect small portion patient stock market today esperion share dove much pare loss finishing regeneron pharmaceutical regn amgen amgn make different type cholesterol drug add lose respectively patient study have liver function issue result drug study esperion bempedoic acid patient have elevated liver function issue still needham analyst chad messer keep esperion top pick point be well labele incidence liver function test elevation approve statin messer write note client believe concern datum be unfounded be buyer esperion weakness today use ibd marketsmith free march
32,REGN,see stock buy point get chart pattern recognition run custom screen start nowbempedoic acid be test vs placebo patient risk heart disease high cholesterol inadequately treat other therapy week study meet key goal lower bad ldl cholesterol vs placebo esperion say news release ldl cholesterol be cut bempedoic acid patient vs increase patient receive placebo patient treat bempedoic acid also achieve cut high sensitivity reaction protein marker inflammation tie heart disease vs increase placebo patient month esperion be also set unveil datum phase trial testing bempedoic acid top therapy psck inhibitor regeneron praluent amgen repatha esperion be expect bempedoic acid be less expensive drug esperion have datum year long safety study study bempedoic acid patient ve fail prior statin august biotech unveil datum combination bempedoic acid ezetimibe market dow jone component merck mrk zetia later year esperion be expect have datum trial bempedoic acid patient heart disease already statin take maximum dose be tolerate messer expect esperion file approval first quarter europe second quarter related trade stock most penny stock fail make investor richlong term retirement investing strategy etfslook next nvidia start simple routine
33,REGN,study result release weekend regeneron pharmaceutical regn sanofi sny validate long term benefit lower bad ldl cholesterol drug giant didn exactly reap reward trading open monday instead relatively obscure biotech esperion therapeutic espr pop initially fall once investor digest impact trial dub odyssey outcome trial show regeneron sanofi drug praluent cut risk cardiovascular event heart attack stroke stronger benefit patient highest risk finding come year amgen amgn tank similar trial result regeneron sanofi announce plan increase patient access praluent offer additional rebate payer agree reduce burdensome access barrier high risk patient bring price drug well amgen drug repatha credit suisse analyst martin call result boon esperion be work drug know bempedoic acid lower ldl cholesterol differ praluent repatha class call psck inhibitor see positive result further validation importance ldl cholesterol lower especially higher risk patient reinforce bempedoic acid approval path bed ldl lower phase program say note client stock market today esperion surge close earlier session share be much investor struggle realize benefit most study amgen fall regeneron gain sanofi be fourier odyssey result amgen regeneron sanofi respectively also benefit medicine company mdco esperion analyst say medicine be work drug call inclisiran used mechanism call rna interference trim cholesterol difference chemical composition rna interference inclisiran vs antibody repatha praluent view positive result large outcome datum derisk inclisiran leerink analyst joseph schwartz say note client sign free ibd newsletter market prep tech reportmedicine have huge advantage prep own cardiovascular outcome trial take lesson prior trial have already recruit key leader amgen regeneron sanofi study share medicine climb medicine company be truly standing shoulder giant materialize result better odyssey schwartz say credit suisse note odyssey result support approval bempedoic acid increase confidence esperion cardiovascular outcome trial expect be release bempedoic acid be expect cost roughly third less recent analysis suggest pcsk inhibitor repatha praluent be cost effective year esperion drug be expect cost annually patient study praluent reduce risk major cardiovascular complication include heart attack stroke more surprising praluent be also associate lower risk death patient benefit be strongest patient high ldl cholesterol take high dose cholesterol lower statin patient praluent cut risk cardiovascular event death respectively regeneron sanofi be now target group patient offer lower net price payer reduce access barrier high risk patient bring cost praluent line recent analysis find cost effective year today praluent amgen repatha cost north year drug have have somewhat lackluster launch rbc analyst kennen mackay call commercial move long overdue note amgen likely have counter strategy repatha have pcsk inhibitor market leerink analyst geoffrey porge say note client repatha didn show same benefit high risk patient do have impact mortality trial dub fourier unveil last year immediate future expect significant share recovery praluent base odyssey result porge say deployment new contract take month result further inflection pace new patient start class amgen likely match regeneron sanofi term pcsk drug help acceleration class say related much volume look stock invest stock free new apps aim trade stock most penny stock fail make investor rich
34,REGN,generalist be still hang biotech sideline analyst say wednesday specialist investor be willing look idea work come tax reform biotech stock end sentiment have weaken approach year high earlier year ibd company biotech industry group be now rank group track first week think investor have yet digest potential positive impact tax reform biotech space credit suisse analyst alethia young say note client repatriation be focus timing play consolidation lead caution president donald trump end year pass sweeping tax reform include cut corporate tax rate legislation also put place new rule allow company bring cash store overseas back cheaper tax rate many company coverage have low foreign earning certainly benefit taxe bottom line young say ibd take biotech chief executive be less experience today be year analyst say recent report cite reason win be big year merger acquisition space head ibd industry theme breakdown count regeneron pharmaceutical regn gilead science gild biogen biib bioverativ bivv unite therapeutic uthr outside tax reform investor be also focuse small midsize biotechs potential takeover target young say note investor seem remain cautious play small mid cap merger acquisition theme related biotechs outperform hyper competition do regeneron pharma have potential blockbuster biotech dife analyst slash expectation cancer drug
35,REGN,regeneron pharmaceutical regn be deck launch several drug blockbuster potential next few year include skin cancer treatment analyst predict thursday argus analyst jasper hellweg keep buy rating regeneron stock cut price target regeneron climb close stock market today regeneron pipeline several product seem particularly promising hellweg say skin cancer drug cemiplimab be know pd antibody compete other class include dow stock merck mrk keytruda bristol myer squibb bmy opdivo regeneron official say tuesday have trial range phase phase study cemiplimab cancer third quarter food drug administration grant drug breakthrough therapy status treat patient form skin cancer know cutaneous squamous cell carcinoma ibd take chief executive large cap biotechs have less experience today do past accord analysis analyst head ibd industry theme more impact potential merger acquisition dec regeneron announce phase study cemiplimab show positive result patient cutaneous squamous cell carcinoma firm plan file application next year approval treat condition europe regeneron also announce earlier month collaboration isa pharmaceutical study immunotherapy drug know isa cemiplimab treatment cancer cause human papillomavirus type also know hpv induced cancer company share clinical trial cost exchange product supply regeneron gain exclusive worldwide licensing right isa exchange upfront payment equity investment future milestone payment hellweg say isa be far regeneron only partner regeneron antibody discovery agreement sanofi sny be set expire end year company have array other deal regeneron also partner bayer bayry antibody discovery agreement sanofi company develop praluent dupixent kevzara well unapproved drug include cemiplimab praluent be used lower cholesterol dupixent treat eczema be be investigate treat asthma kevzara treat rheumatoid arthritis drug be important help regeneron diversify eylea hellweg say eylea be approve treat pair eye disease be market bayer outside third quarter eylea bring regeneron sale face competition novartis nvs believe company financial result benefit potential new indication eylea praluent well increase sale praluent dupixent kevzara say regeneron have marketing commercial ability roll drug quickly see recent product launch related amgen regeneron prep battle cholesterol drugswhy biotech stock feel lovebeware price war big pharma biotech company horizon
36,REGN,european pharmaceutical firm astrazeneca azn nordisk nvo pull upgrade friday analyst look ahead key clinical trial readout ovarian cancer diabetes respectively astrazeneca rise stock market today nordisk dip fraction jpmorgan analyst james gordon upgrade astrazeneca overweight rating jpm richard vosser boost nordisk neutral rating astrazeneca medium term growth outlook be twice european pharma sector gordon write note client expect return topline growth new launch be key see core earning hit floor rise gordon be bearish year clinical trial testing combination immuno oncology drug advanced lung cancer july astrazeneca say regimen didn shrink tumor have pin hope trial dub mystic immuno oncology general now mystic trial be continue goal improve overall survival os bear key point be expectation mystic pfs progression free survival failure overly high base business divestment expectation say mystic pfs have fail low expectation os readout now see only modest downside astrazeneca be also set have datum trial drug lynparza first treatment form ovarian cancer rival clovis oncology clvs tesaro tsro gordon see high likelihood astrazeneca be successful trial be call solo ibd take large cap biotechs drugmaker suffer mount competition newer therapy generic rivalry theme be likely continue analyst say head ibd industry theme closer look trend mean bigger player gordon forecast astrazeneca achieve compound annual growth rate core earning share more twice sector market likely focus key product launch beat consensus view aggregate say expect sale lung cancer drug tagrisso top expectation forecast sale be achievable just half patient specific mutation receive therapy first treatment base much higher penetration comparable therapy competitor horizon think even own forecast prove conservative say outside assume price cut europe japan patient receive drug first treatment china expect eligible patient receive tagrisso assume similar price cut gordon expect sale immuno oncology drug imfinzi be line see lynparza treat ovarian cancer post small beat see downside long term drug astrazeneca be also launch calquence treatment mantle cell lymphoma only patient see term downside astrazeneca be also look drug chronic lymphocytic leukemia affect larger group patient fasenra be also recently approve monthly treatment form asthma drug rival glaxosmithkline gsk nucala be administer monthly likely regeneron pharmaceutical regn sanofi sny dupixent get approval treat asthma nordisk be story oral semaglutide vosser say oral semaglutide be be investigate phase trial dub pioneer treatment type diabetes oral semaglutide belong class drug know glp receptor agonist currently glp drug be only available injection nordisk look be first market oral glp oramed pharmaceutical ormp be also work oral glp drug far nordisk give see oral semaglutide datum live expectation don see pioneer program be source disappointment investor see market leave more difficult commercial question product clinical profile be nail clinical trial result vosser say note client nordisk be testing oral semaglutide vs own victoza dow stock merck mrk januvia eli lilly lly jardiance series trial related clovis good news ovarian cancer prod rival downtesaro take swipe astrazeneca ovarian cancer drug saleswhy tesaro cancer drug miss prompt rival topple
37,REGN,here weekly investing action plan need know investor come week earning season grind result due tesla tsla nvidia nvda grubhub grub disney match group mtch more social medium company restaurant cybersecurity firm chip sector company report well meanwhile
38,REGN,imagine editing gene cure debilitating disease small biotech company combine annual sale less crispr therapeutic crsp intellium therapeutic ntla edita medicine edit say soon be reality biotech stock go public bet big simple premise alter specific gene create curative medicine estimate disease be cure change target gene say former intellium chief executive nessan bermingham world health organization have higher estimate be know monogenic disease say actually north person have be talk personalize medicine year yet ve never have system allow do bermingham tell investor business daily step role dec first time ever actually have system do system be base personalize genome system be know crispr crispr intellium edita be putt chip cheaper faster gene editing method accord bermingham key advance personalize medicine analyst think crispr technology provide platform next generation giant biotech company crispr technology not be confused crispr therapeutic company build project sequence human genome first map cost be complete then cost map individual genome have drop precipitously come just hundred dollar next few year bermingham say large datum analytic also have part play sifting genome ibd take biotech company account large share recent ipo stock yet investing have profit sale be risky learn identify best ipos trade potential big gain first human genome be map investigator be absolutely horrify find just gene human body code protein bermingham say be estimate essentially protein coding gene serve word genetic language investigator also find region dna be initially thought have purpose be controversially call junk dna do not code protein turn sequence do have key purpose regulate expression gene together better understand human genome have allow biotech company utilize crispr acronym technology know cluster regularly interspaced short palindromic repeat be caveat however january paper publish biorxiv say be evidence human immune system fight major form genome editing used enzyme call cas thus render science ineffective paper however have yet be peer review process develop various university essentially used specialize strand dna act molecular scissors scissors be capable editing other dna specific point allow biotech company edit add remove faulty gene responsible disease be vary type scissors crispr intellium edita be used cas crispr technology ark invest analyst manisha samy tell ibd estimate cas reach human genome develop new scissors expand reach more gene disease say gene editing isn new add older technique call talen zinc finger nuclease have be time notably biotech company bluebird bio blue be used variation talen sangamo therapeutic sgmo be used method zinc finger nuclease liken crispr technology word processor think crispr gene editing be analogous dna word processor function find delete say january report addition scientist be work rudimentary paste function allow crispr insert appropriate dna code repair mutation older technology used biotech company be more old fashion typewriter require actual cut paste say crispr technology be also cheaper easier use talen zinc finger say jmp security analyst mike king so powerful crispr be so easy use tell ibd high school student be do experiment biology lab knock gene zinc finger take lot talent time have fiddle lot system create crispr be quite robust january biorxiv online archive distribution service unpublished report life science field publish paper cast doubt durability crispr gene therapy time suggest body build immunity analyst biotech company be not worry however say be nonissue time science catch many company work crispr be do so used cas enzyme short crispr associate protein cas be derive bacterium cause infection human high rate meaning immune system have develop immunity crispr gene editing used enzyme work patient depend crispr therapeutic say follow email ibd important note lead investigator writer biorxiv paper be matthew porteus scientific founder advisory board member crispr therapeutic gene editing be do ex vivo outside body cas enzyme be degraded therefore essentially go time cell be reintroduce patient crispr tell ibd vivo application gene editing be do body crispr therapeutic say used several approach ensure transient expression cas enzyme do not expect pre exist immunity cas cause issue firm say ark samy also note other enzyme be use edita be also used cpf enzyme enzyme be derive other bacterium overcome immunity challenge involve cas intellium tell ibd follow email clinical testing delivery system treatment rodent human primate have yet falter further intellium note used advanced form cas none donor have pre exist immunity study datum be still early edita have do own work immune response crispr genome editing present paper future jmp king say jan note client management have indicated find immune response be much lower report other paper immune response be not uncommon samy say scientist have work decade evade immune recognition be numerous workaround be implement reduce potential side effect cas have prove number other therapeutic modality biotech company crispr therapeutic be ahead competition regulatory standpoint dec firm submit first application clinical trial testing gene therapy know ctx blood disorder know beta thalassemia company be work vertex pharmaceutical vrtx beta thalassemia well sickle cell disease therapy be part crispr ex vivo program gene editing be do cell outside body be reintroduce patient crispr be also look vivo therapy liver muscle lung accord crispr news release trial be set begin europe adult patient be expect be first human trial gene editing treatment base crispr technology crispr also plan file application begin testing ctx treat sickle cell disease intellium also have vivo ex vivo program gene editing also be work sickle cell disease furthest partnership regeneron pharmaceutical regn therapy treat know transthyretin amyloidosis condition characterize buildup abnormal protein deposit body alnylam pharmaceutical alny ionis pharmaceutical ion also be work separately treat disease used different method call rna interference antisense technology respectively meanwhile edita be work inject treatment inherited eye disease know leber congenital amaurosis be characterize severe loss vision birth be also used gene editing sickle cell disease beta thalassemia intellium edita also be expect start human trial analyst say intellium have not say begin testing regulator be get more comfortable idea gene editing crispr therapeutic president sam kulkarni tell ibd benefit gene editing potential trouble be meant be permanent fix biotech company be work ensure hit bull eye time ve show make edit do precise fashion used target industry call molecular zip code say eliminate edit happen outside place want happen manufacture high quality fashion understand pharmacology kulkarni intellium bermingham be succeed john leonard former abbvie abbv executive say room big player group sizing market be challenge ark samy say matter slice number be big lot depend disease company target set pricing crispr be able address monogenic disease diagnosed year market globally say address disease person already live diagnosis be market product be not go cure everything say re see volatility main crispr company doesn really make sense room more come crispr kulkarni say unlikely market remain just publicly trade biotech company crispr technology long run technology be just remarkable once lifetime be little bit stretch maybe not say definitely once generation type advance field last time kind excitement happened biotech field be antibody be apply therapeutic modality basis technology company genentech now own roche rhhby be create add here have basis crispr platform create next big biotech giant related top biotech company innovation earn recognition new awardswhy bluebird downgrade send rival best stock buy watch nowmeet best broker overall investor need
39,REGN,abbvie abbv follow footstep gilead science gild celgene celg analyst suggest monday abbvie guide unexpectedly low tax rate expect narrative stock come month develop buy story similar gilead celgene more recently leerink analyst geoffrey porge write note client acquisition narrative follow abbvie fourth quarter earning friday biopharma giant top quarterly expectation beat guidance prediction also guide tax rate tax rate term also follow announcement last week celgene acquire juno therapeutic juno sanofi sny acquire biogen biib spinoff bioverativ bivv today sanofi also say buy ablynx ablx abbvie do seek acquisition likely be neuroscience early stage immuno oncology solid tumor medicine porge say abbvie seek deal build complement early stage alzheimer disease pipeline ahead key readout so far abbvie be play card close vest firm doesn seem incline make large disruptive transaction porge say credit suisse analyst vamil divan note firm be constantly look asset believe already have strong pipeline further do not have burn platform need acquire asset say isn compelling need company be deal many other thing probably be not best time do merger acquisition ibd take celgene abbvie have already report fourth quarter earning slew biopharmas be still slate issue report head ibd industry theme closer look analyst expect biotech drug group put abbvie slightly different boat gilead celgene gilead acquire kite pharma slow hepatitis drug sale last week celgene say buy juno year begin lose exclusivity cancer drug revlimid divan comment follow conversation abbvie management post fourth quarter earning analyst suggest lower expect tax rate mean abbvie have extra cash hand engage merger acquisition abbvie say look earlier stage single asset build pipeline find anything timeframe even neuroscience readout not necessarily feel need divan say note client divan boost price target abbvie keep neutral rating porge also up price target downgrade abbvie market perform rating outperform current valuation prefer celgene abbvie larger cap name coverage say growth name such vertex pharmaceutical vrtx alexion pharmaceutical alxn regeneron pharmaceutical regn continue offer more upside view abbvie close bell stock market today abbvie dip fraction related celgene reverse fourth quarter otezla sale sanofi ablynx deal spur biopharma buy spree biotech merger spigot turn juno bioverativ
40,REGN,alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx be likely beat fourth quarter earning estimate analyst predict biotech guidance be cautious windfall tax reform fourth quarter earning report season kick next week dow johnson johnson jnj novartis nvs weigh tuesday wednesday pharma side celgene celg biogen biib be deck early thursday abbvie abbv trail friday leerink analyst geoffrey porge expect cautious prediction begin note example celgene pre announcement earlier month uncertainty payer dynamic competition drug access be likely play forecast factor imminent return more challenge political environment suggest management team be more typically cautious guidance first provide financial community earning call say note client fourth quarter porge call vertex cystic fibrosis drug orkambi kalydeco gilead hepatitis hiv drug regeneron pharmaceutical regn eylea dupixent latter eye disease eczema treatment respectively surprise upside ibd take biotechs suffer third quarter high profile drug miss expectation smaller player take headline beating view head industry snapshot more happened prior quarter history be expect repeat see older drug amgen amgn include psoriasis arthritis med enbrel risk disappointing investor biogen multiple sclerosis drug avonex plegridy abbvie cancer med imbruvica also disappoint say needham analyst alan carr see investor focuse merger fourth quarter call week rumor emerge celgene be consider takeover juno therapeutic juno biogen be consider putt bid acorda therapeutic acor continue believe pharma have bias risk asset be market case still regulatory review write note client first half expect food drug administration approve vertex cystic fibrosis regimen kalydeco tezacaftor well hiv combination gilead abbvie neurocrine bioscience nbix also get drug treat severe menstrual pain alnylam pharmaceutical alny be also likely grab approval patisiran drug treat condition abnormal protein deposit body cause systemic problem achaogen akao tetraphase pharmaceutical ttph be also near approval antibiotic related celgene rumore acquisition juno actually make sensedow merck do face release cancer trial hospital plan put pressure generic drug maker
41,REGN,invest disruptor advice wall street giant biotech company incumbent big pharma be brace get crushed more innovative cheaper new drug start continue analyst say generic drug approval be rise interesting new medicine be start take market share legacy maker medication consumer use frequently include big pharma biotech company blockbuster drug represent estimate annual sale be set lose patent protection next decade analyst say disruption come generic drug innovative new biologic alternative come market be brutal jmp security analyst mike king tell investor business daily be knife fight market cholesterol lower drug king expect amgen amgn regeneron pharmaceutical regn sanofi sny feel heat like esperion therapeutic espr medicine co mdco alnylam pharmaceutical alny meanwhile inflammatory treatment celgene celg otezla gain blockbuster status miss sale forecast wide cut third quarter analyst say newly approve drug treat same condition eli lilly lly novartis nvs be take market share gilead science gild be still feel pain mature hepatitis drug unit europe rapid pace gilead hepatitis sale decline be expect slow somewhat newer medicine abbvie abbv mavyret be likely swipe sale big pharma isn get help regulator food drug administration head scott gottlieb continue increase approval copycat drug stoke competition brand generic drug face new rival firm try undercut price big pharma company pfizer pfe be forefront feel sting generic take sale earlier month teva pharmaceutical teva be allow launch generic copy blockbuster erectile dysfunction drug viagra generic drug tend be cheaper brand counterpart viagra be pricey drug tablet accord accessrx pfizer lose exclusivity viagra canada europe worldwide sale fall today generic europe have slash price drug contain same active ingredient viagra generic version viagra cost third price canada viagra price also fall trend repeat generic market teva meanwhile be struggle debt end third quarter thursday teva announce plan cut workforce more quarter close several manufacturing facility suspend dividend ordinary share firm be also plan review generic drug portfolio most specifically change price discontinue product ibd take see giant biotechs fared vs smaller player third quarter visit industry snapshot hint quarter be classify alarm large cap biotech be trouble see more competition traditional moneymaker board spending prescription drug increase just person accord report express script esrx rise represent drop growth rate trend be likely continue fbb capital partner analyst mike bailey tell ibd credit gottlieb decline generic price gottlieb be run fda business allow cycle more approval more competition lower price center medicare medicaid service use tool influence pricing unlikely president trump use executive power enact sweeping drug pricing reform such allow medicare negotiate price enact pricing control bailey say wouldn expect major change trump administration pricing say think mechanically politically difficult get pricing law system politically more acceptable just get more generic drug approval jmp king count drug treat rheumatoid arthritis psoriatic arthritis crowd area drug class cost average prescription benefit increase utilization unit cost accord express script third quarter thing begin look dour like celgene miss expectation inflammation drug otezla lag be even sharper analyst suggest celgene be force take price concession celgene also cut guidance terminate trial drug treat crohn disease condition result chronic inflammation digestive tract now see inflammation immunology drug bring combine outlook issue biotech company big pharma need get realistic pricing competitive arena king say same be say company make treatment hepatitis multiple sclerosis high cholesterol be highly saturate market latter point expect price drug know pcsk inhibitor repatha amgen praluent regeneron sanofi be microscope drug lower bad ldl cholesterol blood evidence show also have benefit cardiovascular outcome repatha be list year praluent cost rival be close medicine co alnylam be work cholesterol drug know inclisiran meanwhile analyst expect bempedoic acid esperion be cheaper big pharma biotech company be probably go get arm twisted lot king say pricing umbrella have create opportunity new company come scale market share be careful own incumbent invest disruptor other area be seemingly immune pricing pressure analyst say price multiple sclerosis drug rise average continue trend fbb bailey say price increase have be so egregious house democrat launch investigation august note many drug carry price tag north year investigation be launch rep elijah cumming peter welch center bayer bayry biogen biib emd sereno novartis roche rhhby sanofi teva pharmaceutical biotech company teva milligram dose copaxone have increase most rise approval annual price today accord national multiple sclerosis society novartis gilenya approve be highest price investigation be year too late say more difficult push price control specialty market multiple sclerosis be massive market now stakeholder view specialty market rare disease innovative cancer therapy also seem immune pricing control analyst say example earlier year novartis gilead acquisition kite pharma gain approval car drug know kymriah yescarta respectively car drug be develop used patient own immune system cell be trained seek destroy cancer cell kymriah go year yescarta be list ark invest analyst manisha samy write recent post gene therapy be begin cure cancer come price cause sticker stock say say compare traditional therapy suppress do not cure cancer cost benefit analysis gene therapy be compelling pricing shock tend tamp excitement really compelling drug bailey say prime example be biogen ionis pharmaceutical ion spinraza first spinal muscular atrophy drug approve cost first year subsequent year sentiment biotech company share be already say so drug pricing concern shouldn be big stock killer past biotech stock go quickly get new drug person be excited lot time someone throw grenade drug pricing bailey say sentiment be already even concern drug pricing see little less downside ibd company biotech industry group be now rank group track have fall first just month share collectively near year high october have shucked almost point same time amgen celgene biggest biotechs have see share price dive respectively regeneron have take hit gilead have tumble meanwhile alnylam esperion look likely rival psck inhibitor drugmaker amgen regeneron have lift respectively abbvie recently launch rival gilead hepatitis franchise be novartis lilly be compete celgene treat inflammatory condition have see share retreat smaller degree respectively share price be match dip ibd company ethical drug industry group generic drug stock rank group have actually broadly rise mid october respective dip teva mylan myl biggest name related teva restructure plan case be here do generic drug maker face pricing issue other pharmas don ttop biotech company innovation earn recognition new award
42,REGN,stock fall new high tuesday apple aapl microsoft msft reversed lower bitcoin sank further spdr spy slide powershare qqq trust qqq slip spdr dow jone industrial average dium be fractionally lower small cap get slam ishare russell iwm tumble apple clear flat base entry friday average volume iphone maker be still buy point relative strength have lag remain consolidation lows microsoft rs line have be flat recent advance record high sector fund real estate healthcare semiconductor lead upside stock market today health care select sector spdr xlv rise record high component stock merck lead dow industrial pop retake day move average marked best level nearly month drugmaker relative strength line be turn rs rating be weak result show cocktail merck keytruda chemotherapy drug stop lung cancer advance extend patient life ishare nasdaq biotechnology ibb be featured later column reversed lower build right side shallow cup handle buy point energy retail home construction lag west texas intermediate crude price slip barrel spdr gold share gld ishare iau hold small gain rise month high friday gold future edge higher ounce bitcoin extend drop accord coindesk earlier high bitcoin ripple ethereum be get hit continue talk south korea potential cryptocurrency ban bitcoin investment trust gbtc be find support day line dec intraday peak large cap growth fund hold apple microsoft be solid start year continue stay ahead broader market top performer base year return jan be ishare edge msci usa momentum factor mtum fund year date gain put third place base measure be jan accord morningstar direct mtum top holding make asset be jpmorgan jpm microsoft apple bank america bac boee ba apple soar last year break past flat base entry friday first clear buy point dec ahead pullback day move average microsoft advanced friday price target upgrade keybanc capital market share be record high powershare qqq trust qqq track tech heavy nasdaq index score year ytd return respectively year old fund count apple microsoft amazon facebook alphabet top holding have amassed nearly asset third place go ishare russell top growth iwy have gather asset september launch iwy hold same top name qqq be less top heavy top account iwy total asset vs qqq etfs have low expense ratio mtum qqq iwy also earn star rating morningstar indicate well fund return have compensate investor amount risk incur rating range star best performer base risk adjust return relative similar fund receive star fund be trading time high be extend ideal buy point fact other etfs accompany table be also record high not too surprising give re now ninth year bull market ibd take make money catch etf uptrend require knowledge read chart learn ibd university so let take look etf not list big cap category be set new base ishare nasdaq biotech fund be shape right side shallow cup handle base potential buy point share advanced june shallow base oct intraday high fund track nasdaq biotechnology index mark anniversary next month biotech represent biggest sector weight asset pharmaceutical life science tool service smaller health care related position make rest top holding jan be gilead science gild celgene celg amgen amgn biogen biib regeneron pharmaceutical regn top stock account nearly total asset most have outperformed broader market so far year gilead amgen biogen have gain respectively vs return ibb year return slightly lag gain etf average annual return past year lag benchmark index lead past year ibb carry expense ratio friday pick powershare low volatility portfolio splv remain buy zone jan rebound day line related apple microsoft fuel dow record bitcoin rebound last apple rise bitcoin dife time buy nvidia ai stock china hit stock buffett vs bitcoin new high cannabis
43,REGN,amgen amgn regeneron pharmaceutical regn battle latter unveil cardiovascular datum cholesterol drug praluent analyst say monday amgen win approval rival drug treat broader set ailment friday food drug administration approve amgen drug repatha reduce risk heart attack stroke bypass procedure patient history cardiovascular disease approval be base datum trial call fourier show reduction risk cardiovascular outcome didn demonstrate impact death credit suisse analyst alethia young say bar mortality be high next year regeneron partner sanofi sny be set unveil cardiovascular outcome datum trial call odyssey praluent young doesn expect trial show praluent reduce risk mortality more follow likely be need trial set deeper rivalry amgen regeneron sanofi say note client drug class know pcsk inhibitor work lower bad ldl cholesterol ibd take do biotechs fare third quarter hint large cap feel pain see visit industry snapshot praluent show mortality benefit put amgen commercial disadvantage praluent fail show benefit reduce major adverse cardiovascular event expect amgen get majority praluent market share do not think differ effectiveness drug be major surprise think amgen manage have benefit successful study label point say close bell stock market today amgen lift close share regeneron rise finish sanofi fall close related regeneron dip month low drug combo bayer failswhy amgen have edge rival prevent migraineswhy medicine co be tumble deal
44,REGN,major stock index be mixed mostly unchanged monday afternoon perfectly fine performance bull nasdaq composite jump last week higher volume nasdaq lead way edge higher dow fall fractionally volume nyse nasdaq be tracking close friday level caterpillar cat be strong gainer dow more jpmorgan make positive comment stock be well extend too late buy early december buy point buyer be fang stock again name facebook fb amazon com amzn netflix nflx alphabet googl show gain range just amazon lead way recent buy point have come light volume baird raise price target amazon maintain overweight ratingin stock market today apple aapl ease hedge fund jana partner urge company take more active role combat youth smartphone addiction gopro gpro trim intraday loss cnbc report company have hire jpmorgan put sale share crumble early company announce job cut give weak guidance ibd more name be more help lift innovator ibd ffty gain bullish move last week see share surge higher volume nvidia nvda gap cup shape base rise nearly conventional entry be weekly chart show lag relative strength line however call quality question monday move be fuel news company be team volkswagen vlkay uber driverless car technology meanwhile jpmorgan healthcare conference kick san francisco monday headline flow be busy wasn good day ishare nasdaq biotechnology ibb be nearly biotechs be worst performer nasdaq name alexion alxn regeneron regn biogen biib shire shpg show loss range share celgene celg give back nearly news plan acquire san diego base impact biomedicine certain milestone be hit impact be work experimental drug type blood cancer call myelofibrosis bright spot share insulet podd gap flat base jump midcap name show solid sale growth recent quarters not profitable yet company specialty be tubeless insulin pump technology related nvidia rev ce consumer tech show autonomous car newsjust many more blockchain pretender bring seagate stock soar report investment ripple cryptocurrency
45,REGN,beleaguered biotech investor likely have get relief trial datum drug approval help stoke ember formerly red hot group take analyst say be relief horizon don expect anything earth shatter say next quarter half be likely feature significant disclosure number company coverage be unlikely be period strongly stock move event leerink analyst geoffrey porge write recent note client porge view follow third quarter large cap struggle historic moneymaker catch double whammy increase competition pricing concern meanwhile smaller cap crushed expectation result ibd company biotech industry group rank first just month be now list group ibd track share touch month high october have lose nearly however flow event be set accelerate early first quarter offer more opportunity meaningful value inflection company stock leerink analyst write recent note frustration depress biotech stock group have post impressive number new approval year jmp security analyst mike king say accord food drug administration original application drug biologic have be approve year need product approval tell investor business daily even most jaded observer sector have say sector whole have produce very satisfactory result come major trial readout don see change regard tack drug approval successful datum readout be key company celgene celg gilead science gild pair large biotech leader face grow field competitor moneymaker revlimid hepatitis drug respectively celgene be set have readout type hodgkin lymphoma have car development partner bluebird bio blue juno therapeutic juno car drug treat cancer used patient own re engineer immune cell be important celgene have long enjoy revenue gain chemotherapy revlimid analyst have be expect generic competition dr reddy laboratory rdy recently dr reddy miss key deadline file generic still less ideal celgene rely so heavily stream revenue fbb partner analyst mike bailey say celgene have be prepare replace patent challenged revlimid sale crohn disease drug firm say october win initiate phase trial drug bull case celgene previously be have new drug limit risk revlimid tell ibd take away risk management piece focus be drug be go go generic point similarly gilead have hiv combination used drug bictegravir set gain potential approval february accelerate hiv sale start second quarter porge say same time ark invest analyst manisha samy say gilead likely get further car gilead also announce thursday acquisition cell design lab privately hold car player october gilead acquire kite pharma nearly follow fda approval kite drug dub yescarta treat large cell lymphoma adult due individualized nature car drug aren likely rake same sale gilead now falter hepatitis drug year line be huge revenue maker tell ibd ibd take big cap struggle third quarter isn surprising consider patent cliff next year be set hit annual sale blockbuster drug say analyst head industry snapshot more biotechs fared period yescarta win replace gilead hepatitis franchise peak grow steadily bailey say guess be hepatitis be go shrink really quickly say point expect car replace hepatitis sale way peak be once ever term gilead do never be big next several month leerink porge look abbvie abbv regeneron pharmaceutical regn disclose pivotal trial regulatory event vertex pharmaceutical vrtx report more value confirm event abbvie have datum inflammatory treatment know upadacitinib say result add more detail evolve landscape be know jak inhibitor treat psoriasis rheumatoid arthritis ulcerative colitis number condition regeneron be deck file result drug dupixent asthma drug be already approve treat eczema firm also report datum eye drug eylea immuno oncology drug cemiplimab type skin cancer also look vertex provide phase datum triple pill combination treat cystic fibrosis total vertex be testing potential regimen bring phase trial firm be also likely gain approval drug combination february big pharma world leerink analyst seamus fernandez say be few significant stock move catalyst left first half be busy dow merck mrk bristol myer squibb bmy astrazeneca azn have immuno oncology combo result lung cancer bristol merck incyte incy be set deliver result regimen melanoma bristol also offer interim datum trial immuno oncology drug opdivo yervoy first treatment lung cancer outside major immuno oncology catalyst thankfully be limit say high bar bristol interim datum require nothing short stopping study early extreme effectiveness unlikely so expectation be probably low say nonetheless early stop be major validation bristol strategy likely drive stock view say continuation study likely increase concern bristol strategy ultimate success study final analysis possibly push stock parp inhibitor yet class cancer drug be set have trial result well astrazeneca have result drug lynparza first maintenance treatment ovarian cancer think parp space be quite large jmp king say hard tell real world doctor see drug better so start produce satisfactory sale figure related biotechs sell drove be investor seek merger biotech just near year high strong cancer regimenthis cancer biotech be fall bayer deal
46,REGN,be orderly day trading major stock index monday perfectly fine performance bull nasdaq composite jump last week higher volume so call fang name facebook fb amazon com amzn netflix nflx alphabet googl outperformed gain range facebook
47,REGN,here weekly investing action plan need know investor come week earning season be here again give top company chance provide more detail tax cut recently sign law change guidance profit come year delta air line dal
48,REGN,regeneron pharmaceutical regn dip month low monday combination eye medicine eylea drug bayer bayry fail pair phase study analyst say failure wasn total surprise regeneron commentary regard regimen be bearish third quarter earning conference call rbc analyst kennen mackay note report client say regeneron call have not see datum have be pretty clear high bar eylea used set potential combination study study aren central regeneron strategy firm have say monday bearish sentiment come fruition regimen eylea bayer angiopoietin fail meet goal study patient eye disease know diabetic macular edema wet age related macular degeneration combination be test vs eylea monotherapy key goal be improve best correct visual acuity week week measure know early treatment diabetic retinopathy study letter score ibd take regeneron begin multiyear run november have enjoy well lose long term support week line visit investor corner more learn study regeneron chart leerink analyst geoffrey porge say didn include combination model regeneron however regeneron stock come pressure today due removal upside eylea scenario second clinical failure year discontinuation suptavumab respiratory syncytial virus write note client work combo treatment be regeneron response increase competition eylea say roche be work angiopoietin combination datum expect have low probability success porge say close bell stock market today regeneron topple finish related regeneron jump issue street top revenue earning top biotech company innovation earn recognition awardsregeneron advance science attack arthritis eye disease more
49,REGN,regeneron pharmaceutical regn jump wednesday crush third quarter expectation continue uptake eczema drug dupixent strong sale eye drug eylea cholesterol drug praluent lag xby close bell stock market today regeneron lift finish earlier rise much week high share partner sanofi sny advanced end regular trading session broad biotech market inched fraction third quarter regeneron report adjust income share sale grow respective vs year period analyst have anticipate adjust profit share sale eylea regeneron biggest moneymaker bring unite state consensus expectation analyst rbc leerink put dupixent eczema drug regeneron launch sanofi account sale be ahead consensus expectation leerink analyst geoffrey porge write note client sale drug be record sanofi company share profit loss ibd take regeneron come saucer base soar past buy zone then faltered september now be day day day move average now rank ibd medical biom biotech group therapeutic top spot cholesterol drug praluent however lag forecast porge say regeneron confirm guidance growth eylea sale firm cut guidance sanofi reimbursement previously regeneron also lower expense tax guidance year regeneron plan file application food drug administration use eylea treat eye disease call diabetic retinopathy biotech also plan submit application dupixent asthma year end upcoming datum include study praluent interim datum trial immuno oncology drug early next year related chart school used regeneron year rally study supportibd biotech innovator awardsregeneron advance science attack arthritis eye disease more
50,REGN,ibd description stock chart often say stock be find support testing support have lose support concept support be not first thing need understand investor quickly become helpful asset assess technical strength stock identify critical transition stock chart status support refer level stock price generally appear trigger buy institution other large investor support occur specific price level move average price line such day day move average stock be say have support powerful shareholder be build position actively interested see stock chart maintain certain level stock chart mean stock tend hold certain price point key technical tool such week move average stock dip back support level price generally rebound often least mild increase volume more large scale buyer step prop price be action create follow buy opportunity call rebound support rebound week move average study support resistance be also often apply study behavior timing overall market level most notably analysis apply method such elliott wave principle fibonacci retracement good example stock enjoy then lose long term support week line be regeneron pharmaceutical regn stock break begin multiyear run november regeneron list many hundred find shareholder also include major institutional shareholder french drugmaker sanofi sny sanofi regeneron partner key drug development deal antibody immune oncology begin company announce august end antibody partnership year addition funding partnership sanofi invest heavily regeneron share reportedly hold much company regeneron sanofi partnership develop regeneron market core drug retinal treatment eylea outside partnership germany bayer bayry stock ride week support early dip consolidation find support week move average year share trend higher breaking basis month january august november week line cradle most run late regeneron once more dip back test week line separate consolidation break again ride support week line late august drugmaker now have logged quarters decline earning revenue growth continue accelerate investor have carefully be monitoring development pipeline indication be company have rich supply new opportunity still earning continue slip end rebound sharply third week august regeneron break support week line heavy trade send clear sell signal week later dove week move average even heavier volume signale investor institutional supporter be longer willing able prop stock face heavy selling such action produce valid double bottom base weekly chart show regeneron past entry point come relatively low volume compare sell base stock eventually rolled trigger golden rule selling cut loss less commence year consolidation battle regain support week move average ibd take slim trading methodology hold successful investing growth stock require tracking act trend smart money institutional investor slim acronym such hedge fund bank index fund insurer drive large portion market behavior also please read investor corner learn more importance institutional activity related regeneron advance science attack arthritis eye disease moreis stock find support hit resistance find great stock start flat base pump big gain trade proper buy point mark time great opportunity stock
51,REGN,share medicine co mdco dove month low wednesday biotech sell infectious disease drug unit first glance lag more bullish view term deal medicine co be selling drug know vabomere orbactiv intravenous minocin melinta therapeutic mlnt deal be cash melinta common stock medicine co say news release close bell stock market today medicine co re-cover much loss be only cent regular trading end share be much earlier trade share fellow infectious disease player achaogen akao however topple close melinta rise close buy side expectation call medicine co get asset evercore analyst umer raffat say note client price doesn take account tiered royalty sale vabomere orbactiv intravenous minocin melinta have pay medicine co raffat say deal also doesn account value milestone medicine co longer have pay vabomere medicine co acquire vabomere intravenous minocin part takeover rempex therapeutic december ibd take large cap biotechs struggle third quarter competition mount key moneymaker meanwhile smaller firm smash expectation head industry snapshot closer look third quarter play medicine co agree pay former rempex shareholder commercial milestone vabomere be approve august treat urinary tract infection upcoming submission europe have trigger milestone together raffat estimate cash stock royalty milestone medicine co win have pay generate net present value biotech term deal line expectation say deal serve recalculate value infectious disease drug leerink analyst paul matteis say note client medicine co acquire rempex buy targanta therapeutic get orbactiv achaogen have already trade lower anticipation upcoming deal matteis say still plan use transaction set more conservative target value potential merger acquisition infectious disease space single datum point also believe medicine co high degree motivation sell year end be probably factor garner upfront consideration be initial cash outflow view also intrinsic value asset say selling infectious disease unit give medicine co more wherewithal cash focus inclisiran drug treat high cholesterol matteis say previously company have look selling equity raise cash need further develop inclisiran upfront cash remove term overhang dilutive capital raise recently announce restructure company enable medicine co execute inclisiran clinical trial say inclisiran used technology develop alnylam pharmaceutical alny approve rival similar drug amgen amgn co brand effort regeneron pharmaceutical regn sanofi sny related teva restructure plan case be here do dow merck announce buyback increase dip month low drug combo bayer fail
52,REGN,treatment common eye disease make regeneron pharmaceutical star now new dermatitis medication bring superstardom fast grow biotechnology company xother breakthrough regeneron regn drug treat arthritis cholesterol company be develop promising asthma cancer treatment be just reason investor business daily name regeneron winner inaugural ibd biotech innovator award regeneron financial back optimism earning share various item shot last year impressive company post loss revenue have sky-rocket more tenfold last year regeneron have be fantastically successful company story say piper jaffray analyst edward tenthoff tenthoff begin cover company stock be change now estimate total revenue ep share rise ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report even regeneron stock be roll have trade recently meteoric decade find share peak august stock hit month high june now trade take hit potential competition eczema abbvie abbv tenthoff price target be regeneron ascent begin approval drug eylea treat disease call wet eye age related macular degeneration major cause blindness elderly relationship french drug giant sanofi sny suite key development tool focus pure science have enabled regeneron grow biotech titan future family antibody drug be used treat number common disease thus address multibillion dollar market human have antibody protein fight disease antibody drug be protein manufacture fight specific disease science be heart regeneron corporate culture success accord analyst company executive ve take mantle purest scientific company industry say geoffrey porge analyst leerink partner pride rigor scientific enquiry rate stock outperform buy price target porge say regeneron commitment research development be virtually unique industry regeneron spend total revenue well norm largest pharma company averaged revenue last year accord april report online newsletter fierce biotech tarrytown base regeneron have have help funding thank relationship other company include year relationship sanofi regeneron sanofi have agreement ongoing development immunotherapy cancer drug agreement antibody drug development licensing terminate end pact regeneron get funding sanofi certain licensing right end pact pose problem say analyst regeneron executive regeneron have become so big really don need sanofi analyst tenthoff say make discovery own commercialize true say regeneron have become very self sufficient end end house david regeneron senior vice president global clinical development tell ibd be self reliant own income stream such don need sanofi contribution research say termination sanofi pact enable regeneron set more partnership make sense cite company development platform build internally key enable rapidly identify therapy regeneron key drug development tool be velocigene velocimmune first aim rapid automate manipulation mouse dna speed modele human disease other aim help identify multitude optimized antibody drug candidate efficiently directly immunize mouse technology allow very quickly screen lot antibody find one have characteristic want say re not huge company term overall size say technology allow go large number target simultaneously wind drug development portfolio regeneron science focus help attract top talent say live motto science come first be not many place say scientist take novel study approach ibd take industry snapshot give depth look most popular industry include recent look rise medtech decline pharma regeneron grant employee stock option say so employee share company success regeneron take biggest drugmaker include roche hold rhhby novartis nvs amgen amgn august company report jump revenue record earning share item rise analyst poll zachs call analyst poll zachs be call ep year earlier quarter eylea continue drive financial sale beat wall street view tenthoff say sale end year see eylea sale rise eylea be sell regeneron partner drug german drug giant bayer bayry regeneron have exclusive right sale eylea bayer have exclusive marketing right outside company share equally profit sale eylea japan regeneron receive royalty net sale eylea be present many industry observer say dupixent be future be be sell treat atopic dermatitis gain fda approval march now regeneron seek eu approval treatment hope drug go much further dupixent have potential number other disease say be used treat asthma nasal polyp multiple allergy include peanut allergy esophageal inflammation more drug very well be pipeline say regeneron be conduct phase trial dupixent treat asthma seek fda approval next year dupixent be big not bigger eylea say analyst tenthoff rate regeneron stock overweight buy just treatment asthma alone annual global sale be say dupixent do well asthma study be most notable new drug year amy brown research firm evaluate pharma write august report other temper enthusiasm dupixent be big drug person have come overvalue say brian skorney analyst baird equity research skorney downgrade regeneron underperform neutral august regeneron have other potential drug hit year fda approve drug kevzara treat rheumatoid arthritis ra affect american accord arthritis foundation american college rheumatology regeneron drug praulent be used treat high level bad cholesterol amgen have sue say drug violate patent amgen compete drug repatha time injunction prevent regeneron selling praulent injunction be stay ruling lawsuit come soon skorney say praulent be pull market still be surprise wall street tenthoff be not worry say lawsuit risk be already baked regeneron stock price related get detail award winning biotech innovator workreason recent biotech stock rallyregeneron pharmaceutical eczema drug rival show promise
53,REGN,cure be strong word come treat cancer other deadly disease brad loncar be biotech stock analyst investor ready employ term first time biotech company be not think technology incrementally say loncar portfolio manager biotech focuse etf re not think alleviate symptom disease re think fix genetic mutation cause disease loncar be speaking cancer comment apply other terrible disease claim thousand life include alzheimer parkinson lou gehrig disease multiple sclerosis muscular dystrophy year first fda approve biotech drug biotech industry be roll innovation breakneck pace new drug pipeline be burst treatment clinical trial industry be grow leap bound many biotech stock be score superior return investor recognize biotechnology industry contribution science patient health investor business daily have create ibd biotech innovator award inaugural edition name award winning biotech company choose groundbreaking treatment recently introduce market well new product pipeline company be celgene celg biogen biib regeneron pharmaceutical regn kite pharma incyte incy loxo oncology loxo winner aren rank way only company trade share be consider biogen have sight firmly cure cancer other intractable disease biogen be target like alzheimer parkinson ms ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report company be just few player huge field closely track investor ibd count publicly trade company biotech industry group doesn include many other company biotech operation aren main focus have combine market cap nearly sale most recent month more thank biotech industry pipeline new drug kind have explode clinicaltrial org count more drug file phase late stage trial food drug administration year fda have more late stage study register ibd biotech industry stock group have climb year shuck pain politically charge election season concern president trump work lower drug price group wednesday hit month high be time high july currently rank group track ibd term performance past month boost group performance be celgene loxo recently hit new high incyte touch record high year biogen touch month high friday regeneron year touch nearly year high biotech focuse fund brad loncar head be loncar cancer immunotherapy etf cncr track biotechs work immunotherapy exchange trade fund be near year anniversary be year comment ibd come series regulatory approval acquisition cancer treatment include gilead science gild foray cellular therapy august agreement acquire kite nearly kite purchase be complete oct kite now operate wholly own gilead unit count loncar bullish today drug immune system identify fight precisely target cancerous cell technology turn edit gene correct genetic condition trial datum be jaw drop say example be car technology kite be leader field be young biotech company be take patient have week month live case be see complete remission loncar say ve never see anything loncar liken chemotherapy bomb kill enemy everything else sight loxo be used smart bomb precision medicine target gene fusion cancer jmp security analyst mike king explain cancer gene be call passenger other driver king tell ibd driver become fuse normal cell normal cell transform cancerous loxo identify target fusion american society clinical oncology conference june loxo show impact work photo sarcoma protrude child chest king say target call trk fusion loxo be able treat cancer tumor shrink away nothing surgery radiation other therapy contribute say be remarkable be pretty staggering even person audience be kind used see kind thing patient drug dub larotrectinib be able partly shrink tumor sign cancer disappear patient drug have breakthrough rare pediatric disease orphan drug designation fda also grab headline be immuno oncology work dow component merck mrk well incyte bristol myer squibb bmy roche rhhby astrazeneca azn kite car therapy be get due like novartis nvs juno therapeutic juno bluebird bio blue immuno oncology car be method teach immune system fight cancer immuno oncology drug do so block specific interaction otherwise prevent immune response car drug individualize process reprogramming patient own extract immune cell ibd take car drug be snag major attention gilead announce plan acquire kite novartis get major drug approval open sector head ibd industry snapshot feature closer look emerge car sector result have impressed immuno oncology drugmaker be take step further combine compound hope see more robust response merck have have success drug keytruda have win approval first treatment chemo lung cancer incyte drug epacadostat be particularly intriguing analyst say prevent interaction involve ido enzyme merck bristol be pairing drug keytruda opdivo class drug know pd inhibitor incyte epacadostat regeneron too be work pd inhibitor regn develop partnership sanofi sny june regeneron sanofi say patient form skin cancer respond treatment regn phase trial car side novartis gain fda approval late august drug treat form acute lymphoblastic leukemia patient age approval help spike gilead just day have announce deal acquire kite kite be near approval car drug treat aggressive form hodgkin lymphoma juno be just drug call jcar treat same cancer kite drug bluebird be work multiple myeloma drug juno bluebird have partner celgene program jmp king call best breed approach celgene put money line potential innovation such partnership be celgene excel wedbush analyst david nierengarten tell ibd ve have innovative deal sector small molecule cell therapy say re innovative cast net widely new technology potential therapy other be reap benefit decade old project map human genome first human genome map cost dollar take almost year complete today cost closer map individual entire genetic makeup gene therapy editing be have renaissance jmp king say analyst point crispr therapeutic crsp make ipo year leader field crispr be also name technology crispr therapeutic audente therapeutic bold intellium therapeutic ntla also be make wave sector technology make much easier edit gene needham analyst alan carr tell ibd btig analyst dane leone see company enter clinic technology used enzyme be actually bacterial organism target area genome dna want make change dna say do used enzyme complex be give direction term target insert cell end enzyme complex attach dna make alteration tell ibd jmp analyst king describe crispr technology have ability repair break gene cut replace defective gene insert functional gene re desire other side gene spectrum rna interference antisense be responsible cut edge drug alnylam pharmaceutical alny biogen partner ionis pharmaceutical ion biogen ionis december win fda approval spinraza first drug type approve treat spinal muscular atrophy needham carr liken rna interference way turn gene have potential be more robust gene therapy most cell body be effective september alnylam stock spiked day drug patisiran prove effective treat rare disease know hereditary attr amyloidosis polyneuropathy disease result buildup abnormal protein cause systemic problem patisiran used rna interference analyst call late stage datum alnylam big concept bluebird be work gene therapy treat blood disorder list innovation go era biotech today gain have be decade make usually steady build then have wave innovation kind collide emerge similar point time jmp king say not traditional tech thing happen overnight related get detail award winning biotech innovator workgilead kite deal boost biotech etf clear buy novartis cancer approval validate gilead kite cure cancer look blood
54,REGN,investor business daily have create ibd biotech innovator award recognize lead company groundbreaking treatment already market close final approval xrecipient inaugural award be celgene celg biogen biib regeneron pharmaceutical regn kite pharma be recently acquire gilead science gild incyte incy loxo oncology loxo man woman research create testing marketing biotech drug represent often medical field best hope conquer cancer alzheimer other hard cure ailment company face many hurdle significant cost get drug approve federal drug administration fda hand prescribe doctor patient ibd biotech innovator award honor ingenuity effort related biotech stock watch pharma industry news
55,REGN,index other major average edge lower thursday tax reform concern weight market snapchat parent snap snap crash weak revenue user growth broadcom avgo make bid fellow apple aapl supplier qualcomm qcom report surface walt disney have hold talk buy much st century fox foxa nasdaq dow industrial give weekly gain fear tax cut be delay close slightly lower still record high earning remain heavy nvidia nvda lead chip earning roku roku stream higher strong first ever earning report fellow recent ipos snap trade desk ttd crash bank stock be notable loser week crude oil future hit year high saudi turmoil production hit record high broadcom avgo launch unsolicited bid buy wireless chip maker qualcomm qcom deal worth make largest technology acquisition ever qualcomm be likely reject share offer basis too low deal also have big antitrust hurdle qualcomm rise spiking nearly nov deal report first hit broadcom retreat stay buy range chipmaker nvidia nvda microchip technology mchp semiconductor post beat raise quarterly report skywork solution swks beat wall street target september quarter give line guidance chip gear maker brook automation brk beat fiscal fourth quarter forecast guide current quarter forecast higher share still tumble thursday friday follow result roku roku rocket thursday stream video firm report much better expect result third quarter first publicly trade company roku then rise record high friday roku end third quarter active user content distribution platform year year average revenue user grow year year roku make hardware software access internet video service netflix nflx hulu amazon amzn prime video analyst tear snapchat owner snap snap third quarter earning report miss estimate many metric include revenue user growth snap ceo evan spiegel acknowledge complaint snapchat be hard use say app be redesign share crash even tencent holding tcehy buy stake social medium firm related snap slam quarterly result tencent acquire china internet company sina sina weibo wb athm report quarterly result beat expectation sina own control stake weibo chinese video game publisher netease nte say push deeper commerce plan spend product europe japan sell local consumer search engine company sogou sogo raise initial public offer selling share high end estimate range share rise thursday debut close friday china base sohu sohu internet service company include gaming hold largest stake sogou be also backed tencent tcehy tencent lead china messaging service field aim deepen relationship sogou pose threat china search engine leader baidu bidu jwn roundly top profit revenue forecast same store sale disappoint upscale department store trim high end profit outlook meanwhile macy miss revenue estimate comp sank beaten share soar better expect earning kohl kss ep miss view retailer lift bottom end ep target penney jcp report better expect result recently slash full year guidance walt disney disclose surprise drop profit revenue report more upcoming espn layoff ceo bob iger announce be brand new star war trilogy give espn stream platform name launch date say disney only top service be price substantially netflix nflx reverse share higher late thursday meanwhile report surface st century fox foxa have hold talk sell bulk disney iger refuse address press speculation call disney rise solidly more st century fox report solid result shot monday oil price rise highest level mid political unrest middle east crude close week gain barrel saudi arabia arrest several member royal family prior week say missile attack yeman support iran be consider act war crude production rise barrel day highest energy information administration begin tracking weekly datum domestic crude supply unexpectedly rise continental resource clr diamondback energy fang matador resource mtdr carrizo oil gas crzo top quarterly forecast parsley energy pe turn mixed result shale producer continue stress capital spending discipline report related crude production hit record high stockpile unexpectedly risevideo game publisher take interactive software report better expect september quarter result guide higher holiday sale quarter activision blizzard atvi electronic art ea recently give disappointing guidance take be benefit continue demand grand theft auto franchise strong sale basketball game nba meanwhile activision say call duty wwii surpass global sale first day availability sage therapeutic sage rise record high upbeat datum postpartum depression drug teva pharmaceutical teva pop news british billionaire buy stake supernus pharma supn top expectation late monday boost product sale guidance ionis pharmaceutical ion dove third quarter miss mallinckrodt mnk offer mixed report tuesday cause lose third value nektar therapeutic nktr acadium pharmaceutical acad tesaro tsro beat top bottom line view tesaro plunge sale ovarian cancer drug zejula lag meanwhile astrazeneca azn have strong ovarian cancer drug overall revenue adjust profit be soft regeneron pharmaceutical regn wednesday top revenue earning view confirm guidance yearly eylea growth priceline group pcln top third quarter estimate online travel agency weak earning outlook send share plunge tuesday priceline accommodation business book room night tripadvisor trip also fall report miss revenue estimate hotel business slow square sq report adjust ep cent cent consensus digital payment processor say net revenue rise top estimate maker credit card reader plug mobile phone tablet raise full year revenue adjust ebitda outlook respectively midpoint guidance digital ad placement company adjust third quarter earning rise cent share revenue climb nearly top consensus estimate trade desk ttd forecast revenue vs estimate also give weak ebitda guidance trade desk crash friday already tumble thursday homebuilder horton dhi meet earning estimate top revenue forecast share rise record high alarm com alrm plunge home security automation software firm forecast full year earning cent share vs estimate cent match group mtch stock jump date site operator forecast december quarter revenue expectation owing mobile app tinder gold miss earning planet fitness plnt put result full year forecast consensus however wedbush say be still cautious give concern decelerate growth store base mature monster beverage mnst beat third quarter sale estimate earning miss share fall buy point intraday thursday buy point close higher week general electric ge sell spin aircraft lease business new ceo john flannery look slash more asset cost trouble industrial giant year ge locomotive health care unit be also recently say face knife industrial laser maker coherent cohr see share blast past buy point deliver better expect september quarter sale earning guide higher current quarter coherent be play oled display production growth global payment gpn expect full year adjust net revenue most gain be due payment processor recent acquisition active network analyst say
56,REGN,anaptysbio anab launch record high tuesday eczema drug appear outperform regeneron pharmaceutical regn sanofi sny potential blockbuster dupixent phase trial xin early trading stock market today anaptysbio more double skyrocket close regeneron lose end regular trading session sanofi dip finish drug dub anb be test adult patient moderate severe eczema first patient receive placebo day enrollment week later patient receive single milligram dose anb onset be rapid day patient see eczema severity extent lessen half patient see same improvement day day patient still have improvement eczema symptom compare phase phase test patient receive weekly dose regeneron sanofi dupixent monotherapy achieve improvement eczema symptom rbc analyst kennen mackay write note client ibd take biotech stock recently hit collective month high news strong player zogenix bluebird bio celgene head ibd industry theme closer look group spiked maintain speed importantly dose schedule anb be highly competitive dupixent other week injection schedule daily oral dose other drug know jak inhibitor mackay say mackay assume anaptysbio have chance success eczema drug earlier view model upside share assume anaptysbio be successful keep price target outperform rating stock related regeneron patent be amgen thinkregeneron pop judge toss ban amgen rivale medgalapago pop eczema drug show promise vs regeneron
57,REGN,biogen biib gilead science gild sarepta therapeutic srpt build momentum biotech sphere beat wall street expectation third quarter analyst predict friday large cap biotech stock have be strong head third quarter report period credit suisse analyst alethia young write note client be focuse biogen spinraza regeneron pharmaceutical regn dupixent gilead hepatitis drug close bell stock market today investor business daily company biotech industry group dip collective group be rank first group track ibd hit month high earlier week momentum likely continue third quarter most large cap young say call biogen gilead sarepta possibly unite therapeutic uthr beat top line biogen be set report quarterly result early oct young call spinraza spinal muscular atrophy drug develop ionis pharmaceutical ion beat consensus view forecast sale cure sma report estimate patient have be dose spinraza third quarter be trial expand access program young write suggest be commercial patient period see patient spinraza third quarter ibd take biotech stock have trend north past several week healthy dose good news several key player head ibd industry theme closer look stock help send group month high do think point spinraza surprise downside patient switch much less expensive maintenance dose vs load dose say however think quarter spinraza very much still be launch phase top line young model biogen report sale adjust income share metric top consensus analyst poll zack investment research respectively multiple sclerosis franchise be likely face more headwind quarter quarter basis tecfidera total prescription fall third quarter price increase result young model tecfidera be consensus view young forecast gilead beating third quarter expectation strong sale drug treat hepatitis hiv help biotech shuck quarters hepatitis malaise still abbvie abbv new hepatitis regimen have impact gilead be set report late oct abbvie mavyret gain approve august treat genotype hepatitis patient typically dose week shorter duration rival drug be price roughly half price competitor wholesale basis reason young drop forecast gilead hepatitis drug sale factor risk abbvie remain bullish third quarter model total sale consensus view forecast be drive consensus top view sale harvoni sale epclusa hiv estimate be largely line consensus view model miss hiv drug truvada estimate consensus due entry generic outside bottom line young call adjust profit share vs consensus analyst poll zack young call regeneron sarepta narrowly beat wall street forecast benefit eczema drug dupixent duchenne muscular dystrophy drug exondys respectively regeneron be set report earning early nov deliver slight beat vs consensus sanofi sny partner eczema drug young model sale dupixent earlier view street dupixent weekly total prescription be average third quarter vs prior period dupixent end third quarter outstanding total prescription young write forecast quarter quarter growth drug third quarter model eylea approve treat number eye condition be trail consensus sarepta again surprise upside exondys second quarter sarepta crushed expectation third quarter young call exondys sale consensus further full year guidance sale be likely conservative young say note management sound upbeat launch trend related abbvie new hepatitis drug chip away gilead biotech break month high keep go regeneron patent be amgen think
58,REGN,dow component merck mrk say late wednesday win submit application approval cholesterol drug follow review clinical profile prod share fall hour trading xmerck drug anacetrapib be be investigate treatment high blood pressure prevent cardiovascular disease june merck say drug prove effective reduce major cardiovascular event patient already receive ldl cholesterol lower drug merck also find earlier study well recently announce phase trial call reveal anacetrapib accumulate fat tissue be deeply grateful researcher patient participate anacetrapib clinical development program particular reveal outcome study merck research laboratory president roger perlmutter say prepared statement unfortunately comprehensive evaluation have conclude clinical profile anacetrapib do not support regulatory filing ibd take merck have be base march year hover share have reach share be consider back buy range hour trading merck fall close nearly cholesterol lower drug have be news frequently amgen amgn partnership regeneron pharmaceutical regn sanofi sny battle patent court amgen argue regeneron sanofi infringe patent cover drug repatha regeneron sanofi make rival drug praluent august esperion therapeutic espr pop nearly year high bump timeline quarter file application food drug administration cholesterol lower drug first quarter related regeneron patent be amgen thinkhow biotech rocket year high breaking outall eye be dow component star drug next week
59,REGN,amgen amgn patent cover ldl cholesterol lower drug repatha be likely be invalidate wake court battle regeneron pharmaceutical regn sanofi sny analyst say friday xon thursday federal judge tossed injunction sale praluent regeneron sanofi rival drug amgen repatha remand case back district court regeneron sanofi argue amgen patent be too broad judge decision thursday effectively end antibody exception patent trademark office leerink analyst geoffrey porge say exception grant new antigen patent right antigen antibody bind case be first time court clear language state antibody exception have justification law rule antibody be different rule small molecule require adequate description specific structural feature claim molecule say repatha praluent class call pcsk inhibitor prevent pcsk protein bound ldl receptor lower bad cholesterol blood patent repatha amgen doesn identify structural feature common genus instead define genus base antibody bind regeneron sanofi say argue praluent have different sequence compare amgen claim regeneron sanofi be prevent present evidence initial trial judge say thursday be allow do so remand trial porge say note client trial span just month give narrower scope ibd take biotech stock be now rank first group ibd track benefit back strong news several player month head ibd industry theme breakdown stock look strong right now specialist believe amgen pcsk patent be invalidate remand district court trial porge write be base narrow higher standard patentability now be demand court require district court result patent antibody medicine now more closely resemble cover small molecule porge say antibody drug be target therapy small molecule drug rely organic compound help regulate biological process decision mean many grant broad antibody genus composition patent be risk future litigation also suggest uspto change standard practice future apply standard such patent file future say further future royalty broad antibody genus patent holder narrow single product infringer be likely be decide favor infringer say put current royalty be paid drug risk case also have legal implication broad antibody dispute amgen regeneron sanofi be likely clash antibody bind il receptor porge say be mechanism dupixent eczema drug regeneron sanofi already regeneron be seek invalidate patent amgen hold immunex acquire patent cover antibody bind il receptor specialist argue amgen be less likely prevail case base thursday ruling thus allow dupixent be market threat sanction patent licensing obligation porge say close bell stock market today amgen sank regeneron lift finish sanofi dip fraction end day related regeneron pop judge toss ban amgen rivale regeneron cholesterol buster get boot amgen battle regeneron sanofi claim amgen ldl buster patent too broad
60,REGN,regeneron pharmaceutical regn amgen amgn stock diverged early thursday appellate court tossed ban sale regeneron sanofi sny cholesterol bust drug praluent rival amgen repatha decision come court appeal federal circuit washington reuter report amgen have previously claim praluent infringe patent january judge ban praluent market siding amgen patent battle month later court stay injunction pending appeal process thursday federal court rule jury be give improper instruction order new trial close bell stock market today regeneron lift finish amgen slide end sanofi rise less drug involved class call pcsk inhibitor work reduce bad ldl cholesterol blood target pcsk protein center case amgen patent cover entire antigen describe bound regeneron say be too broad ibd take remainder be chock full catalyst biotech sector analyst say key trial datum be due like abbvie alexion pharmaceutical vertex pharmaceutical fibrogen visit ibd industry theme closer look spike flop aftermath oral presentation june regeneron argue jury decision be base insufficient information regeneron wasn allow present evidence praluent used different amino acid structure different bound site pcsk protein vs repatha ultimately appellate court side regeneron thursday agree have be allow present critical evidence relate antibody original trial rbc analyst kennen mackay write note client specifically appeal court side regeneron critical evidence relate antibody bound characteristic vs cover amgen patent be improperly exclude jury be improperly instruct written definition say case now be present new judge jury district court level process take year mackay estimate amgen expressed disappointment decision email investor business daily biotech note court do affirm claim cover patent be obvious general requirement patentability regeneron sanofi have challenged amgen point ability deliver new medicine benefit patient depend meaningful patent protection enforcement enable significant investment drug development clinical trial firm say be disappoint court action reverse remand district court decision respect validity patent base select pretrial ruling leerink analyst geoffrey porge say decision help shift market share trend back current state repatha dominance more equal market split long term porge note case also have implication antibody exception patent law exception effectively grant new antigen patent right antigen antibody bind accord report harvard law innovator expect more competition antibody drug class patent procedure litigation decision look more small molecule claim decision write note client expect patent claim antibody case become narrower result related surprising reason regeneron topple beat raisewill regeneron cholesterol buster get boot amgen battle comeback kid regeneron survive amgen cholesterol squeeze
61,REGN,galapago glpg pop wednesday eczema drug compare favorably potential blockbuster dupixent regeneron pharmaceutical regn sanofi sny phase trial xin morning trading stock market today galapago jump close first day black day share break cup earlier month hit buy point galapago be partner morphosys drug know mor phase trial patient roughly treat highest dose see eczema symptom improve least week firm say news release result be maintain month last infusion patient treat placebo only achieve improvement symptom same time period mor now advance phase testing galapago say consider switch drug injection rbc analyst brian abraham note mor compare favorably approve drug call dupixent regeneron sanofi analyst have predict dupixent be blockbuster biopharma giant ibd take galapago be also work cystic fibrosis analyst say lag vertex pharmaceutical lead biotech aim eradicate cystic fibrosis know today head new america deep dive vertex triple pill approach lung disease dupixent combination topical corticosteroid help patient achieve improvement symptom least week accord trial datum drug label monotherapy dupixent achieve similar improvement patient abraham suggest mor also be used treat inflammatory bowel disorder be already treat drug novartis nvs eli lilly lly drug similar class mor be competitive mor need be injection related biotechs mend even glaxo back ionis dealvertex hit record high result cystic fibrosis trialvertex catapult strong trial cystic fibrosis
62,REGN,drugmaker be begin gain steam drug trial result begin determine winner loser industry merck mrk be next break move higher ethical drug industry have jump industry group ranking last week time merck
63,REGN,alexion pharmaceutical alxn cut workforce reinvest research biotech say tuesday just month hire new chief executive away baxalta xby close trading stock market today alexion be alexion have trend past month be year biotech expect deliver pretax saving year result cost cut measure plan reinvest year build pipeline business development add new complement indication approve drug streamline operation create leaner organization greater financial flexibility be highly focuse deliver patient grow rare disease business leverage leadership complement pursue discipline business development expand pipeline chief executive ludwig hantson say statement ibd take alexion recently stage happen head new high stock list closer look potential well competitor alexion have have tough year overall share plummet early year low exec announce departure just month ludwig come alexion baxalta baxalta be acquire shire pharmaceutical shpg last year july alexion confirm investigation department health human service leerink analyst recently list alexion top pick celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx related biotech catch rally add biotechs outperformed pharma brother june quarteralexion pharma stock dife report federal scrutiny
64,REGN,regeneron pharmaceutical regn topple month low monday drug dupixent meet key goal phase asthma trial lag own earlier result amgen amgn patient group xby close bell stock market today regeneron plunge touch low last see mid share partner sanofi sny fall close biotechs broadly lose dupixent be approve treat eczema be be test potential asthma drug ability treat underlie cause phase trial dupixent reduce severe asthma attack improve lung function add standard treatment regeneron say news release week milligram dose dupixent other week reduce severe asthma attack overall population patient medium high level specific white blood cell dupixent cut asthma attack respectively week overall population see average improvement lung function placebo subgroup medium high level specific white blood cell lung function improve average respectively ibd take biotechs pop september number upcoming trial readout head ibd industry theme breakdown line make break month dupixent have less activity patient low number specific white blood cell activity be lower regeneron own earlier phase trial be also lower result phase asthma study amgen astrazeneca azn release last week leerink analyst geoffrey porge blame find regeneron stock pitfall related biotech catch rally add abbvie chip away regeneron potential blockbusterdow member bayer face battle augment aspirin
65,REGN,index dow industrial set record high week weak payroll report end hot streak nasdaq composite eke gain netflix nflx break set new high general motor gm soar strong september sale big plan electric vehicle tesla tsla stock brushed weak model production figure amazon com amzn rise report testing home delivery service index reversed higher friday notch ninth straight gain streak end longest year straight record high marked longest such streak dow have straight gain index fall friday surprise drop september payroll figure still rise week marked fourth consecutive weekly advance nasdaq finished weekly gain dow outpaced rise economy lose job september financial market overlooked temporary hurricane related hit focuse employment report underlie strength jobless rate fall lowest early average hourly wage gain jump match best gain other datum earlier week also point economy seem finally be breaking year run slow growth strength reflect boost hurricane recovery effort institute supply management manufacturing survey index jump year high far neutral mark ism survey gauge also surprised upside register fastest growth august related economy shed job jobless rate hit year lowism manufacturing index jump highest general motor ford motor toyota tm most automaker report stronger expect september sale demand rebound follow hurricane fiat chrysler automobile fcau be exception be due decision slash low margin fleet sale industrywide sale hit annual rate best year related gm ford soar auto sale get post hurricane surgegm vow add electric fuel cell vehicle ll largely finance effort profit gas guzzling suvs truck ford have not be profitable gm have lag evs say slash cost expand production electric vehicle well truck suvs volvo several other automaker have also announce plan rapid expansion ev hybrid model tepid demand china major european country city announce plan ban sale gas only vehicle come decade gm share leap week ford rise related ford focus evs truck suvs ceo say electric push come latetesla have plan make model sedan only turn cite production bottleneck tesla deliver just model car overall delivery reach strong demand more expensive model model model wo be bad sign tesla push make december even faster pace tesla share fall month low extend recent pullback share rebound help nomura initiate tesla buy price target stock rally week related tesla stock fall model production miss due stream video leader raise monthly price midrange high end tier respectively get ready sink content acquisition next year price hike only be start november netflix hadn have major change pricing share break week cup handle base buy point thursday continue rise record high friday already threaten climb buy range week stock shot commerce giant be testing home delivery service time third party merchant use online platform intensify competition longtime partner fedex fdx unite parcel service up bloomberg report new delivery program be call seller flex amazon pick package third party merchant selling platform deliver product consumer amazon com provide free day delivery eligible customer broad rollout be possible alphabet googl google take more shot apple aapl do amazon launch new hardware product include pixel brand smartphone ship ahead iphone google add new member voice activate home automation family didn amazon have sell echo speaker system google rolled new home speaker system compete apple homepod inch screen pixel start inch screen pixel xl start be less iphone more large screen version first pixel rolled google also unveil new pixel brand laptop compete apple macbook related google hardware launch take more shot apple amazonlennar len report better expect earning revenue tuesday slightly raise forecast hurricane related delay builder stock rise week clear buy point meanwhile kb home kbh meritage mth break monday keep rise kb home report strong earning meritage give solid order sale figure tuesday horton dhi lgi home lgih toll bro tol be other recent breakout even treasury yield have rebound recent week related lennar near buy point earning surprise builder break price crude struggle stay barrel crude inventory fall barrel gasoline supply rise accord energy information administration analyst expect barrel decline crude inventory barrel gain gasoline crude production rise barrel day last week bpd week prior russia seem open extend current output deal opec expire march end west texas intermediate end lower week barrel la vegas expose casino stock mgm resort mgm fall gunman kill least person injured other country music concert outside mgm mandalay bay resort casino worst shooting modern history mgm china unit also say delay open new casino cotai strip section macau early next year last half due damage typhoon hato august september gamble revenue macau jump early estimate number visitor macau key golden week holiday period be weak delta air line dal lead airline sector higher carrier offer third quarter unit revenue forecast factor hurricane irma look eye analyst delta american airline aal jetblue jblu spirit airline save be see more vulnerable area storm strike cowen also say guidance suggest stabilize pricing trend delta fare war network carrier low cost rival have earlier ravage airline stock warren buffett berkshire hathaway brkb say take stake pilot fly large truck stop chain plan gobble extra buffett statement call pilot fly key enabler nation economy move boost buffett transportation related holding give way use roughly company have accumulate buffett also praise bank america bac ceo brian effort turn bank billionaire investor say be shareholder long long long time berkshire become bofa biggest shareholder summer avexis avxs touch record high amicus therapeutic fold hit highest point september strong datum spinal muscular atrophy pompe disease treatment respectively acadium pharmaceutical acad rally late wednesday fall thursday fda grant breakthrough designation dementia drug cytomx therapeutic ctmx launch mash amgen amgn immuno oncology wednesday thursday judge tossed ban regeneron pharmaceutical regn sanofi sny praluent court battle amgen prompt regeneron amgen stock diverge costco cost score broad beat stock fall key metric net sale miss view membership base retailer report ep grow revenue climb top estimate do result same store sale investor worry amazon effect costco business retailer commerce sale grow september fourth quarter yum brand yum spinoff increase share buyback initiate dividend also naming new ceo yum china yumc quarterly result be mixed ep cent miss cent revenue top view same store sale jump kfc pizza hut restaurant do better expect wine beer maker ep jump easily top forecast revenue grow beating view constellation brand stz also hike full year ep guidance consensus management say market share operate margin widen
66,REGN,regeneron pharmaceutical regn topple thursday rival abbvie abbv reveal strong result phase trial eczema drug chip away regeneron sanofi sny potential blockbuster dupixent afternoon trading stock market today regeneron sank sanofi lose fraction abbvie pop soar time close high abbvie drug know upadacitinib achieve main goal improve eczema area severity vs placebo week half patient achieve clear almost clear skin milligram once daily dose be excited result study show upadacitinib have potential be important treatment option patient atopic dermatitis say michael severino abbvie chief scientific officer statement upadacitinib be set go phase testing phase study drug reduce itch first week improve skin condition first week common side effect include respiratory tract infection eczema acne ibd take abbvie paid acquire become major blockbuster arthritis drug much do gamble pay head income investor more make dividend leader winner approve abbvie drug chip away sale dupixent injection treat eczema patient condition doesn improve topical cream dupixent bring second quarter sale sale be record regeneron profit loss be split sanofi regeneron sanofi be also phase testing dupixent asthma phase trial be look dupixent treatment chronic allergic immune condition white blood cell build line esophagus related dow member bayer face battle augment fail late stage trial so benefit generic drug stock catch break mylan crash
67,REGN,catch rally biotech sector tack stock celgene celg alexion pharmaceutical alxn regeneron pharmaceutical regn lead charge analyst say week xyear date ishare nasdaq biotechnology etf ibb be same time spdr biotech etf xbi be be currently buy zone strong performance biotech multiple be only just historical time trough leerink analyst geoffrey porge say recovery be underway large cap biotech stock be april beat market handily second quarter still biotechs continue trading significant discount pharma medtech brother porge say note client premium biotechs have enjoy pharma medtech respectively have erode reversed porge be banking return sentiment biotech sector compare revenue multiple group be be still additional upside sentiment sector return prior level say ibd take industry observer say september be make break month biotech sector base number upcoming investor health care conference well expectation nearly dozen trial readout excel be face pitfall head ibd industry theme closer look recovery be already underway late august gilead science gild say pay acquire cancer play kite pharma kite day later rival novartis win approval key treatment set stage key drug kite be approve november announcement ibd company biotech industry group have climb porge call catch rally significant extend be rally investor have be hope look follow surprisingly tepid july group strong second quarter operate result porge say consensus expectation third quarter be pick porge say revenue view be modest call average growth earning share forecast be trend first time year porge be more bullish consensus top pick be outperform rate alexion celgene regeneron vertex pharmaceutical vrtx january even slow grow large cap have deliver outperformance standout include regeneron vertex celgene have more pipeline optionality have not appreciate much lately alexion say be also recommend regeneron vertex current valuation see less upside name celgene alexion related alnylam topple celgene astrazeneca rise drug setbackstop biotech stock buy zone fda drug abbvie chip away regeneron potential blockbuster
68,REGN,major market index fall negative territory early trade thursday major index tech heavy nasdaq dow jone industrial average decline nearly dow industrial home depot hd extend streak trading session advance almost stock have quickly moved striking distance flat base entry downside general electric ge decline be trading just lows fang member amazon com amzn rally almost higher stock market today analyst firm davidson initiate coverage retailer buy rating price target premium wednesday close price stock try recover back day line correction share look build right side potential cup shape base meanwhile fellow commerce giant alibaba baba advanced stock continue form rare ascend base potential entry leaderboard member have be strong performer rise much cup handle entry other lead growth stock graphic chip maker nvidia nvda rise be hold day line stock be currently week potential flat base so need close week reach new high finish pattern company report earning rh rh surge easily beating earning estimate late wednesday company also raise full year earning revenue guidance stock reclaim day line have be trading aug ibd lgi home lgih advanced attempt reclaim day line stock look build right side potential base sharp pullback week line meanwhile celgene celg moved report food drug administration have place trial partial full clinical hold stock break flat base buy point last friday share be trading just entry downside regeneron pharmaceutical regn drop almost plunge back day line heavy volume stock have be build double bottom buy point today action bring pattern doubt related dow jone industrial average dow stock news analysis stock buy point market rebound investing action planfang stock news quote facebook amazon netflix googlerh stock soar ceo tout revolutionary new retail model
69,REGN,dow component johnson johnson jnj bayer bayry have battle persuade doctor add xarelto aspirin therapy heart disease patient analyst say monday trial show complication xxarelto blood thinner be test alone combination aspirin cut risk cardiac event patient heart disease combo reduce risk cardiovascular death stroke heart attack vs aspirin alone be also tie more bleed event event occur patient treat combination vs patient treat aspirin alone most bleed occur tract johnson say news release encouragingly trial find difference rate fatal bleed intracranial bleed symptomatic bleed critical organ rbc analyst glenn novarro write note client result appear sufficient food drug administration approve xarelto combination aspirin set novarro say doctor commonly use aspirin only therapy help cut risk cardiac event heart disease patient novarro note benefit risk profile have potential impact peak sale xarelto credit suisse analyst vamil divan be more bullish note combo cut risk stroke cardiovascular death respectively none bleed trial prove fatal occur brain write note client result drive re acceleration growth xarelto expand potential treatment population product more say ibd take biotech stock have see better day july sector hit month high anticipation second quarter earning season then long term view company have investor shake head ibd industry theme closer look setup fellow drugmaker novartis nvs be more challenged drug know ilaris leerink analyst seamus fernandez say note client phase trial ilaris cut risk major cardiac event heart attack survivor vs placebo see result together lack significant benefit cardiovascular mortality underwhelm unlikely result reasonable commercial opportunity drug overall population write overall ilaris show relative reduction risk heart attack cut risk cardiovascular death subgroup patient hit specific level inflammation first dose ilaris result cut risk major cardiovascular event ilaris have leg group novartis define subgroup regulator negotiate health insurer fernandez say believe drug still struggle gain meaningful uptake base recent experience pcsk antibody note current patent life drug extend only write pcsk inhibitor be cholesterol reduce drug like amgen amgn regeneron pharmaceutical regn sanofi sny cut bad ldl cholesterol have be show have benefit cardiovascular side well pcsk inhibitor have struggle gain uptake close stock market today tick cent novartis sank finish bayer be fractionally related big pharma face tough road upcoming drug test celgene abbvie benefit growth marketall eye be dow component star drug next week
70,REGN,regeneron pharmaceutical regn see positive improvement relative strength rs rating wednesday increase exclusive rating investor business daily identify market leadership worst best score score show stock price performance trail week compare other stock database year market history show stock go make biggest gain tend have higher rs rating early stage move regeneron pharmaceutical be try complete consolidation entry see stock clear price volume least higher normal earning grow last quarter prior report revenue also increase company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
71,REGN,important metric look stock be higher relative strength rating regeneron pharmaceutical regn just hit mark jump monday ibd unique rs rating track market leadership used worst best score indicate stock price action last week match rest market year market history show top perform stock tend have rs rating launch biggest price move now be not ideal time jump isn proper buy zone see stock go offer clear proper buy point earning grow last quarter prior report revenue also increase regeneron pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
72,REGN,regeneron pharmaceutical regn gilead science gild be most likely beat wall street view june quarter sale profit analyst say monday xleerink analyst geoffrey porge say star align widespread beat biopharma result large cap also see abbvie abbv celgene celg biogen biib gilead most likely top revenue expectation quarter quarter sale abbvie alexion pharmaceutical alxn biogen vertex pharmaceutical vrtx be likely be slow say abbvie biogen be face competition pricing pressure alexion vertex be still high growth company temporary slow revenue growth trajectory pending new indication formulation product write note client health tracker im see abbvie leukemia drug imbruvica testosterone gel androgel likely come materially north consensus humira landing street view other major project be expect miss im datum suggest biogen multiple sclerosis drug tysabri tecfidera beat porge estimate respectively tecfidera however be expect miss street ms drug plegridy avonex be forecast be light come grow competition ms field like roche rhhby novartis nvs sanofi sny roche drug ocrevus be approve earlier year treat relapse remit well primary progressive ms first industry ibd take biotech stock be rank group track sentiment tick ahead second quarter earning season make sure bookmark ibd biotech stock watch pharma industry news latest sector major drug celgene be expect top consensus chemotherapy revlimid likely come consensus porge write pomalyst drug treat blood cancer be expect be higher consensus gilead be likely be biggest second quarter surprise im datum gilead sale top be largely dependent reliability recent hepatitis datum have be unreliable past hepatitis drug sale topple high cure rate accounting highly variable sale hepatitis drug gilead total sale miss porge forecast analyst consensus target same time gilead genvoya hiv drug beat consensus porge write note client amgen amgn be most likely match slightly underperform consensus porge say rheumatoid arthritis drug enbrel be expect be line consensus view top porge view much im datum bone health drug prolium bone marrow stimulating aranesp be project beat help offset expect sale miss bone health drug xgeva other bone marrow stimulant drug porge say however change price dynamic many amgen product make im adjustment factor less reliable porge write call amgen hike price july bump price cancer drug kyproli april adjust profit share side gilead have chance beat consensus view porge say regeneron vertex also top expectation respectively biogen miss earning view due time research development expense not fully recognize analyst estimate porge say abbvie too be likely miss adjust earning share say afternoon trading stock market today ibd medical biom biotech group be fractionally related surprise spike beleaguered biotech stock gilead acquire biotech vertex be still better analystwhy biotech be poise run topple june
73,REGN,dow jone industrial average be driver seat again monday help strength share chevron cvx boee ba verizon vz technology stock be pressure stock market today hurt part weakness share amazon com amzn fall more test support day move average again share be volatile last week amazon miss earning report strong quarter sale dow add good time high nasdaq composite ease be virtually unchanged volume nyse nasdaq be tracking lower friday level other laggard nasdaq include tesla tsla alphabet googl facebook fb loss tesla be get resistance day move average earning report wednesday close apple aapl slip seek support day line earning be due tuesday close big regional bank outperformed pnc financial pnc gain trade just cup handle buy point bb corp bbt be pace eighth gain session work right side cup shape base share also rise more other news discovery communication disca strike deal acquire scripps network interactive sni include debt share discovery slump more scripps add health care space sanofi sny give back earning miss second straight quarter accelerate sale growth regeneron regn suffer collateral damage fall nearly sanofi say sale eczema treatment dupixent launch earlier year regeneron totale disappointing analyst regeneron be testing day line work flat base ibd essent group esnt picked nearly work flat base entry earning be due friday open downside altrium group mo extend loss fall plunge friday federal regulator vow crack nicotine level cigarette make less addictive related tobacco stock continue fall fda longer safe income play baidu soar other chinese stock try rev clovis regeneron be lead biotech deluge today
74,REGN,blue chip lead stock market midday monday dow jone industrial average head fifth session row outperformance vs major index dow rise nasdaq fall stay flat small cap russell drop volume stock market today be lower major exchange compare friday level integrate oil gas stock chevron cvx aerospace giant boee ba boost component dow jone industrial average advanced chevron be track fifth consecutive day west texas intermediate crude oil be rise day last week wti be try retake barrel price level boee score new high appear head seventh day row boee announce monday expect india order new aircraft next year chicago headquarter company say india aviation market be grow more vs global average ibd proxy top rate stock loser lead winner ratio medical sector stock be take hit centene cnc regeneron pharmaceutical regn align technology algn ibd industry group lowly rate group include office supply coal food score day best gain oil natural gas group suffer biggest loss chicago purchasing manager index july rolled miss consensus view pending home sale june jump easily beating consensus view ishare home construction etf itb retreat track fifth loss session dalla federal reserve manufacturing survey general activity index hit july trouncing view production index rise vs prior close restaurant chain texas roadhouse txrh report quarterly result street expect earning rise cent share revenue be expect rise related have tobacco stock lose safe dividend play
75,REGN,major market index look end july positive note early gain peter rapidly nasdaq lead reversal trading fall dow jone industrial average remain higher rise hit time high soon market open xearly economic news be also weak growth chicago region manufacturing slow sharply july kingsbury international report chicago purchasing manager index slip month steep drop june read gauge lowest read month economist have forecast mild slowdown read month dow industrial boee ba set pace rise more apiece airplane maker add recent gain be more flat base buy point intel intc find resistance try retake day line longtime lead stock fang member facebook fb be hit downgrade early monday pivotal research cause share fall social medium giant be cut sell hold base valuation concern analyst have price target almost discount friday close price fellow fang stock amazon com amzn google parent alphabet googl also trade lower early trade commerce giant drop more company say be be review iran related sale share be trading flat base entry testing day line alphabet fall have be day line relatively disappointing earning release last week finally netflix nflx decline remain solidly nearly new high earning release send share soar july other analyst action ulta beauty ulta be downgrade perform outperform oppenheimer share fall share have be pressure early june fall more high lead biotech stock hold heavy loss early monday regeneron pharmaceutical regn drop stock be back day line first time buy point stock also be build new base ibd china base tal education tal momo momo advanced fractionally china education provider be flat base entry momo be approach cup shape base buy point downside centene corp cnc fall have rapidly approach day line past trading day meanwhile align technology algn moved remain squarely new high invisalign maker surge more friday strong quarterly earning result related apple tesla need know investor next risk facebook overlooked american air be compelling dow jone industrial average dow stock news stock news quote facebook amazon netflix google
76,REGN,pair nasdaq tracking fund be respective buy point tech heavy index climb new high monday powershare qqq trust qqq be buy range rise past entry last week etf rally prior flat base december start pattern just clear pull back rebound day move average mid april set buy opportunity fund have attract march launch be weight technology july consumer cyclical contribute health care top holding apple aapl microsoft msft amazon com amzn facebook fb alphabet googl account nearly asset apple regain day line last week have rally more year iphone maker report fiscal result aug close expect launch upcoming iphone year qqq gain year july respective year period accord morningstar inc have return ytd same timeframe etf carry expense ratio first trust nasdaq equal weight index fund qqew name suggest be equal weight play nasdaq track nasdaq equal weight index be rebalance quarter index be reconstitute december be update year reflect replacement nasdaq index fund top holding be biotechs vertex pharmaceutical vrtx gilead science gild regeneron pharmaceutical regn alexion pharmaceutical alxn netflix nflx be other stock fund have also outpaced ytd return year year accord morningstar qqew launch april be trading just buy point flat base expense ratio be friday etf pick pull back slightly remain respective buy point first trust europe alphadex fep be just flat base entry europe small cap dividend dfe be shy flat base buy point bank homebuilder retail be winning sector early tuesday utility tech health care lag spdr retail xrt rebound regain day line component stock barne noble bks gap soar speculation put sale key index fund spdr dow jone industrial average dium gain spdr spy add powershare qqq trust qqq be fractionally lower remain flat base buy point spdr oil gas exploration production xop leap retake day line hit resistance late january share be still week high vaneck vector oil service oih ishare energy iye energy select sector spdr xle gain more show similar action xop unite state oil uso rise west texas intermediate crude price surge barrel gold play be mixed gold future slip ounce vaneck vector gold miner gdx advanced vaneck vector junior gold miner gdxj dip ishare gold trust iau spdr gold share gld be respectively related retail slip sector gain top fund buy point top growth play buy range gold lead sectorsapple iphone launch timing initial supply subject debate
77,REGN,stock index coast nearly flat finish thursday even major index push new high intraday nasdaq rise be essentially flat blue chip dow jone industrial average fall small cap russell be fractionally volume fall nasdaq rise nyse streak
78,REGN,nasdaq dow hit record high week apple aapl unveil latest iphone model release be delay several week traveler trv other insurer stock rally hurricane irma cause less damage fear tesla tsla break get blame fatal crash oracle orcl give weak guidance bitcoin tumble index rise dow industrial nasdaq hit record high tesla tsla boee ba nvidia nvda square sq be notable breakout week apple drift lower follow release latest iphone insurer rally post hurricane oil stock climb crude future apple aapl introduce generation smartphone splashy medium event new headquarters cupertino calif new flagship handset iphone pronounce be most expensive yet start feature inch oled display sleek new design win be available nov week apple come iphone iphone upgrade model current iphone series phone lcd screen phone hit store preorder start friday iphone phone feature wireless charge augment reality capability apple also trot third generation smartwatch apple watch series have build cellular connectivity well new apple tv set top box stream ultra high definition video share drift lower follow iphone event climb week related late debut iphone disappoint apple investorsu crude future rise barrel intraday thursday key level profitability capital spending plan close week crude stockpile develop country hit fall year average very soon international energy agency say year average be key benchmark opec cartel mull extend output deal russia other opec member iea also see crude oil demand growth fastest year opec say see higher demand oil global market tighten crude inventory rise barrel increase analyst expect energy information administration say domestic crude production rebound barrel day bpd prior week related oil stock eye buy zone crude near investing action plantesla tsla be knock deadly model crash federal investigator say tuesday safeguard be lack autopilot system semiautonomous driver assist feature same day trump administration unveil update safety policy self drive car voluntary guideline make easier auto tech company get test vehicle road offer best practice cull public congressional hearing ceo elon musk tweet late wednesday tesla unveil unreal electric big rig next month tentative oct date be set china plan phase gas power car eventually also be bullish tesla evs generally lithium producer tesla share break base surge week value bitcoin plummet week report china shut exchange trading cryptocurrency have ban initial coin offering exchange btcchina say stop bitcoin trading remark jpmorgan ceo jamie dimon call bitcoin fraud chief economic advisor mohame el erian say bitcoin be far overvalue didn help value cryptocurrency climb much year have plunge month equifax efx ceo richard be set testify house panel oct follow outrage credit report giant handle massive consumer datum breach many consumer identity theft ftc be probe incident reuter report state have come together look breach jpmorgan analyst cut ep estimate roughly wake hack be disclose week company first learn company have be harshly criticize have be see insufficient customer support follow breach have temporarily waive credit freeze fee equifax share plunge nearly week lose prior week oracle orcl report better expect fiscal first quarter profit revenue growth gradually accelerate top bottom line cloud revenue soar business software giant current quarter guidance be midpoint consensus oracle fall friday undercut buy point clear monday day move average related oracle earning top software giant fall outlookinsurer stock include traveler co trv universal insurance uve allstate progressive pgr rally follow report flood hurricane irma not be bad flood hurricane harvey verisk analytic air worldwide estimate insure loss irma less project related harvey netflix nflx cfo david well say stream platform lure away scandal creator shonda rhime have be little bit surprise say still have good relationship disney even disney pull movie netflix well also reiterate company win stop spending money content anytime soon investor expect negative free cash flow continue many year come investor sell cbs cbs share ceo moonfe claim cord cut be good rate tv network jpmorgan jpm say trading revenue be track drop citigroup say trading revenue be head slide period forecast come bank year lap active unexpected event brexit president trump election inspire more bet security bigger market churn goldman sachs gs say fix income currency commodity trading be still pretty challenge introduce plan increase revenue next year bank stock rally bond yield continue climb biotech stock dip week variety notable headline alexion pharmaceutical alxn say cut workforce invest research sage therapeutic sage plummet week low fail result seizure drug trial regeneron pharmaceutical regn also topple month low phase asthma trial meet key goal lag expectation subgroup patient intercept pharmaceutical icpt dove issue letter warning physician overdose patient liver disease drug call ocaliva loxo oncology loxo pop record high set date announce phase datum several cancer jwn share rise wednesday follow report founding family be deal private equity firm leonard green financing help fund deal take upscale department store private mcdonald mcd fall tuesday worst drop year analytic firm science say burger chain domestic same store sale revenue be track miss analyst estimate stock slide come day flat base hit record high wake activist investor scrutiny dowdupont dwdp be tweak way split shift business material science division specialty product division share dow industrial component rise week breaking base hit new high teva pharmaceutical teva rocket announce former nordisk nvo executive take chief executive officer share also rise teva agree sell paragard implantable contraceptive coopersurgical cash
79,REGN,long absence apple aapl make ibd latest monthly list new buy top perform mutual fund get ready unveil latest iphone analyst say launch be delay due production issue tech giant be joined slew medical sector stock include manage care provider unitedhealth unh aetna aet well lead biotech company celgene celg regeneron regn defense contractor boee ba raytheon rtn heico hei also make list tension north korea anticipate defense spending increase be expect drive demand last month top fund manager invest stock list unitedhealth fund invest apple electronic art ea celgene heavy institutional buy have help push apple electronic art celgene new buy zone have already lift unitedhealth buy range see stock watch list be be buy mutual fund manager proven track record success be positive sign mean ve do due diligence see doesn mean stock be necessarily proper buy zone right now more time be need set proper buy opportunity addition apple celgene stock month list be form base buy range also include boee medical software firm cerner cern casino operator mgm resort mgm apple have distinction make new buy screen also top list new sell month net number fund selling apple selling buy be mastercard have second most net seller follow nxp semiconductor nxpi biotech giant amgen amgn number seller stock continue show strength amgen be testing new potential buy zone monday amgen jump past entry heavy volume buy range extend related mutual fund manager be bet tech quality stocksfind track best mutual fund
80,REGN,late stage failure regeneron pharmaceutical regn bolster biotech rival abbvie abbv treat infant infected serious lung disease analyst say late monday xregeneron drug know suptavumab be be develop treatment respiratory syncytial virus common virus lead mild coldlike symptom adult older child be serious infant suptavumab prove efficient subgroup preterm infant test phase trial didn meet goal study regeneron say news release regeneron discontinue development drug find company have decide discontinue development program presumably base limit opportunity such subgroup offer cost conduct pivotal trial leerink analyst geoffrey porge say regeneron failure be abbvie benefit porge say drug be meant be more convenient option abbvie synagis be give patient virus season start month season suptavumab be test milligram single dose dose week apart ibd take ibd company biotech industry group be rank sixth group spiked higher monday biotech fever have chill sector hit month peak late july head ibd industry theme closer look affect sector porge cut revenue forecast regeneron eliminate potential upside catalyst regeneron year cut price target keep outperform rating note strength dupixent eczema drug remain positive regeneron stock base expectation long term dupixent trajectory positive upcoming catalyst dupixent asthma datum supplemental biologic license application say dupixent be approve eczema treatment march be develop regeneron sanofi sny agreement set end year analyst be bullish dupixent be also be look asthma treatment remove suptavumab forecast porge say sale expectation be still ahead consensus porge revenue forecast be north consensus respectively tuesday close regeneron have slip abbvie lose stock market today related generic drug stock catch break mylan crash alnylam report lag sale wider expect lossesthe surprising reason regeneron topple beat raise
81,REGN,stock moved solidly higher gain be begin fade early tuesday federal reserve begin day policy meeting economic news producer price index come unchanged vs expect increase expect nasdaq lead way early advance dow jone industrial average follow gain respectively dow industrial visa microsoft msft pace advancer gain follow closely apple aapl rise early trading blue chip index laggard be merck mrk coca cola ko ethical drug manufacturer drop snack maker fall fang stock rebound nicely early monday day considerable weakness facebook fb amazon amzn netflix nflx google parent alphabet googl rise more video stream giant close day line first time mid april monday look recover tuesday lead stock tesla tsla jump nearly stock market today be upgrade buy berenberg analyst raise price target electric automaker base lack competition other automaker currently build electric vehicle alibaba baba rise remain just time high recent sell tech stock other analyst action include western digital wdc seagate technology stx datum storage provider receive buy rating aegis capital western digital jump almost seagate climb ibd member mercadolibre meli be downgrade neutral goldman sachs prompt latin american commerce company fall open have moved higher action ibd be predominantly positive early trading tech stock snap back recent weakness lead charge upside be lumentum holding lite new oriental education edu ichor holding ichr fiber optic name advanced china education stock rise chip stock ichor moved downside discount retailer decline biotech regeneron pharmaceutical regn drop related fed game plan soothe market wednesdaydow jone industrial average dow stock news analysisno rival tesla see western digital seagate start buyfang stock news quote facebook amazon netflix google
82,REGN,coherus bioscience chrs stock plunge year low monday regulator ask reanalysis datum more information regard copy amgen amgn chemotherapy drug neulasta close bell stock market today coherus share fall share amgen lift news mylan myl stock fall mylan be also work copy neulasta neulasta be bone marrow stimulant design reduce side effect chemotherapy radiation treatment coherus mylan be work copy amgen drug call biosimilar biosimilar be biological medical product be nearly identical copy original drug food drug administration request more datum monday be speed bump coherus fda be ask coherus reanalyze datum show copycat drug provoke immune response well more manufacturing information coherus note news release fda be not ask additional trial cancer patient biosimilar know ch additional trial prompt much bigger delay drug approval be disappoint delay additional request have cause remain confident ability address fda request purpose obtain approval ch chief executive denny lanfear say statement ibd take amgen isn just face neulasta competition regeneron pharmaceutical regn sanofi sny be rivale biotech cholesterol lower drug head ibd breakdown litigation surround company lanfear expect coherus be able respond fda definite path move forward come month approve expect ch generate health saving cost biosimilar be typically less expensive counterpart next mylan have guide late early copy neulasta indian partner biocon evercore analyst umer raffat write note client analyst broadly project neulasta sale topple come year biosimilar chip away consensus model drop wall street see just neulasta sale related teva pharma run migraine trial lilly amgen watch top fund buy biotech ipo small biotech ruffle market migraine drug
83,REGN,regeneron regn sanofi sny rheumatoid arthritis drug be cheaper rival drug amgen amgn abbvie abbv roche rhhby analyst say tuesday duo kevzara grab food drug administration approval kevzara approval come month fda delay approval issue manufacturing french factory drug be filled approval be patient moderate severe rheumatoid arthritis don respond other rheumatic drug approval come time label more less match expectation leerink analyst geoffrey porge say note client kevzara be prescribe alone combination fda approve methotrexate be self administer injection roche actemra belong same class drug kevzara be associate increase risk serious minor infection liver issue injection site reaction also discount actemra annually discount offer cost effective treatment option payer set porge say kevzara cost less amgen enbrel abbvie humira be widely prescribe rheumatoid arthritis different drug class ibd take regeneron be lead biotech resurgence year analyst say head ibd technology page deeper dive amgen gilead science gild biogen biib aren expect be forefront revitalization regeneron sanofi expect european approval come later year see kevzara hit market few week porge see drug minimal driver forecast sale year grow number drug class address rheumatoid arthritis note field be likely become more crowd later year dow component johnson johnson jnj add drug sirukimab lineup more class dub jak inhibitor arrive kevzara contribute approximately expect sale joint sanofi regeneron product fall long term expect growth eczema drug dupixent even cholesterol lower drug praluent rapidly eclipse kevzara importance porge say consensus forecast kevzara sale year grow hit stock market today regeneron stock rise sanofi stock fall share rival amgen abbvie be respectively roche dip related comeback kid regeneron survive amgen cholesterol squeeze regeneron pop better fear eye cholesterol drug sale
84,REGN,stock market open higher major index look cap week record high dow jone industrial average moved nasdaq climb dow industrial financial component goldman sachs gs jpmorgan jpm outperformed second straight day rise respectively early trading blue chip index laggard be visa intel intc fall financial be best performer early friday retail broker trade financial etfc advanced superregional bank comerica cma moved other strong mover include chip designer advanced micro device amd dish network dish rise respectively downside salesforce com crm regeneron pharmaceutical regn trade lead stock graphic chipmaker market leader nvidia nvda continue impressive move breaking base rise additional stock market today meanwhile electric auto maker tesla tsla increase analyst action domino pizza dpz find downgrade buy neutral longbow research share decline remain well flat base entry alibaba baba have price target raise follow thursday surge company raise full year revenue guidance share moved action ibd be mixed early trade stamp com stmp gain look extend day winning streak share be extend cup base entry food delivery platform grubhub grub advanced nearly downside dave buster play fall second straight day drop live video streamer momo momo trade share continue battle support day line related alibaba leverage hailed snap cut user zynga upgradeddow jone industrial average dow stock news analysisapple echo amazon alibaba tesla soar macy warn again week review
85,REGN,major stock index be mixed mostly unchanged afternoon trading thursday money flow bond again year treasury yield be lower basis point yield plunge basis point tuesday take longer term support level economic news weekly jobless claim jump last week well consensus estimate much jump be due hurricane harvey meanwhile consumer confidence hit month high september accord latest read ibd tipp economic optimism index financial lag badly again financial select sector spdr xlf slump nearly give day move average longer term support level stock market today share gopro gpro surge lift outlook current quarter early august maker adventure camera raise sale guidance gopro thursday say sale be high end forecast rh rh vault report solid earning thank fewer product promotion shift membership model makeover distribution network stock be not picture technical health head earning recently find support day move average pullback share abbvie abbv jump positive midstage result trial eczema drug upadacitinib good news abbvie be bad new regeneron regn fall nearly regeneron make compete eczema treatment be approve fda march share abbvie be now extend flat base entry ibd china stock do heavy lift again new oriental education edu surge weibo wb yy yy sina sina show gain range related ibd tipp economic optimism index finally snap year slumpbreaking rh big talk carpe say ceo trump debt deal democrat sink tax cut hope goldman sachs
86,REGN,hurricane harvey irma index other major index edge lower week prior week big gain walt disney comcast cmcsa alert medium news old medium be old news bank tumble fall interest rate tax cut hope unite technology utx agree buy rockwell collin col boee ba objected equifax efx say american be expose massive cyber intrusion index fall week nasdaq composite dow jone industrial average big gain prior week nasdaq test day move average tuesday close key level bank stock break key support treasury yield hit postelection lows medium stock tumble warning be several breakout setup lead stock unite technology utx announce buy aircraft supplier rockwell collin col share share cash rest stock include assume debt make biggest aerospace deal ever boee ba indicated try block deal look keep share lucrative maintenance repair business analyst say unite tech sell build business help unlock more shareholder value unite tech share fall related boee challenge unite tech buyout rockwell credit tracking service discover massive intrusion july disclose incident late thursday american be expose name birthday social security number other datum threaten credit card number consumer certain dispute document personal identify information approximately consumer be also expose top exec include cfo sell share day breach discovery equifax efx claim be not aware cyberattack equifax tumble thursday several cybersecurity stock rally pare gain friday close related equifax american affected huge datum breachwalt disney ceo bob iger say los angele base medium conference earning share current fiscal year end september be line fiscal analyst have see gain disney also say expect stream network now set late have exclusive online right marvel star war content dash hope extend deal netflix nflx meanwhile comcast cmcsa same conference warn video subscriber loss disney share tumble low thursday comcast lose several other medium stock sell well related disney warn profit keep star war marvel netflixcomcast stock plunge video subscriber loss hurricane impactdelta air line dal unite airline ual southwest luv spirit airline save jetblue jblu cut third quarter unit revenue forecast steeper airfare competition rise fuel cost spirit be engage fare war unite cowen say last mid say discounting have spread market represent sale base impact hurricane irma remain unclear friday follow hurricane harvey unite say deliver largest operational impact ve have company history crude stockpile rise barrel latest week energy information administration say slightly more expect gasoline inventory fall barrel less view refinery capacity run well normal many gulf mexico site shut ahead hurricane harvey domestic crude output fall barrel day barrel day week prior crude future edge higher week give nearly gain friday hurricane irma close florida gasoline future tumble spiking prior week luxury furnishing retailer rh rh earn cent share revenue adjust net revenue well estimate cent ep comparable brand revenue grow also top rh up outlook management have bold word ceo tout revolutionary new retail model include restaurant store distribution house last mile delivery initiative share spiked thursday biotech stock be relatively flat rise ibd group track eighth several rise sharply result strong clinical trial datum tuesday insm insm bellerophon therapeutic blph ligand pharmaceutical lgnd pop strong drug trial datum cellect biotechnology apop lift fda grant orphan drug status treatment organ transplant rejection sarepta therapeutic srpt hit month high positive datum duchenne muscular dystrophy trial thursday alnylam pharmaceutical alny sank suspend testing hemophilia trial celgene celg astrazeneca azn rise fda putt several cancer trial full partial clinical hold abbvie abbv rally positive trial datum eczema drug hit share regeneron regn have own eczema treatment largest pure play grocer narrowly top sale same store sale forecast earning come just view margin come pressure kroger kr other grocer be face intense competition long threat online deliver amazon amzn have already cut price just acquire whole food wal mart wmt largest grocery seller have be key driver food price deflation kroger share fall friday related kroger report mixed result shadow amazon wal martthe nissan nsany leaf debut tuesday give popular electric vehicle long overdue design refresh japanese automaker tout new model longer range lower price better performance semi autonomous technology sale nissan leaf have drop fourth place ev segment year tesla tsla model model general motor gm chevy bolt accord edmund tesla less expensive model just roll initial reviews new leaf be mixed call big improvement model tesla sale begin early hewlett packard enterprise hpe report fiscal adjust earning revenue expectation restructure continue ceo meg whitman say not go anywhere have interview uber ceo position recently hpe update guidance account sale software business do not discuss plan return cash shareholder bank america downgrade maker computer networking datum storage system say free cash flow growth be challenged next year hpe share fall arcade restaurant chain dave buster splay raise full year net income guidance previously cut same store sale growth forecast prior view comp growth fall well short estimate ep jump cent easily top view cent revenue climb narrowly miss view share sank nearly week insurance industry software provider guidewire software gwre earn cent share exclude item fiscal fourth quarter year year revenue analyst expect cent fiscal first quarter guidewire guide loss cent share sale wall street be modele profit cent share sale however full year outlook be ahead view guidewire share rise record high close coupa software coup report narrower expect fiscal loss revenue top view competition oracle orcl sap sap enterprise software firm stock initially pop close week fractionally higher target tgt announce friday be slash price thousand item retail competition get tougher target share fall wal mart wmt lose mobile tmus announce exclusive partnership netflix nflx include popular video stream service family plan provide unlimited datum start line monthly exist mobile netflix customer also opt have wireless firm pay bill mastercard touch record high thursday credit card giant raise full year adjust net revenue outlook growth high end low double digit compare earlier outlook low double digit growth china solar company jinko solar jks report second quarter revenue beating consensus adjust earning cent miss consensus estimate cent solar module shipment rise gigawatt industrial distributor hd supply hds report ep rise just beating view adjust revenue climb line management see ep cent better consensus cent revenue midpoint slightly consensus
87,REGN,biotech stock have show somewhat predictable pattern ibd first identify biotech stock industry group innovative power new medicine biotech stock naturally have period steep climb also have sharp sell off monthly chart be easiest place see pattern most recent sell start june
88,REGN,september be make break month number biotechs include alnylam pharmaceutical alny axovant science axon versartis vsar be expect present phase datum upcoming week xbiotech stock be poise run say loncar investment chief executive brad loncar year date ve rise hit month high share have rise follow gilead science gild announcement acquire kite pharma kite come incredibly newsworthy september feature least major medical conference least big investor conference nearly dozen phase trial expect read loncar tell investor business daily be most newsworthy month biotech history say so amazing september be be ton phase trial be schedule read company be go succeed fail trial readout count be make break company loncar say loncar count key trial readout september principal note be alnylam be expect unveil result trial drug dub patisiran rare disease cause buildup abnormal material call amyloid body success be major catalyst technology know rna interference antisense essentially turn malfunctioning gene leerink analyst paul matteis write note client tuesday ibd take novartis ibd relative strength rating be boost friday best possible grade show stock price moved past week other stock database head ibd datum story see novartis stack rival ionis pharmaceutical ion be also work phase drug know inotersen treat disease call ttr amyloidosis matteis call upside depend magnitude success safety downside drug prove effective mixed safety see downside alnylam drug fail completely trial accord loncar most person be convince go succeed cite note see range failure success putt alnylam stock price share close tuesday company window say be bellwether biotech company everyone be count succeed probably trial fail stock crash alnylam loncar note axovant be expect announce result drug dub intepirdine mild moderate alzheimer disease recently biogen biib stock break strong phase datum alzheimer trial axovant be work different theory treat alzheimer intepirdine be know serotonin receptor antagonist have potential cognition memory learn enhance side effect be originally develop glaxosmithkline gsk sell axovant so far nothing have work alzheimer so always excitement trepidation trial readout disease loncar say last december eli lilly lly topple drug solanezumab fail phase trial alzheimer axovant do succeed see stock go day say axovant close tuesday extreme kind euphoria alzheimer create also note trial versartis zogenix zgnx growth hormone deficiency form epilepsy know dravet syndrome respectively win just be september chock full catalyst leerink analyst write note client tuesday solid year return biopharma stock be still number catalyst back half year large cap leerink geoffrey porge note abbvie abbv have datum trial inflammatory cancer drug alexion pharmaceutical alxn be expect grab approval drug soliris treat disease immune system attack healthy cell amgen amgn update label ldl cholesterol lower drug repatha include add benefit cardiovascular outcome meanwhile regeneron pharmaceutical regn sanofi sny be appeal court decision vs amgen rival drug praluent celgene celg have readout ulcerative colitis form hodgkin lymphoma fibrogen fgen be expect have datum fibrosis anemia drug analyst expect vertex pharmaceutical vrtx provide update datum cystic fibrosis trial gilead kite car drug likely be approve treat aggressive form hodgkin lymphoma november follow approval novartis nvs kymriah car drug treat form acute lymphoblastic leukemia patient age expect car remain most closely follow emerge area biotech second half leerink analyst michael schmidt write note launch kymriah read drug bluebird bio blue juno therapeutic juno adaptimmune therapeutic adap related biogen alzheimer drug show promise break partnership bit dust gilead kite break biotech giant close buy novartis cancer approval validate gilead kite dealgilead kite deal boost biotech etf clear buy point
89,REGN,nasdaq composite rise record close thursday index climb fifth straight session fuel several breakout biotech play clear buy point biogen biib bluebird bio blue supernus pharmaceutical supn biotech etf ishare nasdaq biotechnology ibb xbe lookout celgene celg close just entry thursday several biotechs have form new basis nasdaq composite so far week be now just july time high dow industrial be less record level biogen shot thursday stock market trading nearly double normal volume follow gain wednesday biogen soar past buy point consolidation go way back early august biotech long consolidation strong market gain mean stock relative strength line have lag be not great sign biogen report encourage early stage datum alzheimer treatment earlier week ishare nasdaq biotechnology etf better know ibb ticker jump crest buy point short flat base really base base formation ibb other biotech etfs such spdr biotech xbi be way play sector rally avoid company specific blowup weak earning fail drug trial more bluebird bio rocket huge volume month high full point cup base entry bluebird bio be develop car gene therapy treatment cancer have surge week big car news gilead science gild be buy kite pharma kite novartis nvs win first ever fda approval car therapy supernus rise thursday retake flat base entry rebound day move average supernus originally moved buy zone aug have pull back somewhat fashion celgene rise just buy point flat base base base formation celgene edge premarket trading friday suggest open celgene be bigger biotechs partner car play bluebird bio juno therapeutic juno amgen amgn vertex pharmaceutical vrx regeneron pharmaceutical regn be other notable biotechs set new basis related big picture reason be bullish nowbiogen alzheimer drug show promise break breakout prevail new high market pick upbiotech pharma industry newsstock buy watch top ipos big small cap growth stock
90,REGN,new high list wasn overly impressive thursday just day remove wednesday sharp market sell stock reach new high be noteworthy especially re breaking nudge cup shape base entry thursday close just advance volume have
91,REGN,stock stage less spirite advance thursday large cap techs be show more fortitude nasdaq composite be lead major index rise nearly et still well morning high just sliver wednesday walloping nasdaq have gain much early nasdaq get support like apple aapl still extend recent week tight entry point netflix nflx nicely march sturdy uptrend well be slightly outperform gain more apple netflix be recently ibd leaderboard be true leader respective industry still show excellent prospect further top bottom line growth mild gain be sticking lunchtime wall street wake news justice department have appoint former fbi chief robert mueller special counsel investigate potential dealing white house staff russia dow jone industrial average be just break even day slide more pierce day move average heavy volume volume be nyse vs same time wednesday slightly lower nasdaq gain roughly boost strength biotech sector news come well follow asco conference regeneron pharmaceutical regn incyte incy sage therapeutic sage bluebird bio blue be top gainer ibd biotech industry group regeneron hold best ibd composite rating good reason revenue have grow more fold past year be recognize leader treatment reflect excellent science have change face treatment age related macular degeneration regeneron stop lose money earn share earning have grow almost year then share stock have bounce nicely hit week low august last year now be work first stage bottom base pattern street see regeneron earning lift year share other rise industry group stock market today include diversify operation medical software fabless semiconductor chipmake fiber optic gear shire group shpg meanwhile advanced nearly heavy trading further add distance day move average positive datum treatment hereditary angioedema shire part ethical drug industry group regeneron be still early stage form right side potential new basis important have patience see other name beaten medical industry group flex enough price strength get proper position break market general price volume action note wednesday big picture column represent notable change character institutional investor compare prior decline dow key intermediate term support line therefore ibd change current outlook confirm uptrend uptrend pressure meaning new buy be permissible be do extra caution dow industrial accumulation distribution rating be now yet still positive ibd accumulation rating cover week worth price volume action grade higher indicate mutual fund hedge fund insurer pension bank be overall accumulate equity see general market indicator page be pdf link find bottom big picture column day least name member dow jone industrial average still have accumulation distribution rating higher good sign see stock rating top dow jone daily chart link small cap also rebound yet rather meekly compare wednesday carnage smallcap rally sink too fall sharply day move average wednesday low be time high other financial market wti crude oil continue rebound fading dollar rise nearly hit month high gold future comex cool nearly troy ounce have bounce more hit low yield year treasury bond continue sink edge yet accord latest analysis fed fund rate future cme group probability new basis point hike short term interest rate federal reserve june meeting be still more related market direction go ibd daily big picturebear bite bank techs hard gold continue rebound investor corner be week tight pattern incyte team dow merck trounce roche case new bull run gold
92,REGN,new high be understandably rare stock index be selling wednesday market do feature stock make new high red robin rrgb gap gain stock close volume be red hot small cap company report quarterly result close tuesday earning come cent share
93,REGN,regeneron pharmaceutical regn vertex pharmaceutical vrtx alexion pharmaceutical alxn look likely catch next wave biotech analyst say friday suggest year sector be slate boom win be value stock gilead science gild amgen amgn biogen biib drive boom leerink analyst geoffrey porge tell client note large cap drag performance index exchange trade fund growth stock already seem be capture sustain new investor interest say advice investor remain identify scrutinize evidence competitive advantage look management maximize profitability exist business first foremost ibd company biom biotech industry group be first month finishing boom year stock tack growth group close stock market today such be pattern biotech market porge say typical correction run quarters follow year sideway performance today much excitement mid have dissipate leave share long term median relative multiple consensus expectation biotech sale profit have decline respectively last year sign be get better porge say first quarter result yielded mixture positive negative result vs consensus prompt additional negative revision so far quarter estimate have be remarkably stable ibd take regeneron stock outperformed broad market plunge thursday top saucer buy point head ibd new high list look other strong performer political pressure be also begin subside say president trump have promise introduce competitive system cut escalate drug price meanwhile industry have seemingly begin self regulate drug pricing be exception biogen ionis pharmaceutical ion spinraza spinal muscular atrophy drug debut year treatment first year porge see price tag regeneron sanofi sny eczema drug dupixent price roche rhhby multiple sclerosis drug ocrevus more reasonable furthermore manufacturer establish brand be take more modest price increase fewer be adopt voluntary price increase limit remain too high be step right direction porge say approval many time earlier expect have accelerate year food drug administration hit year low so far year drug have grab fda approval match total last year label also appear broader meaning drug have greater use porge see number drug launch come next month outdo consensus view key be gene therapy rare disease treatment end stage cancer therapy severe disease create process harness rna molecule inhibit certain gene process finally validate capital be invest remarkable technology boom year have seeming head disappointment many point bust last month porge say related biogen takeover prospect soured mere comeback kid regeneron survive amgen cholesterol squeeze
94,REGN,major market index edge higher morning trade thursday tech heavy nasdaq aim extend winning streak day set record high rise inched take new high own dow jone industrial average moved dow industrial nike nke look break again flat base entry stock market today share moved almost higher morgan stanley upgrade apparel maker overweight equal weight initially stock break june solid earning release downside home depot hd be dow big loser day decline heavy volume possibly response deal sear holding shld begin offer kenmore appliance online amazon com amzn sear share shot amazon rise home depot share have be consolidate break day move average june american express axp fall company announce strong earning result raise loan loss provision second quarter today fall stock be still hold flat base buy point other company report earning mobile tmus turn early gain slight loss meeting resistance day line late wednesday cellular provider top earning sale estimate meanwhile mining giant alcoa aa reversed early loss rise warning higher input cost reduce full year net performance share be still build right side potential cup shape base other analyst action tesla tsla be initiate neutral citigroup share rise remain stick day line lead stock fang member facebook fb moved higher initially report indicated company be plan launch subscription base news product edge lower social medium giant be track record high have rise last trading day ibd regeneron pharmaceutical regn yy yy be early advancer rise respectively regeneron be cup shape base entry yy continue add gain flat base entry downside flooring retailer floor decor fnd fall company price secondary offer discount wednesday close price stock have be trading day line fail ipo base buy point related mobile smash second quarter earning dow giant buy range ahead earning investing action planfang stock news quote facebook amazon netflix googledow jone industrial average dow stock news analysis
95,REGN,merck mrk cholesterol bust drug isn strong wall street initially thought analyst argue tuesday dow component say hold filing application sell medication regulator drug know anacetrapid reduce heart attack cardiac death need certain heart surgery patient already receive cholesterol lower drug know statin merck note anacetrapid continue build fat tissue issue have be discover earlier study leerink analyst seamus fernandez say ultimately prevent merck filing drug approval believe mention press release highlight potential long term regulatory concern believe require very robust impact key cardiac event death merck file anacetrapid say merck didn look anacetrapid ability cut stroke be typically goal examine cardiac benefit cholesterol lower drug fernandez write note client consider file approval food drug administration merck plan unveil full trial result european society cardiology meeting august ibd take ibd stock regeneron pharmaceutical regn have approve cholesterol bust drug partner sanofi sny know praluent praluent be face competition litigation amgen amgn repatha head ibd see regeneron look fare court battle still evercore analyst umer raffat argue merck file approval drug be know cetp inhibitor most analyst didn expect drug succeed trial only expect anacetrapid work say ultimately be need add control statin write research report need modestly more benefit consider merck vytroin now anacetrapid patient need much more benefit consider used be call pcsk inhibitor like regeneron sanofi amgen say stock market today share merck component dow jone industrial average slip end regular trading session related dow merck be still beating bristol roche immuno oncologybiotech stock growth positive trial result near buy zone
96,REGN,bellwether johnson johnson jnj second quarter report bode well biotech sector analyst say tuesday dow component top profit expectation narrowly lag sale view stock market today stock climb biotech stock drop nearly group generic drugmaker inched leerink analyst geoffrey porge remain bullish biotech sector needham analyst mike matson say second quarter result point stable period medtech player boston scientific bsx medtronic mdt stryker syk zimmer biomet zbh quarter drug sale grow sequentially fall vs year earlier period porge partially blame time positive rebate adjustment eliminate year year volume price growth second quarter sale remicade decline year year rivalry biosimilar contribute just decline be lower guidance decline porge write note client ibd take cancer rare disease specialist be expect do well second half positive sentiment return biotech space visit ibd industry snapshot look outperform second quarter also expect currency headwind subside second half call acceleration pharmaceutical unit well positive trend sale outside base presume currency impact firm raise outlook adjust profit share outside drug sale grow sequentially second quarter beating view growth porge say support expectation sequential outside revenue growth company due weaken dollar second quarter say porge expect guidance increase biotechs second quarter earlier week call regeneron pharmaceutical regn easily beat june quarter sale view gilead science gild handily top profit expectation cover company not be negatively impact same prior period adjustment current imminent biosimilar competition surprise consensus remicade market dynamic be view proxy say abbvie abbv see pain sale cancer drug imbruvica grow outside say be partner abbvie imbruvica typically book imbruvica sale porge say translate abbvie imbruvica sale be miss vs consensus estimate say abbvie imbruvica be consider largest growth driver humira patent cliff continue miss consensus expectation repeat second quarter be negative stock related star align biotechs crush earning consensusthese drug giant buy range just beat earning novartis fda cancer also be boon rival
97,REGN,key index cool tuesday volume heated vantage point daily chart action appear be more step forward step back nature nasdaq composite still premier index lead broad decline drop follow tuesday gap
98,REGN,major stock index strengthen late afternoon trading thursday sharp loss wednesday higher volume put market uptrend pressure outperformer dow jone industrial average include wal mart wmt share rise wall street seem focus jump commerce sale dow component cisco system csco meanwhile plunge report earning issue tepid guidance nasdaq rise help strength chip stock nvidia nvda skywork swks analog device adi show gain more dow add volume nyse be tracking higher wednesday level nasdaq volume be bit lower year treasury fall basis point plunge basis point wednesday odd interest rate hike fed june meeting have be fading recent day stock market today share facebook fb rally unfazed news be fine european union mislead statement acquisition messaging service whatsapp alibaba baba reversed higher rise fall much intraday investor initially focuse earning miss other metric look good include rise sale company also announce share buyback elsewhere leaderboard name trade desk ttd re-cover nicely wednesday rout share jump extend buy point biotechs be move headline flow asco cancer conference chicago incyte incy soar news immuno oncology drug prove effective merck mrk keytruda treat patient advanced lung cancer incyte impressive move thursday still day move average potential resistance level watch other big gainer biotech group include regeneron regn share rise early stage clear cup shape base buy point related incyte team dow merck trounce roche canceralibaba earning miss revenue soar share falter nvidia stock price target hike macom rate buy
99,REGN,medical related exchange trade fund have rac healthy gain year ongoing quest longer healthier life outperformer be ishare medical device ihi gain year date well ahead gain period fund boast year average annual return vs benchmark index accord morningstar inc ihi launch track dow jone select medical equipment index top holding etf include medtronic mdt abbott laboratory thermo fisher scientific tmo abbott developer generic drug disease screening system other product be buy range clear flat base entry thursday xihi be etf pick featured ibd last month oscar pursche chief executive bruderman brother bruderman asset management opposed take broad view health care sector do overall see great opportunity medical device space investor get exposure ishare medical device etf say also note fund top holding account nearly portfolio increase risk profile ihi be extend past buy point clear april ibd take find biotechs stand benefit most president trump propose tax reform recent tech column spdr health care equipment xhe return ytd year average year old fund track health care equipment select industry index have gather asset top holding include align technology algn intuitive surgical isrg edward lifescience ew account portfolio xhe be trading record high be extend recent bounce day line spdr biotech xbi year have average annual gain past year fund launch january be form flat base buy point entry still july peak vertex pharmaceutical vrtx regeneron pharmaceutical regn abbvie abbv be top name hold xbi top holding make asset related be best health care etf gop move replace etf ride industry recovery
100,REGN,regeneron pharmaceutical regn stock pop month high thursday biotech report sale fail meet view weren dire analyst fear eye drug eylea cholesterol drug praluent first quarter close bell stock market today regeneron stock leap touch high last achieve november surpass potential buy point first quarter end march regeneron report adjust income share revenue respective analyst have expect earning share sale globally eylea sale grow vs year earlier quarter consensus leerink analyst geoffrey porge write note client eylea sell miss analyst view outside sale lag porge say sale be nowhere fear downside ibd take biotech investing be oftentimes matter simply pick right stock catalyst get most attention head ibd technology page better look stock be poise do well praluent be weak sale come consensus model sale grow vs year earlier quarter praluent rival amgen amgn repatha be know pcsk inhibitor regeneron blame adjust earning miss higher expect taxe quarter regeneron paid taxe consensus expectation company also announce positive result eczema drug dupixent phase trial inflammation esophagus associate chronic allergy immune condition present full result trial later medical conference dupixent also be pediatric trial year moderate severe eczema year old patient uncontrolled persistent asthma year old year regeneron reaffirm guidance single digit growth eylea also expect lower reimbursement partner sanofi sny expense guide earlier view related do regeneron sanofi just launch blockbuster drug amgen trip rival sale miss earning topamgen trump regeneron sanofi cholesterol drug sale
101,REGN,esperion therapeutic espr rocket nearly year high tuesday bump timeline file application food drug administration cholesterol lower drug xin midday trading stock market today esperion pop hit high last see late august share break cup buy point june be now almost extend point esperion say tuesday plan file application fda bempedoic acid combination used bempedoic acid ezetimibe first quarter move timeline quarter bempedoic acid be be study phase trial method lower bad ldl cholesterol patient high risk cardiovascular disease trial be fully enrolled month esperion say biotech also announce topline result phase trial bempedoic acid combo used ezetimibe atorvastatin vs placebo patient high cholesterol week study combo lower ldl cholesterol baseline vs placebo patient treat combo see ldl cholesterol lower more baseline patient achieve ldl cholesterol level less milligram less milligram be consider optimal esperion note serious side effect combination include increase liver enzyme needham analyst chad messer see trial result help drive adoption bempedoic acid doctor patient statin ibd take ibd company biotech industry group be now rank fourth group track gain spot last week recent hot streak send higher head ibd industry theme deep dive analyst also expect bempedoic acid be competitive class drug know pcsk inhibitor amgen amgn regeneron pharmaceutical regn sanofi sny have drug class bempedoic acid be expect have lower price believe represent largest commercial opportunity bempedoic acid write note client messer keep buy rating esperion boost price target related news esperion reiterate desire attract large global regional pharma partner maximize commercial potential bempedoic acid messer note firm emphasize doesn see beholden timeline deal esperion wrapped second quarter cash guide cash year end expect cash hand be sufficient early readout phase trial bempedoic acid messer write related esperion break cholesterol tie dow merckesperion medicine co recover amgen induced pitfallesperion dive amgen heart study pricing
102,REGN,mylan myl hit year low take generic drug stock report second quarter metric lag wall street cut guidance next year then re-cover post slight gain wednesday xon stock market today mylan end trading day earlier fall much hit low last see june be sixth consecutive day mylan have spend red follow disappointing report fellow generic drugmaker teva pharmaceutical teva crash initially send ibd company generic drug industry group much sector re-cover recent trade rise nearly close still taro pharmaceutical taro collegium pharmaceutical coll perrigo prgo remain respectively second quarter end june mylan report sale year year miss consensus adjust earning share lag cent fall revenue north america be hit hardest sale europe rest world grow respectively vs year earlier period sale epipen injection allergic reaction decline due increase competition ibd take mylan have ibd composite rating meaning perform bottom half stock term key growth metric get look better rate stock ibd stock checkup mylan also cut guidance sale adjust profit share now see adjust earning least earlier view new target be expectation midpoint give region ongoing challenge uncertain regulatory environment have elect defer major launch full year financial guidance include generic advair copaxone mylan say news release advair be used prevent asthma attack flare up chronic obstructive pulmonary disease brand glaxosmithkline gsk mylan other be work generic version food drug administration delay mylan application drug mylan other be also work generic version teva multiple sclerosis drug copaxone lose key patent earlier year medicine company mdco pop lag second quarter revenue loss beat expectation promising clinical update include ldl cholesterol lower drug rival amgen amgn regeneron pharmaceutical regn sanofi sny medicine co note second quarter come agreement regulator europe drug inclisiran cholesterol buster total expect enroll patient phase trial design support submission application approval inclisiran be know pcsk synthesis inhibitor have slightly different mechanism psck inhibitor amgen regeneron sanofi medicine co be also work study patient determine cardiovascular benefit inclisiran second quarter end june medicine co report sale miss consensus analyst poll zack investment research revenue adjust loss share widen cent loss year earlier period top consensus view adjust loss share medicine co lift close related tesaro beat sale view loss nektar miss teva crash day be hurt generic drugmakersmylan fda limbo generic multiple sclerosis drug
103,REGN,alnylam pharmaceutical alny report quarterly metric lag view late wednesday keep guidance announce plan file application key drug end year xin hour trading stock market today alnylam lift fraction end regular session share have be form flat base buy point late june second quarter end june alnylam revenue spiked miss analyst view loss share widen share loss year earlier period miss consensus loss share be shape be pivotal year alnylam chief executive john maraganore say statement next few week alnylam plan announce top line result phase study drug call patisiran patisiran be be develop treatment hereditary attr amyloidosis rare condition abnormal protein build multiple organ damage impede positive result support alnylam filing application fda patisiran end year launch mid assume approval alnylam say news release ibd take alnylam have ibd composite rating best possible meaning outperform stock term key growth metric still lag ibd biotech leader celgene cr head ibd stock checkup list top rate biotechs hemophilia drug fitusiran recently begin phase trial year end alnylam plan begin phase trial givosiran acute hepatic porphyria series disorder involve buildup chemical body medicine company mdco alnylam be also work inclisiran drug combat high ldl cholesterol approve inclisiran rival similar drug amgen amgn product jointly develop regeneron pharmaceutical regn sanofi sny alnylam maintain guidance end more cash equivalent fix marketable security include restrict investment related alnylam have edge smaller biotech rare disease be gilead fortune change acquisition biotechs gain last week keep go
104,REGN,regeneron pharmaceutical regn dove week low thursday light revenue eczema drug dupixent weigh stock broader second quarter beat raise dupixent lag have be baked leerink analyst geoffrey porge say late monday partner sanofi sny report lighter expect sale dupixent second quarter regeneron crash day sanofi report share continue fall thursday stock market today regeneron topple earlier fall low low last see june sanofi other hand lift quarter end june regeneron report sale top consensus analyst poll zack investment research grow adjust income advanced share beating view sale eylea grow year year easily top analyst model porge write note client outside eylea sale narrowly miss consensus view ibd take analyst have tap regeneron most likely beat earning expectation head ibd technology page other second quarter biotech prediction period cholesterol drug praluent nearly double top consensus porge say praluent be face patent battle amgen amgn repatha class drug call pcsk inhibitor dupixent sale be line consensus lag porge model earlier week sanofi report dupixent sale miss most estimate regeneron also note contract sanofi win be renew come agreement regeneron sanofi have develop drug include praluent dupixent kevzara rheumatoid arthritis drug approve year company continue develop commercialize drug together agreement expire regeneron also boost guidance growth sale eylea vs earlier view single digit percentage growth regeneron now expect sanofi reimburse also predict lower tax rate vs prior model related sanofi earning spook regeneron share week lowteva pharmaceutical miss earning cut guidance stock divesallergan boost outlook beating forecastswhy clovis regeneron be lead biotech deluge small biotech launch month high today here way
105,REGN,regeneron pharmaceutical regn tank week low tuesday wake partner sanofi sny report lag sale dupixent spooking investor worry prescription eczema drug be slow xon stock market today regeneron dove share trade well day move average fall flat base begin form late june buy point regeneron be set report second quarter earning early thursday analyst poll zack investment research expect report adjust income share sale sanofi second quarter report be tell several key drug sanofi report dupixent sale miss view accord reuter sell side analyst see buy side analyst modeled credit suisse analyst althea young say early sign dupixent launch be encourage view key question be patient growth continue be bolus upfront write note client physician have written dupixent prescription thus far result quarter full year young see number grow prescription end third quarter year end call sanofi say prescriber target company have written prescription dupixent lion share prescription have be most severe patient meaning still room grow key question come month remain drive prescriber put more patient drug write be get more comfort reimbursement used drug ibd take biotechs have be hot streak recently be now rank fifth group track ibd slip spot last week merger acquisition send higher say industry observer head ibd industry theme breakdown leerink analyst geoffrey porge other hand say dupixent launch be indeed flatten still be patient moderate severe eczema meaning dupixent hasn yet hit ceiling sanofi also plan launch dupixent germany year regeneron sanofi be also look dupixent asthma sanofi say expect final result asthma phase trial future look bigger picture regeneron stand chance narrowing valuation gap sanofi come year duo be joined hip partnership feature regeneron research development sanofi wallet sanofi have say remain very very commit make praluent success praluent be pcsk inhibitor aim lower bad cholesterol currently lock patent battle amgen amgn also have psck inhibitor know repatha be also finishing registration trial pd inhibitor form skin cancer plan file food drug administration early next year drug possibly rival similar cancer medicine dow merck mrk bristol myer squibb bmy regeneron sanofi be also look pd inhibitor advanced lung cancer second form skin cancer duo also plan combine pd inhibitor drug several trial related clovis regeneron be lead biotech deluge todayhow astrazeneca fail not once twice cancer drugsdow merck crushed keytruda sale view
106,REGN,boost explosive earning growth recent quarters recent gain fellow biotech stock celgene celg exelixis exel regeneron regn innoviva inva see sharp improvement relative strength rs rating monday rise ibd unique rs rating measure market leadership used worst best score indicate stock price action last week match other stock decade market research show stock go make biggest gain often have rs rating north launch biggest climb see innoviva continue rebound clear threshold innoviva be try complete cup handle buy point monday rise light trade close entry see stock break volume least average company show ep growth latest quarterly report putt average gain last quarters sale growth have slow triple digit growth recent quarters still strong company earn rank peer medical biom biotech industry group celgene supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
107,REGN,biotech stock celgene celg regeneron regn biogen biib spinoff bioverativ bivv move cancer drug developer exelixis exel be track new several day big gain biotech sector regeneron bluebird bio blue pull back friday celgene bioverativ continue climb afternoon trading friday stock
108,REGN,biotech stock reversed course friday day run month high regeneron pharmaceutical regn bluebird bio blue lose most cara therapeutic cara defy trend xon stock market today bluebird bio stock topple share regeneron close intraday lows close week strong gain cara stock lead sector biotechs trading stock lift cara win breakthrough designation drug treat itch chronic kidney disease patient group sell didn last long ibd company biotech industry group dip intraday then close nearly run june analyst credit rally subside concern president trump tackle drug price analyst see potential upside sector bluebird stock plunge unveil early result drug call lentiglobin patient pair blood disorder characterize low production abnormal hemoglobin patient reduce hemoglobin be able discontinue blood transfusion month treatment lentiglobin bluebird say separate study patient blood disorder prove stable year follow exciting see patient have go year regular blood transfusion year single blood transfusion time treatment lentiglobin gene therapy say marina cavazzana investigator study ibd take rally see share celgene regeneron break help exelixis stock buy point head ibd industry theme complete breakdown sector benefit still rally regeneron stock pitfall follow detail royalty agreement novartis nvs thursday deal regeneron receive royalty sale ilaris inflammatory have strong datum week heart attack survivor cara stock other hand pop receive breakthrough designation food drug administration drug know cr patient chronic kidney disease experience itch result dialysis fda deny breakthrough designation request more often approve janney analyst ken say research report now see cara drug gain priority review once company submit application related biotech rally still tack upsidenovartis pop month high strong trial heart attack survivorsthese biotechs be lead sector month high today
109,REGN,cara therapeutic cara stock launch nearly year high friday chronic liver disease drug grab breakthrough designation beating odd food drug administration stock market today cara stock pop earlier rise much touch high last see august share break cup handle pattern wednesday hit buy point only third application breakthrough designation fda be approve janney analyst ken say note client july march fda approve just request receive cara drug know intravenous cr receive breakthrough designation treat chronic liver disease patient experience itch result hemodialysis see cara drug get priority review now have achieve new designation drug priority review be typically approve month vs typical month review process ibd take analyst predict biotech surge small cap innovative techs lead charge oncology focuse drugmaker kite pharma be predict run head industry snapshot closer look have buy rating price target cara stock friday cara share defy broad dive biotech sector follow day run view president trump pledge reduce drug price be merely lip service ibd company biotech industry group rebound morning retreat climb nearly rally prior trading day bluebird bio blue regeneron pharmaceutical regn stock be hardest hit respective related biotechs hit pause day rally regeneron bluebird topplewhy biotech rally still tack upsidethese biotechs be lead sector month high today
110,REGN,major market average erased early gain stock market today nasdaq composite turn lower nasdaq fall dow jone industrial average advanced less supreme court lift ban president trump travel ban order foreigner majority muslim nation unclear move have impact open weak durable good order have little impact durable good order fall vs expect decline dow industrial financial component goldman sachs gs american express axp lead way rise respectively apple aapl moved more intraday trade late morning action iphone maker be attempt recapture day line downside performer be limit exxon mobil xom pfizer pfe fall micron technology mu jump freeport mcmoran fcx rise well session high martin marietta material mlm advanced graphic chip maker nvidia nvda reversed trade move lower be incyte incy humana hum qorvo qrvo
111,REGN,analyst action stock market today ibd stock regeneron pharmaceutical regn grubhub grub find downgrade early monday red hot biotech trade be moved market perform outperform sanford bernstein share food deliverer fall nearly morgan stanley downgrade firm equal weight increase competition ubereat grubhub be now well buy point
112,REGN,meanwhile retailer coach coh costco cost be upgrade coach be upgrade buy neutral buckingham research costco be moved outperform market perform raymond james share coach rise costco advanced be try end deep slide
113,REGN,fang stock be motion early monday lead early advance also late morning retreat facebook fb fall hit record high intraday netflix nflx sank amazon amzn google parent alphabet googl lose respectively
114,REGN,alphabet waymo announce deal monday rental car giant avis car avis manage waymo fleet autonomous vehicle avis share rise more
115,REGN,ibd chip stock macom technology solution mtsi ichor holding ichr jump respectively well session high macom be extend ichor be rise sharp pullback week average china education stock tal education tal follow rise be rise support again day line
116,REGN,downside medidata solution mdso fall veeva system veev decline be extend most recent entry
117,REGN,related
118,REGN,durable good order fall business investment weak
119,REGN,costco upgrade grubhub downgrade amazon effect paypal pt hike
120,REGN,dow jone industrial average dow stock news analysis
121,REGN,fang stock news quote facebook amazon netflix google
122,REGN,analyst action stock market today ibd stock regeneron pharmaceutical regn grubhub grub find downgrade early monday red hot biotech trade be moved market perform outperform sanford bernstein share food deliverer fall nearly morgan stanley downgrade firm equal weight increase competition ubereat grubhub be now well buy point meanwhile retailer coach coh costco cost be upgrade coach be upgrade buy neutral buckingham research costco be moved outperform market perform raymond james share coach rise costco advanced be try end deep slide fang stock be motion early monday lead early advance also late morning retreat facebook fb fall hit record high intraday netflix nflx sank amazon amzn google parent alphabet googl lose respectively alphabet waymo announce deal monday rental car giant avis car avis manage waymo fleet autonomous vehicle avis share rise more ibd chip stock macom technology solution mtsi ichor holding ichr jump respectively well session high macom be extend ichor be rise sharp pullback week average china education stock tal education tal follow rise be rise support again day line downside medidata solution mdso fall veeva system veev decline be extend most recent entry related durable good order fall business investment weakcostco upgrade grubhub downgrade amazon effect paypal pt hikeddow jone industrial average dow stock news stock news quote facebook amazon netflix google
123,REGN,wall street be bullish regeneron pharmaceutical regn chance selling eczema treatment comeback kid be see rival amgen amgn squeeze opportunity cholesterol medication analyst say friday afternoon trading stock market today regeneron stock dip first loss trading day share begin form cup november possible buy point leerink analyst geoffrey porge classify regeneron comeback kid credit firm bring growth back sector keep outperform rating regeneron stock raise price target follow regeneron early thursday first quarter report sale narrowly top view grow adjust income share be lag cent higher expect taxe eczema drug dupixent see strong launch prescription written fourth full week nearly increase number prescribe physician dupixent be first injectable drug treat eczema be resistant topical cream regeneron say median time fill written dupixent prescription be approximately week suggest total filled prescription volume grow substantially have be filled accord health care tracker im ibd take have trouble navigate volatile biotech sector porge other analyst say stock picker market head ibd technology page tip pick better biotech stock canaccord analyst john newman upgrade regeneron stock buy rating price target also note enthusiastic dupixent sentiment estimate sale dupixent reach sale hit estimate include only moderate severe eczema suffer likely first candidate dupixent newman project share eczema dupixent peak sale porge note softness other area regeneron eylea sale be flat vs prior quarter grow year year still miss consensus eylea be elephant room call miss consensus only question be ask drug write note client reaction investor be relatively muted downside add however give eylea sale constitute vast majority regeneron revenue least next year revenue trajectory remain very important watch leerink porge note look cholesterol lower drug praluent lose quite bit share quarter regeneron report praluent sale miss consensus regeneron sanofi sny praluent co developer be engage patent battle biotech amgen judge recently ban sale praluent siding amgen stay ban pending appeal several month amgen unveil result year study drug repatha time repatha be able cut risk heart attack stroke lower bad ldl cholesterol didn trim risk cardiovascular death study have implication other ldl cholesterol lower drug include regeneron sanofi praluent not yet approve drug medicine company mdco esperion therapeutic espr appear regeneron partner sanofi have lose significant share possibly price rival amgen district court decision possibly associate amgen positive cardiovascular outcome datum quarter porge say related regeneron pop better fear eye cholesterol drug salesdid regeneron sanofi just launch blockbuster drug amgen trip rival sale miss earning top
124,REGN,re national basketball association playoff want steph curry lebron james team re manage retirement account taxable portfolio not tap fidelity investment brain trust include army analyst know cumulative stock move fidelity many mutual fund help choose own buy sell not fidelity fund make same buy sell instructive see lead stock fidelity overall bet more shareholder money first quarter lighten weighting normally have track then sift security exchange commission filing fidelity stock balanced fund cfra independent research firm have do crunch number already cfra find be fidelity biggest sector weight be information technology consumer discretionary end fidelity have nearly shareholder money work tech have more shareholder cash place consumer discretionary stock head economically sensitive information technology stock be poise benefit risk environment say todd rosenbluth cfra director etf mutual fund research further fidelity offer number growth oriented strategy tend favor tech stock fidelity largest stock position stock balanced portfolio paypal pypl qualcomm qcom be tech sector stock fidelity complex increase share count percentage most fidelity add share paypal increase add share qualcomm hike fidelity contrafund fcntx firm largest stock mutual fund magellan fmagx be fund investing paypal latest disclosure fidelity otc focpx balanced fbalx fund be holder qualcomm still fidelity make even bigger percentage increase share count lyondellbasell industry lyb add share fund fidelity share count jump nearly netherlands base company make chemical polymer be used packaging home furnishing automotive component material manufacturer stand benefit global expansion gdp such appear be underway fidelity magellan balanced otc fund be investor lyondellbasell drugmaker amgen amgn have third largest percentage boost share count fidelity fund share boost be increase amgen be lead seller ldl cholesterol battle drug judge recently side amgen patent lawsuit regeneron pharmaceutical regn sanofi sny ruling be appeal fidelity select biotechnology fbiox blue chip growth fbgrx fund be amgen holder fidelity fourth largest share count percentage hike be charter communication chtr fidelity increase nearly share be boost charter be stock ibd telecom service integrate industry group earning share rise latest quarter rise sale year sale growth rate be ibd take see charter additional easy understand fundamental technical datum stack rival ibd stock checkup fidelity dividend growth fdgfx trend fund be charter investor fidelity build qualcomm share be fund family fifth biggest increase boost citigroup goldman sachs gs be next largest percentage increase fidelity boost share count citigroup share increase step share goldman sachs be also increase related be fidelity recent stock buy sell retirement account hot sauce st here fidelity have be buy sellingwhy many millennial retirement saving be more twice baby boomer
125,REGN,regeneron regn sanofi sny eczema drug dupixent outstripped psoriasis drug rival company fourth week prescription analyst write monday suggest consensus view drug be beatable friday sanofi say earning call prescription have be written physician dupixent first month market health care tracker im suggest prescription be filled fourth week dupixent launch comparison prescription psoriasis drug novartis nvs cosentyx taltz eli lilly lly have be written point follow launch celgene celg otezla have script most successful drug have be otezla fourth week dupixent launch be double prescription volume otezla leerink analyst geoffrey porge write note client also note recent successful launch cholesterol lower drug amgen amgn repatha regeneron sanofi praluent see prescription otezla estimate monthly net price period be be likely net price dupixent porge write adjust only higher price dupixent sale be base otezla sale record however dupixent indeed continue see double prescription volume otezla revenue be closer beat compare consensus say early post launch information thus far be very encourage ibd take do survive investing market relatively unheard company esperion therapeutic espr launch nearly mere month matter identify right catalyst analyst say head ibd technology page more base sanofi disclosure written dupixent prescription first month porge model fill rate april grow fill rate december more payer open access lead potentially prescription filled fifth week be not unreasonable give prior week week growth prescription porge say analyst broadly model dupixent sale second quarter third fourth porge see dupixent sale grow comparatively otezla cosentyx bring first quarters market comparison dupixent be more expensive otezla significantly cheaper cosentyx be enter much less competitive category more untreated patient appear be faster access major pharmacy benefit manager formulary write porge reiterate outperform rating price target regeneron stock stock market today regeneron stock be sanofi stock fall related amgen trump regeneron sanofi post trial cholesterol drug scriptsamgen payer pushback likely sting battle regeneron sanofiregeneron sanofi get approval eczema drug price
126,REGN,do get handle biotech market unknown stock esperion therapeutic espr nearly january outperform like industry top name amgen amgn sure esperion have have breakthrough cholesterol medication amgen recently have own moment cholesterol drug prove decrease bad ldl cholesterol also cut risk heart attack stroke still amgen isn get respect smaller biotech player be get comparatively paltry year don get discourage analyst say just amgen isn get lot love doesn mean other biotech stock be slouch really question navigate be complex sector leerink analyst geoffrey porge say biotechs have do well election stock be subject whim political debate drug pricing health care re worry donald trump health care reform re worry fda reform now re worry drug pricing regulation say just doesn seem accumulate worry be go go away hurry overall group look strong now rank group track week be rank ibd take drugmaker allergan be sweeping medical aesthetic market hologic want play head industry snapshot breakdown battle porge mizuho analyst salim sy call stock picker market biotechs be bound do well number catalyst still ahead other be more likely struggle macroeconomic politic be still pressure investor need be cognitive drug pricing sy tell ibd folk thought be presidential platform topic keep come now postelection ibd company biom biotech industry group be year major exchange trade fund ishare nasdaq biotechnology index ibb spdr biotech xbi be respectively top biotechs include amgen gilead science gild celgene celg biogen biib regeneron pharmaceutical regn have be news none stock price amgen have gain most gilead lag january sy have buy rating amgen celgene gilead stock neutral rating biogen stock smaller player potential takeout candidate incyte incy tesaro tsro have see big gain wall street tesaro be likely remain stand alone company grab fda approval ovarian cancer drug zejula stock rise much mid february be now only year incyte other hand have tack january rumor biotech gilead be look acquire incyte open gilead oncology world hepatitis franchise struggle high cure rate once again re start year best perform stock be be cheapest more takeout candidate porge tell ibd so make prediction have definitely be somewhat challenge earlier month nektar therapeutic nktr stock hit year high strong datum pain pill be alternative potentially addictive oxycodone nektar stock catapult single day share extend cup handle formation late march have give back gain stock remain year other big stock earner include kite pharma kite bluebird bio blue be work drug class call car cell therapy drug engineer patient immune cell treat cancer kite stock be whopping lead rise bluebird stock esperion rocket amgen heart study so too do medicine company mdco share be january porge list medicine co stock watch note spectacular return have right stock right set event then still generate incredibly attractive return excitement biotech porge say be company be approach critical readout ongoing development program investor think reasonable chance critical trial critical milestone turn positively mizuho sy suggest look individual stock equity rather hope broad biotech resurgence see good number catalyst market note drug pricing debate be likely still weigh market president trump have key drug pricing debate limit detail say have plan competitive base system bring price drug trump pick run fda scott gottlieb have say drug pricing need be more transparent struggle unfold porge layer rule pick biotech stock likely have better return want be growth company early life cycle treat very serious illness say follow rule be generally go end portfolio go perform better average better index better benchmark rule porge say epizyme epzm vertex pharmaceutical vrtx alexion pharmaceutical alxn be interesting epizyme stock be january have top buy point cup handle formation early february vertex stock have gain year alexion stock be actually year date stock fit bill used porge rule rare disease company be work drug treat disorder central nervous system blood disease genetic disorder worst thing do biotech investing be sell just stock be porge say don hesitate buy stock same reason axiom investing biotech be always never want say not go buy stock be industry routinely see tenfold increase value cycle emergence product say so often see stock investor say only go market cap market cap scheme thing be pretty small say have real drug re go be company related esperion medicine co recover amgen induced edward best stock own gilead be pay price actually cure disease
127,REGN,major stock index be listless late afternoon trading thursday dow jone industrial average show small gain less nasdaq fall modestly xin stock market today several earning report spark bullish gap price ubiquiti network ubnt vault entry pull back bit share still soar telecom infrastructure firm report fifth straight quarter sale growth ibd component stamp com stmp meanwhile gap rise buy point do postage firm be hold day move average ahead earning stock be extend price now accord nasdaq com share be hold short july total float so good bet part today surge be due short cover tesla tsla gap day move average rise nearly second quarter sale more double consensus estimate end year tesla hope be build model sedan week end video game maker take interactive surge past buy point earning sale blow past analyst estimate share jump tableau software datum gap flat base buy point share gain technical picture be strong fundamental be bit hazy company report second straight quarter decelerate sale growth be different story biotech regeneron regn solid earning raise guidance share pop early be afternoon trading get resistance day move average economic news weekly jobless claim fall ahead friday employment report be expect show job growth close watch earning report apply optoelectronic aaoi arista network anet impinj pi mercadolibre meli universal display oled related here analyst don tesla top stock be soar buy zone big number stock friday job report isn jobsstamp com deliver strong earning report stock surprising reason regeneron topple beat raise
128,REGN,stock open tightly mixed trade quickly fade narrow loss thursday strong early move wal mart wmt tesla tsla dow jone industrial average open fraction higher then fall back just breakeven line fight hold level index top first time wednesday trade drug distribution giant abc centurylink ctl drop more apiece weak report nasdaq composite notch incremental decline apple aapl backed surge wednesday fang stock post early loss lead netflix nflx slip dow wal mart unitedhealth unh lead index wal mart jump open unitedhealth rise caterpillar cat open boost upgrade neutral underweight atlantic equity tesla share rac gain company late wednesday report show smaller forecast loss forecast revenue growth tesla share be consolidate find resistance week move average tight close past week suggest institutional support stock form possible floor base effort online postage innovator stamp com stmp be early hero report solid beat second quarter earning revenue soar management also lift full year earning revenue guidance consensus view gap gain left ibd stock extend first test week support late ibd name regeneron pharmaceutical regn tack gain report late wednesday second quarter earning past analyst target revenue also top view management sale guidance regeneron eyelea drug be better expect stock be work sixth week flat base offer buy point hotel operator wyndham worldwide wyn book early gain single digit growth second quarter revenue earning best analyst estimate company make official plan split publicly trade entity wyndham share be trading just buy point week flat base aetna aet power strong second quarter result lift share easily new high injured list system ddd fall teva pharmaceutical teva skid lower weak second quarter report early job datum be positive employer announce layoff worker july june smallest count november accord monthly job report consultant challenger gray christmas employer also announce hiring best july total record first time unemployment claim ease week end july labor department report be prior week claim consensus view new application claim have remain generally consider level show healthy job market week et ihs markit deliver service sector estimate july june factory order number commerce department july service index institute supply management be due et overseas market asia book broad loss thursday hong kong hang seng index nikkei tokyo fall europe major index remain widely mixed afternoon trade london ftse lead gain bank england elect hold interest rate unchanged trim growth forecast next year frankfurt dax drop related get grubhub game face too investing action big picture apple break factor soured be apple be bullish sale not iphone
129,REGN,major market index moved lower early trading thursday tech heavy nasdaq decline respectively dow jone industrial average dip less xamong dow industrial wal mart store wmt reclaim cup shape base entry rise early trade ahead next week earning release downside chip giant intel intc drop give back week gain have lift stock back day move average line late wednesday tesla tsla exceed earning forecast revenue more double share have be languish day line race ahead attempt reclaim key level electric automaker be build right side potential base clear entry be evident other company report earning payment processor square sq fall top expectation raise full year outlook stock have have tremendous move so far more flat base buy point last week high stock be approach day line video game maker be show solid action stock market today take interactive software report solid earning spark rally share stock jump back cup base entry competitor electronic art ea activision atvi report own earning bell thursday advanced respectively lead biotechs regeneron regn earning beat send share surge initially turn red fall stock have see heavy selling pressure week head release wednesday session meanwhile recent spinoff bioverativ bivv also beat street target wednesday send share higher stock have moved back buy range cup handle buy point ibd stamp com stmp be clear winner soar almost beating top bottom line estimate company also raise full year profit outlook downside masimo masi plunge top street profit revenue forecast share have be build cup handle view daily chart entry never break instead stock break day line huge volume related tesla second quarter result beat model production rampsapple set soar buy zone ceo tease plansdow jone industrial average dow stock news analysisbiotech stock watch pharma industry news
130,REGN,stock index grip slender gain midday thursday strength biotechs offset weakness chip stock celgene celg be lead big cap biotechs add gain recent nasdaq composite dow jone industrial average rise et small cap russell add just volume stock market midday be run higher nyse lower nasdaq biotech industry group be track fifth consecutive daily gain action group be bullish regeneron pharmaceutical regn push higher stock be now buy point celgene head ninth gain session stock add almost midday thursday clear buy point wednesday buy zone be capped bioverativ bivv february initial public offer new member leaderboard slow gain breaking monday stock remain buy zone buy point bioverativ regeneron celgene have ep rating respectively mean be grow earning faster entire ibd database publicly trade company biotechs hustle higher past few day be still post annual loss investing company be lose money be not prudent action point conviction group go thursday market biotech group be group week biotechs be meanwhile chip designer chipmaker chip equipment maker group be moderately oil stock be rebound west texas intermediate crude oil pop price crude oil recently touch month lows blue chip be evenly split day day dow jone industrial average component wal mart store wmt drop unitedhealth unh rise ahead news senate be set unveil new plan reform affordable care act ibd proxy lead stock medical software provider medidata solution mdso lead thrust president trump be work executive order ease regulation drugmaker new york time report tuesday related morgan stanley say trump tax plan be delayedapple face delay smartphone update
131,REGN,nasdaq composite index dow industrial rise slightly thursday more stock set new possible entry sound basis here be big cap stock be buy point amgen amgn general motor gm visa mastercard asml asml pnc financial service pnc xgeneral motor have market cap smallest visa amgen gm mastercard asml edge past entry point intraday close market uptrend be pressure earning season kick high gear so investor be especially cautious take new position now amgen rise thursday stock market trading biotech stock rise high briefly pass buy point cup handle base couldn hold level volume be normal highest week amgen hasn be market leader lately relative strength line be well recent high amgen lag index several other biotechs include celgene celg regeneron regn have already break general motor rise high thursday afternoon briefly pass cup handle entry gm settle gain slightly average volume meanwhile fiat chrysler fcau volkswagen vlkay clear buy point thursday follow move ferrari race wednesday general motor rs line have be lag meanwhile auto sale have peaked shift suv truck purchase be support profit visa climb intraday new time high not quite trigger buy point flat base visa reversed close mastercard edge cent rise intraday briefly top flat base entry volume be average visa mastercard rs line be high reflect strong performance short consolidation however several other payment stock have break week include paypal pypl square sq visa have earning next week few other card firm such american express axp be still range june meanwhile jpmorgan chase jpm citigroup well fargo wfc pnc financial provide insight credit card trend friday second quarter earning report conference call chip equipment giant fall second straight day asml inched past buy point flat base go back nearly month asml rs line be high good sign asml report quarterly earning next week pnc financial be superregional bank be overshadowed money center bank jpmorgan citigroup well fargo pnc be expect deliver ep gain larger rival deliver essentially flat profit pnc rise build entry shallow cup handle base jpmorgan be still range double bottom base citigroup be extend well fargo be close buy point cup handle pattern related big picture analyze apple stock big bank earning duepeak auto auto stock be buy zone be group smaller stock outshine big gunsjpmorgan citigroup well fargo earning be tepid so be bank stock hot
132,REGN,nasdaq composite wednesday deflect yet pound crude oil future related company stock market move moderately higher dow jone industrial average harbore light loss late wall street regular session nasdaq composite new york time be stretch year date lead fractionally wednesday dow jone industrial show distribution day past session volume wednesday be run higher nyse vs same time tuesday lower nasdaq ibd big picture column track heavy institutional selling form distribution day witness nasdaq tuesday higher volume monday sudden rash big decline heavier volume prior session be enough bull market nasdaq be nearly jan towering advance dow jone industrial average be also lag gain so far year buy biotech software sector continue unabated aftermath solid quarterly result like adobe system adbe extend january red hat rht also extend early entry long choppy first stage base biotech group jump ibd industry group term month relative price performance celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx pump more higher heavy turnover show kind action see iphone giant apple aapl big run mid early part celgene have market value regeneron be vertex vs iphone ipad macbook maker stock break tend already be close week time high already be trading day move average show tremendous increase share volume show strong finish session price definitely case biomedical name mentioned be highly profitable developer novel therapy address difficult disease chronic condition celgene run higher power past cup base buy point volume be currently triple usual level stock day average volume be share cup be see part long saucer base go way back july peak notice weekly chart celgene have break month saucer pattern july do hairpin curve lower undercut low base such action be healthy shakeout uncommitted investor reset base count back street see first quarter profit summit firm rise share celgene have post ep increase prior quarters celgene sport outstanding composite rating ep rating ibd stock checkup watch see relative price strength score improve term regeneron composite rating ep rating be extend first stage bottom base entry share have soar more so far week however notice weekly chart stock run upside resistance price level vertex composite ep surge fast turnover be move further past recent handle long base give solid entry cent intraday high handle stock slope lower intraday lows correct more back apple megacap tech be show still have wherewithal recover sharp sell prior week trigger key sell signal read stock market today column learn more exact sell rule apple gain volume be light stock be limit drop day move average apple relative price strength rating remain strong now much better lowly see start year however keep mind rs rating cover month worth price action vs rest market extra weight be give most recent month worth action be plenty reason long term holder thick profit cushion keep hold apple be still well long term day move average earning picture be improve fy profit see fy profit revenue growth apple service unit be currently solid double digit pace likelihood major iphone replacement cycle begin fourth quarter current calendar year be very high ibd take way track emerge industry sector rotation market be watch change ibd right now still chock full electronic internet computer networking related stock medical biotechs stage larger presence go here day watch new leader unfold present wonderful new opportunity investing profit ibd tech leader nvidia nvda coherent cohr apply optoelectronic aaoi have re-cover nicely price spill prior week remain solid uptrend related investor corner bottom base make money astute tradersinvestor corner ii apple form bottom base be market head correction soon check big simple way detect key stock market best brightest large cap land today big cap
133,REGN,american airline aal spirit airline save be upgrade tuesday regeneron regn be downgrade rockwell collin col have price target raise american airline be upgrade overweight neutral have price target be raise jpmorgan analyst also upgrade spirit airline overweight neutral cut budget carrier price target analyst jamie baker write american management have more aggressive focus revenue doesn expect round layoff anytime soon labor efficiency productivity improve monday cowen upgrade american say airline outlook next year be compelling segment more product last week american report strong result predict weaker unit revenue do spirit american share rise stock market today spirit jump baird downgrade regeneron underperform share tumble monday french partner sanofi say sale eczema drug dupixent fall short expectation regeneron fall tuesday tumble day move average rockwell collin be upgrade buy canaccord genuity have price target raise rockwell face increase competition boee ba boee enter avionic space monday boee say have already start work build aircraft control electronic military civil space vehicle aviation giant be just work component own aircraft first eventually start selling other aviation company canaccord analyst ken herbert write boee announcement represent long term risk believe col be relatively well protected market rockwell have very strong reputation boee airbus top preform supplier rockwell share rise plunge monday boee fall discovery disca price target be lower fbr co announce monday buy scripps network sni deal give company nearly fifth ad support television discovery slide tumble monday related risk facebook overlooked american air be compelling
134,REGN,major market index rally modestly dow jone industrial average hit fresh time high earlier index advanced tech heavy nasdaq climb briefly turn negative xamong dow industrial financial component jp morgan jpm goldman sachs gs set pace rise more downside pfizer pfe decline report mixed result tuesday drugmaker top earning estimate fall short revenue side share have be consolidate mid thirty year longtime lead stock fang member amazon amzn advanced early trade attempt recapture day line be lose monday heavy volume armour uaa beat top bottom line estimate early tuesday disappoint investor lower full year guidance newly announce restructure cut workforce share fall nearly have languish price level late january stock have fall high september other apparel retailer also feel burn foot locker fl ralph lauren rl decline respectively stock be trading day line other company report earning leader be breaking stock market today cognex cgnx be breaking cup shape base stock market today rise blast buy point machine vision system maker beat estimate raise revenue forecast meanwhile shopify shop jump session high buy point finally investor turn attention apple aapl close release earning analyst expect iphone maker earn share revenue year year increase respectively share edge higher analyst action regeneron pharmaceutical regn fall monday decline early tuesday robert baird downgrade biotech underperform neutral share fall day line first time ibd essent group esnt advanced cautiously approach flat base entry downside china base yirendai yrd plunge result thin stock be still cup base entry related apple tesla need know investor next armour top view cut guidance announce jone industrial average dow stock news stock news quote facebook amazon netflix google
135,REGN,clovis oncology clvs regeneron pharmaceutical regn be biggest biotech stock loser monday news related clinical partnership bristol myer squibb bmy sanofi sny respectively xin early trading stock market today clovis topple close announce immuno oncology partnership bristol myer test combination drug call rubraca opdivo treat breast ovarian prostate cancer broadly biotechs be decision come heel recent deal tesaro tsro takeda pharmaceutical astrazeneca azn dow merck mrk clovis tesaro astrazeneca have drug call parp inhibitor be consider strong drug used battle ovarian cancer clovis case pairing bristol myer close door term acquisition leerink analyst michael schmidt say note client previously clovis have only free parp inhibitor not otherwise tie deal top rival investor have hope acquisition clovis bristol myer term think deal doesn preclude future acquisition company view increase competitiveness value rubraca write schmidt keep outperform rating clovis stock call pitfall buy opportunity see clovis benefit more bristol myer partnership astrazeneca deal merck astrazeneca sell half right parp inhibitor lynparza get access merck pd inhibitor keytruda clovis other hand keep ownership rubraca ibd take biotech stock be now rank fifth group track ibd slip spot last week merger acquisition send higher head ibd industry theme closer look potentially shopping spree matchup have parp inhibitor pair pd inhibitor immuno oncological combination thought generate more robust response drug alone deal clovis share half development cost combination bristol myer importantly clovis gain access lead pd inhibitor clinical development expertise bristol myer schmidt write meanwhile regeneron tank finish regular trading session french partner sanofi report sale eczema drug dupixent miss expectation accord reuter first full quarter dupixent pull miss consensus view analyst expect dupixent be key drug regeneron sanofi already approve have receive positive recommendation european regulator approval duo be also look dupixent severe asthma intercept pharmaceutical icpt too plunge follow second quarter earning report adjust loss grow share be better analyst forecast loss sale top view dynavax technology dvax other hand catapult close earlier rise much food drug administration panel vote recommend safety hepatitis drug support approval treat adult typical hepatitis medication be administer dose month dynavax say news release drug dub heplisav be dose twice month dynavax hope launch drug early related astrazeneca fail not once twice cancer beat stock dife drug failure more reportdow merck crushed keytruda sale view
136,REGN,jpmorgan large cap growth fund seegx be barrele fast lane manager giri devulapally fuel lot financial technology stock include morgan stanley ms mastercard apply material amat ibd friday rally broad market midday key fund holding be rise too chip gear maker apply material be internet television network netflix nflx be regeneron pharmaceutical regn maker eylea macular degeneration eye treatment be consumer electronic colossus apple aapl be credit card provider visa be fund be year go friday top large cap growth fund peer track morningstar inc averaged be mutual fund gain past month top peer well have fund achieve such eye pop gain start fund investment approach fund literature boil target company large market sustainable competitive advantage strong price momentum large cap growth fund seek harness return potential america fastest grow company fund be rare naming strong price momentum trait seek stock indicate acknowledgement technical analysis play important role stock selection financial tech be jpmorgan large cap growth largest sector overweight june vs benchmark russell growth index devulapally recently tell shareholder financial still have positive view company exposure capital market interest rate information technology overweight add continue be drive variety industry such payment semiconductor video game software mobility outlook have lead devulapally fund such holding money center bank morgan stanley stock be so far year brokerage charle schwab schw year benefit float customer cash float be profit cash time customer authorize disbursement cash actually leave account rise interest rate lift profit float tech stock grouping credit payment processor mastercard be year chip gear maker apply material be ibd take apply material be member ibd list stock strong relative price strength fundamental video game publisher electronic art ea member ibd be year earning share grow past quarters nice rally prior quarters ep fall software space digital medium marketing software firm adobe system adbe vault past wall street estimate fiscal second quarter june report accelerate sale earning growth period also guide analyst higher ep grow past stanzas digital medium segment provide total corporate revenue online payment processor paypal pypl ibd stock be year other holding vertex pharmaceutical vrtx have ibd composite rating share price have soar year strong datum triple pill treat underlie genetic mutation tie cystic fibrosis have be key driver stock biotech company expect spend more research development cost year continue development triple pill graphic chipmaker nvidia nvda yet member ibd benefit shift more use graphic process unit away regular cpu computer chip faster process speed application such gaming artificial intelligence self drive car ep grow triple digit pace past quarters nvidia be stock ibd electronic semiconductor fabless industry group earn spot part post jump sale last quarter annual pretax margin compare other technical fundamental strength rival ibd easy use stock checkup tool else do fund have go large cap stock mutual fund have outperformed other diversify stock fund category past month well past year reflect fund commitment large cap stock own dow jone industrial stock visa microsoft msft apple home depot hd visa be also fund payment stock be year software titan microsoft be year iphone maker apple year be devulapally mobility stock home improvement retailer home depot fall nearly tuesday company report result beat wall street expectation ibd report analyst see potential slowdown stronger full year outlook pull back thursday friday share be year related reynold american bolster jpmorgan large cap growth make boss add
137,REGN,amgen amgn stock topple hour trading wednesday report first quarter sale miss increase competition key drug arsenal enbrel bone marrow stimulant neupogen biotech giant say sale enbrel neupogen fall respectively meanwhile sale anemia drug epogen fall due decline net selling price higher demand help sale spike several drug include repatha amgen bad ldl cholesterol buster repatha sale pop year year worldwide competition like regeneron regn sanofi sny quarter end march amgen report adjust profit share vs year earlier quarter top consensus sale dip miss analyst view hour trading amgen stock be close fraction regular session share be currently form flat base buy point have trade day move average mid march be well position long term newer product demonstrate value growth world tight operational expense management company say chief executive robert bradway statement ibd take dow johnson johnson jnj report drug sale advanced just see ibd technology page multiple issue be bleak harbinger sector quarter amgen unveil result trial last more year dub fourier patient take cholesterol lower medicine reduce bad ldl cholesterol blood lead decrease risk heart attack stroke amgen find analyst have say amgen be face pushback payer don want reimburse wholesale acquisition cost repatha regeneron sanofi esperion therapeutic espr be work same area add robust repatha outcome datum be work payer improve access important therapy patient risk heart attack stroke key spike quarter include sale bone drug prolium xgeva respective revenue multiple myeloma drug kyproli grow blincyto second line treatment chromosomal disorder leukemia see sale grow amgen boost guidance adjust profit share lag consensus year year basis adjust profit be midpoint guidance sale guidance be reiterate related amgen rival pop cholesterol bust drug
138,REGN,biotech amgen amgn likely have wall street tune wednesday first quarter earning call see long term cholesterol study prompt stronger reimbursement trend amgen first quarter earning be set market close wednesday street broadly view sale profit grow vs year earlier quarter particular note be amgen comment study cardiovascular benefit lower bad ldl cholesterol trial last more year dub fourier amgen find ldl cholesterol lower drug repatha cut risk heart attack stroke coronary didn reduce risk cardiovascular death result have read like regeneron regn sanofi sny medicine co mdco esperion therapeutic espr be work ldl buster drug regeneron sanofi praluent be closest mechanism repatha regeneron sanofi be embroil patent battle amgen judge recently side amgen say praluent infringe patent repatha praluent stay shelve pending outcome appeal process analyst also look more color ongoing litigation ibd take biotech exchange trade fund be fire march anything send higher head ibd etf page deep dive consensus street widely expect amgen report adjust earning share sale respectively vs year earlier period guidance second quarter analyst expect amgen guide sale adjust earning share analyst see sale adjust earning share year stock action midday trading stock market today amgen stock be fraction share have trade day move average march related amgen trump regeneron sanofi cholesterol drug biotechs save drug sector notregeneron sanofi look crush amgen rival say
139,REGN,biotech amgen amgn trump regeneron regn sanofi sny week prescription ldl cholesterol buster repatha outstripped praluent figure analyst say friday analysis prescription trend repatha prescription rise week week praluent prescription fall mizuho analyst salim sy write note client march amgen release result study matter dub fourier conduct period more year repatha script be praluent close stock market today amgen stock fall share regeneron lose sanofi be regenero sanofi be partner praluent ldl cholesterol battle amgen regeneron sanofi stem ongoing patent lawsuit judge recently side amgen say regeneron sanofi infringe pair patent ruling protected repatha ban sale praluent praluent remain shelve pending appeal process praluent repatha be pcsk inhibitor work block interaction pcsk protein ldl receptor cut bad ldl cholesterol blood ibd take earning season kick analyst be hesitant drug biotech space dow component johnson johnson announce first quarter drug sale advanced just report highlight multiple issue sector affect head ibd technology page closer look fourier study find cut bad cholesterol lead reduction risk heart attack stroke coronary do not cut risk cardiovascular death still amgen be hopeful study help persuade payer reimburse patient cost cholesterol reduce medication analyst be doubtful payer see year fair value repatha amgen charge amgen datum get backup regeneron sanofi medicine co mdco regeneron sanofi be enrolling higher risk patient similar trial year medicine co be also plan heart study cholesterol drug sy have buy rating price target amgen stock related regeneron sanofi look crush amgen rival say canesperion medicine co recover amgen induced pitfallamgen tank heart study share other drugmaker tumble
140,REGN,biotechs software lead solid nasdaq advance dow jone industrial average index hit record high boee ba announce slew paris air show order oil price keep fall fed clear big bank annual stress test china crack weibo wb amazon amzn spook more retailer nasdaq rise week biotechs other medical soar ease fear price control also reaction senate gop health bill celgene celg be biotech breakout regeneron pharmaceutical regn soar buy range desktop software also be big winner oracle orcl breaking earning amazon fear intensified apparel sporting good story dow industrial index hit record high monday pare gain weakness oil retail stock dow finished fractionally higher rise biotech stock surge week concern president trump tamp drug price begin subside big winner rally include regeneron pharmaceutical regn celgene celg pop nearly respectively clovis oncology clvs spiked strong trial datum suggest much wider use ovarian cancer drug analyst call growth stock gain most see rally continue traditional drug giant also fared well novartis nvs breaking buy point merck mrk near entry boee ba beat airbus eadsy commercial jet order paris air show event typically win european aerospace giant boee say have incremental order commitment airplane value list price analyst say staggering boee order show weren firm airbus say book firm order plane value memorandum understand aircraft value analyst weren expect many deal paris order be double see last year show farnborough england boee share rise week hit new high airbus set record high monday pare weekly gain related boee paris air show order be staggering hybrid design new boee midrange jet hit sweet spotwhy lockheed move production india texasoracle orcl earning easily top view revenue advanced software giant overall cloud revenue shot vs year earlier oracle have be latecomer demand cloud software shift transition be full force now share surge breaking record high meanwhile other software database leader soar record high stronger expect earning adobe system adbe raise guidance report ep gain fiscal red hat rht ep climb fiscal revenue rise open source linux software provider also give bullish current quarter guidance adobe rise red hat climb crude oil price fall month lows week continue oversupply concern weekly crude stockpile fall barrel energy information administration say double be expect domestic crude production nudge barrel day meanwhile libyan oil production rise sharply dispute end german oil company export nigeria be expect hit bpd august vs bpd july accord reuter saudi arabia deputy crown prince moham bin salman be appoint heir kingdom throne be widely expect continue current oil policy be major force riyadh saudi vision reform initiative aim curb country reliance crude related oil reverse sharply lower supply fearsjpmorgan jpm bank america bac nation biggest global bank have enough capital continue lend economic meltdown first round federal reserve annual stress result show none bank test have key capital level minimum set fed bank stock generally edge lower friday wall street attention turn result second portion exam come wednesday portion determine bank give buyback dividend ultimately firm pass fail test quantitative qualitative ground jpmorgan bofa goldman citi well fargo pass fed stress testchina order weibo wb other online platform shut audiovisual stream presumably user content violate country political standard weibo tumble thursday majority owner sina corp sina lose alibaba baba own big minority stake twitter twtr weibo edge lower momo momo yy yy social medium firm lot stream video sell initially momo close yy pare loss sina momo yy be ibd stock related weibo crackdown spur selling not panic china internetsamazon strike fear more retail group slam many apparel sporting good chain commerce giant announce amazon prime wardrobe home try system let user have more item ship free try home then be charge keep hit macy jwn tjx tjx more meanwhile bloomberg source say nike nke sell footwear directly amazon brand registry program send share already reel dick sporting good dks foot locker fl other sharply lower finish line finl rebound friday mixed quarterly result meanwhile whole food market wfm push little further share takeover price amazon lead wonder bidder be ready emerge even bigger offer barclay say not be surprised be be bidding war jpmorgan analyst have peg wal mart wmt possible contender reuter report late friday wal mart be not plan whole food bid whole food close week hit friday afternoon related here latest group have amazon induced anxiety attackprime wardrobe be amazon kill macy fashion game uber technology founder travis kalanick resign chief executive officer follow shareholder revolt ride hail company have be expose have workplace culture include sexual harassment discrimination uber also have be lose market share lyft twitter twtr stock rise bullish research report say struggle company have improve video strategy execution report come same day twitter announce way person earn money stream live periscope video service snapchat operator snap snap be increase pressure instagram story feature facebook fb have grow user vs snapchat snap be trading close ipo price advanced micro device amd surge nearly week launch latest server processor datum center amd new epyc server chip compete processor industry leader intel intc join amd launch event austin texas be customer partner back epyc include microsoft msft azure baidu bidu dell technology dvmt hewlett packard enterprise hpe intel share fall low share fedex fdx rise week hit record high move buy range package delivery giant easily top expectation fiscal fourth quarter tuesday shake ep miss last quarters earning climb jump revenue investment modernize aircraft fleet expand ground operation paid fedex guide full year profit high rival up announce monday charge retailer extra fee holiday delivery fedex say consider shipping giant be challenged key customer amazon amzn expand own delivery service related fedex easily top earning revenue forecast guide profit highstrong suv truck sale help drive board beat wednesday used car superstore carmax kmx first quarter ep climb almost year year rise revenue total unit sale used vehicle jump even large medium suvs truck accounting bigger share mix average used vehicle price fall vs year earlier accelerate drop prior quarter flood lease car be hit pricing reason new car sale be slumping carmax rise week msci msci tuesday finally greenlighted inclusion mainland china stock key emerge market index wall street have be closely watch decision several fund include ishare emerge market etf eem track be benchmark index china weight benchmark jump upward current move surprised market msci have give red light mainland stock share previous try eqt corp eqt agree buy rice energy rice deal set close create largest natural gas producer strengthen eqt position marcellus utica shale region accenture acn report line fiscal profit report top line growth slightly view new digital cloud security product service reach revenue management commentary weakness health care market send share
141,REGN,regeneron pharmaceutical regn stock rocket month high tuesday loom launch novartis nvs drug likely chip away regeneron blockbuster eye disease drug eylea stock market today regeneron stock pop touch first time early january settle back gain share hit buy point mid saucer begin form november stock be now extend novartis be early tuesday novartis say drug know brolucizumab prove inferior regeneron eylea pair phase trial examine patient eye disease cause vision loss call wet age related macular degeneration amd more half patient trial be able be dose week less frequently week schedule patient regeneron eylea leerink analyst geoffrey porge note research report brolucizumab likely be highly competitive eylea say trial be signal brolucizumab be able gain meaningful market share wet amd segment physician patient preference less frequently administer medicine say ibd take regeneron stock be be watch list head ibd industry theme closer look make regeneron peer interesting right now brolucizumab also prove safe allay concern cardiac toxicity severe vision loss crop phase testing phase study also look brolucizumab vs lucentis be market roche rhhby novartis outside north america porge note novartis win be able file food drug administration give regeneron time continue build eylea sale eylea be biggest value driver regeneron porge say outside eylea regeneron be likely continue do well partnership sanofi sny have yielded recent launch eczema drug dupixent kevzara drug treat rheumatoid arthritis related biotechs be lead sector month high todaysmall biotech pop rival novartis struggle keep tesaro overcome clovis lead combo merck co
142,REGN,xstock moved mildly lower friday nasdaq dow industrial dip slip slip tech heavy nasdaq composite be pace weekly gain come consecutive week relatively heavy loss dow jone industrial average show fractional loss week edge early friday defend slim gain week dow industrial upside advancer be scarce jpmorgan jpm coca cola ko procter gamble pg cling small gain downside unitedhealth group unh caterpillar cat fall home depot hd nike nke decline eqt eqt align technology algn pace upside advancer rise respectively downside sysco corp sys drop signet jeweler sig decline harley davidson hog fall analyst action restoration hardware rh vertex vrtx receive upgrade cause retailer vertex reversed lower early gain meanwhile piper jaffray hike price target electronic art ea jpmorgan initiate coverage servicenow now overweight rating share ea servicenow fall earning front bloodbath brick mortar store continue stock market today bed bath bbby fiscal result late thursday retailer miss top bottom line estimate result plunge stock price meanwhile finish line finl revenue come street estimate early friday share still advanced nearly lead retailer ollie bargain outlet olli burlington store burl haven be spare sector carnage last month have see ollie fall back week line be attempt muster support burlington plunge day line thursday early friday ollie decline burlington fall ibd grubhub grub jump macom tech solution mtsi rise momo momo advanced downside regeneron pharmaceutical regn fall mercadolibre meli decline video game maker activision blizzard atvi trade related earning calendar analyst estimate stock watcharista network ea get pt hike logmein rate buy lumentum holddow jone industrial average dow stock news analysisfinish line sale miss amazon nike threat rattle sectorretail commerce news stock watch
143,REGN,biotech stock celgene celg bluebird bio blue regeneron regn biogen biib spinoff bioverativ bivv move cancer treatment developer exelixis exel be poise pop new buy zone exelixis share price have soar week follow confirmation positive result phase trial so call cabosun trial compare cabozantinib exelixis used
144,REGN,celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx lead biotech sector more upside follow second quarter analyst say thursday share trek fifth straight day xat close bell stock market today ibd company biotech industry group be trading month high leerink analyst geoffrey porge credit lack drug pricing headwind day uptrend current rally reflect lift perceive fear pricing regulation favorable tone fda do not yet reflect more positive operate result not mention industry consolidation still expect write note client porge expect industry tack upside follow likely be strong second quarter earning season biotech stock have add june thursday leader include number small cap trading riser porge prefer call growth stock celgene regeneron vertex alexion pharmaceutical alxn mid regeneron stock have add follow gain celgene vertex stock gilead science gild perform worst only gain be still higher overall market say major biotech index have add last month broader market have only tack growth ibd take analyst begin predict biotech rally last month be sign benefit most head industry snapshot closer look analyst have say reason sector surge be fear be subside prospect president donald trump take action curb pricing analyst now say trump rhetoric tamp pricing appear be lip service wall street expectation amgen amgn gilead regeneron second quarter earning have dip last month revenue view have be largely flat decline amgen gilead large cap biotechs have beat second quarter view gain upside porge say last year large cap have beat second quarter expectation time amgen celgene gilead beating view time guidance increase be more likely second quarter first say expect biotech sector rally much compare long term relative multiple vs medtech pharma sector related small biotech pique interest gilead other biotechs surge generalist return subside trump biotechs be lead sector month high today
145,REGN,stock pare early loss thursday tech heavy nasdaq lag major index slip trim early loss trade effectively flat dow jone industrial average edge positive territory dow industrial unitedhealth group unh caterpillar cat be lead advancer rise xon downside wal mart store wmt nike nke decline apiece staple spls advanced private equity firm sycamore partner reportedly say acquire office supply company other advancer include airliner medical stock american airline aal moved delta airline dal southwest airline luv rise almost ibd member regeneron pharmaceutical regn incyte incy moved respectively downside mallinckrodt mnk decline accenture acn trade china stock sell stock market today chinese government crack weibo wb audio video service weibo fall sharply majority owner sina sina drop jd com jd edge lower alibaba baba moved netease nte trade earning front oracle orcl jump almost exceed fiscal earning sale estimate late wednesday stock break flat base buy point meanwhile carnival ccl beat top bottom line forecast provide upbeat guidance share fall lead stock thursday tesla tsla rally travel book company trivago trvg jump almost ibd medidata solution mdso pace advancer soar mercury system mrcy rise downside chip stock ichor holding ichr apply material amat fall respectively coherent cohr drop related earning calendar analyst estimate stock weibo ibd chinese internet stock be selling offdow jone industrial average dow stock news analysisoracle soar cloud revenue skyrocket best chinese stock buy watch
146,REGN,future index nasdaq dow jone industrial average be mixed early thursday software biotech stock have become key leader ongoing market rally oracle orcl surge overnight strong earning report regular session celgene celg roar buy zone amgen amgn regeneron regn biogen biib peer show bullish action investor pay attention sector rotation stock performance be closely tie broader industry stronger industry sector performance reflect improve business condition company be momentum shift market become more enamored disenchant group nasdaq future rise more fair value overnight high future dow industrial climb nearly index future turn slightly higher crude oil future have plunge week edge last session medical biom biotech group have be top performer ibd industry group soar amgen regeneron biogen celgene be more just week biogen regeneron more ibd take celgene be rate ibd biom biotech group best possible composite rating find be other top rate biotechs stack vs objective critera go ibd stock checkup several other drug group be big recent winner ethical drug group include dow stock merck mrk merck rise wednesday new approval immuno oncology treatment keytruda merck have conventional buy point aggressive entry meanwhile ibd software desktop group home oracle be fourth best industry past day dow microsoft msft adobe system adbe red hat rht be also member other software group include enterprise software medical software also have have big gain celgene leap blast past buy point hold just chase zone grow feel investor president trump not crack drug price various comment have make campaign regeneron rise further extend buy point trading best level begin amgen advanced build right side base biogen gain retake day move average day vaulting day recent biogen spinoff bioverativ bivv edge be hold buy zone monday bioverativ be leaderboard ibd premium service highlight select cull stock mostly growth play buy zone clovis oncology clvs have sky-rocket week report strong trial datum suggest ovarian cancer drug get much wider use gilead science gild rise day line hepatitis hiv biotech try break downtrend go back more year good way play biotech boom be etfs such spdr biotech xbi ishare nasdaq biotech ibb xbi ibb break consolidation week oracle report much stronger expect earning late wednesday revenue growth also edge past view share business software giant shot premarket trading stock market today be record high well buy point overnight trading doesn always carry regular session still oracle already top aggressive entry wednesday rise heavy volume addition desktop software name microsoft adobe red hat be long time time high several other business software stock have be breaking hit high recent month include cloud base payroll software player such workday wday paylocity pcty paycom payc well servicenow now salesforce com crm veeva system veev asian trading thursday japan nikkei dip china shanghai composite slide europe intraday ftse retreat germany dax be flat france cac fall related big picture biotechs lift nasdaq oil bloodbath breakout biogen spinoff bioverativ buy zoneoracle earning come ahead top bottom linesbiotech surge generalist return subside trump dow merck be still beating bristol roche immuno oncologyis medical cloud compute play set rebound crash
147,REGN,stock open modest gain monday tech merger drug industry news power largest early move dow jone industrial open gain strong early move merck mrk be partially hold back intel intc intel share respond latest development broadcom avgo effort take qualcomm qcom rise higher nasdaq composite open gain broadcom micron technology mu lead index early trade amgen amgn intel fall bottom list market uptrend get groove back friday surprisingly strong february job report trigger rally major index clear key level resistance nasdaq shake distribution day monday action provide test durable gain market upgrade status be merck advanced lead dow open trade new jersey base drugmaker last week announce invest jointly develop japan eisai lenvima ketruda combination cancer treatment january earn food drug administration breakthrough designation kidney cancer treatment intel post dow few early loss report friday company be consider takeover bid broadcom mean upend broadcom effort merge qualcomm broadcom open more higher stock have be wrestling retake support converge week move average month consolidation qualcomm add early trade sign free ibd newsletter market prep tech reportoclaro oclr spiked start bell lumentum lite announce acquire company cash stock deal lumentum reportedly supplier technology used apple aapl face id application say combination aim fast forward participation market sense technology oclaro share trade lumentum share end friday february low buy range buy point month cup base ibd stock future rise open trade share micron technology swung more open boise idaho base storage chip leader break past buy point heavy trade week end friday buy range entry amgen slip more worst early decline nasdaq stock amgen other competitor regeneron pharmaceutical regn cholesterol drug praleunt fall regeneron announce plan lower price drug regeneron share rise open initial public offering also play part early action china base qudian qd pop stronger forecast result fourth quarter include surge number borrower increase total transaction period share end friday november low still stock october ipo price tech unicorn dropbox file update prospectus announce plan offer share ipo midpoint range value online file storage sharing company company revenue rise last year net loss be halved share trade ticker dbx offer date be not yet clear asia stock market logged strong gain dollar climb heel friday job report hong kong hang seng index jump nikkei tokyo vault higher market europe slip mixed action afternoon trade frankfurt dax lead ftse london slip loss be interested big picture market outlook have changedapple supplier lam research lead chip stock buy zonesthese top china net have new buy point now study chartschip stock watch semiconductor industry news
148,REGN,eczema treatment dupilumab add regeneron regn top line multiply expect sale factor estimate patient be treat topical ointment rbc analyst adnan butt say tuesday survey dermatologist treat average patient month rbc find patient respectively suffer severe moderate eczema majority survey doctor say have pool patient benefit dupilumab immediately minority expect prescribe dupilumab pediatric patient ahead approval food drug administration provide upside butt write research report total estimate market patient ibd take biotechs have nearly return pre donald trump election level worry president elect make good recent promise go spiking drug price biotech pick get catch fallout estimate be roughly patient moderate severe atopic dermatitis have fail treatment topical treatment arrive addressable market patient write butt expect regeneron pull sale dependent prescription drug user fee act date set march manufacturing issue drugmaker partner sanofi sny factory snag approval dupilumab rheumatoid arthritis treatment sarilumab say regeneron stock close more stock market today work deep price correction monday share jump rival ophthotech opht report blurry eye drug fail late stage trial analyst see regeneron default winner battle sanofi stock climb nearly tuesday also go long consolidation regeneron be ibd biotech industry group be top group sanofi be ethical drug group be bottom ranking related
149,REGN,amgen regeneron ldl buster boost small cap biotech
150,REGN,biotechs aerie medicine co tesaro rocket be buy rbc
151,REGN,regeneron regn eylea become default blurry eye drug ophthotech opht fovista fail late stage trial monday send stock record low rbc analyst adnan butt say ophthotech stock plummet stock market today regeneron stock other hand rise rival news retake day move average news have little impact roche rhhby novartis nvs novartis acquire right ex sale genentech drug lucentis genentech be acquire roche ophthotech trial test fovista conjunction lucentis ibd take biotech drug stock be underperform recent rally donald trump election president elect say go rise drug price get full scoop ibd technology page novartis roche stock dip respectively monday duo have split outside sale ophthotech fovista aim treat wet age related macular degeneration amd ophthotech test fovista lucentis vs lucentis alone patient combination regimen gain mean letter vision early treatment diabetic retinopathy study etdrs chart year monthly treatment counterpart lucentis monotherapy gain average letter result weren statistically significant ophthotech say secondary endpoint change baseline combination patient gain more etdrs letter month mark compare lucentis monotherapy patient follow ophthotech flop rbc butt posit regeneron rival treatment eylea become standard care wet amd diabetic macular edema butt have outperform rating price target way regeneron stock overhang be fovista success approval disrupt market eylea more doctor try combine nearly free avastin label fovista improve outcome patient write research report still other overhang persist butt write regeneron remain patent litigation ldl buster praluent develop sanofi sny amgen amgn amgen repatha be approve summer also belong class drug call pcsk inhibitor manufacturing concern linger regard eczema treatment dupilumab rheumatoid arthritis med sarilumab butt note sarilumab be develop conjunction sanofi compete abbvie abbv humira currently drug sale related ophthotech eye disease med beat rival pharmaceutical fall combo therapy eylea alone
152,REGN,biotech stock have nearly round trip donald trump inspire rally rbc analyst michael yee see upcoming food drug administration appointment datum roche rhhby biogen biib act catalyst ishare nasdaq biotechnology ibb spdr biotech xbi exchange trade fund be follow rally trump election wednesday trump dump water analyst theory be less likely go spiraling drug price go bring drug price tell time magazine don have happened drug price trump commentary send biotech stock tumble wednesday ibd company medical biom biotech industry group close ishare biotech etfs end day respectively sink more thursday biotech stock manage climb hole stock market today ibd company biotech group be fractionally be etfs ibd take biotechs recover trump pledge curb drug price get deep dive ibd industry theme yee note trump effect extend far commentary trump have appoint georgia rep tom price health human service secretary price have say favor major overhaul medicare system have advocate affordable care act next appointment light fire biotech stock yee write deck trump be prep announce next commissioner food drug administration medium report target jim neill scott gottlieb lead candidate neill be former venture capitalist manage director peter theil mithril capital have advocate relax fda regulation drug approval gottlieb be vc partner practice physician have serve fda center medicare medicaid service decision follow congress approval late wednesday bill speed fda process trump commentary drug pricing be far set stone yee write research note note republican congress next year be unlikely break conservative dogma work ease drug price worry trump mention drug pricing remind investor have say lot thing past year seem negotiate public eye hasn necessarily be truly perceive actually want do lot yee write outside trump biotechs have suffer industry specific injury include eli lilly lly miss key alzheimer datum lag metric teva pharmaceutical teva medtronic mdt yee write biogen roche have upcoming datum help industry biogen have phase datum alzheimer drug aducanumab due friday roche phase hemophilia datum be due imminently yee say prescription drug free user pdufa be due dec roche multiple sclerosis drug ocrelizumab regeneron regn rival ophthotech opht have phase datum come soon meanwhile look imminent sector johnson johnson jnj be talk buy european biotech actelion sanofi sny be rumore have informal interest actelion insider say pull generalist investor back space yee write perception major term catalyst biotech other cheap need much more get stock rally again write trump tax cut plan republican congress spur biotech trump make drug development great again
153,REGN,ibd be look biggest week second quarter report season more company set file report fortuitous development investor majority name be coil valid basis xmonday roll quiet start name list due report cognex ticker
154,REGN,stock stick very close home thursday mixed economic datum earning report frayed attempt build momentum better expect weekly jobless claim june consumer confidence number be positive sharp drop manufacturing growth report philadelphia fed open help stoke investor concern investor response earning report cut sharply direction mostly soft trade session result give nasdaq technical new high straight gain increase be less weak trade mean feat check point software chkp tripadvisor trip qualcomm qcom turn broad loss apple aapl netflix nflx google parent alphabet googl end minor loss day drugmaker mylan myl regeneron pharmaceutical regn lead nasdaq mylan jump positive phase trial result report late wednesday ibd stock regeneron also swung weak trade work new consolidation slip fraction back away new high notch intraday drugmaker be key leader also perrigo prgo mallinckrodt mnk post gain trade be weak dow jone industrial average close valiant effort nike nke buck more day stock have fall buy point entry remain play home depot hd fall ratchete drag dow catalyst appear be agreement sear holding shld sell respect kenmore brand home appliance amazon com amzn news send sear share nearly gain amazon sketch advance macom technology solution mtsi lead ibd more average trade be sufficient take new high share be already extend early july rebound week move average chipmaker plan report fiscal third quarter result aug side floor decor fnd tumble fast trade fall back week move average company price share follow offer just wednesday close price stock remain april ipo price related financial be buy range earning tonightamazon team sear new retail group tumblespaypal stock record high jpmorgan deal online payment sizzle
155,REGN,stock market wasn do much afternoon trading thursday mixed mostly unchanged wall street weigh more earning report economic news weekly jobless claim be lower expect philadelphia fed manufacturing index slightly miss expectation news didn move stock market much xsmall cap lead way russell dow jone industrial average nasdaq composite be flat line volume nyse be tracking higher wednesday level nasdaq volume be pace be slightly lower stock market today biotech space regeneron regn jump more stock first break early interpretation be stock be work big cup handle base buy point so be play separately recent biogen biib spinoff leaderboard name bioverativ bivv gain approach alternate entry nike nke outperformed dow rise nearly help morgan stanley upgrade overweight equal weight share nike surge june news go start selling amazon com amzn elsewhere sear holding shld gap day move average price level be session lows news ll start selling alexa enabled appliance amazon share be sear news wasn good share dow component home depot hd best buy bby large seller appliance name lose heavy volume earning news check point software chkp gap day move average fall company report better expect earning issue weak outlook group peer fortinet ftnt proofpoint pfpt hold well news fortinet report next week be session high work base buy point proofpoint also report next week share dip also carve base buy point ibd momo momo add work right side later stage cup shape base buy point now be microsoft msft report earning close share be mostly unchanged ahead result microsoft recently clear base buy point light volume related financial be buy range earning tonightamazon team sear new retail group tumblespaypal stock record high jpmorgan deal online payment sizzle
156,REGN,biotech investor likely be key launch biogen biib spinraza regeneron regn dupixent first quarter result roll analyst say wednesday sector preview ibd company biotech industry group be rank group track just week first quarter be choppy inventory seasonality challenge leerink analyst geoffrey porge say wednesday analysis suggest be not go be particularly impressive quarter large cap name coverage universe neither be go be disaster slow result suggest write note client give flux shipping day inventory level investor be likely pay most attention key launch already underway anticipate biogen spinal muscular atrophy drug ionis pharmaceutical ion be likely be scrutinize recent payer pushback meanwhile investor be look commentary roche rhhby multiple sclerosis drug ocrevus hurt biogen ms franchise celgene celg be also work ms drug ozanimod expectation be still high regeneron sanofi sny dupixent eczema injection launch end first quarter initial feedback company physician month be critical assess launch sale trend especially anecdote accessibility patient price announcement write ibd take gilead science be suffering slow hepatitis drug franchise buy decline head ibd industry theme better look gilead have sight acquire amgen amgn regeneron be also likely get question reimbursement change medicine lower bad ldl cholesterol amgen show recent study lower ldl cholesterol reduce risk heart attack stroke street be hope push payer reimburse drug upcoming filing investor look amgen commentary migraine drug erenumab romosozumab drug treat osteoporosis postmenopausal woman alexion pharmaceutical alxn be work soliris neuromuscular disease vertex pharmaceutical vrtx be testing tezacaftor cystic fibrosis gilead science gild be likely comment hiv drug bictegravir gilead be push hiv drug potential replacement decline sale hepatitis drug company hepatitis unit rake north year fall related gilead hiv franchise plan be dash trumpcare gilead be pay price actually cure diseasebiotech etfs defy trump tweet rally send higher
157,REGN,biotech amgen amgn face pushback cholesterol bust drug repatha analyst say wednesday payer survey say recent study drug wouldn prompt reimbursement policy change jeffery analyst eun yang survey payer represent patient nearly say amgen recent study show repatha cut risk heart attack stroke wouldn prompt change reimbursement policy drug cardiovascular outcome datum be thought be major event unlock significant sale potential yang write report client half survey view datum incrementally positive positive neutral none say game change midmorning trading stock market today amgen stock fall yang downgrade stock hold rating buy also cut price target amgen follow poll payer view patient year fair value base price repatha say amgen charge year only survey expect improvement reimbursement do not ibd take biotech exchange trade fund trade march head ibd etf page find send higher main reason initial reimbursement rejection include unjustified cost benefit patient not candidate base cardiovascular risk profile insufficient evidence physician lack cardiovascular outcome datum yang report say latter point change regeneron regn sanofi sny odyssey outcome trial enrolled higher risk patient population likely experience more event year trial medicine co mdco be also plan heart study cholesterol drug related regeneron sanofi look crush amgen rival say canamgen tank heart study share other drugmaker tumble
158,REGN,regeneron regn sanofi sny dupixent grab fda approval tuesday be price annually patient moderate severe eczema company say share regeneron close stock market today earlier fall much sanofi stock dip fda approval remove pricing overhang leerink analyst geoffrey porge say news earlier day porge suggest regeneron sanofi price dupixent annually expect fda approve dupixent allow recent manufacturing overhang be lift approval mean dupixent be available commercially soon next week say now expect regeneron sanofi sarilumab rheumatoid arthritis grab fda approval second quarter dupixent sarilumab be filled sanofi french facility issue facility delay sarilumab last year reaction announce price have be mixed porge say expect decision result significantly higher demand faster company have hew traditional premium price strategy add be hundred thousand eczema patient set porge say most important regeneron sanofi ensure access price payer likely open access most eczema patient price be also earlier analysis compare dupixent price psoriasis treatment average gross price comparable injectable psoriasis treatment run patient year porge write earlier note client see good start point dupixent pfizer pfe eucrisa leerink analyst also look measure disease burden quality quantity life used scale analyst find patient severe eczema be willing pay year patient moderate eczema be willing pay ibd take monday regeneron be medical stock gain big see other biggest point winner stock market today level cost be usually accept willingness pay threshold porge say regardless price investigator find dupixent be likely improve health outcome compare usual exist care do so additional cost porge reiterate outperform rating price target regeneron stock related regeneron sanofi look crush amgen rival say canesperion medicine co recover amgen induced pitfallamgen tank heart study share other drugmaker tumble
159,REGN,top biotech stock amgen amgn celgene celg regeneron regn bluebird bio blue have rally week biogen biib spinoff ipo bioverativ bivv have jump new buy zone developer treatment hemophilia other disorder see positive improvement relative strength rs rating tuesday increase exclusive rating investor business daily identify market leadership worst best score score show stock price performance last week hold other stock database decade market research reveal stock go make biggest gain typically have higher rs rating begin new run bioverativ be still buy range breaking past buy point cup handle wednesday stock be fractionally day still entry once stock move more initial buy point consider buy range revenue growth fall last quarter ep grow prior report company hold rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx celgene be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
160,REGN,thing be look regeneron pharmaceutical regn sanofi sny analyst say monday suggest duo eczema drug dupixent easily outperform wall street model second quarter overall week prescription launch trajectory remain very robust leerink analyst geoffrey porge say note client confusion much drug be sell prescription porge expect dupixent sale top expectation second quarter analyst model just dupixent sale porge view year porge project revenue vs consensus expectation expect cumulative total prescription volume grow north end second quarter more year hit june accord health tracker pace new start continue report full year sale be even higher estimate porge say reiterate outperform rating price target regeneron stock ibd take regeneron stock be know ibd stock track list premier growth stock head ibd breakdown list well look strongest today porge view come day regeneron sanofi announce strong datum cholesterol buster praluent late stage trial patient diabetes diabetes patient be particularly risk develop cardiovascular disease regeneron stock close stock market today sanofi fall related regeneron cholesterol buster get boot amgen battle biogen ionis stock pop europe approve drugwhich biotechs benefit most trump tax vision
161,REGN,share cancer focuse biotechs bluebird bio blue clovis oncology clvs kite pharma kite pop tuesday lead sectorwide boom eventually settle close close stock market today ibd company biom biotech industry group tick hit high last see mid march bluebird stock lift continue strong run begin first week june small cap biotech present datum celgene trial patient blood cancer know multiple myeloma drug know temporary name bb show headline grab objective response rate patient meaning patient see tumor shrinkage nearly quarters achieve score very good partial response drug kite stock too continue run begin earlier month american society clinical oncology meeting strong datum adult blood cancer call acute lymphoblastic leukemia kite share be stock hit buy point june consolidation period begin mid march ibd take drug bluebird kite class know car therapy immune system cell be extract body then reprogram fight cancer stoke sector rally head industry snapshot deep dive fellow cancer biotech clovis gain continue trend begin monday share rocket strong trial ovarian cancer rivale like tesaro tsro astrazeneca azn loxo oncology loxo stock rise food drug administration say simplify approval process drug treat genetic mutation cause tumor growth loxo be work arena have strong result earlier june regeneron pharmaceutical regn stock pop trial rival novartis nvs show drug know brolucizumab be not inferior regeneron blockbuster drug eylea analyst remain bullish regeneron investment bank piper jaffray boost price target stock bank have outperform rating share novartis win file brolucizumab fda leerink analyst seamus fernandez say research report give regeneron eylea plenty time continue build sale war chest related small biotech soar celgene partner trialcould tesaro overcome clovis lead combo merck co astrazeneca keep clovis tesaro unveil blockbuster drug
162,REGN,small cap biotech esperion therapeutic espr trade cholesterol buster drug datum amgen amgn regeneron regn come positive rbc capital market say friday amgen regeneron be slate report datum pcsk inhibitor new drug target inactivate specific protein liver reduce amount harmful ldl low density lipoprotein cholesterol bloodstream describe harvard university esperion win have ldl cholesterol datum have complete phase phase study etc bempedoic acid etc aim treat side effect associate ldl lower therapy esperion say datum amgen regeneron be positive confirm ldl hypothesis increase investor confidence fda view ldl surrogate approve drug rbc analyst michel yee write research report friday highly unlikely amgen pcsk fail prompt esperion stock topple yee write amgen report be fundamental derisk ldl thesis say ibd take ibd company medical biom biotech industry group be year other group have be stronger continental resource parsley energy hit buy zone week check deep dive industry theme esperion be seek potential partner outside upfront cash ahead phase trial yee write esperion reach fall solidify partner yee say company hold phase trial better just get datum value program go way then be easier raise capital back datum write yee keep sector weight rating price target esperion stock afternoon trading stock market today share rise friday esperion stock have tumble year related
163,REGN,medicine co alnylam split amgen rivale cholesterol buster
164,REGN,amgen biogen celgene eye trump pro biotech world
165,REGN,biotechs aerie medicine co tesaro rocket be buy rbc
166,REGN,biotech stock likely close double digit be filled catalyst least wall street firm be key aerie pharmaceutical aeri intra cellular therapy itci medicine co mdco regeneron regn seattle genetic sgen tesaro tsro company have important clinical phase pivotal regulatory event come rbc analyst adnan butt write research report thursday coincidentally also be name coverage greatest likelihood be takeout candidate butt note company slate release phase pivotal datum proof concept datum expect ibd company medical biom biotech industry group be year date fall stock market today rough day tech drug stock still be potential catalyst remain month clinical trial alzheimer disease conference start dec american society hematology conference start saturday launch drug regeneron sanofi sny dupilumab tesaro niraparib be key butt write dupilumab be topical treatment moderate extreme eczema niraparib be oral parp inhibitor used treat breast ovarian cancer ibd take sucampo pharmaceutical lead biotech industry group ibd composite rating meaning perform top stock term key growth metric do biotech bet stack find ibd stock checkup regeneron sanofi tesaro also land list company await approval food drug administration medicine co ocular therapeutix ocul prescription drug free user act pdufa date be important butt say similarly aerie ocular be prep refile new drug application respectively glaucoma med rhopressa dextenza drug treat post ocular surgery pain aerie withdraw nda october manufacturing issue ocular say august have issue remain nda intra cellular therapy be also wait fda approval file nda iti schizophrenia drug september iti miss primary endpoint change positive negative syndrome scale panss safety be good be show improve sleep maintenance antipsychotic efficacy outside fda action firm be near point seek bigger biopharma partner late stage drug potentially become candidate say butt butt name aerie curis cris intra cellular medicine co ocular seattle genetic tesaro related aerie pharma dip minor glaucoma setback miss
167,REGN,nasdaq slide open monday leap oil price skewer early trading dow industrial rise fall nasdaq lose nasdaq dow industrial start week new high last week bullish rally ahead expect increase target interest rate hike federal open market committee wednesday energy related stock dominate premarket trade have trim early gain oil rumble higher follow report minister organization petroleum export country secure agreement key opec member include russia reduce production collective barrel day bring total global production trim link opec late november agreement barrel day news send west texas intermediate more barrel highest mark july europe brent crude benchmark also trade more just exxon mobil xom chevron cvx rise more dow transocean rig marathon oil mro ensco esv rise more apiece parsley energy pe diamondback energy fang energy leader buy point rise respectively premarket trade outside energy sector share lockheed martin lmt drop open president elect donald trump tweet company fighter jet program cost be control billion dollar be save military other purchase january boee ba didn get immediate benefit signing deal sell iran passenger jet boee share be open techs apple aapl alphabet googl amazon com amzn trade modestly lower drag nasdaq pharmaceutical stock be also busy early monday lead regeneron pharmaceutical regn jump ophthotech opht dive more ophthotech report fovista treatment wet age related macular degeneration fail meet target end point phase trial trial test combination fovista novartis nvs lucentis key competitor regeneron eyelea novartis share drop open chardan capital upgrade regeneron neutral sell lift price target alexion pharmaceutical alxn dive company report chief executive david hallal chief financial officer vikas sinha have resign effective immediately internal accounting probe near completion company say have not yet identify factor require restatement result board member david brennan be name interim ceo david anderson be hire cfo gold drop ounce dollar be mixed sharply vs yen euro pound bond drop send year yield basis point week economic calendar get light start monday treasury department deliver november budget report et international market trade generally lower china shanghai composite dive hong kong hang seng index dump monday japan tokyo nikkei rise europe market deepen early loss afternoon trade ftse london dip frankfurt dax be cac be related oil soar month high opec producer limit parsley lead shale stock buy point
168,REGN,stock index book solid gain wednesday afternoon biom stock dive president elect donald trump vow bring drug price nasdaq advanced dow jone industrial average gain respectively small cap russell rise volume stock market today be run higher major exchange medical stock struggle trump say time magazine interview doesn happened drug price bring price trump make mention investment research development be never free company such celgene celg regeneron pharmaceutical regn put revenue research development big cap stock incyte incy put revenue last year strong growth revenue profit budget shrink odd develop new drug also fade high end biomed rely most lead retreat wednesday group meanwhile rest market be business usual bank stock have lead trump rally be little change exchange trade fund powershare kbw bank kbwb inched bank etf have gain election day close steel have be area strength stock market continue wednesday afternoon gainer steel producer include unite state steel ak steel ak nucor nue steel alloy stock also show strength carpenter technology crs pop retook day line allegheny technology atus rise try clear base economic news labor department job opening labor turnover survey be little change october layoff slip so do rate hire job opening gauge be federal reserve chief janet yellen watch closely cme group fedwatch tool be unchanged wednesday chance interest rate hike december related trump target drug price apple seek minute offshore firm chip stock get buy air delta break basis
169,REGN,stock be show impressive rebound monday open sell nasdaq composite turn loss gain nasdaq reflect resilience large megacap techs rise dow jone industrial average be turn drop nearly loss just fall more last week early monday dow jone industrial average briefly clip day move average first time fall south side key support resistance line back then take nearly month stock dow rebound back day line help dow be dupont dd be sole component rise point more diversify manufacturer be legitimate leader stock market today jan share also be recent nov past flat base buy point be less ibd best mutual fund award view winner categoryamong new issue snap snap be get plenty attention back positive comment analyst new buy rating share stride more higher possibly set highest close more week market debut snapchat social medium site operator leap past share ipo finish then catapult high come earth next session snap slide low normal cup double bottom base decline usually run more high low base ibd research big winner past bull bear market cycle so snap case decline be heavy side especially give fact gain share ipo do not exceed more recent positive wall street comment snap be course lose money consensus estimate net loss cent share still stock deserve close watch rebound continue stock get peak most excellent cup handle pattern stock tend form handle last final shakeout uncommitted holder big new high trading more week time high trump support american health care act never see light day friday investor continue watch lead name medical health care service industry group celgene celg intuitive surgical isrg regeneron pharmaceutical regn be day biggest point winner celgene rank big cap see whole list latest ibd weekly page failure american health care act future change former president obama affordable care act be unlikely suppress demand superior medicine treat patient deadly disease such multiple myeloma celgene be field also be become force treatment chronic illness such psoriasis celgene get wonderful ep rating ibd stock checkup due consistent pattern long term profit increase solid gain short term well past quarters earning share rise vs year level average ep gain be outstanding company market cap higher celgene have market value share outstanding be large not excessively so point comparison pfizer pfe have share outstanding street see fiscal year profit rise share lift revenue revenue rise vs year level prior year intuitive meanwhile remain top hill field robotic surgery system wall street see earning rise share current quarter accelerate increase see sale be see rise growth intuitive present buy point so far feb stock spurt past cup base entry volume expand nearly day average sign healthy demand mutual fund large investment adviser pension insurer go daily chart ll also see very narrow handle form jan feb create hard see early buy point add cent highest price handle obtain handle entry point notice daily chart stock gap huge volume jan reaction decent fourth quarter result ep revenue intuitive currently get solid composite rating better regeneron score watch see regeneron muster strength rise back day day line create space key resistance line earnest start form right side new base pattern related invest add week line pullback trading invest key great cup handle basestock market today do lead chipmaker deserve spot watch list ibd do big winner have common tech news ibd snap be get love wall street
170,REGN,regeneron regn expect top biotech amgen amgn cholesterol drug own medication reduce risk heart attack stroke angina get vote support unexpected corner regeneron be team sanofi sny upcoming study result drug praluent hope blow amgen repatha water repatha disappoint own recent heart drug testing unusual be rival medicine company mdco alnylam pharmaceutical alny agree regeneron sanofi have better chance succeed reason be regeneron sanofi test be last much longer suggest apparent effect size magnitude risk reduction be greater regeneron study leerink analyst geoffrey porge write recent note client regeneron achieve result later appear have high confidence likely result leerink recent biotech mountain meeting snowbird utah representative regeneron medicine company alnylam delve impact amgen recent fourier study cholesterol statin space panelist agree regeneron sanofi odyssey outcome trial enrolled higher risk patient population likely experience more event year trial vs amgen year trial porge say regeneron sanofi be look praluent effect reduce risk heart attack stroke unstable angina require hospitalization patient age elevated bad ldl cholesterol acute coronary syndrome event last year panelist agree amgen recent fourier study help get payer reimburse patient cost cholesterol drug be know pcsk inhibitor class drug work reduce bad ldl cholesterol blood release long anticipate fourier result late last week amgen say show reduce harmful ldl cholesterol cut risk heart attack stroke coronary first year second year drug cut risk heart attack stroke ibd take biotechs celgene have strong week last week breaking unveil strong result trial otezla patient moderate plaque psoriasis head ibd stock analysis deep dive amgen say drug repatha didn make difference reduce risk cardiovascular death cause share amgen regeneron sanofi medicine company esperion espr pfizer pfe work cholesterol drug fall sharply amgen gambit meant deliver outcome trial result earlier competitor also undermined effect treatment intervention be materially greater second year exposure first porge say regeneron have even more robust effect size base length trial expect have datum december likely be present early esperion medicine company re-cover week analyst note esperion drug bempedoic acid likely be price lower amgen repatha repatha go year net price patient porge say medicine company also plan cardiovascular outcome trial drug inclisiran be be develop alnylam porge doesn expect datum trial earliest related esperion medicine company recover amgen induced pitfallesperion dive amgen heart study pricingamgen tank heart study share other drugmaker tumble
171,REGN,dow jone industrial average index nasdaq composite rebound week investor moved past concern health care bill failure derail tax cut other part president trump agenda dave buster play darden restaurant dri red hat rise strong earning lululemon athletica lulu plunge weak ep guidance chinese internet giant tencent tcehy acquire tesla tsla stake help china car market worst weekly loss major average rebound somewhat lead retailer fang stock facebook fb amazon amzn netflix nflx google parent alphabet googl apple aapl apple amazon netflix hit retook buy point beaten retailer be big winner lead chain such dave buster prosper earning nasdaq composite climb week nearly hit fresh time high index rise dow jone industrial average nasdaq jump be dow related stock aren wait trump make america greatdave buster play fourth quarter earning jump cent share beating analyst view cent revenue rise also view same store sale only rise fall short estimate arcade sport bar see full year revenue midpoint view dave buster share fall wednesday mixed message rally time high thursday closeout retailer earn cent share vs year earlier revenue hit third straight quarter analyst have expect fourth quarter ep cent sale ollie bargain outlet olli also guide current year estimate higher ollie stock rise just buy range spiking record week related lululemon athletica lulu report better expect revenue earning fall short yoga apparel maker retailer also give full year guidance view see same store sale fall mid single digit cite slow start year lululemon share haven make headway past year plunge thursday lowest level end related rh rh run restoration hardware upscale furnishing chain report earning revenue be modestly view also give bullish guidance rh stock shot wednesday hit month high give batter retail sector lift oil future rise barrel week variety factor suggest supply be not hand crude stockpile only rise barrel latest week accord energy information administration vs barrel expect gasoline stockpile fall barrel oil price also get support libya national oil corp declare force majeure tuesday protester block field send output month low opec member make more noise extend production curb past midyear crude production do rise barrel day highest february oilfield service firm baker hughe bhi expect oil gas industry condition remain challenge longer period big datum initiative merger partner general electric ge help create more efficiency producer conocophillip cop agree sell nonoperated interest oil sand partnership most western canada deep basin gas asset double repurchase program reduce debt big weekly gain crude oil be nearly so far related china internet giant tencent holding tcehy acquire stake tesla tsla purchasing stock open market investment be part tencent pursuit self drive car electric vehicle china rival alibaba baba baidu bidu have be aggressively chasing tesla get strong partner help overcome hurdle penetrating chinese market tesla share rise work cup base buy point tesla earlier month announce plan raise more electric vehicle maker work expand manufacturing operation upcoming model related red hat rht report fiscal revenue rise top view line ep red hat forecast full year fiscal earning expectation provider open source linux software now have more customer run openstack cloud compute software standard red hat share advanced week hit record high related general motor gm share ascend push david einhorn greenlight capital create class stock lift automaker value propose class pay dividend other entitle holder earning buyback post dividend payment say wall street journal source gm reject idea call unprecedented untested gm share rise week meanwhile more datum suggest auto industry wo include rise inventory subprime lend problem follow earlier report fall used car price related darden restaurant dri parent olive garden longhorn steakhouse other eatery announce buy cheddar scratch kitchen cash meanwhile darden report better expect result same store sale growth restaurant yard house year company raise profit outlook narrow comp forecast share rise week hit record high delta air line dal agree form joint venture korean air share sale cost schedule american airline aal agree invest china southern airline znh move follow international air transport association expectation eastward shift travel demand iata october say asia pacific region likely be source more half new passenger next year network carrier also face low cost rival home europe related paychex payx report fiscal third quarter earning share beat wall street expectation sale miss provider payroll human resource service keep full year forecast share tumble week drop day day line vertex pharmaceutical vrtx stock lead ibd biotech group wednesday spiking day drug pill cystic fibrosis improve lung function pair late stage trial regeneron pharmaceutical regn sanofi sny stock tumble tuesday grab fda approval eczema drug dupixent analyst split annual price tesaro tsro stock too fall monday announce fda approval ovarian cancer drug zejula approval lessen tesaro likelihood be acquire term related
172,REGN,largest biotech etfs serve reminder march investor high growth industry expect bumpy ride hit best level year early then take nasty tumble bounce back smartly loss tuesday spdr biotech xbi ishare nasdaq biotechnology ibb be modestly lower hold week move average bullish sign recent test critical marker support stumble march so far be hold double digit gain first quarter vs nice turnaround plunge more many biotech exchange trade fund prior quarter coincide hawkish election rhetoric price gouge drug industry latest rally come major setback month include trump tweet drug price serious blow big name biotechs amgen amgn biogen biib cast pall entire industry biotechnology etfs rally sharply january february higher beta name swung favor president trump shock election investor see stock value play growth industry say matthew bartolini head research spdr americas market analyst still see fair attractive valuation sector year date outperformance help ibb earn upgrade recently light improve valuation however thing be key next leg industry bartolini view first biotechs have deliver promise growth many smaller firm kite pharma kite esperion espr be unprofitable have sale even industry bellwether such gilead science gild incyte incy be earning slump however earning momentum sector whole be start look more favorable analyst say top biotech celgene celg earn extremely high ep rating ibd have score upward revision forward estimate secondly merger acquisition come fruition boost share price intercept icpt regeneron regn biogen be name be bandy takeover target xbi have outpaced peer so far have consistently past year be year date march vs gain ishare rival be cap weight skews larger company bartolini consider spdr biotech be well place look ahead well equal weight indexing method give small cap tilt be beneficial industry such biotechnology smaller more speculative company have strong potential long term growth play say relative cap weight rival xbi be less tie fortune largest name industry hand make spdr etf more immune single stock risk tweet risk bartolini word however also benefit less big price gain industry giant trump tweet drug pricing hit xbi ibb hard march related etfs be make big move
173,REGN,xstock trek lower tuesday give back only piece ground gain monday nasdaq take hardest hit fall drop dow jone industrial average drift preliminary datum show volume exchange come higher monday level west texas intermediate crude drop just barrel oil slough undercut low settle lowest point november move ve send oil related stock crowd lowest slot dow barely even register chevron cvx exxon mobil xom drop less oil stock post only day worst loss stock general electric ge be dow worst performer weak trade apple aapl tumble fang stock end lower price target increase netflix nflx medical drugmaker biotechs post strong session merck mrk pfizer pfe easily top dow industrial respectively ibd stock regeneron pharmaceutical regn alexion pharmaceutical alxn lead nasdaq biotechs drugmaker take day top gain nasdaq stock regeneron surge reach month high novartis nvs report rth macular degeneration drug have outperformed regeneron eylea head head clinical trial regeneron be clear month cup base novartis share rise tuesday alexion jump regulatory filing show ceo ludwig hanson make purchase company share worth ibd leaderboard stock floor decor fnd end higher back early high gain left share buy range buy point settle april ipo price retail be tuesday worst perform industry dd penney jcp drop ross store rost shed almost worst decline nasdaq stock several big name be schedule roll earning report close adobe system adbe fedex fdx red hat rht top list related biotechs be lead industry month highamazon get rating upgrade whole food buy be grubhub next
174,REGN,nasdaq composite follow monday bullish gain lower volume decline higher volume late trading tuesday dow ease buoy strength merck mrk pfizer pfe lose hurt weakness oil gas name distribution day be take shape nasdaq stock market today volume be tracking quite bit higher monday level benchmark west texas intermediate crude oil hit multimonth low settle barrel big biotech rally lift share ibd name regeneron regn share pop well extend buy point other biotechs move include celgene celg share rise right side current base show nice accumulation higher volume gain celgene approach buy point contract research organization provide outsourced service biotech big pharma get lift parexel prxl agree be take private private equity firm share parexel rise tesla tsla be session lows still rise report release national safety transportation board find fault tesla automate pilot system involved highly publicize crash model driver be kill chipotle cmg tumble company offer lukewarm same store sale guidance also warn higher cost earning news lennar len jump nearly early fade share gain company report better expect earning third straight quarter accelerate earning growth financial be pressure year treasury yield ease basis point loss select sector spdr financial xlf be tame set nice base buy point many other financial have do good job hold gain recent breakout related netflix price target hike nvidia upgrade nike pt loweredlennar earning top view share eye buy pointthese biotechs be lead sector month high today
175,REGN,stock plow higher friday open lift dow positive ground week payroll datum show employer add more worker expect june dow jone industrial average pop start bell rise nasdaq rumble ahead american airline group aal apple aapl lead nasadq nonfarm employer increase payroll worker june labor department estimate initial estimate new job economist forecast increase department revise estimate upward new hire unemployment rate tick prior level economist have expect change hourly earning also edge higher vs gain estimate advance energy name be take premarket session hardest hit oil price drop putt west texas intermediate back barrel week platt report forecasting rise production nigeria libya appear be cause early decline oil price see impact baker hughe bhi weekly rig count report due et intelintc surge head dow note cowen co speculate escalate legal battle apple aapl qualcomm qcom incentivize apple use intel increase portion iphone chip apple advanced fang stock turn positive netflix nflx easily lead group gain transaction management software developer synchronoss technology sncr be open board announce late thursday have retain goldman sachs explore strategic alternative maximize shareholder value siris capital group have deliver bound indication interest acquire company june synchronoss share sell december mid june tesla tsla perked muster slight rebound follow day sell tesla share remain nearly week trigger multiple sell signal lgi home lgih add report surge home closing june gain hoist share back buy point month cup base ibd stock regeneron pharmaceutical regn leane higher stock be extend clear month base advisory board abco leap follow bloomberg report late thursday unitedhealth unh vista equity partner be deal acquire divide company unnamed source place value overall deal say vista buy advisory education unit much unitedhealth share open ahead related big picture stock be turn pointfiber optic stock rate strong buy get big price target friday job report win make market happythese stock poise benefit sense apple iphone
176,REGN,biotech group be perch high ibd industry group ranking good reason several high quality name continue show exceptional relative price strength biotechs be basically be divide group make institutional quality name top fundamental high caliber fund sponsorship other be more speculative name many great potential
177,REGN,janus henderson fund jacax be hot kevin durant be nba final be very fund stock have double digit percentage gain so far year go june accord morningstar inc electric car maker tesla tsla video game publisher activision blizzard atvi railroad csx csx be more year result go wednesday fund year date gain top large cap growth peer track morningstar inc averaged gain fund get more good news friday hold amazon amzn be nearly afternoon broad market measure be roughly amazon boost reflect market thumb vote favor internet giant takeover whole food market wfm be announce morning put amazon year investor appear believe amazon be able sweeten whole food revenue earning thomson reuter rank deal amazon biggest time biggest global retail deal ever already fund be outperform direct rival past year respectively lead manager dougla rao have be helm june nick schommer have be manager jan fund be growth oriented be concentrated true name fund limit portfolio best idea yes concentration make fund more volatile benchmark russell growth index example fourth quarter fund lose vs loss russell bogey gain fund be hurt part market rotation away secular growth stock like company potential improve cyclical prospect manager explain recent semiannual report cyclical energy material industrial instance benefit trump bump surge bet company gain increase spending infrastructure fund top performer have trend higher market indecisive seesaw cyclical secular growth stock recent month look again fund top performer ibd gillian rich report tuesday tesla be upgrade buy berenberg have price target raise effort bmw kia general motor gm analyst haissl say other automaker be currently build electric vehicle mass market compete tesla offering model be expect go production year haissl also say company free cash flow potential be superior tesla be ibd automobile manufacturer industry group rank group tesla close record high trading session wednesday trading stock be extend outside buy range investor look optimal entry point also yellow caution flag be flap stock earning post third quarter profit company resume loss next quarters narrowing loss year earlier period have slow recent earning estimate revision have be downward activision be also extend trading high stock be member ibd list stock strong relative price strength fundamental last month activision first quarter sale earning top estimate company revenue forecast top expectation ep outlook be analyst view csx run rail system state district columbia canadian province service include intermodal rail truck transload process tesla activision share csx have slip back buy range entry ep grow past quarters quarters decline energy shipment stronger economy have boost rail firm revenue ibd take csx rank ibd transportation rail industry group have annual pretax margin see additional easy understand fundamental technical datum stack rival datum ibd stock checkup other holding regeneron pharmaceutical regn be member ibd trading have slip back buy range entry long cup base ep grow past quarters drugmaker eylea macular degeneration treatment have be drive growth not only piston regeneron engine leerink analyst geoffrey porge recently write client dupixent eczema treatment market regeneron sanofi sny easily outperform wall street model second quarter overall ibd allison gatlin have report aerospace defense stock general dynamic gd be trading so be still buy range buy point ep grow past quarters company be position benefit president trump budget proposal boost defense spending fiscal company be several defense contractor other be raytheon rtn lockheed martin lmt boee ba sign memorandum understand saudi arabia part last month saudi arabia arm deal merger janus capital group base henderson group close create janus henderson group jhg shareholder have be janus fund watch see combine entity create economy scale pass form lower mutual fund fee shareholder also keep eye peel manager departure fund case other company veteran manager ownership stake cash leave don want deal culture clash fallout corporate integration other be push due performance cost cut janus henderson merger make sense distribution viewpoint asset manager have larger footprint different geographic area accord morningstar inc firm pare fund lineup run merger janus merged fund other fund run include janus janus henderson henderson portfolio also close fund henderson make comparable move addition janus henderson be process merge have be other janus fund related janus manager bet proven champ comer calculate turn glass wine bump ira
178,REGN,stock snap back head open monday lead index find support day move average dow industrial dive open nasdaq drop nasdaq reversed first half hour end ahead stock market today dow industrial trim loss aggressively end respectively small cap also rebound lift russell finish gain failure congress push health care reform last week end cancele vote last friday cause stock adjust continuation affordable care act foreseeable future describe house speaker paul ryan stock also value reaction alter view white house ability marshal support legislative priority industry generic drug maker hospital operator post session best gain rank telecom fiber optic group gold miner be also day leader oil driller service company office supply retailer post monday worst decline key player nasdaq reversal be medical software maker cerner cern biotech regeneron pharmaceutical regn cerner jump strong trade give stock breathe room week line climb right side month consolidation regeneron swung average trade share remain long term consolidation end day viacom viab be lead nasdaq average volume tesla tsla also make index top move nearly moderate trade start sixth week consolidation dow industrial dupont dd be session winner news european union have grant provisional approval dupont plan merger dow chemical dow dow share pop low end dow chevron cvx goldman sachs gs verizon vz book decline more ibd stock patient monitoring system provider biotelemetry beat pulse heavy trade just enough hoist share new high laser manufacturer coherent cohr knock gain remain buy range flat base buy point close digital ally dgly raven industry ravn red hat rht be handful company expect report quarterly result dennis kaplan president dalla federal reserve bank be schedule speak et evening related ryancare flop lift trump trade health gold stock hot stock buy range ahead report investing action plan
179,REGN,instinet nomura hike price target momo momo ub start amgen amgn gilead science gild neutral initiate regeneron pharmaceutical regn buy jpmorgan start mercury system mrcy overweight instinet nomura hike price target china social medium firm momo report fourth quarter earning tuesday morning beat estimate do first quarter outlook live broadcasting service account momo revenue have maintain strong growth say instinet analyst jialong shi report momo stock crash stock market today soar wednesday top thursday spike related momo momentum continue facebook hover record highub initiate regeneron pharma acceleron pharma xlrn buy rating start coverage amgen gilead science incyte incy neutral rating ub set price target regeneron stock price target acceleron amgen stock rise incyte regeneron climb acceleron amgen stock have shot be extend buy point come cup handle formation related top biotech unveil breakthrough treatment moveincyte revenue top view jakafi sale narrowly missregeneron defy light sale eylea outlook amgen rivale ldl winjpmorgan initiate mercury system overweight price target computer system integrator be rank ibd roster fast grow company mercury stock rise related do stock post huge gain first show big ep growthraymond james downgrade aerie pharmaceutical aeri developer eye treatment medication market perform aerie stock fall still extend buy point other analyst move barclay initiate biotech versartis vsar overweight citigroup upgrade callom petroleum cpe buy valuation cowen co upgrade orbital atk oa buy stifel raise price target orbital
180,REGN,tense late stage maneuvering white house capitol keep market edge straight friday close major index end mixed dow jone industrial average chalk worst week nov presidential election dow lose friday week goldman sachs gs jpmorgan jpm take be far away dow worst loss week respectively also dow apple aapl mcdonald mcd manage modest gain week nike nke wednesday dive more weak earning report friday trim decline week less sag end week loss also worst week just election heavy engineering steel supplier construction material take heaviest hit friday vulcan material vmc martin marietta mlm fluor flr nucor nue dump more friday session well worth note loss occur light trade micron technology mu armour ua peg best gain micron spiked earning rise cent share penny year quarter revenue soar industry take particular heart micron outlook place midpoint earning guidance consensus view micron share end week new high extend february rebound week support armour pop follow upgrade buy hold jeffery stock suffer sell past month jeffery note diagnosed correction have form bottom give market circumstance inflection have form buy opportunity be now slim investor minimize risk wait proper base form nasdaq composite hold loss friday less end sharpest weekly slip december micron top nasdaq western digital wdc tesla tsla cerner cern regeneron pharmaceutical regn advance more tesla chairman elon musk tease investor tweet reveal new detail regard company upcoming model more distant model roadster vehicle tesla share be week consolidation hold nice support stock week move average slightly too deep qualify flat base ibd stock china tal education group tal jump friday eighth straight daily advance share be take new high be well extend week tight buy point biotelemetry beat also gain narrowing loss week less stock bounce week move average thursday week volume nullify move buy opportunity related obamacare repeal vote failure threaten tax cut stock rallychip gear maker rise upbeat micron outlookstock market today do chip name have shot big gain
181,REGN,sanofi sny make sense acquirer flexion therapeutic flxn analyst say friday rumor flexion accept offer french drugmaker flexion investor be dubious flexion stock jump thursday tumble much stock market today then rally much close sanofi stock edge rbc analyst randal stanicky see flexion likely be take write research report sanofi make sense give sell synvisc injection supplement fluid patient knee relieve osteoarthritis flexion be now work fda approval process zilretta joint injection extend release formulation steroid knee pain stanicky see zilretta well position take meaningful share exist steroid hyaluronic acid market pre fda approval timing allow flexion avoid sale force ramp rep sanofi allow participation launch activity flexion be expect be write market be person worth size brand marketing cantor analyst chiara russo see flexion capable launch zilretta help say rumore mid share takeover price accord unidentified source comment fiercepharma be too low significant change competitive landscape past year give zilretta sole new voice space see mid price be little low strategic buyer russo write note client ibd take flexion have middling ibd composite rating meaning underperform more stock better biotech bet be celgene best possible cr visit stock checkup list strongest leader russo maintain price target maintain rating flexion stock expect zilretta take significant market share rbc stanicky see share takeover price reasonable note see support deal north perhaps closer add specialty valuation have come recently deal be pre zilretta approval have outperform rating price target flexion stock rumore bid come just month sanofi lose contentious battle swiss biotech actelion dow component johnson johnson jnj scoop deal member dow jone industrial average pfizer pfe beat sanofi acquire medivation sanofi have also be rumore have consider deal biomarin pharmaceutical bmrn medicine company mdco aftermath judge ban cholesterol drug praluent regeneron regn ban have be stay pending appeal case amgen amgn flexion sanofi decline comment ibd related do sanofi just bag biotech johnson johnson exclusive talk acquire actelion sanofi sanofi acquire biomarin wake amgen ldl brouhaha
182,REGN,sell friday esperion therapeutic espr stock light amgen amgn heart study result be unwarranted analyst say argue esperion drug likely be price much lower needham analyst chad messer say note client esperion drug bempedoic acid have different method reduce bad ldl cholesterol be offer much cheaper price amgen repatha year well praluent alternative jointly develop regeneron regn sanofi sny sell bempedoic acid likely be price more line other oral cholesterol therapy year write see negative read esperion drug be currently phase testing amgen drug regeneron sanofi treatment be injectable bempedoic acid be oral therapy midday trading stock market today esperion stock fall hardest company develop cholesterol drug similar amgen tumble close share medicine co mdco also take beating loss be much higher earlier day amgen medicine co also be work drug reduce bad ldl cholesterol also injection similar pcsk function amgen stock be end day regeneron fall sanofi slip ibd take other biotech news gilead science be near deal small powerful biotech do analyst plea gilead buy something pan head ibd industry theme scoop early friday amgen announce cholesterol drug repatha reduce risk heart attack stroke coronary respective share topple amgen say drug have effect cardiovascular death patient exist cardiovascular disease see reduction risk major adverse cardiovascular event such hospitalization unstable angina coronary heart attack stroke cardiovascular death base previous trial investor have be expect reduction more range messer write report be hope impressive reduction event get payer start pay repatha disappointing result amgen prove thesis reduction bad ldl cholesterol have clinical benefit cardiovascular health not help amgen regeneron sanofi be work drug classify pcsk inhibitor help esperion say management medicine co be bullish drug inclisiran leerink analyst joseph schwartz say separate report company criticize amgen design trial include change health be less modifiable ldl cholesterol lower fda have already give medicine co positive feedback propose phase trial design schwartz say trial be longer amgen minimum follow year schwartz have outperform rating share medicine co related amgen tank heart study share other drugmaker tumbleamgen top heart study rival regeneron sanofi courtamgen boost rival positive heart disease study analyst
183,REGN,federal reserve raise interest rate didn signal plan be more aggressive send stock slightly higher bond yield sharply lower intel intc be buy mobileye mbly putt chip self drive car tesla tsla raise cash big bet model oracle orcl adobe system adbe report strong cloud revenue snap snap continue tumble fresh post ipo lows other new issue have strong debut nasdaq composite rise week briefly hit time high friday afternoon help oracle well ongoing strength apple aapl fang internet stock dow jone industrial average climb index fed raise rate didn signal faster pace hike go forward year treasury yield tumble recent peak dovish rate hike pressure bank stock such dow jpmorgan chase jpm goldman sachs gs homebuilder rally lower yield steel stock climb bullish earning forecast federal reserve give financial market want hike rate quarter point expect stick plan more hike year next year policymaker recent hawkish signal have market brace quicker ramp news be great homebuilder lennar len toll brother tol mean mortgage rate stabilize time recent run help boost spring selling season financial bank america bac goldman sachs gs have be push higher hope faster rate hike help lift net interest margin take breather fed news related chip giant intel intc announce deal buy mobileye mbly maker advanced driver assistance system analyst describe deal defensive acquisition intel compete nvidia nvda have be score numerous partnership supply artificial intelligence process power self drive car nvidia latest partnership be auto part supplier bosch bring self drive car mass truck maker paccar pcar develop autonomous truck tesla announce sell convertible debt stock underwriter option tesla likely raise less analyst have expect ceo elon musk warn model push cash level close edge tesla rise funding news soar report company release small suv next year tesla share rise week related oracle report fiscal earning cruised past estimate software giant transition cloud base model pick momentum oracle year begin concerted push cloud compute say software service platform service gaap revenue jump total cloud revenue reach oracle traditional software licensing business fall company transition oracle leap thursday hit time intraday high related digital medium marketing software firm adobe system adbe post better expect sale earning fiscal first quarter give target ahead forecast adobe stock jump record high territory news adobe earn cent share exclude item year year sale analyst be look cent adobe guide analyst estimate slightly higher adobe share soar record high friday related mulesoft mule pop friday trading debut pricing ipo late thursday upwardly revise range outdoor apparel maker canada goose goos pop thursday debut keep rise friday oilfield service provider propetro pump price low rise debut hope have be recent ipo snapchat operator snap lead burst new issue strong ipo pricing first day gain record high next day snap share have plunge post ipo lows tumble week related crude oil price rise barrel week big session sell international energy agency say opec keep production level steady june market see deficit barrel day first half year right cue energy information administration report surprise barrel drop weekly crude stockpile last week earlier saudi arabia say raise crude output barrel day february january still target agree production cut deal related delta air line dal unite airline ual american airline aal get ding early week winter storm stella force thousand flight cancellation airline get potential break federal judge halter key provision president trump travel ban unite raise full year capacity outlook give traveler more option expansion carry risk overestimate demand competitive response rival airline unite last month say add service new destination serve area connect airport hub meanwhile alaska air group alk week step offering west coast unite stock slide week delta lose american related tesaro tsro stock crash tuesday astrazeneca azn post strong ovarian cancer trial result also boost clovis oncology clvs stock month high astrazeneca lynparza meet primary endpoint hit median month progression free survival vs month patient placebo similar trial tesaro niraparib delay reoccurrence ovarian cancer month best case review find lynparza delay ovarian cancer return median month meanwhile valeant pharmaceutical stock plunge year low william ackman sell persh square entire stake ailing drugmaker persh hold valeant share amgen announce cholesterol drug repatha trim risk heart attack stroke cardiovascular death not much have hope amgen share fall friday regeneron regn medicine co mdco esperion espr also tumble related share hospital medicaid focuse insurer slide follow monday late day congressional budget office score show house speaker paul ryan obamacare repeal bill slash medicaid funding third leave more american uninsured political blowback ryancare moderate conservative republican uncertainty bill chance cloud remain hospital group thursday trading tenet healthcare thc be sharply week hca holding hca also slide insurer bounce back molina healthcare moh centene cnc anthem antm close week slim gain related china social networking company yy yy report earning beat estimate deliver first quarter outlook consensus view yy report adjust earning american depositary receipt top consensus estimate revenue rise local currency fuel user pay live stream service yy share initially reversed lower outlook rally end week meanwhile momo momo recently report boom revenue live stream video continue rally fresh high nucor nue steel dynamic stld raise first quarter earning guidance well view send steel stock higher
184,REGN,regeneron regn stock defy light sale eylea guidance lag wall street thursday pop day federal judge stay ban amgen amgn rivale ldl buster praluent order allow regeneron partner sanofi sny continue marketing praluent pending outcome appeal process judge earlier find praluent violate amgen patent fellow pcsk repatha drug remove bad ldl cholesterol blood regeneron stock finished higher stock market today close wednesday then be momentarily halter ahead news amgen case sanofi rise thursday amgen dip credit suisse analyst alethia young say movement regeneron amgen stock be likely headline news note stay help lift negative sentiment regeneron appeal likely span year month estimate settlement be still possible ibd take analyst have suggest patent amgen repatha reduce bad ldl cholesterol be too broad see mean regeneron sanofi share long run
185,REGN,catalyst help lift regeneron stock thursday dupilumab regeneron sanofi eczema drug be near approval outcome study praluent be due later year rbc analyst michael yee say pdufa date have be push month sanofi have say duo be also work iron manufacturing issue surround rheumatoid arthritis drug sarilumab last year food drug administration refuse approve sarilumab follow inspection sanofi le trait facility normandy france drug be filled yee also expect update regeneron sanofi eylea combination treat wet age related macular degeneration diabetic macular edema disease eye duo be also look dupilumab asthma be mixed quarter note regeneron report sale earning share ex item vs year earlier quarter sale lag consensus ep narrowly beat view guidance single digit eylea growth fall short consensus view growth rbc analyst michael yee say research note evercore analyst mark schoenebaum note research report regeneron tend offer conservative guidance guidance appear imply roughly flat slight growth second half annualize note also regeneron tend guide conservatively schoenebaum write initial guidance last year be growth end do related amgen ldl buster boost medicine co regeneron slidesamgen crush view see light sale repatha top cv studyregeneron sanofi appease ldl frustrated buyer eczema drug
186,REGN,federal judge grant regeneron regn sanofi sny request stay ban ldl buster praluent late wednesday meaning drug stay shelve continue rivale amgen amgn repatha pending appeal process hour trading amgen stock dip close fraction wednesday regular session regeneron stock trading be halter hour ahead news close regular session sanofi stock be fraction hour follow gain regular session report early wednesday wall street have largely expect federal judge deny regeneron sanofi request make praluent first brand drug be pull market result patent litigation now duo have chance make case appellate court ban praluent treat high cholesterol be set go effect feb regeneron sanofi argue amgen patent repatha be too broad patent amgen didn identify structural feature common genus rather defined genus base antibody bind say amgen be not back respect court decision stay injunction pending appeal amgen remain confident validity patent correctness jury verdict district court judgment amgen say statement email look forward present case lack merit defendant appeal regeneron sanofi have already jump high hurdle leerink analyst write jan report permanent injunction federal district court only be grant stay ibd take regeneron have middling ibd composite rating meaning perform top half stock term key metric sale growth visit ibd stock checkup see regeneron stack rival related amgen ldl buster boost medicine co regeneron slidesamgen crush view see light sale repatha top cv studyregeneron sanofi appease ldl frustrated buyer eczema drug
187,REGN,major market index open higher gain quickly fade final trading session second quarter tech heavy nasdaq composite be just fractionally higher meanwhile dow jone industrial average be respectively xamong dow industrial nike nke be big winner early trade surge nearly inking deal amazon com amzn sell shoe clothe accessory directly amazon com apparel company also report fiscal earning late thursday exceed street top bottom line forecast analyst action lead biotech celgene celg be downgrade neutral buy btig research share fall fellow leader industry include regeneron pharmaceutical regn vertex pharmaceutical vrtx regeneron fall vertex rise nearly stock be extend proper buy point company report earning micron technology mu fall beating earning sale target late thursday memory chip maker be look test day line trade buy range flat base entry have be rather choppy move lead chip stock look regain recently lose momentum stock market today apply material amat broadcom avgo be fractionally higher rise early friday stock have fall day line recent trading session be attempt reclaim action ibd be mixed thursday bloodbath coherent cohr jump list lead share pierce day line june trigger sell signal grubhub grub rise early turn flat food delivery service trigger sell rule june fail flat base entry related micron technology beat earning sale target stock risesnike deal amazon send dow stock soaringdow jone industrial average dow stock news analysis
188,REGN,judge price volume trend amgen amgn recently wall street be optimistic future growth share amgen gap buy point feb report earning also say ldl cholesterol lower drug repatha meet primary secondary endpoint late stage trial more detail result be due american college
189,REGN,stock index take divergent path thursday afternoon nasdaq head biggest loss almost week barely fall nasdaq shed be flat blue chip dow jone industrial average rise lead index small cap russell sag volume stock market today be run higher nyse only higher nasdaq account divergence nasdaq nasdaq be stock suffering sharp loss chip designer nvidia nvda fall cut day line tesla tsla skid bearish gap china base internet gaming stock netease nte lose also nasdaq biotech giant regeneron pharmaceutical regn fall online travel booker tripadvisor trip stumble drive deeper day line meanwhile blue chip show normal action mildly day dow jone industrial average advance issue outnumber decline issue ratio biggest drag component dow be caterpillar cat caterpillar drop more test day line analyst expect heavy equipment maker suffer earning decline third year row decline earning year year basis street expect earning grow ibd industry group energy financial mortgage utility stock lead upside automaker steel cement stock be hardest hit segment dow jone utility average rise philadelphia semiconductor index fall related tesla drop cash burnsteel material mining stock dive trump mull infrastructure delay be quick spot stock change invest trump revive reagan stock market magic
190,REGN,analyst action friday include price target hike nike nke micron technology mu regeneron pharmaceutical regn upgrade walgreen boot alliance wba downgrade rite aid rad xdeutsche bank raise price target nike keep buy rating dow jone industrial average component top fiscal earning sale estimate analyst paul trussell say nike long term prospect look good challenge year endorse consumer direct offense strategy include pilot plan announce thursday sell assortment footwear apparel accessory amazon amzn goldman sachs previously estimate selling footwear directly amazon add revenue nike piper jaffray analyst erinn murphy still see reason concern include apparent acceleration market share gain adida addyy keep target neutral rating share nike jump stock market today rise high intraday month high briefly top buy point stifel raise price target memory chip maker keep buy rating micron beat fiscal third quarter earning revenue estimate late thursday guide higher current quarter analyst kevin cassidy say fundamental memory market have transform diverse end market rational capacity growth drive profit gain boost ep estimate vs consensus other research firm also hike price target lesser degree deutsche bank lift target buy rating jpmorgan raise target overweight rating share micron rise overnight close back buy point just day line ibd take ibd change market outlook uptrend pressure tuesday signal investor exercise extra caution buy stock take money table deploy turbulence subside make sure read ibd big picture day get latest market trend mean investment needham upgrade walgreen buy hold give target drugstore chain scrap plan buy rite aid antitrust scrutiny instead rite aid sell store walgreen analyst kevin caliendo say target reflect chance sale store be approve upside be meanwhile evercore isi resume coverage rite aid underperform rating price target asset sale help term finance analyst ross muken see long term challenge include threat online competition limit strategic option amazon be say be mull incursion prescription drug category walgreen slide thursday share walgreen rise rite aid thursday tumble intraday friday rally gain btig raise target biotech keep buy rating analyst dane leone think investor gain greater appreciation pipeline second half expect be positive datum regard nesvacumab drug dupixent drug asthma share regeneron slide related nike spike buy zone score earning amazonmicron technology beat earning sale target stock risesamid ftc pushback rite aid buyout walgreen split differencewhy biotech rally still tack upside
191,REGN,future nasdaq dow jone industrial average turn higher friday nasdaq composite close thursday day move average microsoft msft google parent alphabet googl fall back day line join apple netflix many other stock such facebook fb amazon amzn be hold support be fight tide nasdaq future rise vs fair value fall much overnight session future advanced dow future climb crude future rise nearly gain several day row year broad tech rally be fuel several big trend fang facebook amazon netflix nflx google parent alphabet apple china internet chipmaker optical gear play more recently enterprise software firm more more stock be breaking day line round trip breakout apple tumble day move average june hasn find way back even recent struggle include thursday loss apple be still third best performer dow jone industrial average microsoft alphabet tuesday close just day line bounce back wednesday thursday microsoft google parent fall more decisively key support line microsoft alphabet be biggest cloud compute rival much larger amazon web service ibd take market direction be still uptrend pressure mean investor be cautious take new position ready take profit cut loss quickly pay attention lead stock major average read big picture daily facebook trade day line intraday fifth time june once again close line facebook announce week have top monthly user make even more amazing be social giant be block china world largest internet market amazon have pull back day line have find support so far amazon continue roil retail apparel broader consumer field nike nke confirm thursday night earning call sell shoe directly commerce giant weibo wb momo momo have fall day line netease nte be once again round trip late stage tencent tcehy pull back week tight pattern alibaba baba remain strong yy yy find support day be still buy range ibd semiconductor manufacturing semiconductor fabless group have fall day move average few day chip equipment group undercut level apple iphone chipmaker particular be struggle broadcom avgo finally fall day line thursday several other apple chip play do same include skywork swks qorvo qrvo texas instrument txn analog device adi slew top rate chip equipment maker include lam research lrcx apply material amat be day line nvidia nvda remain standout fiber optic stock have be volatile leader past year internet giant ramp datum center china beef infrastructure verizon vz expand high speed metro network telecom fiber optic group have fall day line apply optoelectronic aaoi hottest stock group be find resistance week lumentum lite be see possible apple iphone sensor play be close round trip salesforce crm shopify shop sap sap be day move average oracle orcl adobe adbe have strong earning last week be hold well so far many techs be weak financial be make gain jpmorgan chase jpm notable week big bank announce huge dividend hike stock buyback late wednesday pass second round federal reserve annual stress test meanwhile higher treasury yield negative broader stock market housing stock particular also be give lift financial meanwhile biotechs have be big winner june celgene celg regeneron regn be big name breakout have be other defense aerospace firm boee ba lockheed martin lmt have hold well buy range just extend asian market japan nikkei fall australia asx china shanghai composite rise european trading intraday ftse rise germany dax climb france cac related be dow top stock apple isn big picture be summer pullback underway stock market today time take gain apple big cap chip cybersecurity stock near buy point investing action plandraghi drama undercut key stock market support
192,REGN,apple aapl continue prove rally bottom base october last year january not be yet biotechs select chip stock help sustain rebound stock wednesday nasdaq composite rally more et outperform gain dow jone industrial average small cap be do even better smallcap gain turnover be run mildly lower vs same time tuesday main exchange note latest big picture column ibd downgrade outlook market uptrend pressure due sell nasdaq higher volume tuesday know distribution flurry big distribution day be enough halt bull market advance even turn bear market lower turnover less hour remain stock market today volume have be average past trading session nasdaq banking stock meanwhile resume advance follow comment federal reserve chief janet yellen appear indicate hike short term interest rate be card rest year yield year treasury benchmark bond edge highest wti crude oil future add more barrel silver future rise gold edge fractionally higher nearly troy ounce comex apple nearly be still hold large portion gain jan excellent cup handle base furnished buy point cent handle high apple then gain much space just month further rebound iphone giant produce new buy point share be hop back day move average currently watch see stock retake line street see apple sale rebound current fiscal year end september follow rare slide fy profit be expect climb share apple hold annualize dividend yield ibd take apple be get boost top line recent quarters due strong demand service observer question apple need make acquisition fuel continue revenue gain area business fulfill goal double business read ibd latest tech team coverage increasingly vital part apple business model see ibd stock checkup apple relative price strength rating continue be positive meaning now beating publicly trade company term month relative price performance meanwhile biotech industry group be show not intend backtrack leadership position stock market today large industry group biggest name celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx be behave well be trading respective day move average sign strength celgene more be wipe away loss prior session break cup base buy point last week chase zone go celgene sport highest possible composite rating earning share rating accumulation distribution mean past week stock have show evidence heavy share accumulation mutual fund bank insurer pension regeneron vertex be extend now provide follow buy point future watch mild pullback day week move average make sure ibd current outlook be show confirm uptrend uptrend pressure signify odd make money be higher vertex more be now extend more past recent past entry long deep first stage base similar bottom base pattern base vertex crumble create massive shakeout chip sector broadcom avgo nvidia nvda be also show leadership quality gain former be also find continue support day line recent flat base nvidia composite ep be extend have yet challenge holder test day move average have be climb sharply more week street see fiscal second quarter earning jump cent share be very impressive light fact nvidia score increase adjust ep year quarter accord research william neil co related buy sell latest investor cornerwhen do current market outlook go uptrend pressure see big top growth stock be perform ibd invest new ipos avoid initial trap
193,REGN,amgen amgn ldl buster meet key endpoint widely anticipate cardiovascular study biotech say thursday help further separate regeneron regn sanofi sny be recently ban selling rival drug praluent biotech leader also crushed wall street expectation lead amgen stock spike hour trading end regular session fraction share regeneron sanofi jump less hour amgen report sale earning share ex item respective vs year earlier period metric top consensus analyst poll thomson reuter amgen wrapped sale ep item figure top view guidance sale be light high end amgen outlook miss consensus sale amgen also guide ep ex item bracketing consensus ibd take gilead science report next week analyst have be bearish gilead have say amgen post strong do grab more biotech leader sphere ibd industry theme fourier result show unequivocally connection lower ldl cholesterol repatha cardiovascular risk reduction even population already treat optimized statin therapy dr sean harper executive vice president amgen say release repatha meet key endpoint show reduction risk cardiovascular event cardiovascular death fatal myocardial infarction fatal stroke hospitalization unstable angina coronary patient clinically evident atherosclerotic cardiovascular disease amgen present full result american college cardiology acc annual scientific session late breaking clinical trial march washington related regeneron sanofi appease ldl frustrated buyer eczema druggilead clobber hep too little value too late nash hiv unit
194,REGN,share medicine company mdco outperformed amgen amgn early friday rocket biotech amgen say ldl buster repatha curb cardiac event lend credibility rival drug rbc analyst michael yee say amgen stock bound near month high close stock market today share fly buy zone friday hit entry point cup handle formation medicine company do better share soar close strong datum amgen be likely boost rival ldl program like medicine company gempshire therapeutic gemp partner regeneron regn sanofi sny yee say regeneron stock slide news partner sanofi see share rise fourier study look amgen repatha help reduce cv event risk patient late thursday amgen say drug meet primary secondary endpoint wouldn elaborate pending american college cardiology conference march repatha positive study keep open possibility regulator continue approve drug lower ldl cholesterol especially one work similar pathway prior outcome datum read such medicine company inclisiran yee write research report ibd take gilead science be slate report earning offer guidance next week rbc be call gilead have slow outlook decline sale hepatitis drug check ibd industry theme better picture ldl buster amgen regeneron sanofi class drug call pcsk inhibitor pcsk enzyme bound ldl cholesterol receptor stop ldl be remove blood pcsk inhibitor block enzyme allow more ldl receptor get work medicine company inclisiran be different class pcsk inhibitor block pcsk synthesis liver rna interference difference be important last month judge ban regeneron sanofi selling praluent say infringe amgen patent repatha amgen likely be able expand label repatha aftermath fourier study yee say efficacy specific be key expect efficacy anything better be unequivocal positive late thursday amgen also announce result crush consensus sale guidance be bit light earning share item just meet still lot air repatha vs praluent yee say regeneron sanofi be appeal decision ask stay injunction pending ongoing litigation guidance include range pcsk dynamic be swing factor yee say related regeneron sanofi appease ldl frustrated buyer eczema drugamgen gouge top pick abbvie humira biosimilar stock catalyze plunge key sector
195,REGN,regeneron regn sanofi sny ldl buster lose patent battle amgen amgn duo appease investor time approval extreme eczema drug dupilumab say rbc analyst adnan butt butt expect dupilumab beat expectation turn momentum positive latter be particularly important district court judge jan side amgen patent battle pit amgen repatha praluent decision judge ban regeneron sanofi praluent regeneron stock topple day sanofi share dip then regeneron share have fall additional praluent be slate be pull shelve feb federal circuit judge doesn grant stay injunction pending appeal analyst have already largely remove praluent expectation regeneron butt write research report monday fortunately regeneron sanofi time approval dupilumab treat extreme atopic dermatitis look likely say fda deem sanofi facility acceptable regeneron have backup third party facility use need write research report forecast sale consensus be ibd take analyst be largely cautious biotechs enter earning season incyte be grab bullish view slew potential blockbuster drug get more new america butt keep outperform rating price target regeneron stock stock market today regeneron stock slip sanofi edge fraction regeneron pipeline have deliver more disappoint butt say dupilumab bullish eylea injection wet macular degeneration diabetic macular edema macular edema follow retinal vein occlusion regeneron face competition novartis nvs earning conference call analyst last week novartis note phase datum wet amd drug rth be due novartis be seemingly aim fewer objection adnan write eylea set high bar add be worth watch be rth dry patient remain nonresponsive eylea similar eylea gain share lucentis avastin write month regeneron preannounce eylea sale sequentially growth have slow past quarters consensus still see year year growth guide be well receive butt write related regeneron sanofi claim amgen ldl buster patent too broadodd be regeneron sanofi amgen patent battle sanofi hammer judge ban amgen rivale ldl buster
196,REGN,dow jone industrial average index nasdaq composite hit fresh record high president trump say ll have phenomenal news tax cut soon nvidia nvda crushed earning view share fall raft earning twitter twtr growth have come standstill whole food market wfm plan close store lockheed martin lmt other defense firm mull deal tweeter chief dow jone industrial average index nasdaq composite rally fresh time high fuel trump pledge airline executive ll announce big news taxe few week earning be still heavy nvidia headline several highly rate chipmaker yum brand yum restaurant report well cybersecurity fiber optic play gold price rise year treasury yield fall once again find support day line semiconductor company nvidia nvda maxlinear mxl microchip technology mchp inphi iphi top wall street target december quarter result nvidia earn share ex item year year january sale rise straight quarter accelerate revenue growth analyst have expect cent ep sale nvidia guide line sale slightly lower gross profit margin nvidia share initially rally friday morning reversed finish session maxlinear guide sale slightly analyst target microchip inphi guide sale earning estimate higher current quarter intel intc say expect datum center profit margin decline time send share thursday month low trading day line recent session day earlier white house intel announce investment arizona plant related nvidia earning sale crush view guidance be so socrude price rise cent barrel international energy agency say opec compliance output cut be more qatar say opec extend production curb midyear gasoline supply unexpectedly fall latest week crude stockpile rise far more expect domestic production picked parsley energy pe announce be buy net acre permian basin second acquisition lucrative shale region month bp bp swung profit fall short analyst view company expect spend more oil major overall have give mixed capital spending outlook year related struggle expand power user base face competition facebook fb snapchat other twitter twtr report growth have essentially stall adjust earning be flat do top view revenue rise just far analyst estimate sale growth decelerate straight quarter ad revenue actually dip election year donald trump headline grab daily tweeting twitter also give dismal guidance share tumble thursday friday related president trump meet airline executive white house thursday discuss cut regulation modernize air traffic control system obsolete aviation infrastructure also tease announcement come next week be phenomenal term tax airline related group praise trump understand support airline industry delta air line dal american airline aal other take follow meeting overall market earlier week alaska air group alk beat view forecast flat unit cost even industry face higher expense due new labor agreement related lumentum lite report gaap fiscal earning beat view revenue miss expectation also give mixed guidance share lumentum core business be optical communication surge week ceo discuss emerge sensor market opportunity not include company guidance analyst speculate apple iphone design apple have multiple device supplier fabrinet fn provide optical packaging assemble optical electronic device other manufacturer report fiscal earning growth revenue better expect be second straight quarter accelerate profit growth best ep gain year fabrinet gain more related president trump be major topic cowen aerospace defense industrial conference lockheed martin lmt cfo bruce tanner say official fill key acquisition spot pentagon have bigger impact demand trump involvement deal northrop grumman noc say contract negotiation lockheed drive price haven change trump blast plane high cost raytheon rtn be wait see trump do corporate tax plan regard export boee ba ceo dennis muilenburg be still bullish deal sell airplane iran trump threaten reverse nuclear deal company confirm commitment singapore airline good sign post broader widebody market related yum brand yum parent kfc taco bell pizza hut report mixed result company say bring outside expert evaluate pizza hut chain turn disappointing not acceptable result instinet analyst mark kalinowski say be time pizza hut be divest yum rise nearly week breaking month high buffalo wild wing bwld result badly miss view analyst point loyalty program delivery test future positive activist investor want sport centric chain refranchise more also boost share buffalo wild share rally sharp weekly loss solid weekly gain yum china yumc recent spin yum china business report mixed result do panera bread pnra yum china stock fall panera share shot more bust base record high dunkin brand dnkn report better expect earning sale send share higher online food delivery service provider grubhub grub report ep cent miss consensus cent face increase competition amazon other grubhub revenue rise slightly beating more consumer use service year year grubhub stock skid nearly week fall day line entertainment heavyweight walt disney turn mixed result tuesday better expect ep decline surprise revenue drop espn abc parent also say expect debut stream sport service year address chatter surround succession plan ceo bob iger say do be best interest company be open stay top spot june expiration contract disney share fall hasbro have report earning jump share analyst view revenue climb also beating view disney princess frozen toy be bright spot sluggish holiday season retail sector hasbro stock rise more time high ibd tipp economic optimism index hit year high february rise tenth point sign confidence trumponomic reading signal optimism economist be still unsure growth live rise confidence least term positive sign come drop initial jobless claim week end feb second lowest level year related gilead science gild top revenue adjust ep share crash month low light hepatitis drug sale guidance segment slip year year allergan agn beat expectation crushed view sanofi sny result be mixed ep lag penny mallinckrodt mnk top analyst model guidance specialty generic be light regeneron regn ep just beat sale lag eylea guidance be light federal judge stay halt sale praluent pending appeal regeneron partner sanofi patent ruling favor amgen cholesterol fighter repatha related system reseller cdw cdw earn cent nickel view sale rise just slightly view share still shot akamai technology akam earn cent share flat vs year earlier revenue climb top view share tumble content delivery network specialist plan heavy spending beef global server internet infrastructure whole food market wfm meet view ep decline natural food grocer sale rise less expect same store sale fall again whole food also give weak guidance announce plan cut store count first time whole food share rebound rise nearly qualys qlys earn cent view sale just view tech security firm give weak full year earning revenue guidance qualys share fall nearly so far week flirt buy point twilio twlo unexpectedly break even revenue rise also view twilio give weak ep guidance twilio cloud base software provide real time messaging service business alert client brink bco earn cent share year earlier cent view armored car service revenue grow best year vs estimate brink stock shot coherent cohr spiked so far week hit fresh time high laser maker report ep gain revenue rise accelerate growth easily beating view vulcan material vmc earning fall cent share cent estimate revenue rise vs view gain vulcan material also give ebitda guidance be slightly view construction aggregate firm have rally follow donald trump election hope infrastructure boom stronger economic growth lower taxe fall nearly friday morning zillow earn cent share revenue beating view real estate information web site sale guidance have midpoint be slightly consensus zillow zg class share tumble close day average
197,REGN,regeneron regn sanofi sny argue amgen amgn patent cover ldl buster repatha be too broad friday duo ask federal judge stay permanent injunction rival drug praluent pending appeal ban praluent be set go effect feb regeneron sanofi argue request injunction be likely be invalidate appeal base numerous flaw underlie judgment include validity amgen patent patent amgen didn identify structural feature common genus rather defined genus base antibody bind regeneron sanofi write repatha praluent prevent pcsk bound ldl receptor praluent be different antibody different structure remarkably however district court preclude appellant present evidence praluent own structure thereby prevent appellant show jury repatha be more structurally similar antibody influenza rabies virus be praluent write ibd take drug stock take beating last week commentary president elect donald trump require new bidding procedure curb spiraling drug price get scoop ibd industry theme argument regeneron sanofi say injunction cause irreparable harm stay pending appeal not irreparably harm amgen injunction praluent be counter public interest regeneron sanofi say cite case involve ebay ebay case set number prerequisite issue permanent injunction case involve thousand patient shouldn be first court grant ban public interest put simply be not case cellphone tablet be heart attack stroke regeneron sanofi write be exaggeration say injunction take lifesave medicine away thousand patient leave adequate replacement close bell stock market today regeneron stock have topple hardest sanofi stock follow amgen stock dip fraction close related sanofi acquire biomarin wake amgen ldl brouhaha regeneron sanofi hammer judge ban amgen rivale ldl busteramgen regeneron ldl buster boost small cap biotech
198,REGN,biotech amgen amgn likely triumph patent battle regeneron pharmaceutical regn sanofi sny require duo pull ldl buster praluent shelve unprecedented first leerink analyst geoffrey porge say friday regeneron sanofi have ask federal circuit judge grant stay injunction day allow market praluent appeal typically run month porge write research report friday odd don look good specialist believe regardless ultimate merit regeneron sanofi case face unprecedented probably first brand pharmaceutical product withdrawal middle quarter write most important catalyst be federal circuit extend stay porge say permanent injunction pis grant federal district court case involve ebay only party be grant stay ibd take alnylam pharmaceutical medicine company have different enough ldl drug shouldn touch amgen patent analyst say medicine co present datum annual jpmorgan healthcare conference check key take away meeting regeneron sanofi case be first time brand drug be pull shelve result patent litigation have make argument public interest not be serve pull praluent offer lower dosage amgen repatha examine medical device case district court have stay pi case federal level pi be affirm not extend result removal product market precedent appear be stack regeneron sanofi porge say regeneron sanofi public interest argument porge note public interest be actually better serve siding patent holder thus encourage risky investment require bring innovative product market porge also look several outcome possible case be remand district court federal circuit also require amgen regeneron sanofi seek settlement assistance circuit mediation office process only happen case amgen biotech firm market cap be unlikely settle write company notoriously take stance never settle ip dispute vigorously defend company ip evidence blockage market entry roche epogen competitor mircera infringe patent expire stock market today amgen stock rise regeneron rise sanofi rise related sanofi acquire biomarin wake amgen ldl brouhaha regeneron sanofi hammer judge ban amgen rivale ldl buster
199,REGN,regeneron regn sanofi sny stock be hammer friday district judge ban ldl buster praluent selling ruling infringe pair patent biotech amgen amgn see share jump stock market today regeneron stock topple sanofi stock fall amgen stock other hand rise hit highest price late october regeneron sanofi have say plan appeal decision amgen ceo robert bradway praise injunction statement late thursday protect intellectual property be essential industry reinforce incentive large risky investment make innovation bring forward new medicine treat serious disease amgen repatha praluent be pcsk inhibitor lower bad ldl cholesterol blood defense regeneron sanofi argue more patient praluent be able hit acceptable ldl level low milligram dose ibd take bradway discuss amgen expectation exclusive interview ibd amgen argue suffer irreparable harm say monetary damage be insufficient judge side amgen note public interest be serve have low dose praluent available patient injunction set praluent removal shelve win go effect day give regeneron sanofi time appeal seek settlement amgen leerink analyst seamus fernandez doubt amgen cave stance settlement believe stay injunction pending outcome appeal be most likely outcome view write research note amgen firm stance settlement suggest drag time permanent injunction go effect end january be unlikely actually be earning positive sanofi fernandez note pcsk sale have be lackluster sanofi add euro earning share ex item eliminate praluent marketing say fellow leerink analyst geoffrey porge say regeneron sanofi have be overspending praluent product associate quarter loss loss be increase company work promote praluent outside note fernandez keep outperform rating sanofi stock rbc analyst michael yee estimate long term peak sale repatha hit worldwide result praluent removal market bottom line important development today significantly improve visibility long term peak sale repatha write report medium term amgen investor still want see better visibility enbrel pricing neulasta biosimilar coherus bioscience say yee maintain outperform rating amgen stock fellow rbc analyst adnan butt cut price target regeneron stock keep outperform rating chance reversal be low write regeneron still have strength eylea dupilumab morgan stanley analyst matthew harrison call ruling amgen expect expedite review process run month other analyst expect amgen drag appeal process year harrison have line view biotech sector whole worst amgen now receive likely sizable royalty praluent sale best injunction stand amgen be monopoly player large market write note scenario allow amgen accelerate sale ramp repatha related regeneron sanofi ldl buster risk judge uphold amgen patentswhich top biotech stock be slate triple digit gain
200,REGN,xu stock open higher monday follow lead european bourse make marked stride afternoon trading wall street be unfazed weaker expect durable good report nasdaq climb so call fang stock facebook fb amazon com amzn netflix nflx google alphabet googl show gain less dow jone industrial average add facebook add wall street journal report company be interested produce original content follow lead netflix amazon facebook indicated willing commit production budget high episode european index be make solid gain paris cac lead way germany dax add london ftse picked share nestle nsrgy make headline early trading activist investor dan loeb third point disclose stake company chief executive marc schneider take ceo post nestle begin year nestle share open higher elsewhere grubhub grub slump morgan stanley downgrade share equal weight overweight price target other analyst move make headline share regeneron regn slip open sanford bernstein downgrade market perform outperform price target costco cost add raymond james upgrade retailer outperform market perform institutional investor have be selling share recent day costco gap day move june amazon announce plan acquire whole food market crude oil august delivery edge barrel year treasury yield edge lower basis point related tech giant lead stock watch name be actionable best stock buy watch
201,REGN,even nasdaq reversal monday trading many lead stock have significantly rebound past week sector rotation have continue rout technology stock biotechs homebuilder see increase institutional interest biotech stock once again rotate back favor celgene celg be lead stock head charge big
202,REGN,regeneron pharmaceutical regn go heart debate tuesday question validity amgen amgn patent ldl cholesterol bust drug repatha analyst say follow court hearing wall street be split wednesday appeal court process land analyst investment bank evercore expect regeneron sanofi sny triumph counterpart mizuho say chance amgen succeed stock market today regeneron rise amgen climb share regeneron partner sanofi be tuesday regeneron amgen battle minute appeal court hearing stake be fate regeneron sanofi drug praluent judge previously side amgen say regeneron sanofi praluent infringe amgen patent drug repatha judge stay injunction praluent pending appeal court process be likely end line appeal court side amgen mizuho analyst salim sy say note client supreme court take very few patent case decision have broad implication future patent struggle evercore analyst umer raffat say audio record follow meeting amgen patent cover entire antigen describe bound regeneron say be too broad regeneron do be go heart debate say know patent shouldn be valid begin say regeneron be say be amgen patent focus invention be not do amgen say praluent be too similar drug repatha antibody patent be circumvent tweak amino acid then point investing drug development return win be realize sy say ibd take bioverativ bivv biogen biib spinoff have year average return growth rate see be smart investment visit ibd stock analysis regeneron note dow pfizer pfe time try unsuccessfully develop similar drug also belong pcsk inhibitor class pfizer hold intellectual property pcsk inhibitor neither repatha praluent exist example illustrate even similar antibody be different sy say raffat note report eli lilly lly several other file brief support regeneron important note praluent be boot market amgen repatha be sole pcsk inhibitor market so case boil policy vs emotion sy say amgen win praluent be take market be pushback only have pcsk market lessen competition say praluent be beat injunction signal patent be not relevant think so judge really seem be consider ramification decision evercore analyst akash tewari say record amgen strategy patenting antigen broader antibody have yet be test court related regeneron sanofi undercut amgen abbvie rheumatoid arthritisteva pharma run migraine trial lilly amgen biotechs fall cancer partnership bristol myer
203,REGN,relatively quiet week market be anything quiet ibd stock ibd index be week friday morning easily outpace general market boost handful breakout rash new high group end week only few chart show valid basis
204,REGN,xbiotech stock regeneron regn amgen amgn biogen biib spin bioverativ bivv have be boom week celgene celg have also joined party now trading upper end buy zone follow wednesday important metric look stock be higher relative strength rating celgene now clear threshold jump thursday ibd proprietary rating identify market leadership worst best score rating show stock price behavior trail week compare other stock database year market history reveal top perform stock often have rs rating least begin biggest price move celgene break wednesday first stage flat base end thursday session just upper end buy range once stock be more initial entry price consider extend earning growth decrease last quarter revenue gain moved higher company earn rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx be also group highest rate stock related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
205,REGN,key index fund be modestly higher thursday biotechs help regeneron pharmaceutical regn lead upside oil gold bank homebuilder lag xsmall cap outperformed ishare russell iwm powershare qqq qqq add spdr spy spdr dow jone industrial average dium be slightly higher remain buy range respective flat base entry financial homebuilder semiconductor be lower spdr regional banking kre spdr banking kbe fall breach day move average line continue shape flat basis ishare home construction itb slip remain multiyear high spdr homebuilder xhb be back flat base buy point vaneck vector semiconductor smh ishare phlx semiconductor soxx be slightly hold day line biotechs extend gain ishare nasdaq biotechnology ibb rise nearly spdr biotech xbi add etfs be extend recent flat base buy point regeneron pharmaceutical gain celgene celg advanced gold play advanced gold future gain ounce vaneck vector junior gold miner gdxj vaneck vector gold miner gdx be respectively spdr gold trust gld ishare gold trust iau climb apiece oil fund be mixed spdr oil gas exploration production xop pare gain vaneck vector oil service oih be flat powershare db oil dbo unite state oil uso lift stem recent slide be trading more week high related find happen stock market today celgene regeneron breakout biotech stock be next top biotech stock just buy range boom continue
206,REGN,biogen biib ionis pharmaceutical ion stock pop thursday european commission approve application costly spinal disease drug spinraza month drug launch close bell stock market today biogen stock climb share partner spinraza ionis jump finish regular session increase outperformed ibd company biom biotech industry group rise just fraction european regulator approve spinraza treat most common form spinal muscular atrophy affect patient biogen say news release drug cost treatment cost first year spinal muscular atrophy be cause degeneration certain cell lead wasting various muscle group approval come european medicine agency accelerate assessment program program similar effort food drug administration aim expedite access drug patient unmet medical need access spinraza vary country local reimbursement pathway biogen say company have be work health system government agency europe open access spinraza ibd take domicile biotechs pharmas benefit most president trump propose tax plan list include regeneron pharmaceutical regn gilead science gild biogen head ibd technology page closer look potential winner loser tax reform spinraza be approve type spinal muscular atrophy analyst have worry payer pushback hurt sale first quarter follow launch spinraza sale hit biogen say april help biogen ionis stock pop respectively ionis say biogen exercise right spinraza become responsible marketing development ionis have receive milestone payment date get tiered royalty sale percentage midteen related biogen earning top drug start biogen takeover prospect soured mere monthsamgen gilead biogen win lead biotech boom so
207,REGN,big cap have lose luster even have gain biotech stock such celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx xso far year big cap still lead advantage have fluctuated recent session low percentage point
208,REGN,xu stock index rally midday wednesday strength biom space nasdaq advanced add less blue chip dow jone industrial average be barely day break even line volume rise major exchange biom stock show exceptional strength nasdaq day top gainer be biom stock regeneron pharmaceutical regn rise incyte incy biomarin pharmaceutical bmrn biogen biib celgene celg celgene break consolidation clear buy point volume soar more average pattern be first stage celgene have be consolidate almost year consolidation long push relative price strength rating be have happened celgene rs rating see ibd stock checkup be mean stock be lag third market price performance ibd style investor put less emphasis rs rating come long consolidation celgene earning picture be solid street expect earning rise year pretax margin last year be best least year blue chip meanwhile be mostly loser lead winner ratio intel intc caterpillar cat be day biggest loser stock dow fall day top gainer be inc business software provider gap volume stock usual pace stock be move rumor potential merger privately hold bmc software related real secret stock be so simple forget itprice target raise boee red hat adobe lower chevronis bull market still healthy be sign major correction see ibd big picture
209,REGN,xstock trade mixed wednesday apparently unaffected surprising reshuffle saudi arabia succession plan country king replace nephew son heir throne wednesday action come late sell tuesday send general market fall record high tech heavy nasdaq lead major market index rise edge slightly higher dow jone industrial average turn negative dow industrial nike nke set pace advance merck mrk follow rise downside chevron cvx fall be downgrade neutral macquarie crude oil price have fall bear market status high boee ba fall cowen raise price target airplane maker intel intc decline software company surge almost news report company go private merger deal bmc software private company other advancer include advanced micro device amd carmax kmx rise respectively downside retailer foot locker fl decline energy firm continue recent slide helmerich payne hp chesapeake energy chk fall respectively earning front red hat rht jump beating fiscal earning sale target late tuesday stock have be testing week line recent trading session extend buy point computer software company adobe system adbe trade higher exceed street estimate fiscal lead stock stock market today paypal pypl rally receive upgrade pacific crest security analyst raise stock overweight sector weight ibd recent ipo floor decor fnd look extend day winning streak rise share hover ipo base buy point other top performer include regeneron pharmaceutical regn paycom software payc regeneron rise gruhub moved downside regional bank east west bancorp ewbc fall china stock new oriental education edu decline transunion tru fall related earning calendar analyst estimate stock watchboeing adobe red hat price target hike chevron downgradeddow jone industrial average dow stock news analysisadobe crush wall street estimate guide higher
210,REGN,share medicine company mdco continue day uptrend wednesday splitting partner alnylam pharmaceutical alny duo unveil robust phase result cholesterol bust drug afternoon trading stock market today medicine co stock climb nearly close nearly month high stock be upswing begin nov biotech stock have benefit election donald trump be see less likely tackle high drug price alnylam stock finished more fall second straight day still share be past week tuesday medicine co alnylam reveal strong result inclisiran belong class ldl lower drug call psck inhibitor pcsk be enzyme bound ldl cholesterol prevent ldl be remove blood rival pcsk inhibitor include repatha amgen amgn praluent regeneron regn sanofi sny ibd take biotech drug stock have benefit election donald trump worry linger ll appeal affordable care act get full scoop include potential winner loser ibd industry theme inclisiran reduce ldl cholesterol day day patient receive milligram dose patient trial day inclisiran cut ldl day company say patient receive dose day see ldl reduction day day rbc analyst adnan butt estimate patient likely not have be dose more time year butt say safety question have be address single patient die heart attack say medicine co key opinion leader say inclisiran wasn blame liver enzyme elevation single patient be attribute statin therapy importantly do not appear be dose dependent relationship safety parameter butt write research report have outperform rating medicine co stock boost price target still payor block pcsk prescription rbc analyst michael yee write separate report adjust payor hurdle medicine co pull annualize sale butt say base percentage pcsk prescription block sale amgen regeneron duo be printing run rate restriction be open yee write happen amgen present positive cardiovascular outcome trial cvot datum be incremental positive fundamental sentiment driver pcsk help move needle get payor open access time change guideline drive more usage write yee have outperform rating amgen stock be fraction wednesday afternoon related biotechs be derisked buyable ahead election day medicine co jump bullish cholesterol drug viewsalnylam dife end heart drug development mortality imbalance
211,REGN,ibd medical biotech biom group continue post election advance monday rise nearly intraday regeneron pharmaceutical regn be few big cap biotechs move heavily strong volume slew smaller biotechs big gain loss include supernus pharmaceutical supn corbus pharmaceutical crbp dynavax technology dvax puma biotechnology pbyi regeneron pharmaceutical rise stock market today nearly hit month high stock market today best know eye care drug eylea regeneron have surge hit year low nov report quarterly earning supernus pharmaceutical leap cross back day move average supernus have rally straight session regain day last week stock break short consolidation september hit record high supernus break render old buy point moot supernus develop drug central nervous system disease monday say sale rise corbus technology shot back day line corbus rise high intraday last month peak corbus announce positive stage clinical trial result resunab treat diffuse cutaneous systemic sclerosis be safe exceed company expectation downside dynavax technology crater hit lowest level december fda didn approve hepatitis treament request additional information complete response letter puma biotechnology lose stock struggle make headway crash peak puma bio announce breast cancer patient take experimental treatment neratinib need drug not deal serious diarrhea side effect
212,REGN,ibd company medical biom biotech industry group surge monday top broader nasdaq market ahead election day only name be derisked buyable now say rbc analyst adnan butt butt suggest investor share aerie pharmaceutical aeri medicine co mdco seattle genetic sgen tesaro tsro recently complete strong trial result be less risky other drug stock also potential candidate none be ibd buy zone most recently seattle genetic stock achieve cup handle formation july then gain more early september so investor be encourage take least profit stock close higher stock market today aerie stock rise seattle genetic gap tesaro add medicine co gain collectively biotech industry group rise medicine sank hour say discontinue development mdco potential cholesterol drug ibd take biotech ionis be more key spinal muscular atrophy drug study partner biogen neither be ibd stock move list so really speeding today check last week aerie pull new drug application food drug administration rhopressa glaucoma drug third party manufacturer say facility wasn prepared extension give aerie time include successful datum additional trial stock be derisked rhopressa phase datum make appear approvable glaucoma butt write research report monday carbavance urinary tract infection cholesterol bust pcsk medicine co look good butt write seattle have adcetris hodgkin lymphoma anaplastic large cell lymphoma opportunity expand other cancer meanwhile tesaro be likely expand niraparib outside ovarian cancer lung breast prostate cancer butt say niraparib be battle already approve lynparza rival astrazeneca azn analyst say astrazeneca olaparib appear be capable treat much smaller patient population niraparib butt second bucket drug stock pick risk still remain bioscience apto curis cris gempshire therapeutic gemp intra cellular therapy itci nabriva therapeutic nbrv synthetic biologic syn valuation appear very cheap cancer drug start phase trial say arqule arql endoctye ecyt ocular therapeutix ocul biopharma pdli regeneron regn scynexis scyx spectrum pharmaceutical sppi xoma xoma buy be matter timing butt write upcoming datum event be consider overhang reason be simply not enough datum available related tesaro bolt ovarian cancer vs astrazeneca abbvieclovis oncology fda skip panel review new drug
213,REGN,be etf market story week election uncertainty jangled investor nerve voter head poll tuesday elect next president unite state spdr spy wobble stock market today close lower fourth straight trading session exchange trade fund proxy broad market sit august high post weekly loss close almost even week move average support level sector fall week material fared relatively well fall week gold break resistance ounce level give mining company boost technology fared worst tumble week facebook fb forecast slower revenue growth send stock sharply lower friday biggest gain nonleveraged etfs come biotechs spdr biotech xbi jump nearly post weekly loss big volume share regeneron regn pop drugmaker soundly beat earning estimate be not enough keep stock fall sixth week row alexion pharmaceutical alxn give early gain more close continue post earning surge too book weekly loss unite state oil uso commodity exchange trade investing crude future fall third consecutive day post weekly loss west texas intermediate wti crude future fall sharply concern inventory well ability major oil producer strike deal curb output ibd take best stock tend have high margin be steady grow so look company have pricing power withstand rise wage primer profit margin read investor corner ibd make research easier proprietary smr rating combine sale growth profit margin return equity official figure october release friday show unemployment rate dip expect average hourly wage rise better expect here look performance major exchange trade fund key asset class stock market today relative strength rating rs rating measure stock price performance last month vs stock etfs scale best possible spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
214,REGN,regeneron pharmaceutical regn stock bound friday cent earning beat share be largely muzzle pending court decision pit regeneron sanofi sny biotech amgen amgn stock market today regeneron stock rise earlier rise much share be year ibd company medical biom biotech industry group have fall volatile election season high high drug price controversy several disruptor rout regeneron stock rbc analyst adnan butt write research note regeneron sanofi be await delaware court decision amgen file lawsuit say cholesterol drug praluent violate patent repatha be pcsk inhibitor pfizer pfe just end development similar drug suit amgen be ask praluent be take shelve ibd take spdr biotech etf jump regeneron earning beat alexion pharmaceutical continue wave get foot wet etfs visit etfs fund page good datum rival ophthotech opht novartis nvs be work phase trial fovista also be painful regeneron butt note fovista drug combat wet age related macular degeneration amd compete regeneron bread butter drug eylea eylea pull sale vs year earlier quarter edge view regeneron raise low end eylea guidance now see growth be sale praluent come vs amgen repatha be line consensus butt write year consensus expect praluent sale sanofi reimbursement praluent be expect dip high end guidance early friday regeneron post earning share ex item sale respectively vs year earlier quarter ep top consensus analyst poll thomson reuter sale miss expectation update guidance imply regeneron end evercore analyst john scottus estimate report be midpoint related align incyte grubhub best stock play goldman sachs
215,REGN,share drug giant pfizer pfe fall tuesday company say end development cholesterol lower drug project be blockbuster reduce earning outlook current quarter post ep just miss wall street expectation pfizer stock fall stock market today member dow jone industrial be trading nearly month low touch year high aug cease work injection drug call bococizumab be unexpected company say prove have unexpected side effect be become less effective wall street have modeled peak annual sale bococizumab evercore isi analyst john scottus say note client pfe be clear do not see attenuation benefit competitive datum amgen amgn regeneron regn write problem appear be bococizumab specific scottus say ibd take pfizer megadeal buy allergan go bust april takeover time warner go same direction drugmaker say revenue rise year earlier quarter earning share inched cent revenue meet view ep miss penny accord evercore isi analyst john scottus pfizer now guide ep earlier guidance sale vs earlier guidance pfizer attribute miss higher expect cog cost good sell tie foreign exchange rate scottus say sale breast cancer drug ibrance be marginally consensus scottus say prevnar deliver small beat sale prevnar pneumococcal conjugate vaccine miss forecast innovative health business execute strongly latest product launch recent acquisition medivation anacor be provide new term opportunity potentially drive incremental growth business product pipeline continue mature pfizer ceo ian read say earning release see business highly focuse therapeutic area be best position deliver value patient maintain overall high level financial flexibility discipline be strong position support strategic initiative business remain opportunistic business development activity addition continue actively manage cost structure august pfizer announce agreement acquire medivation maker prostate cancer drug xtandi come new york base pfizer ireland base allergan agn april call plan merger have be industry largest ever regulator set roadblock so call tax inversion merger company look set headquarters lower tax region such ireland september pfizer say not split separate company move have mulled several year have be expect separate essential health business consist older patent medication innovative health business be dedicate newer drug related surprise twist pfizer win split uplilly abbvie lead ranking pfizer challenged
216,REGN,spending research development have leveled company increase stock buyback dividend say goldman sachs company do better other get most bang buck new research report goldman name company say be best position make dollar work make list be align technology algn amazon com amzn alphabet googl grubhub grub incyte incy universal display oled palo alto network panw regeneron pharmaceutical regn meanwhile intel intc microsoft msft google parent alphabet amazon drugmaker johnson johnson jnj lead way total spending goldman sachs also analyze intensity measure percentage sale other metric regeneron salesforce com crm apple aapl amazon netflix nflx have experience outsized growth come gross profit well price return same period say goldman report ibd take goldman sach favorite palo alto network belong ibd learn many growth stock grubhub sport highest possible composite rating align technology have cr composite rating be part slim investing share total spend pie have be pretty stable suggest corporation have likely be maintenance mode spend opposed be expansion mode say report tech company lead spending follow health care consumer discretionary industrial sector say goldman related do tend buy stock too late lesson align stoke fire deep durable melanoma drug resultsole leader universal display crack misscisco palo alto symantec gear cloud cybersecurity shift
217,REGN,stock market open lower tuesday appear settle follow monday record breaking advance dow jone industrial average logged fresh record high monday tuesday moved blue chip index trade tech heavy nasdaq decline yesterday surge dow industrial mcdonald mcd pace advancer rise american express axp follow gain american express break flat base buy point downside dow component drop more early tuesday chevron cvx verizon communication vz exxon mobil xom general electric ge advanced micro device amd rise alexion pharmaceutical alxn moved homebuilder lennar len gap higher report earning sale beat street expectation other homebuilder follow suit pulte home phm toll bro tol rise downside chipotle grill cmg drop update outlook show higher operate cost automotive part retailer reilly automotive orly advance auto part aap decline apiece remain week lows energy name decline unison price crude oil drop transocean rig marathon oil mro fall more lead stock stock market today tesla tsla give back early gain still rise report release national safety transportation board find fault tesla automate pilot system involved highly publicize crash model driver be kill meanwhile fang member netflix nflx fall slightly have price target raise guggenheim security analyst have best idea rating video streamer other analyst action include upgrade graphic chipmaker nvidia nvda moved pacific crest security raise nvidia sector weight underweight action ibd show new issue floor decor fnd jump follow monday regeneron pharmaceutical regn rise downside china education stock new oriental education edu tal education tal decline more related lennar earning top view share eye buy pointnetflix price target hike nvidia upgrade nike pt lowereddow jone industrial average dow stock news stock news quote facebook amazon netflix google
218,REGN,small cap outperformed second straight session afternoon trading friday major stock index didn do too bad dow jone industrial average nasdaq composite hit time high nasdaq lead way rise help strength broadcom avgo biotech regeneron regn dow add russell gain heel thursday gain small cap index be back day move average try punch level volume nyse nasdaq be tracking slightly lower thursday level broadcom surge strong earning head friday be still buy range buy point extend price now regeneron meanwhile look poise sixth straight weekly price gain share rise nearly extend buy point boee ba microsoft msft outperformed dow rise friday job report show sluggish job growth market didn seem mind nonfarm payroll rise well consensus estimate unemployment rate edge lower datum be good news dove bad news hawk money flow bond news send year treasury yield lower basis point stock market today airline outperformed delta air line dal report strong traffic datum share jump reclaim buy point slumping tuesday heavy volume ibd ttm technology ttmi be nice gainer work flat base conventional entry new york mercantile exchange benchmark wti crude oil july delivery fall barrel goldman sachs note caution recent production cut opec have be extend even more cut expire early next year related hot chipmaker broadcom soar strong earning growth guidancebig airline fly buy range strong revenue traffic oil war shale opec consumer
219,REGN,xu stock index pop higher midday monday nasdaq wake week slumber tech lean nasdaq advanced dow jone industrial average rise respectively volume stock market afternoon be run lower major exchange friday be option future expiration day boost volume make tough comparison dow score new high nasdaq be still almost high nasdaq lose last week week previous ibd industry group day leadership come variety group growth oriented other defensive growth group more include retail internet lodging homebuilder biomedical biotechs defensive play more include tobacco water utility food grain internet retail space latin american online marketplace mercadolibre meli rise follow recent bounce day line establish secondary buy zone china base jd com jd gap also follow recent bounce day line hong kong base alibaba baba gap lodging midcap extend stay america stay advanced week high homebuilder lennar len rise average volume company report quarterly result tuesday open street expect earning cent share be year figure revenue be expect rise accord zack investment research regeneron pharmaceutical regn chug higher remain buy zone defensive side tobacco firm vector group vgr gain find support converge day day line related cancer kill drug stock ignite biotechs look best stock buy start search here
220,REGN,federal judge side biotech amgen amgn late tuesday uphold pair patent related ldl cholesterol buster repatha deal blow regeneron regn sanofi sny make rival drug rbc analyst michael yee say unlikely district court judge sue robinson issue injunction pull regeneron sanofi praluent shelve create hole size billion amgen fill importantly estimate consensus view sanofi regeneron not be block market yee write research report wednesday be think amgen stock go more pretty quickly give billion revenue risk competitor ibd take exclusive interview ibd amgen ceo robert bradway touch cgrp migraine alzheimer oncology market decision tuesday be just step resolve matter robinson order injunction praluent regeneron sanofi appeal higher court more likely determine royalty potentially be paid amgen say yee most investor believe court not block second drug regeneron add competition support public good write suit begin october amgen accuse regeneron sanofi violate patent also target pcsk protein block bad cholesterol food drug administration approve praluent regeneron sanofi drug july march jury agree amgen regeneron sanofi ask robinson begin new trial stock market today amgen stock rise regeneron stock rise sanofi stock however fall yee keep outperform rating amgen regeneron stock related top biotechs be slate triple digit gainsregeneron likely jump amgen ldl buster expectation too high
221,REGN,regeneron regn sanofi sny eye biomarin bmrn medicine co mdco wake judge ban amgen amgn rivale ldl buster rbc leerink analyst suggest friday late thursday district judge rule regeneron sanofi praluent infringe pair amgen patent repatha pcsk inhibitor lower ldl bad cholesterol blood decision send regeneron sanofi stock red stock market today regeneron stock fall sanofi stock fall amgen have patent reaffirm enjoy gain ibd take biotech sector suffer raucous election year leader end year triple digit gain be stock pick list get deep dive ibd industry theme biomarin pharmaceutical stock rise medicine co jump suggestion regeneron pharmaceutical sanofi issue bid make lose potential removal praluent market biomarin have market cap medicine co have cap france base sanofi have market cap have be particularly vexed recent year lose medivation blockbuster cancer drug xtandi battle pfizer pfe last year last month sanofi be say be jockey johnson johnson jnj swiss biotech actelion pharmaceutical revenue loss theoretically cause sanofi continue increase activity have written biomarin make good fit pure play orphan franchise be synergistic sanofi orphan franchise rbc analyst michael yee say friday research note yee estimate biomarin deal slightly sanofi acquisition price genzyme several year have outperform rating price target biomarin stock leerink analyst joseph schwartz see medicine co appeal regeneron sanofi party interested pcsk space medicine co alnylam pharmaceutical alny have partner inclisiran drug aim lower ldl cholesterol schwartz note aftermath praluent injunction set go effect day inclisiran be second line come market pcsk space new england journal medicine article describe inclisiran rna interference therapeutic inhibitor pcsk november medicine co alnylam deliver strong result inclisiran phase trial investor expect more clarity phase testing schwartz write have outperform rating share medicine co related regeneron sanofi ldl buster risk judge uphold amgen downgrade increase boston st jude rivalry
222,REGN,walt disney gopro gpro mcdonald mcd jack box jack shake shack shak regeneron pharmaceutical regn see analyst action friday rbc capital market upgrade medium titan outperform sector perform up price target think tide be turn sentiment drive improve affiliate trend portfolio optionality rotation time warner write analyst steven cahall late thursday disney share close stock market today still buy range wednesday time warner twx share dip action camera maker receive downgrade underperform longbow research share drop friday gopro ceo nick woodman tell ibd late thursday company be work consumer degree video camera mass interest spherical capture vr be still early ibd take more news stock analysis ce vegas week check full coverage major tech event ub cut golden arch rating neutral buckingham research downgrade shake shack neutral buy shake shack say late thursday cfo jeff uttz retire march name zach koff new coo meanwhile telsey advisory increase price target jack box have outperform rating stock mcdonald share rise shake shack tumble jack box fall rbc capital market cut drug stock price target outperform rating thursday federal judge rule regeneron partner sanofi sny infringe patent hold amgen amgn regeneron share tumble
223,REGN,investor want sharpen selling skill growth stock always pay attention happen chart be ibd philosophy daily weekly chart truly be best friend stock market give fact not opinion just investor now use chart correctly don have sit watch tick view daily chart session close determine red flag have be raise weekly chart provide most insight supply vs demand end week big red flag help time exit watch downside price reversal close session lows especially volume soar well normal level downside negative reversal take place stock run sharply intraday then change course end price flat day reversal take place daily chart appear weekly monthly chart reversal occur individual stock well market index nasdaq not downside reversal be cause concern high price stock turn tail end point lower average volume isn necessarily worrisome intraday boom bust take place stock doesn resume rally keep close watch mean institutional investor be not come grab share negative reversal close day price low be especially bad follow long sharp run many time turnover be sharply average level past trading session ibd daily chart feature red line run volume bar signify day move average weekly chart red line represent week move average volume sometimes reversal mark fail late stage base such case sell fast cut loss take profit big downside reversal coincide climax run be key sell signal bad reversal involve heaviest daily volume start stock big move largest day point loss widest daily weekly price spread ever solar stock be red hot sunpower spwr best performer re-cover third pullback day move average follow initial december september stock ramp new high nov sunpower surge much intraday hit time high best level day stock be more start rebound month sunpower then show big change heart end lower huge volume price spread high low be nearly sunpower fall march keep slide last year trade single digit rebound do same signal happen today certainly regeneron pharmaceutical regn post sharp reversal aug last year even stock rise day big volume hit new high daily chart show finishing lower half intraday trading range stock cool form month double bottom base then break oct run past pivot point however just week later biotech stage unsavory price reversal nov regeneron rise high close more volume jump sharply rally quickly unraveled share be now more time high gold mining industry group randgold gold present very rare island top formation peaked july year day stock rally more volume more double share be also heaviest session jan however randgold finished lower half intraday range create price gap day low exceed prior day high note stock be already rise nearly vertical climax run state daily chart june july editor note column originally publish edition ibd view long historical chart stock please go ibd marketsmith charting stock screening service advanced investor
224,REGN,president elect donald trump republican congress be likely create friendly tax scenario prod more acquisition small mid cap biotech pool rbc analyst adnan butt say thursday early campaign trump propose cut tax repatriate cash stash abroad big drugmaker company such apple aapl alphabet googl microsoft msft avoid higher taxe keep billion dollar overseas similar effort former president george bush bring back accord fortune biopharma sector see boon trump proposal butt write research report pace accelerate change tax code support trend facilitate repatriation cash trap overseas bigger biopharma company write add trend be especially beneficial truly innovative biotechs cancer drug company bioscience apto arqule arql endocyte ecyt curis cris seattle genetic sgen tesaro tsro have advantage boost progression free survival pfs drug candidate write curis oral checkpoint inhibitor be truly disruptive say ibd take uncertainty linger drug biotech market concern trump upend american health care repeal affordable care act obamacare check industry theme more mean sector seattle genetic tesaro be work area keen biopharma interest write seattle have trial hodgkin lymphoma diffuse large cell lymphoma acute myeloid leukemia several solid tumor type tesaro be work treat ovarian breast lung prostate cancer butt also see promise aerie pharmaceutical aeri glaucoma drug regeneron regn wet dry age related macular degeneration diabetic macular edema medicine company mdco nabriva therapeutic nbrv scynexis scyn synthetic biologic syn xoma xoma be work treat unmet medical need gempshire gemp intra cellular therapy itci be look treat high cholesterol schizophrenia respectively used new mechanism more broadly rbc analyst michael yee call biotech coil spring post trump election world biotech stock have suffer uncertainty democratic nominee hillary clinton call tighter control drug price department justice investigation allege collusion long play biotechs yee say generalist investor aren totally ready jump back biotechs ibd company medical biom biotech industry group be year climb nearly wednesday postelection hype stock market today biotech group again rise time more larger biotechs leader be axovant science axon ultragenyx pharmaceutical rare respectively new environment biotech be not much bullseye republican congress sen bernie sander clinton lose bully pit think future rhetoric doesn mean much anything now make biotech more investable folk yee say related biotechs be derisked buyable ahead election day tesaro ovarian cancer drug have edge vs astrazeneca analyst
225,REGN,biotech stock climb third consecutive day tuesday mid cap tesaro tsro forge way largest company amgen amgn gilead science gild celgene celg be buyable now say mizuho analyst salim sy sy initiate coverage tuesday amgen gilead celgene stock buy rating also initiate biogen biib neutral rating lack medium term catalyst uncertainty former ceo george scango resign july be clear still think biogen have good program be matter time get excited again just not right now sy write research report have price target biogen stock slip cent tuesday ibd company medical biom biotech industry group lift fraction stock market today volatile election season have strangle share cause group topple past week ibd take sy have neutral rating biogen stock share be look better biogen ionis announce early efficacy phase testing spinal muscular atrophy drug check industry theme full take sy liken amgen jogger have price target stock fraction tuesday amgen most recent call thought amgen largely hum steady stock jogger write however amgen call week stock have come enbrel commentary call spook investor say sale be flat give contract negotiation amgen expect relatively little benefit net selling price change enbrel wall street have be predict decline amgen legacy business time sy see silver line new drug amgen repatha cholesterol bust pcsk rival sanofi sny regeneron regn praluent repatha already have food drug administration approval sale have suffer restrict access sy write repatha be currently phase testing treat cardiovascular outcome september meet primary secondary endpoint phase test coronary artery disease cv datum be expect sy call most important datum event amgen positive event pull amgen stock dump share hit year low friday manage close fractionally day gilead manage impossible launch hepatitis hcv drug sovaldi harvoni triple revenue become company sy write separate report duo be cure hcv therefore win last forever flip side develop cure be eventually disease be eradicate write great patient mean decline revenue time have be weigh gilead stock answer slope decline isn exactly clear gilead hep trio sovaldi harvoni epclusa bring sale vs year earlier quarter epclusa launch june july europe help offset decline sovaldi harvoni sy model year year decline hcv sale gilead gilead be work next leg growth sy say have price target gilead stock nonalcoholic steatohepatitis nash hepatitis hbv drug be still too early pipeline gilead be face nash competition intercept pharmaceutical icpt allergan agn gilead isn table pound buy stock be undervalue company likely perform time reward patient investor sy write gilead stock rise cent tuesday celgene be castle chemotherapy drug revlimid be moat sy say revlimid sale grow vs last year drive new market share gain increase duration revlimid be used treat myelodysplastic syndrome mds multiple myeloma mantle cell lymphoma mcl revlimid allow celgene grow next source revenue sy write separate report revlimid be still grow part business value add celgene part business be fairly well establish mature moat celgene have cancer drug durvalumab car conjunction astrazeneca azn juno therapeutic juno respectively celgene be also work next generation replacement revlimid be expect go generic be fully generic core celgene have ozanimod currently phase testing multiple sclerosis ulcerative colitis ged investigational crohn disease drug be central celgene investment thesis say sy have price target celgene stock rise tuesday related biotechs be derisked buyable ahead election day amgen gilead eli lilly eat abbvie humira sale analystgilead nash drug active promising lag challenge intercept tobira nash drug
226,REGN,major stock index hold big gain afternoon trading monday cheer news weekend fbi close investigation hillary clinton email issue second time various poll still point tight race day ahead election day latest ibd tipp poll show republican trump democrat clinton libertarian gary johnson green jill stein margin error poll be nasdaq composite rally help strength biotech stock rise dow jone industrial average add volume be tracking slightly lower friday level stock market today jpmorgan jpm unitedhealth unh microsoft msft outperformed dow gain apple aapl lag rise kgi security say iphone shipment be likely drop first half primarily due weak demand china biotechs lead nasdaq oo name biogen biib regeneron regn incyte incy show gain ibd component rise more include nvidia nvda report earning thursday close extend recent flat base entry group peer inphi iphi also do well monday rise nearly back day move average fail buy point ferrari race thunder higher score strong third quarter beat raise guidance year old new issue be buy point deep cup handle base recently just complete new handle alternate entry cent oct intraday high related trump lead widen point biggest yet november surprise ibd tipp pollapple iphone shipment likely drop first half biogen ionis rocket drug opportunity post trial
227,REGN,total prescription pfizer pfe eczema drug eucrisa have flattened recent week regeneron pharmaceutical regn sanofi sny dupixent have picked steam accord datum health care tracker ms meteoric rise prescription week eucrisa launch script topical eczema ointment have tally past week injection dupixent have yet see dip hit prescription week pfizer attribute flatter trend decrease free trial voucher eucrisa evercore analyst umer raffat write research report pfizer estimate third total script eucrisa be free trial voucher still eucrisa total prescription exclude free trial voucher be grow well most recent roll week vs previous week free trial voucher prescription be same period raffat say ibd take least analyst be predict boom biotech win be big name lead charge say head ibd technology page closer look stock look strong year demand look likely continue upward trend dupixent leerink analyst geoffrey porge say cite physician work dermatology biggest takeaway discussion be consistent suggestion physician believe moderate severe atopic dermatitis population be large larger moderate severe psoriasis population say physician interview expect start patient dupixent year end physician not comment dupixent use eczema be similar percentage patient receive biologic treatment psoriasis say believe have huge potential physician gain comparable experience overall average eczema patient see doctor be adult dupixent have potential be game changer pediatric eczema porge say child be likely be drug longer term adult physician believe moderate severe eczema pediatrics experience continue disease adulthood now recognize be associate more complex multisystem disease previously appreciate say dupixent be currently approve only adult be clinical testing child related ibd stock veeva fly record high exceptional quarter regeneron sanofi undercut amgen abbvie rheumatoid arthritis
228,REGN,official start summer just few day away mid large cap fund have turn best performance so far year small cap techs go early break take beating week contribute market outlook downgrade market uptrend pressure dow jone industrial average have continue climb new high lead diversify stock fund be ishare edge msci usa momentum factor mtum month gain june accord morningstar inc etf boost year date return well ahead advance also capture ibd relative strength rating second best top perform diversify stock etfs other top performer month period include vanguard dividend appreciation vig guggenheim pure growth rpg vaneck vector morningstar wide moat moat click here see list best perform etfs be expectation earning head second quarter earning momentum be strong richard turnill blackrock global chief investment strategist write june note prospect tax reform have be fading depress expectation lower bar positive surprise value financial technology select health care dividend grower also have positive view overseas earning europe european central bank recently maintain dovish policy stance point lift growth forecast trimming inflation outlook see global reflation improve earning outlook support cyclical exporter particularly industrial multinational emerge market exposure say see level support populism european election partly shape investor sentiment here be etfs key asset class have produce big gain so far year past month mtum mentioned come first diversify stock etfs top holding include blue chip such apple aapl bank america bac jpmorgan jpm microsoft msft heavy tech presence biggest sector weighting mtum be still time high be well extend february subsequent bounce day line fund turn year old april have outperformed longer haul year average annual return be vs benchmark index gain tech stock get batter recently tech focuse fund be top sector performer social medium robotic semiconductor make show medical tech play spdr biotech xbi rise month bring ytd return june thank part big recent gain stock such abbvie abbv regeneron pharmaceutical regn fund launch january have produce solid return respective year period share be flat base buy point climb past entry intraday wednesday foreign stock space spdr china gxc gain month ytd return year old etf have attract asset count top holding tencent tcehy alibaba baba jd com jd recent economic datum show sign china economy be slow blackrock turnill doesn expect hard landing be good news china slower growth say modest slowdown first quarter unexpectedly strong pace be welcome view china rebalance economy downshift more sustainable pace growth less reliant credit related strategist best pick include bond emerge market etfssocial medium china internet stock fuel top etfs
229,REGN,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
230,REGN,regeneron pharmaceutical regn see ibd smartselect composite rating jump thursday day revise score mean stock currently top other stock term key performance metric technical strength regeneron pharmaceutical break earlier be currently trading right buy point saucer handle see stock climb decisively back buy zone heavy volume keep mind later stage base make riskier entry point stock sport ep rating mean recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company post increase earning revenue growth fall prior quarter regeneron pharmaceutical earn rank peer medical biom biotech industry group biospecific technology bstc be top rank stock group related company be now outperform stock
231,REGN,eli lilly lly pfizer pfe novartis nvs be pit battle treat breast cancer wall street struggle thursday compare effectiveness drug lilly unveil new datum drug class call cdk work inhibit specific protein prevent proliferation cancer cell pfizer ibrance be first approve area novartis kisqali grab approval year lilly abemaciclib look promising phase trial lilly abemaciclib combine chemotherapy increase progression free survival median month vs month placebo chemo combo hazard ratio measure likelihood death be pfizer drug ibrance be combine chemo earlier trial combo have lower hazard ratio meaning be lower risk death only extend progression free survival median month vs month placebo combo compare boil wall street see better effectiveness metric evercore analyst umer raffat write report note trial study different population breast cancer patient make apple apple comparison tricky still diarrhea remain concern lilly abemaciclib patient experience diarrhea vs patient placebo chemo combination lilly advise patient begin diarrheal medicine first sign diarrhea ibd take want keep tab market american society clinical oncology meeting next month bookmark ibd biotech pharma industry stock news page result be present late wednesday ahead american society clinical oncology meeting june chicago other abstract upload wednesday include merck mrk bristol myer squibb bmy roche rhhby tesaro tsro regeneron regn sanofi sny incyte incy stock spiked month high thursday epacadostat prove effective combo merck keytruda bristol opdivo outdo roche tecentriq newlink genetic nlnk rival epacadostat wasn merck only note interest merck also offer pair update famous trial dub keynote have find keytruda be better chemo first treatment advanced lung cancer hazard ratio keytruda drop merck say be not statistically significant favorable trend have help recent fda approval evercore raffat say note merck keytruda bristol opdivo be know immuno oncology drug work block interaction pd protein immune system cell pd protein cancer cell help immune system identify cancer keynote trial merck also find lung cancer patient treat keytruda initial round see continue benefit keytruda second round cancer progressed cement role pd inhibitor first line treatment even further raffat say phase trial regeneron sanofi find pd drug know regn have benefit rate patient common form skin cancer drug have control rate be very encourage disease set leerink analyst geoffrey porge say american cancer society estimate patient be diagnosed die basal squamous cell skin cancer year longer term be potential regn treat patient advanced not necessarily fatal skin cancer patient enrolled regeneron sanofi trial show complete response month meaning discernible sign cancer disappear porge keep outperform rating regeneron stock be little note tesaro abstract ahead conference leerink analyst seamus fernandez say most interesting datum present next month be combination trial tesaro zejula merck keytruda breast ovarian cancer zejula compete vs astrazeneca azn clovis oncology clvs class drug call parp inhibitor work block specific enzyme treat ovarian cancer parp inhibitor be currently be investigate breast cancer well combine parp inhibitor immuno oncology drug merck keytruda be thought be more potent treat cancer tesaro be also look zejula pd keytruda advanced lung cancer company be slate present datum dozen patient treat zejula keytruda fernandez note bar be fairly low outperform alone pd inhibitor have response rate group patient parp inhibitor have mid response rate recently publish datum small trial astrazeneca imfinzi pd inhibitor lynparza parp inhibitor show somewhat disappointing response rate ovarian cancer patient tesaro believe combination pd antibody zejula be superior fernandez say related incyte team dow merck trounce roche cancerdid astrazeneca rival just launch potential blockbuster drug
232,REGN,nasdaq composite climb level friday dow jone industrial average fall just short friday nasdaq rise best level day picked dow well major index set record high intraday goldman sachs gs disney outperformed dow gain goldman be trading just week tight add entry disney remain buy range low volume cup handle base disney be help positive comment rbc capital market upgrade share outperform sector perform up price target nasdaq bellwether facebook fb just reclaim day day move average thursday jump alphabet googl pop buy point rise amazon amzn be try crack level rise netflix nflx faltered late close glaukos gkos be heavy volume gainer rise top cup handle buy point ophthalmic medical technology company be schedule present jpmorgan healthcare conference wednesday et glaukos have be add ibd leaderboard biotech regeneron regn take hit fall judge rule cholesterol drug violate amgen amgn patent share amgen jump week financial be spotlight come week watch earning report next friday bank america bac jpmorgan jpm well fargo wfc related apple alphabet break buy join netflix big techs leadregeneron sanofi hammer judge ban amgen rivale ldl busterdisney tide be turn gopro mcdonald serve firm win battle glaucoma putt stick eye
233,REGN,stock open lower friday follow weak december job report dow industrial fall nasdaq december payroll center attention investor stock market today increase worker november labor department report be well new job economist consensus department revise estimate job add november upward labor participation rate hold steady unemployment rate tick line expectation hourly earning be bright spot rise dip november expectation increase november trade deficit widen less expect commerce department report october trade gap have clock economist have forecast increase december commerce also release november factory order datum et baker hughe bhi report weekly rig count string federal reserve official be set speak session begin chicago federal reserve bank president charle evan et premarket action be mixed bag friday biotechs be clearly busy medicine co mdco climb open neurocrine bioscience nbix vault stemline therapeutic stml spiked amgen amgn swung regeneron pharmaceutical regn dump value federal judge thursday permanently bar regeneron partner sanofi sny selling cholesterol drug praluent due patent infringement amgen repatha sanofi share trade ionis pharmaceutical ion soar open announce collaboration deal switzerland novartis nvs agree pay right cardiovascular drug develop ionis akcea therapeutic unit ionis share be find support week move average be extend november double bottom base novartis share dip premarket trade verizon vz open gain investor respond conflict comment executive thursday regard company propose acquisition web portal yahoo yhoo yahoo share dip also verizon be climb right side month cup base buy point dollar steepen early gain follow payroll report bounce back day decline person bank china ratchete yuan peg vs dollar overnight lend rate hong kong soar month high bond slip year yield basis point crude oil trim early gain less half percent west texas intermediate trading just barrel work fourth straight weekly gain gold dip ounce still week related december job report expect answer big questionsat join facebook google snapchat mobile video ad chase
234,REGN,gap gps share rebound late thursday apparel retail giant report solid holiday sale other hour mover burger chain shake shack shak see cfo leave helen troy hele top earning view iii apparel giii ruby tuesday rt have poor result meanwhile amgen amgn jump late winning ban rival drugmaker cholesterol fighter gap report november december same store sale rise december comp gain defy view drop be biggest gain year also contrast macy kohl kss report november december comp sank late wednesday gap raise full year ep target slightly gap share rise late trade fall regular stock market trading retailer tumble department store warning amgen win ban regeneron regn sanofi sny cholesterol fighter praluent compete drug repatha amgen share rise late trading france sanofi tumble regeneron be halter amgen have win patent ruling tuesday regard repatha vs praluent sanofi regeneron presumably seek emergency stay temporarily block ban related regeneron sanofi ldl buster risk judge uphold amgen patentsshake shack announce cfo jeff uttz retire step march upscale burger chain also name zach koff new chief operate officer position share fall late trading share have close thursday just buy point soar wednesday shake shack be add small cap wednesday close helen troy maker various household health beauty product announce ep revenue crushed ep view sale be little light forecast share rise late casual dine chain ruby tuesday report wider expect loss cent share revenue sink ruby tuesday share tumble late trade iii apparel say retail sale operate profit be weaker expect cite unseasonably warm weather early quarter now see ep vs view share fall late tumble regular session
235,REGN,bird fly flock fish swim school wolf hunt pack stock move industry group hard believe research show lead stock price movement be directly tie performance industry group ibd chairman william neil write make money stock ibd research also show additional winning stock price move be owing industry sector mean nearly winning stock rally strength borrow stock industry economic sector industry also move new economic trend such housing retail gain drive recover consumer spending also be significant structural shift technical advance industry be shale gas oil development advanced safety technology new automobile follow industry trend read daily industry theme column ibd investor com biotech ethical drug industry produce welter lead stock period smaller biomedical firm see influx investment big pharma industry see historic lapse patent protection age blockbuster drug larger firm find need bulk compete many seize overseas acquisition shift headquarters overseas order sidestep tax burden regeneron pharmaceutical regn break month cup base april see chart stock already have be climb year tarrytown base regeneron only manage pull earning growth together prior basis be volatile produce numerous pullback yet april composite rs rating be best possible medical sector rank economic sector track ibd list daily ibd smart nyse nasdaq table be position january group sector medical biomedical biotech rank medical group top ibd have also show group have climb group ranking january post year date gain track movement industry group go stock list section investor com click ibd datum table then choose industry sub group ranking ibd weekly top group list form part market trend page usually entire table be also publish second section newspaper investor buy regeneron share april have logged gain june ibd take find stock be breaking verge do so go stock move table update real time investor com see table right home page go stock list section focus stock strong ep rs rating be rise average turnover editor note column be originally publish june edition ibd related basic don buy stock big fund be snubbing spot bottom base pattern spot bottom base pattern part ii
236,REGN,ophthotech opht temporarily beat share rival regeneron regn phase testing wet age related macular degeneration drug prove fruitful year end rbc analyst adnan butt say thursday regeneron make eylea ophthotech manufacture fovista drug compete treat wet amd chronic eye disorder vision be blur mar blind spot ophthotech pressure likely be short live butt say expect regeneron eylea gain share wet amd diabetic macular degeneration market next year be successful see more overhang remove vs permanent cap regeneron share degree success also matter butt write research report ibd take regeneron stock have ibd composite rating meaning perform top stock term key growth metric supernus pharmaceutical top ibd company medical biom biotech industry group cr get stock checkup regeneron too have pressured ophthotech stock late last month ophthotech stock be strangle regeneron eylea fail show improvement patient wet amd combine antibody rinucumab regeneron stock be hit news ophthotech fall ahead result phase testing fovista due year end still eylea be expect be important regeneron butt say outside eylea regeneron sanofi sny dupilumab drug atopic dermatitis also know eczema appear promising butt write dupilumab have highest market potential approve late stage drug regeneron sanofi pipeline write butt trim price target regeneron stock reflect slower expect ramp dupilumab keep outperform rating food drug administration approval dupilumab be expect march similarly sarilumab be move swimmingly fda approval process regeneron sanofi co develop drug battle rheumatoid arthritis consensus put sarilumab sale far rbc expectation butt write wall street broader view be reduce sarilumab say stock market today ophthotech stock fall regeneron stock fall share fall key day support line last week
237,REGN,election year have add pressure hit biotechnology stock hard look hood sibling biotech etfs be reveal show more speculative company extremely heterogeneous industry cause much hurt bioshare biotechnology product bbp be year date oct invest establish company have bring least drug market stock holding exchange trade fund include biogen biib amgen amgn celgene celg gilead science gild regeneron regn ibd take largest cap weight biotech etfs stand benefit most top company climb wall worry have build industry bioshare biotechnology clinical trial bbc be so far invest young smaller company drug be experimental testing stage portfolio include sarepta therapeutic srpt share rocket september fda approve drug treat duchenne muscular dystrophy approval mean sarepta move bbp portfolio bioshare etfs next rebalance december etf pair allow investor decide much mix term combine more risky less risky biotechs say paul yook founder bioshare bbp focus household name make relatively less volatile fund contrast bbc hold riskiest biotechs highflying company share double triple overnight crash burn just well yook describe bbp bbc only exchange trade fund separate clinical trial company product company distinct stand alone investment investor don seem much enamored idea custom tailor risk fund be extremely small thinly trade nearly year debut have however see combine net inflow first quarters bbp fund be best performer biotech etfs so far year bbc worst meanwhile bellwether ishare nasdaq biotechnology ibb have give year date sit december high biotechnology etfs crumble past year come pressure lackluster earning well negative scrutiny health care peer valeant pharmaceutical vrx mylan myl politically charge season wall worry industry group least analyst have favorable outlook biotechs nov presidential election yook point promising sign pickup mouthwater sticker price target company allergan agn announce september acquire vitae pharmaceutical vtae roughly premium share biotechs be attractively price too be rare corner stock market valuation be cheaper have be historically yook tell ibd phone interview many etf investor be wait buy biotechnology stock november election believe fear hillary clinton presidency be price democratic presidential contender remark drug price gouge have trigger sharp biotech decline yook add most political scrutiny be face specialty pharmaceutical company such valeant mylan horizon hznp bioshare fund avoid related top biotechs climb wall worry rbc call rally
238,REGN,regeneron pharmaceutical regn disclose combination therapy include blockbuster drug eylea didn perform well treat wet age related macular degeneration eylea alone send regeneron share sharply lower stock market today wet amd rival also tumble regeneron have combine eylea rinucumab pdgfr beta antibody patient take combo therapy phase trial see letter eye chart test week eylea only patient see gain letter regeneron share fall friday sink low thursday regeneron sank undercut day day move average eylea codevelop bayer bayry have be big seller regeneron meanwhile ophthotech opht crash ophthotech be work combo therapy wet amd combine own antibody lucentis roche rhhby combo therapy be phase trial provide superior performance roche lucentis alone phase trial biotech etf ishare nasdaq biotech ibb rise close just day line ibb tumble thursday ibd take drug biotech stock have be pressured concern government impose price control here amgen biogen gilead hike va drug price related regeneron sanofi beat pfizer roche astrazeneca eczemawhat gilead try buy next poll offer incyte
239,REGN,california ballot initiative require state medicaid arm buy drug comparable price department veteran affair pay backfire thus preserve sale nation biggest drugmaker rbc analyst michael yee say thursday proposition california drug price relief act cdpra sound good theory yee write research report assume drugmaker don simply eliminate steep discount already provide va say happened year congress pass law require drugmaker grant medicaid similar discount give manufacturer larger customer write law ultimately prompt manufacturer raise price paid larger customer include va likely be fate cdpra write californian appear overwhelmingly support initiative early month university southern california los angele time survey find respondent approve cdpra san francisco firm poll july find support drugmaker amgen amgn gilead gild celgene celg biogen biib regeneron regn vertex vrtx cdpra offer merely headline risk yee write assume large price cut medicaid sale earning decrease only company product be expose medicaid state enact such measure mean earning share risk large cap player yee write year california be alone initiative ohio proposition didn make ballot however va price discount then probably become nonexistent lower va price lead reduce medicaid price write note medicaid already get discount date cdpra opposition have only spend donation yee expect spending ramp significantly ahead nov ballot rbc research show proposition be win side have most funding cdpra supporter have raise only supporter include former presidential candidate bernie sander say cdpra save californian taxpayer year va pay less other government agency prescription drug opponent argue cdpra invalidate exist contract state drugmaker force increase state drug price reduce funding medi cal initiative also increase state expense employee spend time resource match state price va pay ibd take ibd company medical biom biotech industry group rank group track have climb just week stock have heated wall street expectation major big pharma action however stock market today group close hurt intra cellular therapy stock plunge
240,REGN,eli lilly lly be set outperform bigger drugmaker novartis nvs sanofi sny term first quarter diabetes sale help tug lilly rheumatoid arthritis drug be delay fda analyst say tuesday leerink analyst seamus fernandez keep outperform rating lilly sanofi stock market perform rating novartis ahead first quarter earning note client lilly novartis be set report earning april sanofi come april believe lilly be poise deliver strong top line bottom line performance fernandez say pullback stock follow fda complete response letter baricitinib create attractive trading opportunity view monday lilly stock lose fda say application lilly rheumatoid arthritis drug baricitinib be incomplete further clinical dose information request likely hamper baricitinib produce partnership incyte incy least year other analyst have say baricitinib be likely delay year fernandez see lilly incyte drug delay month late cut annual global sale forecast drug sale diabetes drug trulicity psoriasis drug talz more offset delay baricitinib fernandez say raise peak sale trulicity talz respectively overall consensus analyst poll yahoo yhoo expect lilly report sale vs year earlier period adjust earning cent share fernandez be more bullish cent boost price target lilly share fernandez expect sanofi novartis deliver line revenue firm basal insulin diabetes franchise face pricing pressure drug include lantus toujeo sanofi levemir tresiba novartis ibd take eli lilly have middling ibd composite rating base key growth metric earning sale performance better stock bet include like jazz pharmaceutical jazz have cr best possible head stock checkup see pick stack lantus toujeo prescription be perform better expect face launch basaglar lilly fernandez say note client still see year year pricing decline lantus silver line sanofi be dupixent eczema treat injection conjunction partner regeneron regn drug be approve march so win have sale first quarter consensus see sanofi sale dip first quarter novartis fernandez note victoza be still grow tresiba uptake be track pricing pressure be likely weigh diabetes drug least end third quarter broadly analyst expect novartis report sale growth adjust earning share cent vs year earlier period sanofi fall close stock market today lilly drop novartis dip follow johnson johnson lackluster first quarter result see drug sale eke gain related lilly survive rheumatoid arthritis flop breast cancer drug dow johnson johnson set lackluster result sector
241,REGN,index other major average rise modestly week even apple aapl facebook fb dip earning tesla tsla tumble wider loss auto sale fall again crude price crash month lows solid job growth show economy be track keep federal reserve course well nasdaq rise nearly week dow jone industrial average index advanced modestly big headwind apple dow component facebook especially tesla pull back follow quarterly report crude oil future tumble lowest level november drag energy stock metal price also fall sharply hit miner general motor gm other automaker report decline sale yet again fiber optic stock warn sluggish china demand cite boom growth consumer electronic giant apple aapl earn share year year revenue march fiscal second quarter analyst expect sell iphone last quarter view ceo tim cook blame slowdown iphone sale consumer delay purchase speculation next generation device rumore iphone apple hike dividend add stock buyback program edge lower wednesday thursday apple stock rally fresh record high friday related apple beat view earning come short grow doubt opec lead production cut offset boom sale crude price tumble lowest level cartel begin curb output crude fall electronic trading overnight friday rally close barrel oil price still lose week meanwhile bp beat estimate royal dutch shell rdsa top view massive increase cash flow conocophillip cop report surprise loss shale producer be mixed bag pioneer natural resource pxd highlighted new drill technique include possibility employ artificial intelligence future related oil crash chart show opec be trappedrevenue rise beating consensus estimate gaap earning share beating view monthly daily active user growth also exceed expectation facebook once again caution ad revenue growth slow meaningfully share edge lower thursday friday related facebook applaud analyst follow strong earning reporttesla show larger loss expect strong revenue growth first quarter earning tesla revenue rise beating wall street estimate yet luxury electric car maker report adjust loss share exceed cent share loss wall street expect ceo elon musk say model plan be track say robot software day make tesla valuable apple tesla share tumble thursday extend loss ahead company result rebound friday related tesla get mixed reviews analyst earning reportmeanwhile auto sale april miss view board tuesday general motor ford fiat chrysler fcau nearly foreign peer report decline demand miss view auto sale have fall year year straight month longest string recession end industrywide sale come annual rate accord autodata expect auto part giant delphi dlph soar report strong earning announce plan spin powertrain segment focus autonomous electric vehicle related auto review tesla loss sale slump delphi break economy add job april slightly more expect sluggish march hire weak overall economic activity start year jobless rate edge fresh year low report suggest economic growth rebound spring also keep federal reserve track policymaker expect raise rate more time have hint take step pare central bank massive balance sheet related job add april jobless rate sink year low hollywood writer studio broker peace avoid writer strike medium stock get slam time warner twx report soft ad revenue subscriber loss dish network dish have mixed result be mar subscription loss be high industrywide viacom viab beat handily paramount perform well share be hit cable bundle distribution worry hulu debut channel live tv beta bundle month join several other stream tv offering cbs cbs result come mixed house panel scold airline treat customer better be sign lawmaker plan legislative remedy hearing follow well publicize video polouse drag unite airline ual passenger flight incident rep steve cohen say remind trump campaign rally alaska airline exec say company be review policy overbooking american airline aal say hadn establish ceiling payout offer person need bump flight southwest luv plan end overbooking say wouldn go break result even lawmaker batter executive airline stock soar delta air line dal traffic result april show positive unit revenue storm atlanta oclaro oclr inphi iphi lumentum lite warn slacken demand china clearest sign yet key market fiber optic gear component be struggle generally see temporary tout strong demand base datum center metro expansion oclaro initially crash wednesday morning end day flat inphi do lose day lumentum actually rally thursday cite progress sensor apple iphone speculation apply optoelectronic aaoi sky-rocket beating already raise earning estimate related lumentum have apple iphone sensor design bag analystdow component merck mrk tuesday top view sale cent ep lighter expect sale immuno oncology drug keytruda weigh stock close fraction pfizer pfe sale be light adjust income cent beat penny regeneron pharmaceutical regn thursday miss sale ep view eylea sale praluent sale be less dire expect yum brand yum papa john pzza put earning beat estimate help taco bell yum own digital order have be great pizza business shake shack shak sank late thursday weak same store sale guidance soar friday morning dunkin brand dnkn sale miss increasingly challenge environment retail restaurant wingstop wing surge beating estimate hike ep full year growth forecast cheesecake factory cake tumble miss habit restaurant habt have mixed result guidance sprint say fiscal revenue operate revenue rise top view postpaid phone subscriber addition be line stock fall disappointing free cash flow guidance speculation mobile merger cool paycom software payc report ep revenue top view raise full year revenue outlook year earlier square sq stock rise payment processor swung adjust cent profit year earlier loss raise full year revenue guidance revenue rise top view ebitda be vs consensus estimate square share soar record high twilio twlo share crash communication software maker forecast larger expect current quarter loss reveal change relationship largest customer ride sharing giant uber twilio report adjust loss cent share revenue gain ahead expectation match group mtch report revenue year earlier adjust ebitda top view strong growth paid subscriber mobile date app tinder management guide revenue be range vs consensus casino stock rally news macau gaming revenue rise april vs year earlier higher most estimate melco resort mlco report better expect earning follow upbeat report last week wynn resort wynn mgm resort mgm la vegas sand lvs bullet jg mlm cmi ec pi ec
242,REGN,major index rise mixed close thursday successful health care reform vote congress outweighed negative effect sharp dive oil price nasdaq rebound midsession lows grasp fractional gain close bell dow jone industrial average fought good fight also rise lows end thinnest loss small cap lag russell end vote house representative moved gop health care reform bill american health care act senate move congress closer pledge repeal affordable care act oil price clearly hinder session west texas intermediate crude drop nearly barrel lowest price nov oil related stock post widest loss oil related industry post session worst loss caterpillar cat have high correlation oil price tumble bottom dow industrial follow closely chevron cvx exxon mobil xom decline stock pound big gain earning railcar america rail spiked air transport service group atsg soar fitbit fit rise fiber optic communication gear maker lumentum holding lite notch gain regeneron phamaceutical regn be top dog stock spring report mixed result robust sale eyelea treatment macular degeneration cheer investor send stock less buy point flat base aggressive investor have chart alternative buy point animal health drugmaker zoetis zts claw gain deliver first quarter result analyst target move retook buy point month flat base share end extend buy point new high ferrari race ahead stretch new high extend rebound week line april downside avon product avp crumble steel producer ryerson hold ryi collapse facebook fb post mild loss report stronger expect earning sale growth first quarter jeffery lift stock price target follow late wednesday report share remain extend april rebound week move average tesla tsla drop erase stock gain flat base buy point receive price upgrade jpmorgan brokerage continue be cautious stock give market weight rating related top stock buy zone investing action planfitbit pulse race beat much still prove
243,REGN,generic chip away sanofi sny multiple sclerosis drug then treatment help offset erosion company diabetes market analyst say tuesday upgrade sanofi stock jpmorgan analyst richard vosser upgrade sanofi stock neutral buy rating early trading stock market today sanofi stock be close share have trade well day move average mid february diabetes erosion be largely reflect consensus be offset growth multiple sclerosis franchise write report sanofi multiple sclerosis drug aubagio be likely have competition vosser see silver line sanofi regeneron regn eczema drug dupixent see roughly peak sale start grow even projection be respectively consensus ibd take sanofi be consider bid french drugmaker detail much head ibd technology page regeneron sanofi be also work biotech amgen amgn sell praluent drug design lower bad ldl cholesterol trio be wrapped patent battle sanofi regeneron appeal judge decision pull praluent shelve vosser model praluent number be respectively consensus related regeneron sanofi get approval eczema drug price roche multiple sclerosis drug bittersweet beleaguered biogenamgen payer pushback likely sting battle regeneron sanofi
244,REGN,san francisco less hour president elect donald trump wednesday refer drug industry disastrous aldr ceo randall schatzman classify tone annual jpmorgan healthcare conference cautiously optimistic wide departure event time say sentiment be decidedly pessimistic enter turn be raucous election year drug pricing debate be alive biotech sentiment be grow stronger year schatzman tell ibd interview conference drug industry major event hold week san francisco talk biotech industry whole think finally come maturity say last year almost drug have be approve have come innovation biotechnology not large pharma so dollar be really pay back re see real game changer schatzman include cgrp migraine drug compete directly similar med eli lilly lly teva pharmaceutical teva amgen amgn migraine market be big enough grab sizable share drug hit shelve likely acknowledge trump comment didn help stock price hold phone schatzman pull screen biotech stock red arrow indicate descent point ishare nasdaq biotechnology index ibb exchange trade fund fall wednesday rise fraction thursday friday ibd take trump commentary send drug stock tailspin wednesday get deep dive mean drug biotech pick ibd industry theme so rally wall street expect jpmorgan event didn unfold here be key takeaway investor note trump take office drug firm look sidestep lilly alzheimer flop get early start trump isn alone fixation drug price celgene celg ceo mark alle parry back reporter question biotech follow allergan agn footstep apply so call social contract not raise price more annually celgene have offer free access program year alle say estimate biotech give away drug year free drug price increase help fund new drug add cfo peter kellogg estimate celgene reinvest fund accounting partnership alle say celgene go thoughtful process accounting innovation spending bring drug market price new med schatzman used same word describe plan price cgrp drug once near fda approval head market healthprize technology ceo tom kottler call pricing spike easy way drug company healthprize be software service firm marry behavioral economic consumer marketing analyze improve patient adherence prescription pharma leave worldwide revenue table year not push patient take med kottler tell ibd bridge gap company bring new product market prompt doctor more prescription raise price typically choose latter re miss easy money kottler say raise price be easiest thing say drugmaker merck mrk announce immuno oncology io drug keytruda combination chemo eli lilly alimta have win priority review fda small cell lung cancer have prescription drug free user act pdufa date meanwhile merck incyte incy be move keytruda epacadostat phase trial tumor type small cell lung cancer renal cell carcinoma bladder cancer squamous cell carcinoma head neck incyte stock jump jan news bristol myer squibb bmy be merck tail analyst say bristol myer be testing combination opdivo yervoy io therapy nsclc analyst expect bristol myer readout first half io combo be likely be more effective durable io chemo say monday japan takeda pharmaceutical put share bid ariad pharmaceutical ariad oncology firm base massachusett ariad stock fly news help share oncology firm tesaro tsro lift tesaro stock ipos lead ibd company medical biom biotech industry group stock see triple digit gain tesaro jump group overall fall painful election cycle now analyst wonder tesaro success oncology mind atmosphere reiterate takeda offer ariad garner bid tesaro leerink analyst seamus fernandez see potential takeout price share tesaro stock close friday rise tesaro remain well position grow independently validate parp inhibitor niraparib ovarian cancer drug still development offer durable strategically important product opportunity multiple suitor fernandez write research report jan regeneron regn sanofi sny be ask federal judge stay ban ldl bust drug praluent aftermath patent battle land biotech amgen praluent infringe amgen patent pcsk inhibitor repatha judge say meanwhile ldl buster alnylam pharmaceutical alny medicine co mdco be slowly advance jan medicine co announce day interim analysis study examine pcsk inclisiran datum show inclisiran significantly lower ldl day rbc analyst adnan butt expect month datum be similar efficacy safety detail be expect american college cardiology conference march washington inclisiran do well strong datum patent litigation amgen regeneron sanofi inclisiran be differentiate have patent litigation overhang butt say research report wednesday axovant axon ceo vivek ramaswamy say biotech drug industry have utterly fail alzheimer oncology inflammation cardiology ve see significant advancement last year disease alzheimer dementia include lewy body haven say don find treatment major threat society tell ibd interview wednesday be single area health care have fail deliver major advancement last decade ramaswamy say be root eli lilly december lilly highly laud solanezumab fail meet primary endpoint late stage trial cause lilly stock plunge day announcement lilly drug drug development biogen biib work remove plaque buildup brain associate alzheimer silver bullet theory ramaswamy doesn buy instead see necessary treat various behavioral psychological neurological piece alzheimer dementia axovant be aim build new therapy top older one axovant be next be alzheimer field deliver readout datum be slate say ramaswamy be look just major piece news alzheimer advancement say ramaswamy rise tide lift boat
245,REGN,first news conference surprise president elect trump wednesday indicated issue escalate drug price be priority used harsh word describe situation drug industry have be disastrous say trump drugmaker be subject new bidding procedure re get away murder say hit issue already have be get increase attention federal state lawmaker mylan myl ceo heather bresch be skewer house committee september plenty other have be heavily criticize include valeant pharmaceutical vrx teva pharmaceutical teva mylan teva acquire generic drugmaker actavis last year allergan agn be publicly trade company company december be sue attorney general state price fix charge field generic drug day earlier first action similar investigation justice department charge former ceo president privately hold heritage pharmaceutical price fix ibd take event such news conference president elect move stock see ibd stock move learn latest big mover number drugmaker currently move list interview time name magazine man year trump pledge bring high drug price wednesday marked first substantive comment subject pharma have lot lobby lot lobbyist lot power very little bidding drug say news conference re largest buyer drug world yet don bid properly re go start bidding re go save billion dollar period time actavis have boost price hydrocortisone tablet number year mylan epipen treat allergic reaction see price increase year end last year product treat potentially life threaten situation ishare nasdaq biotechnology ibb etf fall stock market today fall back day line already depress share mylan teva fall respectively wednesday valeant tumble ibd company biotech industry group fall again fall day day line larger biotech stock aldr fall spark therapeutic once plunge unite therapeutic uthr fall larger drugmaker amgen amgn end day regeneron pharmaceutical regn fall gilead science gild fall biogen biib tumble related trump drugmaker get away murder mylan teva sue allege price fix
246,REGN,datum biotech amgen amgn ldl bust drug boost regeneron regn disappoint too high expectation amgen investor credit suisse analyst alethia young say tuesday young upgrade regeneron stock outperform rating up price target cite april launch dupixent eczema drug sanofi sny pcsk datum top rival amgen due also also be catalyst regeneron own pcsk drug write research report amgen investor however have set expectation too high repatha amgen pcsk inhibitor follow successful datum study september say coronary intravascular imaging trial repatha meet primary secondary endpoint coronary artery disease still see upside repatha outcome datum write research note think risk reward be unfavorable expectation be pretty high success glagov study ibd take trump break republican pressure drug price look more more likely biotechs survive political pressure young downgrade amgen stock neutral rating cut price target see amgen base business rheumatoid arthritis drug enbrel become weaker trim total product sale view enbrel sale come flat contract negotiation next year enbrel sale be drive volume rather net selling price company say earning conference call analyst company up guidance time celgene celg vertex pharmaceutical vrtx top young biotech watchlist be cautious general however give comment president elect donald trump go escalate drug price week follow election biotech drug stock have nearly round trip first rise then fall ibd company medical biom biotech industry group hit week high nov trump election be then still share remain close nov rise stock market today amgen stock fall tuesday regeneron stock slip don expect drug pricing chatter moderate especially consider comment already make president elect young write think company best execution have best stock performance related amgen biogen celgene eye trump pro biotech worldbiotech climb third straight day leader be buyable
247,REGN,food drug administration approve breakthrough adult eczema treatment regeneron pharmaceutical regn sanofi sny soon march drugmaker say monday share plod lower day market overall joint release regeneron sanofi say fda accept priority review biologic license agreement bla dupilumab treatment mid severe eczema cure eczema rash typically treat corticosteroid ibd take pfizer too be work eczema treatment acquisition anacor pharmaceutical early monday pfizer say have decide splitting end year speculation dupilumab inhibit signale interleukin interleukin company say il il be cytokine protein signal cell be tie immune response clinical study frequently link il il eczema asthma dupilumab be grant breakthrough drug designation now path receive prescription drug user fee act target activation date march allow fda collect fee drugmaker fund approval process bla dupilumab contain datum phase testing include more patient eczema wasn controlled topical treatment cortisone cream regeneron sanofi evaluate dupilumab singular treatment conjunction corticosteroid pfizer pfe roche rhhby astrazeneca azn be regeneron sanofi heel treatment acute dermatitis well end pfizer acquire anacor june give access anacor nonsteroid gel treat eczema crisaborole announcement regeneron stock be stock market today hot stock mid late regeneron share be year sanofi stock be related regeneron sanofi drug rheumatoid arthritis beat abbvie humira
248,REGN,biotech gilead gild be most likely scoop incyte incy next month accord survey industry watcher evercore isi investment bank ahead presidential election pit donald trump hillary clinton survey say most see gilead purchase incyte identify incyte biopharma most likely be acquire next year nearly respectively see biogen biib biomarin pharmaceutical bmrn target gilead acadium pharmaceutical acad celgene celg kite pharma kite be least likely be target only industry expert identify likely takeover candidate departure needham analysis last week identify potential suitor acadium incyte takeover likely come heavy price june gilead have cash equivalent market security hand market cap gilead be biotech trail only amgen widely view big biotechs most need be active front incyte have market capitulation smaller coalition say gilead buy vertex vrtx bristol myer squibb bmy outside lion share expert expect biotechs outperform broader market next month respondent say biopharmas merely be line trade election say expert ibd company medical biom biotech industry group be year loss be early year overall market tumble group be more late june now rank group track just week close stock market today group be more buck day downtrend ibd take latest industry snapshot explore biotech promising new drug stock be lead biotech sector drug pricing initiative rout stock year rbc analyst say thursday acknowledge drugmaker amgen amgn gilead celgene biogen regeneron regn vertex easily find loophole skirt new regulation still fewer person poll evercore expect government take meaningful action drug pricing nearly largest chunk say government win ever push reduction drug price other prediction stem specific company only expect eli lilly lly alzheimer drug solanezumab hit cognition function endpoint more broadly say hit cognition miss function more half say celgene phase testing ged oral mongersen treatment crohn fail reach overwhelming efficacy see phase testing phase patient take milligram be clinical remission day small say celgene see better result phase testing only expect study fail entirely result show endoscopic improvement respondent say celgene stock pop third expect share remain stagnant related gilead paralyzed likely hep share lossamgen biogen gilead spike va pricing skirt california pharmaceutical fall combo therapy eylea alone
249,REGN,strength biotech stock buoy nasdaq composite wednesday strong show apple aapl didn help dow much afternoon selling remind investor market uptrend be pressure close nasdaq rise dow jone industrial average lose fall less sell oil gas stock preliminary datum show volume nyse nasdaq come lower tuesday level solar oil gas airline stock underperform stock market today dow component apple surge past buy point heavy volume rise nearly extend gain tuesday move be fuel news strong preorder iphone skywork swks broadcom avgo outperformed nasdaq several biotech name alexion alxn celgene celg regeneron regn several recent ipos outperformed name impinj pi penumbra pen lumentum lite rise more ibd name rise more gigamon gimo have nice day presentation positive comment william blair ibd take gigamon be top performer ibd internet network solution group plenty other competitor be act well see be ibd stock checkup ibd component netease nte continue assault new high rise share be so far week report tuesday say company plan divest news business focus fast grow online gaming sector new york mercantile exchange wti crude oil future october delivery fall barrel year treasury yield be basis point
250,REGN,stock kick week decent gain monday be lackluster week trading ahead long labor day weekend friday job report stir excitement dow rise picked nasdaq composite add tesla tsla netease nte large cap biotechs gilead gild alexion ticker
251,REGN,big biotech regeneron pharmaceutical regn close stock market today report mixed quarter guidance earning share beat analyst consensus revenue be lighter expect shortfall be due less collaboration revenue sanofi sny be difficult model interpret note evercore isi analyst mark schoenebaum email wall street generally judge company health more product sale front regeneron beat expectation sale flagship eye drug eylea rise year year company affirm previous guidance growth full year year old cholesterol drug praluent miss consensus again doctor payer await datum cardiovascular effect expect early next year ibd take slim be new be regeneron challenge right now eylea be year old sale growth be slow so eye be new drug such praluent dupilumab see also turn blockbuster regeneron doesn provide earning guidance raise expense guidance have be recur theme last few quarters schoenebaum write imply ep guidance still bracket consensus regeneron also announce have file approval atopic dermatitis drug dupilumab fruit sanofi partnership fda decision deadline oct earning conference call regeneron executive say dupilumab launch be faster praluent atopic dermatitis be large unmet need share drugmaker briefly rise open thursday touch month high regeneron stock close thursday
252,REGN,esperion therapeutic espr stock re-cover monday last week amgen amgn induced pitfall touch month high esperion outlined path fda approval cholesterol bust drug bempedoic acid share medicine co mdco also get jump start monday partner alnylam pharmaceutical alny report strong result cholesterol drug inclisiran midstage trial stock market today esperion shot medicine co stock lift amgen stock edge price target cut esperion say monday seek have bempedoic acid approve lower bad ldl cholesterol reduce risk cardiovascular disease propose label allow bempedoic acid be used adjunct statin therapy fda say ongoing phase trial patient elevated bad ldl cholesterol be sufficient approval esperion be also plan look cardiovascular benefit bempedoic acid reduce heart disease patient intolerant statin monday fda esperion settle definition statin intolerance inability tolerate more statin lowest approve daily dose due adverse effect patient esperion hope have bempedoic acid approve adjunct therapy biotech plan enroll patient high risk cardiovascular disease cardiovascular outcome trial biotech expect report top line safety tolerability datum second quarter have efficacy datum mid esperion expect file application bempedoic acid europe first half ibd take celgene stock break last week strong result otezla breakdown factor lead celgene head ibd stock analysis late friday medicine co alnylam pharmaceutical say inclisiran cut bad ldl cholesterol average day optimal start dose regimen inclisiran be well tolerate material safety issue patient trial medicine co say news release inclisiran belong class drug call pcsk inhibitor pcsk inhibitor work block interaction pcsk protein ldl receptor do so cut bad ldl cholesterol blood drug amgen regeneron regn sanofi sny have similar mechanism share alnylam be partner medicine co inclisiran be biotech amgen see more fallout monday disappointing fourier result early friday investment bank goldman sachs cut price target amgen stock lower estimate cholesterol drug repatha bank keep buy rating amgen stock follow fourier amgen say plan offer innovative contract pharmacy benefit manager payer goal be expand insurance coverage repatha cardiovascular benefit not just lower bad ldl cholesterol be positive point datum amgen present friday goldman sachs analyst terrence flynn say then amgen say repatha cut major adverse cardiovascular event analyst broadly expect better say investor have point lack benefit cardiovascular death say physician feedback suggest be not realistic expectation trial be not power demonstrate take statin long time demonstrate benefit here amgen result send share esperion medicine co tailspin friday share esperion close medicine co stock lose amgen stock close related esperion dive amgen heart study pricingamgen tank heart study share other drugmaker tumble
253,REGN,xamgen amgn stock crash friday announce cholesterol drug repatha long await study didn significantly reduce risk cardiovascular death prompt share rival tumble well amgen study know fourier find difference repatha patient take benign placebo term cardiovascular death repatha however cut risk heart attack stroke coronary announcement come american college cardiology annual meeting washington average participant be know amgen fourier study be year old third take moderate statin lower cholesterol follow result amgen stock tank stock market today find support day line result amgen fourier study be tell drug rival company show stock action friday share rival medicine company mdco dove nearly point settle back loss nearly half analyst see medicine company cholesterol drug inclisiran have cardiovascular benefit esperion espr stock tumble more point re-cover somewhat close only analyst expect cholesterol drug bempedoic acid have cardiovascular benefit accord investment bank rbc repatha disappoint front amgen do meet main goal primary endpoint reduce risk major adverse cardiovascular event include hospitalization unstable angina coronary heart attack stroke cardiovascular death ibd take celgene stock break week unveil strong result trial otezla patient moderate plaque psoriasis breakdown celgene strong suit similarly well position company head ibd stock analysis add optimized statin therapy repatha be successful reduce combine risk heart attack stroke cardiovascular death line broad view reduction further week repatha cut bad ldl cholesterol cholesterol stay level year study amgen say cholesterol dove milligram less milligram be consider good level repatha effect grow time first year repatha cut major adverse cardiovascular event grow second year repatha reduce risk heart attack first year now show first time dedicate outcome study decrease ldl cholesterol pcsk inhibition cholesterol drug result clinically meaningful cardiovascular benefit say dr marc sabatine chairman timi study group lead study repatha work block interaction pcsk protein ldl receptor do so cut bad ldl cholesterol blood praluent regeneron regn sanofi sny have similar mechanism company be battle patent court judge recently side amgen say partner regeneron sanofi have infringe patent protect repatha injunction praluent have be stay pending appeal sympathy regeneron sanofi stock topple respectively bullish analyst have call reduction major adverse cardiovascular benefit rbc analyst michael yee note research report be really compelling note appreciate be short term profit take give datum wasn expectation yee say note amgen stock have run begin year think stock pause short term give such big run recover grind back higher year fourier datum be short term disappointment amgen stock remain relatively cheap say reduction major adverse cardiovascular event be likely improve time statin have more year datum back repatha statin fourier have just year leerink analyst geoffrey porge be more bearish result be lower end investor expectation commentator have already point be effect cardiovascular overall mortality write report other hand benefit term cardiovascular event risk be so be tie lower bad ldl cholesterol cardiovascular health say high risk patient group seem likely such medicine become standard care virtually regardless ldl level say however lower risk patient study still leave payor significant ammunition restrict access repatha cost just north year regeneron sanofi praluent cost more related amgen top heart study rival regeneron sanofi courtamgen boost rival positive heart disease study
254,REGN,biotech amgen amgn be prep unveil result key cholesterol study later week only rival drug regeneron regn sanofi sny remain entangled patent court monday amgen offer top line result separate study examine effect amgen drug repatha reduce ldl cholesterol repatha meet primary endpoint reduce need apheresis medical procedure blood be filter outside body also meet secondary endpoint reduction cholesterol level week amgen be expect release full result fourier study et friday american college cardiology annual meeting washington fourier look repatha ability reduce heart attack stroke cardiovascular disease patient bad ldl cholesterol repatha belong class drug call pcsk inhibitor work reduce bad ldl cholesterol patient blood compete directly praluent drug regeneron sanofi medicine company mdco have rival drug slightly different mechanism ibd take amgen regeneron sanofi duke patent court gilead be face own slew issue arise slow sale hepatitis drug analyst call gilead buy something have paid head ibd industry theme more earlier year judge ban sale praluent say regeneron sanofi have infringe amgen patent repatha last month judge stay ban pending regeneron sanofi appeal meaning continue selling praluent now amgen be successful be first time brand product be yanked shelve result patent litigation amgen be unlikely settle analyst say regeneron sanofi argue amgen patent be too broad amgen share fall stock market today regeneron rise sanofi dip related abbvie stronger bet gilead amgen least sanofi temporarily stave ban amgen rivale ldl buster
255,REGN,spectacular rise even more spectacular collapse valeant pharmaceutical have multiple cause heart story be much biotech company rely big drug price increase growth not only do price hike make valeant vrx politically unpopular also meant business be ultimately unsustainable money manager prefer biotechs pharmas produce drug grow customer demand signale growth sale volume think preferable avenue revenue growth be volume significant price increase have see past year only be repeat few year leonard yaffe health care portfolio manager kessef capital tell ibd email more revenue increase be due volume more value be assign drug re hunting big growth stock biotechs catch eye look past headline revenue number help see company have more sustainable even accelerate growth volume growth lag sale increase company be lean price not last most price increase be far more moderate valeant price hike heart drug nitropress isuprel respectively many company regularly lift price well past inflation rate prop revenue disguise actual demand ibd take big cap deliver still deliver big gain often less volatility smaller cap stock also true biotech have strong big cap company amgen biogen be current resident ibd big cap compare volume revenue be worthwhile reason volume growth be more overall revenue growth signal company be have rebate more list price do last year move product be roll drug country extract lower price be often case europe investor don signal insurer other payor be putt thumbscrew company payor mix obviously be very critical well large consolidated payor cover many many life have negotiating power pick choose rationalize product base price efficacy alternative etc thomas vandeventer portfolio manager tocqueville asset management tell ibd email second quarter earning report conference call comment reveal biotech giant hot stock rely almost solely price increase growth other expand mostly volume increase still other credit mix amgen amgn be classic example lean price revenue rise volume growth be much stem age amgen lead drug top seller rheumatoid arthritis drug enbrel be decade old volume shrank quarter still contribute growth thank pricing drug be even older epogen neupogen shrank price volume re face new biosimilar competition newer drug prolium xgeva make difference grow front be reason fact beat estimate raise guidance amgen stock initially drop earning report contrast amgen celgene celg revenue rise percentage point come volume growth accord company didn break percentage individual drug amgen do company say demand be good board celgene also beat forecast raise guidance future sale profit stock jump report medivation mdvn demonstrate sneaky power rebate list price prostate cancer drug xtandi now medivation only market drug rise second quarter revenue overall rise bit less analyst expect volume grow growth underlie demand xtandi be partially offset lower net price xtandi due year year increase gross net rate say cfo jennifer jarrett earning conference call gross net be industry speak rebate level xtandi have be tight competition johnson johnson jnj zytiga prostate cancer market have be undercut price cvs health cvs recently release drug formulary pass xtandi zytiga reason follow report here rundown other big biotechs be fare price vs volume question unite state lion share change year year basis be price be pretty stable unit trend tecfidera pretty stable unit trend tysabri modest gradual decline interferon franchise include avonex plegridy clancy say ex unite state be not see pricing increase year year basis gain be attributable volume unit expansion biogen overall revenue rise quarter beating expectation lead drug soliris provide vast majority revenue volume rise hike sale rest top line come newly launch drug have year year comparison incyte revenue jump year year beating expectation related be biotechs make comeback stock watchbiotech be make case leadership be good
256,REGN,job report push stock fresh time high busy week tesla motor tsla announce deal buy solarcity scty tech be strong general motor gm ford fuel sell consumer related stock oil price briefly undercut barrel also bank england cut rate revive bond buy major average be little change thursday rally friday strong job report nasdaq climb week record close friday just point july intraday peak rise hit fresh intraday best dow jone industrial average advanced energy stock fall oil undercut early week rally crude re-cover somewhat economy add job july second straight month much better expect hire allay fear economy ism manufacturing index index fall little more forecast still point growth strong hire wage gain support consumer spending housing demand many consumer related firm report stall demand tesla take step closer acquire solarcity special committee independent disinterested solarcity board member evaluate proposal alternative state approval merger deal still need be approve shareholder regulator tesla report earning miss estimate show improvement electric car production production be track support delivery second half reaffirm previous guidance electric car company loss balloon share cent year earlier figure much greater cent loss estimate tesla report gaap revenue miss consensus tesla fall week solarcity lose more ride hail giant uber technology be selling chinese operation apple aapl backed rival didi chux technology capitulate expensive battle foothold china deal have uber swap chinese business stake didi make former foe largest stakeholder didi turn didi become facto ride hail leader china value more uber most recent valuation put north verizon communication vz agree buy fleetmatic fltx vehicle tracking system maker share acquisition expand verizon push web connect vehicle part internet thing ireland base fleetmatic mobile software platform let business manage commercial fleet provide datum vehicle location fuel usage speed mileage verizon fall week drop buy point day move average fleetmatic jump time warner twx st century fox foxa turn mixed result time warner move buy stake netflix nflx rival hulu join current co owner walt disney fox comcast cmcsa steal headline viacom viab report better expect earning revenue do lion gate lgf post surprise profit oil price fall barrel early week follow july tumble opec production climb strong output nigeria iraq saudi arabia continue pump oil record high crude stockpile rise latest week accord energy information administration production dip gasoline supply fall shale producer continental resource clr oasis petroleum oas laredo petroleum lpi lift output forecast oil close week higher bristol myer squibb bmy plunge friday cancer drug opdivo end string clinical trial success failure trial single therapy newly diagnosed lung cancer patient merck mrk have succeed similar patient group trial compete drug keytruda be aim smaller potential market merck stock jump hit highest level june earlier merck be report be talk biogen biib possible biogen buyout be allergan agn further boost biogen stock day partner ionis pharmaceutical ion announce unexpected success clinical trial nusinersen treatment rare spinal disease blockbuster potential biogen rise nearly week meanwhile specialty drugmaker mallinckrodt mnk shire shpg rise respectively beat estimate raise guidance pfizer pfe nordisk nvo regeneron pharmaceutical regn slip beat number issue so so guidance animal health company zoetis zts also rise beating raise general motor gm ford lead auto stock lower report slower sale month july ford project industry sale fall year big gain department store grocery store restaurant airline also decline re-cover somewhat week end sell consumer stock trigger warning broader economy fall business investment homebuilder spending consumer spending rise strong annual rate falter economy not be able match anemic gdp growth texas roadhouse txrh beat earning estimate ep cent revenue growth miss view steakhouse chain also say early same restaurant sale growth have slow outlook come grow worry restaurant sector overall starbucks sbux mcdonald recently report weak comp warning analyst retail sector pizza delivery chain include papa john pzza be buck trend papa john say ep jump cent top view raise guidance rest year also chicken theme el pollo wingstop wing rally result jack box jack soar earning separately monster beverage mnst report weaker expect earning growth top revenue forecast monster beverage leaderboard stock rally friday hit new high ibd take investor look growth stock clear proper buy point ibd leaderboard be premium service provide detailed chart analysis lead stock see other top rate growth name be buy point bank england cut interest rate quarter point expect economy slow reaction brexit vote policymaker go further revive government bond purchase announce boe buy corporate debt also signale rate cut be likely year end boe gov mark carney say opposed negative rate helicopter money martin marietta material mlm make crushed stone sand other aggregate used construction fall short second quarter forecast rival aggregate supplier vulcan material vmc also badly miss related ready mix concrete market concrete uscr report ep plunge cent miss cent revenue rise also miss blame bad weather say expect better result second half martin marietta ceo nye cite record record rainfall attendant effect many key market share trio fall hard earning miss re-cover lose ground end week delta air line dal report decrease passenger unit revenue july say drop be line expectation investor appear worry tone result set third quarter delta say key metric operate efficiency fall german carrier lufthansa warn terror attack economic uncertainty affect travel also hurt sector delta stock fall american airline aal jetblue jblu also sank unite airline ual southwest luv close week higher aetna aet humana hum wellcare wcg put estimate beating quarterly result week however aetna say abandon expansion plan obamacare exchange humana recently say exit most obamacare exchange market next year follow unitedhealth unh aetna humana try overcome antitrust objection merger safety security concern person mind wake series officer involved shooting polouse officer polouse unarmed civilian sale sturm ruger rgr firearm grow second quarter rise earning climb share fbi report firearm background check see indicator future gun sale rise july june be july share fall day earning ruger ceo say be step close week only meanwhile taser international tasr say ep fall cent share cent year beat forecast cent share sale pop easily top view stun gun maker say booking axon body camera soar taser stock rise hit year high
257,REGN,leerink offer mostly bullish preview come earning season big biotechs wednesday offer hope lag sector analyst geoffrey porge raise estimate alexion pharmaceutical alxn biogen biib celgene celg gilead science gild regeneron pharmaceutical regn write prescription datum im health im indicate flat slightly trend celgene standing year year volume growth drive new psoriasis drug otezla top drugmaker evidently shrug recent political criticism raise price number product wac wholesale acquisition cost price celgene otezla increase april follow raise january increase last june represent year year cumulative increase celgene also raise price abraxane april year year cumulative increase porge write other price increase include amgen kyproli yoy biogen tecfidera avonex plegridy medivation mdvn xtandi leerink nonetheless lower estimate medivation base lower xtandi sale well lower royalty sale outside also modestly lower forecast amgen amgn vertex pharmaceutical vrtx add be still consensus company celgene stock climb stock market today stock also have be help anonymously source report be company sign disclosure agreement medivation ahead possible buyout regeneron stock climb alexion advanced biogen rise gilead vertex stock rise announce licensing deal moderna therapeutic develop cystic fibrosis treatment used moderna messenger rna technology vertex agree cash investment upfront milestone payment drug succeed
258,REGN,type diabetes be battle best selling drug world biggest drugmaker company be eyee even bigger sale new generation treatment change field have prove more evolutionary revolutionary several event next few month start soon monday eventually move billion dollar make compliance treatment easier even prevent death heart disease diabetes drug provide single best selling product johnson johnson jnj merck mrk almost nordisk nvo annual revenue come diabetes treatment health care research firm globaldata say diabetes treatment bring nearly re get better better manage diabetes general say funtleyder health care portfolio manager square asset management have more option next phase be go be get person adhere regimen work diabetes patient type diabetes be world most common disease sticking treatment be difficult medication routine get increasingly complicate disease progress diet exercise fail patient go oral drug start cheap generic such metformin prove insufficient doctor add newer brand oral medicine come class dpp inhibitor lead merck januvia more recent sglt inhibitor lead invokana class work different mechanism be sometimes combine yet further intervention be require patient move injectable drug nowadays glucagon peptide glp analog be usually first line attack class include nordisk victoza eli lilly lly trulicity ibd take eli lilly stock have nice year run end year now sport weak composite relative strength rating respectively shouldn get much stock pick attention company aim rebound ceo tell ibd exclusive year come most familiar treatment diabetes insulin modern insulin come different variety include long act version sanofi sny lantus tresiba need be inject only once day faster act one use mealtime such lilly humalog novolog pile med patient have trouble keep so approach simplify routine be create combination drug be do successfully hiv market sanofi nordisk be await fda decision combination insulin glp back back fda advisory panel recommend approval xultophy win unanimous support sanofi lixilan have couple dissenter due safety issue related pen injector used administer drug fda deadline decide xultophy be monday sanofi decision be due next month hasn reveal specific deadline leerink analyst seamus fernandez see blockbuster potential drug expect ll take year hit peak sale have see other recent major primary care launch such pcsk sanofi regeneron regn amgen amgn entresto novartis nvs breo ellipta glaxosmithkline gsk expect slow initial launch class first few year fernandez write research note view xultophy have slight upper hand drug device profile position treatment algorithm lead better physician acceptance market uptake say overall diabetes model forecast peak sale xultophy peak sale lixilan fda decision much anticipate wall street be already approve drug lilly sglt inhibitor jardiance last year lilly stunned industry large year trial show jardiance significantly extend lifespan diabetes patient reduce death rate death cardiovascular cause also sharply reduce hospitalization heart failure analyst say jardiance see instant uptick sale so spectacular be result didn happen lilly closely study issue say enrique conterno president lilly diabetes realize potential thing need happen conterno tell ibd first be need datum label second be need new treatment guideline be establish canada already make change relevant medical society treatment guideline conterno say expect same early next year get label change mean lilly sale rep be able talk cardiovascular benefit customer be important primary care doctor most diabetes prescription aren always specialist research lilly have apply expand label include information least put clinical trial result packaging approval however isn quite slam dunk expect trial result way lilly design trial primary endpoint be normally most important fda be composite different measurement cardiovascular health produce mixed result specific finding heart failure overall death be exploratory endpoint thus fda advisory panel only narrowly recommend change label meet june change label basis secondary endpoint set precedent so remain so unclear fda do analyst compare coin flip view approval actual cv death indication have coin flip odd give unprecedented nature result trial write evercore isi analyst mark schoenebaum email june say also feel better chance fda allow datum be add label also remain be see competition shape last month nordisk report glp call victoza also reduce cardiovascular death not quite much jardiance jardiance be oral victoza be injectable occupy slightly different position treatment regimen jardiance most direct competitor invokana be also subject cardiovascular outcome trial due completion february initial result possibly come earlier different variable company do best diabetes be broadest portfolio funtleyder say cite lilly nordisk have have particularly comprehensive program give advantage salesforce leverage basis same sale guy sample multiple drug say have benefit payer bundle drug together big bill instead pbms pharmacy benefit manager have negotiate separate pill eli lilly share rise stock market today best level late january nordisk climb dip
259,REGN,amgen amgn haul share medicine company mdco esperion therapeutic espr friday ldl cholesterol buster repatha show cardiovascular benefit long await study analyst say tuesday amgen biotech be set release result fourier study et friday american college cardiology annual meeting washington fourier examine repatha ability reduce heart attack stroke cardiovascular disease repatha be already approve reduce bad ldl cholesterol compete praluent drug regeneron regn sanofi sny judge recently rule praluent infringe amgen patent repatha injunction praluent have be stay pending appeal meanwhile amgen be face mount pressure like medicine company merck mrk esperion repatha praluent work block enzyme degrade receptor responsible remove bad ldl cholesterol blood specific market amgen regeneron sanofi drug class call pcsk inhibitor grow least worldwide sale next year rbc estimate theoretical patient ibd take amgen lead market cap trail celgene term key growth metric amgen have ibd composite rating best possible celgene lead cr visit stock checkup breakdown top rate biotechs drug medicine company merck esperion have slightly different mechanism also help reduce cardiovascular disease accord doctor survey investment bank rbc survey say amgen datum be strong repatha reduce cardiovascular disease nearly half think inclisiran medicine company have cardiovascular benefit nearly third think merck anacetrapib be able reduce cardiovascular disease esperion other hand still need get build awareness rbc analyst write research report only doctor expect esperion bempedoic acid meet goal reduce ldl cholesterol show cardiovascular benefit study still think stock grind higher give small market cap wholly own right phase datum start rbc say amgen share fall stock market today related amgen top heart study regeneron sanofi courtabbvie stronger bet amgen least leerink
260,REGN,reason wall street main street scrutinize warren buffett portfolio quarter renown billionaire be know world greatest investor do have common buffett own stock ibd dividend leader screen berkshire hathaway brka chief be shareholder company full
261,REGN,first half be exceptionally difficult drug stock not just overall sentiment relative dearth good news compare previous few year second half year however bring very important clinical trial news several lead player potential move stock sharply here look major event ahead probably most anticipate datum drop year be eli lilly lly initial report alzheimer disease drug solanezumab expect december almost sufferer worldwide alzheimer be largest disease doesn have current treatment many company have attempt create have long history failure phase trial suggest solanezumab isn miracle cure only create statistically significant improvement lilly parsed datum focus early stage case lilly create patient pool phase trial expedition compose entirely such case interview year lilly ceo john lechleiter tell ibd alzheimer probably be treat more product not way diabetes be treat today not way cancer be treat lilly first have primary endpoint trial improvement cognitive decline improvement functional decline however march demote functional decline measurement secondary endpoint analyst take sign lilly think miss credit suisse analyst vamil divan note pooled datum previous trial show impact slow cognitive decline only impact slow functional decline regulatory perspective however be able show sign functional benefit remain important point be now incrementally more cautious divan write march research note biogen biib investor be interested spectator lilly report biogen earlier stage drug aducanumab be base same theory solanezumab reduce amyloid plaque form alzheimer patient brain slow disease progression so far hypothesis hasn be definitively proven gilead science gild also have risky potentially high reward program work garner somewhat less attention conquer hepatitis drug sovaldi harvoni epclusa gilead have turn attention hepatitis virus even more common hep only cure rate current treatment june report leerink analyst geoffrey porge say gilead chief science officer norbert bischofberger be place most confidence gs year read first datum human dr bischofberger explain first cohort study be always virally suppress patient datum be available patient presentation november american association study liver disease aasld conference datum second cohort virally naive patient be available next year european association study liver easl conference porge write regeneron pharmaceutical regn big pharma partner sanofi sny report first datum cholesterol lower drug praluent reduce death cardiovascular disease full result trial aren expect next year regeneron do interim analysis see result have achieve overwhelming efficacy justify stopping trial early initially amgen amgn be expect be first report such datum pcsk inhibitor class drug praluent amgen repatha early june however amgen push report early praluent repatha have underperform expectation launch last year regeneron amgen have warn sale likely be slow prove payer drug actually improve patient health earning report april amgen say repatha prescription be reject pharmacy require prior authorization insurer biogen share rise stock market today gilead science climb regeneron amgen ibd take biogen gilead regeneron be trading well high day day move average investor worry slow growth drug pricing pressure regulator politician
262,REGN,swiss pharma giant novartis nvs cut licensing deal california biotech xencor xncr early stage blood cancer treatment be worth company announce tuesday novartis agree pay upfront rest clinical regulatory sale milestone drug candidate xmab xmab make market candidate acute myeloid leukemia cell malignancy be set begin clinical development year novartis pay royalty foreign sale xencor retain right novartis also have right select more candidate development use xencor bispecific antibody technology develop more drug bispecific antibody be fragment different antibody used direct body immune system attack cancer cell deploy body cell new technology be pursue several company include amgen amgn make own licensing deal xencor september well abbvie abbv regeneron pharmaceutical regn view favorable term receive xencor consistent thesis bispecific antibody be poise play more important role cancer immunotherapy write leerink analyst michael schmidt research note praise great economic deal xencor deal also enlarge novartis toolkit blood cancer company have be leader develop much watch chimeric antigen receptor cell therapy most advanced candidate be ctl acute lymphoblastic leukemia xencor stock catapult close stock market today touch month high novartis stock be
263,REGN,biotech stock analyst ponder potential impact brexit friday morning find most big biotechs have low exposure run other headach exposure european union general range regeneron pharmaceutical regn celgene celg accord jeffery celgene nevertheless tell evercore isi less revenue come gilead science gild eu exposure be exposure be accord evercore calculation vertex pharmaceutical vrtx eu exposure be britain rbc capital market note expect grow vertex latest cystic fibrosis drug orkambi be suppose get reimbursement next year rbc analyst michael yee say research note not clear reimbursement negotiation be impact way however edison investment analyst maxim jacob opined research note measurement exposure be look wrong kind risk risk be global bear market kill biotech funding needham analyst alan carr write britain separation eu also bring regulatory complication road european medicine agency ema conduct centralize drug review process europe be base london carr write research note article withdrawal clause be invoked ema need move need establish new separate regulatory organization do not expect meaningful impact company drug now review ema brexit lead less efficient more expensive potentially lengthier regulatory process company seek approval eu biotechs be hammer rest market stock market today celgene fall regeneron be lowest level october gilead faltered year low vertex shed ibd biotech industry group plunge
264,REGN,treasury department annual financial review medicare find growth rate win trigger cost cut panel week send drug stock higher wednesday ahead report tuesday speculation have break growth be high enough trigger independent payment advisory board ipab come way cut spending brooking institution have schedule event thursday discuss issue last year report project hospital insurance trust fund be deplete just year now brooking say report also predict more immediate controversial event independent payment advisory board ipab famously nickname death panel be require submit proposal reduce medicare spending reduction take place report medicare board trustee actually moved depletion date year earlier say still wasn enough growth cost trigger ipab seem turn major medical group biotech stock have head south tuesday afternoon mid morning announcement ibd medical biotech group rise ethical drug group be even ipab have be trigger analyst doubt impact have be big give restriction sort cut panel make late tuesday rbc capital market michael yee run number note dual eligible add medicaid patient thus grow yee write research note take amgen amgn biogen biib celgene celg gilead science gild regeneron pharmaceutical regn vertex pharmaceutical vrtx medicaid exposure grow get larger medicaid rebate calculation show change revenue more so happened celgene stock fall heavy trading tuesday rise more intraday close stock market today regeneron stock climb intraday set rise drop tuesday amgen biogen share rise fractionally sank nearly tuesday timing hedge fund manager leonard yaffe wasn convince ipab business be actual reason stock move biotechs have be trend downward early june rebound biopharma stock today be much more offset concern mentioned yesterday well likelihood fund redemption stock have become very attractive prospect several company be bright yaffe write email
265,REGN,stock turn negative afternoon trading positive news drug stock homebuilder tesla motor tsla plunge shareholder objected surprise bid solarcity scty dow jone industrial average fall nasdaq volume stock market today be run tuesday level nyse nasdaq stock hit session high late morning lead drug biotech stock such gilead science gild regeneron pharmaceutical regn government say next year create independent payment advisory board cost cut body investor have expect ipab sometimes refer obamacare death panel critic take effect year gilead science climb sucampo pharmaceutical scmp rise regeneron pharmaceutical add more session also rise sale exist home hit year high kb home kbh report better expect earning los angele base kb home say late tuesday profit latest quarter jump cent share easily beating wall street forecast revenue increase biggest increase quarters kb home rise intraday stock reach briefly clear buy point long deep cup handle base beazer home bzh turn negative lennar len rise do kb home stack rival building industry find ibd stock checkupbuild product stock tile shop holding tts also fared well jump new high intraday trading just buy point cup base heavy volume meanwhile restoration hardware rh vault analyst bb say merger luxury home furnishing retailer rival william sonoma wsm make even more sense do year william sonoma sell furniture accessory own name brand such pottery barn rise more downside tesla motor plunge announce plan late tuesday buy money lose solarcity affiliated installer solar panel roughly solarcity jump billionaire entrepreneur elon musk be biggest shareholder tesla solarcity say win vote deal
266,REGN,past week insider trade include higher up cisco system csco regeneron pharmaceutical regn skywork solution swks lendingclub lc skecher skx karen walker cisco chief marketing officer senior vice president file thursday sale share worth company debut new tetration analytic platform thursday beef datum center security capability share fall week french pharmaceutical giant sanofi increase stake regeneron share accord thursday filing last month regeneron bump full year guidance flagship drug eylea turn mixed first quarter result earning miss penny regeneron stock fall week settle friday lowest close october skywork executive chairman david aldrich file sale share worth apple aapl chip supplier follow aldrich sale last week share value share be almost so far week director jeffrey greenberg thursday file sale share athletic shoe maker value share skecher break support day line last week continue build cup handle base peer nike nke armour ua remain lock heated battle star endorser lebron james stephen curry go head head game nba final sunday skecher stock fall week major shareholder shanda group ceo tianqiao chen acquire share accord thursday filing lend club stock price take knock hike credit standard most interest rate allege misconduct company executive share shot week
267,REGN,big pharma pfizer pfe say monday acquire small biopharma anacor pharmaceutical anac cash send latter stock more monday pfizer agree pay share anacor premium friday close price share close monday just total transaction value be assume conversion anacor outstanding convertible note pfizer say anacor sole commercial product be toenail fungus ointment call kerydin distribute novartis nvs pfizer press release merger play anacor eczema treatment crisaborole be fda review due completion jan believe acquisition anacor represent attractive opportunity address significant unmet medical need large patient population mild moderate atopic dermatitis currently have few safe topical treatment available say albert bourla head pfizer innovative business release pfizer estimate crisaborole reach peak annual sale buyout add asset pfizer innovate drug business be widely expect separate establish product business sometime next few year pfizer have say make decision split year end pfizer already have significant presence inflammation immunology include blockbuster rheumatoid arthritis treatment enbrel sell partnership amgen amgn xeljanz regeneron pharmaceutical regn recently report strong late stage datum injectable drug dupilumab atopic dermatitis so market be currently underserved soon become more competitive be not easy make cross trial comparison crisaborole dupi regenron treatment target moderate severe patient crisa target mild moderate patient well different route administration injectable vs topical different primary endpoint write evercore be analyst mark schoenebaum email client look top line datum investigator global assessment drug be relatively comparable dupi appear be more effective correct placebo dupilumab phase demonstrated achieve clear clear skin lesion week compare placebo crisaborole patient achieve clearance much larger placebo background placebo patient achieve clearance crisaborole week regeneron roche rhhby astrazeneca azn have injectable atopic dermatitis treatment midstage testing anacor stock close stock market today pfizer stock rise fraction regeneron stock rise roche astrazeneca be
268,REGN,average average be term often hear not well understood begin investor average be happen add position rise stock time make new purchase cost new share be higher last purchase price drife average cost position total investment averaged accumulate share average be opposite buy decline stock new purchase cost less so average cost decline investor buy decline be convince stock recover current level be slightly distorted way look buy low sell high axiom time average cost basis go lower so ability profit be increase miss proof require slim investing technique be heavy institutional interest decline stock typically show fund other big investor shipping stock chart show distribution decline high trading volume stock chart begin show evidence accumulation day increase price heavy trade big investor move establish position individual investor belief stock story confidence historical trend stock industry be purely gamble average be smart stock investor strategy graft strong price move drive institutional support basis show turnover institutional holder distribution left side accumulation right breakout past buy point occur accumulation big money buyer constrain supply available share investor step point be solid position begin average regeneron pharmaceutical be former stock market leader see stock now lead biom industry ibd stock checkup concept grate nerve investor trained seek bargain rather buy low sell high ibd approach say buy proper point not low then add add finally sell entire position higher approach doesn work sell original position never book deeper loss seriously rally stock add buy average well profit go year so much average be acceptable look regeneron pharmaceutical regn january let say investor place position stock do step technique call pyramid add position smaller measure buy february week tight pattern buy point earlier entry be justifiable august cup handle buy point april cup handle buy point february cup base buy point march flat base buy point image provide shutterstock
269,REGN,regeneron pharmaceutical regn say monday experimental antibody arthritis pain succeed mid stage trial share be flat early trading result be expect study enrolled sufferer moderate severe hip knee pain be unsuccessful standard painkiller week treatment group take regeneron fasinumab have improve more point point pain scale significantly better placebo group group take fasinumab experience adverse event regeneron say include inflammatory joint pain prickle burn sensation skin numbness swell investigator also do extensive imaging subject class medicine fasinumab belong nerve growth factor ngf antibody have be associate joint damage wound exclude subject due imaging result patient remainder suffer subchondral insufficiency fracture stress fracture abnormal bone regeneron stock be early trading stock market today share touch month late march regeneron stock have weak ibd composite rating putt lower half stock basis key metric such earning sale growth regeneron have already signale trial be go well earlier year start large phase trial drug so result weren especially surprising analyst also lose potential competitor late march johnson johnson jnj stop development own ngf antibody fulranumab be late stage trial arthritis pain rbc capital market analyst adnan butt write time decision be base pipeline prioritization not problem drug monday butt praise effectiveness fasinumab trial write safety bear watch overall program succeed be blockbuster candidate other be upside driver come regulatory mechanistic safety concern hence be not major focus investor time aside development cost timeline standpoint butt write research note
270,REGN,big cap drugmaker regeneron pharmaceutical regn merck mrk be move opposite direction thursday trading earning report company raise guidance regeneron quarterly revenue rise year earlier period beating analyst consensus accord thomson reuter earning share be penny short estimate last year crucial metric sale flagship drug eylea regeneron report growth beating consensus company raise full year growth estimate vs previous earning miss stem higher spending selling general administrative cost spending guidance year remain unchanged also cholesterol drug praluent be launch last july miss consensus again number remain small company await result cardiovascular outcome trial praluent rival amgen amgn repatha later year regeneron say payer coverage praluent be good so far commercially insure medicare have access drug regeneron stock be midday trading stock market today merck post earning cent share year earlier period beating consensus cent sale decline miss wall street number merck stock be midday thursday merck add few cent ep guidance range now also raise low end revenue guidance now echo number global pharmas earning season merck cite improve foreign exchange rate revenue shortfall be spread number different drug include blockbuster diabetes drug januvia immunology drug remicade more interesting analyst be come cancer drug keytruda miss estimate beat slightly worldwide especially rival bristol myer squibb bmy opdivo beat consensus last week bristol myer also moved report date trial opdivo first line treatment lung cancer previously guide erode advantage merck expect report result similar trial keytruda midyear drug be now approve only previously treat patient so first line approval significantly expand market merck also report sale hepatitis drug zepatier just launch late january tiny compare report market leader gilead science gild gilead abbvie abbv say earning call last week merck aggressive discounting have affected own business nonetheless rbc capital market analyst michael yee write not have be directly responsible gilead miss merck suggest negotiation important parity access remain ongoing exception veteran administration market have good access interestingly suggest many commercial payor access deal be impact contract be already complete yee write research note so gilead say lower sale be mostly due just higher gross net healthier patient come not so much competition be true realize price competition be still ongoing come need be watch
271,REGN,analyst think good time take ride electric carmaker tesla motor tsla fossil fuel giant exxon mobil xom price target be raise tjx co tjx agio pharmaceutical agio cigna ci goldman sachs say tesla not reach production target vehicle still upgrade luxury electric car maker buy neutral keep price target say more ground investor expectation now offer good entry point goldman doesn see big term catalyst next model update not come goldman saystesla share close stock market today drop late trading tesla announce secondary stock offer argus research raise exxon rating buy hold price target crude oil future have rally recent week sign global supply glut be ease well production disruption canada nigeria exxon share close crude future dip tjx beat earning tuesday see lot room expand store base see price target bump rbc capital market price retailer stock fall rise tuesday cigna be aim close merger rival health insurer anthem antm be keep sector perform rbc price target hike last week cigna reach deal pay sanofi sny regeneron regn base well customer respond drugmaker cholesterol lower treatment cigna share fall sun trust keep buy agio raise target late tuesday agio expand cancer drug partnership celgene celg agio share jump pre market action fall celgene rise
272,REGN,biotech stock fall deepest crater history start last summer rumbling recovery be sound year bull run more quadruple value peak last july ibd medical biom biotech industry group plunge early february hurt backlash high drug price merger seek lower corporate taxe group have gain feb low lead stock have do better biotech stock buoy potential blockbuster drugsbiomarin pharmaceutical bmrn be feb low incyte incy have gain low point same week ligand pharmaceutical lgnd have climb medivation mdvn boost buyout talk be group be even more take hit past week negative earning news several industry player fund manager tell ibd rebound be here say spate bad news have already be factor stock price more see climate favore rejuvenate hot drug new product pipeline pricing power innovate product bottom line positive factor drive runup never go away say just get drown noise very key point be group be very high beta group particularly small midcap stock don have sale don have earning say tom vandeventer portfolio manager tocqueville asset management history group be elevated macro uncertainty definitely hit vandeventer say own opinion be group trade more sentiment fundamental time period vandeventer point trouble china emblematic macroeconomic concern hit biotech stock sentiment drive factor be politic many candidate presidential race have bash drugmaker high price have propose way clamp wall street have dismiss idea impossible ineffective seem be generate most concern be democrat proposal let medicare medicaid negotiate drug price be not allow do now already center medicare medicaid service have show tooth announce pilot program change reimbursement medicare part cover drug administer hospital clinic part reimbursement scheme be long criticize encourage use expensive drug reimburse health care provider entire cost drug top propose scheme reduce premium add flat fee unrelated price drug theory encourage doctor choose cheaper option front treasury department last month issue new guideline tax inversion deal derail have be drug industry biggest ever merger pfizer pfe allergan agn tax inversion have become popular way drugmaker boost bottom line get access cash allergan earlier merger be base ireland have low taxe think tax regulation call inversion bottom bad press associate health care industry create bottom mind say robert bombace senior portfolio manager frost investment advisor lot bad news have already be baked company fact number industry insider say breakup pfizer allergan merger turn be good biotech stock make acquisition target company allergan have long history acquisitiveness pfizer be think splitting innovative drug business other product evercore isi analyst mark schoenebaum say pfizer want bulk innovative business make valuable standalone pipeline be modest compare big pharma competitor schoenebaum have also say biotech board be balk buyout offer much valuation have drop so ve be unwilling sell market price suspect lead hostile takeover deal big player be willing do partly come fruition late april sanofi sny make unsolicited bid medivation rumor swirl astrazeneca azn pfizer be also interested medivation response reflect attitude schoenebaum speak market be underprice stock sanofi time proposal come period significant market dislocation several important term event company be design seize sanofi value rightly belong stockholder medivation founder ceo david hung say statement reject offer bombace however say biotechs reluctance be show think just bargaining chip say reality be most company have partner anyway larger pharma biotech name reach point pipeline be so dry force hand bombace see lot exciting biotechnology science go fill pipeline put re go model stage space shuttle stage decline name specific company point work biomarker include pd inhibitor such bristol myer squibb bmy opdivo merck mrk keytruda also cite work genetic mutation focus many rare disease firm such biomarin bluebird bio blue discovery be keep money flow biotechnology say leonard yaffe manage health care hedge fund kessef capital management tell ibd specialty drug largely biologic drug prescribe specialist opposed primary care doctor contribute only prescription last year dollar spend drug year earlier thing think drive biotech stock be look drug introduce last year revenue derive drug be biological yaffe say so most attractive sector pharmaceutical area also most publicly trade biotech stock don have earning have successfully launch drug remain highly profitable top biotechs market cap gilead science gild amgen amgn celgene celg biogen biib regeneron pharmaceutical regn have ibd ep rank range putt top stock ep growth regeneron have ep rank number however reflect pricing power biologic drug be precisely political attack day vandeventer say price uncertainty be biggest risk bull thesis group right now also point democratic presidential front runner hillary clinton attempt previous overhaul health care system back mid depress drug stock short term be follow late boom boom be drive first wave biotech innovation company amgen roche rhhby genentech prove biotechnology produce blockbuster vandeventer say innovation remain key maintain pricing power even political pressure point gilead portfolio hepatitis drug start late launch sovaldi much political criticism sovaldi high price stop drug be so superior anything else market company have do research ll continue get price increase say company be particularly rare disease orphan disease arena oncology space company have drug era target medicine have higher efficacy rather shotgun try hit disease be go have pricing power promise such drug still make small stock explode celator pharmaceutical cpxx have surge march favorable late stage trial result acute myeloid leukemia treatment company also see hedge fund take position stock attract favorable initial coverage analyst be sign even generalist investor think biotech stock have get cheap say yaffe first quarter common lament be biotech stock get punish bad news good news get reward biogen issue mixed earning report draw mostly negative reaction wall street april stock rise more biogen have fall even harder other big cap biotechs drop march high feb low so be ready bounce say yaffe overview comment be sector have correct point get level stock be very attractive say
273,REGN,stock finished lower wednesday good quarterly result whole food market wfm tesla motor tsla close help set positive tone thursday open nasdaq fall dow jone industrial average drop volume be lighter exchange accord preliminary datum whole food report earning share cent penny better year earlier more analyst expect revenue come vs estimate investor hour focuse earning beat bidding stock higher do same tesla report first quarter loss cent share street expect cent loss company promise deliver car second quarter tesla share drop regular session announcement executive be leave company investor jim chano highlighted case company former leader fleetcor flt lose ground hour score earning beat ep cent estimate miss revenue give line guidance thursday open labor department be forecast report jobless claim week end april vs prior week company report earning thursday include gopro gpro regeneron regn square sq cerner cern motorola solution msi
274,REGN,stock open modestly higher thursday market gear earning heavy session dow jone industrial average rise nasdaq climb day light economic calendar open monthly job cut report challenger gray christmas job consultant say layoff rise more april vs march job cut higher year earlier number energy industry cutback continue report say rise layoff activity retail computer industry labor department report initial jobless claim rise week end april prior week economist have project milder rise claim oil price bound more higher send brent crude barrel lift west texas intermediate past wildfire canada northern alberta province be apparently factor news report say fire have not threaten alberta oil sand facility production have be affected oil company assist evacuation town ft mcmurray gold rise nearly ounce dollar rise vs euro slip yen stock dow issue be flat positive exxon mobil xom chevron cvx more apeice weight watcher wtw soar first quarter report regeneron pharmaceutical regn punch solid first quarter china alibaba group baba jump alibaba fiscal earning show higher expect revenue adjust ep stop short estimate gain net income sustain growth margin allay fear effect china slow economy stock end wednesday buy point cup handle base tesla motor tsla trim early gain be quarterly report stock end wednesday buy point cup handle base system ddd trim early gain mixed result gross profit margin jump maker additive printer shift away consumer oriented market stock end wednesday nearly week week line support still january low chip maker qorvo qrvo rumble fiscal revenue earning fall less expect share correct past week decliner include drug wholesaler abc follow fiscal result overseas market europe china be narrowly mixed japan tokyo stock exchange remain close holiday friday
275,REGN,biotech regeneron pharmaceutical regn core ophthalmology business still have huge upside eylea sale grow treat variety eye disease say rbc capital rbc also say legal settlement amgen amgn praluent drug intend lower bad ldl cholesterol be positive most regeneron sale come eylea launch treat age related vision loss elderly regeneron aim build sale eylea market treat diabetic macular edema dme cause blindness work age person well related eye disease affect older person turn dme market opportunity be important likely adnan butt rbc capital analyst say research report tuesday dme eylea compete roche hold rhhby lucentis regeneron typically report earning early roche novartis nvs bayer bayry report earning april respectively commentary provide insight eylea growth say rbc butt say consensus expectation recently launch cholesterol drug praluent have only december quarter sale still need come amgen make rival drug call repatha march federal jury upheld validity amgen patent related cholesterol drug deal blow regeneron partner sanofi sny settlement amgen be positive butt say report rate regeneron stock outperform price target regeneron stock be more early afternoon trading stock market today amgen report earning april follow sanofi april earning call provide read status praluent litigation say butt regeneron stock have plunge broad sell biotech stock include celgene celg gilead science gild regeneron share touch month low last month jump april company announce strong phase clinical result dupilumab drug eczema itchy skin condition regeneron be develop drug sanofi landmark deal sanofi provide year fund antibody discovery year give regeneron profit defer development cost partnership be profitable add butt startup intellium therapeutic late monday announce licensing deal regeneron cambridge mass base intellium have develop gene editing technology treat liver blood disease plan go public regeneron have ibd composite rating possible lower celgene gilead ibd medical biom biotech group rank just industry group month past week best span therapeutic anik supernus pharmaceutical supn ligand pharmaceutical lgnd have highest ibd composite rating biotech group
276,REGN,big biotech regeneron pharmaceutical regn big pharma partner sanofi sny say friday potential blockbuster eczema drug candidate sail late stage trial be submit approval year regeneron share spiked friday head best day percentage gain year regeneron sanofi drug dupilumab clear nearly clear symptom atopic dermatitis eczema more third patient compare less patient placebo group clinical trial comprise total person patient dupilumab general average improvement eczema area severity index easi placebo group improve range be approve systemic therapy person moderate severe atopic dermatitis underscore clear unmet need sanofi head elias say statement dupilumab ad atopic dermatitis have be grant breakthrough therapy designation fda plan submit regulatory application third quarter year work bring innovative therapy patient quickly possible evercore isi analyst mark schoenebaum write analyst consensus peak annual sale estimate dupilumab be quite bit variation individual analyst believe current debate dupilumab be focuse size commercial opportunity be also late stage study severe asthma dupilumab demonstrated high efficacy phase comer population well chronic sinusitis nasal polyp eosinophilic esophagitis schoenebaum write email client be relatively new market segment dupilumab be first therapeutic candidate address high unmet need commercial opportunity severe asthma be similarly attractive however dupilumab be face more crowd competitive landscape asthma regeneron share shot afternoon trading stock market today move day move average first time regeneron stock touch month low march sanofi stock rise fraction
277,REGN,stock stage big upward reversal close first trading day april positive note flurry mostly positive economic report nasdaq lead gain dow jone industrial average add volume rise major exchange vs thursday accord early figure loser outpaced winner small margin nyse advancer beat decliner nearly nasdaq week nasdaq rise dow climb close friday economic news payroll increase worker march slightly expectation slight uptick jobless rate consumer confidence march also edge past forecast february ism manufacturing index rise march february first foray neutral level august economist expect west texas intermediate crude price slide barrel top gainer today stock market action include biotechs carmaker other drug stock tesla motor tsla surge much intraday settle gain fast turnover order electric car maker model mass market sedan be unveil thursday evening start be pour ceo elon musk confirm least order stock nearly feb low be now week high biotechs regeneron pharmaceutical regn soar robust trade regain day line first time late december share be still well day line week high biotech partner sanofi sny say dupilumab atopic dermatitis drug meet key goal late stage trial plan file fda approval sanofi gain average volume ibd wesson swhc sturm ruger rgr flag entertainment rise more turnover higher usual flag be featured friday stock spotlight column energy hotel car dealer lag starwood hotel resort hot fall marriott international mar give investor group lead china insurance withdraw offer buy starwood marriott most recent offer hotel chain be economic datum come monday include february personal income outlay pending home sale index february dalla fed manufacturing survey march
278,REGN,stock get bullish start new quarter hold moderate gain rise volume roughly hour left trading wall street nasdaq composite lead gain trading virtually session high stretch further key day move average dow jone industrial rise nearly small cap lag inch volume be tracking sharply higher exchange tesla motor tsla look poise strong weekly finish back friday early intraday high stock highest price oct stock be nearly raise price target research analyst tesla be find support day move average good sign stock remain potential buy point electric vehicle firm be get shower order model mass market sedan start least order confirm tesla ceo elon musk potential revenue fulfill order next year already dwarf revenue tesla notch full year elsewhere stock market today retail apparel stock be rally en masse include former big winner urban outfitter urbn lululemon lulu former be build deep cup style base latter be extend past handle entry medical sector be also rocking first day new quarter disastrous january march period biotechs pace upside regeneron pharmaceutical regn punch downward slant day move average stock still show awful ibd rating include composite maximum relative strength wall street expect first quarter profit fall share ibd ethical drug research equipment service industry subgroup be also lead friday upside gain approach ibd medical biomedical biotech subgroup still rank lower half ibd ranking term month relative performance see table subgroup find other ibd datum stock list tab investor com homepage biotech stock be big winner market rally extend way back market bottom need more time consolidate gain charge capitol hill atmosphere member congress be express outrage high drug price downside stamp com stmp extend pullback far enough clip day move average stock drop more volume run nearly typical pace stock have fall more recent cup handle entry keep mind breakout late stage basis show much higher risk failure stamp com case stock initial be back april power past buy point then build new basis break again february august november
279,REGN,stock market turn solid performance wednesday release minute march federal reserve meeting didn do much overall bullish tone close nasdaq be add dow jone industrial average picked preliminary datum show volume nyse come slightly lower tuesday level nasdaq volume rise bit new york mercantile exchange west texas intermediate crude oil delivery jump barrel government report unexpected drop crude inventory biotechs do heavy lift nasdaq ishare nasdaq biotechnology etf ibb outperformed rise regeneron regn biogen biib be best performer nasdaq respectively nutshell fed minute show sentiment be run rate hike later month cme group fedwatch currently have odd rate hike year treasury yield add basis point stock market today fast grow homebuilder lgi home lgih jump nearly strong trade clear resistance work right side possible base late tuesday company say new home closing surge march most ibd stock be higher lead acuity brand ayi bolt more upward follow strong quarterly earning report stock rocket past alternate entry hesitate earlier entry cup handle base pfizer pfe allergan agn rise drugmaker abandon deal have shift pfizer headquarters ireland provide company overseas tax shelter allergan rise plunge almost tuesday follow treasury department unveil rule aim discourage such tax inversion deal pfizer gain meanwhile oil field service giant baker hughe bhi halliburton hal outperformed jump respectively justice department file lawsuit halt plan merger concern combine company stifle competition sector close watch earning retailer bed bath bbby small cap ollie bargain outlet olli
280,REGN,amgen amgn win patent suit fellow biotech regeneron pharmaceutical regn partner sanofi sny related rival cholesterol drug wednesday amgen sue october charge regeneron sanofi co develop drug praluent violate patent amgen hold drug repatha drug be similar be proprotein convertase subtilisin kexin type pcsk inhibitor amgen have be slightly ahead development timeline regeneron buy priority review voucher let launch praluent last july month ahead repatha case go jury wednesday rule favor amgen patent be valid amgen also ask permanent injunction be decide hearing schedule march regeneron general counsel joseph larosa say press release company appeal be complex area law science believe fact control law support position say larosa look forward take case federal circuit court appeal appellate court hear patent appeal evercore isi analyst mark schoenebaum write appeal take additional month recall new argument be able be present appeal court appeal be fact base so bar be relatively high write email client analyst have expect likeliest outcome suit be royalty paid amgen praluent sale schoenebaum estimate royalty peel regeneron ep trading regeneron share be halter midday stock market today news come rise morning trading trading resume early afternoon regeneron stock be more amgen stock meanwhile be fraction wednesday afternoon sanofi stock be not halter be nearly
281,REGN,something everyone vast universe sector fund consumer staple health care technology sector be favor fund rack big return also be prone bigger decline re more concentrated specific area diversify fund ibd run screen actively manage fund least asset have beaten benchmark past year sector be clear winner best sector fund rank year performance focus biotech health science see full list best sector mutual fund highlight best mutual fund top perform sector best best list ibd best mutual fund award winner include top fund sector click here view table top perform mutual fund select biotechnology portfolio fbiox come top year average annual return well ahead fund hold net asset feb expense ratio be rajiv kaul have manage fund october most sector biotech have see fair share volatility not necessarily negative next year go be renaissance industry term golden age innovation kaul tell ibd not go be straight line biotech be volatile investor amazing opportunity happen jan biotech stock make portfolio pharmaceutical fidelity select biotech hold stock top holding end include alexion pharmaceutical alxn regeneron pharmaceutical regn vertex pharmaceutical vrtx gilead science gild celgene celg stock ibd biotech industry group surge more november low july peak turnover fund tend run fairly low be high barrier entry biotech field include expertise capital regulatory hurdle kaul point do get major breakthrough medication really improve person life help save cost health care system do kaul pick stock fund have understand management be track record success say have kind historical understand depth understand industry individual player equally important be ability company access capital low cost want company be self reliant top biotech fund own big cap biotech soliris maker alexion recently report quarters fund also hold biotechs celgene gilead focus cancer hepatitis respectively generic drug maker track ibd soar more march july ethical drug stock rally nearly march august rowe price health science prhsx take second place biotech fund year return fund have net asset have be close new retail investor june feb portfolio hold stock service account asset follow biotech pharmaceutical product device life science top holding include aetna aet alexion pharmaceutical allergan agn becton dickinson bdx cigna ci focus innovative medicine diagnostic device business model have be core driver success taymour tamaddon have manage fund february say mail past year strength have be broad base biotech likely have highest level performance fund expense ratio be prudential jennison health science phlax return past year have be close new investor end june fund have total net asset expense ratio david michael del balso debra netschert manage fund biotech make biggest weighting jan asset pharmaceutical account health care provider service be health care equipment supply be life science tool service be biggest holding stock portfolio include celgene biomarin pharmaceutical bmrn bristol myer squibb bmy shire shpg allergan remain focuse longer term outlook fund believe continue be very positive base range industry trend health care reform advent oncology active immune therapy manager say jan fund commentary realization company value encounter intermittent setback believe market recognize reward longer term franklin biotechnology discovery fbdix total net asset feb have year return biotech stock make portfolio follow pharmaceutical nearly life science tool service focus biotechnology generally have limit exposure other area health care evan mcculloch senior vice president lead portfolio manager fund say avoid more traditional large cap pharmaceutical company have less favorable growth prospect do not show same level innovation see biotechnology celgene gilead science biogen biib amgen amgn regeneron pharmaceutical be top position stock fund fund close new investor july have expense ratio overall believe be strong fundamental underlie biotechnology sector recent growth have also help fund mcculloch say innovation remain very strong promising new treatment area immuno oncology gene therapy alzheimer disease gi disorder central nervous system disease other rydex biotechnology ryoax round top sector fund year return expense ratio be biotech account net asset feb pharmaceutical life science tool service top holding march include gilead amgen celgene biogen regeneron health care clearly dominate sector fund past decade other fund lead respective category rowe price global technology prgtx net asset end february lead tech sector fund year average annual return medium semiconductor software make biggest weighting stock fund top holding include alphabet googl amazon com amzn jd com jd have expense ratio lead consumer cyclical sector be fidelity select retail portfolio fsrpx asset feb year average annual return expense ratio be internet retail home improvement retail apparel retail account top subindustry end january amazon home depot hd netflix nflx be top holding rowe price medium prmtx top communication sector average annual return fund have net asset feb expense ratio be medium telecom service software be biggest investment area alphabet amazon american tower amt stock portfolio recent top holding rydex consumer product rycix average annual return expense ratio lead consumer defensive sector food product beverage household product account more half net asset procter gamble pg coca cola ko philip morris international pm be recent top holding burnham financial service burkx hold asset head financial sector average annual return yadkin financial ydkn bnc bancorp bncn atlantic capital bancshare acbi be fund top holding jan fund gross expense ratio be net expense ratio be
282,REGN,hardest thing champion do again again again just ask repeat super bowl titlist baseball horse race triple crown winner tennis grand slam champ just hard best mutual fund too relatively few fund be able pull feat deserve recognition deserve consideration addition replacement retirement account ira well taxable account help identify special mutual fund ibd be introduce best mutual fund award stock mutual fund qualify exclusive recognition only have beaten broad market past year period not just award be earn mutual fund category top rank year performance top case sector fund be highlighted best best deserving special recognition be time winner be easy task mutual fund meet criterium have least asset year operation only beat benchmark period diversify stock mutual fund business entire decade track morningstar inc only pull feat growth mutual fund only emerge award winner category be much harder only value mutual fund beat benchmark time period just small cap fund get award winning stock mutual fund include category growth blend value well large mid small cap be compare index period dec international stock fund have beat msci eafe index best taxable bond fund trump barclay aggregate bond index tax exempt fund conquer barclay municipal index foreign taxable bond fund outperformed barclay global aggregate click here view table top fund categorywhether be look mutual fund strengthen current portfolio just start ibd award list be great place start here ll find top perform fund run smartest portfolio manager award winner be array category stock bond fund be most often used build core position diversify portfolio large mid small cap growth blend value stock foreign stock equity sector bond re market large cap growth foreign bond fund check category award winner be available plan get fund prospectuse quarterly report manager commentary see choice make best fit term investment horizon risk tolerance start top take time consider award winner category re interested already be familiar fund company have fund top mutual fund add confidence selection fund own be not award winner win want rush dump be perfectly good fund run competent portfolio manager fit unique need portfolio consider outperformed benchmark most period narrowly miss exactly do fund outperform so consistently achieve award status fund have show ability survive market correction bear market rac loss ruin long term return several manager claim secret involve ability ignore short term zig zag market individual expect short term performance not be type person invest fund say lee manager brown capital management small company fund explain team preference stock provide fund consistently superior growth long run have also outperformed past year aim strong long term return really mean be ability put together portfolio build weather market storm many fund mean focus company be not highly cyclical business such involve commodity many also mean sticking business strong balance sheet little debt many mean look sustainable earning not short term flash pan gavin baker manager fidelity otc portfolio focpx have similar view have long term time horizon be look year think be big advantage baker tell reporter billy fisher profile gavin fund be also best stock mutual fund large cap stock mutual fund many award winning manager take step further not only do ignore call short term noise market also stick own long term game plan tim parton manager jpmorgan growth advantage vhiax top fund large cap category helm team look lead stock regardless market capitalization work closely colleague run small large cap fund parton team mix name midcap stock focus other beauty strategy be re never force sell good stock just get too big be perennial problem small midcap manager parton say past fund have have bigger weighting small midcap stock team be find more growth opportunity attractive valuation market cap parton think long term team do not ignore here now tough period focus fundamental company say make sure name be not too affected environment re trim size position reduce risk volatile market ve be experience make name team like even more attractively price parton nibble only very cautiously only margin say explain caution stock have be knock price reason already have slightly higher risk portfolio value fund manager parton invest stock stock still sector weight show expect find leader biggest sector be information technology weighting feb nearly double second largest sector consumer discretionary tech holding range small cap medical software maker veeva system veev midcap database software maker splunk splk large cap gaming software maker electronic art ea giant cap microsoft msft winning manager many diversify stock fund category make point think long term base investment decision individual stock much more hot sector sector fund manager plumb respective pond fish hot trend land dominant shark water ibd nancy gondo explain diagnosis top perform sector fund biotech health science have be clear outperformer past year stock alexion pharmaceutical alxn regeneron pharmaceutical regn celgene celg gilead science gild pop recent portfolio disclosure top rank sector fund trait share best best focus well manage company able maintain pricing power even toughest time report scott stoddard examination best best international stock fund sector fund success bond fund often hinge ability play hottest part fix income market avoid segment be favor marie beeren report special report tcw total return bond tglmx be year outperformer thank large part surfing recovery mortgage credit crisis tcw manager bryan whalen tell beeren fund also avoid headwind have almost exposure corporate credit market dramatically lag similar duration treasury so be best best mutual fund need portfolio not stand alone fund parton say portfolio be growth fund do not give holistic exposure be exposure part market be used other other better choice consider ibd award winner have proven mettle year various market segment again again
283,REGN,stock wrench early loss heavy trade friday then ease mixed trade follow flurry early economic report dow backed narrow loss slight gain hold red nasdaq wrestle fractional loss volume jump nearly nasdaq nyse compare trading volume same time thursday friday early slip stock market remain good standing week nasdaq be more vs last thursday close be track end first weekly close day move average early january be fight hold gain remain comfortably day line blue chip lag week dow jone industrial average gain small cap outpaced send russell friday session advance entire group open second quarter burst momentum nasdaq russell mid february low labor department march payroll report show hire slow less expect wage rise firmly unemployment rate tick upward vs consensus expectation change morning first read march manufacturing be mildly disappointing researcher markit putt purchasing manager index month february forecast similar gauge form institute supply management be more positive pop march february clear consensus forecast march consumer confidence also improve expectation university michigan place final consumer sentiment survey month economist have project uptick february final tally oil future dig deeper more west texas intermediate crude just penny barrel price see effect baker hughe bhi weekly rig count datum due et almost third dow stock post loss deeper chevron cvx slide furthest mcdonald mcd add top dow few advance issue tesla motor tsla be center stage follow thursday evening introduction model sedan share spiked nearly heavy trade open breaking buy point shape cup handle base stock quickly pare gain hold just pivot regeneron pharmaceutical regn urban outfitter urbn lead apiece oil energy related stock packed low end index airline stock be take hard early hit deutsche bank downgrade unite continental holding ual hold buy base challenge outlook unite drop fast trade american airline aal dump delta air line dal slip ibd list concrete uscr trowele gain announce have acquire haskell texas base bridge term be not disclose company say deal expand capability market abilene texas
284,REGN,soar growth facebook fb soon take step ease tax burden accord morgan stanley report morgan stanley say facebook be list technology pharmaceutical company gain congress create patent box part corporate tax reform other company benefit patent box also call innovation box be qualcomm qcom chip maker xilinx xlnx well drug company regeneron pharmaceutical regn alexion pharmaceutical alxn say report patent box provide lower tax rate royalty income generate licensing intellectual property include patent trademark design logo qualcomm morgan stanley note ip licensing business be conduct almost entirely unite state such believe generally pay full corporate taxe share facebook jump early afternoon stock market today social networking giant late wednesday say revenue jump year earlier estimate facebook revenue be generate internationally fact estimate facebook have approximate adjust tax rate very close federal statutory rate go forward facebook take step reduce tax burden morgan stanley report say congress pass legislation overhaul corporate taxe say senator chuck schumer rob portman have propose tax reform aim tax inversion deal company relocate headquarters lower tax nation usually follow acquisition patent innovation box be unite state best mean combat inversion remain competitive other country say morgan stanley report supporter say patent box also help keep research development
285,REGN,biotech pharma stock sell sharply thursday busy earning week even overall market rise ibd medical biom biotech industry group hit month low stock market today be early afternoon separately ethical drug group be number company group report earning thursday
286,REGN,biggest key fundamental analysis be examine company past record earning share growth current growth prospect growth ahead ep growth drife stock performance so make sense be focal point research process analyze earning be just part fundamental analysis also important have good handle sale profit margin return equity ibd smr sale profit margin roe rating look assign letter grade stock rate stock be top name ibd database rate stock be bottom sale growth be robust preferably range higher recent quarters annual pace profit margin answer question many cent profit do company generate sale widget cost cent make company sell buck gross profit margin be benchmark percentage profit margin margin vary industry be good see annual pretax margin quarterly tax margin peak level evaluate stock return equity roe help separate well manage company poorly manage one also expressed percentage calculate divide net income shareholder equity asset liability be careful high return equity be result heavy debt load look high roe firm low debt ibd study past market winner show average annual roe major price move investor focus be stock high smr rating keep mind new issue fall bit short rating company be still early stage business just verge profitability stock pass muster other key fundamental technical area lukewarm smr rating shouldn be deal breaker regeneron pharmaceutical regn recently have smr rating help big sale growth recent quarters pretax margin return equity institutional investor have be selling share spade recent week stock be early stage breaking late stage base gopro gpro strong sale growth profit margin return equity give smr rating be hit hard institutional selling recent month due concern future growth last week company announce job cut issue weak sale guidance due poor holiday sale solid smr rating stock be almost high epam system epam own smr rating blast cup shape base late october high rating be help annual pretax margin time return equity quarterly sale growth be stellar show year year growth excess
287,REGN,share biotech medicine co mdco jump wednesday report company be explore sale bloomberg cite anonymous source report early wednesday do not name potential buyer medicine co financial have be suffering lately due loss patent exclusivity lead drug angiomax stock have stay relatively buoyant
288,REGN,drug candidate regeneron pharmaceutical regn sanofi sny jointly develop have beaten abbvie abbv best selling rheumatoid arthritis ra drug late stage study company say friday regeneron france base sanofi say monoclonal antibody sarilumab meet trial main goal improve symptom week biweekly dose regimen patient sarilumab achieve
289,REGN,drug candidate regeneron pharmaceutical regn sanofi sny jointly develop have beaten abbvie abbv best selling rheumatoid arthritis ra drug late stage study company say friday regeneron sanofi say monoclonal antibody sarilumab meet trial main goal improve symptom week biweekly dose regimen patient sarilumab achieve least improvement sign symptom base american college rheumatology criterium contrast patient humira group group experience same rate negative side effect sarilumab group show higher rate neutropenia lower white blood cell humira be currently top selling ra drug indeed top selling drug kind world today number competitor be rise last fall baricitinib drug eli lilly lly incyte incy co develop also beat humira head head trial injectable humira sarilumab be deliver orally roche rhhby intravenous medicine actemra have also best humira trial regeneron sanofi have already apply fda approval sarilumab base earlier datum decision due oct rbc capital market analyst adnan butt call news modest positive add investor be still concern nearer term issue regeneron stock be pilot program test change medicare part announce week affect great deal reimbursement regeneron flagship drug eylea patent lawsuit amgen amgn file monoclonal antibody regeneron sanofi partnership praluent else be equal beating humira be certainly better not beating least discuss overhang need clear pipeline receive more credit write butt research note late morning stock market today abbvie stock be almost sanofi be regeneron stock be fraction
290,REGN,stock have be move line price oil year wednesday be different major average end higher nasdaq rise dow jone industrial average edge volume stock market today fall nyse nasdaq compare tuesday accord preliminary datum investor have used oil price barometer global economy selling oil price fall then buy crude rise crude price jump more wednesday rise back barrel be expect oil stock lead gain chevron cvx pace dow industrial rise more outside dow tesoro tso refiner rise more be pocket success elsewhere lgi home lgih pop nearly huge volume homebuilder post gain profit cent share beating wall street forecast sale rise slightly view meanwhile biotech stock take hit government announce test program lower medicare drug cost regeneron pharmaceutical regn plunge amgen amgn drop nearly celgene celg lose more dollar general dg el pollo child place plce be due report quarterly result thursday economic datum schedule thursday include initial jobless claim week end march treasury budget february meanwhile european central bank hold policy meeting thursday image provide shutterstock
291,REGN,stock bounce back soft start tuesday be still slightly lower earning report mild rebound stir early trade dow jone industrial average lose give nasdaq fall intraday nasdaq lose stock market today fought bottle selling begin europe have carry monday be picked japan market tuesday tokyo nikkei dive loss worst day september europe market trade lower tuesday have backed early loss london ftse slip less frankfurt dax be cac paris trim loss afternoon trade employer report number available unfilled position increase december more accord labor department job opening labor turnover survey department revise number unfilled post november oil price backed early gain trade put west texas intermediate just barrel brent crude gold be effectively flat ounce walt disney pare early loss fraction ahead fiscal first quarter earning report due today close left wal mart wmt dow worst early performer loss home depot hd make best move dow stock more company announce report result feb canada base fortis dump announce buy novi michigan base itc holding itc deal value fortis be diversify utility base st johns itc own operate power transmission line reach midwestern state itc share fall cabinet paint maker masco mas top stride higher fourth quarter earning gain easily clear analyst estimate revenue slip line expectation stock remain converge week move average nov high viacom viab take low spot drop mixed fiscal report hospital management reit hcp hcp gas pipeline operator oneok oke slump regeneron pharmaceutical regn discovery communication disca fall apiece ibd stock universal display oled pop take back piece monday dive heavy volume ligand pharmaceutical lgnd step very strong trade share remain week move average mid december high aerospace component maker transdigm tdg pare loss less fall nearly start trade cleveland ohio manufacturer report fiscal first quarter earning revenue forecast
292,REGN,be helpful check ibd smart nyse nasdaq table regular basis watch industry sector change ranking time much have be say recently utility defensive stock friday smart table show utility sit top sector ranking next line be office sector include adhesive
293,REGN,market beat hasty retreat last week insider sale be notable executive health related company include gene sequence giant illumina ilmn ceo jazz pharmaceutical jazz chairman lead way be also couple big buy health related sector include major purchase walgreen boot alliance wba
294,REGN,drug stock fall wednesday wall street sort impact propose change medicare part reimbursement design drive price expensive hospital drug late tuesday center medicare medicaid service propose pilot program testing new reimbursement scheme medicare part cover drug administer hospital doctor office currently cms pay back price drug health care provider critic say encourage doctor prescribe more expensive drug propose rule doctor get just premium flat fee drug day somewhat reduce disparity different price drug cms also propose reduce eliminate portion patient have pay drug tie reimbursement level effectiveness drug give indication thus same drug work well condition only so so cms reimburse different level condition agency also want create online decision support tool help physician determine most effective drug use give situation test let cms enter voluntary risk sharing agreement drug maker link price adjustment patient outcome be comment period cms proposal point cms plan place provider different group used old reimbursement method new study difference group course year plan start testing other idea start january reimbursement proposal draw most attention wall street cover drug be mostly infuse inject treatment serious condition opposed pill patient take own so potentially affect drug industry biggest cash cow big biotechs most notable drug fall theoretical test be drug include amgen amgn neupogen neulasta also kyproli xgeva prolium vectibix total sale celgene celg abraxane be revenue other notable drug be oral write rbc capital market analyst michael yee research note credit suisse analyst vamil divan agree amgen add regeneron pharmaceutical regn biogen biib also depend drug medicare part umbrella new immunotherapy drug bristol myer squibb bmy merck mrk such opdivo keytruda yervoy also be cover part yee argue aren choose price reason consensus understand drug be choose high efficacy aren equivalent drug aren also infuse not reimbursement yee write amgen stock hit month low end day regeneron tumble celgene fall biogen be bristol myer stock fall merck slip fraction
295,REGN,stock step moderate gain wednesday open earning report oil price propel large share early action rise dow industrial add nasdaq re-cover early slip trade bit less loss biotech stock drag heavily index volume decrease sharply stock market today nasdaq lower nyse relative action same time tuesday weak volume suggest institutional investor be largely sideline oil price upshifted early gain rise more put west texas intermediate barrel nearly so far work possible fourth straight weekly gain price see reaction weekly inventory number due energy information administration et stock chevron cvx lead dow gain nike nke drop more darden restaurant dri jump more start trade owner olive garden restaurant chain report strong same store sale fiscal third quarter give strong preliminary guidance fourth quarter announce chief financial officer retire immediately light volume gain lift share back stock week move average further right side month consolidation blue buffalo buff be morning rockstar spiking better forecast report late tuesday big volume gain send share back july ipo price further right side month deep consolidation biotech stock be take broad loss early wednesday possibly owing propose change medicare drug reimbursement announce late tuesday regeneron pharmaceutical regn gap loss second straight slip brean murray initiate coverage company tuesday buy rating price target chipotle grill cmg gap more company say shut billerica mass location outbreak norovirus employee chipotle have be fight climb month consolidation ibd list wesson swhc tick higher weak trade move put share almost back buy point stock have clear strong volume friday big dip monday retest support just buy point bottom list ligand pharmaceutical lgnd drop carve back converge week move average heavy trade stock have be try climb right side month consolidation
296,REGN,valeant pharmaceutical vrx suffer cut price target tuesday coverage be start regeneron pharmaceutical regn panera bread pnra be upgrade urban outfitter urbn score several price target hike mizuho lower price target valeant maintain neutral rating stock monday valeant say report result march more week drug maker originally schedule date feb valeant delay report due return ceo michael pearson have be leave month be treat severe pneumonia company stock price tumble late last month withdraw guidance news surface be subject previously undisclosed sec investigation valeant share close stock market today meanwhile brean capital assume coverage regeneron pharmaceutical buy rating price target regeneron share lose panera be upgrade overweight price target morgan stanley share fast casual chain set new high monday continue grab market share chipotle grill cmg have be give share ever last fall news coli outbreak restaurant panera share fall chipotle stock lose urban outfitter receive series price target hike report mixed quarterly result stifel raise price target stock maintain buy rating hike price target telsey advisory group raise mizuho raise monday close apparel chain beat fourth quarter earning view meet revenue expectation also logged steeper expect dip comparable store sale urban outfitter share leap tuesday morning biomarin pharmaceutical bmrn be upgrade outperform neutral robert baird have price target stock last week rare disease specialist say drug batten disease be track approval successful trial biomarin say plan submit drug approval fda european medicine agency middle year still share retreat upgrade autonation be downgrade sell neutral goldman sachs have price target stock share sank shopify shop be upgrade overweight sector weight pacific crest share climb miller tabak initiate coverage trio department store chain start macy hold price target jwn sell price target penney jcp buy price target macy dip gain penney rally image provide shutterstock
297,REGN,stock end strong gain higher volume wednesday bullish reversal nasdaq kick gear rise lag portion session add help strength energy stock dow jone industrial average gain blue chip index lead exxon mobil xom chevron cvx preliminary datum show volume nyse nasdaq come slightly higher wednesday level stock market today advance stock top decliner major exchange slightly more year treasury yield be unchanged investor be better mood oil price firm day top perform industry group ibd database hailed oil gas sector crude oil future settle barrel cent earlier day st loui fed president james bullard say oil precipitous drop have implication fed monetary policy go forward also say inflation expectation be fall dow component intel intc rise nearly regular session fall more hour trading report better expect earning sale health care name particularly biotech stock lead nasdaq alexion alxn amgen amgn biogen biib celgene celg regeneron regn rise connect ken shreve twitter ibd_kshreve facebook
298,REGN,san francisco jpmorgan healthcare conference continue yield mixed result investor second day tuesday several company tweak guidance big pharmas offer incremental update specialty drugmaker horizon pharma hznp have best day share rise company update guidance ahead presentation wednesday horizon say
299,REGN,stock step modest early gain rise trade thursday pop oil price augment heavy slate big name earning report volume pulse higher stock market today rise nyse nasdaq compare action same time wednesday early economic news be mixed surprise fall
300,REGN,give thursday market sell not too surprising more sector leader fall list leave stock friday ibd linkedin lnkd arista network anet make exit regeneron pharmaceutical regn rejoin netease nte ulta beauty ulta latter have be hold much better other lead stock many
301,REGN,big cap biotech regeneron pharmaceutical regn hit month low tuesday earning disappoint investor last month regeneron reveal sale eye drug eylea account great majority revenue result announce early tuesday show recently launch cholesterol drug praluent sell well short expectation collaboration revenue partner sanofi sny be also lower expect overall revenue rise year earlier quarter analyst consensus accord thomson reuter earning share also miss wall street average estimate ep rise just year earlier quarter breaking quarter streak double digit growth regeneron last month also guide expense tuesday add eylea sale grow year be slightly analyst consensus growth company do not provide overall revenue earning guidance evercore isi analyst mark schoenebaum calculate imply earning guide expense forecast be be low side consensus projection weak praluent number be less half consensus estimate follow likewise underwhelm report amgen amgn similar drug repatha result last month slow start be consistent current market feedback praluent initial launch be certainly go put pressure long term revenue expectation product class write leerink analyst geoffrey porge research note regeneron stock drop much early trading stock market today lowest point october share close day also be stock lowest close price october sanofi stock fall fraction tuesday
302,REGN,major stock etfs pull modest gain close tuesday choppy trading session volume run low major exchange volatile oil price uncertain fed rate hike outlook keep most investor sideline wti crude future dive barrel international energy agency warn demand oil ease considerably
303,REGN,stock future trade lower head tuesday open bell show resistance banking sector sell europe japan dow future hung fair market value nasdaq future trade small cap be weak spot russell future show loss look stock
304,REGN,happened stock market leadership already know answer sense leadership pretty much vanished few day be stock make sector leader screen ibd most stringent monday ibd just stock be left so happened other let look arista network anet drop jan
305,REGN,facebook fb netease nte regeneron pharmaceutical regn fall sharply monday linkedin lnkd show relative strength sector leader emerge market sell decent shape linkedin pare loss find support just day move average decline monday do chart stock have drop much nov
306,REGN,gilead science gild regeneron pharmaceutical regn alexion pharmaceutical alxn be focus screen day top fundamental company top fundamental be highly rate ibd have year sale earning growth rate least gilead broaden fight hcv not bring huge drug launch see previous year gilead science know highly effective highly price hepatitis drug sovaldi harvoni have seek approval combination pill use hcv genotype ibd report fda be set rule drug june company have ibd composite rating best possible also have year ep growth rate year sale growth rate stock take wild ride weave day move average share close stock market today make way consolidation begin june praluent lift pharmaceutical develop cholesterol drug praluent sanofi sny have year ep growth rate year sale growth rate composite rating be stock rise share sank earlier week fda datum erroneously indicated praluent patient be prone suicide forbe report share fall thursday rebound wednesday last month unitedhealth unh nation largest health insurer choose give praluent prefer access regeneron drug eye drug eyelea have also perform strongly alexion score approvalrare disease biotech alexion last month get fda approval kanuma rare disease drug use genetic organ disease lysosomal acid lipase deficiency kanuma be first drug get fda disease alexion have year ep growth rate year sale growth rate company composite rating be stock drop thursday stock clear month long cup handle base dec share have slip follow bill peter twitter ibd_bpeter
307,REGN,gilead science gild regeneron pharmaceutical regn alexion pharmaceutical alxn be focus screen day top fundamental company top fundamental be highly rate ibd have year sale earning growth rate least gilead broaden fight hcv not bring huge drug launch see previous year gilead science know highly effective highly price hepatitis drug sovaldi harvoni have seek approval combination pill use hcv genotype ibd report fda be set rule drug june company have ibd composite rating best possible also have year ep growth rate year sale growth rate stock take wild ride weave day move average share close stock market today make way consolidation begin june praluent lift pharmaceutical develop cholesterol drug praluent sanofi sny have year ep growth rate year sale growth rate composite rating be stock rise share sank earlier week fda datum erroneously indicated praluent patientswere prone suicide forbe report share rebound wednesday last month unitedhealth unh nation largest health insurer choose give praluent prefer access regeneron drug eye drug eyelea have also perform strongly alexion score approvalrare disease biotech alexion last month get fda approval kanuma rare disease drug use genetic organ disease lysosomal acid lipase deficiency kanuma be first drug get fda disease alexion have year ep growth rate year sale growth rate company composite rating be stock slip wednesday stock clear month long cup handle base dec share have slip follow bill peter twitter ibd_bpeter
308,REGN,etf investor get taste snap back market action be hope tuesday choppy trading session major index steady modestly sharp drop kick stock reversed lower intraday oil briefly dip barrel first time december however etfs tracking dow finished higher well session lows health care help lead advance sector utility real estate post loss powershare qqq qqq tech biotech heavy exchange trade fund pop stock market today etf be dec high stock holding celgene celg jump illumina ilmn vertex pharmaceutical vrtx give regeneron regn investor seem have digest monday biotech related news big biotechs celgene vertex have offer mixed outlook major investor conference cause disappointment illumina meanwhile announce new unit call grail focuse detect cancer early simple blood sample apple aapl hold qqq portfolio weighting gain tuesday iphone maker stock briefly re-cover level first time day buoy analyst upgrade well rumor cheaper base model iphone apple electric car stock be week high diving deeply day move average december spdr biotech xbi surge massive volume however equal weight etf hold stock be july high xbi monday undercut late september lows be spur presidential candidate hillary clinton comment price gouge drug industry recent slump analyst rbc capital market be report reaffirm confidence growth prospect biotech sector tuesday note ishare nasdaq biotechnology ibb advanced cap weight etf also breach late september low monday be week high hold stock biggest stake celgene biogen biib amgen amgn gilead gild regeneron regn xbi smaller cap skew help give performance boost rise vs gain ibb gold dollargold price fall third straight session tuesday gold price be moderately lower tuesday more profit take chart consolidation follow recent gain see price hit month high late last week jim senior technical analyst write commodity monitor kitco news less anxious world market scene day firmer dollar index be also help pressure safe haven gold market etf bullish dollar extend gain retake day line monday greenback rise vs other major world currency bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
309,REGN,lot change wall street just few day so far week market have fall correction number sector leader have be nearly halved lead stock remain facebook fb paycom software payc regeneron pharmaceutical regn fall earlier week let take look
310,REGN,be year distinct part drug stock first month continue bull run last year sudden resurface drug pricing debate lead rocky month overall group come ahead top perform big cap show solid story make political worry eye investor incyte incy be wednesday close year steady gain lone market product jakafi well pipeline potential blockbuster march jakafi win eu approval blood cancer polycythemia vera be already approve blood cancer myelofibrosis disease be rare incyte be shooting much bigger market late stage candidate baricitinib epacadostat baricitinib incyte be develop partnership eli lilly lly test successfully phase trial rheumatoid arthritis placebo methotrexate current market leader abbvie abbv humira nov initiation report incyte goldman sachs analyst richter estimate peak annual sale more expect launch richter add more important future driver share likely be incyte entry bud field immuno oncology incyte have be testing lead candidate field epacadostat combination merck mrk keytruda variety cancer early november incyte stock fall small study combo patient advanced cancer disappoint wall street richter write likely bring more clarity more result come incyte have be operate loss due research spending analyst expect turn first annual profit next year stock current ibd composite rating be danish diabetes giant nordisk nvo be end year flat base follow early gain march stock rise sharply say refile approval long act insulin analogue tresiba shorter act sister drug ryzodeg drug suffer surprise rejection fda seek more datum possible risk heart time agency be convince approve also boost stock early year be february release positive clinical trial datum latest glucagon peptide glp receptor agonist og have be selling earlier glp agonist victoza market have get more competitive last couple year new glp launch sanofi sny glaxosmithkline gsk eli lilly drug be injectable however new candidate be oral announce further positive result drug july september financial result currency suffer foreign exchange headwind hit global drugmaker year still manage solid ibd ep rank relative strength rating regeneron pharmaceutical regn continue multiyear run stock market hit lifetime high aug get catch larger biotech sell still year regeneron flagship eye drug eylea continue perform well aid new approval diabetic retinopathy march draw more attention be launch cholesterol drug praluent july praluent be not only first new class cholesterol drug be follow shortly market amgen amgn repatha also first number novel monoclonal antibody regeneron have be develop partnership sanofi next entry dupilumab be late stage testing asthma eczema be also expect attain multibillion dollar annual sale regeneron be also highest rate stock list highest possible composite rating eli lilly be top perform traditional big pharma year gain sale growth have be flat due age drug well currency headwind company have improve profit margin cost control get lot investor excited pipeline note partnership incyte have bear fruit baricitinib trial lilly doesn have much presence rheumatoid arthritis other immunology disease lilly be plan change not only baricitinib ixekizumab psoriasis treatment plan launch next year be expect sell billion eventually lilly already launch diabetes drug jardiance yielded pharma biggest upside surprise year giant study effect cardiovascular health show reduce death heart failure drive stock year high september turn cup handle base stock hold cr baxalta bxlt be start trading july spin baxter international bax seek unlock shareholder value biopharma arm just day later company receive unsolicited buyout offer british drugmaker shire shpg see baxalta hemophilia franchise ideal addition rare disease portfolio baxalta reject offer situation remain unresolved last week rumor be buzz shire bid hasn yet baxalta financial have be slow steady lead ep rank acquisition hope have lift stock rs rating
311,REGN,shopping stock investor have look well hood fundamental datum show company be grow fast be likely keep grow fast earning sale growth number investor check be pretax margin return equity sector leader make ibd most stringent screen show strength
312,REGN,sector leader list be deplete tired month slop chop stock market action don believe look ibd accumulation distribution rating remain issue proprietary measure analyze price volume action gauge stock be be buy sell net basis big institution rating
313,REGN,first stage base late stage base difference slim investing stock stage initial then climb least base buy point begin next base have moved first second stage base rise less mean next base be still first stage
314,REGN,sector leader be ibd toughest proprietary stock screen so tough rocky market few stock meet stringent criterium spot stock list today ibd almost surely go have ep relative strength rating high other smartselect rating be sure be high ibd run weekly minichart sector leader stock day paper chart time leader meet criterium be find stock table head sector listing many sector win have leader recent day sag market briefly reduce sector leader list savvy investor have powder dry bear market once market turn stock begin appear feature be sure highly rate stock be worth further study many make superior buy candidate always consult chart find proper buy point buy stock have form proper base break buy extend stock be invite disaster even stock be highly rate sector leader screen have superior long term track record original follow day march list have gain vs gain ibd feb edition gauge strength market investor not only study price volume action major index also watch action lead stock sector leader be good place do be diminish number sector leader appear ibd day be stock show poor action weak accumulation distribution rating mean market be hard time be often case late dec article accompany sector leader chart note weak accumulation distribution rating remain stock list only netease nte have strong rating linkedin lnkd have arista network anet facebook fb regeneron regn paycom payc have indicate intense institutional selling be wake call new year start sharp sell have persist february priceline group pcln be undisputed winner bull market begin be scanning ibd stock table feb have noticed priceline be sector leader member leisure sector rank sector sector be already year average ep increase prior quarters be last quarterly report show increase roe be composite rating be ep rs strong overall have noticed earning be due couple week add risk solid run first month priceline cool form new long base finally break past handle buy point make gain top march
315,REGN,biotech giant amgen beat analyst estimate late thursday send share fraction hour trading rough day drug stock amgen amgn earning totale year earlier quarter soundly beating analyst consensus estimate accord thomson reuter revenue rise vs analyst full year
316,REGN,biotech pioneer amgen have long depend flagship drug revenue stream next few year see change guard new medication overshadow old
317,REGN,currently more half amgen amgn sale come drug debut sister drug neulasta neupogen stimulate production white blood cell enbrel treat immunology condition such rheumatoid arthritis psoriasis amgen legacy anemia treatment epogen still provide sale be approve way back
318,REGN,however earliest therefore simplest biologic drug ve also be first target rival wait sell be know biosimilar once patent lapse amgen product biosimilar aren quite generic drug be identical copy original be similar enough be used interchangeably least physician
319,REGN,biosimilar neupogen have be sell few year europe year novartis nvs version zarxio enter american market have put more weight growth amgen launch
320,REGN,repatha launch
321,REGN,probably most anticipate amgen launch year be repatha treatment high cholesterol approve europe july august
322,REGN,repatha be new class cholesterol medication call pcsk inhibitor also be develop several other drugmaker fact regeneron pharmaceutical regn partner sanofi sny launch own pcsk inhibitor praluent just month earlier repatha
323,REGN,clinical trial indicate similar effectiveness drug have be duke payer deal last month amgen be put prefer formulary cvs health cvs regeneron sanofi do same unitedhealth unh
324,REGN,analyst agree however crucial test repatha come next year amgen report first result trial measure repatha effect cardiovascular outcome be actually reduce cardiovascular event heart attack stroke praluent corresponding test come shortly
325,REGN,fda approve repatha praluent base ability lower ldl bad cholesterol ability doesn mean automatically improve heart health
326,REGN,better expect
327,REGN,dec note upgrading amgen overweight morgan stanley analyst matthew harrison estimate outcome datum add annual sale repatha even praluent be likely get same result upgrade be drive survey cardiologist find do better expect even
328,REGN,be first acknowledge survey datum tend skew high uptake cardiologist pcps primary care physician survey believe pcsk inhibitor obtain share patient prior outcome datum harrison write be well consensus model see even penetration be cut half still be consensus
329,REGN,see upside
330,REGN,analyst call peak annual repatha sale harrison isn only analyst see upside number rbc capital market analyst michael yee recently write think sale be twice
331,REGN,however peak isn expect need negotiate payer be keep launch fairly slow term
332,REGN,amgen have few other card play start blood cancer drug kyproli
333,REGN,amgen come kyproli acquire onyx pharmaceutical many investor time balk price tag amgen have be work justify do more research expand drug label
334,REGN,fda first approve kyproli multiple myeloma clear drug only advanced case have least prior treatment only combination drug call velcade also amgen couldn put survival benefit kyproli label clinical trial hadn proven benefit
335,REGN,amgen win approval somewhat less advanced multiple myeloma summer produce study demonstrate survival benefit well kyproli effectiveness velcade most recently report third quarter kyproli sale jump year
336,REGN,overall amgen earning rise share quarter beating analyst estimate cent sale increase also ahead street view
337,REGN,unusual event
338,REGN,be best sale growth year amgen acknowledge be due time event such customer abnormally large purchase enbrel amgen guidance be more modest analyst overall be expect slowdown earning current quarter next year
339,REGN,street expect earning growth jump year longer term outlook depend success drug currently pipeline
340,REGN,analyst harrison peg june likely report date result late stage study romosozumab medicine amgen be develop osteoporosis succeed drug eventually reach blockbuster status more year sale
341,REGN,nearer term amgen doesn have many lever left keep growth pump say well fargo analyst jim birchenough
342,REGN,highly leverage balance sheet commitment dividend policy view amgen business development opportunity much more limit peer birchenough write dec report initiate coverage neutral
343,REGN,amgen have be able beat consensus estimate past year share repurchase aggressive cost cut believe further cost cut be difficult achieve focus increasingly be top line performance birchenough say biotech pioneer amgen have long depend flagship drug revenue stream next few year see change guard new medication overshadow old currently more half amgen amgn sale come drug debut sister drug neulasta neupogen stimulate production white blood cell enbrel treat immunology condition such rheumatoid arthritis psoriasis amgen legacy anemia treatment epogen still provide sale be approve way back however earliest therefore simplest biologic drug ve also be first target rival wait sell be know biosimilar once patent lapse amgen product biosimilar aren quite generic drug be identical copy original be similar enough be used interchangeably least physician biosimilar neupogen have be sell few year europe year novartis nvs version zarxio enter american market have put more weight growth amgen launch repatha launchprobably most anticipate amgen launch year be repatha treatment high cholesterol approve europe july august repatha be new class cholesterol medication call pcsk inhibitor also be develop several other drugmaker fact regeneron pharmaceutical regn partner sanofi sny launch own pcsk inhibitor praluent just month earlier repatha clinical trial indicate similar effectiveness drug have be duke payer deal last month amgen be put prefer formulary cvs health cvs regeneron sanofi do same unitedhealth unh analyst agree however crucial test repatha come next year amgen report first result trial measure repatha effect cardiovascular outcome be actually reduce cardiovascular event heart attack stroke praluent corresponding test come shortly fda approve repatha praluent base ability lower ldl bad cholesterol ability doesn mean automatically improve heart health better expect dec note upgrading amgen overweight morgan stanley analyst matthew harrison estimate outcome datum add annual sale repatha even praluent be likely get same result upgrade be drive survey cardiologist find do better expect even be first acknowledge survey datum tend skew high uptake cardiologist pcps primary care physician survey believe pcsk inhibitor obtain share patient prior outcome datum harrison write be well consensus model see even penetration be cut half still be consensus see upsideanalyst call peak annual repatha sale harrison isn only analyst see upside number rbc capital market analyst michael yee recently write think sale be twice however peak isn expect need negotiate payer be keep launch fairly slow term amgen have few other card play start blood cancer drug kyproli amgen come kyproli acquire onyx pharmaceutical many investor time balk price tag amgen have be work justify do more research expand drug label fda first approve kyproli multiple myeloma clear drug only advanced case have least prior treatment only combination drug call velcade also amgen couldn put survival benefit kyproli label clinical trial hadn proven benefit amgen win approval somewhat less advanced multiple myeloma summer produce study demonstrate survival benefit well kyproli effectiveness velcade most recently report third quarter kyproli sale jump year overall amgen earning rise share quarter beating analyst estimate cent sale increase also ahead street view unusual eventsit be best sale growth year amgen acknowledge be due time event such customer abnormally large purchase enbrel amgen guidance be more modest analyst overall be expect slowdown earning current quarter next year street expect earning growth jump year longer term outlook depend success drug currently pipeline analyst harrison peg june likely report date result late stage study romosozumab medicine amgen be develop osteoporosis succeed drug eventually reach blockbuster status more year sale nearer term amgen doesn have many lever left keep growth pump say well fargo analyst jim birchenough highly leverage balance sheet commitment dividend policy view amgen business development opportunity much more limit peer birchenough write dec report initiate coverage neutral amgen have be able beat consensus estimate past year share repurchase aggressive cost cut believe further cost cut be difficult achieve focus increasingly be top line performance birchenough say
344,REGN,federal reserve be get ready announce big news wednesday afternoon decision market be likely react stock market go ibd current sector leader be buy point position bounce week move average chart status bank ozark ozrk be mixed
345,REGN,wednesday sector leader screen offer stock week move average be week line significant key support level institutional investor often step add share current position even buy first time model book past market winner show many ride week line higher
346,REGN,father time be hand rein baby new year top executive google parent alphabet googl dish network dish palo alto network panw salesforce com crm sell surrender company share final hour tick alphabet chief executive officer larry page monday inform security exchange commission sale share other alphabet executive have similar notion week tuesday chief financial officer ruth porat disclose surrender share worth sundar pichai ceo alphabet subsidiary google wednesday disclose surrender share worth mountain view calif base search engine giant be finishing year positive note share climb close week alphabet have be trading time high steadily day average google subsidiary reportedly be talk ford motor develop self drive car autonomous drive be likely be big topic upcoming consumer electronic show salesforce com founder chairman ceo marc benioff wednesday inform sec plan sale share nearly block company vice chairman president monday announce sale share worth san francisco base cloud compute company have be trading slightly record high steadily day line stock rise week finish week salesforce com announce purchase steelbrick palo alto calif base quote cash software company steelbrick software be primarily aim small midsize business palo alto network director jim goetz wednesday announce sale share worth cybersecurity software company be set finish note stock fall week close dish network director david moskowitz wednesday announce plan sale share worth dish time warner cable twc subsidiary directv reportedly be increase rate new year dish network share fall week close regeneron pharmaceutical regn vice president dougla mccorkle tuesday disclose plan sale share worth tarrytown base regeneron stock rise week finishing celgene celg director ernest mario wednesday inform sec sale share worth monday michael casey celgene director disclose have sell share worth company stock be week last week christmas gift settlement lengthy patent dispute blockbuster blood cancer drug revlimid natco indian company want market generic version drug nike nke president product merchandising jeanne jackson wednesday disclose have sell nike share worth beaverton ore base athletic apparel giant share slip week close boston beer sam co founder chairman jim koch tuesday disclose plan sale share worth brewer sam adam lager have have not so sudsy week share fall close company have have bit hangover late stock steadily trading day move average fall day line june insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
347,REGN,tuesday etf investor cheer upbeat datum consumer confidence housing well sign steadying oil gas price upbeat mood spdr spy rise conviction day line first time more week etfs tracking dow nasdaq also retook key move average average
348,REGN,sector leader screen be home plenty strong performer recent breakout few name underscore importance demand heavy volume stock break volume breakout be sluggish take regeneron pharmaceutical regn clear double bottom entry oct light volume didn make much headway
349,REGN,share regeneron pharmaceutical regn be volatile company report mixed third quarter result week stock fall much wednesday follow earning release close loss more heavy trading share week remain buy point oct mark distinction
350,REGN,good company have high earning estimate better continue rise rise estimate screen day highlight here be top rate tech company linkedin lnkd palo alto network panw regeneron pharmaceutical regn have see sizable increase earning estimate revision week investor connect linkedin professional
351,REGN,stock stage be still modestly lower cut loss late monday be pace end month november gain nasdaq pare deficit less
352,REGN,month nasdaq appear be head gain meanwhile dow jone industrial average be just benchmark index appear be poise modest gain
353,REGN,improvement market lululemon athletica lulu drop fresh session low heavy trading stock gap day line morning fbr co downgrade share underperform market perform cut price target
354,REGN,lululemon be recently add ibd leaderboard cut list provide short selling stock idea
355,REGN,regeneron pharmaceutical regn be session low still nearly fast trade intraday stock slump double bottom handle buy point mark sell signal
356,REGN,universal display oled reversed lose fractional ground rally nearly morning stock have be recent session speculation product be used future generation apple aapl iphone reversal universal be cup base buy point
357,REGN,upside tal education group xrs climb dip negative territory earlier stock market today have perform well first clear buy point handle nov chinese profit school operator be featured stock spotlight week
358,REGN,follow vincent mao twitter ibd_vmao stock stage be still modestly lower cut loss late monday be pace end month november gain nasdaq pare deficit less month nasdaq appear be head gain meanwhile dow jone industrial average be just benchmark index appear be poise modest gain improvement market lululemon athletica lulu drop fresh session low heavy trading stock gap day line morning fbr co downgrade share underperform market perform cut price target lululemon be recently add ibd leaderboard cut list provide short selling stock idea regeneron pharmaceutical regn be session low still nearly fast trade intraday stock slump double bottom handle buy point mark sell signal universal display oled reversed lose fractional ground rally nearly morning stock have be recent session speculation product be used future generation apple aapl iphone reversal universal be cup base buy point upside tal education group xrs climb dip negative territory earlier stock market today have perform well first clear buy point handle nov chinese profit school operator be featured stock spotlight week follow vincent mao twitter ibd_vmao
359,REGN,stock market close lower monday retailer have bumpy session nasdaq dow jone industrial average fall slip volume rise be surprise friday half session decline stock lead advancer nyse nasdaq stock market today transportation medical retail industry group be weakest monday energy mining stock be strongest lululemon athletica lulu gap loss sink right back day move average analyst fbr capital market downgrade lululemon underperform market perform cut price target investor grow pessimistic early holiday shopping indication other retailer sell heavy trading include ulta beauty ulta urban outfitter urbn regeneron pharmaceutical regn have worst loss ibd bid past buy point have unraveled close unitedhealth group unh say be back forecast earning share revenue be project be health insurer warn nov earning hit obamacare exchange related business cite higher medical cost individual market customer soft enrollment outlook unitedhealth share rise slightly extend trading several economic report be due tuesday manufacturing report purchasing manager institute supply management be due morning automaker report november sale earning report tuesday include fifth street finance fsc guidewire software gwre follow juan carlos arancibia twitter ibd_jarancibia
360,REGN,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
361,REGN,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
362,REGN,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
363,REGN,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
364,REGN,worst performer ibd be regeneron pharmaceutical regn more
365,REGN,energy name be day best perform industry group push oil price be higher
366,REGN,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
367,REGN,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
368,REGN,half sector leader stock break past few week result normally bullish move have be mixed leader be do extraordinarily well netease nte have become most successful breakout sell signal share china base operator online game break past buy point nov
369,REGN,biotech etfs charge ahead wednesday broad stock market struggle gain holiday shorten week investor digest mixed economic datum oil report show stockpile rise less expect best perform sector equity etf so far give etf investor more be thankful alp medical breakthrough sbio rise stock market today
370,REGN,biggest company ibd biotech industry group regeneron pharmaceutical regn stand alone term current relative price strength good bad good stock be demonstrate demand institutional level investor have not wane accord analysis william neil co mutual fund hedge fund build new position
371,REGN,cvs health cvs announcement monday cover amgen amgn cholesterol drug repatha exclusively regeneron regn sanofi sny rival version praluent put pressure praluent maker deliver same say analyst repatha be only pcsk inhibitor cvs caremark commercial formulary say nation drugstore chain
372,REGN,seller be back market tuesday nasdaq close high session erase good portion early loss nasdaq give fall much lose close top half intraday range add distribution day count bring
373,REGN,bounce back biotech sell follow hillary clinton accusation big pharma price gouge regeneron pharmaceutical regn now face new test resistance latest buy point maker eylea eye injection have be float buy range oct catalyst push stock
374,REGN,championship boxer mutual fund manager outperform extend period know roll market punch attack open portfolio manager mainstay large cap growth fund have demonstrated skill recently cope market summer volatility add portfolio strategically upgrade portfolio great growth company price correct say co manager justin kelly subadvisor capital management fund have generate average annual return past year vs large cap growth peer track morningstar year go tuesday fund gain vs peer fund carry ibd month performance rating third quarter stock market nose dive pull regeneron regn mainstay manager see attractive entry point fund invest type growth stock long term sustainable earning growth quality cyclical earning growth industry rapid growth fund buy share regeneron have lead treatment retinal eye disease compelling pipeline include new cholesterol drug kelly say investor follow ibd slim method stock show entry point regeneron have ibd composite rating powerful scale more health stocksin fund start stake edward lifescience ew product treat advanced cardiovascular disorder kelly cite edward leadership transcatheter heart valf end market be bigger most investor believe propel earning growth street expect say stock have composite rating be trading little cup handle entry bristol myer squibb bmy be health care name fund begin position kelly like company new lung cancer drug opdivo company blood thinner plavix be world second best selling drug also active other sector mainstay fund boost overweight consumer discretionary sector fund start position armour ua kelly say company continue take market share grow athletic leisurewear market stock advanced have trend lower then slip week move average dick sporting good dks weak hurt armour accord piper jaffray dick also issue weak outlook tuesday stock market news help send armour day mainstay manager kelly clark patrick burton add stake amazon amzn home depot hd kelly like amazon web service business be mushrooming say amazon have comp rating be extend past buy point quarters earning share decline amazon ep rise past stanzas home depot comp rating be entry point benefit demand home improvement company report jump ep tuesday
375,REGN,gopro gpro be downgrade friday chip supplier ambarella amba have price target cut action camera maker face headwind robert baird downgrade gopro neutral outperform slash price target thursday cleveland research analyst say gopro face order cut busy holiday shopping season
376,REGN,heel terrorist attack paris general think be monday be rough day stock market wasn case stock strengthen early afternoon trading
377,REGN,dow jone industrial average add nasdaq rise volume exchange be tracking well friday level stock market today
378,REGN,economic news new york fed empire state manufacturing index register read november consensus estimate new order fall sixth straight month
379,REGN,yield year treasury note be basis point
380,REGN,online travel firm department store biotechs airline stock lag badly
381,REGN,priceline pcln slump nearly bring day decline share fall hard nov company earning report include disappointing guidance
382,REGN,urban outfitter urbn crater company announce plan acquire vetri family restaurant group deal isn huge surprise urban have be make big push recent year integrate food dine store
383,REGN,day gainer ulta beauty ulta bounce back friday retail sell share rise strong volume last week decline higher volume cause technical damage most likely take time repair
384,REGN,ibd china base noah holding noah look poise halt session slide ahead earning report close share rise fellow china name tal education xrs also gain ground ibd share rise clear cup handle buy point last week
385,REGN,sector leader regeneron regn hold well softness biotech group monday share rise low volume add handle area double bottom base give new entry
386,REGN,news marriott mar agree buy starwood hotel hot share starwood shed more marriott ease
387,REGN,follow ken shreve twitter ibd_kshreve facebookon heel terrorist attack paris general think be monday be rough day stock market wasn case stock strengthen early afternoon trading dow jone industrial average add nasdaq rise volume exchange be tracking well friday level stock market today economic news new york fed empire state manufacturing index register read november consensus estimate new order fall sixth straight month yield year treasury note be basis point online travel firm department store biotechs airline stock lag badly priceline pcln slump nearly bring day decline share fall hard nov company earning report include disappointing guidanceurban outfitter urbn crater company announce plan acquire vetri family restaurant group deal isn huge surprise urban have be make big push recent year integrate food dine store day gainer ulta beauty ulta bounce back friday retail sell share rise strong volume last week decline higher volume cause technical damage most likely take time repair ibd china base noah holding noah look poise halt session slide ahead earning report close share rise fellow china name tal education xrs also gain ground ibd share rise clear cup handle buy point last week sector leader regeneron regn hold well softness biotech group monday share rise low volume add handle area double bottom base give new entry news marriott mar agree buy starwood hotel hot share starwood shed more marriott ease follow ken shreve twitter ibd_kshreve facebook
388,REGN,biotech stock drugmaker valeant pharmaceutical vrx take beating september hillary clinton accuse big pharma price gouge regeneron pharmaceutical regn have now bounce back buy zone new york base drugmaker develop treatment eye ailment inflammatory disease cancer earlier week regeneron partner sanofi sny present positive result
389,REGN,medical sector have be ailing lately be ibd sector monday issue sector leader hail health care regeneron pharmaceutical regn be featured friday column have pull back buy zone briefly climb range last week stock fall sharply wednesday
390,REGN,recent week have not be friendly pharmaceutical industry stock sector such valeant pharmaceutical vrx horizon pharma hznp wither criticism industry drug pricing practice fear greater regulation biotechs top fundamental gilead science gild regeneron pharmaceutical regn focus screen day have maintain strong rating hold stock market furor company top fundamental ibd definition have year ep sale growth rate least gilead science have face raft criticism price hepatitis wonder drug sovaldi have year ep growth rate year sale growth rate company handily beat estimate last month raise full year sale guidance be just shy expectation gilead other pharma stock fall democratic presidential hopeful hillary clinton say introduce plan crack call price gouge industry clinton announcement come turing pharmaceutical be harshly criticize decision buy decade old drug quickly raise price more gilead breach day line day sank further month clear day day line stock have find support day move average share close stock market today regeneron pharmaceutical regn make cholesterol fighter praluent sanofi sny have year ep growth rate year sale growth rate sale praluent see possible blockbuster be less half analyst expect ep overall sale beat forecast regeneron fall day clinton announcement finished higher next day then descend day line stock have climb day line regeneron stock dip thursday stock form handle month consolidation regeneron gilead have turn stronger showing recently stock such valeant pharmaceutical mallinckrodt mnk horizon pharma have be hit hard short seller citron research last month accuse valeant shady sale practice criticize drugmaker price hike acquire drug citron month attack mallinckrodt say sale drug acthar have lag question gel effectiveness express script esrx wednesday sue horizon pharma say owe million unpaid drug rebate cut network specialty pharmacy horizon be used valeant also have be hammer specialty pharmacy ty mallinckrodt valeant horizon be trading day day line valeant share end thursday horizon lose mallinckrodt fall express script slide follow bill peter twitter ibd_bpeter
391,REGN,big biotech regeneron pharmaceutical regn beat analyst estimate raise guidance wednesday stock slide expense guidance go newly launch cholesterol drug praluent miss expectation regeneron earning rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb consensus regeneron raise full year guidance sale lead drug eylea be traditionally only revenue guide foreign sale be handled partner bayer bayry yet other drug contribute significant income company now expect sale grow earlier guidance do not offer ep guidance do raise expense outlook spending be now forecast higher previously guide guidance range sale general administrative expense be raise low end now praluent potential blockbuster cholesterol drug launch late july take vs consensus company conference call discuss result robert terifay senior vice president say launch be slow payer be take time assess reimbursement policy prefer formulary so regeneron be provide free prescription many patient immediate need terifay say regeneron be gauge demand number doctor prescription submit mypraluent program say be consistent expectation chief scientific officer george yancopoulos say crucial trial effect praluent cardiovascular outcome prevent heart attack stroke produce final result be interim analysis next year respect regeneron be somewhat rival amgen amgn be expect produce result outcome trial similar drug repatha late next year none be entirely new marketing partner sanofi sny have report praluent number own report last week commentary launch expectation timeline be consistent regeneron have previously say however regeneron stock be nearly afternoon trading stock market today lead morningstar analyst stefan quenneville suspect investor be hope more upside think person realize amgen guidance outcome trial be bit earlier quenneville tell ibd maybe just put together follow amy reeve twitter ibd_areeve facebook
392,REGN,stock extend gain boost major index session high head last hour regular trading session nasdaq rally rise dow jone industrial average be volume be tracking slightly lower board vs same time friday
393,REGN,computer hardware biotechs automaker be top gainer stock market today retail apparel maker stock lag
394,REGN,ibd stock celgene celg regeneron pharmaceutical regn gain respectively celgene be shape right side consolidation buy point biotech report thursday open say friday european official approve vidaza treatment patient age acute myeloid leukemia
395,REGN,regeneron be buy zone double bottom entry clear oct also friday biotech say bayer healthcare unit win european approval eylea treat visual impairment due myopic choroidal regeneron report wednesday open
396,REGN,tesla motor tsla cruised higher average volume ahead earning due tuesday close analyst expect electric car maker post cent loss sale jump share be still well day day line
397,REGN,fitbit fit jump fast pace turnover ahead quarterly report close soar friday bullish analyst report fitness tracking device maker be expect earn cent share sale expect revenue gain be
398,REGN,ryanair holding ryaay gap rise fast trade shape flat base buy point irish discount airline report fiscal profit sale top view say expect full year earning upper end forecast
399,REGN,other carrier volume jetblue airway jblu lift virgin america va
400,REGN,follow nancy gondo twitter ibd_ngondo stock extend gain boost major index session high head last hour regular trading session nasdaq rally rise dow jone industrial average be volume be tracking slightly lower board vs same time friday computer hardware biotechs automaker be top gainer stock market today retail apparel maker stock lag ibd stock celgene celg regeneron pharmaceutical regn gain respectively celgene be shape right side consolidation buy point biotech report thursday open say friday european official approve vidaza treatment patient age acute myeloid leukemia regeneron be buy zone double bottom entry clear oct also friday biotech say bayer healthcare unit win european approval eylea treat visual impairment due myopic choroidal regeneron report wednesday open tesla motor tsla cruised higher average volume ahead earning due tuesday close analyst expect electric car maker post cent loss sale jump share be still well day day line fitbit fit jump fast pace turnover ahead quarterly report close soar friday bullish analyst report fitness tracking device maker be expect earn cent share sale expect revenue gain be ryanair holding ryaay gap rise fast trade shape flat base buy point irish discount airline report fiscal profit sale top view say expect full year earning upper end forecast other carrier volume jetblue airway jblu lift virgin america va follow nancy gondo twitter ibd_ngondo
401,REGN,biotechs still be generally favor group have be firm recent week hold own ibd industry group ranking even large cap name biogen biib celgene celg unite therapeutic uthr have come selling pressure be still plenty top rate name group show relative strength amgen amgn
402,REGN,stock future point sharply higher be early high ahead wednesday start trade follow mixed early economic news market rally europe
403,REGN,dow future steer point nasdaq future trade point fair market value future show point gain small cap be positive steady russell future hold point gain
404,REGN,stock market today open day rally belt nasdaq end higher trading range tuesday index remain day move average nasdaq be position possible test line week
405,REGN,personal spending rise november commerce department say welcome improvement october gain show line economist expectation personal income rise tad october gain better view advance
406,REGN,durable good order be flat month sharply october downwardly revise gain better contraction project economist consensus transportation order dip vs estimate change
407,REGN,et university michigan be schedule report final consumer sentiment estimate december commerce department give new home sale number november
408,REGN,dollar be mixed early wednesday vs euro yen bond slip send year yield basis point
409,REGN,crude price moved higher brent crude west texas intermediate benchmark trading tandem just barrel crude price see effect weekly inventory datum energy information administration due et metal agricultural commodity be mixed
410,REGN,mining company appear poise rally day bhp billiton bbl rio rio freeport mcmoran fcx vale vale jump bounce oil mining issue trip rally european market send london ftse more cac paris frankfurt dax nearly much midday trade
411,REGN,stock nike nke vault nearly lead dow well ibd list premarket action athletic wear maker report late tuesday fiscal second quarter earning top consensus forecast revenue rise just shy expectation gross margin increase more forecast primarily due higher selling price stock have be testing support week move average just flat base buy point
412,REGN,devon energy dvn spiked devon have be highly active acquisition front month pay asset anadarko powder river basin sell san juan river holding new mexico bp bp
413,REGN,celgene celg muster gain open drug maker announce settlement litigation vs india natco pharma partner arrow international subsidiary allergan agn pertain patent oral cancer drug revlimid celgene share have be consolidate july
414,REGN,micron technology mu tank hurt fiscal earning result deliver late tuesday idaho base chip maker score narrow earning beat revenue miss analyst target management guide revenue earning consensus forecast stock future point sharply higher be early high ahead wednesday start trade follow mixed early economic news market rally europe dow future steer point nasdaq future trade point fair market value future show point gain small cap be positive steady russell future hold point gain stock market today open day rally belt nasdaq end higher trading range tuesday index remain day move average nasdaq be position possible test line week personal spending rise november commerce department say welcome improvement october gain show line economist expectation personal income rise tad october gain better view advance durable good order be flat month sharply october downwardly revise gain better contraction project economist consensus transportation order dip vs estimate change et university michigan be schedule report final consumer sentiment estimate december commerce department give new home sale number november dollar be mixed early wednesday vs euro yen bond slip send year yield basis point crude price moved higher brent crude west texas intermediate benchmark trading tandem just barrel crude price see effect weekly inventory datum energy information administration due et metal agricultural commodity be mixed mining company appear poise rally day bhp billiton bbl rio rio freeport mcmoran fcx vale vale jump bounce oil mining issue trip rally european market send london ftse more cac paris frankfurt dax nearly much midday trade stock nike nke vault nearly lead dow well ibd list premarket action athletic wear maker report late tuesday fiscal second quarter earning top consensus forecast revenue rise just shy expectation gross margin increase more forecast primarily due higher selling price stock have be testing support week move average just flat base buy point devon energy dvn spiked devon have be highly active acquisition front month pay asset anadarko powder river basin sell san juan river holding new mexico bp bp celgene celg muster gain open drug maker announce settlement litigation vs india natco pharma partner arrow international subsidiary allergan agn pertain patent oral cancer drug revlimid celgene share have be consolidate july micron technology mu tank hurt fiscal earning result deliver late tuesday idaho base chip maker score narrow earning beat revenue miss analyst target management guide revenue earning consensus forecast
415,REGN,facebook fb whole food market wfm st century fox be notable company report quarterly result wednesday here look expect
416,REGN,analyst expect social medium pioneer facebook third quarter earning share surge year cent revenue acceleration prior quarters
417,REGN,company past year have make public post searchable try recast more news centric site rapidly expand video user advertiser develop array new video feature deepen user engagement
418,REGN,site user be view video day jeffery say research note last month investment firm expect video ad become multibillion dollar business next year digital ad format become more expensive
419,REGN,video consumption explode fb massive user base think fb look well position capture increase portion tv ad budget marketer migrate datum drive highly target online video ad campaign jeffery say firm also say facebook app instagram beautiful visual layout highly engage audience make good advertising environment
420,REGN,share close stock market today
421,REGN,upscale grocery chain whole food have struggle whole paycheck reputation allegation overcharge consumer competition traditional grocery chain kroger kr have push more aggressively whole food turf offer higher quality fare
422,REGN,whole food september say lay worker partly keep price lower invest technology
423,REGN,whole food be try draw younger shopper less disposable income launch new chain store call whole food market store be set open next year
424,REGN,analyst expect whole food ep fall cent sale be see rise slow prior quarters share rise
425,REGN,medium giant report wednesday st century fox foxa time warner twx have be pressured rise online programming service netflix nflx amazon amzn prime video investor be tune company ad sale subscriber figure other sign ve adapt digitization television
426,REGN,analyst see st century fox ep slip cent revenue edge time warner ep be expect fall revenue
427,REGN,time warner share rise fox rise
428,REGN,pharmaceutical company regeneron pharmaceutical regn allergan agn also report wednesday
429,REGN,botox maker allergan ep be see fall cent street forecast sale rise gain strong pale comparison prior quarter sale jump actavis acquire company march
430,REGN,regeneron third quarter ep be expect leap sale lift
431,REGN,regeneron drug fail eyesight eyelea have propel company growth drug praluent injectable pcsk inhibitor co develop sanofi sa launch summer
432,REGN,special focus be expect be give initial figure praluent launch roth capital partner say regeneron upcoming quarterly result note previous note expect gradual launch eventually expect praluent repatha achieve blockbuster status believe doctor first look optimize statin therapy other modality merck mrk zetia vytorin move injectable therapy
433,REGN,regeneron share fall allergan fall
434,REGN,follow bill peter twitter ibd_bpeter facebook fb whole food market wfm st century fox be notable company report quarterly result wednesday here look expect analyst expect social medium pioneer facebook third quarter earning share surge year cent revenue acceleration prior quarters company past year have make public post searchable try recast more news centric site rapidly expand video user advertiser develop array new video feature deepen user engagement site user be view video day jeffery say research note last month investment firm expect video ad become multibillion dollar business next year digital ad format become more expensive video consumption explode fb massive user base think fb look well position capture increase portion tv ad budget marketer migrate datum drive highly target online video ad campaign jeffery say firm also say facebook app instagram beautiful visual layout highly engage audience make good advertising environment share close stock market today upscale grocery chain whole food have struggle whole paycheck reputation allegation overcharge consumer competition traditional grocery chain kroger kr have push more aggressively whole food turf offer higher quality fare whole food september say lay worker partly keep price lower invest technology whole food be try draw younger shopper less disposable income launch new chain store call whole food market store be set open next year analyst expect whole food ep fall cent sale be see rise slow prior quarters share rise medium giant report wednesday st century fox foxa time warner twx have be pressured rise online programming service netflix nflx amazon amzn prime video investor be tune company ad sale subscriber figure other sign ve adapt digitization television analyst see st century fox ep slip cent revenue edge time warner ep be expect fall revenue time warner share rise fox rise pharmaceutical company regeneron pharmaceutical regn allergan agn also report wednesday botox maker allergan ep be see fall cent street forecast sale rise gain strong pale comparison prior quarter sale jump actavis acquire company march regeneron third quarter ep be expect leap sale lift regeneron drug fail eyesight eyelea have propel company growth drug praluent injectable pcsk inhibitor co develop sanofi sa launch summer special focus be expect be give initial figure praluent launch roth capital partner say regeneron upcoming quarterly result note previous note expect gradual launch eventually expect praluent repatha achieve blockbuster status believe doctor first look optimize statin therapy other modality merck mrk zetia vytorin move injectable therapy regeneron share fall allergan fall follow bill peter twitter ibd_bpeter
435,REGN,earning season ibd be near peak leader facebook fb visa due report come week more third company have release quarterly result so far thomson reuter report say top earning estimate ibd stock facebook visa regeneron pharmaceutical regn paycom software payc gray television gtn also beat forecast credit card debit payment processor be forecast report increase fiscal ep cent report early monday visa have beaten profit estimate last quarters row revenue be expect grow thursday rival mastercard report hike ep cent beat view revenue edge just consensus payment space have be draw increase attention especially tech giant apple aapl alphabet googl roll mobile pay service monday jpmorgan chase jpm say launch mobile wallet call chase pay meanwhile visa be promote visa checkout let cardholder pay smartphone tablet laptop desktop virtually anywhere paycom softwaresmall fast grow cloud base employment management software maker paycom have be ibd list company adopt software cut cost help talent acquisition payroll other task also offer tool help client manage obamacare plan paycom be slate report tuesday market close analyst consensus be ep rise cent paycom have beaten street earning target quarters row revenue be project climb gray small fast grow ibd stock gray television have spotty earning record acquisition cost rise miss estimate last quarters report tuesday analyst expect earning drop cent share revenue be see increase gray television have buy more dozen mostly small tv station last year oct atlanta base gray say buy more tv station new market other move latest transaction close expect end year gray own operate more station serve market facebooksocial network giant facebook boast more regular user globally search daily facebook be slate report market close wednesday consensus be ep cent earning have top estimate least consecutive quarters revenue be see increase mark sixth quarter row decelerate growth headline number facebook expense mobile growth have come scrutiny expense spiked facebook spend heavily drive future growth mobile ad revenue account total ad revenue year earlier regeneron pharmaceutical wet age related macular degeneration isn everyday term most common eye disease related age baby boomer move retirement age regeneron blockbuster eylea eye disease treatment continue generate huge revenue jump putt track nearly yearly run rate analyst be look regeneron report wednesday surge revenue ep rise regeneron top profit view last quarters meanwhile also have be develop treatment colorectal cancer rheumatoid arthritis asthma july fda approve praluent cholesterol fighter part new class drug know pcsk inhibitor follow james detar twitter ibd_jdetar facebook
436,REGN,stock hold solid gain be session high early afternoon trading monday cheer busy day merger acquisition nasdaq gain rise dow jone industrial average picked small cap do well again russell volume nyse nasdaq be tracking slightly lower friday level stock market today chevron cvx pfizer pfe be top performer dow chevron be help price target raise credit suisse credit suisse maintain neutral rating biotechs celgene celg regeneron regn be top percentage gainer nasdaq rise respectively regeneron report earning wednesday open celgene report thursday open economic news come mostly line expectation read marked fourth straight monthly decline october job report be due friday bond price fall monday lift yield year treasury note merger news dyax dyax soar ireland base shire shpg agree buy orphan drug specialist meanwhile medasset mda surge agree be take private private equity firm cash other gainer include interactive broker ibkr share rise climb time high work right side base online brokerage offer pretty compelling growth story latest quarter earning jump year cent share sale jump downside visa slump earning miss expectation company also announce plan buy visa europe follow ken shreve twitter ibd_kshreve facebook
437,REGN,ibd screen day top fundamental be long term company track record superior earning sale growth
438,REGN,article focus fundamental stock report earning next week linkedin lnkd facebook fb paycom software payc regeneron pharmaceutical regn molina healthcare moh
439,REGN,linkedin report close thursday analyst have expect earning fall cent share expand sale force boost research development spending revenue be project grow instead linkedin ep jump cent ex item revenue rise include lynda com
440,REGN,professional social network have ibd composite rating shot late trading close stock market today
441,REGN,molina healthcare also report much better expect earning late thursday share rise late close slightly day line
442,REGN,molina provider manage health care service low income family have composite rating year ep growth rate
443,REGN,paycom software be expect see earning rise cent report close next tuesday nov revenue be see increase
444,REGN,provider cloud base employment management software earn best composite rating paycom have be big winner fall thursday just day line
445,REGN,facebook issue result close next wednesday social networking giant earning be project rise adjust cent share revenue be see climb
446,REGN,company have be public only little year have year earning growth rate
447,REGN,facebook recently break base be trading time high rise thursday stock have composite rating
448,REGN,regeneron pharmaceutical report next wednesday open project see earning climb revenue increase
449,REGN,biotech year ep growth rate be facebook regeneron also have composite rating share nearly recently clear double bottom base buy point
450,REGN,follow alissa william twitter ibd_awilliam facebook ibd screen day top fundamental be long term company track record superior earning sale growth article focus fundamental stock report earning next week linkedin lnkd facebook fb paycom software payc regeneron pharmaceutical regn molina healthcare moh linkedin report close thursday analyst have expect earning fall cent share expand sale force boost research development spending revenue be project grow instead linkedin ep jump cent ex item revenue rise include lynda com professional social network have ibd composite rating shot late trading close stock market today molina healthcare also report much better expect earning late thursday share rise late close slightly day line molina provider manage health care service low income family have composite rating year ep growth rate paycom software be expect see earning rise cent report close next tuesday nov revenue be see increase provider cloud base employment management software earn best composite rating paycom have be big winner fall thursday just day line facebook issue result close next wednesday social networking giant earning be project rise adjust cent share revenue be see climb company have be public only little year have year earning growth rate facebook recently break base be trading time high rise thursday stock have composite rating regeneron pharmaceutical report next wednesday open project see earning climb revenue increase biotech year ep growth rate be facebook regeneron also have composite rating share nearly recently clear double bottom base buy point follow alissa william twitter ibd_awilliam facebook
451,REGN,stock edge higher wednesday open earning push early action ahead fed policy announcement afternoon dow jone industrial average gain nasdaq add hold back heavy loss akamai technology akam verisk analytic vrsk
452,REGN,volume be soft nasdaq lower nyse vs trade same time tuesday
453,REGN,fed policy announcement due et remain focal point stock market today keep eye oil price energy information administration report weekly oil inventory datum
454,REGN,pfizer pfe jump nearly lead dow unitedhealth unh drop dow worst decline
455,REGN,apple aapl power bit less report healthy fiscal second quarter late tuesday
456,REGN,cbre group cbg gap gain big revenue earning beat big volume move put share well right side possible cup base
457,REGN,northrop grumman noc new high rise massive trade ace contract defense department contract build long range bomber report solid result
458,REGN,ibd stock cirrus logic crus jump nearly start gate gain be enough lift share back day move average chip developer drop heavy trade monday trigger sell signal cut day move average company report fiscal earning revenue today close
459,REGN,ibd fabless chip play technology avgo climb place share back day move average stock be seventh week pattern become cup handle base buy point form month consolidation
460,REGN,ellie mae elli fade fraction early trade online mortgage service provider be build right side possible base back day move average climb oct low report result close
461,REGN,regeneron pharmaceutical regn fade bit less stock be due rest straight daily advance boost past buy point double bottom base stock reset base count undercut prior flat base make current pattern first stage structure increase potential stock remain buy range buy point company report result nov
462,REGN,follow alan elliott twitter ibd_aelliott facebookstock edge higher wednesday open earning push early action ahead fed policy announcement afternoon dow jone industrial average gain nasdaq add hold back heavy loss akamai technology akam verisk analytic vrsk volume be soft nasdaq lower nyse vs trade same time tuesday fed policy announcement due et remain focal point stock market today keep eye oil price energy information administration report weekly oil inventory datum pfizer pfe jump nearly lead dow unitedhealth unh drop dow worst decline apple aapl power bit less report healthy fiscal second quarter late tuesday cbre group cbg gap gain big revenue earning beat big volume move put share well right side possible cup base northrop grumman noc new high rise massive trade ace contract defense department contract build long range bomber report solid result ibd stock cirrus logic crus jump nearly start gate gain be enough lift share back day move average chip developer drop heavy trade monday trigger sell signal cut day move average company report fiscal earning revenue today close ibd fabless chip play technology avgo climb place share back day move average stock be seventh week pattern become cup handle base buy point form month consolidation ellie mae elli fade fraction early trade online mortgage service provider be build right side possible base back day move average climb oct low report result close regeneron pharmaceutical regn fade bit less stock be due rest straight daily advance boost past buy point double bottom base stock reset base count undercut prior flat base make current pattern first stage structure increase potential stock remain buy range buy point company report result nov follow alan elliott twitter ibd_aelliott facebook
463,REGN,transportation stock get hit hard tuesday small cap lag badly good news bull be damage didn show major average lose dow jone industrial average fall nasdaq ease volume rise monday level give mild distribution day nasdaq
464,REGN,stock hold mild gain quiet columbus day trade ahead busy week earning dow jone industrial average lead gain nasdaq climb finished volume be quiet board accord preliminary datum winner edge past loser nyse decliner outpaced advancer nearly margin nasdaq
465,REGN,airline travel booker video game maker lead upside stock market today energy stock lag crude oil price fall barrel skywest skyw soar clear flat base buy point fast trade
466,REGN,ibd stock advanced decline hawaiian extend gain fourth straight session rise new high share be extend past cup handle entry analyst expect carrier grow ep revenue dip report oct close
467,REGN,other ibd stock volume include regeneron pharmaceutical regn gap rise nearly regain day move average overall biotech slide regeneron develop cholesterol treatment praluent sanofi sny have get boost news eli lilly lly end late stage trial experimental cholesterol drug lilly share sank
468,REGN,universal insurance uve advanced trigger week hold rule rally more intraday cup handle buy point clear
469,REGN,twitter twtr fall brisk trade report real time messaging platform plan announce companywide layoff week last monday twitter officially name interim ceo jack dorsey chief
470,REGN,other internet player facebook fb alphabet googl add facebook say testing new app let user shop leave social network app
471,REGN,earning watch tuesday include bank ozark ozrk blackhawk network hawk intel intc johnson johnson jnj jpmorgan chase jpm
472,REGN,economic datum tap tuesday include treasury september budget report small business optimism index september national federation independent business fed james bullard be also schedule speak
473,REGN,follow nancy gondo twitter ibd_ngondo stock hold mild gain quiet columbus day trade ahead busy week earning dow jone industrial average lead gain nasdaq climb finished volume be quiet board accord preliminary datum winner edge past loser nyse decliner outpaced advancer nearly margin nasdaq airline travel booker video game maker lead upside stock market today energy stock lag crude oil price fall barrel skywest skyw soar clear flat base buy point fast trade ibd stock advanced decline hawaiian extend gain fourth straight session rise new high share be extend past cup handle entry analyst expect carrier grow ep revenue dip report oct close other ibd stock volume include regeneron pharmaceutical regn gap rise nearly regain day move average overall biotech slide regeneron develop cholesterol treatment praluent sanofi sny have get boost news eli lilly lly end late stage trial experimental cholesterol drug lilly share sank universal insurance uve advanced trigger week hold rule rally more intraday cup handle buy point clear twitter twtr fall brisk trade report real time messaging platform plan announce companywide layoff week last monday twitter officially name interim ceo jack dorsey chief other internet player facebook fb alphabet googl add facebook say testing new app let user shop leave social network app earning watch tuesday include bank ozark ozrk blackhawk network hawk intel intc johnson johnson jnj jpmorgan chase jpm economic datum tap tuesday include treasury september budget report small business optimism index september national federation independent business fed james bullard be also schedule speak follow nancy gondo twitter ibd_ngondo
474,REGN,growth stock fared mildly better wednesday major index etfs lose early sizzle choppy session investor digest news slower manufacturing activity china cheer slight rally european market spdr biotechnology xbi close lower stock market today midpoint day trading range equal weight etf tilt
475,REGN,big biotechs amgen amgn regeneron pharmaceutical regn be trading wednesday morning pharmacy benefit manager express script esrx say late tuesday include new cholesterol bust drug prefer formulary express script have long be say make effort keep price amgen repatha regeneron praluent
476,REGN,big biotechs amgen regeneron launch new cholesterol drug repatha praluent summer wall street uniformly predict blockbuster sale debate just big
477,REGN,adult american have high cholesterol pfizer pfe lipitor be biggest selling drug world go patent get generic rival
478,REGN,yet statin drug class lipitor belong aren enough everyone repatha praluent new class call pcsk inhibitor promise help many person cholesterol be still too high
479,REGN,mid september amgen amgn make acquisition signale future lie company agree pay upfront dezima pharma company develop drug call cholesteryl ester transfer protein cetp inhibitor drug class be also be develop merck mrk eli lilly lly also promise lower cholesterol inadequately treat statin lower ldl bad cholesterol ve also show ability raise hdl good cholesterol
480,REGN,contrast biweekly injection require amgen regeneron regn treatment cetps be take daily pill
481,REGN,dezima drug candidate succeed amgen be hook milestone payment be well worth cetp class turn be real threat
482,REGN,provide natural hedge amgen important cardiovascular franchise give pcsk repatha be drug be injectable phase iii competitor cetp inhibitor lilly merck be oral write rbc capital market analyst michael yee research note day deal be announce
483,REGN,wall street success be big drug class first make phase testing pfizer torcetrapib come screeching halt pfizer realize drug be raise patient death rate increase blood pressure
484,REGN,really shake field be high hope torcetrapib daniel bloomfield vice president clinical research merck cardiovascular program tell ibd announce result put program hold start work issue
485,REGN,bloomfield say merck isolate hormone be responsible raise blood pressure pfizer trial demonstrate own drug anacetrapib do not have risk factor lilly also say confident cetp inhibitor evacetrapib be safer predecessor
486,REGN,enrolled first patient have patient most be many many month treatment evidence safety signal say jeffrey riesmeyer senior medical director lilly cardiovascular program
487,REGN,same time danger make drug too weak happened roche rhhby cetp inhibitor dalcetrapib phase trial show safety problem raise hdl only other candidate have typically raise triple digit didn affect ldl
488,REGN,history be reason pcsk be available now cetp inhibitor win be market least year amgen regeneron be able approval basis cholesterol lower power company demonstrated drug effect overall cardiovascular health merck lilly however be go complete cardiovascular outcome study apply approval
489,REGN,first start work anacetrapib have alignment fda approve drug base ldl lower bloomfield say think now fda want see evidence outcome benefit approve drug class think want see well give shadow overhang mechanism
490,REGN,lilly trial be expect be do mid merck early be also pcsk datum be expect start come company be study similar patient group pcsk trial mainly already have heart disease virtually be already statin many be also take diabetes medicine riesmeyer note
491,REGN,lilly diabetes drug jardiance be recently show improve heart health drug work tandem riesmeyer note
492,REGN,main difference drug be merck anacetrapib have longer half life time drug remain body trace drug have be detected patient year last dose lilly riesmeyer point potential safety issue have yet be prove
493,REGN,so far cetp inhibitor ability lower ldl have lag pcsk phase trial praluent reduce ldl repatha perform similarly anacetripib evacetrapib have lower ve also raise hdl much dezima drug ta have go phase lower ldl raise hdl amgen advertised announce deal
494,REGN,assume ldl hypothesis hold true cetp ta potentially be best class write leerink analyst july deep dive report cholesterol market
495,REGN,uncertainty exact connection cholesterol heart health leave unclear just translate market share merck bloomfield say likely be key factor
496,REGN,not say magnitude benefit safety tolerability profile price vs generic aren go be important say factor be important expect outcome be require entry take significant market share big biotechs amgen regeneron launch new cholesterol drug repatha praluent summer wall street uniformly predict blockbuster sale debate just big adult american have high cholesterol pfizer pfe lipitor be biggest selling drug world go patent get generic rival yet statin drug class lipitor belong aren enough everyone repatha praluent new class call pcsk inhibitor promise help many person cholesterol be still too high mid september amgen amgn make acquisition signale future lie company agree pay upfront dezima pharma company develop drug call cholesteryl ester transfer protein cetp inhibitor drug class be also be develop merck mrk eli lilly lly also promise lower cholesterol inadequately treat statin lower ldl bad cholesterol ve also show ability raise hdl good cholesterol contrast biweekly injection require amgen regeneron regn treatment cetps be take daily pill dezima drug candidate succeed amgen be hook milestone payment be well worth cetp class turn be real threat provide natural hedge amgen important cardiovascular franchise give pcsk repatha be drug be injectable phase iii competitor cetp inhibitor lilly merck be oral write rbc capital market analyst michael yee research note day deal be announce wall street success be big drug class first make phase testing pfizer torcetrapib come screeching halt pfizer realize drug be raise patient death rate increase blood pressure really shake field be high hope torcetrapib daniel bloomfield vice president clinical research merck cardiovascular program tell ibd announce result put program hold start work issue bloomfield say merck isolate hormone be responsible raise blood pressure pfizer trial demonstrate own drug anacetrapib do not have risk factor lilly also say confident cetp inhibitor evacetrapib be safer predecessor enrolled first patient have patient most be many many month treatment evidence safety signal say jeffrey riesmeyer senior medical director lilly cardiovascular program same time danger make drug too weak happened roche rhhby cetp inhibitor dalcetrapib phase trial show safety problem raise hdl only other candidate have typically raise triple digit didn affect ldl history be reason pcsk be available now cetp inhibitor win be market least year amgen regeneron be able approval basis cholesterol lower power company demonstrated drug effect overall cardiovascular health merck lilly however be go complete cardiovascular outcome study apply approval first start work anacetrapib have alignment fda approve drug base ldl lower bloomfield say think now fda want see evidence outcome benefit approve drug class think want see well give shadow overhang mechanism lilly trial be expect be do mid merck early be also pcsk datum be expect start come company be study similar patient group pcsk trial mainly already have heart disease virtually be already statin many be also take diabetes medicine riesmeyer note lilly diabetes drug jardiance be recently show improve heart health drug work tandem riesmeyer note main difference drug be merck anacetrapib have longer half life time drug remain body trace drug have be detected patient year last dose lilly riesmeyer point potential safety issue have yet be prove so far cetp inhibitor ability lower ldl have lag pcsk phase trial praluent reduce ldl repatha perform similarly anacetripib evacetrapib have lower ve also raise hdl much dezima drug ta have go phase lower ldl raise hdl amgen advertised announce deal assume ldl hypothesis hold true cetp ta potentially be best class write leerink analyst july deep dive report cholesterol market uncertainty exact connection cholesterol heart health leave unclear just translate market share merck bloomfield say likely be key factor not say magnitude benefit safety tolerability profile price vs generic aren go be important say factor be important expect outcome be require entry take significant market share
497,REGN,facebook fb revenue growth be see decelerate compare estimate be goldman sachs list largest stock rank growth exclude financial utility social networking leader be expect see sale growth next year vs estimate rise goldman analyst see
498,REGN,stock power early trade wednesday market launch second straight early rally nasdaq flex vault dow jone industrial average claim gain
499,REGN,volume be bit lower tuesday level fraction nasdaq nyse exchange
500,REGN,stock market today borrow early strength rebound market europe market hold early gain frankfurt dax paris cac london ftse show gain afternoon trade quarter ftse be tracking loss cac june dax
501,REGN,nasdaq be trading june be
502,REGN,strong september hire report adp help boost stock wednesday start bell midwest manufacturing put hitch giddyap kingsbury international report september purchasing manager index drop be far august read consensus expectation mild slip fifth time year gauge have dip mark divide sector expansion contraction
503,REGN,stumble dow stock be unanimously positive intel intc lead group better gain unitedhealth unh be close
504,REGN,western digital wdc jump start trade lead nasdaq china tsinghua unisplendour agree buy stake datum storage company other datum storage player tap western momentum seagate technology stx climb sandisk sndk surge
505,REGN,ralph lauren rl fashion advance report late tuesday founder ralph lauren turn chief executive duty stefan larsson be exit president post gap gsp old navy brand change become effective nov company say mizuho security downgrade gap underperform neutral cite larsson departure gap share fall
506,REGN,drugmaker be rebound biomarin pharmaceutical bmrn alexion pharmaceutical alxn regeneron regn biogen biib more early action drugmaker also rebound early tuesday falter group late session
507,REGN,leader stock ibd climb start gate
508,REGN,head pack regeneron leap huge trade stock now face test regain day move average lose bid regain support day line
509,REGN,universal uve muscle nearly property casualty insurance provider announce late tuesday state insurance commissioner approve universal universal property casualty insurance subsidiary license entity west virginia stock be just buy point cup handle base
510,REGN,other market dollar gain bond slip commodity turn tightly mixed trade mild loss oil fraction hold barrel gold more copper be holdout hold steady gain nearly keep eye oil price energy information administration report weekly crude inventory et
511,REGN,follow alan elliott twitter ibd_aelliott stock power early trade wednesday market launch second straight early rally nasdaq flex vault dow jone industrial average claim gain volume be bit lower tuesday level fraction nasdaq nyse exchange stock market today borrow early strength rebound market europe market hold early gain frankfurt dax paris cac london ftse show gain afternoon trade quarter ftse be tracking loss cac june dax nasdaq be trading june be strong september hire report adp help boost stock wednesday start bell midwest manufacturing put hitch giddyap kingsbury international report september purchasing manager index drop be far august read consensus expectation mild slip fifth time year gauge have dip mark divide sector expansion contraction stumble dow stock be unanimously positive intel intc lead group better gain unitedhealth unh be close western digital wdc jump start trade lead nasdaq china tsinghua unisplendour agree buy stake datum storage company other datum storage player tap western momentum seagate technology stx climb sandisk sndk surge ralph lauren rl fashion advance report late tuesday founder ralph lauren turn chief executive duty stefan larsson be exit president post gap gsp old navy brand change become effective nov company say mizuho security downgrade gap underperform neutral cite larsson departure gap share fall drugmaker be rebound biomarin pharmaceutical bmrn alexion pharmaceutical alxn regeneron regn biogen biib more early action drugmaker also rebound early tuesday falter group late session leader stock ibd climb start gate head pack regeneron leap huge trade stock now face test regain day move average lose bid regain support day line universal uve muscle nearly property casualty insurance provider announce late tuesday state insurance commissioner approve universal universal property casualty insurance subsidiary license entity west virginia stock be just buy point cup handle base other market dollar gain bond slip commodity turn tightly mixed trade mild loss oil fraction hold barrel gold more copper be holdout hold steady gain nearly keep eye oil price energy information administration report weekly crude inventory et follow alan elliott twitter ibd_aelliott
512,REGN,tyson food tsn boee ba be company expect benefit tran pacific partnership trade agreement drugmaker biotechs primarily develop brand drug have emerge top loser nation accord include mexico canada japan australia vietnam be agree monday still require ratification congress agreement give brand
513,REGN,biom realty trust bmr jump more wednesday bloomberg report company be explore sale bloomberg say blackstone group bx be interested buy biom realty be real estate investment trust specialize provide home laboratory life science industry focus effort core market boston san francisco san diego new york pennsylvania seattle company serve want be part research hub university biom be founder realization traditional reit weren able satisfy unique need research company say own square foot office laboratory space lease company research institution big university house be harvard yale university california san diego april company announce new build suit transaction regeneron pharmaceutical regn new building totale square foot parking structure landmark eastview tarrytown expand regeneron campus square foot biom realty say laboratory office space be pre lease year term june year announce illumina ilmn sign year lease square foot research build cambridge england stock have be underperform last several year basically move sideway high january slip recent week company pay dividend cent share work annualize yield year annualize dividend growth rate be
514,REGN,seller turn heat send major average fresh session lows late monday nasdaq crater biotechs heavy selling once again lose dow jone industrial average be turnover be run sharply higher board stock market today especially nasdaq stock ibd be lower cal maine food calm be worst performer huge turnover open egg producer post fiscal earning surge share still fall short expectation stock slice day move average regeneron pharmaceutical regn slump breach long term support day line stock fall lowest level month elsewhere cambrex cbm sucampo pharmaceutical scmp shed respectively latter slide more buy point cup base friday sucampo already trigger sell signal erase double digit gain past entry outside ibd valeant pharmaceutical vrx cave stage huge downside reversal share be fire congressional democrat be push canadian drugmaker be subpoena document related price hike couple drug post holding post tumble nearly take day line stock slump more buy point week tight pattern clear follow vincent mao twitter ibd_vmao
515,REGN,high rate tech stock adobe system adbe pair biotechs lead ibd stock move go wednesday tough tuesday index more adobe lift high volume indicator institutional investor be likely buy company make photoshop other creative cloud software graphic video
516,REGN,lead stock day move average be key support level watch stock break base strongest stock tend ride average higher early stage use day line vital tool screen stock well build watch list stock used growth screen ibd update day leaderboard ipo leader ibd tuesday thursday big cap most tuesday make sure stock be consolidate gain day move average mini chart ibd be weekly chart therefore show stock week move average stock have better chance breaking successfully base day week line stock trading comfortably week line be show relative strength important see stock be build base common stock fall week line build base start regain momentum make sure week line near area point only resistance level have overcome be prior high week line overhead supply become issue week line turn resistance level buy point flat base appear week line same hold true double bottom pattern cup handle pattern handle area form week line be be case week line be difficult price area stock punch amazon com amzn have be solid performer year clear series basis show support action week move average first occur week end april second be week end july third be week end oct soon follow day oct today several other top rate growth name be build basis week line include monster beverage mnst alliance datum system ad logmein logm regeneron regn recently clear double bottom buy point add handle area show alternate buy point linkedin lnkd be work right side deep jagged base share soar nearly week end oct have yet overtake high
517,REGN,stock market be place be certainly case monday major average end solid gain lower volume be shortage market chatter weekend monday be go be tough session stock market light terror attack paris didn turn
518,REGN,several industry etfs packed wicked punch recent week robust earning here look standout report season wind ishare nasdaq biotechnology ibb ishare pharmaceutical ihe past month respectively biotech pharma exchange trade fund sell aggressively third quarter political rhetoric fear
519,REGN,hillary clinton have demonstrated knack striking fear heart investor first pharmaceutical then health insurance now cable tv example begin valeant vrx nearly plunge last month be trace back tweet democratic presidential front runner vice president joe biden have
520,REGN,bull case amgen amgn new cholesterol drug repatha continue be build tuesday nomura raise long term estimate drug sale ub defend optimistic thesis repatha rival drug praluent sanofi sny regeneron regn survey cardiologist be enthusiastic new pcsk drug class nomura analyst ian
521,REGN,valeant pharmaceutical find plenty company market misery last week drugmaker biotech stock sell hillary clinton accuse big pharma price gouge valeant vrx close nearly lower week biogen biib gilead science gild regeneron pharmaceutical regn amgen amgn allergan agn horizon pharma hznp also fall bloomberg report clinton plan
522,REGN,foresight help june commentary make china broad market meltdown picked steam rowe price fund manager daniel martino warn investor new america growth greece be get bigger headline china be more worrisome plan move forward intend focus identify season growth company ability increase earning even volatile macroeconomic environment write have enabled fund lose less large cap growth mutual fund peer track morningstar inc month go tuesday have also outperformed year date trail month gain ground cycle proof holding have be be see next batch quarterly earning report come meanwhile share price relative strength several key name have help fund cope market volatility low point broad market sell top hold amazon amzn have plunge july high go tuesday have regain more half loss retake week move average stock be still buy range relative strength line have power new high ground be bullish sign see many investor napoleon internet general store online retailer have also become leader cloud compute service demand video stream now crank own original content fool streetamazon fool street report second quarter profit cent share gain consensus forecast be cent loss analyst expect net loss cent share profit share full year earning be see jump rbc capital lift amazon price target friday regeneron pharmaceutical regn be fund hold aug fund have boost weighting least past quarters share price be slide august consensus earning estimate be be revise upward accord zack equity research company make treatment eye disease inflammatory disease cancer sale growth have accelerate rise past quarters return equity be past year just do itnike nke fall week line broad market sell week average point tuesday afternoon have regain day line nike have be climb way thank part shopper buy athletic leisure wear back school season earning share grow past quarters apparel maker beat analyst consensus earning estimate most recent quarter
523,REGN,strong open stock fade early afternoon trading monday
524,REGN,nasdaq reversed early gain fall tech rich composite be hurt weakness biotech stock apparently trigger tweet presidential candidate hillary clinton complain exorbitantly high price certain ethical drug edge higher dow jone industrial average rise nearly nyse nasdaq volume be tracking lower friday level stock market today economic news exist home sale drop sharply august national association realtor say annualize pace economist consensus have expect mild slowdown july pace lennar len pop early reversed loss more open miami base homebuilder report stronger expect fiscal sale earning tesla motor tsla be high still gain work new base buy point chipmaker atmel atml soar germany base dialog semiconductor say buy atmel cash stock deal value deal be expect close wedbush topeka fbr capital downgrade atmel follow news oil gas stock outperformed new york mercantile exchange crude oil future rise barrel downside volkswagen vlkay plunge federal state regulator say german automaker used software diesel vehicle cheat emission test ibd biotechs regeneron regn celgene celg take hit fall
525,REGN,initial post fed statement relief rally fuel major index bigger advance fade stock sharply pare gain close nasdaq hold slim gain biotechs outperformed give dow jone industrial average shed volume be higher board stock market today accord preliminary datum widely expect fed left rate unchanged record lows recent global economic financial development restrain economic activity somewhat be likely put further downward pressure inflation term say statement biotechs drugmaker airline stock be day biggest gainer bank toy maker machinery related stock lag unite continental ual soar reclaim day move average fast trade analyst think chicago base carrier multiyear credit card deal extension jpmorgan chase jpm visa announce wednesday boost full year profit virgin america va rise also average volume share november ipo be dec high more offer price biotechs sucampo pharmaceutical scmp surge new close high stock be now extend cup base buy point clear july biotech be featured thursday industry theme column ibd biotechs celgene celg regeneron pharmaceutical regn advanced winner ibd edge loser margin follow nancy gondo twitter ibd_ngondo
526,REGN,stock make welcome gain week bruise couple month senior management top company such apple aapl twitter twtr gopro gpro well top executive yahoo yhoo be buy selling mood come own business share gilead science gild chairman ceo john martin monday announce plan sale share gilead president chief operate officer john milligan wednesday file plan sale share last month martin sell share worth milligan sell share gilead stock gain week gopro chairman ceo nichola woodman wednesday file plan purchase share worth be tough week action camera company suffer price target cut morgan stanley analyst cite weak sale hero session company apparent slowness improve video editing sharing software gopro share slide week friday rally thursday gopro stock hit record trading low intraday near ipo price twitter cfo anthony noto announce sale share coo adam bain disclose have sell share disclosure come leadership upheaval twitter earlier stock sell be fuel worry slow growth june twitter say dick costolo be resign ceo san francisco base social medium company monday announce co founder interim chief jack dorsey be permanent ceo dorsey also run square mobile payment company twitter share climb week best performance february apple cfo luca maestri tuesday disclose plan sale share sale apple macintosh shrank lowest rate year industry research firm gartner idc report thursday meanwhile apple mobile payment service apple pay roll thousand more store year secure deal starbucks sbux yum brand yum apple share gain week dave buster entertainment play ceo stephen king tuesday disclose sale share cfo brian jenkin announce plan sell share meanwhile david jone director company sell share arcade restaurant chain share be track fall week yahoo ceo marissa mayer tuesday announce purchase share last month mayer complete net acquisition share yahoo cfo kenneth goldman file net acquisition share late september yahoo say go ahead spinoff alibaba baba stake uncertain tax status yahoo stock rise week regeneron pharmaceutical regn stockholder sanofi sny tuesday buy more regeneron share thursday sanofi disclose have buy share regeneron regeneron share rise week sanofi stock gain restoration hardware rh director carlos alberini wednesday announce have sell share stock gain week insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock follow ciaran mcevoy twitter ibd_cmcevoy facebook
527,REGN,health care etfs revive tuesday major stock index trade mixed investor eye higher oil price stock sell china surprise interest rate cut india spdr spdr dow jone industrial average ishare russell close monday correction territory more week high biotech stock take chin monday lead rally tuesday morning ishare nasdaq biotechnology ibb pop be week high largest most popular exchange trade fund segment ibb hold roughly nasdaq list biotech stock biogen biib stock ibb have largest stake lead advance top holding gain gilead gild celgene celg amgen amgn regeneron pharmaceutical regn climb health care select sector spdr fund xlv rise stock market today boost biotech surge international etfs india marched ahead japan bring rear india earning epi jab higher top holding hdfc hdb india largest private bank advance nearly infosys infy outsource firm oil energy fund lead commodity higher gold ease fraction here look benchmark exchange trade fund be perform today follow daily etf market action be critical investment success bellwether etfs spdr spy rs powershare qqq qqq rs ishare russell iwm rs sdpr dow jone industrial average dium rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs ishare core mid cap ijh rs spdr gold share gld rs powershare db dollar bullish uup rs ishare core aggregate bond agg rs follow aparna narayanan twitter ibd_anarayanan
528,REGN,stock show modest loss afternoon trading day fed meeting get underway lose dow jone industrial average nasdaq give volume nyse nasdaq be tracking higher monday level stock market today dow component apple aapl be mostly unchanged ahead earning report close sharp pullback apple still have lot overhead supply work get back week high also dow ibm ibm slump news sec investigation revenue recognition practice economic news order durable good fall slightly more expect september consumer confidence plunge odd rate hike wednesday be quite low fed fund future trader have odd december rate hike ibd top perform breakout continue face selling pressure lgi home lgih slump still hold day move average universal insurance uve meanwhile give still well extend cup handle buy point biotechs outperformed ibd name regeneron regn add clear double bottom buy point volume hasn come stock chip designer integrate device idti monolithic power mpwr outperformed rise respectively report strong earning group peer inphi iphi also outperformed rise ahead earning report close walgreen boot alliance wba soar report advanced talk acquire rite aid rad rite aid jump new york mercantile exchange december crude oil continue slide fall barrel follow ken shreve twitter ibd_kshreve facebook
529,REGN,stock future build early gain ahead wednesday open dow future be ahead point climb nasdaq future trade point future rise strong point
530,REGN,stock market today be open bond trader be observe veteran day holiday overseas market asia post tightly mixed session stock europe be knock healthy gain midday
531,REGN,most government office be close make sparse economic calendar labor department report job opening labor turnover survey thursday friday commerce department report october retail sale labor department give october producer price datum university michigan deliver initial read november consumer sentiment
532,REGN,stock action early wednesday show cisco system csco lead dow gain coal miner consol energy cnx drop worst premarket loss stock
533,REGN,belgium anheuser busch inbev bud be flat announce have agree buy base brewing peer sabmiller deal miller share rise nearly london exchange
534,REGN,jcpenney jcp spiked third quarter earning beat macy dive nearly earning top expectation revenue guidance be weak
535,REGN,leader number big tech name be motion facebook fb linkedin lnkd alphabet googl lean higher open apple aapl show fractional premarket loss follow gap loss tuesday
536,REGN,overall lead stock be generally quiet clear exception be horizon pharma hznp tank bell pharmacy benefit manager express script holding esrx announce have end relation linden care claim pharmacy dispense only horizon pharma medication fail meet contract distribution agreement
537,REGN,express script also say be investigate other pharmacy tie horizon horizon share have be fight recover steep month sell express script share dip premarket trade
538,REGN,upside regeneron pharmaceutical regn briefly flash premarket gain top ibd list then return flat trade drug maker partner sanofi sny report positive result phase clinical trial injectable ldl cholesterol treatment praluent regeneron end tuesday buy point double bottom base stock future build early gain ahead wednesday open dow future be ahead point climb nasdaq future trade point future rise strong point stock market today be open bond trader be observe veteran day holiday overseas market asia post tightly mixed session stock europe be knock healthy gain midday most government office be close make sparse economic calendar labor department report job opening labor turnover survey thursday friday commerce department report october retail sale labor department give october producer price datum university michigan deliver initial read november consumer sentiment stock action early wednesday show cisco system csco lead dow gain coal miner consol energy cnx drop worst premarket loss stock belgium anheuser busch inbev bud be flat announce have agree buy base brewing peer sabmiller deal miller share rise nearly london exchange jcpenney jcp spiked third quarter earning beat macy dive nearly earning top expectation revenue guidance be weak leader number big tech name be motion facebook fb linkedin lnkd alphabet googl lean higher open apple aapl show fractional premarket loss follow gap loss tuesday overall lead stock be generally quiet clear exception be horizon pharma hznp tank bell pharmacy benefit manager express script holding esrx announce have end relation linden care claim pharmacy dispense only horizon pharma medication fail meet contract distribution agreement express script also say be investigate other pharmacy tie horizon horizon share have be fight recover steep month sell express script share dip premarket trade upside regeneron pharmaceutical regn briefly flash premarket gain top ibd list then return flat trade drug maker partner sanofi sny report positive result phase clinical trial injectable ldl cholesterol treatment praluent regeneron end tuesday buy point double bottom base
539,REGN,stock end mixed tuesday mostly quiet session be far quiet come apple aapl semiconductor stock nasdaq dow open lower end session high buyer come market afternoon trading nasdaq lose nearly early trim loss close
540,REGN,put follow signal oct be shortage buy opportunity many lead stock have stage breakout day day many leader such hawaiian holding manhattan associate manh bank ozark ozrk have already grab nice gain universal holding uve be also boat break
541,REGN,time most lead biotechs be still try recover aug market sell sucampo pharmaceutical scmp be run far ahead pack share specialty drugmaker be well extend past buy point subsequent rebound week move average re more year vs nasdaq
542,REGN,strong open stock fade mixed performance midday wednesday nasdaq fall weigh weakness adobe system adbe tesla motor tsla dow jone industrial average add johnson johnson jnj merck mrk boee ba be early leader dow
543,REGN,nyse volume be tracking higher tuesday level stock market today nasdaq volume be tracking close tuesday level
544,REGN,adobe gap day move average fall company issue lukewarm fiscal guidance
545,REGN,tesla slump negative analyst chatter
546,REGN,amgen amgn be high still rise pharmacy benefit manager express script esrx name amgen repatha prefer supplemental cholesterol reduction treatment other praluent be make sanofi sny regeneron pharmaceutical regn sanofi share slip regeneron climb early trade
547,REGN,ipo news pure storage pstg price last night midpoint propose range provider flash memory base enterprise storage hardware open share be recently trading
548,REGN,earning winner include ibd firm global payment gpn share gap week base rise result top expectation outlook be solid company also declare stock split
549,REGN,follow ken shreve twitter ibd_kshreve facebook strong open stock fade mixed performance midday wednesday nasdaq fall weigh weakness adobe system adbe tesla motor tsla dow jone industrial average add johnson johnson jnj merck mrk boee ba be early leader dow nyse volume be tracking higher tuesday level stock market today nasdaq volume be tracking close tuesday level adobe gap day move average fall company issue lukewarm fiscal guidance tesla slump negative analyst chatter amgen amgn be high still rise pharmacy benefit manager express script esrx name amgen repatha prefer supplemental cholesterol reduction treatment other praluent be make sanofi sny regeneron pharmaceutical regn sanofi share slip regeneron climb early trade ipo news pure storage pstg price last night midpoint propose range provider flash memory base enterprise storage hardware open share be recently trading earning winner include ibd firm global payment gpn share gap week base rise result top expectation outlook be solid company also declare stock split follow ken shreve twitter ibd_kshreve facebook
550,REGN,stock climb back session high go last hour trading nasdaq be dow jone industrial average rise volume be mixed run higher nyse slightly lower nasdaq winner trump loser more margin exchange
551,REGN,biotechs be mend big player alexion pharmaceutical alxn celgene celg gilead science gild regeneron pharmaceutical regn score better gain other industry group lead wednesday session include wholesale food nonalcoholic beverage maker
552,REGN,big gainer ibd include global payment gpn gap soar cup handle base heavy trade fiscal result top view electronic payment processor also declare stock split
553,REGN,telecom contractor dycom industry dy chinese wealth management service firm noah noah rise respectively also big volume
554,REGN,automaker software meat product stock lag stock market today tesla motor tsla again drag automaker group slide look support day move average
555,REGN,robert baird lower tesla rating neutral outperform price target morgan stanley tuesday cut model delivery forecast higher expect price tag
556,REGN,nu skin enterprise nus gap sank massive volume personal care product marketer slash revenue forecast due currency headwind china weakness analyst be expect
557,REGN,follow nancy gondo twitter ibd_ngondo stock climb back session high go last hour trading nasdaq be dow jone industrial average rise volume be mixed run higher nyse slightly lower nasdaq winner trump loser more margin exchange biotechs be mend big player alexion pharmaceutical alxn celgene celg gilead science gild regeneron pharmaceutical regn score better gain other industry group lead wednesday session include wholesale food nonalcoholic beverage maker big gainer ibd include global payment gpn gap soar cup handle base heavy trade fiscal result top view electronic payment processor also declare stock split telecom contractor dycom industry dy chinese wealth management service firm noah noah rise respectively also big volume automaker software meat product stock lag stock market today tesla motor tsla again drag automaker group slide look support day move average robert baird lower tesla rating neutral outperform price target morgan stanley tuesday cut model delivery forecast higher expect price tag nu skin enterprise nus gap sank massive volume personal care product marketer slash revenue forecast due currency headwind china weakness analyst be expect follow nancy gondo twitter ibd_ngondo
558,REGN,major stock etfs rally close wednesday choppy session buoy health care stock volatility oil dominate much today market action crude stockpile rise more expect oil price pull back surge tuesday highest level late august opec signale reduction supply spdr oil gas exploration production xop close lower give much intraday etf offer target exposure energy company explore produce oil gas many top holding claw back loss finish higher stock market chesapeake energy chk rise conocophillip cop chevron cvx investor grapple muddle price action ahead alcoa aa report close thursday unofficially usher earning season stock be trading week high set november ishare nasdaq biotechnology ibb gain top holding celgene celg regeneron regn ibd stock be biggest advancer ishare north american tech software igv end essentially flat top half day range top hold adobe system adbe take tumble profit outlook disappoint analyst stronger dollar be see part weigh photoshop maker transition web base subscription model technology select sector spdr xlk gain top holding apple aapl facebook fb google parent alphabet googl sustain damage microsoft msft notch gain largest gold etf lose fraction here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs vanguard ftse emerge market vwo rs ishare russell iwm rs ishare core mid cap ijh rs ishare msci eafe efa rs spdr spy rs spdr dow jone industrial average dium rs powershare qqq qqq rs powershare db bullish uup rs ishare core aggregate bond agg rs spdr gold share gld rs follow aparna narayanan twitter ibd_anarayanan
559,REGN,solid open stock fade hour wednesday session afternoon rally close high be welcome development bull camp early rise nasdaq fade loss morning trade buyer lift tech heavy index gain close
560,REGN,stock seesaw be little change monday quiet trading news blockbuster deal tech sector nasdaq be fractionally lower slip dow jone industrial average tick fraction
561,REGN,volume be run sharply lower board stock market today columbus day holiday compare same time friday nasdaq trade be run lower nyse turnover be tracking lower
562,REGN,netease com nte regeneron pharmaceutical regn pace gain ibd rise former be build right side new base accumulation have sharply improve stock late august regeneron early jump put right resistance day move average
563,REGN,downside palo alto network panw fall more erase friday work stock be cup handle base buy point have waver day line recent session last month cybersecurity firm post pop fiscal earning mark second straight triple digit gain digit increase be expect current quarter
564,REGN,follow vincent mao twitter ibd_vmao stock seesaw be little change monday quiet trading news blockbuster deal tech sector nasdaq be fractionally lower slip dow jone industrial average tick fraction volume be run sharply lower board stock market today columbus day holiday compare same time friday nasdaq trade be run lower nyse turnover be tracking lower netease com nte regeneron pharmaceutical regn pace gain ibd rise former be build right side new base accumulation have sharply improve stock late august regeneron early jump put right resistance day move average downside palo alto network panw fall more erase friday work stock be cup handle base buy point have waver day line recent session last month cybersecurity firm post pop fiscal earning mark second straight triple digit gain digit increase be expect current quarter follow vincent mao twitter ibd_vmao
565,REGN,regeneron pharmaceutical regn pop stock market today share be hit resistance key level biotech now face less competition cholesterol drug eli lilly lly be discontinue development heart disease treatment rbc capital market note be big benefit regeneron larger peer amgen amgn regeneron gap
566,REGN,flash pan be exciting great stock tend have great track record earning sale today screen day be top fundamental be company year ep sale growth rate least ll look tech stock stellar fundamental apple aapl supplier technology avgo facebook ticker
567,REGN,stock kick week solid ground score big gain busy day merger news small cap outperformed nasdaq hit year high russell small cap index jump nasdaq add rise dow picked volume fall friday level breadth be solid
568,REGN,big pharma eli lilly say monday stopping development cholesterol drug evacetrapib review phase trial datum show wasn have much effect eli lilly lly have be conduct giant study cardiovascular effect evacetrapib isn due completion next year independent datum monitoring committee however review
569,REGN,columbus day holiday result quiet low volume session stock market monday dow jone industrial average add nasdaq be mostly unchanged
570,REGN,investor have more fedspeak digest atlanta fed president dennis lockhart say improve job market warrant rate hike end year
571,REGN,advance stock have slight edge decliner exchange new york mercantile exchange crude oil future slump
572,REGN,stock market today emc emc add more company agree merger privately hold dell
573,REGN,elsewhere skywest skyw clear base base pattern soar ibd airline group be day top performer rise utility tobacco stock also outperformed
574,REGN,ibd universal insurance uve rise additional now wear crown first gainer follow day oct stock have be tear clear cup handle buy point
575,REGN,biotech space ibd name regeneron regn jump try clear resistance day move average sharp pullback regeneron strength be help news eli lilly lly be end late stage development experimental cholesterol drug last week share regeneron rise help news pharmacy benefit manager express script esrx be cover pcsk inhibitor cholesterol drug alirocumbab praluent
576,REGN,ipo news pure storage pstg soar inauspicious debut last week company make flash chip base storage product enterprise customer columbus day holiday result quiet low volume session stock market monday dow jone industrial average add nasdaq be mostly unchanged investor have more fedspeak digest atlanta fed president dennis lockhart say improve job market warrant rate hike end year advance stock have slight edge decliner exchange new york mercantile exchange crude oil future slump stock market today emc emc add more company agree merger privately hold dell elsewhere skywest skyw clear base base pattern soar ibd airline group be day top performer rise utility tobacco stock also outperformed ibd universal insurance uve rise additional now wear crown first gainer follow day oct stock have be tear clear cup handle buy point biotech space ibd name regeneron regn jump try clear resistance day move average sharp pullback regeneron strength be help news eli lilly lly be end late stage development experimental cholesterol drug last week share regeneron rise help news pharmacy benefit manager express script esrx be cover pcsk inhibitor cholesterol drug alirocumbab praluent ipo news pure storage pstg soar inauspicious debut last week company make flash chip base storage product enterprise customer
577,REGN,biotechs drugmaker stock be lead today loss regeneron pharmaceutical regn be show particular weakness announce european commission marketing approval cholesterol drug praluent biotech share be crumble stock be afternoon trade volume be heavy move be substantial blow share be now trading day line
578,REGN,stock weaken be narrowly mixed late tuesday dow jone industrial average be nasdaq lose turnover be run lower major exchange stock market today compare same time monday
579,REGN,major average have seesaw mixed economic datum
580,REGN,medical stock be comeback mode be slam monday biogen biib celgene celg regeneron pharmaceutical regn have gain range fraction amn healthcare service universal health service uhs impax laboratory ipxl lose
581,REGN,elsewhere chuy chuy ease be still share restaurant operator be nearly be start outperform give price target research firm telsey advisory group
582,REGN,post holding post drop lowest level aug monday stock have already tumble trigger sell rule entry week tight pattern
583,REGN,follow vincent mao twitter ibd_vmao stock weaken be narrowly mixed late tuesday dow jone industrial average be nasdaq lose turnover be run lower major exchange stock market today compare same time monday major average have seesaw mixed economic datum medical stock be comeback mode be slam monday biogen biib celgene celg regeneron pharmaceutical regn have gain range fraction amn healthcare service universal health service uhs impax laboratory ipxl lose elsewhere chuy chuy ease be still share restaurant operator be nearly be start outperform give price target research firm telsey advisory group post holding post drop lowest level aug monday stock have already tumble trigger sell rule entry week tight pattern follow vincent mao twitter ibd_vmao
584,REGN,stock market show mixed action hour left friday session buyer show fatigue late afternoon trade be give early gain more dow industrial gain nasdaq composite be trading session lows volume be run lower nyse nasdaq nike nke continue help boost buy athleisure space follow better expect fiscal first quarter result include jump future order adjust currency swing much higher analyst expect nike score huge gap price open be jan foot locker fl rise flat base entry point volume be run twice usual pace today also stock market today biotechs ethical drugmaker continue wallow friday rebound investor be apparently still feel aftershock hillary clinton proposal cap household prescription expenditure month regeneron pharmaceutical regn fall nearly average trade maker blockbuster eylea treatment macular degeneration be testing support level third time august regeneron also recently win fda approval praluent cholesterol fighter be used patient need more help lower cholesterol level even be treat statin stock sport composite rating company be expect boost full year earning year next however regeneron share have begin spend more time day move average telltale sign digest big gain past month need time build new base generate proper new buy point ibd biotech group be clearly correction mode nearly start third quarter however group still harbor year date gain nearly remain jan follow david saito chung twitter ibd_dchung
585,REGN,stock sank deeper red early afternoon trading disappointing housing consumer income datum weigh nasdaq slump dow jone industrial average trade have picked volume be run higher board stock market today vs same time friday medical stock continue bleed heavily hospital biotechs generic drug maker suffering big decline solar stock be also take hit sunpower spwr jinkosolar jks trina solar tsl more metal product distributor utility radio tv stock be few gainer artesian resource artna thinly trade water utility delaware climb year high triple normal trade stock be buy point long flat base defensive play rise be bread bakery product maker flower food flo be dime heavy volume stock track sixth straight advance new week close high be extend flat base buy point first clear mid august ibd stock cal maine food calm plunge slice day move average fast trade still work consolidation start shell egg producer report fiscal sale beat earning miss view due increase bird flu related cost other ibd stock big loss volume include amn healthcare service breach day line regeneron pharmaceutical regn pierce day line only paycom software payc hold slight gain buck downdraft follow nancy gondo twitter ibd_ngondo
586,REGN,growth stock tend be smaller capitalization quite few big cap ibd be make case bigger be better least just good median market capitalization last week ibd be squarely midcap range stock have market cap be term small cap
587,REGN,more dozen component top market cap big cap be perform just well case better minnow
588,REGN,starbucks sbux be try rise buy point fundamental reflect company still spry leg already record history best stock run ep growth accelerate past couple quarters revenue gain also have accelerate coffeehouse chain
589,REGN,measure performance breakout nike nke be better perform ibd stock share be buy point
590,REGN,athletic apparel maker earning report beat expectation spark stock latest rally
591,REGN,public storage psa be buy range oct share self storage real estate investment trust stall get lift past week
592,REGN,visa chipotle cmg netease nte edward lifescience ew cognizant technology solution ctsh ando reilly automotive orly be form basis
593,REGN,friday facebook fb edge past buy point cup handle base volume be normal however
594,REGN,most company post earning gain lower most recent quarters weaker typical number winning stock produce ahead big price move
595,REGN,yet profit gain haven stop ibd leader such reilly make big run
596,REGN,big cap be elephantine growth best one draw considerable demand mutual fund pension fund other institution
597,REGN,example regeneron pharmaceutical regn see ep slip second quarter be still nearly institutional investor own share more start year
598,REGN,week ibd climb line major index gain growth stock tend be smaller capitalization quite few big cap ibd be make case bigger be better least just good median market capitalization last week ibd be squarely midcap range stock have market cap be term small cap more dozen component top market cap big cap be perform just well case better minnow starbucks sbux be try rise buy point fundamental reflect company still spry leg already record history best stock run ep growth accelerate past couple quarters revenue gain also have accelerate coffeehouse chain measure performance breakout nike nke be better perform ibd stock share be buy point athletic apparel maker earning report beat expectation spark stock latest rally public storage psa be buy range oct share self storage real estate investment trust stall get lift past week visa chipotle cmg netease nte edward lifescience ew cognizant technology solution ctsh ando reilly automotive orly be form basis friday facebook fb edge past buy point cup handle base volume be normal however most company post earning gain lower most recent quarters weaker typical number winning stock produce ahead big price move yet profit gain haven stop ibd leader such reilly make big run big cap be elephantine growth best one draw considerable demand mutual fund pension fund other institution example regeneron pharmaceutical regn see ep slip second quarter be still nearly institutional investor own share more start year week ibd climb line major index gain
599,REGN,health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount
600,REGN,china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view
601,REGN,ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive
602,REGN,ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more
603,REGN,ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly
604,REGN,spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault
605,REGN,here look benchmark exchange trade fund tracking various asset class perform today
606,REGN,follow daily etf market action be key successful investing
607,REGN,bellwether etfs
608,REGN,ishare msci eafe efa rs
609,REGN,spdr dow jone industrial average dium rs
610,REGN,powershare db bullish uup rs
611,REGN,spdr spy rs
612,REGN,ishare core aggregate bond agg rs
613,REGN,ishare core mid cap ijh rs
614,REGN,spdr gold share gld rs
615,REGN,powershare qqq qqq rs
616,REGN,vanguard ftse emerge market vwo rs
617,REGN,ishare russell iwm rs
618,REGN,follow aparna narayanan twitter ibd_anarayanan health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs ishare msci eafe efa rs spdr dow jone industrial average dium rs powershare db bullish uup rs spdr spy rs ishare core aggregate bond agg rs ishare core mid cap ijh rs spdr gold share gld rs powershare qqq qqq rs vanguard ftse emerge market vwo rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
619,REGN,stock market be lower early wednesday afternoon number top rate stock be higher nasdaq be only fraction be dow jone industrial average shed
620,REGN,volume be tracking sharply lower decline stock lead advancer nasdaq nyse
621,REGN,energy metal transportation machinery stock be weakest
622,REGN,volkswagen vlkay bounce ceo martin winterkorn resign say volkswagen need fresh start
623,REGN,share german automaker plummet previous day revelation software vehicle circumvent air pollution regulation
624,REGN,lot pharmaceutical stock get hammer prior day be higher stock market today
625,REGN,regeneron regn valeant vrx be biotechs other drug company come fire earlier week presidential candidate hillary clinton attack call price gouge industry
626,REGN,travel leisure area couple leader be higher
627,REGN,ryanair ryaay hit new high pare gain share ireland base airline have be trend higher thank strong passenger traffic europe cause ryanair raise full year profit guidance
628,REGN,carnival ccl climb nearly double average volume cruise line operator top analyst estimate tuesday share slide weak guidance report say analyst make bullish comment profit report help share recover stock be form base
629,REGN,fleetmatic group fltx climb nearly active trading be buy point cup shape base stock relative strength line be already new high be good sign eventual stock market be lower early wednesday afternoon number top rate stock be higher nasdaq be only fraction be dow jone industrial average shed volume be tracking sharply lower decline stock lead advancer nasdaq nyse energy metal transportation machinery stock be weakest volkswagen vlkay bounce ceo martin winterkorn resign say volkswagen need fresh start share german automaker plummet previous day revelation software vehicle circumvent air pollution regulation lot pharmaceutical stock get hammer prior day be higher stock market today regeneron regn valeant vrx be biotechs other drug company come fire earlier week presidential candidate hillary clinton attack call price gouge industry travel leisure area couple leader be higher ryanair ryaay hit new high pare gain share ireland base airline have be trend higher thank strong passenger traffic europe cause ryanair raise full year profit guidance carnival ccl climb nearly double average volume cruise line operator top analyst estimate tuesday share slide weak guidance report say analyst make bullish comment profit report help share recover stock be form base fleetmatic group fltx climb nearly active trading be buy point cup shape base stock relative strength line be already new high be good sign eventual
630,REGN,biotech stock tumble monday presidential candidate hillary clinton say propose plan address high drug price tuesday
631,REGN,price gouge specialty drug market be outrageous clinton write twitter account monday morning tomorrow ll lay plan take clinton link new york time article daraprim drug price be hike more fold be acquire privately hold turing pharmaceutical
632,REGN,rbc capital market analyst michael yee write note other reason biotechs rough monday be confirmation progressive multifocal pml case associate biogen biib multiple sclerosis franchise also say biotechs have be trading inversely crude price jump monday
633,REGN,biotechs lead drug sell
634,REGN,ishare nasdaq biotech etf ibb fall monday biogen stock skid gilead science gild start day slightly report good drug trial news lose
635,REGN,regeneron regn fall amgen amgn regeneron partner sanofi sny amgen recently win separate approval new class cholesterol fighter
636,REGN,leader other drug group also fall allergan agn sank valeant pharmaceutical vrx drug pricing policy have draw criticism retreat
637,REGN,politician have be criticize drug cost year price have keep go especially specialty drug segment drug prescribe specialist instead primary care doctor gilead sovaldi be target such criticism march company price week round
638,REGN,have written extensively specialty drug segment account prescription dollar spend vs year leonard yaffe manage health care hedge fund kessel capital management write email give dramatic rise spending drug average annually past decade annual cost often excess year represent easy target criticism
639,REGN,clinton impact see limit
640,REGN,ultimately political furor sovaldi didn lead actual legislation wasn government drive sovaldi price competition abbvie abbv unveil rival regimen december company get rebate war
641,REGN,so clinton really make difference terry haine evercore isi policy analyst former washington lobbyist find unlikely
642,REGN,even democratic president be assume congress almost certainly not approve drug pricing regulation legislation haine write note client
643,REGN,still wasn drug stock need struggle recover ibd medical biotech group dive july high aug low broader macroeconomic valuation concern analyst yee write continue current environment
644,REGN,investor prepare drug pricing volatility noise go have say drug pricing noise turn due election year write biotech stock tumble monday presidential candidate hillary clinton say propose plan address high drug price tuesday price gouge specialty drug market be outrageous clinton write twitter account monday morning tomorrow ll lay plan take clinton link new york time article daraprim drug price be hike more fold be acquire privately hold turing pharmaceutical rbc capital market analyst michael yee write note other reason biotechs rough monday be confirmation progressive multifocal pml case associate biogen biib multiple sclerosis franchise also say biotechs have be trading inversely crude price jump monday biotechs lead drug sell ishare nasdaq biotech etf ibb fall monday biogen stock skid gilead science gild start day slightly report good drug trial news lose regeneron regn fall amgen amgn regeneron partner sanofi sny amgen recently win separate approval new class cholesterol fighter leader other drug group also fall allergan agn sank valeant pharmaceutical vrx drug pricing policy have draw criticism retreat politician have be criticize drug cost year price have keep go especially specialty drug segment drug prescribe specialist instead primary care doctor gilead sovaldi be target such criticism march company price week round have written extensively specialty drug segment account prescription dollar spend vs year leonard yaffe manage health care hedge fund kessel capital management write email give dramatic rise spending drug average annually past decade annual cost often excess year represent easy target criticism clinton impact see political furor sovaldi didn lead actual legislation wasn government drive sovaldi price competition abbvie abbv unveil rival regimen december company get rebate war so clinton really make difference terry haine evercore isi policy analyst former washington lobbyist find unlikely even democratic president be assume congress almost certainly not approve drug pricing regulation legislation haine write note client still wasn drug stock need struggle recover ibd medical biotech group dive july high aug low broader macroeconomic valuation concern analyst yee write continue current environment investor prepare drug pricing volatility noise go have say drug pricing noise turn due election year write
645,REGN,major index etfs shave loss late trade thursday close lower session high global growth concern weigh investor demand gold safe haven asset send exchange trade fund hold physical bullion week high spdr dow jone industrial average dium lose stock market today climb hour
646,REGN,valeant pharmaceutical vrx be specialty drug maker biotech stock get clobber week hillary clinton send tweet accuse big pharma price gouge reaction democratic front runner comment valeant fall monday misery find plenty company biogen biib gilead science gild regeneron pharmaceutical regn amgen amgn
647,REGN,stock have come session lows be still mixed late monday nasdaq cut deficit tech laden index be much intraday edge dow jone industrial average outperformed gain volume be run mixed stock market today compare same time friday nyse trade be tracking sharply lower nasdaq volume be run pinch higher volume surge friday due quadruple witching biotechs other medical issue be session lows still hard follow tweet hillary clinton valeant pharmaceutical vrx turn gain loss reversal send back day line lannett lci drop breach day line stock appear be try support day move average elsewhere regeneron pharmaceutical regn illumina ilmn allergan agn shed allergan be featured monday sector leader review upside cyberark software cybr be session high still nearly be upgrade buy hold deutsche bank stock be stabilize tumble june record high red hat rht rise little more poke day line software maker report earning close analyst poll thomson reuter see profit rise cent share follow vincent mao twitter ibd_vmao
648,REGN,fda approve amgen amgn cholesterol drug repatha late thursday give similar label recently approve rival regeneron regn sanofi sny slightly lower price agency say have clear repatha new pcsk inhibitor class drug patient heterozygous familial hefh homozygous familial hofh patient heart disease need more cholesterol bust power standard treatment statin be essentially same label give regeneron sanofi praluent be approve last month praluent be not approve hofh company do not seek approval group have hope broader label include patient don yet have heart disease primary prevention praluent be approve wall street generally expect similar label believe fda adopt class labele repatha make primary prevention claim unlikely nomura analyst ian somaiya write july research note however believe label include secondary prevention statin intolerant patient be sufficiently broad support current peak sale estimate estimate pcsk class capture share patient segment fda press release didn specifically mention statin intolerance much dispute condition regeneron sanofi have be hope include praluent label esperion therapeutic espr have also be target group cholesterol lower drug candidate different class lead much stock volatility pcsk drama have unfold amgen press release say drug cost year bit praluent year praluent repatha be basically similar arrival new drug have be widely expect apply pricing pressure wasn clear much pharmacy benefit manager express script esrx have signale intention spark price war keep cost amgen price only modestly undercut real world pricing often involve great deal rebate consensus call repatha bring revenue third quarter accord rbc capital market amgen rise fraction hour trading thursday climb regular trade close regeneron be flat hour trade close fraction esperion dip regular trade bounce hour connect amy reeve ibd_areeve facebook
649,REGN,small drug developer esperion therapeutic espr close seesaw heavy stock trading tuesday analyst give mixed reception company update late monday cholesterol drug candidate esperion say monday end phase meeting fda candidate etc last week agency say not require cardiovascular outcome datum
650,REGN,netflix nflx price target be boost monday twitter twtr google googl be give buy rating
651,REGN,netflix stream movie tv service have price target raise stifel have buy rating stock topeka capital market raise netflix price target
652,REGN,share netflix rise high reversed close stock market today stock hit record last week
653,REGN,netflix have be expand original content include popular show orange be new black house card unbreakable kimmy schmidt have expand coverage overseas be look enter china next year
654,REGN,last week quarterly report traditional medium giant walt disney viacom viab st century fox foxa also add sign more viewer be cut cord ditch cable package favor stream service netflix
655,REGN,twitter be upgrade buy monness crespi hardt social medium site announce partnership nfl early monday league post time much content include video highlight twitter vs last year part year contract meanwhile interim ceo jack dorsey make first twitter stock buy network ipo
656,REGN,twitter share close hit time record low friday
657,REGN,search giant google be initiate outperform rating price target robert baird
658,REGN,google rise high end day
659,REGN,cvs health cvs price target be raise argus have buy rating pharmacy last week cvs report earning beat estimate revenue miss offer weak guidance current quarter
660,REGN,share close cvs hit record july
661,REGN,regeneron regn price target be raise roth capital last week biotech post better expect earning send regeneron stock record intraday
662,REGN,regeneron share close
663,REGN,cvs win cover praulent new cholesterol fighter regeneron sanofi sny rival drug be approve drug store pharmacy benefit manager tell reuter
664,REGN,piper jaffray initiate coverage ollie bargain outlet olli neutral rating price target
665,REGN,be neutral share due current valuation be very positive company long term growth prospect write analyst peter ollie focus brand close out allow healthy niche discount retail support company view grow store
666,REGN,recent ipo make stock market debut late july price
667,REGN,jeffery group initiate coverage stock buy rating rbc capital market give outperform rating price target credit suisse bank america start ollie bargain outlet neutral jpmorgan give ollie overweight rating
668,REGN,share close
669,REGN,follow gillian rich twitter ibd_grich netflix nflx price target be boost monday twitter twtr google googl be give buy rating netflix stream movie tv service have price target raise stifel have buy rating stock topeka capital market raise netflix price target share netflix rise high reversed close stock market today stock hit record last week netflix have be expand original content include popular show orange be new black house card unbreakable kimmy schmidt have expand coverage overseas be look enter china next year last week quarterly report traditional medium giant walt disney viacom viab st century fox foxa also add sign more viewer be cut cord ditch cable package favor stream service netflix twitter be upgrade buy monness crespi hardt social medium site announce partnership nfl early monday league post time much content include video highlight twitter vs last year part year contract meanwhile interim ceo jack dorsey make first twitter stock buy network ipo twitter share close hit time record low friday search giant google be initiate outperform rating price target robert baird google rise high end day cvs health cvs price target be raise argus have buy rating pharmacy last week cvs report earning beat estimate revenue miss offer weak guidance current quarter share close cvs hit record july regeneron regn price target be raise roth capital last week biotech post better expect earning send regeneron stock record intraday regeneron share close cvs win cover praulent new cholesterol fighter regeneron sanofi sny rival drug be approve drug store pharmacy benefit manager tell reuter piper jaffray initiate coverage ollie bargain outlet olli neutral rating price target be neutral share due current valuation be very positive company long term growth prospect write analyst peter ollie focus brand close out allow healthy niche discount retail support company view grow store recent ipo make stock market debut late july price jeffery group initiate coverage stock buy rating rbc capital market give outperform rating price target credit suisse bank america start ollie bargain outlet neutral jpmorgan give ollie overweight rating share close follow gillian rich twitter ibd_grich
670,REGN,apple aapl walt disney be downgrade wednesday first solar fslr have price target cut report earning bank america downgrade apple neutral buy trim price target analyst wamsi see term pressure sale iphone slow add be time
671,REGN,whew week fall much nasdaq notch weekly gain upside reversal see nasdaq have look capitulation be often see market bottom market remain correction proven otherwise drop much ibd add
672,REGN,share top rate medical firm regeneron pharmaceutical abiom hit new high stock market early tuesday company beat quarterly earning estimate raise guidance regeneron regn report earning share exclude time item year earlier cent analyst consensus accord thomson reuter revenue jump
673,REGN,stock remain lower early afternoon trading tuesday analyst warning new apple iphone hurt share company supplier nasdaq be dow jone industrial average be volume be tracking lower nyse higher nasdaq decline stock have small edge advancer nyse loser lead nasdaq solar energy automaker staffing dairy product company be poorest performer stock market today tesla tsla skid more sink deeper day day move average metal retail utility real estate investment trust industry group be best tuesday supplier apple aapl iphone be lower credit suisse warn company be cut back component order iphone model apple share gap loss average volume cirrus logic crus slide busy trading fall day move average skywork solution swks gap day move average shed heavy trading side ruth hospitality ruth better know ruth chris steak house clear buy point double bottom base active trading company beat earning expectation couple week ep jump restaurant industry group have be trend lower ibd group ranking
674,REGN,stock future be pace weak start tuesday rebound oil price
675,REGN,nasdaq future drop point vs fair value future lose point future dow jone industrial average slump point
676,REGN,major average stumble monday brent crude tumble west texas intermediate lose stock end well session lows thank late rally
677,REGN,wti brent be more tuesday morning barrel barrel respectively
678,REGN,overseas stock market be mixed
679,REGN,shanghai composite bolt chinese official take further measure curb short selling hong kong hang seng ease fraction
680,REGN,european index be lower greece index fall additional plunge monday france cac fall germany dax lose
681,REGN,stock news regeneron pharmaceutical regn rally premarket trade post better expect earning company report profit share sale view be share revenue regeneron also raise growth forecast key eylea drug stock clear buy point late stage flat base last month
682,REGN,community health cyh rally premarket late monday quarterly result spinoff plan stock be flat base buy point
683,REGN,aetna aet rise premarket trading post mixed result health insurer post adjust earning share easily beating view sale rise vs view
684,REGN,datum june factory order be et
685,REGN,view be increase drop
686,REGN,activision blizzard atvi boot barn boot cerner cern chuy chuy epam system epam etsy etsy first solar fslr walt disney be notable company report earning close stock market today stock future be pace weak start tuesday rebound oil price nasdaq future drop point vs fair value future lose point future dow jone industrial average slump point major average stumble monday brent crude tumble west texas intermediate lose stock end well session lows thank late rally wti brent be more tuesday morning barrel barrel respectively overseas stock market be mixed shanghai composite bolt chinese official take further measure curb short selling hong kong hang seng ease fraction european index be lower greece index fall additional plunge monday france cac fall germany dax lose stock news regeneron pharmaceutical regn rally premarket trade post better expect earning company report profit share sale view be share revenue regeneron also raise growth forecast key eylea drug stock clear buy point late stage flat base last month community health cyh rally premarket late monday quarterly result spinoff plan stock be flat base buy point aetna aet rise premarket trading post mixed result health insurer post adjust earning share easily beating view sale rise vs view datum june factory order be et view be increase drop activision blizzard atvi boot barn boot cerner cern chuy chuy epam system epam etsy etsy first solar fslr walt disney be notable company report earning close stock market today
687,REGN,dow jone industrial average notch fresh time high tuesday cheer robust upward revision gross domestic product
688,REGN,dow be driver seat early afternoon trading nasdaq have hard time keep due sell biotech stock
689,REGN,dow add buoy dupont dd boee ba rise nasdaq ease volume nyse nasdaq be tracking just monday level same time
690,REGN,economic news final revision gross domestic product come much better expect heel growth
691,REGN,stock market today biotechs sell again ibd biotech group fall more follow loss monday regeneron regn celgene celg slice day line fall respectively sharp decline be sign institutional investor be ready rotate group be lead market month
692,REGN,day worst perform group ibd database hailed medical sector
693,REGN,ibd epam system epam continue firm day move average rise
694,REGN,group peer cdw cdw also do well rise nearly recent cup handle continue work well dow jone industrial average notch fresh time high tuesday cheer robust upward revision gross domestic product dow be driver seat early afternoon trading nasdaq have hard time keep due sell biotech stock dow add buoy dupont dd boee ba rise nasdaq ease volume nyse nasdaq be tracking just monday level same time economic news final revision gross domestic product come much better expect heel growth stock market today biotechs sell again ibd biotech group fall more follow loss monday regeneron regn celgene celg slice day line fall respectively sharp decline be sign institutional investor be ready rotate group be lead market month day worst perform group ibd database hailed medical sector ibd epam system epam continue firm day move average rise group peer cdw cdw also do well rise nearly recent cup handle continue work well
695,REGN,stock have rough go monday reverse early gain crude oil continue descent
696,REGN,little hour remain session nasdaq be rise early still hold day move average not much give day line fall dow jone industrial average also lose
697,REGN,nyse nasdaq volume be tracking slightly higher friday level more so nasdaq
698,REGN,wti crude oil lose nearly barrel lower oil price be good consumer not so good macro level fear be grow financial crisis be brewing big oil exporter russia venezuela
699,REGN,economic datum be mixed ahead tuesday day fed meeting industrial production surge november be offset news factory activity new york region contract december new york fed empire state manufacturing index register december read well consensus estimate
700,REGN,stock market today gold miner coal producer biotechs homebuilding stock lag
701,REGN,growth stock have rough session several name ibd slump more tech service group epam system epam cdw cdw lose respectively
702,REGN,biotech space regeneron regn slump selling pressure have be muted stock today look poise visit day move average
703,REGN,bitauto bita be top performer ibd rise technical health remain question trigger sell signal still day move average
704,REGN,elsewhere restoration hardware rh rise recover friday reversal home furnishing retailer report strong earning last week stock have rough go monday reverse early gain crude oil continue descent little hour remain session nasdaq be rise early still hold day move average not much give day line fall dow jone industrial average also lose nyse nasdaq volume be tracking slightly higher friday level more so nasdaq wti crude oil lose nearly barrel lower oil price be good consumer not so good macro level fear be grow financial crisis be brewing big oil exporter russia venezuela economic datum be mixed ahead tuesday day fed meeting industrial production surge november be offset news factory activity new york region contract december new york fed empire state manufacturing index register december read well consensus estimate stock market today gold miner coal producer biotechs homebuilding stock lag growth stock have rough session several name ibd slump more tech service group epam system epam cdw cdw lose respectively biotech space regeneron regn slump selling pressure have be muted stock today look poise visit day move average bitauto bita be top performer ibd rise technical health remain question trigger sell signal still day move average elsewhere restoration hardware rh rise recover friday reversal home furnishing retailer report strong earning last week
705,REGN,stock build early gain go last hour trading friday little way corporate announcement economic datum many trader take day volume be dull nasdaq rise gain dow jone industrial average climb stock market today industry group gold precious metal automaker be top performer gold rise oil driller be worst performer west texas intermediate oil drop tesla motor tsla rise ceo elon musk say christmas day tweet new roadster production vehicle have battery range mile twice car range today select airline have strong day ryanair ryaay rise solid volume be high break base early november virgin america va break ipo base wednesday follow friday nearly lead biotech stock pummeled earlier week rally friday several be find support day line include celgene celg amgen amgn regeneron regn cal maine food calm fall still feel effect tuesday report revenue come wall street forecast gopro gpro rise fourth straight advance day lock period insider be prohibit selling share expire earlier week
706,REGN,stock be session lows early afternoon trading oil price fall hard again
707,REGN,nasdaq lose fall dow jone industrial average give also
708,REGN,nasdaq nyse volume be tracking slightly higher friday level crude oil sell again fall barrel
709,REGN,stock market today dow component mcdonald mcd fall nearly soft november global same store sale burger giant sale fall more expect domestic sale slump
710,REGN,ibd biotech industry group be once again day top performer rise nearly top rate name group celgene celg regeneron regn gilead science gild unite therapeutic uthr be do well
711,REGN,meanwhile cubist pharmaceutical cbst soar news be acquire merck mrk
712,REGN,gopro gpro slump be clear news account downdraft stock have be act weak not abnormal action big run past ipo base buy point ambarella amba chip be find gopro wearable camera also give heel strong earning report last week
713,REGN,meanwhile couple high profile ipos be set week lendingclub alibaba backed momo debut thursday symbol lc momo respectively stock be session lows early afternoon trading oil price fall hard again nasdaq lose fall dow jone industrial average give also nasdaq nyse volume be tracking slightly higher friday level crude oil sell again fall barrel stock market today dow component mcdonald mcd fall nearly soft november global same store sale burger giant sale fall more expect domestic sale slump ibd biotech industry group be once again day top performer rise nearly top rate name group celgene celg regeneron regn gilead science gild unite therapeutic uthr be do well meanwhile cubist pharmaceutical cbst soar news be acquire merck mrk gopro gpro slump be clear news account downdraft stock have be act weak not abnormal action big run past ipo base buy point ambarella amba chip be find gopro wearable camera also give heel strong earning report last week meanwhile couple high profile ipos be set week lendingclub alibaba backed momo debut thursday symbol lc momo respectively
714,REGN,etfs tracking major benchmark extend gain second straight day investor cheer china stock surge first time several session gdp datum show strength economy relief rally midday see exchange trade fund follow major index recover damage recent day
715,REGN,wall street escape summer vacation maker drug medical device be greeting august frantic week earning report here be lead stock report week tuesday morning big biotech regeneron pharmaceutical regn be expect report earning share year earlier quarter accord analyst
716,REGN,big pharmas pfizer pfe merck mrk beat estimate raise guidance tuesday merck french counterpart sanofi sny enter separate deal develop immunotherapy drug cancer pfizer earning dip cent share top analyst consensus cent accord thomson reuter sale decline more
717,REGN,stock go wild ride past week swath earning report big name roller coaster result isn slow just yet
718,REGN,top rate ibd stock be gear issue quarterly performance allergan agn regeneron pharmaceutical regn jazz pharmaceutical jazz monster beverage mnst gray television gtn paycom software payc criteo crto epam system epam amc network amcx papa john pzza
719,REGN,here look analyst expect
720,REGN,more drug stock tap
721,REGN,regeneron pharmaceutical report open tuesday analyst project earning rise slowdown first quarter gain sale be estimate climb mark third quarter growth acceleration
722,REGN,biotech development partner sanofi sny announce tuesday re collaborate new pd inhibitor sanofi give biotech upfront milestone payment sale cancer drug pass july drugmaker win fda approval praluent first new class pcsk cholesterol fighter clear sale
723,REGN,regeneron have highest possible ibd composite rating share be still trading buy range flat base buy point initially clear july stock be year
724,REGN,ethical drug maker jazz pharmaceutical also have composite rating report close wednesday earning be expect rise bottom line gain revenue be see rise slowest gain least
725,REGN,jazz break flat base buy point wednesday be still trading buy zone
726,REGN,allergan earning be project jump report open thursday revenue be expect surge
727,REGN,last monday generic drug maker announce be selling actavis unit teva pharmaceutical teva
728,REGN,allergan have composite rating too stock be nearly
729,REGN,scary good result monster
730,REGN,energy drink maker monster beverage report close thursday ep see rise slight slowdown growth see sale be expect increase also slower gain
731,REGN,monster be trading new high have gain more year stock have composite rating
732,REGN,more
733,REGN,gray television have composite rating report wednesday afternoon owner local broadcast station be expect grow earning revenue rise
734,REGN,gray have composite rating share have increase more
735,REGN,criteo deliver earning open tuesday paycom software epam system papa john report close tuesday amc network issue result thursday morning
736,REGN,follow alissa william twitter ibd_awilliam stock go wild ride past week swath earning report big name roller coaster result isn slow just yet top rate ibd stock be gear issue quarterly performance allergan agn regeneron pharmaceutical regn jazz pharmaceutical jazz monster beverage mnst gray television gtn paycom software payc criteo crto epam system epam amc network amcx papa john pzza here look analyst expect more drug stock tapregeneron pharmaceutical report open tuesday analyst project earning rise slowdown first quarter gain sale be estimate climb mark third quarter growth acceleration biotech development partner sanofi sny announce tuesday re collaborate new pd inhibitor sanofi give biotech upfront milestone payment sale cancer drug pass july drugmaker win fda approval praluent first new class pcsk cholesterol fighter clear sale regeneron have highest possible ibd composite rating share be still trading buy range flat base buy point initially clear july stock be year ethical drug maker jazz pharmaceutical also have composite rating report close wednesday earning be expect rise bottom line gain revenue be see rise slowest gain least jazz break flat base buy point wednesday be still trading buy zone allergan earning be project jump report open thursday revenue be expect surge last monday generic drug maker announce be selling actavis unit teva pharmaceutical teva allergan have composite rating too stock be nearly scary good result monster energy drink maker monster beverage report close thursday ep see rise slight slowdown growth see sale be expect increase also slower gain monster be trading new high have gain more year stock have composite rating moregray television have composite rating report wednesday afternoon owner local broadcast station be expect grow earning revenue rise gray have composite rating share have increase more criteo deliver earning open tuesday paycom software epam system papa john report close tuesday amc network issue result thursday morning follow alissa william twitter ibd_awilliam
737,REGN,merck mrk cholesterol drug vytorin ezetimibe simvastatin combo successfully cut risk heart attack stroke high risk patient more simvastatin alone say drugmaker nearly decade long patient study improve patient take ldl cholesterol lower medicine vytorin combine simvastatin nonstatin zetia ezetimibe experience significantly fewer major cardiovascular event measure
738,REGN,french big pharma sanofi layer year plan drug launch say bring cumulative euro first year sale sanofi stock slip early trading stock market today diabetes outlook be soft
739,REGN,sanofi sny issue update press release ahead ir thematic seminar new medicine seek reassure investor fire ceo follow weak quarterly report last month
740,REGN,firm prepared presentation new drug include alirocumab cholesterol fighter co develop regeneron pharmaceutical regn now go brand name praluent recently approve multiple sclerosis pill lemtrada toujeo currently fda eu review update version bestselling sanofi diabetes drug lantus
741,REGN,related note thursday fda also grant breakthrough therapy designation dupilumab drug develop same regeneron partnership alirocumab treatment atopic dermatitis
742,REGN,leerink analyst seamus fernandez write note early thursday pipeline valuation be nearly twice own estimate still concern diabetes franchise be main issue sanofi report
743,REGN,headline grab estimate product launch guidance sny global diabetes business be flat slightly grow constant exchange rate assume substantial conversion patient lantus toujeo europe be assume diabetes sale growth same period write
744,REGN,fernandez add wasn sell widespread toujeo conversion especially light more competitive landscape similar product come online nordisk nvo eli lilly lly
745,REGN,positive side write approval praluent be virtually assured merck mrk recent long term study prove lower ldl cholesterol really do lower death rate heart disease
746,REGN,follow amy reeve twitter ibd_areeve french big pharma sanofi layer year plan drug launch say bring cumulative euro first year sale sanofi stock slip early trading stock market today diabetes outlook be soft sanofi sny issue update press release ahead ir thematic seminar new medicine seek reassure investor fire ceo follow weak quarterly report last month firm prepared presentation new drug include alirocumab cholesterol fighter co develop regeneron pharmaceutical regn now go brand name praluent recently approve multiple sclerosis pill lemtrada toujeo currently fda eu review update version bestselling sanofi diabetes drug lantus related note thursday fda also grant breakthrough therapy designation dupilumab drug develop same regeneron partnership alirocumab treatment atopic dermatitis leerink analyst seamus fernandez write note early thursday pipeline valuation be nearly twice own estimate still concern diabetes franchise be main issue sanofi report headline grab estimate product launch guidance sny global diabetes business be flat slightly grow constant exchange rate assume substantial conversion patient lantus toujeo europe be assume diabetes sale growth same period write fernandez add wasn sell widespread toujeo conversion especially light more competitive landscape similar product come online nordisk nvo eli lilly lly positive side write approval praluent be virtually assured merck mrk recent long term study prove lower ldl cholesterol really do lower death rate heart disease follow amy reeve twitter ibd_areeve
747,REGN,market confirm uptrend stock index approach new high focuse company best fundamental such regeneron pharmaceutical be ticket winner be likely outperform market today screen day be top fundamental feature highly rate company year sale earning growth rate least usually far more today list include technology biotech stock regeneron regn develop eye disease treatment include blockbuster eylea biopharma wednesday say partner sanofi sfy have see encourage result midstage trial drug dupilumab treat adult asthma affect estimate regeneron earning share grow average quarterly rate past year revenue grow quarter regeneron stock rise wednesday be time high tableau software datum sell cloud base visual datum analytic software help business track revenue earning other datum tableau be prepare new product plan expand globally get piece market tracker idc say be business analytic software market tableau quarterly ep growth averaged last year revenue grow quarter rate share be less wednesday linkedin lnkd link professional company build strong web presence great recession pursue new business opportunity china country business community expand linkedin get upgrade rbc capital market canaccord genuity other report strong earning oct ease concern growth be slow contrast facebook fb twitter twtr sell concern future growth linkedin stock be ibd leaderboard list top rate stock rise fractionally palo alto network panw provide network security software other product company revenue earning have climb rapidly spate high profile cyberattack target tgt jpmorgan chase jpm several large military contractor other santa clara calif base company be expand europe capital market say recent report raise price target palo alto network ep have climb quarterly sale last year share rise fellow cybersecurity stock cyberark software cybr late wednesday report much stronger expect earning revenue recent ipo shot late trading be record high alexion pharmaceutical alxn large biotech regeneron develop drug treat blood disease include blockbuster soliris well inflammatory ailment other disorder ceo leonard bell say alexion last earning call company have complete last phase roll fda submission approval second drug alfa treat genetic bone disease year ep average quarterly growth rate be revenue grow alexion stock boast best possible ibd composite rating be follow james detar twitter ibd_jdetar
748,REGN,big biotech amgen amgn hit new high early trading friday get several price target increase analyst strong guidance increase late thursday cowen analyst eric schmidt raise price target base not only thursday number also clinical trial datum blood cancer drug kyproli be used
749,REGN,biotechs generic drug maker ethical drug maker be highest rank industry group ibd track recent view top earning report fda approval strategic divestment re prove strength hot drug stock lead ibd screen day big cap leader gilead science gild jazz pharmaceutical jazz allergan agn regeneron pharmaceutical regn mallinckrodt ticker
750,REGN,technology semiconductor etfs be gouge tuesday asapple aapl drop alarm early afternoon trade iphone maker slice day move average monday further loss stock market today cupertino calif base company be april high
751,REGN,apple massive market cap give dominant position etf world more exchange trade fund count top hold loss week be have predictable effect
752,REGN,ishare technology iyw fall intraday tuesday hold apple get portfolio weighting etf hold facebook fb ibd leaderboard stock ease
753,REGN,powershare qqq qqq slip apple be top hold stock accounting asset hold facebook get asset
754,REGN,qqq etf get boost top hold regeneron regn
755,REGN,biotech drugmaker spiked time high midday trade score big earning revenue beat monday power strong sale eye drug eylea
756,REGN,regeneron be ibd stock
757,REGN,ishare phlx semiconductor soxx shrank etf boast clutch apple equipment supplier
758,REGN,chip stock be reel part apple tumble hold avgo give more intraday skywork solution swks shrank arm holding armh nxp nxpi qorvo qrvo sell roughly
759,REGN,most major etfs struggle choppy trade investor digest weak consumer spending manufacturing datum report factory activity monday suggest growth world largest economy be stall
760,REGN,meanwhile china lead international etfs higher country be crack short selling share speculator prevent stock market collapse
761,REGN,here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing
762,REGN,bellwether etfs
763,REGN,vanguard ftse emerge market vwo rs
764,REGN,spdr gold share gld rs
765,REGN,ishare core mid cap ijh rs
766,REGN,ishare russell iwm rs
767,REGN,ishare msci eafe efa rs
768,REGN,ishare core aggregate bond agg rs
769,REGN,powershare db bullish uup rs
770,REGN,spdr spy rs
771,REGN,spdr dow jone industrial average dium rs
772,REGN,powershare qqq qqq rs
773,REGN,follow aparna narayanan twitter ibd_anarayanan technology semiconductor etfs be gouge tuesday asapple aapl drop alarm early afternoon trade iphone maker slice day move average monday further loss stock market today cupertino calif base company be april high apple massive market cap give dominant position etf world more exchange trade fund count top hold loss week be have predictable effect ishare technology iyw fall intraday tuesday hold apple get portfolio weighting etf hold facebook fb ibd leaderboard stock ease powershare qqq qqq slip apple be top hold stock accounting asset hold facebook get asset qqq etf get boost top hold regeneron regn biotech drugmaker spiked time high midday trade score big earning revenue beat monday power strong sale eye drug eylea regeneron be ibd stock ishare phlx semiconductor soxx shrank etf boast clutch apple equipment supplier chip stock be reel part apple tumble hold avgo give more intraday skywork solution swks shrank arm holding armh nxp nxpi qorvo qrvo sell roughly most major etfs struggle choppy trade investor digest weak consumer spending manufacturing datum report factory activity monday suggest growth world largest economy be stall meanwhile china lead international etfs higher country be crack short selling share speculator prevent stock market collapse here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs ishare core aggregate bond agg rs powershare db bullish uup rs spdr spy rs spdr dow jone industrial average dium rs powershare qqq qqq rs follow aparna narayanan twitter ibd_anarayanan
774,REGN,flagship etfs nudge lower first trading day august par manufacturing spending datum well fall oil price weigh investor spdr spy exchange trade fund proxy broad market shrank early afternoon trade utility sector buck trend notch small gain energy be
775,REGN,stock market slide tuesday quickly deflate bullish sentiment prior day rally have build nasdaq skid composite lag main index good day top component google googl jump wall street applaud reorganization plan google class share together account nearly
776,REGN,top rate midsize drugmaker deliver sharply different third quarter report tuesday send stock opposite direction jazz pharmaceutical jazz report close say earning rise year earlier quarter share beating consensus view cent accord thomson reuter sale climb analyst estimate company
777,REGN,big cap biotech regeneron pharmaceutical regn miss wall street estimate cut top end guidance range best selling drug send stock early trading stock market today regeneron earning exclude time item rise year earlier quarter share miss analyst consensus cent accord thomson
778,REGN,stock open lower quickly turn mixed tuesday earning report soft oil price mixed economic datum drive bulk early trade
779,REGN,dow jone industrial average shed early loss rise nasdaq narrow open loss be
780,REGN,stock market today rolled mixed trade volume be nyse lower nasdaq
781,REGN,factory order slow september commerce department report be vast improvement august decline line economist projection slip
782,REGN,earning report put number big mover book early trade priceline group pcln slump herbalife hlf tank michael kor kor tumble
783,REGN,alibaba baba shake premarket loss rise start trade china base diversify internet giant report stronger expect surge second quarter revenue boost increase mobile revenue adjust earning rise line consensus expectation stock be almost buy point short ipo base
784,REGN,regeneron pharmaceutical regn sag lower tarrytown biotech turn earning revenue shy analyst projection gap loss left share last week high
785,REGN,ibd list amtrust financial service afsi pop start trade worker compensation property insurance leader report late monday third quarter earning soundly beat analyst consensus forecast net premium also best estimate stock be extend almost retake buy point cup base
786,REGN,other end list foot locker fl drop apparently news chief executive ken hick be retire chief operate officer richard johnson assume ceo role foot locker share so far year be work retake week move average shallow monthlong consolidation stock open lower quickly turn mixed tuesday earning report soft oil price mixed economic datum drive bulk early trade dow jone industrial average shed early loss rise nasdaq narrow open loss be stock market today rolled mixed trade volume be nyse lower nasdaq factory order slow september commerce department report be vast improvement august decline line economist projection slip earning report put number big mover book early trade priceline group pcln slump herbalife hlf tank michael kor kor tumble alibaba baba shake premarket loss rise start trade china base diversify internet giant report stronger expect surge second quarter revenue boost increase mobile revenue adjust earning rise line consensus expectation stock be almost buy point short ipo base regeneron pharmaceutical regn sag lower tarrytown biotech turn earning revenue shy analyst projection gap loss left share last week high ibd list amtrust financial service afsi pop start trade worker compensation property insurance leader report late monday third quarter earning soundly beat analyst consensus forecast net premium also best estimate stock be extend almost retake buy point cup base other end list foot locker fl drop apparently news chief executive ken hick be retire chief operate officer richard johnson assume ceo role foot locker share so far year be work retake week move average shallow monthlong consolidation
787,REGN,alibaba world largest ipo date be set report first quarterly earning public company open tuesday analyst expect chinese commerce giant earn cent share exclude item revenue alibaba baba have ibd composite rating meaning share outperform stock
788,REGN,close new high tuesday technically put market back uptrend condition remain difficult dow jone industrial average extend winning streak session nasdaq couldn keep weigh burst institutional selling biotech space dow hit milestone
789,REGN,bird fly flock fish swim school wolf hunt pack stock move industry group hard believe research show lead stock price movement be directly tie performance industry group ibd chairman william neil write make money stock
790,REGN,ibd research also show winning stock price move be owing industry sector mean nearly winning stock rally strength borrow stock industry economic sector
791,REGN,industry also move economic trend such housing retail gain drive recover consumer spending also be significant structural shift technical advance industry be shale gas oil development advanced safety technology new automobile follow industry trend read daily industry theme column ibd investor com
792,REGN,biotech ethical drug industry have produce welter lead stock past year smaller biomedical firm see influx investment big pharma industry see historic lapse patent protection age blockbuster drug larger firm find need bulk compete many seize overseas acquisition shift headquarters overseas order sidestep tax burden
793,REGN,regeneron pharmaceutical regn break month cup base april stock already have be climb year tarrytown base regeneron only manage pull earning growth together
794,REGN,prior basis be volatile produce numerous pullback yet april composite rs rating be best possible
795,REGN,medical sector rank economic sector track ibd list daily ibd smart nyse nasdaq table be position january
796,REGN,group sector medical biom biotech rank medical group top ibd daily top group list page paper show group have climb group ranking january post year date gain
797,REGN,investor buy have logged gain monday bird fly flock fish swim school wolf hunt pack stock move industry group hard believe research show lead stock price movement be directly tie performance industry group ibd chairman william neil write make money stock ibd research also show winning stock price move be owing industry sector mean nearly winning stock rally strength borrow stock industry economic sector industry also move economic trend such housing retail gain drive recover consumer spending also be significant structural shift technical advance industry be shale gas oil development advanced safety technology new automobile follow industry trend read daily industry theme column ibd investor com biotech ethical drug industry have produce welter lead stock past year smaller biomedical firm see influx investment big pharma industry see historic lapse patent protection age blockbuster drug larger firm find need bulk compete many seize overseas acquisition shift headquarters overseas order sidestep tax burden regeneron pharmaceutical regn break month cup base april stock already have be climb year tarrytown base regeneron only manage pull earning growth together prior basis be volatile produce numerous pullback yet april composite rs rating be best possible medical sector rank economic sector track ibd list daily ibd smart nyse nasdaq table be position january group sector medical biom biotech rank medical group top ibd daily top group list page paper show group have climb group ranking january post year date gain investor buy have logged gain monday
798,REGN,week list lead stock buy point include healthy dose medical name biotechs manage care provider biotech revival begin prior celgene celg jump wednesday buy receptos rcpt celgene be extend past cup handle buy point gilead science gild be still play entry find support week move average move didn create new buy opportunity occur buy point stock be buy zone also buy range be regeneron pharmaceutical regn trading just flat base buy point pattern be late stage be not surprising give eye drug maker advance past year unite therapeutic uthr hasn yet break near buy point late stage flat base ibd stock lead drug be orenitram remodulin get composite rating biotechs moved ibd industry group week hospital claim top spot vs week back represent rank generic drug group allergan agn be just handle buy point clear monday formerly know actavis botox makerad double chin injection kybella june buy kythera mallinckrodt mnk also generic drug maker be work month consolidation buy point stock look poise third straight weekly gain close week line other medical stock ethical drug maker valeant pharmaceutical vrx be build flat base entry canadian company be leader rank group highest possible composite rating molina healthcare moh provider manage health care service low income family be near flat base buy point stock sharing composite manage care group
799,REGN,stock split share especially manner more often mark top regular reader column know too many large stock split offer alert investor timely sell signal
800,REGN,market also offer subtle change nowadays be fewer split
801,REGN,company manager think nothing let stock run share even small subset lead stock encounter extreme share split
802,REGN,sharp increase share outstanding have long term consequence stock fundamental technical be very strong not be negative effect term
803,REGN,here dramatic statistic ibd later become ibd be unveil april not single issue trade century mark highest price stock be ebay ebay trade
804,REGN,fast forward ibd publish july name be price regeneron pharmaceutical regn be just north
805,REGN,original trade teen only most recent ibd stock trade
806,REGN,amazon com amzn late be typical usually happen stock split time bull market second split january stock shot week price december high not surpass year
807,REGN,also dot com boom qualcomm qcom split last week nov stock split news ultimate high first trading day stock rocket top precisely
808,REGN,more recent example be baidu bidu be trading split stock rise week then build month base baidu break again advanced more year top chinese search engine then correct year breaking again september
809,REGN,apple aapl split june seem have little effect stock marched higher month split seem tailor make apple fit comfortably dow jone industrial average
810,REGN,now come netflix nflx announce split effective july shareholder record july june announcement have little impact stock be interesting see happen
811,REGN,growth company have show little interest split priceline group pcln see share rise split sight intuitive surgical isrg rise nearly have never split
812,REGN,ibd founder chairman william neil write make money stock prefer see company split share rather conduct more extreme split company add often split stock extravagantly end bull market
813,REGN,say stock be likely top second third time stock split neil own study winning stock show only have split year make big move stock split share especially manner more often mark top regular reader column know too many large stock split offer alert investor timely sell signal market also offer subtle change nowadays be fewer split company manager think nothing let stock run share even small subset lead stock encounter extreme share split sharp increase share outstanding have long term consequence stock fundamental technical be very strong not be negative effect term here dramatic statistic ibd later become ibd be unveil april not single issue trade century mark highest price stock be ebay ebay trade fast forward ibd publish july name be price regeneron pharmaceutical regn be just north original trade teen only most recent ibd stock trade amazon com amzn late be typical usually happen stock split time bull market second split january stock shot week price december high not surpass year also dot com boom qualcomm qcom split last week nov stock split news ultimate high first trading day stock rocket top precisely more recent example be baidu bidu be trading split stock rise week then build month base baidu break again advanced more year top chinese search engine then correct year breaking again september apple aapl split june seem have little effect stock marched higher month split seem tailor make apple fit comfortably dow jone industrial average now come netflix nflx announce split effective july shareholder record july june announcement have little impact stock be interesting see happen growth company have show little interest split priceline group pcln see share rise split sight intuitive surgical isrg rise nearly have never split ibd founder chairman william neil write make money stock prefer see company split share rather conduct more extreme split company add often split stock extravagantly end bull market say stock be likely top second third time stock split neil own study winning stock show only have split year make big move
814,REGN,top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis
815,REGN,share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move
816,REGN,allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition
817,REGN,also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average
818,REGN,biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july
819,REGN,regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break
820,REGN,alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring
821,REGN,ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open
822,REGN,abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target
823,REGN,analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early
824,REGN,big french pharma sanofi sny fire ceo wednesday push stock sharply second day row spark slew downgrade wall street sanofi sny board issue short statement say have vote unanimously remove christopher year office chairman serge weinberg take
825,REGN,big cap biotech amgen amgn beat wall street third quarter estimate guide full year earning bit consensus monday send recently hot stock hour trading amgen earning exclude time item rise year quarter share beating analyst consensus cent accord thomson reuter sale increase ahead estimate conference call discuss result ceo robert bradway note last year include order anemia drug neupogen government inflate quarter sale back sale growth be consistent first half year sale neulasta drug stimulating white blood cell beat consensus more be last year third quarter be drive price increase more volume accord amgen story be virtually identical anemia drug epogen sale rise last year also price reason total analyst have expect rheumatoid arthritis drug enbrel miss estimate dip sale unit grow year year call cfo david meline remind analyst have see inventory build be burn mask strength demand nonetheless enbrel help drive overall profit growth be longer profit sharing agreement pfizer pfe research development spending be more lower analyst consensus sale general administrative spending be also street estimate company add full year revenue guidance now slightly street forecast last year guide full year ep previous range analyst target however imply ep be short street average last year company make share full year fourth quarter conference call meline say amgen be lift tax rate estimate percentage point due uncertainty extension federal tax credit however cowen analyst eric schmidt comment even accounting increase operate expense be imply guidance meline answer expense usually increase end year so be nothing unusual however bradway add company be prepare product launch next year also increase spending most anticipate street be evolocumab first new class cholesterol drug call pcsk analyst expect sale run forecast remain uncertain regeneron pharmaceutical regn be see launch compete product shortly thereafter management keep call short plan hold business review meeting tuesday re expect give longer term outlook company business strategy re also expect address shareholder pressure split part get extra publicity last week daniel loeb hedge fund manager third point capital loeb take idea propose sanford bernstein analyst geoffrey porge june argue make abbott laboratory pfizer splitting establish legacy drug such enbrel newer more innovative product unlock hide value chatter general recovery biotech stock have help drive amgen stock last week regular trading monday hit new high eventually close
826,REGN,few big cap leader remain buy point even market correction isn ideal time buy union pacific unp run resistance june same day edge past flat base buy point close entry next week pull back much not quite enough
827,REGN,medical stock be flex muscle latest big cap list ve more double number prior week even few medical sector make cut biotechs be well represent group earn top ranking monday issue industry group track ibd big improvement week alexion pharmaceutical alxn reversed upward edge higher follow last week gain stock be extend past entry second stage base trigger sell rule oct quickly re-cover buy point biotech thursday beat view earning year increase sale also lift full year profit sale guidance cheshire conn base company sole commercial drug soliris treat rare blood disease now submission process fda approval second drug alfa treat genetic bone disease call amgen amgn new high be extend cup handle buy point clear late july stock correct oct didn undercut entry share be hour oak calif base biotech be announce earning rise share sale increase consensus estimate amgen recently say work bill melinda gate foundation other group try find alternative method produce zmapp experimental ebola drug make mapp san diego celgene celg close slightly lower striking new high intraday monday be still extend past buy point surpass mid august alexion trigger sell rule oct quickly bounce back summit base biotech thursday report earning top view revenue line forecast celgene focus drug treat chancer immune inflammatory related disease revlimid vidaza abraxane be biggest seller regeneron pharmaceutical regn extend gain fifth straight session be now extend past flat base buy point tarrytown base biotech develop drug treat eye disease inflammatory disease cancer oct report clinical trial result eylea eye drug outperformed compete treatment patient diabetic macular edema other health care stock big cap include genetic analysis system maker illumina ilmn valeant pharmaceutical vrx maker dermatology neurology eye health drug
828,REGN,stock market often do least expect certainly have be case lately consider recent occurrence heavy distribution day count nasdaq recent week didn do much damage market fact market uptrend resume thursday nasdaq marked time close high rise higher volume show sign climax top last month ambarella amba find support week move average again rise nearly week regeneron regn be hold high series breakout late stage basis right look centene cnc be go roll massive price run back day move averageso go today market good news be action several other ibd name have be far confuse ibd rise week ahead gain gain nasdaq celgene celg gap week cup shape base wednesday rise strong volume announce plan acquire receptos rcpt just receptos key drug be multiple sclerosis ulcerative colitis treatment ozanimod not approve yet early trial have be promising celgene weekly chart look solid still buy range just buy point small cap fleetmatic fltx member wednesday list be high end buy range cup handle buy point monster beverage mnst be similar boat trade buy point meanwhile several ibd name be report earning week illumina ilmn blackhawk network hawk report tuesday close celgene valeant vrx report thursday close valeant be work late stage flat base buy point base be strengthen several tight weekly close valeant have pursue aggressive growth acquisition strategy recent year earlier year buy salix pharmaceutical scoop bausch lomb nearly profit valeant be see rise year share
829,REGN,best mutual fund july performance report ibd new buy list show country lead stock mutual fund past month have continue gobble top rate medical stock such allergan agn celgene celg regeneron pharmaceutical regn molina healthcare moh acadium healthcare achc stock market july most part help mutual fund make
830,REGN,baidu tumble mixed result take internet focuse etfs intraday trade tuesday major exchange trade fund rally early action series decline bring tepid earning season thus far ugly china sell yesterday baidu bidu stock nosedive earning miss late monday china base search engine
831,REGN,stock ease tuesday day find direction prove be elusive task nasdaq fall hold small price range volume rise board give distribution day nasdaq loss be too small be consider heavy institutional selling day result widen gap
832,REGN,rocky week trading create turmoil ibd semiconductor stock particular have be fire longtime chip leader ibd have flash sell signal make huge move market technology avgo fall more week buy point late stage base pattern previously
833,REGN,large cap stock often get labele bore overall sluggish price action latest ibd big cap list lead large cap growth be far bore
834,REGN,recent health care related name alexion pharmaceutical alxn illumina ilmn celgene celg regeneron pharmaceutical continue trade well post technology name haven disappoint
835,REGN,linkedin lnkd look solid report strong earning last week close just buy point monday
836,REGN,quarterly profit rise year cent share sale rise total revenue come talent solution segment get fee company headhunter seek hire sale rise year
837,REGN,company end quarter member year period new member come outside china be burgeon market linkedin
838,REGN,elsewhere big cap salesforce com crm be trading well recent enterprise software maker recently enter boom datum analytic market wave software
839,REGN,earning growth have be bit choppy recent quarters full year earning be expect ramp fiscal fiscal sale growth have be remarkably consistent recent quarters range past quarters
840,REGN,meanwhile headline have be positive lately regeneron regn ahead earning report tuesday open thomson reuter consensus estimate call profit share year sale be see rise
841,REGN,regeneron blockbuster drug be eylea popular treatment age related wet macular degeneration lead cause blindness elderly fda recently approve eylea additional indication treatment diabetic macular edema
842,REGN,regeneron pipeline be strong company partner sanofi recently announce start phase study dupilumab patient atopic dermatitis drug also perform well phase study patient chronic sinusitis
843,REGN,alriocumab meanwhile be show promise ldl cholesterol lower treatment
844,REGN,caveat regeneron be lengthy uptrend regeneron never reset base count latest be stage base argue however recent consolidation start october start earlier year march be enough shake seller stock go line thought then regeneron latest be consider early stage large cap stock often get labele bore overall sluggish price action latest ibd big cap list lead large cap growth be far bore recent health care related name alexion pharmaceutical alxn illumina ilmn celgene celg regeneron pharmaceutical continue trade well post technology name haven disappoint linkedin lnkd look solid report strong earning last week close just buy point monday quarterly profit rise year cent share sale rise total revenue come talent solution segment get fee company headhunter seek hire sale rise year company end quarter member year period new member come outside china be burgeon market linkedin elsewhere big cap salesforce com crm be trading well recent enterprise software maker recently enter boom datum analytic market wave software earning growth have be bit choppy recent quarters full year earning be expect ramp fiscal fiscal sale growth have be remarkably consistent recent quarters range past quarters meanwhile headline have be positive lately regeneron regn ahead earning report tuesday open thomson reuter consensus estimate call profit share year sale be see rise regeneron blockbuster drug be eylea popular treatment age related wet macular degeneration lead cause blindness elderly fda recently approve eylea additional indication treatment diabetic macular edema regeneron pipeline be strong company partner sanofi recently announce start phase study dupilumab patient atopic dermatitis drug also perform well phase study patient chronic sinusitis alriocumab meanwhile be show promise ldl cholesterol lower treatment caveat regeneron be lengthy uptrend regeneron never reset base count latest be stage base argue however recent consolidation start october start earlier year march be enough shake seller stock go line thought then regeneron latest be consider early stage
845,REGN,major average never find foot monday end session lows sluggish open selling picked pace et close nasdaq lose give dow jone industrial average fall weak economic datum china be partly blame import shrank unexpectedly november
846,REGN,several lead stock hit new high friday market rebound second day new high list have be short compose mostly low quality stock market correction begin oct list composition have improve tad past couple day regeneron pharmaceutical regn soar heavy volume
847,REGN,biotech regeneron pharmaceutical get good news bad news friday morning drug eylea outperformed competition clinical trial also get sue patent infringement amgen cholesterol drug
848,REGN,investor focuse positive regeneron pharmaceutical regn stock be morning trading stock market today earlier regeneron stock touch time high
849,REGN,trial make head head comparison eylea roche popular drug avastin lucentis patient diabetic macular edema dme form vision loss induced diabetes week patient eylea show significantly more improvement eyesight company report
850,REGN,outcome be better expect addition better efficacy eylea also show better safety especially compare lucentis arterial thromboembolic event cardiovascular event write rbc capital market analyst adnan butt research note friday datum have be something get bring modest overhang eylea potential regn share today result be likely show anything help eylea launch dme potential be even more impactful difference persist year
851,REGN,amgen amgn meanwhile sue federal court stop regeneron marketing partner sanofi sny make selling alirocumab cholesterol drug be expect be approve second half next year amgen claim infringe patent describe claim monoclonal antibody proprotein convertase subtilisin kexin type pcsk
852,REGN,amgen own pcsk drug evolocumab be await fda approval be also expect launch next year
853,REGN,butt write be surprised not overly concern lawsuit expect end settlement rather actual prevention alirocumab launch regeneron roche settle similar dispute eylea note
854,REGN,investor sanofi also seem unfazed sanofi stock be morning trading analyst be expect peak annual sale drug
855,REGN,follow amy reeve twitter ibd_areeve biotech regeneron pharmaceutical get good news bad news friday morning drug eylea outperformed competition clinical trial also get sue patent infringement amgen cholesterol drug investor focuse positive regeneron pharmaceutical regn stock be morning trading stock market today earlier regeneron stock touch time high trial make head head comparison eylea roche popular drug avastin lucentis patient diabetic macular edema dme form vision loss induced diabetes week patient eylea show significantly more improvement eyesight company report outcome be better expect addition better efficacy eylea also show better safety especially compare lucentis arterial thromboembolic event cardiovascular event write rbc capital market analyst adnan butt research note friday datum have be something get bring modest overhang eylea potential regn share today result be likely show anything help eylea launch dme potential be even more impactful difference persist year amgen amgn meanwhile sue federal court stop regeneron marketing partner sanofi sny make selling alirocumab cholesterol drug be expect be approve second half next year amgen claim infringe patent describe claim monoclonal antibody proprotein convertase subtilisin kexin type pcsk amgen own pcsk drug evolocumab be await fda approval be also expect launch next year butt write be surprised not overly concern lawsuit expect end settlement rather actual prevention alirocumab launch regeneron roche settle similar dispute eylea note investor sanofi also seem unfazed sanofi stock be morning trading analyst be expect peak annual sale drug follow amy reeve twitter ibd_areeve
856,REGN,stock end lower wednesday buyer come last minute lift major average session lows still be unsettling session distribution day higher volume decline nasdaq have be formidable head wind now market have problem deal wednesday fed chairwoman janet yellen cite potential danger stock valuation
857,REGN,close dow jone industrial average lose nasdaq give preliminary datum show nasdaq volume come higher tuesday nyse trading rise
858,REGN,economic news private employer add job april accord payroll processor adp new read be well consensus estimate come ahead friday job report
859,REGN,bond be pressured again send yield year treasury note higher basis point crude oil settle barrel cent government report first weekly decline crude inventory january
860,REGN,stock market today biotechs rebound technical damage be do group last week likely take time repair regeneron regn be exception group rise ahead earning report thursday open regeneron be work cup handle base buy point late stage base
861,REGN,meanwhile recent new issue healthequity hqy jump late tuesday company price share offer healthequity be back cup handle buy point
862,REGN,paycom software payc picked ahead earning close quarterly profit be expect surge year quarter cent share
863,REGN,other growth company set report close include epam system epam fleetmatic fltx lannett lci mercadolibre meli stock end lower wednesday buyer come last minute lift major average session lows still be unsettling session distribution day higher volume decline nasdaq have be formidable head wind now market have problem deal wednesday fed chairwoman janet yellen cite potential danger stock valuation close dow jone industrial average lose nasdaq give preliminary datum show nasdaq volume come higher tuesday nyse trading rise economic news private employer add job april accord payroll processor adp new read be well consensus estimate come ahead friday job report bond be pressured again send yield year treasury note higher basis point crude oil settle barrel cent government report first weekly decline crude inventory january stock market today biotechs rebound technical damage be do group last week likely take time repair regeneron regn be exception group rise ahead earning report thursday open regeneron be work cup handle base buy point late stage base meanwhile recent new issue healthequity hqy jump late tuesday company price share offer healthequity be back cup handle buy point paycom software payc picked ahead earning close quarterly profit be expect surge year quarter cent share other growth company set report close include epam system epam fleetmatic fltx lannett lci mercadolibre meli
864,REGN,selling major average picked pace little hour remain wednesday session stock market be rattle earlier comment fed chair janet yellen cite potential danger stock valuation
865,REGN,nasdaq dow jone industrial average moved lockstep nasdaq volume be tracking higher tuesday nyse volume be tracking close tuesday level
866,REGN,economic news private employer add job april accord payroll processor adp new read be well consensus estimate come ahead friday job report
867,REGN,treasury be pressure again send yield year treasury note higher basis point
868,REGN,stock market today biotechs rebound recent weakness regeneron regn edge higher ahead earning report thursday open regeneron be close cup handle buy point late stage base
869,REGN,recent new issue healthequity hqy jump late tuesday company price share offer healthequity be back cup handle buy point
870,REGN,tesla tsla ease just ahead earning report close stock have be rally mode lately hit low late march
871,REGN,downside apple aapl be poise sixth decline session share fall recent hasn work linkedin lnkd meanwhile lose share crater last week report earning issue weak guidance
872,REGN,growth name set report close include epam system epam fleetmatic fltx paycom payc lannett lci mercadolibre meli selling major average picked pace little hour remain wednesday session stock market be rattle earlier comment fed chair janet yellen cite potential danger stock valuation nasdaq dow jone industrial average moved lockstep nasdaq volume be tracking higher tuesday nyse volume be tracking close tuesday level economic news private employer add job april accord payroll processor adp new read be well consensus estimate come ahead friday job report treasury be pressure again send yield year treasury note higher basis point stock market today biotechs rebound recent weakness regeneron regn edge higher ahead earning report thursday open regeneron be close cup handle buy point late stage base recent new issue healthequity hqy jump late tuesday company price share offer healthequity be back cup handle buy point tesla tsla ease just ahead earning report close stock have be rally mode lately hit low late march downside apple aapl be poise sixth decline session share fall recent hasn work linkedin lnkd meanwhile lose share crater last week report earning issue weak guidance growth name set report close include epam system epam fleetmatic fltx paycom payc lannett lci mercadolibre meli
873,REGN,earning season be wind be still top stock due report include drug giant actavis act several drug stock report earning day include intrexon xon impax laboratory ipxl juno therapeutic juno actavis be ibd list very best stock other ibd stock regeneron pharmaceutical regn monster
874,REGN,first quarter earning report correct market have shake industry group rank here look winner loser week biotech group outperformed re-cover portion prior week harsh loss group member ligand pharmaceutical lgnd be trading buy point cup handle base find support
875,REGN,rise biotech star medivation start lose altitude hour trading thursday report miss estimate day several high rate drug stock report medivation mdvn earning exclude time item totale cent share reverse year earlier loss miss analyst consensus cent accord thomson reuter revenue climb short consensus nonetheless company affirm full year guidance revenue do not offer ep guidance forecast expense remain same conference call discuss result analyst cfo rick bierly say company have warn call quarter be likely be slow cite buildup inventory company sole market drug xtandi have now return normal well unusually high refund rate due reset medicare part donut hole start year also anticipate return normal year go stock take hit hour trading rise regular trade close also fall late trading be specialty drugmaker jazz pharmaceutical jazz also affirm guidance report mixed quarter jazz revenue rise previous year hair short wall street estimate profit also increase share miss consensus cent jazz also announce have decide not move forward clinical trial jzp product develop partnership concert pharmaceutical cnce possible successor jazz bestselling narcolepsy drug xyrem company say underwhelm result phase study lead decision continue evaluate possible used drug earlier day big cap biotech regeneron pharmaceutical regn report more positive quarter raise guidance stock still close fraction regeneron earning rise year earlier quarter share beating analyst consensus cent sale climb consensus beat come sale regeneron flagship eye drug eylea jump street expect accord rbc capital market firm now expect eylea sale rise year previous guidance company do not provide overall revenue guidance foreign eylea sale be handled bayer bayry other sale come collaboration milestone payment regeneron executive stress importance protocol study compare eylea head head chief competitor roche rhhby lucentis avastin patient diabetic macular edema dme type vision loss associate diabetes commercial head robert terifay tell analyst company earning conference call regeneron market research indicated study publish february be drive uptake drug take share competitor ceo len schleifer add anecdotal account indicated also be help sale eylea original target wet age related macular degeneration specialist have only have avastin stock now have eylea available used have previously thought eylea lucentis share least equilibrate now believe eylea overtake lucentis maybe even grow market share away avastin least dme write rbc capital market analyst adnan butt research note thursday regn also have power post surprise pipeline pipeline product draw most discussion call be praluent cholesterol fighter be fda review expect be approve july call terifay remain bullish drug blockbuster potential acknowledge negotiation payer slow launch express script esrx have make clear praluent drug class be next target price war be work player involved market access decision make process focus patient good terifay say say likely take several month commercial government payer take formulary reviews make reimbursement coverage decision
876,REGN,stock pull together nice gain early wednesday investor ignore weak housing datum ahead afternoon release fed minute
877,REGN,dow jone industrial nasdaq climb grab gain
878,REGN,volume be quietly mixed nasdaq lower nyse relative trade same time tuesday
879,REGN,stock market today get reasonably healthy start commerce department datum show october housing start slump month low market be tune et release minute federal open market committee oct meeting seek sign timing interest rate increase
880,REGN,dow stock be mostly positive apple aapl pound gain top group be add goldman sachs conviction buy list
881,REGN,norfolk southern nsc lead nearly canadian pacific railway cp offer buy rail peer cash stock deal value more
882,REGN,conagra cag rally more omaha neb base package food giant announce strip frozen potato business separate lamb weston name begin next year
883,REGN,base oil driller ensco esv be close gain nearly energy stock make strong show early action oil price rise modestly
884,REGN,array retail stock post mixed early move follow quarterly report energy information administration report weekly inventory datum
885,REGN,china base vipshop vip spiked jack box jack climb staple spls slip target tgt give premarket gain slump report third quarter result
886,REGN,leader healthcare staffing agency amn healthcare rumble start trade san diego base operation say late tuesday agree buy privately hold cash amn say deal be immediately accretive adjust ep stock have be scrawl erratic pattern attempt regain support week move average
887,REGN,citrix system ctxs shed early action developer enterprise software solution announce late tuesday lay worker spin goto unit separate business company say move result pretax charge create saving year loss send share week move average heavy trade buy point cup handle base stock pull together nice gain early wednesday investor ignore weak housing datum ahead afternoon release fed minute dow jone industrial nasdaq climb grab gain volume be quietly mixed nasdaq lower nyse relative trade same time tuesday stock market today get reasonably healthy start commerce department datum show october housing start slump month low market be tune et release minute federal open market committee oct meeting seek sign timing interest rate increase dow stock be mostly positive apple aapl pound gain top group be add goldman sachs conviction buy list norfolk southern nsc lead nearly canadian pacific railway cp offer buy rail peer cash stock deal value more conagra cag rally more omaha neb base package food giant announce strip frozen potato business separate lamb weston name begin next year base oil driller ensco esv be close gain nearly energy stock make strong show early action oil price rise modestly array retail stock post mixed early move follow quarterly report energy information administration report weekly inventory datum china base vipshop vip spiked jack box jack climb staple spls slip target tgt give premarket gain slump report third quarter result leader healthcare staffing agency amn healthcare rumble start trade san diego base operation say late tuesday agree buy privately hold cash amn say deal be immediately accretive adjust ep stock have be scrawl erratic pattern attempt regain support week move average citrix system ctxs shed early action developer enterprise software solution announce late tuesday lay worker spin goto unit separate business company say move result pretax charge create saving year loss send share week move average heavy trade buy point cup handle base
888,REGN,material etfs track higher tuesday get boost spike chemical giant dupont dd investor digest news dupont ceo ellen kullman step oct even company announce plan curb expense overall stock etfs follow nasdaq index fail extend recent rally investor eye weak trade datum start earning season gold price rise dollar ease vs euro yen british pound meanwhile ishare silver trust slv largest silver etf hit month high close session low have surge past day spdr dow jone industrial average dium eke gain stock market today cushion gain dupont well caterpillar cat microsoft msft however ibd leaderboard stock visa inched lower dow tracking etf hold industrial leader be high material select sector spdr xlb pop material energy sector lead index higher xlb hold company chemical metal mining paper forest product container packaging construction material industry chemical company dominate third asset accord morningstar inc dow chemical dow dupont largest holding alone account combine portfolio weighting etfs hold biotech stock get slam tuesday rally lows ishare nasdaq biotechnology ibb tumble nearly close midpoint day range ibb top holding take hit illumina ilmn tank revenue miss gene sequence firm preannounce quarterly result monday report final number oct ibb top holding celgene celg biogen biib give ibd stock regeneron pharmaceutical regn fall indonesia brazil russia top international etfs china india trail here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs ishare core aggregate bond agg rs ishare msci eafe efa rs spdr dow jone industrial average dium rs vanguard ftse emerge market vwo rs spdr spy rs ishare core mid cap ijh rs powershare qqq qqq rs powershare db bullish uup rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
889,REGN,sector rotation be pretty much do deal big cap be guide last spring summer medical sector be provide third half name big cap summer leader chart now look sad biogen biib be high illumina ilmn be high plunge hour preannounce revenue full year guidance miss view regeneron regn be high tuesday big cap only medical stock make list heart valve maker edward lifescience ew be list couple breakout offer meager gain march yielded gain session then stock consolidated july yielded gain week stock consolidated small gain do not give individual investor much chance make money edward be now form new consolidation be good news monday ibd medical sector be sector be top most year september medical sector be finished leader have replace medical stock investor just well ask hasn replace medical stock big cap leadership be now more diverse have be year stock be many sector include retail software tobacco leisure many be early stage pattern thank reset breakout didn advance more reset occur stock low undercut low previous base reset count first second stage base have better shot success later stage base follow big cap stock feature first stage basis software sector play salesforce com crm be work first stage consolidation stock have regain day day line be only new high breakout year lead gain stock hasn post gain august november retail sector stock chipotle grill cmg be work first stage pattern stock be high be battle retake day line breakout year lead gain most recently tobacco sector stock reynold american rai clear buy point monday strong volume be miss valid usually deliver volume spike least average strong volume be mark institutional activity food meat stock hormel hrl rushed past buy point monday volume be average stock be defensive seldom deliver big gain breakout hormel last big gain be pop november
890,REGN,top rate drugmaker such valeant pharmaceutical international vrx celgene celg have be busy lab wall street take part big merger deal today ibd list feature top rate drugmaker addition valeant celgene list include regeneron pharmaceutical regn lannett lci allergan agn friday biogen idec biib price
891,REGN,market new confirm rally investor pay close attention lead stock new buy opportunity biogen idec biib other medical company hold well correction have be leader week
892,REGN,biogen idec be pharmaceutical company featured today ibd big cap screen day screen feature institutional quality stock be highly liquid have excellent fundamental
893,REGN,medical biom biotech group be top rank group industry group ibd track
894,REGN,biotechs be screen report earning week start biogen early wednesday
895,REGN,analyst poll thomson reuter expect maker multiple sclerosis drug report jump earning seventh straight quarter double digit ep growth revenue be see rise
896,REGN,biogen share rise nearly stock market today climb monday
897,REGN,celgene celg report earning thursday oct analyst expect cancer therapy maker report jump earning cent rise revenue
898,REGN,tuesday celgene report strong phase trial result mongersen drug treat crohn disease
899,REGN,view bottom line be have high chance work phase ultimately read be key growth driver think upside long term guidance eventually be give rbc capital market analyst michael yee write note
900,REGN,celgene share rise more tuesday follow monday advance
901,REGN,alexion pharmaceutical alxn be also expect report earning result thursday analyst expect rise earning share revenue climb
902,REGN,alexion make only drug soliris treatment blood disease paroxysmal nocturnal hemoglobinurium company have other drug development
903,REGN,alexion show biotechs make enormous profit orphan drug medication treat extremely rare deadly disease
904,REGN,share alexion be nearly week
905,REGN,gilead science gild be slate report result oct earlier month fda approve gilead hepatitis combo pill harvoni combine megablockbuster sovaldi interferon treatment
906,REGN,gilead ep be see soar revenue climb
907,REGN,gilead share also be nearly so far week
908,REGN,regeneron pharmaceutical regn round top monday company announce have start phase study possible drug dupilumab treatment moderate severe atopic dermatitis
909,REGN,regeneron isn slate report earning nov analyst expect earning double share revenue jump nearly
910,REGN,share regeneron jump new high tuesday
911,REGN,follow gillian rich twitter ibd_grich market new confirm rally investor pay close attention lead stock new buy opportunity biogen idec biib other medical company hold well correction have be leader week biogen idec be pharmaceutical company featured today ibd big cap screen day screen feature institutional quality stock be highly liquid have excellent fundamental medical biom biotech group be top rank group industry group ibd track biotechs be screen report earning week start biogen early wednesday analyst poll thomson reuter expect maker multiple sclerosis drug report jump earning seventh straight quarter double digit ep growth revenue be see rise biogen share rise nearly stock market today climb monday celgene celg report earning thursday oct analyst expect cancer therapy maker report jump earning cent rise revenue tuesday celgene report strong phase trial result mongersen drug treat crohn disease view bottom line be have high chance work phase ultimately read be key growth driver think upside long term guidance eventually be give rbc capital market analyst michael yee write note celgene share rise more tuesday follow monday advance alexion pharmaceutical alxn be also expect report earning result thursday analyst expect rise earning share revenue climb alexion make only drug soliris treatment blood disease paroxysmal nocturnal hemoglobinurium company have other drug development alexion show biotechs make enormous profit orphan drug medication treat extremely rare deadly disease share alexion be nearly week gilead science gild be slate report result oct earlier month fda approve gilead hepatitis combo pill harvoni combine megablockbuster sovaldi interferon treatment gilead ep be see soar revenue climb gilead share also be nearly so far week regeneron pharmaceutical regn round top monday company announce have start phase study possible drug dupilumab treatment moderate severe atopic dermatitis regeneron isn slate report earning nov analyst expect earning double share revenue jump nearly share regeneron jump new high tuesday follow gillian rich twitter ibd_grich
912,REGN,stock open higher quickly begin trim gain friday dollar edge higher oil price hold steady dow jone industrial average add apiece nasdaq hold advance
913,REGN,volume be soft nasdaq lower nyse compare trade same time thursday
914,REGN,stock market today be rebound still correct nasdaq deep hole week market receive early assist today china rule change federally engineer buy help lift market first healthy close week
915,REGN,december hire be also factor labor department report payroll jump month far expectation
916,REGN,wholesale inventory drop november commerce department say be even october slip expectation change
917,REGN,market have ear post payroll comment san francisco federal reserve bank president john william speak et richmond federal reserve bank president jeffrey lacker docket speech
918,REGN,apple aapl dupont dd race head dow nearly wynn resort wynn head gain
919,REGN,gap gps crater announce late thursday december same store sale slip vs consensus view decline
920,REGN,chipmaker apple supplier qorvo qrvo drop greensboro company late thursday lower revenue guidance well consensus expectation company also say repurchase share quarter leave share repurchase program cash balance more share trade week june high
921,REGN,ibd list universal display oled flash ahead nearly open maker organic light emit diode chip used high definition tv computer screen be trading buy point cup base trigger automatic sell signal diving more mark
922,REGN,hawaiian jump more report total number passenger rise load factor fourth quarter stock remain well day move average be attempt build right side deep consolidation
923,REGN,aircraft carrier mechanic huntington ingall industry hii sail ahead nearly cowen co upgrade stock outperform market perform huntington be trading buy point long cup handle base stock open higher quickly begin trim gain friday dollar edge higher oil price hold steady dow jone industrial average add apiece nasdaq hold advance volume be soft nasdaq lower nyse compare trade same time thursday stock market today be rebound still correct nasdaq deep hole week market receive early assist today china rule change federally engineer buy help lift market first healthy close week december hire be also factor labor department report payroll jump month far expectation wholesale inventory drop november commerce department say be even october slip expectation change market have ear post payroll comment san francisco federal reserve bank president john william speak et richmond federal reserve bank president jeffrey lacker docket speech apple aapl dupont dd race head dow nearly wynn resort wynn head gain gap gps crater announce late thursday december same store sale slip vs consensus view decline chipmaker apple supplier qorvo qrvo drop greensboro company late thursday lower revenue guidance well consensus expectation company also say repurchase share quarter leave share repurchase program cash balance more share trade week june high ibd list universal display oled flash ahead nearly open maker organic light emit diode chip used high definition tv computer screen be trading buy point cup base trigger automatic sell signal diving more mark hawaiian jump more report total number passenger rise load factor fourth quarter stock remain well day move average be attempt build right side deep consolidation aircraft carrier mechanic huntington ingall industry hii sail ahead nearly cowen co upgrade stock outperform market perform huntington be trading buy point long cup handle base
924,REGN,current volatile market share company boast strong fundamental regeneron pharmaceutical regn michael kor kor likely hold well be top prospect stock watch list
925,REGN,today screen day be top fundamental highly rate company year sale earning growth rate least
926,REGN,here be company list have see earning sale make robust gain recent year
927,REGN,yy yy be lead social network china counterpart facebook fb grow fast world most populous nation also have distinction be ibd young gun list have go public november
928,REGN,yy boast amazing year earning share growth rate year sale growth rate demonstrate inherent stability yy stock be also ibd list top rate stock rise wednesday big drop overall stock market
929,REGN,august yy top earning view sale music entertainment segment triple company revenue guidance also beat view
930,REGN,regeneron make drug treat cancer other disease ailment be best know blockbuster age related macular degeneration eye disease treatment eylea
931,REGN,french drug giant partner sanofi early july raise stake regeneron european medicine agency endorsement expand eylea use europe other type vision loss
932,REGN,regeneron have year ep growth rate year sale growth rate share rise wednesday
933,REGN,linkedin lnkd have be hook professional prospective employer online boom great recession employment have drop normal level continue grow widening service offering
934,REGN,cowen co upgrade stock outperform market perform linkedin introduce sale navigator enterprise august upgrade tool sale professional linkedin year ep growth rate be sale growth rate be share be wednesday
935,REGN,michael kor maker luxury clothing accessory have strike cord consumer hong kong base company mainly operate be expand globally
936,REGN,sterne agee report week say investor be mainly bullish growth prospect europe little concern continue hold leadership position highly competitive market
937,REGN,kor have year ep growth rate sale growth rate share fall wednesday
938,REGN,alexion pharmaceutical alxn regeneron have blockbuster drug soliris treat rare blood disease march alexion guide soliris sale year be range
939,REGN,company be go regulatory process now analyst say be second hugely successful drug currently call alfa drug be design treat hpp rare genetic disease affect bone formation child
940,REGN,alexion year ep growth rate be sale rate share rise
941,REGN,follow james detar twitter ibd_jdetar current volatile market share company boast strong fundamental regeneron pharmaceutical regn michael kor kor likely hold well be top prospect stock watch list today screen day be top fundamental highly rate company year sale earning growth rate least here be company list have see earning sale make robust gain recent year yy yy be lead social network china counterpart facebook fb grow fast world most populous nation also have distinction be ibd young gun list have go public november yy boast amazing year earning share growth rate year sale growth rate demonstrate inherent stability yy stock be also ibd list top rate stock rise wednesday big drop overall stock market august yy top earning view sale music entertainment segment triple company revenue guidance also beat view regeneron make drug treat cancer other disease ailment be best know blockbuster age related macular degeneration eye disease treatment eylea french drug giant partner sanofi early july raise stake regeneron european medicine agency endorsement expand eylea use europe other type vision loss regeneron have year ep growth rate year sale growth rate share rise wednesday linkedin lnkd have be hook professional prospective employer online boom great recession employment have drop normal level continue grow widening service offering cowen co upgrade stock outperform market perform linkedin introduce sale navigator enterprise august upgrade tool sale professional linkedin year ep growth rate be sale growth rate be share be wednesday michael kor maker luxury clothing accessory have strike cord consumer hong kong base company mainly operate be expand globally sterne agee report week say investor be mainly bullish growth prospect europe little concern continue hold leadership position highly competitive market kor have year ep growth rate sale growth rate share fall wednesday alexion pharmaceutical alxn regeneron have blockbuster drug soliris treat rare blood disease march alexion guide soliris sale year be range company be go regulatory process now analyst say be second hugely successful drug currently call alfa drug be design treat hpp rare genetic disease affect bone formation child alexion year ep growth rate be sale rate share rise follow james detar twitter ibd_jdetar
942,REGN,major average score big percentage gain higher volume tuesday result plenty firework new high list
943,REGN,several top rate name break heavy volume
944,REGN,property casualty insurer amtrust financial service afsi jump heavy volume clear double bottom buy point earning be due nov open thomson reuter consensus estimate expect profit share year sale
945,REGN,drugmaker akorn akrx clear flat base rise strong turnover buy point be range antibiotic steroid vaccine have fuel growth akorn recent quarters recently enter dermatology market purchase versapharm earning be due nov open
946,REGN,regeneron pharmaceutical regn soar share pop friday company say head head study show eylea treatment diabetic macular edema work better genentech avastin lucentis friday regeneron reclaim handle buy point late stage base
947,REGN,amgen amgn gain more double average volume back week move average recent cup handle
948,REGN,china base online gaming firm netease nte rally heavy trade clear flat base buy point company focus have shift pc game mobile game netease be not generate meaningful sale mobile august sale online game rise make nearly total sale
949,REGN,meanwhile trucking stock score new high landstar system lstr rally ahead earning report thursday open volume be average earning sale growth have ramp past quarters several quarters sluggish result
950,REGN,heartland express htld meanwhile add cent fast trade reclaim flat base buy point monday company specialize short medium haul transport general commodity
951,REGN,click here view full list week new high lows major average score big percentage gain higher volume tuesday result plenty firework new high list several top rate name break heavy volume property casualty insurer amtrust financial service afsi jump heavy volume clear double bottom buy point earning be due nov open thomson reuter consensus estimate expect profit share year sale drugmaker akorn akrx clear flat base rise strong turnover buy point be range antibiotic steroid vaccine have fuel growth akorn recent quarters recently enter dermatology market purchase versapharm earning be due nov open regeneron pharmaceutical regn soar share pop friday company say head head study show eylea treatment diabetic macular edema work better genentech avastin lucentis friday regeneron reclaim handle buy point late stage base amgen amgn gain more double average volume back week move average recent cup handle china base online gaming firm netease nte rally heavy trade clear flat base buy point company focus have shift pc game mobile game netease be not generate meaningful sale mobile august sale online game rise make nearly total sale meanwhile trucking stock score new high landstar system lstr rally ahead earning report thursday open volume be average earning sale growth have ramp past quarters several quarters sluggish result heartland express htld meanwhile add cent fast trade reclaim flat base buy point monday company specialize short medium haul transport general commodity click here view full list week new high lows
952,REGN,big cap biotech regeneron pharmaceutical regn beat wall street estimate raise guidance thursday send stock more early trading
953,REGN,regeneron earning rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb consensus
954,REGN,beat come sale regeneron flagship eye drug eylea jump street expect accord rbc capital market company say now expect eylea sale rise year previous guidance company do not provide overall revenue guidance foreign eylea sale be handled bayer bayry other sale come collaboration milestone payment
955,REGN,regeneron executive stress importance protocol study compare eylea head head chief competitor roche rhhby lucentis avastin patient diabetic macular edema dme type vision loss associate diabetes commercial head robert terifay tell analyst company earning conference call regeneron market research indicated study publish february be drive uptake drug take share competitor
956,REGN,see open vs avastin
957,REGN,ceo len schleifer add anecdotal account indicated also be help sale eylea original target wet age related macular degeneration specialist have previously only have avastin stock now have eylea available used
958,REGN,have previously thought eylea lucentis share least equilibrate now believe eylea overtake lucentis maybe even grow market share away avastin least dme write rbc capital market analyst adnan butt research note thursday regn also have power post surprise pipeline
959,REGN,pipeline product draw most discussion call be praluent cholesterol fighter fda review be expect be approve july call terifay remain bullish drug blockbuster potential acknowledge negotiation payer slow launch express script esrx have make clear praluent drug class be next target price war
960,REGN,be work player involved market access decision make process focus patient good say terifay say likely take several month commercial government payer take formulary reviews make reimbursement coverage decision begin process patient claim give reason expect initial gradual uptake launch
961,REGN,terifay say expect most patient begin lower mg dose praluent then move mg dose need regeneron executive see potential approval dosage important difference praluent amgen amgn repatha similar drug approval deadline be only month later
962,REGN,regeneron stock rise much early trading stock market today morning trading be fraction regeneron stock touch time high march
963,REGN,follow amy reeve twitter ibd_areeve big cap biotech regeneron pharmaceutical regn beat wall street estimate raise guidance thursday send stock more early trading regeneron earning rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb consensus beat come sale regeneron flagship eye drug eylea jump street expect accord rbc capital market company say now expect eylea sale rise year previous guidance company do not provide overall revenue guidance foreign eylea sale be handled bayer bayry other sale come collaboration milestone payment regeneron executive stress importance protocol study compare eylea head head chief competitor roche rhhby lucentis avastin patient diabetic macular edema dme type vision loss associate diabetes commercial head robert terifay tell analyst company earning conference call regeneron market research indicated study publish february be drive uptake drug take share competitor see open vs avastinceo len schleifer add anecdotal account indicated also be help sale eylea original target wet age related macular degeneration specialist have previously only have avastin stock now have eylea available used have previously thought eylea lucentis share least equilibrate now believe eylea overtake lucentis maybe even grow market share away avastin least dme write rbc capital market analyst adnan butt research note thursday regn also have power post surprise pipeline pipeline product draw most discussion call be praluent cholesterol fighter fda review be expect be approve july call terifay remain bullish drug blockbuster potential acknowledge negotiation payer slow launch express script esrx have make clear praluent drug class be next target price war be work player involved market access decision make process focus patient good say terifay say likely take several month commercial government payer take formulary reviews make reimbursement coverage decision begin process patient claim give reason expect initial gradual uptake launch terifay say expect most patient begin lower mg dose praluent then move mg dose need regeneron executive see potential approval dosage important difference praluent amgen amgn repatha similar drug approval deadline be only month later regeneron stock rise much early trading stock market today morning trading be fraction regeneron stock touch time high march follow amy reeve twitter ibd_areeve
964,REGN,best etfs performance update
965,REGN,several sector etfs have solar power investor double digit gain so far brightest gain american turn foreign shore china lord
966,REGN,equity exchange trade fund re-cover recent trading session broad loss april give way higher interest rate mixed earning weigh stock
967,REGN,don expect more modest increase rate even be enough push volatility higher be likely be headwind many most popular so call momentum stock russ global chief investment strategist blackrock write
968,REGN,cite biotech social medium stock example peaked april then tumble hard uptick volatility
969,REGN,spdr spy proxy broad market gain past month year date
970,REGN,spdr biotech xbi be be month have soar so far similarly global social medium socl inched past month year date recent high back day move average bullish sign
971,REGN,think loss momentum continue suggest increase value oriented stake namely integrate oil company trade deep discount rally recent lows
972,REGN,eog eog pioneer pes plan resume drill rig deployment new supply slow rally stabilize oil price say
973,REGN,overall investor expect good not great growth allocate healthy amount international stock advise
974,REGN,indeed even best perform sector etf year date guggenheim solar tan trail foreign focuse etfs margin market vector chinaamc sme chinext cnxt surge past month alone take year date return
975,REGN,invest small midsize china share have explode popularity asian nation open economy also be help tilt tech consumer startup sector company drive innovation growth china expense ratio be lower rival share etfs
976,REGN,deutsche tracker harvest csi china share small cap ashs so far be more diversify hold roughly company
977,REGN,past month several etfs hold single country european equity turkey russia austria portugal have peg tidiest profit
978,REGN,re feel directly indirectly benefit aggressive monetary ease eurozone
979,REGN,peter westaway chief european economist vanguard say optimistic outlook region light measure expect recovery be slog
980,REGN,go be long haul lot bump way say recently only need look political turmoil greece moment see be still unresolved issue
981,REGN,growth stock still rule
982,REGN,broadly diversify domestic etfs growth oriented focus continue pay first trust dorsey focus fv fund fund have benefit health care biotech tilt
983,REGN,hold ibd sector leader stock such regeneron regn biogen biib celgene celg fv be best perform diversify etfs so far advance
984,REGN,fix income front investor have show appetite riskier asset interest rate be mired historic lows several emerge market high yield bond fund have outperformed
985,REGN,precious metal etfs have rebound strongly gold silver price shot dollar sank weak job datum ishare silver trust slv have rise past month take gain powershare db dollar bullish uup have give past month gap tuesday stock market newsbest etfs performance updateseveral sector etfs have solar power investor double digit gain so far brightest gain american turn foreign shore china lord equity exchange trade fund re-cover recent trading session broad loss april give way higher interest rate mixed earning weigh stock don expect more modest increase rate even be enough push volatility higher be likely be headwind many most popular so call momentum stock russ global chief investment strategist blackrock write cite biotech social medium stock example peaked april then tumble hard uptick volatility spdr spy proxy broad market gain past month year date spdr biotech xbi be be month have soar so far similarly global social medium socl inched past month year date recent high back day move average bullish sign think loss momentum continue suggest increase value oriented stake namely integrate oil company trade deep discount rally recent lows eog eog pioneer pes plan resume drill rig deployment new supply slow rally stabilize oil price say overall investor expect good not great growth allocate healthy amount international stock advise indeed even best perform sector etf year date guggenheim solar tan trail foreign focuse etfs margin market vector chinaamc sme chinext cnxt surge past month alone take year date return invest small midsize china share have explode popularity asian nation open economy also be help tilt tech consumer startup sector company drive innovation growth china expense ratio be lower rival share etfs deutsche tracker harvest csi china share small cap ashs so far be more diversify hold roughly company past month several etfs hold single country european equity turkey russia austria portugal have peg tidiest profit re feel directly indirectly benefit aggressive monetary ease eurozone peter westaway chief european economist vanguard say optimistic outlook region light measure expect recovery be slog go be long haul lot bump way say recently only need look political turmoil greece moment see be still unresolved issue growth stock still ruleamong broadly diversify domestic etfs growth oriented focus continue pay first trust dorsey focus fv fund fund have benefit health care biotech tilt hold ibd sector leader stock such regeneron regn biogen biib celgene celg fv be best perform diversify etfs so far advance fix income front investor have show appetite riskier asset interest rate be mired historic lows several emerge market high yield bond fund have outperformed precious metal etfs have rebound strongly gold silver price shot dollar sank weak job datum ishare silver trust slv have rise past month take gain powershare db dollar bullish uup have give past month gap tuesday stock market news
986,REGN,best mutual fund performance report
987,REGN,country lead stock mutual fund past month have be add medical issue latest report period
988,REGN,treat many position kindly nasdaq forge ahead month rise most gain be make second part market confirm uptrend
989,REGN,so much adage sell go away next few month tell thing turn mutual fund
990,REGN,ibd industry medical subgroup rank top tuesday
991,REGN,manager best perform fund have be gathering mallinckrodt mnk abc regeneron pharmaceutical regn unite therapeutic uthr portfolio
992,REGN,demand cheaper chip new product power mobile phone internet connect gadget be drive competition consolidation tech arena
993,REGN,recent intel intc altera altr merger bring more buzz chip sector last week technology avgo say buy broadcom brcm deal worth march nxp semiconductor nxpi buy freescale semiconductor fsl deal value
994,REGN,other chipmaker do well include macom mtsi skywork solution swks cirrus logic crus
995,REGN,ibd spot top perform fund add mallinckrodt investing estimate fidelity mid cap value fund own stake firm dublin base firm make generic brand drug treat pain also make diagnostic imaging system
996,REGN,company have be boost product line acquire other successful drug firm such ikarium cadence pharmaceutical questcor pharmaceutical thus mallinckrodt deliver strong earning result past quarters rise respectively
997,REGN,mallinckrodt stock have be etching right side shape base near buy point volume have be average
998,REGN,sell side
999,REGN,top mutual fund have be take profit big manage care firm such unitedhealth unh anthem antm latest report period biotechs firm gilead science gild isis pharmaceutical isis also be sell lead fund best mutual fund performance country lead stock mutual fund past month have be add medical issue latest report period treat many position kindly nasdaq forge ahead month rise most gain be make second part market confirm uptrend so much adage sell go away next few month tell thing turn mutual fund ibd industry medical subgroup rank top tuesday manager best perform fund have be gathering mallinckrodt mnk abc regeneron pharmaceutical regn unite therapeutic uthr portfolio demand cheaper chip new product power mobile phone internet connect gadget be drive competition consolidation tech arena recent intel intc altera altr merger bring more buzz chip sector last week technology avgo say buy broadcom brcm deal worth march nxp semiconductor nxpi buy freescale semiconductor fsl deal value other chipmaker do well include macom mtsi skywork solution swks cirrus logic crus ibd spot top perform fund add mallinckrodt investing estimate fidelity mid cap value fund own stake firm dublin base firm make generic brand drug treat pain also make diagnostic imaging system company have be boost product line acquire other successful drug firm such ikarium cadence pharmaceutical questcor pharmaceutical thus mallinckrodt deliver strong earning result past quarters rise respectively mallinckrodt stock have be etching right side shape base near buy point volume have be average sell sidetop mutual fund have be take profit big manage care firm such unitedhealth unh anthem antm latest report period biotechs firm gilead science gild isis pharmaceutical isis also be sell lead fund
1000,REGN,ibd big cap leader screen filter highly liquid large cap stock strong record earning growth top notch medical stock make screen cut be valeant pharmaceutical vrx gilead science gild celgene celg actavis act biogen biib regeneron regn shire shpg illumina ilmn
1001,REGN,valeant pharmaceutical have highest possible ibd composite rating meaning share outperform stock market measure fundamental technical factor factor be earning sale growth profit margin return equity relative price performance
1002,REGN,valeant complete acquisition salix pharmaceutical april salix partner pharm group come monday good interim datum phase clinical trial conestat alfa drug ruconest develop treatment angioedema attack allergy related swell
1003,REGN,valeant share ease tuesday be extend past cup handle base buy point initially clear last december
1004,REGN,actavis partner perrigo prgo announce tuesday new drug application guaifenesin pseudoephedrine tablet mucinex alternative be give fda approval
1005,REGN,last week eluxadoline drug viberzi treatment irritable bowel syndrome also receive fda approval
1006,REGN,actavis be try stay cup handle base buy point initially clear last wednesday close tuesday actavis have composite rating best
1007,REGN,gilead have ibd composite rating biotech announce sunday phase trial result idelalisib drug zydelig combination ofatumumab show improvement progression free survival previously treat patient chronic lymphocytic leukemia cll
1008,REGN,last week european medicine agency validate gilead marketing application emtricitabine tenofovir alafenamide combination hiv treatment investigational combination be now evaluation european medicine agency
1009,REGN,share barely close tuesday be buy point month long price consolidation
1010,REGN,celgene be biotech composite rating bmo capital last week reiterate outperform rating celgene part future prospect pleiotropic modulator cc
1011,REGN,stock be form price consolidation buy point
1012,REGN,biogen biotech earn composite rating be now trading march peak price be reach nearly month long run price consolidation
1013,REGN,regeneron break cup handle base buy point mid gain much level tuesday session biotech share dip back buy range regeneron boast composite rating
1014,REGN,shire clear buy point flat base ethical drug maker stock be now trading back level shire have composite rating
1015,REGN,illumina make gene sequence system be work price consolidation buy point last week share get pivot be now trading level
1016,REGN,follow alissa william twitter ibd_awilliam ibd big cap leader screen filter highly liquid large cap stock strong record earning growth top notch medical stock make screen cut be valeant pharmaceutical vrx gilead science gild celgene celg actavis act biogen biib regeneron regn shire shpg illumina ilmn valeant pharmaceutical have highest possible ibd composite rating meaning share outperform stock market measure fundamental technical factor factor be earning sale growth profit margin return equity relative price performance valeant complete acquisition salix pharmaceutical april salix partner pharm group come monday good interim datum phase clinical trial conestat alfa drug ruconest develop treatment angioedema attack allergy related swell valeant share ease tuesday be extend past cup handle base buy point initially clear last december actavis partner perrigo prgo announce tuesday new drug application guaifenesin pseudoephedrine tablet mucinex alternative be give fda approval last week eluxadoline drug viberzi treatment irritable bowel syndrome also receive fda approval actavis be try stay cup handle base buy point initially clear last wednesday close tuesday actavis have composite rating best gilead have ibd composite rating biotech announce sunday phase trial result idelalisib drug zydelig combination ofatumumab show improvement progression free survival previously treat patient chronic lymphocytic leukemia cll last week european medicine agency validate gilead marketing application emtricitabine tenofovir alafenamide combination hiv treatment investigational combination be now evaluation european medicine agency share barely close tuesday be buy point month long price consolidation celgene be biotech composite rating bmo capital last week reiterate outperform rating celgene part future prospect pleiotropic modulator cc stock be form price consolidation buy point biogen biotech earn composite rating be now trading march peak price be reach nearly month long run price consolidation regeneron break cup handle base buy point mid gain much level tuesday session biotech share dip back buy range regeneron boast composite rating shire clear buy point flat base ethical drug maker stock be now trading back level shire have composite rating illumina make gene sequence system be work price consolidation buy point last week share get pivot be now trading level follow alissa william twitter ibd_awilliam
1017,REGN,stock hold solid gain early afternoon trading friday april employment report reveal not too hot not too cold job growth dow jone industrial average lead way rise add nasdaq gain volume be curiously quiet gain nyse volume be tracking lower thursday nasdaq volume fall stock market today
1018,REGN,employer add job april confirm suspicion sluggish growth march be anomaly april job growth help lower unemployment rate march
1019,REGN,stock market today ibd medical biom biotech group outperformed again rise
1020,REGN,regeneron regn be top performer nasdaq rise more heel solid result yesterday earning sale growth accelerate second straight quarter total revenue grow
1021,REGN,sale regeneron flagship eye drug eylea jump company expect eylea sale rise year previous guidance regeneron be approach buy late stage cup handle pattern
1022,REGN,jump more offer buy swiss firm syngenta syt share syngenta soar nearly news say offer be too low be near flat base buy point
1023,REGN,ibd molina healthcare moh gap day move average soar earning sale growth easily top expectation
1024,REGN,day report solid earning paycom software payc clear buy point solid volume rise
1025,REGN,monster beverage mnst wasn so lucky gap day move average fall disappointing earning goldman sachs remove monster conviction buy list downgrade share neutral stock hold solid gain early afternoon trading friday april employment report reveal not too hot not too cold job growth dow jone industrial average lead way rise add nasdaq gain volume be curiously quiet gain nyse volume be tracking lower thursday nasdaq volume fall stock market today employer add job april confirm suspicion sluggish growth march be anomaly april job growth help lower unemployment rate march stock market today ibd medical biom biotech group outperformed again rise regeneron regn be top performer nasdaq rise more heel solid result yesterday earning sale growth accelerate second straight quarter total revenue grow sale regeneron flagship eye drug eylea jump company expect eylea sale rise year previous guidance regeneron be approach buy late stage cup handle pattern jump more offer buy swiss firm syngenta syt share syngenta soar nearly news say offer be too low be near flat base buy point ibd molina healthcare moh gap day move average soar earning sale growth easily top expectation day report solid earning paycom software payc clear buy point solid volume rise monster beverage mnst wasn so lucky gap day move average fall disappointing earning goldman sachs remove monster conviction buy list downgrade share neutral
1026,REGN,stock market today receive early boost overseas start late rally china datum fed run european market stock hold add solid early gain leave nasdaq dow jone industrial higher index close top trading range
1027,REGN,volume continue track higher nasdaq higher nyse relative late trade friday accord preliminary datum
1028,REGN,chipmaker ore miner biotechs oil driller lead top advance industry group only group lose ground coal bottom heap
1029,REGN,teco energy te rolled gain spur friday news be acquire nova scotia base emera top
1030,REGN,tempur sealy tpx bounce advance naming former dollar thrifty automotive group ceo chairman scott thompson new chairman chief executive stock rebound week support left share just fresh high
1031,REGN,regeneron pharmaceutical regn muscle formidable trade end just even day move average stock be week possible base undercut low previous base mean new base form be first stage pattern
1032,REGN,netflix nflx stream lower continue volatile pullback early august high end session high mark week move average august low stock market today receive early boost overseas start late rally china datum fed run european market stock hold add solid early gain leave nasdaq dow jone industrial higher index close top trading range volume continue track higher nasdaq higher nyse relative late trade friday accord preliminary datum chipmaker ore miner biotechs oil driller lead top advance industry group only group lose ground coal bottom heap teco energy te rolled gain spur friday news be acquire nova scotia base emera top tempur sealy tpx bounce advance naming former dollar thrifty automotive group ceo chairman scott thompson new chairman chief executive stock rebound week support left share just fresh high regeneron pharmaceutical regn muscle formidable trade end just even day move average stock be week possible base undercut low previous base mean new base form be first stage pattern netflix nflx stream lower continue volatile pullback early august high end session high mark week move average august low
1033,REGN,amgen amgn regeneron pharmaceutical regn be tuesday upgrade ub survey suggest sale new cholesterol drug be even bigger expect analyst matthew roden raise rating regeneron way buy sell amgen buy neutral survey european physician
1034,REGN,stock veer south start gate friday market recoil surprisingly weak september payroll report dow fall nasdaq drop apiece volume rise fraction vs thursday early trade level stock market today trip labor department september job datum show much weaker expect hire september news compound spike september layoff report thursday challenger gray christmas surprise jump initial weekly unemployment claim just keep ugly ball roll commerce department report factory order august reversed downwardly revise gain july undercut consensus forecast slip dollar tumble bond thump higher oil reversed early gain dive putt west texas intermediate brent crude more week europe market reversed sharp gain moderate loss afternoon trade stock action bank financial be clear pressure weak job report call question federal reserve be moved raise rate end year dow stock dive goldman sachs gs jpmorgan jpm lead loss more nearly stock open lower charle schwab schw etrade financial etfc stake low end loss respectively nasdaq gilead science gild regeneron pharmaceutical regn keurig green mountain gmcr fall more wynn resort wynn surge nearly erase loss week stock be march high fall august september micron technology mu jump fiscal fourth quarter earning revenue decline less expect analyst ibd list signature bank new york sbny fall more stock have be meeting resistance week move average attempt climb right side week consolidation telecom engineering firm dycom dy slump almost slip week move average stock have turn advance past buy point decline signal sell stock particularly correct market sucampo pharmaceutical scmp be only stock list post early gain attempt rebound day move average
1035,REGN,day weekend do stock market good tuesday major average hold strong gain midday volume nyse nasdaq be tracking nicely friday light pre holiday level stock market today
1036,REGN,nyse advance stock outnumber decliner ratio be just nasdaq
1037,REGN,regeneron regn be top gainer nasdaq rise accord streetinsider com ub upgrade biotech buy sell price target regeneron have make huge move recent year reset base count week end aug share hit low undercut low most recent flat base
1038,REGN,elsewhere facebook fb pop nearly also positive analyst commentary
1039,REGN,fitbit fit be still damage good term technical health share surge morgan stanley upgrade stock overweight move recent new issue be still high
1040,REGN,tempur sealy tpx bounce day move average rise company name scott thompson new ceo effective immediately thompson be most recently ceo dollar thrifty automotive group
1041,REGN,second quarter earning season be pretty much fast grow healthequity hqy report close company be lead health saving account hsa administrator offer hsa product network health plan employer partnership share rise ahead result
1042,REGN,new york mercantile exchange crude oil be trading barrel meanwhile money flow bond yield year note rise basis point day weekend do stock market good tuesday major average hold strong gain midday volume nyse nasdaq be tracking nicely friday light pre holiday level stock market today nyse advance stock outnumber decliner ratio be just nasdaq regeneron regn be top gainer nasdaq rise accord streetinsider com ub upgrade biotech buy sell price target regeneron have make huge move recent year reset base count week end aug share hit low undercut low most recent flat base elsewhere facebook fb pop nearly also positive analyst commentary fitbit fit be still damage good term technical health share surge morgan stanley upgrade stock overweight move recent new issue be still high tempur sealy tpx bounce day move average rise company name scott thompson new ceo effective immediately thompson be most recently ceo dollar thrifty automotive group second quarter earning season be pretty much fast grow healthequity hqy report close company be lead health saving account hsa administrator offer hsa product network health plan employer partnership share rise ahead result new york mercantile exchange crude oil be trading barrel meanwhile money flow bond yield year note rise basis point
1043,REGN,exchange trade fund jab higher wednesday investor cheer biotech rally strong performance overseas market major asian market close higher release positive datum chinese consumer sentiment upbeat mood ripple europe wednesday open most benchmark defy be historically worst trading day year etfs tracking
1044,REGN,stock future point sharply higher be early high ahead wednesday start trade follow mixed early economic news market rally europe
1045,REGN,dow future steer point nasdaq future trade point fair market value future show point gain small cap be positive steady russell future hold point gain
1046,REGN,stock market today open day rally belt nasdaq end higher trading range tuesday index remain day move average nasdaq be position possible test line week
1047,REGN,personal spending rise november commerce department say welcome improvement october gain show line economist expectation personal income rise tad october gain better view advance
1048,REGN,durable good order be flat month sharply october downwardly revise gain better contraction project economist consensus transportation order dip vs estimate change
1049,REGN,et university michigan be schedule report final consumer sentiment estimate december commerce department give new home sale number november
1050,REGN,dollar be mixed early wednesday vs euro yen bond slip send year yield basis point
1051,REGN,crude price moved higher brent crude west texas intermediate benchmark trading tandem just barrel crude price see effect weekly inventory datum energy information administration due et metal agricultural commodity be mixed
1052,REGN,mining company appear poise rally day bhp billiton bbl rio rio freeport mcmoran fcx vale vale jump bounce oil mining issue trip rally european market send london ftse more cac paris frankfurt dax nearly much midday trade
1053,REGN,stock nike nke vault nearly lead dow well ibd list premarket action athletic wear maker report late tuesday fiscal second quarter earning top consensus forecast revenue rise just shy expectation gross margin increase more forecast primarily due higher selling price stock have be testing support week move average just flat base buy point
1054,REGN,devon energy dvn spiked devon have be highly active acquisition front month pay asset anadarko powder river basin sell san juan river holding new mexico bp bp
1055,REGN,celgene celg muster gain open drug maker announce settlement litigation vs india natco pharma partner arrow international subsidiary allergan agn pertain patent oral cancer drug revlimid celgene share have be consolidate july
1056,REGN,micron technology mu tank hurt fiscal earning result deliver late tuesday idaho base chip maker score narrow earning beat revenue miss analyst target management guide revenue earning consensus forecast stock future point sharply higher be early high ahead wednesday start trade follow mixed early economic news market rally europe dow future steer point nasdaq future trade point fair market value future show point gain small cap be positive steady russell future hold point gain stock market today open day rally belt nasdaq end higher trading range tuesday index remain day move average nasdaq be position possible test line week personal spending rise november commerce department say welcome improvement october gain show line economist expectation personal income rise tad october gain better view advance durable good order be flat month sharply october downwardly revise gain better contraction project economist consensus transportation order dip vs estimate change et university michigan be schedule report final consumer sentiment estimate december commerce department give new home sale number november dollar be mixed early wednesday vs euro yen bond slip send year yield basis point crude price moved higher brent crude west texas intermediate benchmark trading tandem just barrel crude price see effect weekly inventory datum energy information administration due et metal agricultural commodity be mixed mining company appear poise rally day bhp billiton bbl rio rio freeport mcmoran fcx vale vale jump bounce oil mining issue trip rally european market send london ftse more cac paris frankfurt dax nearly much midday trade stock nike nke vault nearly lead dow well ibd list premarket action athletic wear maker report late tuesday fiscal second quarter earning top consensus forecast revenue rise just shy expectation gross margin increase more forecast primarily due higher selling price stock have be testing support week move average just flat base buy point devon energy dvn spiked devon have be highly active acquisition front month pay asset anadarko powder river basin sell san juan river holding new mexico bp bp celgene celg muster gain open drug maker announce settlement litigation vs india natco pharma partner arrow international subsidiary allergan agn pertain patent oral cancer drug revlimid celgene share have be consolidate july micron technology mu tank hurt fiscal earning result deliver late tuesday idaho base chip maker score narrow earning beat revenue miss analyst target management guide revenue earning consensus forecast
1057,REGN,many lead stock have be form flat basis market undergo series fairly shallow pullback flat base stock correct less ideal buy point typically cent high left side leader hold market correction be have trouble advance thus remain flat base
1058,REGN,profit margin be much company make earning dollar sale profit margin mean company earn cent sale strong profit margin give indication well company leverage rise demand additional profit fuel share ibd screen day be healthy profit margin
1059,REGN,market be correction savvy investor look top stock strong long term fundamental recent ipo alibaba baba top fundamental screen day be good place careful investor start create watch list potential stock market turn stock have year earning sale growth
1060,REGN,major average close higher thursday cheer part better expect weekly job claim datum ahead friday employment report
1061,REGN,nasdaq dow jone industrial average rise tack preliminary datum show nyse nasdaq volume come slightly wednesday level
1062,REGN,wall street find comfort better expect weekly jobless datum open claim fall last week april job report be friday et
1063,REGN,oil gas name lag june crude oil settle barrel airline be beneficiary unite continental ual american aal delta dal score gain
1064,REGN,stock market today investor cheer earning tesla motor tsla late wednesday share jolted nearly higher company report narrower expect loss sale jump wall street be still worry company cash burn rate
1065,REGN,meanwhile earning season be minefield several more growth company include epam system epam fleetmatic fltx fall hard early end session high
1066,REGN,selling be less intense regeneron regn rise nearly early regeneron lose report better expect earning second straight quarter accelerate sale growth major average close higher thursday cheer part better expect weekly job claim datum ahead friday employment report nasdaq dow jone industrial average rise tack preliminary datum show nyse nasdaq volume come slightly wednesday level wall street find comfort better expect weekly jobless datum open claim fall last week april job report be friday et oil gas name lag june crude oil settle barrel airline be beneficiary unite continental ual american aal delta dal score gain stock market today investor cheer earning tesla motor tsla late wednesday share jolted nearly higher company report narrower expect loss sale jump wall street be still worry company cash burn rate meanwhile earning season be minefield several more growth company include epam system epam fleetmatic fltx fall hard early end session high selling be less intense regeneron regn rise nearly early regeneron lose report better expect earning second straight quarter accelerate sale growth
1067,REGN,ibd stock have outperformed new rally be confirm then ibd have gain nasdaq be just outperformance just handful breakout follow day have produce decent gain skywork solution swks technology avgo synaptic syna regeneron pharmaceutical regn papa john pzza
1068,REGN,stock open tightly mixed wednesday investor patiently wait afternoon release fed minute
1069,REGN,nasdaq slip edge fraction lower dow jone industrial average hold positive territory just tuesday intraday high
1070,REGN,stock market today get quiet start trade fraction lower nasdaq nyse compare volume same time tuesday trading be likely remain quiet ahead release minute federal open market committee april meeting due afternoon
1071,REGN,move be generally subdue early action dow pfizer pfe lead mcdonald mcd lag move less nasdaq biggest mover be vertex pharmaceutical vrtx drop more better gain analog device adi
1072,REGN,airline be take hard hit early southwest airline luv diving american airline aal delta air line dal tumble
1073,REGN,telecom service provider dycom industry dy roar ahead start trade palm beach garden fla company fiscal sale earning be far expectation management boost earning revenue guidance well consensus projection
1074,REGN,american eagle aeo soar report healthy sale earning beat put stock back week move average week pullback april high
1075,REGN,hormel food hrl climb follow fiscal second quarter result earning outpaced analyst expectation revenue growth come bit short management say lower pork cost be impact avian influenza challenge turkey business hormel be base buy point
1076,REGN,lowe low slump revenue earning stop short consensus expectation management full year earning guidance be also just forecast stock have be struggle regain support week move average trading march high
1077,REGN,ibd stock open generally lower bottom list alaska air alk broadsoft bsft drop regeneron regn noah noah horizon pharma hznp post best gain nearly apiece stock open tightly mixed wednesday investor patiently wait afternoon release fed minute nasdaq slip edge fraction lower dow jone industrial average hold positive territory just tuesday intraday high stock market today get quiet start trade fraction lower nasdaq nyse compare volume same time tuesday trading be likely remain quiet ahead release minute federal open market committee april meeting due afternoon move be generally subdue early action dow pfizer pfe lead mcdonald mcd lag move less nasdaq biggest mover be vertex pharmaceutical vrtx drop more better gain analog device adi airline be take hard hit early southwest airline luv diving american airline aal delta air line dal tumble telecom service provider dycom industry dy roar ahead start trade palm beach garden fla company fiscal sale earning be far expectation management boost earning revenue guidance well consensus projection american eagle aeo soar report healthy sale earning beat put stock back week move average week pullback april high hormel food hrl climb follow fiscal second quarter result earning outpaced analyst expectation revenue growth come bit short management say lower pork cost be impact avian influenza challenge turkey business hormel be base buy point lowe low slump revenue earning stop short consensus expectation management full year earning guidance be also just forecast stock have be struggle regain support week move average trading march high ibd stock open generally lower bottom list alaska air alk broadsoft bsft drop regeneron regn noah noah horizon pharma hznp post best gain nearly apiece
1078,REGN,stock market close higher thursday index pare gain
1079,REGN,nasdaq climb dow jone industrial average add
1080,REGN,volume rise nyse fall nasdaq accord early figure advance stock lead decliner nasdaq winner barely edge loser nyse
1081,REGN,computer trucking financial rank day top perform sector retail metal energy stock lag
1082,REGN,weak forecast send homebuilding stock stock market today
1083,REGN,meritage home mth cut forecast earning cite rise labor cost delay closing slower expect business company newer market southeast stock fall heavy trading lowest level early february
1084,REGN,be shortage skilled labor many market subcontractor struggle catch increase demand continue recovery homebuilding say chairman ceo steven hilton competition labor be raise cost lengthen construction time statement add bad weather part texas colorado further hurt company
1085,REGN,homebuilder industry group have be market leader be worst group thursday ibd track
1086,REGN,day biggest loser be lululemon athletica lulu plunge yoga style apparel chain guide full year earning expectation share fall lowest level december
1087,REGN,google googl rise share continue rise support day move average volume google be light
1088,REGN,close share action sport retailer zumiez zumz slide company announce quarterly result stock close regular trading week low
1089,REGN,follow juan carlos arancibia twitter ibd_jarancibia stock market close higher thursday index pare gain nasdaq climb dow jone industrial average add volume rise nyse fall nasdaq accord early figure advance stock lead decliner nasdaq winner barely edge loser nyse computer trucking financial rank day top perform sector retail metal energy stock lag weak forecast send homebuilding stock stock market today meritage home mth cut forecast earning cite rise labor cost delay closing slower expect business company newer market southeast stock fall heavy trading lowest level early february be shortage skilled labor many market subcontractor struggle catch increase demand continue recovery homebuilding say chairman ceo steven hilton competition labor be raise cost lengthen construction time statement add bad weather part texas colorado further hurt company homebuilder industry group have be market leader be worst group thursday ibd track day biggest loser be lululemon athletica lulu plunge yoga style apparel chain guide full year earning expectation share fall lowest level december google googl rise share continue rise support day move average volume google be light close share action sport retailer zumiez zumz slide company announce quarterly result stock close regular trading week low follow juan carlos arancibia twitter ibd_jarancibia
1090,REGN,share development stage pharmaceutical firm esperion therapeutic espr jump wednesday ub initiate coverage esperion stock buy rating praise cholesterol drug candidate analyst andrew peter write etc drug lower ldl cholesterol yielded positive phase trial result last month present further upside even stock already more double
1091,REGN,stock open hole then dig deeper wednesday datum drive rally china europe
1092,REGN,nasdaq tumble dow jone industrial average drop show loss
1093,REGN,volume be sharply higher nasdaq higher nyse compare trade same time tuesday
1094,REGN,job news do stock market today favor adp march national employment report show job growth weakest last
1095,REGN,manufacturing datum be mixed researcher markit report march purchasing manager index rise vs february economist consensus bet mild uptick
1096,REGN,institute supply management march ism manufacturing index ease consensus view project dip
1097,REGN,construction spending fall second month be less weak february decline vs slip january economist consensus have estimate gain
1098,REGN,stock dow component open lower merck mrk nike nke johnson johnson jnj hit hardest none nasdaq stock manage gain bottom list regeneron pharmaceutical regn slip heavy trade pull back test support day move average
1099,REGN,twitter twtr rise heavy trade jeffery co initiate coverage stock buy rating price target report note stock be particularly well position benefit online video ad mobile tailwind twitter have be battle clear cup handle buy point
1100,REGN,sear shld jump assign property partnership retail reit general growth property ggp sear have post annual loss continue operate store receive cash stake partnership general growth share dip fraction have shape cup handle base late january high
1101,REGN,lead stock get weak start nearly ibd list downshifting open only noah holding noah unite therapeutic uthr post narrow gain
1102,REGN,ambarella amba take hardest early hit be more left stock bit less most recent buy point stock open hole then dig deeper wednesday datum drive rally china europe nasdaq tumble dow jone industrial average drop show loss volume be sharply higher nasdaq higher nyse compare trade same time tuesday job news do stock market today favor adp march national employment report show job growth weakest last manufacturing datum be mixed researcher markit report march purchasing manager index rise vs february economist consensus bet mild uptick institute supply management march ism manufacturing index ease consensus view project dip construction spending fall second month be less weak february decline vs slip january economist consensus have estimate gain stock dow component open lower merck mrk nike nke johnson johnson jnj hit hardest none nasdaq stock manage gain bottom list regeneron pharmaceutical regn slip heavy trade pull back test support day move average twitter twtr rise heavy trade jeffery co initiate coverage stock buy rating price target report note stock be particularly well position benefit online video ad mobile tailwind twitter have be battle clear cup handle buy point sear shld jump assign property partnership retail reit general growth property ggp sear have post annual loss continue operate store receive cash stake partnership general growth share dip fraction have shape cup handle base late january high lead stock get weak start nearly ibd list downshifting open only noah holding noah unite therapeutic uthr post narrow gain ambarella amba take hardest early hit be more left stock bit less most recent buy point
1103,REGN,market be still correction mean not best time buy never hurt keep eye top performer such hot drugmaker ibd valeant pharmaceutical vrx say start month shell psoriasis drug licensing
1104,REGN,stock future point weak start monday market head last trading day august final week summer
1105,REGN,dow future trade point fair market value nasdaq future be point future show point loss be early lows
1106,REGN,stock market today launch nasdaq so far august tracking worst monthly performance index have be much
1107,REGN,nasdaq open way month trading range rebound dive open just midpoint trading range month
1108,REGN,market remain correction savvy investor put pause good use build watch list stock strong fundamental form possible basis
1109,REGN,fairly light week economic news get federal reserve september beige book report due wednesday ramp labor department august payroll report friday
1110,REGN,today kingsbury international report chicago purchasing manager index august et dalla federal reserve deliver regional manufacturing survey
1111,REGN,stock second quarter earning season be mostly pass only handful big name mostly retailer expect week
1112,REGN,new jersey base biotech medicine co mdco pop ahead open early stage trial result present london sunday show shot administer cholesterol treatment aln pcssc develop partner alnylam pharmaceutical alny lower ldl cholesterol level average more day result suggest drug manage cholesterol level shot time year alnylam rise fraction open
1113,REGN,lead stock be early pressure bulk ibd list steering mostly lower premarket trade loss be mild however regeneron pharmaceutical regn alaska airline alk slip furthest fall less
1114,REGN,overseas china market post moderately mixed session hong kong hang seng index shanghai composite japan tokyo nikkei dive europe market be also mixed lead index paris frankfurt half percent london ftse midday
1115,REGN,dollar ease vs euro yen bond edge higher oil price slip range west texas intermediate trading barrel brent crude gold be fraction ounce stock future point weak start monday market head last trading day august final week summer dow future trade point fair market value nasdaq future be point future show point loss be early lows stock market today launch nasdaq so far august tracking worst monthly performance index have be much nasdaq open way month trading range rebound dive open just midpoint trading range month market remain correction savvy investor put pause good use build watch list stock strong fundamental form possible basis fairly light week economic news get federal reserve september beige book report due wednesday ramp labor department august payroll report friday today kingsbury international report chicago purchasing manager index august et dalla federal reserve deliver regional manufacturing survey stock second quarter earning season be mostly pass only handful big name mostly retailer expect week new jersey base biotech medicine co mdco pop ahead open early stage trial result present london sunday show shot administer cholesterol treatment aln pcssc develop partner alnylam pharmaceutical alny lower ldl cholesterol level average more day result suggest drug manage cholesterol level shot time year alnylam rise fraction open lead stock be early pressure bulk ibd list steering mostly lower premarket trade loss be mild however regeneron pharmaceutical regn alaska airline alk slip furthest fall less overseas china market post moderately mixed session hong kong hang seng index shanghai composite japan tokyo nikkei dive europe market be also mixed lead index paris frankfurt half percent london ftse midday dollar ease vs euro yen bond edge higher oil price slip range west texas intermediate trading barrel brent crude gold be fraction ounce
1116,REGN,nearly universal experience get older fail eyesight middle age many start need glass focus fine detail problem get much more severe form old age vision loss be age related macular degeneration amd macula be very center retina so
1117,REGN,biotech etfs get smash late trade friday bank diversify financial etfs maintain gain rate liftoff bogey dominate investor mood major index etfs reversed early gain close lower session week upbeat number gdp datum consumer confidence thursday ceo lead etf sponsor expressed disappointment
1118,REGN,stock be still hard pare loss head last hour thursday trading session nasdaq lose dow jone industrial average fall give volume swell board vs same time wednesday decliner outpaced advancer nearly nyse more nasdaq gold miner utility nonalcoholic beverage stock lead scant list outperformer stock market today downside be lead construction gear maker solar medical stock biotechs continue take beating democratic presidential candidate hillary clinton tweet monday allege price gouge specialty drug maker lead biotechs sizable loss include sucampo pharmaceutical scmp celgene celg gilead science gild regeneron pharmaceutical regn be upside diamond food dmnd reclaim day move average soar month high massive trade maker emerald nut pop secret popcorn other snack have tap credit suisse explore potential sale accord kellogg snack food jjsf pepsico pep be potential suitor ibd stock paycom software payc be biggest loser slumping heavy trade day move average first time month company provide cloud base payroll human resource software also enterprise software group paylocity hold pcty gap fall fast turnover breach day line payroll software maker late wednesday announce secondary offer share follow nancy gondo twitter ibd_ngondo
1119,REGN,large cap stock variety sector continue hold relatively well increase higher volume decline major average overall market uncertainty valeant pharmaceutical vrx be new entrant week list drugmaker have be try acquire botox maker allergan agn april avail allergan think valeant hostile offer be
1120,REGN,biotech stock be gainer stock market friday standout be rare drug company alexion pharmaceutical alxn shot
1121,REGN,biotech group rank group track investor business daily just week
1122,REGN,other medical group be ibd top include hospital ethical drug week
1123,REGN,hospital have benefit health care reform obamacare have see healthy share gain recent month group pull back last week rise nearly friday
1124,REGN,hca holding hca largest hospital group market capitalization rise nearly
1125,REGN,ethical drug group jazz pharmaceutical jazz jump friday botox maker allergan agn shopping acquisition get hostile bidder valeant pharmaceutical vrx back shot nearly jazz have be rumore possible candidate
1126,REGN,biotech group hepatitis drug maker gilead science gild regeneron pharmaceutical regn ibd leaderboard stock end have be disappointing week high note regeneron climb friday gilead nearly
1127,REGN,related jazz pharmaceutical used new cash buy growth biotech stock be gainer stock market friday standout be rare drug company alexion pharmaceutical alxn shot biotech group rank group track investor business daily just week other medical group be ibd top include hospital ethical drug week hospital have benefit health care reform obamacare have see healthy share gain recent month group pull back last week rise nearly friday hca holding hca largest hospital group market capitalization rise nearly ethical drug group jazz pharmaceutical jazz jump friday botox maker allergan agn shopping acquisition get hostile bidder valeant pharmaceutical vrx back shot nearly jazz have be rumore possible candidate biotech group hepatitis drug maker gilead science gild regeneron pharmaceutical regn ibd leaderboard stock end have be disappointing week high note regeneron climb friday gilead nearly related jazz pharmaceutical used new cash buy growth
1128,REGN,acorda therapeutic acor stock pop biotechnology company agree buy privately hold civita therapeutic gain access drug late development used treat parkinson disease acorda obtain global right civita experimental drug cvt inhaled dry powder formulation cvt be used treat certain episode such inability move patient parkinson disease acquisition also include right civita arcus pulmonary delivery technology manufacturing facility chelsea mass acquisition add exciting product candidate acorda pipeline address significant unmet need parkinson disease acorda ceo ron cohen say statement also leverage acorda exist development commercial capability create opportunity develop global presence addition civita arcus technology add proprietary platform potential future development opportunity share acorda be nearly midday trading stock market today ibd medical biom biotech group be rank industry group include gilead science gild regeneron pharmaceutical regn biogen idec biib amgen amgn rbc capital market analyst michael yee say see positive negative aspect deal regard civita acquisition be lukewarm due clinical mostly regulatory risk inhaled old drug yee say note wednesday inhaled drug require specific pre clinical clinical datum related parkinson consistency long term chronic lung safety animal human other regulatory datum specific inhaled drug sometimes aren always clear end regulatory reviews make particularly tricky prior example include alexza mannkind didn get first pass however long term risk be manageable say also commercial opportunity seem logical need be better understood not drive huge value reach market post yee say
1129,REGN,major stock index nurse modest loss be session lows late afternoon trading tuesday nasdaq lose dow jone industrial average lose nyse nasdaq volume be tracking higher monday level economic news home price stall july accord latest case shiller datum consumer confidence unexpectedly fall lowest read stock market today fast grow name exposure auto market fall heavy volume wall street dissed ford earning guidance monday gentherm thrm plunge harman international har lose day gainer ebay ebay surge news spin paypal unit sometime next year regeneron regn meanwhile add company partner sanofi sny report positive phase ii datum experimental drug dupilumab drug significantly reduce nasal polyp congestion dupilumab be also be look treat eczema asthma regeneron be leaderboard name investor com epam system epam stay rally mode share rise hit low stock be just potential buy point online travel firm expedia expe continue firm week move average second time june share rise strong volume news johnson johnson jnj announce small acquisition buy privately hold alio pharmaceutical
1130,REGN,stock hold modest gain hour tuesday session day nasdaq notch third distribution day trading session
1131,REGN,gain dow jone industrial average add nasdaq rise nasdaq volume be tracking slightly lower monday level nyse volume rise bit
1132,REGN,stock market today salix pharmaceutical slxp tack nearly bring day gain late monday food drug administration give tentative approval uceris rectal foam treat patient ulcerative colitis
1133,REGN,regeneron pharmaceutical regn meanwhile add news blockbuster drug eylea be grant fda breakthrough therapy designation diabetic retinopathy patient diabetic macular edema
1134,REGN,huntsman hun bounce back top week flat base rise just buy point market uptrend pressure be not easy environment breakout succeed
1135,REGN,downside netflix nflx gap heavy volume now day move average company recently start offer stream service european country ceo reed hasting say company be still year away profitability region
1136,REGN,adobe system adbe fall ahead earning report close adobe have hold gain relatively well cup handle june week move average accumulation distribution rating ahead result
1137,REGN,rating point institutional selling stock hold modest gain hour tuesday session day nasdaq notch third distribution day trading session gain dow jone industrial average add nasdaq rise nasdaq volume be tracking slightly lower monday level nyse volume rise bit stock market today salix pharmaceutical slxp tack nearly bring day gain late monday food drug administration give tentative approval uceris rectal foam treat patient ulcerative colitis regeneron pharmaceutical regn meanwhile add news blockbuster drug eylea be grant fda breakthrough therapy designation diabetic retinopathy patient diabetic macular edema huntsman hun bounce back top week flat base rise just buy point market uptrend pressure be not easy environment breakout succeed downside netflix nflx gap heavy volume now day move average company recently start offer stream service european country ceo reed hasting say company be still year away profitability region adobe system adbe fall ahead earning report close adobe have hold gain relatively well cup handle june week move average accumulation distribution rating ahead result rating point institutional selling
1138,REGN,biotechs be get hit hard stock market today group have be group ibd industry track worst weekly decline year top rate biotech stock take beating include celgene celg biogen biib regeneron regn watch video ibd chart analysis
1139,REGN,leerink partner upgrade french pharma giant sanofi sny outperform market perform tuesday cite foreign exchange tailwind promising cholesterol fight drug news weekend analyst seamus fernandez write problem plague company last fall notably weak diabetes guidance loss ceo still hasn be replace be now
1140,REGN,share several drugmaker soar monday study publish weekend say next generation cholesterol drug cut risk heart disease be world killer highly rate regeneron regn break close monday session still buy range drug development partner sanofi sny rise news too so do
1141,REGN,akorn akrx share make big gain stock market today drugmaker have restate financial statement error lead overstatement revenue earning investor seem be relieve move watch video breakdown highly rate stock chart action
1142,REGN,ibd top industry week be medical biotech biom medical generic drug several company top group report market move news tuesday market close here be
1143,REGN,akorn restate stock rise
1144,REGN,akorn akrx late tuesday restate financial statement cite error regard asset liability related tech pharmacal buy april error lead overstatement revenue earning share cent
1145,REGN,share specialty drugmaker rise hour stock market today akorn stock have rise regular session akorn hit record feb day powerful earning share fall more march actavis act release rival version clobetasol akorn best selling skin cream march share fall day move average akorn hour action suggest stock retake key support level wednesday
1146,REGN,esperion stock offer pare cholesterol drug spike
1147,REGN,esperion therapeutic espr shot regular session news bad cholesterol statin drug outperformed traditional statin drug pill also compete pricey injectable pcsk drug ceo tim mayleben imply snarky tweet etc be patient friendly physician friendly payer friendly espr
1148,REGN,regeneron regn amgen amgn sanofi sny have rise sharply week weekend study say pcsk drug expect be very expensive show big drop heart disease
1149,REGN,market close share fall esperion announce stock offer proceed go etc development pre launch effort
1150,REGN,nektar breast cancer drug fail
1151,REGN,nektar therapeutic nktr late tuesday report experimental breast cancer drug fail late stage trial nktr drug study very sick patient show survival month vs month standard drug difference survival rate do not have statistical significance
1152,REGN,nektar fall hour regular session share rise cent just close day move average
1153,REGN,teva sell cancer ignyta
1154,REGN,teva pharmaceutical industry teva announce buy share ignyta rxdx exchange oncology asset teva teva buy further share select other investor buy share
1155,REGN,teva stock be little change late share close just buy point short cup base
1156,REGN,ignyta stock rise late trade
1157,REGN,follow ed carson twitter ibd_ecarson ibd top industry week be medical biotech biom medical generic drug several company top group report market move news tuesday market close here be akorn restate stock risesakorn akrx late tuesday restate financial statement cite error regard asset liability related tech pharmacal buy april error lead overstatement revenue earning share cent share specialty drugmaker rise hour stock market today akorn stock have rise regular session akorn hit record feb day powerful earning share fall more march actavis act release rival version clobetasol akorn best selling skin cream march share fall day move average akorn hour action suggest stock retake key support level wednesday esperion stock offer pare cholesterol drug spikeesperion therapeutic espr shot regular session news bad cholesterol statin drug outperformed traditional statin drug pill also compete pricey injectable pcsk drug ceo tim mayleben imply snarky tweet etc be patient friendly physician friendly payer friendly espr regeneron regn amgen amgn sanofi sny have rise sharply week weekend study say pcsk drug expect be very expensive show big drop heart disease market close share fall esperion announce stock offer proceed go etc development pre launch effort nektar breast cancer drug failsnektar therapeutic nktr late tuesday report experimental breast cancer drug fail late stage trial nktr drug study very sick patient show survival month vs month standard drug difference survival rate do not have statistical significance nektar fall hour regular session share rise cent just close day move average teva sell cancer ignytateva pharmaceutical industry teva announce buy share ignyta rxdx exchange oncology asset teva teva buy further share select other investor buy share teva stock be little change late share close just buy point short cup base ignyta stock rise late trade follow ed carson twitter ibd_ecarson
1158,REGN,highly rate drugmaker beat analyst second quarter estimate tuesday generally follow season trend guide conservatively specialty generic giant actavis act earning rise vs year earlier share beating forecast cent sale rise more estimate company offer first guidance buy
1159,REGN,stock market bounce back tuesday session provide encourage sign nasdaq jump close session high small cap continue lag comparison russell picked nasdaq advance be not well round volume nasdaq be lower advance stock top
1160,REGN,initial enthusiasm stronger expect read second quarter gross domestic product fade wednesday major average end mixed performance nasdaq outperformed again hour session akamai technology akam slump earning top expectation revenue come short meanwhile yelp yelp have good news investor hour session share rise nearly late trade customer review service report first ever quarterly profit earn cent share vs consensus estimate loss cent sale rise average monthly unique visitor grow close nasdaq fared best rise rise fractionally dow jone industrial average ease preliminary datum show volume lower nasdaq higher nyse first read gdp show rise much better consensus estimate big improvement contraction first quarter fed day meeting come end wednesday fed expect cut monthly bond buy fifth straight time expect end bond buy october even continue see significant slack labor market stock market today regeneron pharmaceutical regn soar flagship drug eylea be approve treat diabetic macular edema dme blockbuster drug be approve treat age related wet macular degeneration lead cause blindness elderly regeneron also say cholesterol drug alirocumab meet company primary goal phase trial thursday economic docket watch weekly jobless claim latest read chicago purchasing manager index open watch earning fromgildan activewear gil old dominion freight line odfl valeant pharmaceutical vrx
1161,REGN,tech security be worth watch go thursday stock market trading cyberark cybr imperva impv jump wednesday broader market slip index
1162,REGN,stock have see analyst upgrade month rise demand cybersecurity software unconfirmed rumor be circulate week cyberark be ibm ibm acquisition target
1163,REGN,ibd leaderboard security stock palo alto network panw slip slightly wednesday
1164,REGN,techs rise high volume
1165,REGN,high rate cyberark rank ibd stock move midweek gain high volume likely indicate institutional investor be buy cyberark software target threat go privileged account other high value asset company network imperva be datum center security palo alto do advanced firewall
1166,REGN,other tech stock move wednesday higher usual volume include fleet management software firm fleetmatic fltx vpn alternative software maker logmein logm biotech regeneron pharmaceutical regn ibd composite rating least possible open source operate system provider red hat rht have cr
1167,REGN,palo alto network amazon com amzn be only other tech ibd leaderboard moment slip wednesday stock be work build basis
1168,REGN,amazon introduce new fire tablet last week researcher palo alto network recently make headline find malware apps apple aapl app store
1169,REGN,stock market officially uptrend pressure caution be warrant
1170,REGN,follow donna howell twitter ibd_dhowell tech security be worth watch go thursday stock market trading cyberark cybr imperva impv jump wednesday broader market slip index stock have see analyst upgrade month rise demand cybersecurity software unconfirmed rumor be circulate week cyberark be ibm ibm acquisition target ibd leaderboard security stock palo alto network panw slip slightly wednesday techs rise high volumehigh rate cyberark rank ibd stock move midweek gain high volume likely indicate institutional investor be buy cyberark software target threat go privileged account other high value asset company network imperva be datum center security palo alto do advanced firewall other tech stock move wednesday higher usual volume include fleet management software firm fleetmatic fltx vpn alternative software maker logmein logm biotech regeneron pharmaceutical regn ibd composite rating least possible open source operate system provider red hat rht have cr palo alto network amazon com amzn be only other tech ibd leaderboard moment slip wednesday stock be work build basis amazon introduce new fire tablet last week researcher palo alto network recently make headline find malware apps apple aapl app store stock market officially uptrend pressure caution be warrant follow donna howell twitter ibd_dhowell
1171,REGN,volatility be word day stock market drugmaker strong growth prospect proven long term stability such ibd member valeant pharmaceutical vrx be good stock watch list candidate ibd spotlight top performer list stock base combination factor include sale profit growth today roster
1172,REGN,lead industry group market be start show sign wear tear not surprising selling pressure continue build major average top rank group ibd database finance mortgage related service fall thursday week end aug plunge lendingtree tree former big leader group
1173,REGN,analyst be still bullish netflix nflx day report say apple aapl be look original programming bank america bac raise netflix price target tuesday keep buy rating stock netflix share plunge close stock market today apple share end netflix
1174,REGN,weak overseas datum kick global investor selling mood tuesday send stock future sharply lower
1175,REGN,dow future swoon point fair market value nasdaq future be more point lower future trade point small cap be hard hit russell future diving point
1176,REGN,stock market today again appear subject circumstance china official purchasing manager index datum show manufacturing contract august
1177,REGN,independent caixin markit pmi rise slightly earlier estimate august still country quickest deterioration operate condition year caixin markit overall service manufacturing gauge also slip july
1178,REGN,news be compound nearly drop export south korea august far forecast decline
1179,REGN,japanese stock react hardest tokyo nikkei fall weak manufacturing datum china report show japanese company be trimming capital expenditure china market also take considerable loss hong kong hang seng end shanghai composite show loss
1180,REGN,manufacturing datum be mixed eurozone selling nevertheless ripple europe lead index paris frankfurt london be more near midday
1181,REGN,markit release manufacturing pmi august et institute supply management release purchasing manager index commerce department report july construction spending number automaker report august sale figure day early result show fiat chrysler fcau report strong anticipate increase august sale sale be generally expect be weaker due late labor day holiday
1182,REGN,stock dollar tree dltr drop more premarket action chesapeake va base retailer report second quarter sale earning analyst expectation offer weaker forecast revenue guidance share have be hover tight consolidation march high
1183,REGN,qiwi qiwi cyprus base provider online payment service russia former soviet state tumble company result top sale earning forecast guidance appear healthy stock have be unravele high
1184,REGN,chip designer ambarella amba dive ahead report due today close
1185,REGN,leader be clearly pressure ahead open nearly ibd stock trade lower worst hit regeneron pharmaceutical regn fall nearly
1186,REGN,other market dollar be mixed yen euro bond downshift send year yield basis point oil price pull back heel day rally send west texas intermediate brent crude ahead diving year lows last week gold chug ahead ounce most other commodity be narrowly mixed weak overseas datum kick global investor selling mood tuesday send stock future sharply lower dow future swoon point fair market value nasdaq future be more point lower future trade point small cap be hard hit russell future diving point stock market today again appear subject circumstance china official purchasing manager index datum show manufacturing contract august independent caixin markit pmi rise slightly earlier estimate august still country quickest deterioration operate condition year caixin markit overall service manufacturing gauge also slip july news be compound nearly drop export south korea august far forecast decline japanese stock react hardest tokyo nikkei fall weak manufacturing datum china report show japanese company be trimming capital expenditure china market also take considerable loss hong kong hang seng end shanghai composite show loss manufacturing datum be mixed eurozone selling nevertheless ripple europe lead index paris frankfurt london be more near midday markit release manufacturing pmi august et institute supply management release purchasing manager index commerce department report july construction spending number automaker report august sale figure day early result show fiat chrysler fcau report strong anticipate increase august sale sale be generally expect be weaker due late labor day holiday stock dollar tree dltr drop more premarket action chesapeake va base retailer report second quarter sale earning analyst expectation offer weaker forecast revenue guidance share have be hover tight consolidation march high qiwi qiwi cyprus base provider online payment service russia former soviet state tumble company result top sale earning forecast guidance appear healthy stock have be unravele high chip designer ambarella amba dive ahead report due today close leader be clearly pressure ahead open nearly ibd stock trade lower worst hit regeneron pharmaceutical regn fall nearly other market dollar be mixed yen euro bond downshift send year yield basis point oil price pull back heel day rally send west texas intermediate brent crude ahead diving year lows last week gold chug ahead ounce most other commodity be narrowly mixed
1187,REGN,biotechs medicine co mdco alnylam pharmaceutical alny get multiple price target increase monday announce positive datum cholesterol drug candidate weekend
1188,REGN,annual congress european society cardiology medicine co alnylam present result phase trial aln pcssc divide subject high ldl cholesterol ldl various different dosage group receive single dose injectable drug other receive weekly biweekly monthly dose aln pcssc target pcsk same target recently approve repatha amgen amgn praluent regeneron regn sanofi sny
1189,REGN,however repatha praluent be monoclonal antibody aln pcssc work rna interference new platform be study variety used medicine
1190,REGN,single dose result be particular interest appear lower cholesterol much monoclonal antibody longer duration praluent repatha be administer biweekly
1191,REGN,see low volume dosage
1192,REGN,remarkably significant clamp lower ldl be achieve day single dose alnylam chief medical officer akshay vaishnaw say statement sunday accordingly believe result support quarterly possibly annual low volume subcutaneous dose regimen further development
1193,REGN,leerink analyst joseph schwartz raise price target medicine co stock
1194,REGN,patient number dose cohort be small single digit tight error bar particularly pcsk knockdown suggest response be likely be replicate larger program schwartz write research note sunday saes serious adverse event drug related discontinuation occur adverse event be mild moderate severity
1195,REGN,schwartz colleague michael schmidt raise target alnylam note phase testing program lead move medicine co
1196,REGN,be milestone remain alnylam receive addition royalty range low teen top tier write monday note
1197,REGN,medicine co stock rise monday time close high narrowly miss time intraday high alnylam stock jump gate end day
1198,REGN,rbc capital market analyst adnan butt raise price target medicine co do not change rating regeneron
1199,REGN,medicine co phase datum aln pcssc bear pivotal study be more disruptive potentially however be potentially year market butt write research note monday term matter be access quickly potentially multibillion dollar market develop
1200,REGN,however chardan capital downgrade regeneron neutral buy maintain price target regeneron stock fall monday amgen stock slump
1201,REGN,connect amy reeve ibd_areeve facebook biotechs medicine co mdco alnylam pharmaceutical alny get multiple price target increase monday announce positive datum cholesterol drug candidate weekend annual congress european society cardiology medicine co alnylam present result phase trial aln pcssc divide subject high ldl cholesterol ldl various different dosage group receive single dose injectable drug other receive weekly biweekly monthly dose aln pcssc target pcsk same target recently approve repatha amgen amgn praluent regeneron regn sanofi sny however repatha praluent be monoclonal antibody aln pcssc work rna interference new platform be study variety used medicine single dose result be particular interest appear lower cholesterol much monoclonal antibody longer duration praluent repatha be administer biweekly see low volume dosage remarkably significant clamp lower ldl be achieve day single dose alnylam chief medical officer akshay vaishnaw say statement sunday accordingly believe result support quarterly possibly annual low volume subcutaneous dose regimen further development leerink analyst joseph schwartz raise price target medicine co stock patient number dose cohort be small single digit tight error bar particularly pcsk knockdown suggest response be likely be replicate larger program schwartz write research note sunday saes serious adverse event drug related discontinuation occur adverse event be mild moderate severity schwartz colleague michael schmidt raise target alnylam note phase testing program lead move medicine co be milestone remain alnylam receive addition royalty range low teen top tier write monday note medicine co stock rise monday time close high narrowly miss time intraday high alnylam stock jump gate end day rbc capital market analyst adnan butt raise price target medicine co do not change rating regeneron medicine co phase datum aln pcssc bear pivotal study be more disruptive potentially however be potentially year market butt write research note monday term matter be access quickly potentially multibillion dollar market develop however chardan capital downgrade regeneron neutral buy maintain price target regeneron stock fall monday amgen stock slump connect amy reeve ibd_areeve facebook
1202,REGN,twitter twtr stock price moved higher monday follow analyst upgrade intel intc baidu bidu also be upgrade share twitter rise stock market today be upgrade buy suntrust robinson humphrey suntrust say twitter soon name permanant ceo shake board twitter stock price
1203,REGN,celgene have pull back market have come increase selling pressure long term prospect biotech leader remain healthy celgene celg develop cancer immune inflammatory related disease therapy include multiple myeloma treatment revlimid generate total revenue new jersey base firm be report have most product phase phase
1204,REGN,biotech stock be fire be rank group track ibd past year industry group have gain vs industry group be sixth straight week advance week so far biotechs be more have
1205,REGN,pharmacy benefit manager express script esrx say prescription drug spending rise more last year have accord annual review accord drug trend report spending drug commercially insure rise member last year medicare spending rise member medicaid spending climb
1206,REGN,report say spending hepatitis drug account more half increase be not big surprise disease be still treat mainly generic drug gilead science gild premium price sovaldi often prescribe tandem johnson johnson jnj also pricey olysio take market october gilead launch harvoni render olysio obsolete cost more sovaldi
1207,REGN,express script pharmacy benefit management leader be earliest loudest critic sovaldi price amount standard week treatment press release accompany report pbm brag have take bite gilead make exclusive deal abbvie abbv come gilead first serious competitor form viekira pak year end express claim save client year
1208,REGN,not clear however well be work abbvie analyst tracking prescription datum estimate only have market share datum be incomplete win be fully know abbvie report caveat be express price datum do not include rebate be significant part picture especially hepatitis market lately
1209,REGN,gilead report last month investor have minor freak company executive guide gross net adjustment rebate level hepatitis franchise
1210,REGN,express script release also echo comment make ceo january jpmorgan healthcare conference indicated next price war target be pcsk inhibitor new class cholesterol drug expect come market year offering amgen amgn team regeneron pharmaceutical regn sanofi sny
1211,REGN,drug trend report didn specifically mention do drug end cost year
1212,REGN,follow amy reeve twitter ibd_areeve pharmacy benefit manager express script esrx say prescription drug spending rise more last year have accord annual review accord drug trend report spending drug commercially insure rise member last year medicare spending rise member medicaid spending climb report say spending hepatitis drug account more half increase be not big surprise disease be still treat mainly generic drug gilead science gild premium price sovaldi often prescribe tandem johnson johnson jnj also pricey olysio take market october gilead launch harvoni render olysio obsolete cost more sovaldi express script pharmacy benefit management leader be earliest loudest critic sovaldi price amount standard week treatment press release accompany report pbm brag have take bite gilead make exclusive deal abbvie abbv come gilead first serious competitor form viekira pak year end express claim save client year not clear however well be work abbvie analyst tracking prescription datum estimate only have market share datum be incomplete win be fully know abbvie report caveat be express price datum do not include rebate be significant part picture especially hepatitis market lately gilead report last month investor have minor freak company executive guide gross net adjustment rebate level hepatitis franchise express script release also echo comment make ceo january jpmorgan healthcare conference indicated next price war target be pcsk inhibitor new class cholesterol drug expect come market year offering amgen amgn team regeneron pharmaceutical regn sanofi sny drug trend report didn specifically mention do drug end cost year follow amy reeve twitter ibd_areeve
1213,REGN,biotech unite therapeutic uthr receive food drug administration approval first cancer drug tuesday be also award priority review voucher turn be just lucrative agency approve unituxin monoclonal antibody treat ultra rare childhood cancer call neuroblastoma only new case year consensus estimate expect only annual sale drug encourage more such rare disease treatment however fda award company rare pediatric priority review voucher unite therapeutic sell company wish expedite review once buyer file new drug application demand such drug be considerable last july regeneron pharmaceutical regn partner sanofi sny paid acquire similar voucher biomarin pharmaceutical bmrn then used catch amgen amgn race bring first cholesterol bust pcsk inhibitor market currently fda deadline make decision regeneron alirocumab be july amgen evolucumab aug november gilead science gild paid knight therapeutic priority review voucher hasn used yet market seem pleased unite therapeutic stock open stock market today rally news get late morning touch record high mid afternoon share be more unite therapeutic be ibd highest possible ibd composite rating follow amy reeve twitter ibd_areeve
1214,REGN,hot medical stock report fourth quarter earning tuesday regeneron regn develop drug treat eye disease cancer report open earning growth be project triple share have rise last month medical record software maker cerner cern report close earning growth be expect accelerate third straight
1215,REGN,persistently mild distribution broad market turn harsh wednesday major average drop sharply higher volume selling also find way lead stock lead industry group putt market uptrend back pressure nasdaq slump still day move average be tech index largest daily percentage decline
1216,REGN,somebody smack face not always good idea hit back
1217,REGN,stock market think buy stock back again get shake just stock hand loss doesn necessarily mean game still be winner
1218,REGN,natural want move be spurn sometimes second mouse get cheese
1219,REGN,trading isn just easy find stock high rating buy once break base heavy trading nail winner consistent basis be much tougher
1220,REGN,even buy absolute top stock industry lead product service best growth rate show accumulation lead mutual fund still guarantee ll be handed nice profit
1221,REGN,consider linkedin lnkd late last year dec share professional networking clear buy point volume shot day average stock fizzle soon trigger sell rule jan
1222,REGN,get shake stock be frustrate something trader experience way bad news company such disappointing earning weaker expect sale lackluster outlook send stock hurry so downgrade price target change trade market be sketchy environment market sell push stock
1223,REGN,get shake look opportunity get back especially market uptrend resume look buy stock back go take prior buy point preferably big volume continue watch day day action also set alert let know stock be close former buy point again
1224,REGN,human nature want move stock be burn fundamental story company be still good take stab retake buy point
1225,REGN,do buy stock back want think buy few more share do initial try be counter intuitive something preach ibd workshop
1226,REGN,get shake stock also go form base so put watch list base need least week take shape so be buy opportunity present
1227,REGN,aug regeneron pharmaceutical regn pass buy point month cup base volume be well average day not want see stock chopped way high fading
1228,REGN,trading mostly sideway week stock start breaking october oct trigger sell rule
1229,REGN,stock however stage upside reversal next day oct regeneron gap day line rise more clear new handle trigger time break gusto volume be average news positive drug trial
1230,REGN,share rise dec consolidate gain somebody smack face not always good idea hit back stock market think buy stock back again get shake just stock hand loss doesn necessarily mean game still be winner natural want move be spurn sometimes second mouse get cheese trading isn just easy find stock high rating buy once break base heavy trading nail winner consistent basis be much tougher even buy absolute top stock industry lead product service best growth rate show accumulation lead mutual fund still guarantee ll be handed nice profit consider linkedin lnkd late last year dec share professional networking clear buy point volume shot day average stock fizzle soon trigger sell rule jan get shake stock be frustrate something trader experience way bad news company such disappointing earning weaker expect sale lackluster outlook send stock hurry so downgrade price target change trade market be sketchy environment market sell push stock get shake look opportunity get back especially market uptrend resume look buy stock back go take prior buy point preferably big volume continue watch day day action also set alert let know stock be close former buy point again human nature want move stock be burn fundamental story company be still good take stab retake buy point do buy stock back want think buy few more share do initial try be counter intuitive something preach ibd workshop get shake stock also go form base so put watch list base need least week take shape so be buy opportunity present aug regeneron pharmaceutical regn pass buy point month cup base volume be well average day not want see stock chopped way high fading trading mostly sideway week stock start breaking october oct trigger sell rule stock however stage upside reversal next day oct regeneron gap day line rise more clear new handle trigger time break gusto volume be average news positive drug trial share rise dec consolidate gain
1231,REGN,market enjoy shot institutional buy friday cheer additional unexpected stimulus measure bank japan round healthy earning report rise consumer confidence also fuel positive sentiment
1232,REGN,close nasdaq rise add dow jone industrial average gain preliminary datum show nyse nasdaq volume come higher thursday level week dow rise nasdaq picked add
1233,REGN,stock market today several name ibd turn solid performance best performer be ambarella amba share gain stock be beneficiary strong earning gopro gpro late thursday ambarella chip be find gopro wearable camera
1234,REGN,late thursday gopro report earning cent share sharply cent year quarter sale rise company also give rosy holiday outlook gopro surge
1235,REGN,ibd name fleetcor flt also rise sharply share jump strong earning stock close nearly early entry point share hit time high early close well session high
1236,REGN,linkedin lnkd meanwhile gap close just buy point share jump strong profit report be catalyst here well
1237,REGN,december gold slump settle ounce week slump december crude oil lose cent barrel price oil fall october
1238,REGN,here look top rate growth name set report earning next week
1239,REGN,monday epam system epam
1240,REGN,tuesday alibaba baba regeneron regn fiesta restaurant group frgi jazz pharma jazz
1241,REGN,wednesday actavis act atmh tesla motor tsla market enjoy shot institutional buy friday cheer additional unexpected stimulus measure bank japan round healthy earning report rise consumer confidence also fuel positive sentiment close nasdaq rise add dow jone industrial average gain preliminary datum show nyse nasdaq volume come higher thursday level week dow rise nasdaq picked add stock market today several name ibd turn solid performance best performer be ambarella amba share gain stock be beneficiary strong earning gopro gpro late thursday ambarella chip be find gopro wearable camera late thursday gopro report earning cent share sharply cent year quarter sale rise company also give rosy holiday outlook gopro surge ibd name fleetcor flt also rise sharply share jump strong earning stock close nearly early entry point share hit time high early close well session high linkedin lnkd meanwhile gap close just buy point share jump strong profit report be catalyst here well december gold slump settle ounce week slump december crude oil lose cent barrel price oil fall october here look top rate growth name set report earning next week monday epam system epam tuesday alibaba baba regeneron regn fiesta restaurant group frgi jazz pharma jazz wednesday actavis act atmh tesla motor tsla
1242,REGN,war terrorism deadly disease slow economy asia be bad news wouldn know analyst look business expect post solid third quarter earning revenue growth earning season rev next week report big bank jpmorgan chase jpm well fargo wfc bank america bac company be
1243,REGN,wall street reward novartis regeneron tuesday presentation cardiology conference weekend novartis heart failure drug hailed potential game changer european society cardiology esc congress barcelona novartis nvs reveal result phase trial patient suffering heart failure reduce ejection fraction ejection fraction be measure
1244,REGN,big cap biotechs celgene alexion pharmaceutical modestly beat estimate raise guidance early thursday share tumble wall street seem turn sector celgene celg earning rise year earlier quarter cent share beating consensus penny sale increase
1245,REGN,surge biotech stock late trade help several etfs close wednesday trading session high note most major international index etfs jab higher stock market today rally day rout chinese market calm domestic datum show job productivity gain powershare qqq qqq jump trimming loss week
1246,REGN,best mutual fund august performance report
1247,REGN,sophomore slump not joe fath take helm rowe price growth stock fund year half jan first calendar year charge fund gain top only large cap growth rival mutual fund track morningstar inc
1248,REGN,year broad market have imitate buck bronco fund have climb aug outperform whopping peer investor
1249,REGN,fath be more concern longer term broad market rally nearly year have make increasingly hard find attractively value growth stock
1250,REGN,late summer volatility have make harder find gainer
1251,REGN,fath be celebrate birthday talk ibd office baltimore mutual fund be perform so much better year last year be search new market leader
1252,REGN,ibd take charge fund cut size overall portfolio top name initially trim more recently re july be initial retool complete
1253,REGN,fath want be tail end fund be half used be fund now top decrease little bit middle be bigger
1254,REGN,ibd do segment differ
1255,REGN,fath describe philosophy upside pyramid top slice be secular growth name typically make portfolio be innovative disrupter be most dynamic growth company
1256,REGN,middle section be more cyclical opportunity typically be portfolio re likely be more opportunistic have shorter hold period fund average hold
1257,REGN,last section be generally characterize special situation be primary area
1258,REGN,first stock transition value growth
1259,REGN,second company underway last industry structural change have be go last several year airline sector
1260,REGN,third roll up strong management team be good capital allocator be apply discipline efficiency fragmented industry acquisition
1261,REGN,bucket typically be portfolio
1262,REGN,top name be generally most compelling secular idea tail portfolio have smallest holding be typically farm team earlier stage growth name private company own
1263,REGN,ibd give example special situation please
1264,REGN,fath gilead science gild go value growth transition buy pharmasset get treat hep addition core hiv business
1265,REGN,airline be industry structural change category own american airline aal unite continental ual
1266,REGN,valeant pharmaceutical vrx be roll category bring capital allocation discipline pharma industry assertive allocation strategy
1267,REGN,ibd name example secular bucket please
1268,REGN,fath amazon amzn be poster child tesla tsla be bit more extreme come story other name include priceline pcln mastercard visa
1269,REGN,ibd name cyclical bucket please
1270,REGN,fath stuff financial td ameritrade amtd morgan stanley ms degree be also shift business model look more value growth shift
1271,REGN,industrial hold name fedex fdx canadian pacific railway cp flowserve fls energy industrial most part
1272,REGN,ibd have fund performance zoom year least broad sell
1273,REGN,fath be drag last year secular growth name sell lot be due person want see more transparency big name want see amazon break core commerce business amazon web service company be become more discipline expense cost
1274,REGN,re start see google googl
1275,REGN,year ve take health care weighting significantly ve take energy move paid
1276,REGN,have number biotech manage care big pharma name play well be activity space
1277,REGN,ibd so have bigger bet growth year have paid
1278,REGN,fath slowdown growth happened prior sell
1279,REGN,be position cyclical recovery didn play be reverse
1280,REGN,ve be slow growth environment world have be throw exogenous shock greece china be devalue currency
1281,REGN,external factor help make growth more valuable bid valuation company be deliver growth
1282,REGN,ve get be discipline position size
1283,REGN,google priceline outlook look good ve go heavy investment cycle
1284,REGN,google have new cfo ruth porat come morgan stanley re create new hold company call alphabet give more visibility profitability core company go forward person want more transparency google be start provide
1285,REGN,ibd let talk interesting name latest disclosure do share concern person have apple aapl
1286,REGN,fath do well ve be underweight stock peaked be sort trading sideway guard
1287,REGN,most constructive part be valuation capital structure
1288,REGN,worry have be company iphone cycle
1289,REGN,ve do well iphone now issue be replacement cycle underestimated be impactful replacement cycle be
1290,REGN,remain concern ability innovate do drive enough replacement ve do so well grow fast base hard drive higher multiple
1291,REGN,ll see go watch doesn look be success least not move needle enough do own don have overweight
1292,REGN,ibd anyone facebook fb earning share growth have slow lot quarters
1293,REGN,fath ve do everything right right now thing be transition mobile get big base user revenue growth be slow invest new initiative want lot user turn monetization engine
1294,REGN,have user instagram lot whatsapp have user facebook ll monetize time so profit reaccelerate
1295,REGN,ibd thesis facebook oculus be buy israel pebble interface specialize depth sense tool track hand movement
1296,REGN,fath oculus be virtual reality play interesting not needle mover come green banana still need ripen show mark zuckerberg be think multidecade
1297,REGN,ibd visa thesis
1298,REGN,fath ty durability growth be center online payment movement cash check digital disruption
1299,REGN,card still use magnetic swipe be move chip pin card be reissue chip imbed make much harder steal card information
1300,REGN,lot retailer have be reluctant make change have change payment hardware register re finally start change
1301,REGN,visa europe be potential driver visa visa takeover look come fruition maybe be announcement october
1302,REGN,ibd ve build stake celgene celg least quarters do
1303,REGN,fath biotechs want own be go big market
1304,REGN,time celgene have build arsenal go multiple thing revlimid have be anchor do ve acquire company build own franchise
1305,REGN,now ve get otezla immunology drug psoriasis psoriatic arthritis
1306,REGN,ve also get cancer drug pomalyst chemotherapy treatment abraxane acquire abraxis
1307,REGN,drug acquire be gd treatment crohn disease early trial be promising
1308,REGN,patent cliff ahead revlimid ll protect long possible
1309,REGN,recent acquisition receptos be view pretty reasonable price relative other deal attack multiple indication most promising appear be disorder colitis crohn
1310,REGN,ibd have be trimming stake gilead science
1311,REGN,fath re victim own success turn be chronic disease acute disease be treatable
1312,REGN,treatment hepatitis be monster drug cure rate be almost week once someone be cure ve get find new patient
1313,REGN,ibd ve also pare stake regeneron regn outlook
1314,REGN,fath probably shouldn have trim ve get good core franchise eylea be used treat wet age related macular degeneration eye now also used diabetic macular edema retinal vein occlusion
1315,REGN,ve get powerful pipeline
1316,REGN,ibd ve pare starbucks sbux be concern
1317,REGN,fath still feel good core story trim be just position size management
1318,REGN,have lot presence not just globally ve introduce nice food purchase la boulange re drive new traffic afternoon evening ve get good china story menu be be broaden
1319,REGN,next big thing be move body line re roll mobile order pay system pay cellphone dictate delivery time then walk store coffee be ready best mutual fund august performance reportsophomore slump not joe fath take helm rowe price growth stock fund year half jan first calendar year charge fund gain top only large cap growth rival mutual fund track morningstar inc year broad market have imitate buck bronco fund have climb aug outperform whopping peer investor fath be more concern longer term broad market rally nearly year have make increasingly hard find attractively value growth stock late summer volatility have make harder find gainer fath be celebrate birthday talk ibd office baltimore mutual fund be perform so much better year last year be search new market leader ibd take charge fund cut size overall portfolio top name initially trim more recently re july be initial retool complete fath want be tail end fund be half used be fund now top decrease little bit middle be bigger ibd do segment differ fath describe philosophy upside pyramid top slice be secular growth name typically make portfolio be innovative disrupter be most dynamic growth company middle section be more cyclical opportunity typically be portfolio re likely be more opportunistic have shorter hold period fund average hold last section be generally characterize special situation be primary area first stock transition value growth second company underway last industry structural change have be go last several year airline sector third roll up strong management team be good capital allocator be apply discipline efficiency fragmented industry acquisition bucket typically be portfolio top name be generally most compelling secular idea tail portfolio have smallest holding be typically farm team earlier stage growth name private company own ibd give example special situation please fath gilead science gild go value growth transition buy pharmasset get treat hep addition core hiv business airline be industry structural change category own american airline aal unite continental ual valeant pharmaceutical vrx be roll category bring capital allocation discipline pharma industry assertive allocation strategy ibd name example secular bucket please fath amazon amzn be poster child tesla tsla be bit more extreme come story other name include priceline pcln mastercard visa ibd name cyclical bucket please fath stuff financial td ameritrade amtd morgan stanley ms degree be also shift business model look more value growth shift industrial hold name fedex fdx canadian pacific railway cp flowserve fls energy industrial most part ibd have fund performance zoom year least broad sell fath be drag last year secular growth name sell lot be due person want see more transparency big name want see amazon break core commerce business amazon web service company be become more discipline expense cost re start see google googl year ve take health care weighting significantly ve take energy move paid have number biotech manage care big pharma name play well be activity space ibd so have bigger bet growth year have paid fath slowdown growth happened prior sell be position cyclical recovery didn play be reverse ve be slow growth environment world have be throw exogenous shock greece china be devalue currency external factor help make growth more valuable bid valuation company be deliver growth ve get be discipline position size google priceline outlook look good ve go heavy investment cycle google have new cfo ruth porat come morgan stanley re create new hold company call alphabet give more visibility profitability core company go forward person want more transparency google be start provide ibd let talk interesting name latest disclosure do share concern person have apple aapl fath do well ve be underweight stock peaked be sort trading sideway guard most constructive part be valuation capital structure worry have be company iphone cycle ve do well iphone now issue be replacement cycle underestimated be impactful replacement cycle be remain concern ability innovate do drive enough replacement ve do so well grow fast base hard drive higher multiple ll see go watch doesn look be success least not move needle enough do own don have overweight ibd anyone facebook fb earning share growth have slow lot quarters fath ve do everything right right now thing be transition mobile get big base user revenue growth be slow invest new initiative want lot user turn monetization engine have user instagram lot whatsapp have user facebook ll monetize time so profit reaccelerate ibd thesis facebook oculus be buy israel pebble interface specialize depth sense tool track hand movement fath oculus be virtual reality play interesting not needle mover come green banana still need ripen show mark zuckerberg be think multidecade ibd visa thesis fath ty durability growth be center online payment movement cash check digital disruption card still use magnetic swipe be move chip pin card be reissue chip imbed make much harder steal card information lot retailer have be reluctant make change have change payment hardware register re finally start change visa europe be potential driver visa visa takeover look come fruition maybe be announcement october ibd ve build stake celgene celg least quarters do fath biotechs want own be go big market time celgene have build arsenal go multiple thing revlimid have be anchor do ve acquire company build own franchise now ve get otezla immunology drug psoriasis psoriatic arthritis ve also get cancer drug pomalyst chemotherapy treatment abraxane acquire abraxis drug acquire be gd treatment crohn disease early trial be promising patent cliff ahead revlimid ll protect long possible recent acquisition receptos be view pretty reasonable price relative other deal attack multiple indication most promising appear be disorder colitis crohn ibd have be trimming stake gilead science fath re victim own success turn be chronic disease acute disease be treatable treatment hepatitis be monster drug cure rate be almost week once someone be cure ve get find new patient ibd ve also pare stake regeneron regn outlook fath probably shouldn have trim ve get good core franchise eylea be used treat wet age related macular degeneration eye now also used diabetic macular edema retinal vein occlusion ve get powerful pipeline ibd ve pare starbucks sbux be concern fath still feel good core story trim be just position size management have lot presence not just globally ve introduce nice food purchase la boulange re drive new traffic afternoon evening ve get good china story menu be be broaden next big thing be move body line re roll mobile order pay system pay cellphone dictate delivery time then walk store coffee be ready
1320,REGN,big biotech unite therapeutic uthr agree sell priority review voucher abbvie abbv give unite infusion cash abbvie chance speed fda approval drug
1321,REGN,unite gain rare pediatric disease priority review voucher pprv march approval unituxin treatment rare childhood cancer call neuroblastoma fda start pprv program encourage development such drug cut standard review time new drug month
1322,REGN,go price pprv have rise sharply last year july regeneron pharmaceutical regn sanofi sny paid just buy biomarin pharmaceutical bmrn used get cholesterol drug praluent market last month
1323,REGN,november gilead science gild paid get pprv knight therapeutic used last month filing new combination therapy hiv price have rise sanofi acquire pprv retrophin rtrx
1324,REGN,abbvie didn say drug go use voucher have several late stage possibility company have be work expand cancer leukemia drug venetoclax breast cancer drug veliparib be review future
1325,REGN,abbvie be also work next generation hepatitis treatment race market be intense face gilead merck mrk other
1326,REGN,drug stock general be rest market early stock market today late morning unite therapeutic be wednesday midweek update ibd be abbvie stock also be fraction
1327,REGN,connect amy reeve ibd_areeve facebook big biotech unite therapeutic uthr agree sell priority review voucher abbvie abbv give unite infusion cash abbvie chance speed fda approval drug unite gain rare pediatric disease priority review voucher pprv march approval unituxin treatment rare childhood cancer call neuroblastoma fda start pprv program encourage development such drug cut standard review time new drug month go price pprv have rise sharply last year july regeneron pharmaceutical regn sanofi sny paid just buy biomarin pharmaceutical bmrn used get cholesterol drug praluent market last month november gilead science gild paid get pprv knight therapeutic used last month filing new combination therapy hiv price have rise sanofi acquire pprv retrophin rtrx abbvie didn say drug go use voucher have several late stage possibility company have be work expand cancer leukemia drug venetoclax breast cancer drug veliparib be review future abbvie be also work next generation hepatitis treatment race market be intense face gilead merck mrk other drug stock general be rest market early stock market today late morning unite therapeutic be wednesday midweek update ibd be abbvie stock also be fraction connect amy reeve ibd_areeve facebook
1328,REGN,payer be aggressive try drive price new pcsk cholesterol drug accord survey recent comment rbc capital market other hand fear lose money hepatitis drug seem be fading prescription be fall analyst michael yee round comment major health insurer
1329,REGN,stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace
1330,REGN,blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high
1331,REGN,integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner
1332,REGN,ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average
1333,REGN,housing related stock get bad news november pending home sale drop unexpectedly
1334,REGN,however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume stock show hesitation wednesday previous session strong price gain nasdaq slip dow jone industrial average ease respectively volume stock market today drop vs tuesday already average pace blue chip be mostly only handful stock dow rise tiny step downside chevron cvx carved slow turnover west texas intermediate crude oil fall chevron integrate oil company have rebound late august low remain july high integrate oil company be involved many facet business exploration production refine distribution late june crude oil begin fast price slide price oil be now explorer integrate refiner ibd list best stock fundamental technical mortgage software provider ellie mae elli take hardest hit drop more volume be average housing related stock get bad news november pending home sale drop unexpectedly however homebuilder horton dhi leaderboard stock shrug news horton be penny tepid volume
1335,REGN,biotech industry group currently rank group ibd track gilead science share best group score composite rating fellow drugmaker celgene regeneron regn be shortage activity biotech industry recently include celgene celg acquisition receptos july buyout
1336,REGN,second half august be usually desert business news fda schedule be year round several important drug be approval decision month provide upside biotech stock have recently be suffering
1337,REGN,get most attention likely be repatha amgen amgn cholesterol drug expect be approve aug repatha be pcsk inhibitor similar praluent drug regeneron pharmaceutical regn sanofi sny be approve much fanfare last month
1338,REGN,give resemblance drug repatha be widely expect be approve july research note nomura analyst ian somaiya write amgen drug probably also get similar label doesn cover quite many patient have hope be sufficiently broad support peak sale estimate
1339,REGN,be especially interesting investor be pricing dynamic come drug appear market pharmacy benefit manager express script esrx have say hope start price war similar happened abbvie abbv launch rival hepatitis regimen gilead science gild harvoni late last year gilead have maintain dominant market share only rebate half drug list price
1340,REGN,believe rebate drive access sanofi regeneron amgen be directly compete formulary position somaiya write repatha net price month estimate imply discount praluent gross price believe competition result average discounting similar have be see hepatitis
1341,REGN,amgen stock hit new high report have shed larger biotech selloff retain excellent ibd composite rating
1342,REGN,aug fda be due decide label expansion adcetris sole market drug seattle genetic sgen adcetris market partner takeda be already approve patient hodgkin lymphoma ve relapse receive stem cell transplant chemotherapy treatment current filing follow study patient receive transplant hadn relapse find significant improvement progression free survival
1343,REGN,july research note rbc capital market analyst adnan butt write chance approval look good fda didn convene advisory committee approval date normally do have issue drug
1344,REGN,market opportunity post transplant hodgkin lymphoma set take adcetris year higher sale potentially butt write
1345,REGN,get new indication adcetris be key part seattle genetic strategy even drug launch year still hasn make company profitable adcetris be also be test cell lymphoma front line set kind lymphoma january company also announce collaboration bristol myer squibb bmy test bristol hot new cancer drug opdivo adcetris various kind lymphomas
1346,REGN,seattle genetic stock be july high retain good relative strength rating analyst expect turn profitable
1347,REGN,fda have aug deadline decide aristada schizophrenia drug alk create drug take aripiprazole brand name abilify be best seller otsuka bristol myer go patent year add own technology turn dose regimen daily pill monthly injection patient compliance be biggest problem face psychotic medicine generally less frequent dose better
1348,REGN,aristada win be alone long act psychotic market leerink analyst michael schmidt say do nearly well johnson johnson jnj invega sustenna also used technology be therefore provide royalty
1349,REGN,model aristada sale write july research note
1350,REGN,aristada be important component strategy return growth be lead stock last year sacrifice profit growth invest marketing new drug vivitrol most recent quarter revenue also flatlined analyst expect sale growth next year rise profitability be not see return accord thomson reuter
1351,REGN,stock hit high march go form cup handle base fail break slump sector last week be trading fraction wednesday afternoon
1352,REGN,connect amy reeve ibd_areeve facebook second half august be usually desert business news fda schedule be year round several important drug be approval decision month provide upside biotech stock have recently be suffering get most attention likely be repatha amgen amgn cholesterol drug expect be approve aug repatha be pcsk inhibitor similar praluent drug regeneron pharmaceutical regn sanofi sny be approve much fanfare last month give resemblance drug repatha be widely expect be approve july research note nomura analyst ian somaiya write amgen drug probably also get similar label doesn cover quite many patient have hope be sufficiently broad support peak sale estimate be especially interesting investor be pricing dynamic come drug appear market pharmacy benefit manager express script esrx have say hope start price war similar happened abbvie abbv launch rival hepatitis regimen gilead science gild harvoni late last year gilead have maintain dominant market share only rebate half drug list price believe rebate drive access sanofi regeneron amgen be directly compete formulary position somaiya write repatha net price month estimate imply discount praluent gross price believe competition result average discounting similar have be see hepatitis amgen stock hit new high report have shed larger biotech selloff retain excellent ibd composite rating aug fda be due decide label expansion adcetris sole market drug seattle genetic sgen adcetris market partner takeda be already approve patient hodgkin lymphoma ve relapse receive stem cell transplant chemotherapy treatment current filing follow study patient receive transplant hadn relapse find significant improvement progression free survival july research note rbc capital market analyst adnan butt write chance approval look good fda didn convene advisory committee approval date normally do have issue drug market opportunity post transplant hodgkin lymphoma set take adcetris year higher sale potentially butt write get new indication adcetris be key part seattle genetic strategy even drug launch year still hasn make company profitable adcetris be also be test cell lymphoma front line set kind lymphoma january company also announce collaboration bristol myer squibb bmy test bristol hot new cancer drug opdivo adcetris various kind lymphomas seattle genetic stock be july high retain good relative strength rating analyst expect turn profitable fda have aug deadline decide aristada schizophrenia drug alk create drug take aripiprazole brand name abilify be best seller otsuka bristol myer go patent year add own technology turn dose regimen daily pill monthly injection patient compliance be biggest problem face psychotic medicine generally less frequent dose better aristada win be alone long act psychotic market leerink analyst michael schmidt say do nearly well johnson johnson jnj invega sustenna also used technology be therefore provide royalty model aristada sale write july research note aristada be important component strategy return growth be lead stock last year sacrifice profit growth invest marketing new drug vivitrol most recent quarter revenue also flatlined analyst expect sale growth next year rise profitability be not see return accord thomson reuter stock hit high march go form cup handle base fail break slump sector last week be trading fraction wednesday afternoon connect amy reeve ibd_areeve facebook
1353,REGN,re middle big week earning slew medical related company report regeneron regn hit new high stock market today issue better expect earning biotech also raise growth forecast blockbuster eylea drug share gap big volume hit fresh high clear price level first time intraday regeneron be now extend buy point late stage flat base initially clear july stock have be big run gain so far year medical device maker abiom abmd be also now extend buy area surge giant volume enter new high ground stock be more abiom crushed earning sale estimate tuesday company raise full year guidance wall street view meanwhile generic drug maker mallinckrodt mnk drop fast trade miss revenue estimate move have stock undercut prior low price consolidation base day line first time biogen biib rise quick turnover try recover post earning gap late last month biotech share be trading march high follow alissa william twitter ibd_awilliam
1354,REGN,major index etfs downshift further monday china federal reserve have continue weigh stock market last trading day august exchange trade fund tracking dow jone industrial average nasdaq post largest monthly loss last week turbulence stock market whipsaw investor even intensified worry global slowdown raise doubt wisdom fed rate hike next month spdr dow jone industrial average dium slip stock market today etf hold blue chip industrial leader merck mrk pfizer pfe ibd leaderboard stock visa be dium lead decliner hold goldman sachs gs intel intc be only stock dium advanced dium peg decline august worst monthly loss year so do spdr spy proxy broad market powershare qqq qqq track largest nonfinancial stock nasdaq composite index spy fall monday sector energy red qqq give qqq top holding biotech stock gilead science gild amgen amgn celgene celg regeneron pharmaceutical regn be hardest hit monday close lose ishare nasdaq biotechnology ibb take hit market vector biotechnology bbh worst sector industry focuse etfs so call death cross spy daily chart be first appearance year pattern occur short term move average week move average slip long term line week move average see bearish signal warning loss momentum more loss ahead accord market watcher interview cnbc cross daily chart be less relevant longer term cross be more worrisome therefore weekly chart spy dium also show pattern here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs vanguard ftse emerge market vwo rs ishare russell iwm rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare msci eafe efa rs spdr spy rs powershare qqq qqq rs follow aparna narayanan twitter ibd_anarayanan
1355,REGN,ibd medical biom biotech group hold spot list industry group track several member top street forecast past week
1356,REGN,today screen day focus top fundamental stock year earning revenue growth rate more
1357,REGN,gilead science gild have year ep growth rate develop medicine life threaten condition include cancer hiv aids heart disease gilead be perhaps most well know blockbuster hepatitis treatment sovaldi harvoni
1358,REGN,success hepatitis drug have fuel sale foster city calif base company last week soundly top consensus view boost full year guidance
1359,REGN,exclude item share gilead earning climb trouncing street view cent sale growth beat forecast
1360,REGN,gilead share close stock market today stock be build flat base buy point
1361,REGN,gilead have earn ibd highest possible composite rating mean have outperformed other publicly trade company mix fundamental technical factor include earning revenue growth
1362,REGN,regeneron pharmaceutical regn have even higher year ep growth rate too have ibd composite rating
1363,REGN,portfolio include cholesterol treatment praluent eye drug eylea latter make most regeneron revenue
1364,REGN,tuesday stock hit time high follow view top result bump guidance earning grow share beating estimate cent revenue climb top
1365,REGN,regeneron stock have break flat base buy point mid july hover buy range tuesday result boost share right buy territory finished thursday
1366,REGN,other drugmaker top fundamental list include lannett lci insys therapeutic insy ligand pharmaceutical lgnd sucampo pharmaceutical scmp
1367,REGN,thursday insys report ep drop cent miss penny revenue climb estimate insys share tumble
1368,REGN,wednesday sucampo report earning cent share just cent year earlier quarter cent analyst consensus revenue grow more analyst expect
1369,REGN,specialty drug maker also raise full year ep guidance cent top street estimate cent sucampo share gain wednesday rise thursday
1370,REGN,industry peer fellow medical biom biotech group member include celgene celg amgen amgn biogen biib
1371,REGN,related
1372,REGN,regeneron abiom hit new high strong guidance
1373,REGN,gilead get wall street love earning beat
1374,REGN,gilead set flat base bullish reversal
1375,REGN,company be fastest grow big cap biotech ibd medical biom biotech group hold spot list industry group track several member top street forecast past week today screen day focus top fundamental stock year earning revenue growth rate more gilead science gild have year ep growth rate develop medicine life threaten condition include cancer hiv aids heart disease gilead be perhaps most well know blockbuster hepatitis treatment sovaldi harvoni success hepatitis drug have fuel sale foster city calif base company last week soundly top consensus view boost full year guidance exclude item share gilead earning climb trouncing street view cent sale growth beat forecast gilead share close stock market today stock be build flat base buy point gilead have earn ibd highest possible composite rating mean have outperformed other publicly trade company mix fundamental technical factor include earning revenue growth regeneron pharmaceutical regn have even higher year ep growth rate too have ibd composite rating portfolio include cholesterol treatment praluent eye drug eylea latter make most regeneron revenue tuesday stock hit time high follow view top result bump guidance earning grow share beating estimate cent revenue climb top regeneron stock have break flat base buy point mid july hover buy range tuesday result boost share right buy territory finished thursday other drugmaker top fundamental list include lannett lci insys therapeutic insy ligand pharmaceutical lgnd sucampo pharmaceutical scmp thursday insys report ep drop cent miss penny revenue climb estimate insys share tumble wednesday sucampo report earning cent share just cent year earlier quarter cent analyst consensus revenue grow more analyst expect specialty drug maker also raise full year ep guidance cent top street estimate cent sucampo share gain wednesday rise thursday industry peer fellow medical biom biotech group member include celgene celg amgen amgn biogen biib related regeneron abiom hit new high strong guidancegilead get wall street love earning beatgilead set flat base bullish reversalwhat company be fastest grow big cap biotech
1376,REGN,special report best mutual fund january performance report
1377,REGN,january effect elude mutual fund investor violent price swing rocked market last month
1378,REGN,diversify stock mutual fund lose average accord lipper inc datum be buffet several crosscurrent tumble oil price benefit consumer bring worry deflation positive news corporate activity battle worry wage growth
1379,REGN,then final week january stock sell hard decidedly mixed earning season
1380,REGN,large cap multinational such procter gamble pg microsoft msft be start hurt stronger dollar curb export corporate profit
1381,REGN,result broad stock market end month start re start year very interesting way say omar aguilar chief investment officer equity charle schwab investment management volatility seem be pick dispersion sector style seem be pick well
1382,REGN,precious metal commodity fund grow last month energy commodity fund sank precious metal equity soar outperform other sector fund
1383,REGN,lower oil price continue weigh mutual fund hold energy commodity equity aguilar say
1384,REGN,meanwhile gold rebound last year lows help fund hold precious metal commodity equity bounce back result swiss decision break franc peg euro well general investor anxiety higher volatility say david chalupnik head equity asset management
1385,REGN,hold central bank currency feel have lot risk then move precious metal chalupnik say
1386,REGN,growth edge value board january example large cap growth slip value counterpart give suggest market already be recognize stock beat earning estimate have positive growth outlook aguilar say
1387,REGN,health care tech stock
1388,REGN,health care technology sector strongly represent growth fund have post strong earning be poise double digit growth
1389,REGN,tocqueville opportunity midcap growth fund post increase january vs average decline peer allocate asset health care technology top holding include regeneron regn palo alto network panw full list month leader see accompany table
1390,REGN,reform affordable health care act happened last year have help propel health care service provider well certain pharmaceutical aguilar say meanwhile value fund allocate heavily energy financial stock get hit lower oil price fed rate policy
1391,REGN,low interest rate environment squeeze margin financial say chalupnik
1392,REGN,big bank legal bill tie settle mortgage crisis affair government have be heftier expect
1393,REGN,january health biotech fund rally tech fund slip energy equity financial meanwhile shrank respectively
1394,REGN,index fund sell fall cyclical stock underperform defensive stock fared better chalupnik say backdrop tell market be midsingle digit year add honestly be slightly positive very volatile market be good
1395,REGN,domestic global real estate fund be bright spot january advance respectively benefit drop interest rate home abroad chalupnik say yield year treasury highly correlated year mortgage rate fall basis point
1396,REGN,change key market monetary ease policy polish allure world equity fund january india stock fund lead gain china climb
1397,REGN,europe fund grow take hit past week launch european central bank stimulus plan jan lift market temper news far left syriza party greece
1398,REGN,latin american fund sank even region better economy such mexico be suffering due sensitivity energy price chalupnik say need higher commodity price need better global growth add
1399,REGN,look ahead
1400,REGN,aguilar chalupnik favor domestic stock fund successful investing point stable economy strong earning growth corporate america
1401,REGN,aguilar like health care tech have lot cash balance sheet say have be very good investing capital grow business higher quality dividend pay stock also offer opportunity well small cap be more leverage economy be best
1402,REGN,contrarian stance chalupnik favor outlook value fund oil price bottom move say drive energy stock fed rate hike set rise later year help margin financial firm
1403,REGN,fund be overweight consumer firm be look change position more energy more financial year go add
1404,REGN,aguilar chalupnik note good value be become hard find america advise foreign exposure especially give massive scale monetary ease europe japan
1405,REGN,have world central bank stimulating very seldom do market go chalupnik say add be very excited go region
1406,REGN,aguilar call european stock relatively cheap latin america growth prospect aren robust region emerge market generally also offer bargain stock say special report best mutual fund january performance january effect elude mutual fund investor violent price swing rocked market last month diversify stock mutual fund lose average accord lipper inc datum be buffet several crosscurrent tumble oil price benefit consumer bring worry deflation positive news corporate activity battle worry wage growth then final week january stock sell hard decidedly mixed earning season large cap multinational such procter gamble pg microsoft msft be start hurt stronger dollar curb export corporate profit result broad stock market end month start re start year very interesting way say omar aguilar chief investment officer equity charle schwab investment management volatility seem be pick dispersion sector style seem be pick well precious metal commodity fund grow last month energy commodity fund sank precious metal equity soar outperform other sector fund lower oil price continue weigh mutual fund hold energy commodity equity aguilar say meanwhile gold rebound last year lows help fund hold precious metal commodity equity bounce back result swiss decision break franc peg euro well general investor anxiety higher volatility say david chalupnik head equity asset management hold central bank currency feel have lot risk then move precious metal chalupnik say growth edge value board january example large cap growth slip value counterpart give suggest market already be recognize stock beat earning estimate have positive growth outlook aguilar say health care tech stockshealth care technology sector strongly represent growth fund have post strong earning be poise double digit growth tocqueville opportunity midcap growth fund post increase january vs average decline peer allocate asset health care technology top holding include regeneron regn palo alto network panw full list month leader see accompany table reform affordable health care act happened last year have help propel health care service provider well certain pharmaceutical aguilar say meanwhile value fund allocate heavily energy financial stock get hit lower oil price fed rate policy low interest rate environment squeeze margin financial say chalupnik big bank legal bill tie settle mortgage crisis affair government have be heftier expect january health biotech fund rally tech fund slip energy equity financial meanwhile shrank respectively index fund sell fall cyclical stock underperform defensive stock fared better chalupnik say backdrop tell market be midsingle digit year add honestly be slightly positive very volatile market be good domestic global real estate fund be bright spot january advance respectively benefit drop interest rate home abroad chalupnik say yield year treasury highly correlated year mortgage rate fall basis point change key market monetary ease policy polish allure world equity fund january india stock fund lead gain china climb europe fund grow take hit past week launch european central bank stimulus plan jan lift market temper news far left syriza party greece latin american fund sank even region better economy such mexico be suffering due sensitivity energy price chalupnik say need higher commodity price need better global growth add look aheadaguilar chalupnik favor domestic stock fund successful investing point stable economy strong earning growth corporate america aguilar like health care tech have lot cash balance sheet say have be very good investing capital grow business higher quality dividend pay stock also offer opportunity well small cap be more leverage economy be best contrarian stance chalupnik favor outlook value fund oil price bottom move say drive energy stock fed rate hike set rise later year help margin financial firm fund be overweight consumer firm be look change position more energy more financial year go add aguilar chalupnik note good value be become hard find america advise foreign exposure especially give massive scale monetary ease europe japan have world central bank stimulating very seldom do market go chalupnik say add be very excited go region aguilar call european stock relatively cheap latin america growth prospect aren robust region emerge market generally also offer bargain stock say
1407,REGN,second straight quarter disappointing earning share regeneron pharmaceutical be resilient tuesday strong sale eylea eye drug general optimism biotech outlook fourth quarter adjust earning be share prior year cent consensus follow cent miss upside regeneron ticker
1408,REGN,regeneron regn say experimental drug develop sanofi sny be find late stage trial be effective fight bad cholesterol even inject once week instead week report make drug alirocumab easier person high cholesterol take increase likelihood consumer prefer drug be expect
1409,REGN,be year hepatitis immunotherapy cancer produce biggest drug launch be shape be quite different cancer be still big field hep be take back seat cholesterol other cardiology drug make comeback several drug launch year eventually cross blockbuster threshold
1410,REGN,broad range top rate stock hit new high tuesday even market end mixed stock pharmaceutical transportation software industry turn strongest performance regeneron pharmaceutical regn rise result phase trial cholesterol drug alirocumab show reduce risk heart attack stroke volume be
1411,REGN,stock open narrow gain quickly slip tightly mixed territory heavy trade tuesday passel positive economic report nasdaq rise slip negative territory then re-cover fractional gain dow jone industrial average remain stock market today open very heavy trade more share change hand nasdaq nyse exchange vs volume level early friday manufacturing increase august shade better expect accord markit purchasing manager index gauge advanced july number just consensus projection export sale gain fastest pace year report note manufacturing payroll see steepest gain march manufacturing gauge institute supply management manufacturing pmi pop august be well past july tally counter expectation dip construction spending also strengthen increase july commerce department say reversed revise decline june stomp forecast increase regeneron pharmaceutical regn pop clinical trial show experimental cholesterol reduce drug reduce heart attack risk drug alirocumab be joint venture regeneron sanofi sny move put regeneron share almost buy point late stage cup base sanofi share rise fraction wearable video camera maker power higher open digital ally dgly spiked gopro gpro climb putt share buy point ipo base distressed office supply retailer staple spls shot upgrade outperform market perform credit suisse report set price target stock remain year high lead stock get good start ibd list advance start block gain loss stock list be mild arris group arrs jump have be fight retake support day move average carve line heavy trade aug silica holding slca improve more advance new high quarrier sand used energy producer hydraulic fracture process have be tear recently sandbox peer emerge energy service emes spiked new high last week be take breather trading fraction early tuesday
1412,REGN,stock hold decent gain be session high wednesday recover nicely tuesday bout institutional selling nasdaq outperformed rise dow jone industrial average add volume nyse nasdaq be tracking smidge higher tuesday level apple aapl be big reason nasdaq outperformance share rise tuesday bearish reversal news tuesday new payment service apple wasn good news ebay ebay share slump fear paypal product lose market share be quiet week economic datum day fed meeting loom large next week market continue speculate timing fed first rate hike yield year treasury note rise basis point wednesday sharply mid august stock market today money flow biotech sector recent weakness receptos rcpt surge company report more good datum midstage trial multiple sclerosis drug receptos isn profitable yet have nearly quadruple price ipo regeneron regn institutional quality biotech snap back low volume pullback share rise stock be trading right recent buy point ibd fleetcor flt stage nice upside reversal fall early share rise restoration hardware rh add ahead earning report close consensus estimate call profit cent share year sale
1413,REGN,market confirm uptrend company strong fundamental be likely see gain be excellent prospect stock watch list today screen day be top fundamental feature highly rate company year sale earning growth rate least bare minimum sort biggest estimate ep percentage change
1414,REGN,major index close mixed tuesday underlie strength be see lead stock nasdaq add fall less loss too small be consider distribution volume rise sharply trader start come back summer break oil other commodity stock suffer most contribute lag
1415,REGN,better expect economic datum major average be still trading flat slightly lower early afternoon trading
1416,REGN,nasdaq be flat edge dow industrial ease volume be tracking well friday level major exchange stock market today
1417,REGN,preliminary read markit purchasing manager index june hit year high top view exist home sale rise june unit economist forecast
1418,REGN,automaker metal miner solar stock be biggest gainer airline meat processor tobacco stock lead downside
1419,REGN,regeneron pharmaceutical regn fall twice normal trade slide further day move average stock tumble friday report patient be switch drug regeneron lead drug be eylea treat wet age related macular degeneration
1420,REGN,upside actavis act rise again clear cup handle buy point average volume now nearly entry stock initially clear buy point tuesday lower usual trade have waver
1421,REGN,fellow ibd stock salix pharmaceutical slxp add new high slight pickup volume now extend past buy point late stage cup handle base
1422,REGN,tesla motor tsla gain heavy turnover continue shape cup base potential buy point be handle doesn form morgan stanley analyst weekend report make bullish comment electric carmaker stock surge big trade june
1423,REGN,follow nancy gondo twitter email protected better expect economic datum major average be still trading flat slightly lower early afternoon trading nasdaq be flat edge dow industrial ease volume be tracking well friday level major exchange stock market today preliminary read markit purchasing manager index june hit year high top view exist home sale rise june unit economist forecast automaker metal miner solar stock be biggest gainer airline meat processor tobacco stock lead downside regeneron pharmaceutical regn fall twice normal trade slide further day move average stock tumble friday report patient be switch drug regeneron lead drug be eylea treat wet age related macular degeneration upside actavis act rise again clear cup handle buy point average volume now nearly entry stock initially clear buy point tuesday lower usual trade have waver fellow ibd stock salix pharmaceutical slxp add new high slight pickup volume now extend past buy point late stage cup handle base tesla motor tsla gain heavy turnover continue shape cup base potential buy point be handle doesn form morgan stanley analyst weekend report make bullish comment electric carmaker stock surge big trade june follow nancy gondo twitter email protected
1424,REGN,major average edge lower tuesday mostly quiet session
1425,REGN,dow jone industrial average lose nasdaq ease preliminary datum show nyse nasdaq volume come very close monday level
1426,REGN,decline stock only have slight edge advancer exchange stock market today nasdaq advance decline line have be downtrend late june
1427,REGN,day gainer regeneron regn have good day better expect earning company report profit share sale view be share revenue regeneron also raise growth forecast flagship drug eylea popular treatment age related wet macular degeneration stock clear buy point late stage flat base last month
1428,REGN,martin marietta mlm reversed higher early weakness share gain nearly producer stone sand other aggregate deliver earning share year sale view be share revenue
1429,REGN,meanwhile institutional investor continue sell share apple aapl stock lose huge volume give day move average monday concern slow iphone sale china
1430,REGN,apple supplier be also hit hard include skywork swks nxp semiconductor nxpi qorvo qrvo loss range
1431,REGN,wednesday open watch earning priceline group pcln sucampo pharmaceutical scmp fitbit fit jazz pharmaceutical jazz report close
1432,REGN,economic datum due wednesday include adp job report measure change nonfarm private sector employment consensus estimate call job growth datum come ahead friday government job report major average edge lower tuesday mostly quiet session dow jone industrial average lose nasdaq ease preliminary datum show nyse nasdaq volume come very close monday level decline stock only have slight edge advancer exchange stock market today nasdaq advance decline line have be downtrend late june day gainer regeneron regn have good day better expect earning company report profit share sale view be share revenue regeneron also raise growth forecast flagship drug eylea popular treatment age related wet macular degeneration stock clear buy point late stage flat base last month martin marietta mlm reversed higher early weakness share gain nearly producer stone sand other aggregate deliver earning share year sale view be share revenue meanwhile institutional investor continue sell share apple aapl stock lose huge volume give day move average monday concern slow iphone sale china apple supplier be also hit hard include skywork swks nxp semiconductor nxpi qorvo qrvo loss range wednesday open watch earning priceline group pcln sucampo pharmaceutical scmp fitbit fit jazz pharmaceutical jazz report close economic datum due wednesday include adp job report measure change nonfarm private sector employment consensus estimate call job growth datum come ahead friday government job report
1433,REGN,red hot biotechnology semiconductor etfs be cool dramatically lead friday sell sector equity fund head second week steep decline have analyst wring hand red wash biotech stock mean investor be overdue correction frothy sector mere blip rally ishare nasdaq biotechnology ticker
1434,REGN,stock future show healthy gain early tuesday europe market rebound oil price re-cover lows economic news be fair positive
1435,REGN,dow future trade point fair market value point hour earlier nasdaq future add early gain be point future moved point even hour earlier level
1436,REGN,stock market today have eye wednesday afternoon federal open market committee member head day powwow expectation be high policy shift group announce decision wednesday et
1437,REGN,consumer price be flat november labor department report be gain october line economist expectation core price food energy rise equal october increase meeting consensus projection
1438,REGN,manufacturing activity new york region slow improve rate december accord new york federal reserve empire state manufacturing survey show performance vs show november be better read expect economist
1439,REGN,national association home builder release builder confidence index treasury department report long term treasury international capital flow october
1440,REGN,oil price take modest bounce early trade lift west texas intermediate less brent crude more still trading barrel respectively late day recovery market monday fed rebound european market lead index bounce week lows send dax frankfurt cac paris more midday
1441,REGN,stock miner steel market be rebound issue vale vale arcelor mittal mt ahead more dow diversify operator mmm old minnesota mining manufacturing co tank more lower earning guidance chevron cvx top index premarket trade gain
1442,REGN,also notch worst loss stock network ffiv take second hardest hit bit more
1443,REGN,chipmaker nvidia nvda newell rubbermaid nwl southwestern energy swn top list better
1444,REGN,flooring retailer lumber liquidator ll bolt higher news report detailed letter kase capital management manage partner whitney tilson declare have cover short position stock
1445,REGN,tilson have weigh company follow allegation flooring contain unsafe level formaldehyde tilson conclude management probably do not know problem accord bloomberg mean company be sloppy naive not evil tilson write stock end monday news investigation break february
1446,REGN,lead stock stick moderate move premarket action hawaiian top ibd list slightly more premarket trade dave buster play stake low end loss stock future show healthy gain early tuesday europe market rebound oil price re-cover lows economic news be fair positive dow future trade point fair market value point hour earlier nasdaq future add early gain be point future moved point even hour earlier level stock market today have eye wednesday afternoon federal open market committee member head day powwow expectation be high policy shift group announce decision wednesday et consumer price be flat november labor department report be gain october line economist expectation core price food energy rise equal october increase meeting consensus projection manufacturing activity new york region slow improve rate december accord new york federal reserve empire state manufacturing survey show performance vs show november be better read expect economist national association home builder release builder confidence index treasury department report long term treasury international capital flow october oil price take modest bounce early trade lift west texas intermediate less brent crude more still trading barrel respectively late day recovery market monday fed rebound european market lead index bounce week lows send dax frankfurt cac paris more midday stock miner steel market be rebound issue vale vale arcelor mittal mt ahead more dow diversify operator mmm old minnesota mining manufacturing co tank more lower earning guidance chevron cvx top index premarket trade gain also notch worst loss stock network ffiv take second hardest hit bit more chipmaker nvidia nvda newell rubbermaid nwl southwestern energy swn top list better flooring retailer lumber liquidator ll bolt higher news report detailed letter kase capital management manage partner whitney tilson declare have cover short position stock tilson have weigh company follow allegation flooring contain unsafe level formaldehyde tilson conclude management probably do not know problem accord bloomberg mean company be sloppy naive not evil tilson write stock end monday news investigation break february lead stock stick moderate move premarket action hawaiian top ibd list slightly more premarket trade dave buster play stake low end loss
1447,REGN,week list lead big cap issue feature emerge strength technology long time biotech leader be hold well food beverage play biotech field gilead science gild be build new flat base buy point gilead share be try bounce back trigger sell signal july
1448,REGN,american century ultra be have top morningstar inc large cap growth peer group straight quarters be do so again go tuesday fund be year vs mutual fund be direct rival
1449,REGN,fund fare market put investor prolong pullback
1450,REGN,depend behavior stock fund overweight sector fund manager lee michael li jeffrey bourke be overweight vs russell growth index benchmark only sector june fact sheet technology health care consumer discretionary
1451,REGN,also fund largest sector group be fund money be work
1452,REGN,tech facebook fb be so far year time high set july most recent buy point
1453,REGN,social networking site have monthly active user maus march year year mobile maus hop
1454,REGN,july nomura raise price target bank america add facebook conviction buy list
1455,REGN,earning be due july close profit be see rise cent share dampen tough year year comparison earning jump
1456,REGN,apple core
1457,REGN,apple aapl be tech name be fund top hold weighting be more double google googl weighting
1458,REGN,apple seemingly reflect fund attitude tech sector overall ultra manager say commentary favore internet software service computer peripheral company
1459,REGN,position reflect opportunity disruption evident tech sector write
1460,REGN,health care regeneron pharmaceutical regn be so far year share be trading entry late stage base
1461,REGN,friday federal drug administration approve praluent new cholesterol bust drug regeneron sanofi sny investor have hope fda larger patient pool do
1462,REGN,earning share rise past quarters
1463,REGN,starbucks brew earning
1464,REGN,consumer discretionary starbucks sbux be year share hit new high friday be extend january
1465,REGN,ep grow past quarters
1466,REGN,coffee shop chain be expand loyalty program own door exist reward program let customer earn star purchase be redeem food drink
1467,REGN,new program customer also earn star buy product service outside company become loyalty partner
1468,REGN,starbucks be also roll mobile order ahead service link reward program american century ultra be have top morningstar inc large cap growth peer group straight quarters be do so again go tuesday fund be year vs mutual fund be direct rival fund fare market put investor prolong pullback depend behavior stock fund overweight sector fund manager lee michael li jeffrey bourke be overweight vs russell growth index benchmark only sector june fact sheet technology health care consumer discretionary also fund largest sector group be fund money be work tech facebook fb be so far year time high set july most recent buy point social networking site have monthly active user maus march year year mobile maus hop july nomura raise price target bank america add facebook conviction buy list earning be due july close profit be see rise cent share dampen tough year year comparison earning jump apple coreapple aapl be tech name be fund top hold weighting be more double google googl weighting apple seemingly reflect fund attitude tech sector overall ultra manager say commentary favore internet software service computer peripheral company position reflect opportunity disruption evident tech sector write health care regeneron pharmaceutical regn be so far year share be trading entry late stage base friday federal drug administration approve praluent new cholesterol bust drug regeneron sanofi sny investor have hope fda larger patient pool do earning share rise past quarters starbucks brew earningsin consumer discretionary starbucks sbux be year share hit new high friday be extend january ep grow past quarters coffee shop chain be expand loyalty program own door exist reward program let customer earn star purchase be redeem food drink new program customer also earn star buy product service outside company become loyalty partner starbucks be also roll mobile order ahead service link reward program
1469,REGN,seller remain control little more hour remain friday session disappointing performance bull nasdaq sign strength thursday
1470,REGN,dow jone industrial average slump give nasdaq pare intraday loss nyse nasdaq volume be tracking lower thursday level
1471,REGN,friday december job report look good surface wage growth disappoint market market also didn big drop crude oil oil be recently trading barrel more
1472,REGN,gold miner shipping stock homebuilder outperformed stock market today
1473,REGN,homebuilding group lennar len edge higher only high work base buy point share have rally dec
1474,REGN,ibd chip name nxp semiconductor nxpi cavium cavm ambarella amba outperformed again strong showing thursday
1475,REGN,meanwhile retail related group be session worst performer bed bath bbby weigh retail home furnishing group share lose company report weak earning late thursday
1476,REGN,regeneron pharmaceutical regn add company partner sanofi sny release more encourage datum bad cholesterol lower drug alirocumab seller remain control little more hour remain friday session disappointing performance bull nasdaq sign strength thursday dow jone industrial average slump give nasdaq pare intraday loss nyse nasdaq volume be tracking lower thursday level friday december job report look good surface wage growth disappoint market market also didn big drop crude oil oil be recently trading barrel more gold miner shipping stock homebuilder outperformed stock market today homebuilding group lennar len edge higher only high work base buy point share have rally dec ibd chip name nxp semiconductor nxpi cavium cavm ambarella amba outperformed again strong showing thursday meanwhile retail related group be session worst performer bed bath bbby weigh retail home furnishing group share lose company report weak earning late thursday regeneron pharmaceutical regn add company partner sanofi sny release more encourage datum bad cholesterol lower drug alirocumab
1477,REGN,stock reversed early gain initial enthusiasm friday job report fade investor didn sharp drop oil
1478,REGN,dow jone industrial average slump give nasdaq lose nyse nasdaq volume be tracking lower thursday level
1479,REGN,friday december job report look good surface wage growth disappoint
1480,REGN,crude oil fall sharply again drop nearly barrel
1481,REGN,stock market today sector leader ibd name bitauto bita jump china base car announce strategic partnership jd com jd tencent tcehy company invest combine bitauto
1482,REGN,ibd chip name nxp semiconductor nxpi cavium cavm ambarella amba extend gain strong showing thursday
1483,REGN,regeneron regn add company partner sanofi sny release more encourage datum bad cholesterol lower drug alirocumab
1484,REGN,downside fall deep freeze drop weak holiday sale
1485,REGN,biogen idec biib extend loss thursday bearish reversal share fall thursday day biotech release mixed phase datum multiple sclerosis drug stock reversed early gain initial enthusiasm friday job report fade investor didn sharp drop oil dow jone industrial average slump give nasdaq lose nyse nasdaq volume be tracking lower thursday level friday december job report look good surface wage growth disappoint crude oil fall sharply again drop nearly barrel stock market today sector leader ibd name bitauto bita jump china base car announce strategic partnership jd com jd tencent tcehy company invest combine bitauto ibd chip name nxp semiconductor nxpi cavium cavm ambarella amba extend gain strong showing thursday regeneron regn add company partner sanofi sny release more encourage datum bad cholesterol lower drug alirocumab downside fall deep freeze drop weak holiday sale biogen idec biib extend loss thursday bearish reversal share fall thursday day biotech release mixed phase datum multiple sclerosis drug
1486,REGN,regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm
1487,REGN,jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak
1488,REGN,ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market
1489,REGN,pre emptive drug price war
1490,REGN,everyone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline
1491,REGN,be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter
1492,REGN,paz comment seem allude widespread perception street pcsk be basically similar
1493,REGN,regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just
1494,REGN,schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not
1495,REGN,regeneron eylea sale bright
1496,REGN,presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus
1497,REGN,also guide expense item tend do lieu earning be heavily affected option expense
1498,REGN,range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation
1499,REGN,regeneron stock rise nearly intraday reversed overall market close day move average
1500,REGN,separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation
1501,REGN,expect isrg share move higher morning continue believe worst be isrg henry write note market open
1502,REGN,be right first part intuitive surgical rise intraday stock retreat afternoon close regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market pre emptive drug price wareveryone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter paz comment seem allude widespread perception street pcsk be basically similar regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not regeneron eylea sale brightat presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus also guide expense item tend do lieu earning be heavily affected option expense range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation regeneron stock rise nearly intraday reversed overall market close day move average separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation expect isrg share move higher morning continue believe worst be isrg henry write note market open be right first part intuitive surgical rise intraday stock retreat afternoon close
1503,REGN,stock be firmly lower early afternoon trading friday investor weigh december job report sharp drop oil dow jone industrial average slump give nasdaq lose nyse nasdaq volume be tracking lower thursday level friday december job report look good surface wage growth disappoint meanwhile crude oil fall sharply again drop barrel gold miner outperformed retail related group be session worst performer bed bath bbby weigh retail home furnishing group share lose company report weak earning late thursday retailer fall deep freeze company report weak holiday sale stock market today acuity brand ayi gap base rise nearly strong earning elsewhere sector leader ibd name bitauto bita jump china base car announce strategic partnership jd com jd tencent tcehy company invest combine bitauto ibd chip name nxp semiconductor nxpi cavium cavm ambarella amba outperformed again strong showing thursday regeneron regn add close company partner sanofi sny release more encourage datum bad cholesterol lower drug alirocumab
1504,REGN,solid day market monday lower volume result shortage new high several growth name be early stage breaking basis other be hold gain post just want see nascent uptrend celgene celg clear flat base entry rise
1505,REGN,major average show modest loss little hour remain thursday session
1506,REGN,nasdaq lose hurt somewhat fresh round selling dow jone industrial average give respectively nyse volume be tracking close wednesday level nasdaq volume fall
1507,REGN,small cap fared well add
1508,REGN,day outperformance wednesday biotech stock face renew selling pressure nasdaq firm celgene celg fall have almost re-trace gain buy point other nasdaq biotechs be pressured include regeneron regn biogen idec biib gilead science gild lose
1509,REGN,ibd firm akorn akrx be bright spot maker ophthalmic injectable pharmaceutical bounce day move average heavy volume rise
1510,REGN,stock market today stratasys ssys gain approach buy point earlier week company analyst day be well receive
1511,REGN,meanwhile huntsman hun follow wednesday share rise clear early flat base point wednesday still buy range company make organic inorganic chemical product broad range consumer industrial end market
1512,REGN,economic news weekly jobless claim unexpectedly rise month high claim increase upwardly revise prior week economist expect small decline
1513,REGN,close watch earning ulta beauty ulta share edge higher ahead result former leader have be rally mode still sit high quarterly profit be see rise cent share sale major average show modest loss little hour remain thursday session nasdaq lose hurt somewhat fresh round selling dow jone industrial average give respectively nyse volume be tracking close wednesday level nasdaq volume fall small cap fared well add day outperformance wednesday biotech stock face renew selling pressure nasdaq firm celgene celg fall have almost re-trace gain buy point other nasdaq biotechs be pressured include regeneron regn biogen idec biib gilead science gild lose ibd firm akorn akrx be bright spot maker ophthalmic injectable pharmaceutical bounce day move average heavy volume rise stock market today stratasys ssys gain approach buy point earlier week company analyst day be well receive meanwhile huntsman hun follow wednesday share rise clear early flat base point wednesday still buy range company make organic inorganic chemical product broad range consumer industrial end market economic news weekly jobless claim unexpectedly rise month high claim increase upwardly revise prior week economist expect small decline close watch earning ulta beauty ulta share edge higher ahead result former leader have be rally mode still sit high quarterly profit be see rise cent share sale
1514,REGN,stock turn higher early afternoon trade wednesday soft open nasdaq lead way rise dow jone industrial average add volume nyse nasdaq be tracking higher tuesday level stock market today money flow biotech sector recent weakness receptos rcpt surge company report good datum midstage trial multiple sclerosis drug receptos isn profitable yet nearly quadruple price ipo top rate name biotech group gilead science gild biogen idec biib regeneron regn alexion alxn rise earning news palo alto network panw surge report strong earning late tuesday exclude time item fiscal fourth quarter profit rise year cent share sale growth accelerate second straight quarter rise well ahead view company also offer bullish sale guidance recent be slow get go stock be now buy point ibd silica slca snap back straight decline share jump company raise cash flow guidance rest year company make silica used hydraulic frac several low volume decline keurig green mountain gmcr add nearly be back buy range recent restoration hardware rh lose ahead earning report close consensus estimate call profit cent share year sale be expect rise
1515,REGN,nasdaq lead modest market rally light volume friday ahead day weekend early afternoon trading nasdaq rise add dow jone industrial average rise less volume nyse nasdaq be tracking lower thursday light level stock market today technology soar chip designer report strong earning late thursday supply radio frequency chip smartphone maker apple aapl samsung group peer nxp semiconductor nxpi clear flat base buy point rise be featured stock spotlight earlier week ibd oil gas producer diamondback energy fang reclaim day move average rise work right side potential base several firm striking rich permian basin company have deliver triple digit sale growth straight quarters also ibd team health holding tmh reclaim week tight buy point share gain nearly company be provider outsourced health care staffing administrative service biotech space regeneron pharmaceutical regn add nearly be trading just cup handle buy point late july regeneron partner sanofi sny report positive result phase trial cholesterol lower drug alirocumab weekend company be present detailed datum trial conference spain economic news consumer spending fall july first decline january income growth slow weakest show month reminder stock market be close monday observance labor day
1516,REGN,several key drug major drugmaker get endorsement european medicine agency ema friday make commercial approval european union enormous market much more likely
1517,REGN,bristol myer squibb bmy hepatitis drug daclatasvir now brand daklinza be endorse ema committee medicinal product human use chmp use combination other hep drug notably gilead science gild sovaldi
1518,REGN,sovaldi daclatasvir perform outstandingly combine clinical trial gilead decide substitute similar drug own make ledipasvir combo expect be approve later year nonetheless bristol executive tell ibd march still see role drug marketplace especially tough treat case
1519,REGN,chmp also endorse expand label eliquis drug bristol co develop pfizer pfe reduce risk stroke patient atrial fibrillation include deep vein thrombosis pulmonary embolism eliquis launch early last year disappoint street competitor xarelto johnson johnson jnj eat market share bristol pfizer have keep plug away peak annual sale estimate be still run billion
1520,REGN,endorsement drug be not surprise wall street bristol stock be fraction morning trading stock market today pfizer stock be flat
1521,REGN,meanwhile regeneron pharmaceutical regn blockbuster eylea look get even bigger chmp endorse expand use include diabetic macular edema type vision loss result diabetes nonetheless regeneron stock be nearly morning trading friday
1522,REGN,regeneron share have be pressure last week accord rbc capital market analyst adnan butt worry have arise payer particulary medicare medicaid be go mandate use roche avastin eylea cost reason butt write own research do not support theory
1523,REGN,datum be best anecdotal channel check do not show change pattern hence do not see widespread conversion used label avastin write note wednesday
1524,REGN,follow amy reeve twitter ibd_areeve several key drug major drugmaker get endorsement european medicine agency ema friday make commercial approval european union enormous market much more likely bristol myer squibb bmy hepatitis drug daclatasvir now brand daklinza be endorse ema committee medicinal product human use chmp use combination other hep drug notably gilead science gild sovaldi sovaldi daclatasvir perform outstandingly combine clinical trial gilead decide substitute similar drug own make ledipasvir combo expect be approve later year nonetheless bristol executive tell ibd march still see role drug marketplace especially tough treat case chmp also endorse expand label eliquis drug bristol co develop pfizer pfe reduce risk stroke patient atrial fibrillation include deep vein thrombosis pulmonary embolism eliquis launch early last year disappoint street competitor xarelto johnson johnson jnj eat market share bristol pfizer have keep plug away peak annual sale estimate be still run billion endorsement drug be not surprise wall street bristol stock be fraction morning trading stock market today pfizer stock be flat meanwhile regeneron pharmaceutical regn blockbuster eylea look get even bigger chmp endorse expand use include diabetic macular edema type vision loss result diabetes nonetheless regeneron stock be nearly morning trading friday regeneron share have be pressure last week accord rbc capital market analyst adnan butt worry have arise payer particulary medicare medicaid be go mandate use roche avastin eylea cost reason butt write own research do not support theory datum be best anecdotal channel check do not show change pattern hence do not see widespread conversion used label avastin write note wednesday follow amy reeve twitter ibd_areeve
1525,REGN,specialty drugmaker auxilium pharmaceutical auxl say thursday acquire ophthalmology firm qlt qlti stock swap relocate qlt home canada auxilium stock be fraction thursday morning heavy trading stock market qlt much cheaper stock jump auxilium shareholder get share qlt
1526,REGN,praluent new cholesterol bust drug regeneron pharmaceutical regn sanofi sny be grant fda approval friday slightly more limit patient pool have hope regeneron stock close stock market today be little change share be halter much afternoon fda
1527,REGN,biotechs anacor pharmaceutical anac regeneron pharmaceutical regn be trading monday potential drug candidate atopic dermatitis ad anacor stock soar new high strength late stage trial result ointment crisaborole company say half patient mild moderate ad recur skin
1528,REGN,ub downgrade regeneron regn amgen amgn adjust price target several other biotech stock thursday ground sector be slow patch
1529,REGN,still think biotech continue outperform broader market health care spdr xlv be get more selective price target rating consider fewer term catalyst power drive material upward revision key driver stock past year couple fact ultra bullish thesis midcaps have be reward extent have play analyst matthew roden write second quarter earning preview hence now struggle find term conviction idea remain confident big bull case number name look month
1530,REGN,roden downgrade regeneron sell neutral valuation ground model price target remain same regeneron stock have be trading past month make valuation far highest large cap biotech write
1531,REGN,roden downgrade amgen stock neutral buy lower price target remove sale estimate immunology drug brodalumab model revelation suicide risk cause amgen withdraw development partnership astrazeneca azn write point impossible model impact new biosimilar competition amgen flagship neutropenia drug
1532,REGN,think uncertainty create wait game limit upside potential stock year roden write
1533,REGN,roden also maintain rating lower price target number other biotechs include puma biotechnology pbyi price vs previous wake disappointing datum breast cancer drug last month
1534,REGN,none seem hurt stock much morning market be rally couple bad day early trading stock market today share regeneron be just fraction amgen stock be fraction puma stock be more
1535,REGN,regeneron be latest ibd ranking top perform stock trading early thursday be buy point touch regeneron stock touch record high june
1536,REGN,positive side roden raise price target vertex pharmaceutical vrtx wake approval pricing orkambi vertex potential blockbuster cystic fibrosis drug
1537,REGN,conservative patient number be outside consensus come consensus revenue figure view command higher net present value write also believe previously underestimated gross margin together higher revenue drife greater earning power prior forecast ep
1538,REGN,roden also raise price target gilead science gild note number be still go gilead be talk ll do buyout deal year
1539,REGN,vertex gilead stock be fraction early trading thursday
1540,REGN,follow amy reeve twitter ibd_areeve ub downgrade regeneron regn amgen amgn adjust price target several other biotech stock thursday ground sector be slow patch still think biotech continue outperform broader market health care spdr xlv be get more selective price target rating consider fewer term catalyst power drive material upward revision key driver stock past year couple fact ultra bullish thesis midcaps have be reward extent have play analyst matthew roden write second quarter earning preview hence now struggle find term conviction idea remain confident big bull case number name look month roden downgrade regeneron sell neutral valuation ground model price target remain same regeneron stock have be trading past month make valuation far highest large cap biotech write roden downgrade amgen stock neutral buy lower price target remove sale estimate immunology drug brodalumab model revelation suicide risk cause amgen withdraw development partnership astrazeneca azn write point impossible model impact new biosimilar competition amgen flagship neutropenia drug think uncertainty create wait game limit upside potential stock year roden write roden also maintain rating lower price target number other biotechs include puma biotechnology pbyi price vs previous wake disappointing datum breast cancer drug last month none seem hurt stock much morning market be rally couple bad day early trading stock market today share regeneron be just fraction amgen stock be fraction puma stock be more regeneron be latest ibd ranking top perform stock trading early thursday be buy point touch regeneron stock touch record high june positive side roden raise price target vertex pharmaceutical vrtx wake approval pricing orkambi vertex potential blockbuster cystic fibrosis drug conservative patient number be outside consensus come consensus revenue figure view command higher net present value write also believe previously underestimated gross margin together higher revenue drife greater earning power prior forecast ep roden also raise price target gilead science gild note number be still go gilead be talk ll do buyout deal year vertex gilead stock be fraction early trading thursday follow amy reeve twitter ibd_areeve
1541,REGN,stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open
1542,REGN,dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain
1543,REGN,volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading
1544,REGN,start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action
1545,REGN,drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss
1546,REGN,leader leane generally higher gain be limit
1547,REGN,airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october
1548,REGN,drugmaker post list worst decline early trade
1549,REGN,gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction
1550,REGN,celgene biogen also ibd list drop amgen amgn slip lower
1551,REGN,economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss leader leane generally higher gain be limit airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october drugmaker post list worst decline early trade gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction celgene biogen also ibd list drop amgen amgn slip lower economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale
1552,REGN,nasdaq russell small cap index joined new high party friday dow jone industrial average extend winning streak session nasdaq outperformed rise gain dow add russell picked week dow add nasdaq gain crude oil lose barrel week lose fifth straight weekly decline gold meanwhile surge ounce stock market today biotechs padded gain tuesday nasty sell regeneron regn amgen amgn celgene celg outperformed show solid support action day move average elsewhere tesla motor tsla rise ceo elon musk say christmas day tweet new roadster production vehicle have battery range mile twice car current range gopro gpro capped fourth straight gain share rise day post ipo lockup period expire week share be strengthen anticipation robust holiday sale wildly popular wearable camera ambarella amba chip power gopro camera jump new issue virgin america va follow wednesday powerful share rise nearly have quickly become extend buy point
1553,REGN,dow jone industrial average notch fresh time high tuesday nasdaq lag biotech stock sell hard
1554,REGN,dow add third component more rise nasdaq ease volume nyse nasdaq be tracking just monday level
1555,REGN,breadth be pretty good nyse advance stock beating decliner nasdaq winner beat loser margin
1556,REGN,economic news final revision gross domestic product come much better expect heel growth
1557,REGN,stock market today biotechs come pressure ibd biotech group fall more follow loss monday regeneron regn celgene celg slice day line fall respectively
1558,REGN,biogen idec biib also take hit fall still hold day line be well recent buy point sharp decline biotechs be sign institutional investor be ready rotate group be lead market month
1559,REGN,biogen recent attempt have stall many other include baidu bidu fleetcor technology flt valeant pharmaceutical vrx other
1560,REGN,selling wasn just confine biotechs tuesday day worst perform group ibd database hailed medical sector
1561,REGN,top gainer ibd include noah holding noah asbury automotive abg cdw cdw
1562,REGN,close watch earning egg producer cal maine food calm profit be see rise cent share cal maine reclaim day move average last week heavy volume share be mostly unchanged ahead result dow jone industrial average notch fresh time high tuesday nasdaq lag biotech stock sell hard dow add third component more rise nasdaq ease volume nyse nasdaq be tracking just monday level breadth be pretty good nyse advance stock beating decliner nasdaq winner beat loser margin economic news final revision gross domestic product come much better expect heel growth stock market today biotechs come pressure ibd biotech group fall more follow loss monday regeneron regn celgene celg slice day line fall respectively biogen idec biib also take hit fall still hold day line be well recent buy point sharp decline biotechs be sign institutional investor be ready rotate group be lead market month biogen recent attempt have stall many other include baidu bidu fleetcor technology flt valeant pharmaceutical vrx other selling wasn just confine biotechs tuesday day worst perform group ibd database hailed medical sector top gainer ibd include noah holding noah asbury automotive abg cdw cdw close watch earning egg producer cal maine food calm profit be see rise cent share cal maine reclaim day move average last week heavy volume share be mostly unchanged ahead result
1563,REGN,nasdaq hold modest gain blue chip edge lower little hour remain friday session trading volume be light ahead day weekend stock market be close monday observance labor day nasdaq lead way rise gain dow jone industrial average ease stock market today tesla motor tsla race time high news partnership china unicom chu mobile carrier offer charge station store more city share tesla member leaderboard investor com rise meanwhile ihs ihs make more progress recent flat base share picked ihs provide industry datum consult service variety industry stock trade average daily dollar volume be institutional quality name solid mutual fund sponsorship ihs be still buy range technology avgo soar chip designer report strong earning late thursday supply radio frequency chip smartphone maker apple aapl samsung group peer nxp semiconductor nxpi clear flat base buy point rise apple be reportedly work dutch chipmaker add field communication nfc technology iphone be introduce biotech space regeneron pharmaceutical regn add be trading just cup handle buy point late july regeneron partner sanofi sny report positive result phase trial cholesterol lower drug alirocumab weekend company be present detailed datum trial conference spain downside china base vipshop holding vip crash day move average heavy volume fall be news connect drop former leader china qihoo technology qihu have come stiff selling pressure recent week
1564,REGN,major average show modest loss little hour remain thursday session fairly resilient performance heighten violence ukraine
1565,REGN,dow jone industrial average nasdaq lose give nasdaq volume fall wednesday level nyse be tracking equal wednesday
1566,REGN,stock market today medicaid provider centene cnc reclaim day move average work potential base share rise medicaid have become growth story thank obamacare centene be position be prime beneficiary
1567,REGN,dow jone index announce wednesday centene move close trading
1568,REGN,elsewhere ibd name open text otex ease soft volume software maker continue hold gain smartly bullish gap july
1569,REGN,meanwhile regeneron regn lose trading just handle buy point regeneron be present detailed alirocumab datum weekend spain alirocumab be show promise ldl cholesterol lower drug
1570,REGN,earning news william sonoma wsm take hit fall home product retailer report so so earning late wednesday issue disappointing outlook forecast ep cent share revenue analyst have see earning cent sale restoration hardware rh fall sympathy be sharply lows share slump early be recently only
1571,REGN,athm extend loss plunge wednesday heavy volume stock lose additional deep cup base be short live not only do erase gain buy point wednesday also drop buy point thursday be sell signal
1572,REGN,economic news second quarter gross domestic product be revise slightly higher expect major average show modest loss little hour remain thursday session fairly resilient performance heighten violence ukraine dow jone industrial average nasdaq lose give nasdaq volume fall wednesday level nyse be tracking equal wednesday stock market today medicaid provider centene cnc reclaim day move average work potential base share rise medicaid have become growth story thank obamacare centene be position be prime beneficiary dow jone index announce wednesday centene move close trading elsewhere ibd name open text otex ease soft volume software maker continue hold gain smartly bullish gap july meanwhile regeneron regn lose trading just handle buy point regeneron be present detailed alirocumab datum weekend spain alirocumab be show promise ldl cholesterol lower drug earning news william sonoma wsm take hit fall home product retailer report so so earning late wednesday issue disappointing outlook forecast ep cent share revenue analyst have see earning cent sale restoration hardware rh fall sympathy be sharply lows share slump early be recently only athm extend loss plunge wednesday heavy volume stock lose additional deep cup base be short live not only do erase gain buy point wednesday also drop buy point thursday be sell signal economic news second quarter gross domestic product be revise slightly higher expect
1573,REGN,fattest annual profit margin come drugmaker product be meant make person healthier today screen day be healthy profit margin include highly rate drug stock don miss jazz pharmaceutical jazz annual profit margin narcolepsy treatment xyrem have rocket success contribute
1574,REGN,buyer come market spade tuesday growth stock outperformed again
1575,REGN,several headline fuel positive sentiment include better expect manufacturing datum china goldman sachs upgrade netflix nflx
1576,REGN,nasdaq lead way rise dow jone industrial average gain add accumulation day be take shape major average volume nyse nasdaq be tracking higher monday level
1577,REGN,stock market today netflix leap goldman sachs upgrade share buy say subscriber growth continue exceed expectation
1578,REGN,ibd salix pharmaceutical slxp vault positive drug development datum salix clear choppy late stage consolidation week end june stock be now extend past buy point
1579,REGN,group peer ibd name akorn akrx also shine bolt be news accompany rise sale growth have be accelerate recent quarters growth prospect be solid full year earning expect rise year
1580,REGN,new issue arista network anet rocket quiet period analyst research expire slew analyst start coverage disruptive networking technology firm today positive comment bullish price target arista be still work short ipo base high
1581,REGN,meanwhile regeneron pharmaceutical regn be top performer nasdaq share jump news french drugmaker sanofi sny increase stake biotech company company be work several promising drug together include cholesterol drug rheumatoid arthritis drug buyer come market spade tuesday growth stock outperformed again several headline fuel positive sentiment include better expect manufacturing datum china goldman sachs upgrade netflix nflx nasdaq lead way rise dow jone industrial average gain add accumulation day be take shape major average volume nyse nasdaq be tracking higher monday level stock market today netflix leap goldman sachs upgrade share buy say subscriber growth continue exceed expectation ibd salix pharmaceutical slxp vault positive drug development datum salix clear choppy late stage consolidation week end june stock be now extend past buy point group peer ibd name akorn akrx also shine bolt be news accompany rise sale growth have be accelerate recent quarters growth prospect be solid full year earning expect rise year new issue arista network anet rocket quiet period analyst research expire slew analyst start coverage disruptive networking technology firm today positive comment bullish price target arista be still work short ipo base high meanwhile regeneron pharmaceutical regn be top performer nasdaq share jump news french drugmaker sanofi sny increase stake biotech company company be work several promising drug together include cholesterol drug rheumatoid arthritis drug
1582,REGN,biotech pharma stock rally tuesday several lead player report good news buoyant market day ibd specialty drugmaker salix pharmaceutical slxp shot new high close salix say tuesday sufferer irritable bowel syndrome diarrhea show statistically significant improvement symptom take
1583,REGN,major average end modest loss thursday recover impressively early sell wall street be rattle early newfound concern health european bank espirito international parent company portuguese bank banco espirito miss payment debt nasdaq lose fall much earlier day dow jone industrial average give preliminary datum show nyse volume come higher wednesday volume nasdaq be equal wednesday airline utility stock outperformed close share gap inc gps slump june same store sale unexpectedly decline old navy do well sale rise sale banana republic namesake store fall unite continental ual surge late wednesday company say revenue available seat mile rise prior forecast stock market today hardwood flooring retailer lumber liquidator ll crash company announce preliminary second quarter result lower full year guidance sale rise well consensus estimate same store sale tumble lumber liquidator cite weaker expect traffic headwind residential remodel market selling lead growth stock be widespread early several ibd name trim loss akorn akrx be best percentage gainer ibd rise oil gas producer also re-cover leader group look ready test day move average first time recent breakout include pioneer natural resource pxd diamondback energy fang sanchez energy sn meanwhile regeneron pharmaceutical regn rise late wednesday company partner sanofi sny say start late stage trial injectable eczema treatment dupilumab favorable midstage datum drug be also be look treatment asthma sanofi recently increase stake regeneron
1584,REGN,seller come back market thursday rattle news portugal largest bank banco espirito miss payment debt
1585,REGN,just hour session stock be well session lows nasdaq dow jone industrial average lose fall nasdaq have be much volume nyse nasdaq be tracking higher wednesday level gold miner utility stock outperformed
1586,REGN,agnico eagle mine aem top rate name ibd mining gold silver gem industry group rise share have be accumulation phase june already profit take zone past cup handle buy point
1587,REGN,stock market today hardwood flooring retailer lumber liquidator ll crash company announce preliminary second quarter result lower full year guidance sale rise be well consensus estimate same store sale tumble lumber liquidator cite weaker expect traffic headwind residential remodel market
1588,REGN,selling lead growth stock be widespread jazz pharmaceutical jazz lose recent cup handle last week have stumble badly rise past entry now
1589,REGN,oil gas producer also weaken leader group look ready test day move average first time recent breakout include pioneer natural resource pxd diamondback energy fang sanchez energy sn
1590,REGN,meanwhile regeneron pharmaceutical regn ease late wednesday company partner sanofi sny say start late stage trial injectable eczema treatment dupilumab favorable midstage datum drug be also be look treatment asthma
1591,REGN,sanofi recently increase stake regeneron seller come back market thursday rattle news portugal largest bank banco espirito miss payment debt just hour session stock be well session lows nasdaq dow jone industrial average lose fall nasdaq have be much volume nyse nasdaq be tracking higher wednesday level gold miner utility stock outperformed agnico eagle mine aem top rate name ibd mining gold silver gem industry group rise share have be accumulation phase june already profit take zone past cup handle buy point stock market today hardwood flooring retailer lumber liquidator ll crash company announce preliminary second quarter result lower full year guidance sale rise be well consensus estimate same store sale tumble lumber liquidator cite weaker expect traffic headwind residential remodel market selling lead growth stock be widespread jazz pharmaceutical jazz lose recent cup handle last week have stumble badly rise past entry now oil gas producer also weaken leader group look ready test day move average first time recent breakout include pioneer natural resource pxd diamondback energy fang sanchez energy sn meanwhile regeneron pharmaceutical regn ease late wednesday company partner sanofi sny say start late stage trial injectable eczema treatment dupilumab favorable midstage datum drug be also be look treatment asthma sanofi recently increase stake regeneron
1592,REGN,jpmorgan large cap growth fund be build head steam fund have top morningstar large cap growth rival straight quarters past
1593,REGN,month end go tuesday fund be vs large cap growth mutual fund track morningstar inc be direct rival
1594,REGN,outperformance reflect portfolio average ibd composite rating be very strong fund stock have composite rating better
1595,REGN,composite rating summarize earning share growth relative price strength other slim rating rating be best
1596,REGN,fund gain investor have be drive name monster beverage mnst be so far year
1597,REGN,trading stock be form cup handle base buy point
1598,REGN,fund add monster have composite rating first quarter beverage maker benefit partnership coca cola ko gain market share energy drink
1599,REGN,regeneron pharmaceutical regn have be driver eye disease drugmaker be year be form flat base buy point
1600,REGN,earning share grow past quarters
1601,REGN,eye drug eylea be key growth driver regeneron
1602,REGN,zack equity research say eylea sale get boost use treat diabetic retinopathy form macular edema
1603,REGN,await green light
1604,REGN,sanofi sny regeneron hope get approval month regulator cholesterol lower drug praluent
1605,REGN,starbucks sbux composite rating have be third driver share be year
1606,REGN,fund boost stake share march dec
1607,REGN,tuesday coffee shop chain say partner taste holding johannesburg list company open full format store south africa taste own run java joint
1608,REGN,starbucks return equity be past year monday tuesday stock hit new high share be extend january have rebound week line
1609,REGN,illumina ilmn be year early tuesday retook buy point week tight pattern
1610,REGN,gene sequence leader have composite rating be ibd leaderboard
1611,REGN,illumina facebook fb be leaderboard be ibd share be year
1612,REGN,facebook remain new high tuesday afternoon stock be buy point still buy range
1613,REGN,accord medium report friday company be look add music video news feed
1614,REGN,valeant pharmaceutical international vrx be so far year earning share specialty drug medical device company grow past quarters
1615,REGN,toronto list company have history accretive acquisition such takeover brand drugmaker salix pharmaceutical jpmorgan large cap growth fund be build head steam fund have top morningstar large cap growth rival straight quarters past month end go tuesday fund be vs large cap growth mutual fund track morningstar inc be direct rival outperformance reflect portfolio average ibd composite rating be very strong fund stock have composite rating better composite rating summarize earning share growth relative price strength other slim rating rating be best fund gain investor have be drive name monster beverage mnst be so far year trading stock be form cup handle base buy point fund add monster have composite rating first quarter beverage maker benefit partnership coca cola ko gain market share energy drink regeneron pharmaceutical regn have be driver eye disease drugmaker be year be form flat base buy point earning share grow past quarters eye drug eylea be key growth driver regeneron zack equity research say eylea sale get boost use treat diabetic retinopathy form macular edema await green sanofi sny regeneron hope get approval month regulator cholesterol lower drug praluent starbucks sbux composite rating have be third driver share be year fund boost stake share march dec tuesday coffee shop chain say partner taste holding johannesburg list company open full format store south africa taste own run java joint starbucks return equity be past year monday tuesday stock hit new high share be extend january have rebound week line illumina ilmn be year early tuesday retook buy point week tight pattern gene sequence leader have composite rating be ibd leaderboard illumina facebook fb be leaderboard be ibd share be year facebook remain new high tuesday afternoon stock be buy point still buy range accord medium report friday company be look add music video news feed valeant pharmaceutical international vrx be so far year earning share specialty drug medical device company grow past quarters toronto list company have history accretive acquisition such takeover brand drugmaker salix pharmaceutical
1616,REGN,most heavily trade etfs have rally early month lows powershare qqq qqq be so far july past month year date compare ishare russell iwm gain period spdr spy
1617,REGN,qqq hold asset roughly largest nonfinancial stock nasdaq composite index technology sector account more half asset biotechnology company get hefty portfolio weighting
1618,REGN,top perform holding past month include netflix nflx electronic art ea tesla motor tsla also have big stake highly rate stock facebook fb regeneron pharmaceutical regn gilead science gild starbucks sbux celgene celg have ibd composite rating more
1619,REGN,skew technology sector large growth stock have help qqq edge most actively trade rival most past year average annual gain past year trail spy iwm
1620,REGN,successful investor keep eye cost qqq have expense ratio par iwm more spy
1621,REGN,asset qqq spy have shrink year iwm have grow smidge june exchange trade fund have leak more combine investor outflow
1622,REGN,qqq rise thestock market today grasp distance old high
1623,REGN,follow aparna narayanan twitter ibd_anarayanan most heavily trade etfs have rally early month lows powershare qqq qqq be so far july past month year date compare ishare russell iwm gain period spdr spy qqq hold asset roughly largest nonfinancial stock nasdaq composite index technology sector account more half asset biotechnology company get hefty portfolio weighting top perform holding past month include netflix nflx electronic art ea tesla motor tsla also have big stake highly rate stock facebook fb regeneron pharmaceutical regn gilead science gild starbucks sbux celgene celg have ibd composite rating more skew technology sector large growth stock have help qqq edge most actively trade rival most past year average annual gain past year trail spy iwm successful investor keep eye cost qqq have expense ratio par iwm more spy asset qqq spy have shrink year iwm have grow smidge june exchange trade fund have leak more combine investor outflow qqq rise thestock market today grasp distance old high follow aparna narayanan twitter ibd_anarayanan
1624,REGN,person get older be more prone vision loss age related macular degeneration severe wet version condition be lead cause blindness afflict million person cause leaky abnormal blood vessel grow back eye treatment prognosis be dim biologic drug eylea
1625,REGN,investor cast aside worry greece future hike interest rate economy bid stock sharply higher go noon hour thursday
1626,REGN,tech biotech stock lead way nasdaq be push new time intraday high level set march
1627,REGN,nasdaq climb rise dow jone industrial average gain stock market today volume be sharply higher board
1628,REGN,new ipo fitbit fit receive warm wall street welcome rise more offer price company make wearable fitness monitoring device
1629,REGN,ibd stock be higher be lower ambarella amba rise new high stock have rise more find support day move average be show climax type action company make chip used video camera supplier gopro gpro wearable action camera
1630,REGN,leaderboard name palo alto network panw rise nearly stock find support day line rocket time high red hot security software industry group
1631,REGN,biotech stock be lead industry group more piper jaffray analyst richard purkiss say recent note expect big drugmaker see revenue peak follow wave patent expiration
1632,REGN,regeneron pharmaceutical regn gain nearly week specialist eye disease treatment bounce sharply support day move average heavy volume stock accumulation distribution rating be still mediocre belie stock renew strength regeneron also sport volume ratio neutral level investor cast aside worry greece future hike interest rate economy bid stock sharply higher go noon hour thursday tech biotech stock lead way nasdaq be push new time intraday high level set march nasdaq climb rise dow jone industrial average gain stock market today volume be sharply higher board new ipo fitbit fit receive warm wall street welcome rise more offer price company make wearable fitness monitoring device ibd stock be higher be lower ambarella amba rise new high stock have rise more find support day move average be show climax type action company make chip used video camera supplier gopro gpro wearable action camera leaderboard name palo alto network panw rise nearly stock find support day line rocket time high red hot security software industry group biotech stock be lead industry group more piper jaffray analyst richard purkiss say recent note expect big drugmaker see revenue peak follow wave patent expiration regeneron pharmaceutical regn gain nearly week specialist eye disease treatment bounce sharply support day move average heavy volume stock accumulation distribution rating be still mediocre belie stock renew strength regeneron also sport volume ratio neutral level
1633,REGN,stock future point strong open tuesday strength most overseas market nasdaq future rally point vs fair value future climb point future dow jone industrial average jump point
1634,REGN,stock reversed higher monday solid gain volume be lower
1635,REGN,equity market overseas be mostly higher european bourse lead charge france cac bolt germany dax rally meanwhile london ftse gain
1636,REGN,asia hong kong hang seng climb japan nikkei gain shanghai composite be fractionally lower
1637,REGN,gain monday rise tension friday terrorist attack paris crude oil pull back december crude lose cent barrel
1638,REGN,economic front consumer price rise october be first gain month match view
1639,REGN,datum industrial production nahb housing market index be et et respectively fed governor jerome powell daniel tarullo be speaking later today
1640,REGN,stock home depot hd rally premarket trading stock market today beating view home improvement retailer post earning share sale view be ep revenue also peg full year earning share nickel view
1641,REGN,rival lowe low be also premarket trading report quarterly result wednesday
1642,REGN,wal mart wmt rise premarket post mixed quarterly result world biggest retailer report fiscal earning share exclude gain lease earning be cent share sale come analyst poll thomson reuter have expect ep cent revenue
1643,REGN,fitbit fit gain more premarket activity be upgrade buy neutral bank america lynch share maker fitness tracker bounce back monday hit record low friday
1644,REGN,dick sporting good dks plunge premarket trade follow disappointing earning weak outlook retailer post adjust earning cent share revenue view be ep cent sale retailer guide earning share vs view monday share fall lowest level january
1645,REGN,follow vincent mao twitter ibd_vmao stock future point strong open tuesday strength most overseas market nasdaq future rally point vs fair value future climb point future dow jone industrial average jump point stock reversed higher monday solid gain volume be lower equity market overseas be mostly higher european bourse lead charge france cac bolt germany dax rally meanwhile london ftse gain asia hong kong hang seng climb japan nikkei gain shanghai composite be fractionally lower gain monday rise tension friday terrorist attack paris crude oil pull back december crude lose cent barrel economic front consumer price rise october be first gain month match view datum industrial production nahb housing market index be et et respectively fed governor jerome powell daniel tarullo be speaking later today stock home depot hd rally premarket trading stock market today beating view home improvement retailer post earning share sale view be ep revenue also peg full year earning share nickel view rival lowe low be also premarket trading report quarterly result wednesday wal mart wmt rise premarket post mixed quarterly result world biggest retailer report fiscal earning share exclude gain lease earning be cent share sale come analyst poll thomson reuter have expect ep cent revenue fitbit fit gain more premarket activity be upgrade buy neutral bank america lynch share maker fitness tracker bounce back monday hit record low friday dick sporting good dks plunge premarket trade follow disappointing earning weak outlook retailer post adjust earning cent share revenue view be ep cent sale retailer guide earning share vs view monday share fall lowest level january follow vincent mao twitter ibd_vmao
1646,REGN,fda advisory committee vote favor approve amgen amgn cholesterol drug repatha wednesday afternoon voiced similar concern do regeneron regn sanofi sny fellow pcsk inhibitor tuesday
1647,REGN,still amgen stock be hour trading wednesday rise fraction regular session
1648,REGN,panel vote favor approve repatha patient heterozygous familial hefh slightly less ring endorsement vote regeneron praluent get
1649,REGN,however receive unanimous endorsement rarer homozygous familial hofh regeneron have not seek approval ground severe problem unmet clinical need
1650,REGN,voter expressed need datum long term cardiovascular outcome study amgen only just start warn sometimes bad side effect such diabetes have emerge only longer term clinical trial
1651,REGN,be similar reason many yes voter advise used repatha only high risk patient have regeneron praluent
1652,REGN,fda be due make final decision repatha include patient advise treat label aug praluent be due final decision july
1653,REGN,regeneron stock fall wednesday sanofi share rise
1654,REGN,follow amy reeve twitter ibd_areeve fda advisory committee vote favor approve amgen amgn cholesterol drug repatha wednesday afternoon voiced similar concern do regeneron regn sanofi sny fellow pcsk inhibitor tuesday still amgen stock be hour trading wednesday rise fraction regular session panel vote favor approve repatha patient heterozygous familial hefh slightly less ring endorsement vote regeneron praluent get however receive unanimous endorsement rarer homozygous familial hofh regeneron have not seek approval ground severe problem unmet clinical need voter expressed need datum long term cardiovascular outcome study amgen only just start warn sometimes bad side effect such diabetes have emerge only longer term clinical trial be similar reason many yes voter advise used repatha only high risk patient have regeneron praluent fda be due make final decision repatha include patient advise treat label aug praluent be due final decision july regeneron stock fall wednesday sanofi share rise follow amy reeve twitter ibd_areeve
1655,REGN,big biotech regeneron pharmaceutical regn be nearly wednesday wall street digest impact ambiguous fda advisory committee vote cholesterol drug praluent late tuesday meanwhile rival amgen amgn be committee reconven vote similar drug repatha
1656,REGN,panel endorse approval overall caution real connection lower ldl cholesterol cardiovascular health raise question broad fda make label render final decision july leerink analyst joseph schwartz seamus fernandez read fda representative be more positive committee member be independent agency
1657,REGN,fda appear lean broader inclusive label panel member qualitative color panel post voting hint likelihood label initially constitute patient subgroup highest unmet need familial fh population particular heterozygous hefh high very high cardiovascular risk population maximally tolerate statin therapy secondary prevention write
1658,REGN,group patient not get initial label note rbc capital market analyst adnan butt surprise be lack conviction statin intolerant patient most member seem hung lack cardiovascular outcome datum potential compromise ongoing outcome study ldl sufficient marker activity broad population safety light low ldl level reach patient
1659,REGN,last point overall panel agree praluent appear be safe concern happen patient cholesterol get too low point leerink analyst think help regeneron partner sanofi sny be seek approval praluent dose amgen offer repatha only relatively high dose
1660,REGN,initiation treatment lower dose subsequent titrate need initially be favore clinical practice least longer term datum become available ruling safety issue write
1661,REGN,panel be expect vote repatha wednesday afternoon
1662,REGN,sanofi be nearly morning trading stock market today perhaps help conference call hold tuesday diabetes program account larger proportion sale praluent be expect company be bullish launch once daily insulin product toujeo say be cover life commercial plan life medicare part
1663,REGN,meanwhile fda panel concern statin intolerant be likely responsible drubbing esperion therapeutic espr be take wednesday stock nearly midmorning be target statin intolerant market drug candidate etc
1664,REGN,follow amy reeve twitter ibd_areeve big biotech regeneron pharmaceutical regn be nearly wednesday wall street digest impact ambiguous fda advisory committee vote cholesterol drug praluent late tuesday meanwhile rival amgen amgn be committee reconven vote similar drug repatha panel endorse approval overall caution real connection lower ldl cholesterol cardiovascular health raise question broad fda make label render final decision july leerink analyst joseph schwartz seamus fernandez read fda representative be more positive committee member be independent agency fda appear lean broader inclusive label panel member qualitative color panel post voting hint likelihood label initially constitute patient subgroup highest unmet need familial fh population particular heterozygous hefh high very high cardiovascular risk population maximally tolerate statin therapy secondary prevention write group patient not get initial label note rbc capital market analyst adnan butt surprise be lack conviction statin intolerant patient most member seem hung lack cardiovascular outcome datum potential compromise ongoing outcome study ldl sufficient marker activity broad population safety light low ldl level reach patient last point overall panel agree praluent appear be safe concern happen patient cholesterol get too low point leerink analyst think help regeneron partner sanofi sny be seek approval praluent dose amgen offer repatha only relatively high dose initiation treatment lower dose subsequent titrate need initially be favore clinical practice least longer term datum become available ruling safety issue write panel be expect vote repatha wednesday afternoon sanofi be nearly morning trading stock market today perhaps help conference call hold tuesday diabetes program account larger proportion sale praluent be expect company be bullish launch once daily insulin product toujeo say be cover life commercial plan life medicare part meanwhile fda panel concern statin intolerant be likely responsible drubbing esperion therapeutic espr be take wednesday stock nearly midmorning be target statin intolerant market drug candidate etc follow amy reeve twitter ibd_areeve
1665,REGN,solid fundamental be sign solid stock today screen day feature company top fundamental
1666,REGN,firm have year earning growth rate least higher include chinese stock yy yy other
1667,REGN,yy online social platform let user engage share activity web have year earning share growth rate screen day regular rise estimate position international leader
1668,REGN,company have history triple digit earning gain have earn ibd composite rating highest rating possible
1669,REGN,fellow chinese internet stock qihoo technology qihu also top composite rating have year ep growth rate online security software provider internet platform have experience straight quarters triple digit earning advance
1670,REGN,company report earning result monday
1671,REGN,regeneron pharmaceutical regn be stranger healthy profit margin reach sale
1672,REGN,know wet macular degeneration drug eylea drugmaker stock recently hit new high have year ep growth rate
1673,REGN,eagle material exp be build material provider spin centex dalla base company have composite rating
1674,REGN,small cap stock be favore mutual fund eagle have year ep growth rate
1675,REGN,restoration hardware rh be higher end home furnishing retailer akin william sonoma wsm company have year ep growth rate have see earning gain more last quarters
1676,REGN,furniture store get boost sale last week accord icsc goldman sachs chain store sale index
1677,REGN,related
1678,REGN,qihoo restoration hardware be hang tough solid fundamental be sign solid stock today screen day feature company top fundamental firm have year earning growth rate least higher include chinese stock yy yy other yy online social platform let user engage share activity web have year earning share growth rate screen day regular rise estimate position international leader company have history triple digit earning gain have earn ibd composite rating highest rating possible fellow chinese internet stock qihoo technology qihu also top composite rating have year ep growth rate online security software provider internet platform have experience straight quarters triple digit earning advance company report earning result monday regeneron pharmaceutical regn be stranger healthy profit margin reach sale know wet macular degeneration drug eylea drugmaker stock recently hit new high have year ep growth rate eagle material exp be build material provider spin centex dalla base company have composite rating small cap stock be favore mutual fund eagle have year ep growth rate restoration hardware rh be higher end home furnishing retailer akin william sonoma wsm company have year ep growth rate have see earning gain more last quarters furniture store get boost sale last week accord icsc goldman sachs chain store sale index related qihoo restoration hardware be hang tough
1679,REGN,year top perform sector exchange trade fund be rally dip
1680,REGN,market vector junior gold miner gdxj be year average annual past year accord morningstar datum
1681,REGN,market vector gold miner gdx be year date average past year
1682,REGN,first trust nyse arca biotechnology fbt be so far year have provide investor average annual past year fbt holding include intermune itmn have zoom year company develop lung treatment be still lose money sale growth have be triple digit past quarters
1683,REGN,fbt also have stake gilead science gild year gilead have much stronger earning profile carry ibd earning share rating reflect increase past quarters
1684,REGN,eft also hold regeneron pharmaceutical regn be year have ep rating company have loss prior growth rate have improve rate past year year top perform sector exchange trade fund be rally dip market vector junior gold miner gdxj be year average annual past year accord morningstar datum market vector gold miner gdx be year date average past year first trust nyse arca biotechnology fbt be so far year have provide investor average annual past year fbt holding include intermune itmn have zoom year company develop lung treatment be still lose money sale growth have be triple digit past quarters fbt also have stake gilead science gild year gilead have much stronger earning profile carry ibd earning share rating reflect increase past quarters eft also hold regeneron pharmaceutical regn be year have ep rating company have loss prior growth rate have improve rate past year
1685,REGN,fda advisory committee vote late tuesday favor approve cholesterol buster praluent linger question remain just many person treat praluent team regeneron pharmaceutical regn sanofi sny be due final decision approval july analyst expect multibillion dollar annual sale eventually
1686,REGN,stock future hammer powerful gain ahead friday open boost tech sector earning report global currency issue dow future point be rise
1687,REGN,nasdaq future fly high altitude point future show strong point gain small cap show unusual strength russell future rise point
1688,REGN,stock market today see economic calendar kick et researcher markit report preliminary manufacturing purchasing manager index number october oil price be focus baker hughe bhi be schedule release weekly rig count report
1689,REGN,global bond currency continue react thursday news european central bank be consider boost monetary stimulus effort december addition china central bank make number significant move cut target interest rate percentage point trimming bank reserve ratio requirement eliminate deposit rate ceiling
1690,REGN,china shanghai composite hong kong hang seng index rise nikkei tokyo pop europe market be knock solid gain midday dax frankfurt cac paris show gain london ftse ahead
1691,REGN,many name be motion ahead friday open report quarterly result american airline aal royal caribbean rcl shire shpg rise whirlpool whr rise procter gamble pg add vf vfc slip
1692,REGN,morning big move come tech
1693,REGN,alphabet googl google parent company spel premarket gain stomp analyst consensus expectation late thursday ep gain rise revenue share buyback initiative be part third quarter package paid click volume carefully monitored metric jump better expect alphabet finished thursday regular session bit less buy point week cup base
1694,REGN,amazon com amzn hold advance ahead friday open soar extend trading thursday diversify online tech service giant result show cent share profit vs consensus expectation cent loss revenue leap also better expect closely watch cloud service unit only total revenue see sale surge stock end thursday still buy range less buy point cup handle base
1695,REGN,microsoft msft also scale report late thursday fiscal earning outpaced consensus projection ep gain easily top estimate revenue fall less forecast stock close thursday session buy range less past buy point cup handle base
1696,REGN,ibd stock facebook fb bang premarket gain social networking heavyweight end thursday session buy range buy point cup handle base
1697,REGN,downside shoemaker skecher skx collapse weak result jump earning revenue gain stop far short consensus projection currency issue rise rent expense be key factor company say stock have be fight regain support week move average month base effort
1698,REGN,stream music service pandora crumble open calif base operation report earning rise line consensus expectation revenue increase be smaller forecast management lower revenue guidance well consensus view stock have stage comeback rally july be still deep month consolidation end trade thursday stock future hammer powerful gain ahead friday open boost tech sector earning report global currency issue dow future point be rise nasdaq future fly high altitude point future show strong point gain small cap show unusual strength russell future rise point stock market today see economic calendar kick et researcher markit report preliminary manufacturing purchasing manager index number october oil price be focus baker hughe bhi be schedule release weekly rig count report global bond currency continue react thursday news european central bank be consider boost monetary stimulus effort december addition china central bank make number significant move cut target interest rate percentage point trimming bank reserve ratio requirement eliminate deposit rate ceiling china shanghai composite hong kong hang seng index rise nikkei tokyo pop europe market be knock solid gain midday dax frankfurt cac paris show gain london ftse ahead many name be motion ahead friday open report quarterly result american airline aal royal caribbean rcl shire shpg rise whirlpool whr rise procter gamble pg add vf vfc slip morning big move come tech alphabet googl google parent company spel premarket gain stomp analyst consensus expectation late thursday ep gain rise revenue share buyback initiative be part third quarter package paid click volume carefully monitored metric jump better expect alphabet finished thursday regular session bit less buy point week cup base amazon com amzn hold advance ahead friday open soar extend trading thursday diversify online tech service giant result show cent share profit vs consensus expectation cent loss revenue leap also better expect closely watch cloud service unit only total revenue see sale surge stock end thursday still buy range less buy point cup handle base microsoft msft also scale report late thursday fiscal earning outpaced consensus projection ep gain easily top estimate revenue fall less forecast stock close thursday session buy range less past buy point cup handle base ibd stock facebook fb bang premarket gain social networking heavyweight end thursday session buy range buy point cup handle base downside shoemaker skecher skx collapse weak result jump earning revenue gain stop far short consensus projection currency issue rise rent expense be key factor company say stock have be fight regain support week move average month base effort stream music service pandora crumble open calif base operation report earning rise line consensus expectation revenue increase be smaller forecast management lower revenue guidance well consensus view stock have stage comeback rally july be still deep month consolidation end trade thursday
1699,REGN,stock drive higher start gate thursday bolster positive stock action europe china
1700,REGN,nasdaq grab gain dow jone industrial average rise add volume be higher exchange
1701,REGN,stock market today surge labor department disappointing tally weekly jobless claim increase claim week end july run counter expectation slight decrease drive week move average second straight week
1702,REGN,stock rally europe possibly set overnight rebound china sell market signale willingness investor abandon grexit fear bond slip dollar rise oil price gain accelerate open west texas intermediate brent crude benchmark chesapeake energy chk pop top russia base telecom service provider vimpelcom vip jump lead nasdaq third dow stock rise more lead traveler trv jpmorgan jpm
1703,REGN,chip stock be rebound have be tough week lead european union base issue lead philadelphia semiconductor index netherlands base asml asml jump more base arm armh climb
1704,REGN,alcoa aa climb nearly report mixed second quarter result late wednesday earning miss analyst projection revenue top expectation company increase focus aerospace automotive market help offset loss drive global aluminum glut
1705,REGN,wynn resort wynn jump possible due link china casino gamble district macau stock be work second week gain follow month steep decline
1706,REGN,ibd list open almost unanimously higher china base issue lead gain
1707,REGN,netease nte leap heavy trade fight retake support day move average gain narrow stock loss week
1708,REGN,athm be back away early high stock be engage test support day move average
1709,REGN,israel base cyberark software cybr climb rise second straight session strong trade security software developer have narrow loss week remain mid june high well week move average
1710,REGN,low end list regeneron pharmaceutical regn slip fraction ub downgrade stock sell neutral stock drive higher start gate thursday bolster positive stock action europe china nasdaq grab gain dow jone industrial average rise add volume be higher exchange stock market today surge labor department disappointing tally weekly jobless claim increase claim week end july run counter expectation slight decrease drive week move average second straight week stock rally europe possibly set overnight rebound china sell market signale willingness investor abandon grexit fear bond slip dollar rise oil price gain accelerate open west texas intermediate brent crude benchmark chesapeake energy chk pop top russia base telecom service provider vimpelcom vip jump lead nasdaq third dow stock rise more lead traveler trv jpmorgan jpm chip stock be rebound have be tough week lead european union base issue lead philadelphia semiconductor index netherlands base asml asml jump more base arm armh climb alcoa aa climb nearly report mixed second quarter result late wednesday earning miss analyst projection revenue top expectation company increase focus aerospace automotive market help offset loss drive global aluminum glut wynn resort wynn jump possible due link china casino gamble district macau stock be work second week gain follow month steep decline ibd list open almost unanimously higher china base issue lead gain netease nte leap heavy trade fight retake support day move average gain narrow stock loss week athm be back away early high stock be engage test support day move average israel base cyberark software cybr climb rise second straight session strong trade security software developer have narrow loss week remain mid june high well week move average low end list regeneron pharmaceutical regn slip fraction ub downgrade stock sell neutral
1711,REGN,speculation newest class cholesterol drug heated friday fda release briefing document tuesday advisory committee meeting praluent pcsk inhibitor regeneron pharmaceutical regn sanofi sny nevertheless regeneron stock rise fresh time high friday second straight day sanofi retreat document frame issue ponder
1712,REGN,share small biotech ophthotech opht surge morning trading stock market today firm announce big pharma partnership eye drug candidate late monday ophthotech inked deal worth much novartis nvs commercialize fovista treatment wet age related macular degeneration amd now phase testing novartis pay
1713,REGN,valeant pharmaceutical vrx report mixed first quarter thursday busy day drugmaker earning report canadian drugmaker report earning share year earlier quarter beating cent consensus analyst poll thomson reuter sale rise short consensus share fall nearly
1714,REGN,canadian drugmaker valeant pharmaceutical international vrx report mixed mostly line thursday management continue press case merger allergan agn valeant stock rise fractionally stock market today
1715,REGN,valeant report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise bit short consensus
1716,REGN,company do not issue new guidance have already raise forecast week earlier announce hostile bid allergan time valeant guide full year sale range last year ep vs
1717,REGN,quarter growth generally come acquisition especially buyout contact lens giant bausch lomb last august organic sale growth be only valeant face generic competition lead product include skin cream retin micro herpes ointment zovirax however management expect growth pick course year launch new product
1718,REGN,bausch lomb outperformed rest business clocking organic growth significant new product launch valeant now expect synergy merger valeant ceo michael pearson say conference call analyst bausch merger provide model valeant integrate allergan
1719,REGN,bausch have centralize model country have general manager run different business vision care pharmaceutical surgery pearson say combine ihealth group different country earlier structure be exact same structure allergan have
1720,REGN,same time pearson say didn touch bausch sale force likely act lesson learn hard way valeant buy medicis attempt overhaul sale staff result high turnover last year pearson say stabilization situation have help boost north american dermatology business year
1721,REGN,thursday be busy day drugmaker earning other high rate stock report early
1722,REGN,mallinckrodt mnk be process buy questcor pharmaceutical qcor report earning cent share number be nickel year earlier quarter mallinckrodt be still part covidien cov beat analyst consensus cent sale shrank short estimate mallinckrodt guide revenue line ep consensus however probably account company stock rise early trading
1723,REGN,regeneron pharmaceutical regn defy pattern season actually beat sale estimate report growth more consensus sale lead drug eylea miss expectation regeneron stock be late morning company restate earlier guidance full year sale eylea
1724,REGN,ibd stock salix pharmaceutical slxp jazz pharmaceutical jazz be report close
1725,REGN,related allergan report strong weigh valeant bid
1726,REGN,follow amy reeve twitter drugmaker valeant pharmaceutical international vrx report mixed mostly line thursday management continue press case merger allergan agn valeant stock rise fractionally stock market today valeant report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise bit short consensus company do not issue new guidance have already raise forecast week earlier announce hostile bid allergan time valeant guide full year sale range last year ep vs quarter growth generally come acquisition especially buyout contact lens giant bausch lomb last august organic sale growth be only valeant face generic competition lead product include skin cream retin micro herpes ointment zovirax however management expect growth pick course year launch new product bausch lomb outperformed rest business clocking organic growth significant new product launch valeant now expect synergy merger valeant ceo michael pearson say conference call analyst bausch merger provide model valeant integrate allergan bausch have centralize model country have general manager run different business vision care pharmaceutical surgery pearson say combine ihealth group different country earlier structure be exact same structure allergan have same time pearson say didn touch bausch sale force likely act lesson learn hard way valeant buy medicis attempt overhaul sale staff result high turnover last year pearson say stabilization situation have help boost north american dermatology business year thursday be busy day drugmaker earning other high rate stock report early mallinckrodt mnk be process buy questcor pharmaceutical qcor report earning cent share number be nickel year earlier quarter mallinckrodt be still part covidien cov beat analyst consensus cent sale shrank short estimate mallinckrodt guide revenue line ep consensus however probably account company stock rise early trading regeneron pharmaceutical regn defy pattern season actually beat sale estimate report growth more consensus sale lead drug eylea miss expectation regeneron stock be late morning company restate earlier guidance full year sale eylea ibd stock salix pharmaceutical slxp jazz pharmaceutical jazz be report close related allergan report strong weigh valeant bidfollow amy reeve twitter ibd_areeve
1727,REGN,big pharmas report light mixed earning tuesday share go different direction stock market today wall street seem focus different detail report
1728,REGN,bristol myer squibb bmy say earning rise year earlier quarter cent share beating analyst consensus cent sale however fall miss consensus bristol add nickel low end previous ep guidance range now midpoint be analyst sale guidance be squarely line consensus represent modest decline last year
1729,REGN,hiv drug sustiva reyataz be largely responsible miss rheumatoid arthritis drug orencia other hand stroke preventer eliquis finally seem be find leg disappointing launch last year sale beating view diabetes also outperformed bristol sell business february astrazeneca azn still collect royalty
1730,REGN,bristol also announce begin roll fda submission process pd inhibitor nivolumab squamous nonsmall cell lung cancer base study expect complete year end nivolumab perform well disease phase trial present significant opportunity prognosis squamous patient today be poor bristol say report phase result meeting october
1731,REGN,company also acquire privately hold biotech ipierian develop treatment class neurogenerative disease call tauopathy
1732,REGN,bristol stock be midday trading
1733,REGN,merck mrk report similarly mixed quarter street be more impressed stock be profit climb year earlier quarter cent share beating estimate cent sale shrank miss consensus merck affirm previous guidance call ep sale
1734,REGN,isi group analyst mark schoenebaum most interesting thing result be beleaguered diabetes drug januvia beat expectation
1735,REGN,quantify price impact point note favorable year year price impact be good news mrk dpp category be plague new aggressive price competition write email client
1736,REGN,merck say leave pipeline update business review meeting next week also didn comment effort sell consumer business have reportedly draw interest reckitt benckiser procter gamble pg bayer bayry past few day
1737,REGN,sanofi sny report number euro sale converted constant exchange rate miss analyst consensus ep miss consensus cent rise constant exchange rate
1738,REGN,rbc capital market note sanofi moved expect filing timeline alirocumab cholesterol drug develop regeneron pharmaceutical regn previously expect file europe early next year somewhat later now expect eu filing late year
1739,REGN,product regeneron partnership dupilumab be be moved phase trial atopic dermatitis perhaps base encourage report regeneron stock be midday trading even sanofi stock be more
1740,REGN,sanofi be also news tuesday be report allergan agn have approach possible buyer allergan bid fend hostile bid valeant pharmaceutical vrx report be base anonymous source company refuse comment
1741,REGN,follow amy reeve twitter ibd_areeve big pharmas report light mixed earning tuesday share go different direction stock market today wall street seem focus different detail report bristol myer squibb bmy say earning rise year earlier quarter cent share beating analyst consensus cent sale however fall miss consensus bristol add nickel low end previous ep guidance range now midpoint be analyst sale guidance be squarely line consensus represent modest decline last year hiv drug sustiva reyataz be largely responsible miss rheumatoid arthritis drug orencia other hand stroke preventer eliquis finally seem be find leg disappointing launch last year sale beating view diabetes also outperformed bristol sell business february astrazeneca azn still collect royalty bristol also announce begin roll fda submission process pd inhibitor nivolumab squamous nonsmall cell lung cancer base study expect complete year end nivolumab perform well disease phase trial present significant opportunity prognosis squamous patient today be poor bristol say report phase result meeting october company also acquire privately hold biotech ipierian develop treatment class neurogenerative disease call tauopathy bristol stock be midday trading merck mrk report similarly mixed quarter street be more impressed stock be profit climb year earlier quarter cent share beating estimate cent sale shrank miss consensus merck affirm previous guidance call ep sale isi group analyst mark schoenebaum most interesting thing result be beleaguered diabetes drug januvia beat expectation quantify price impact point note favorable year year price impact be good news mrk dpp category be plague new aggressive price competition write email client merck say leave pipeline update business review meeting next week also didn comment effort sell consumer business have reportedly draw interest reckitt benckiser procter gamble pg bayer bayry past few day sanofi sny report number euro sale converted constant exchange rate miss analyst consensus ep miss consensus cent rise constant exchange rate rbc capital market note sanofi moved expect filing timeline alirocumab cholesterol drug develop regeneron pharmaceutical regn previously expect file europe early next year somewhat later now expect eu filing late year product regeneron partnership dupilumab be be moved phase trial atopic dermatitis perhaps base encourage report regeneron stock be midday trading even sanofi stock be more sanofi be also news tuesday be report allergan agn have approach possible buyer allergan bid fend hostile bid valeant pharmaceutical vrx report be base anonymous source company refuse comment follow amy reeve twitter ibd_areeve
1742,REGN,ceo leonard schleifer make sure regeneron pharmaceutical be study drug wide view science have work wonder past decade regeneron regn philosophy spark contention early biotech firm publicly trade life board adviser debate schleifer long range build blockbuster drug drag too long official want regeneron focus strictly opportunity get magic drug market soon possible schleifer have founder company say know overall pharmacology approach pay have regeneron sale hit company ipo april stock be stock turn even healthier wednesday share leap food drug administration approve flagship drug eylea treat diabetic macular edema dme lead cause blindness eylea be initially approve november treat age related wet macular degeneration now thick dme market potentially lucrative regeneron due global diabetes epidemic enlighten path formula be surprisingly easy articulate difficult emulate schleifer tell ibd set have world best science follow science ve do past year schleifer start path pharmaceutical success grow queen go forest hill high school be captain tennis team be also junior new york state chess champion schleifer get work ethic father depression era sweater maker born poor immigrant williamsburg section brooklyn advice be get well educate possible believe education be weapon fight world son recall schleifer hone weapon attend dad alma mater cornell university save family money len finished year earn bachelor degree neurobiology behavior graduate summa cum laude phi beta kappa schleifer then go university virginia doctorate medicine pharmacology uva schleifer study alfr gilman share nobel prize physiology medicine martin rodbell schleifer watch gilman do research lead nobel prize call enormously inspiring be trained scientist clinician schleifer return cornell system work neurologist junior faculty member cornell new york hospital be become fascinate biotech revolution read stack paper genentech industry leader fold roche be trained biochemist have interest molecular biology schleifer say genentech be pioneer dna technology schleifer ponder go business own aim path disease nervous system business be regeneron pharmaceutical name regenerate nerve cell headquarters tarrytown just north new york city help gilman schleifer contact top mind biotech field lead right person regeneron start early mentor be roy vagelos george yancopoulos roy vagelos have hold chairmanship regeneron come merck mrk be greatest ceo american history accord schleifer yancopoulos be regeneron chief scientific officer schleifer recruit columbia university yancopoulos lead research molecular immunology now be star yancopoulos be principal inventor eylea most drug regeneron pipeline schleifer laud greatest scientist entrepreneur generation join regeneron wasn hard decision yancopoulos really believe len be try do say know be do right reason such talent schleifer be key regeneron drug revenue generation decide build company not only value science also scientist do science schleifer say like point work yancopoulos not other way tough early go regeneron be filled adversity firm develop protein early treat amyotrophic lateral sclerosis lou gehrig disease patient lose too much weight side effect company halter trial then regeneron obesity drug never make past fda failure business be just part parcel never really change view be right track schleifer say great success life come failure regeneron first approve drug be arcalyst drug treat rare genetic disease be widely consider success wall regeneron analyst weren impressed drug cost develop wasn contribute meaningfully bottom line arcalyst do just sale first quarter science drug have be critical further drug development regeneron wall street miss whole point yancopoulos say be build company infrastructure technology capability not only innovate once repeat again new drug new therapeutic area open waypipeline prospect be bright alirocumab antibody lower low density lipoprotein cholesterol call bad cholesterol collect wall blood vessel cause blockage wednesday regeneron partner sanofi sny report positive phase result alirocumab phase trial regeneron rheumatoid arthritis drug sarilumab be show progress then dupilumab clinical trial asthma other disease late stage production be regeneron early stage pipeline grow antibody company lab have consider be most enviable pipeline industry home grow yancopoulos say meanwhile regeneron have stay sanofi french firm recently raise stake regeneron sanofi have right own schleifer company regeneron also recently embarked research development initiative avalanche biotechnology aavl develop next generation gene therapy product ophthalmology branch medicine concern treat disorder eye initial public offer thursday avalanche go opposite direction name imply gush early trade buy company acquisition don give competitive advantage schleifer say competitive advantage be science yancopoulos also weigh acquisition used sport metaphor baseball team spend lot money older free agent doesn have farm system believe build internally used farm system re produce prize prospect left right personal side schleifer celebrate year marriage wife harriet december live new york have son say come recreation golf chess occasional poker game good friend persistence have paid ceo other personality trait have also help have exaggerate sense fairness have allow value true value creator company regeneron say combine overall optimistic nature have allow stay true conviction talent regeneron succeed long haul
1743,REGN,regeneron pharmaceutical regn say phase testing dupilumab atopic dermatitis drug have be success set drug phase testing year
1744,REGN,tonight news be clearly positive think be more less line investor expectation write cowen analyst phil nadeau late wednesday research note nadeau rate regeneron stock market perform hold
1745,REGN,drug be expect treat moderate severe atopic dermatitis result phase test be consistent strong phase result investor bullishness write leerink analyst joseph schwartz research note rate stock outperform buy
1746,REGN,regeneron stock be fraction early afternoon trading stock market today share be nearly year
1747,REGN,tarrytown base regneron paris base sanofi sny announce press release late wednesday phase test have positive result
1748,REGN,latest result be consistent be observed earlier clinical study add body evidence investigational dupilumab have role play patient moderate severe atopic dermatitis dr elias president global sanofi say statement
1749,REGN,week phase test be double blind placebo controlled study patient company say
1750,REGN,related bristol myer pfizer regeneron drug get eu nod
1751,REGN,regeneron rise sanofi raise stake biotech
1752,REGN,salix akorn regeneron lead drug stock rally
1753,REGN,follow kevin shalvey twitter ibd_kshalvey regeneron pharmaceutical regn say phase testing dupilumab atopic dermatitis drug have be success set drug phase testing year tonight news be clearly positive think be more less line investor expectation write cowen analyst phil nadeau late wednesday research note nadeau rate regeneron stock market perform hold drug be expect treat moderate severe atopic dermatitis result phase test be consistent strong phase result investor bullishness write leerink analyst joseph schwartz research note rate stock outperform buy regeneron stock be fraction early afternoon trading stock market today share be nearly year tarrytown base regneron paris base sanofi sny announce press release late wednesday phase test have positive result latest result be consistent be observed earlier clinical study add body evidence investigational dupilumab have role play patient moderate severe atopic dermatitis dr elias president global sanofi say statement week phase test be double blind placebo controlled study patient company say related bristol myer pfizer regeneron drug get eu nodsregeneron rise sanofi raise stake biotechsalix akorn regeneron lead drug stock rallyfollow kevin shalvey twitter ibd_kshalvey
1754,REGN,ibd be ranking lead stock base key fundamental technical measure include earning sale growth profit margin return equity relative price performance here closer look drug stock make new list friday regeneron pharmaceutical regn valeant pharmaceutical vrx actavis act gilead science gild regeneron have
1755,REGN,key start point find winning stock be look top rate leader top rank industry group best group score multiple ibd smartselect rating rank biotech industry group gilead science gild fit bill california base firm develop therapy hiv aids liver disease oncology hematology other condition
1756,REGN,study company fundamental often good idea check spending stand research development ibd look cost percentage annual sale find figure ibd minichart such friday weekly review marketsmith chart
1757,REGN,company spend money improve product process service develop new product hard imagine past decade global advance technology commerce
1758,REGN,not company have expense example wouldn expect cal maine food calm largest egg producer have cost report none
1759,REGN,isn top fundamental metric investor study such earning growth sale return equity still worth look
1760,REGN,play key role slim component slim stand something new such new product service good growth stock prospect have something new drive earning sale growth often be go take come new product service
1761,REGN,company be biotech technology field hard imagine enjoy continue success competition be likely surpass company technology quickly
1762,REGN,name last week ibd elite list growth stock report expense nearly be technology biotech drug industry group
1763,REGN,cost enormous amount money develop important new drug get approval regulator so perhaps surprise top ibd stock expense sale ratio be regeneron pharmaceutical regn celgene celg last year stock boast strong composite other ibd rating
1764,REGN,investor be carefully watch regeneron pipeline drug praluent cholesterol fighter fda review be expect be approve july regeneron be develop drug partnership sanofi sny
1765,REGN,celgene have rely cancer drug revlimid account third sale company say most recent earning report expect new drug expand used exist drug result sale sale be study company fundamental often good idea check spending stand research development ibd look cost percentage annual sale find figure ibd minichart such friday weekly review marketsmith chart company spend money improve product process service develop new product hard imagine past decade global advance technology commerce not company have expense example wouldn expect cal maine food calm largest egg producer have cost report none isn top fundamental metric investor study such earning growth sale return equity still worth look play key role slim component slim stand something new such new product service good growth stock prospect have something new drive earning sale growth often be go take come new product service company be biotech technology field hard imagine enjoy continue success competition be likely surpass company technology quickly name last week ibd elite list growth stock report expense nearly be technology biotech drug industry group cost enormous amount money develop important new drug get approval regulator so perhaps surprise top ibd stock expense sale ratio be regeneron pharmaceutical regn celgene celg last year stock boast strong composite other ibd rating investor be carefully watch regeneron pipeline drug praluent cholesterol fighter fda review be expect be approve july regeneron be develop drug partnership sanofi sny celgene have rely cancer drug revlimid account third sale company say most recent earning report expect new drug expand used exist drug result sale sale be
1766,REGN,medical sector continue show strength biotech stock illumina ilmn be get ready break san diego base firm be global leader genomic provide researcher tool conduct large scale analysis genetic variation big pharma leader valeant pharmaceutical vrx abbvie abbv be also recently featured ibd stock
1767,REGN,company sound fundamental such drugmaker lannett regeneron be good prospect stock watch list today screen day be top fundamental feature highly rate firm annual sale earning growth rate least last year fundamentally sound drug stock usually do well matter way market be
1768,REGN,american have unofficially make memorial day kickoff summer go be hot drug industry now labor day company be look fda decision launch blockbuster drug make big impact bottom line first be drug valeant pharmaceutical industry vrx
1769,REGN,big cap growth stock score fine gain new high monday such action bode well market thursday spirite higher nasdaq follow rally market follow signal trend stock have possibly change upward skywork solution swks market cap rise sprint past
1770,REGN,talk pain gain american century ultra fund be show manager faith downtrodden biotech market segment
1771,REGN,group begin sell february plunge picked steam march congressman question nosebleed price gilead science gild hepatitis drug sovaldi
1772,REGN,ultra have stick several holding add price decline ultra stake isis pharmaceutical isis soar share march jan
1773,REGN,position regeneron pharmaceutical regn rise share count celgene celg alexion pharmaceutical alxn be unchanged
1774,REGN,ultra do trim exposure gilead share
1775,REGN,stock gilead hurt fund performance first quarter investor rotate other growth stock value name ultra management team believe market overreact news be unlikely result problem gilead manager write commentary
1776,REGN,reflection fund faith biotech be overweight broader health care sector vs russell growth index
1777,REGN,fund largest overweight vs benchmark march be information technology top holding include apple aapl google googl qualcomm qcom amazon amzn
1778,REGN,hold apple
1779,REGN,fund stake apple stand pat march vs jan be slightly oct share still well april
1780,REGN,go tuesday apple share be trading less past buy point
1781,REGN,emerge market account lot iphone sale growth
1782,REGN,earning share grow past quarters latest earning report april ibd accumulation distribution rating apple have climb solid
1783,REGN,morgan stanley recently say see upside stock upcoming debut iphone iwatch maybe other product
1784,REGN,other holding concho resource cxo be so far year fund share hold steady jan march be oct ep grow past quarters
1785,REGN,concho seek extract oil gas texas benefit frac west texas shale formation rich permian basin
1786,REGN,fund stake reilly automotive orly be share march vs april ep growth have decelerate quarters
1787,REGN,stock be form flat base entry
1788,REGN,new store opening have drive growth auto part retailer
1789,REGN,fund approach have lead gain so far year go tuesday large cap growth rival track morningstar inc averaged gain be
1790,REGN,past year fund average annual gain be vs peer group big cap bogey talk pain gain american century ultra fund be show manager faith downtrodden biotech market segment group begin sell february plunge picked steam march congressman question nosebleed price gilead science gild hepatitis drug sovaldi ultra have stick several holding add price decline ultra stake isis pharmaceutical isis soar share march jan position regeneron pharmaceutical regn rise share count celgene celg alexion pharmaceutical alxn be unchanged ultra do trim exposure gilead share stock gilead hurt fund performance first quarter investor rotate other growth stock value name ultra management team believe market overreact news be unlikely result problem gilead manager write commentary reflection fund faith biotech be overweight broader health care sector vs russell growth index fund largest overweight vs benchmark march be information technology top holding include apple aapl google googl qualcomm qcom amazon amzn hold fund stake apple stand pat march vs jan be slightly oct share still well april go tuesday apple share be trading less past buy point emerge market account lot iphone sale growth earning share grow past quarters latest earning report april ibd accumulation distribution rating apple have climb solid morgan stanley recently say see upside stock upcoming debut iphone iwatch maybe other product other holding concho resource cxo be so far year fund share hold steady jan march be oct ep grow past quarters concho seek extract oil gas texas benefit frac west texas shale formation rich permian basin fund stake reilly automotive orly be share march vs april ep growth have decelerate quarters stock be form flat base entry new store opening have drive growth auto part retailer fund approach have lead gain so far year go tuesday large cap growth rival track morningstar inc averaged gain be past year fund average annual gain be vs peer group big cap bogey
1791,REGN,stock market start third quarter fine fashion tuesday solid percentage gain higher volume nasdaq notch year high marked close high close nasdaq rise add dow jone industrial average gain close point level
1792,REGN,rebound effort greatly fade late friday leave stock mixed territory pace weekly loss nasdaq lose rise much intraday rise session peak meanwhile dow jone industrial average be turnover continue tack sharply lower major exchange stock market todayeven market turn mixed bitauto bita hold session high gain stock have recoup big chunk thursday loss climb back day line downside biotechs be pressure gilead science gild fall be pace third straight loss stock near potential support day move average have trade december gilead have tumble top late february regeneron pharmaceutical regn fall give early gain turn tail again hit resistance day line stock clear late stage base last month fizzle rise past buy point late stage pattern be more prone fail biogen idec biib turn tail fall fast trade have give gain past buy point flat base recent session
1793,REGN,stock market have be sputtering recent week so buy here be dicey proposition market muster little upward conviction big cap stock be worth look vmware vmw have break cup base moved monday just buy range entry point march
1794,REGN,amgen amgn be more early trading stock market today analyst approve big cap biotech earning beat restructure plan announce late tuesday earlier amgen stock touch new high amgen earning beat consensus nearly rise year earlier quarter share sale climb
1795,REGN,big jump durable good order strong read consumer confidence conference board fuel modest gain stock market tuesday
1796,REGN,dow jone industrial average lead way rise exxon mobil xom unitedhealth group unh pfizer pfe outperformed gain nasdaq add
1797,REGN,volume new york stock exchange nasdaq be tracking slightly higher monday level
1798,REGN,stock market today ibd component diamondback energy fang gain fast grow oil gas producer have be consolidate gain june try reclaim day move average recently pull back high group peer sm energy sm meanwhile look poise make win row share jump heavy volume
1799,REGN,day company say be explore strategic alternative comtech cmtl extend gain rise work new base bullish early june
1800,REGN,meanwhile nearly gain share regeneron pharmaceutical regn help lift ibd medical biom biotech group gain nearly regeneron poke cup handle buy point volume be light group peer biogen idec biib ease be sluggish so far clear cup handle buy point
1801,REGN,aruba network arun stay rally mode ahead earning report close share gain pace gain past session big jump durable good order strong read consumer confidence conference board fuel modest gain stock market tuesday dow jone industrial average lead way rise exxon mobil xom unitedhealth group unh pfizer pfe outperformed gain nasdaq add volume new york stock exchange nasdaq be tracking slightly higher monday level stock market today ibd component diamondback energy fang gain fast grow oil gas producer have be consolidate gain june try reclaim day move average recently pull back high group peer sm energy sm meanwhile look poise make win row share jump heavy volume day company say be explore strategic alternative comtech cmtl extend gain rise work new base bullish early june meanwhile nearly gain share regeneron pharmaceutical regn help lift ibd medical biom biotech group gain nearly regeneron poke cup handle buy point volume be light group peer biogen idec biib ease be sluggish so far clear cup handle buy point aruba network arun stay rally mode ahead earning report close share gain pace gain past session
1802,REGN,stock hold session high afternoon trading fuel fresh breakout big gain positive jobless claim datum nasdaq rally ease record intraday high dow jone industrial average rise be volume be tracking higher board compare time wednesday
1803,REGN,weekly jobless claim release open fall prior week come sharply lower expect consumer price inched higher also forecast
1804,REGN,biotechs bigger gain biogen biib celgene celg regeneron regn be ibd lead industry group stock market today follow security stock airline energy steel stock lag
1805,REGN,supernus pharmaceutical supn vault heavy trade now extend more cup base buy point rockville md base biotech develop drug treat epilepsy attention deficit hyperactivity disorder jeffery upgrade stock buy hold
1806,REGN,fitness monitoring device maker fitbit fit continue hold most healthy first day gain offer price
1807,REGN,hain celestial hain gain new high breaking past flat base buy point average volume lynch earlier week add natural organic food product maker list top idea place price target stock
1808,REGN,blackhawk network hawk soar nearly fast trade track eighth straight advance stock clear flat base buy point wednesday volume be average payment network operator last week say buy achiever provider employee recognition reward product
1809,REGN,ibd stock manhattan associate manh rise new high clear buy point late stage flat base volume be just average supply chain management software maker have post double digit profit sale growth past quarters
1810,REGN,follow nancy gondo twitter ibd_ngondo stock hold session high afternoon trading fuel fresh breakout big gain positive jobless claim datum nasdaq rally ease record intraday high dow jone industrial average rise be volume be tracking higher board compare time wednesday weekly jobless claim release open fall prior week come sharply lower expect consumer price inched higher also forecast biotechs bigger gain biogen biib celgene celg regeneron regn be ibd lead industry group stock market today follow security stock airline energy steel stock lag supernus pharmaceutical supn vault heavy trade now extend more cup base buy point rockville md base biotech develop drug treat epilepsy attention deficit hyperactivity disorder jeffery upgrade stock buy hold fitness monitoring device maker fitbit fit continue hold most healthy first day gain offer price hain celestial hain gain new high breaking past flat base buy point average volume lynch earlier week add natural organic food product maker list top idea place price target stock blackhawk network hawk soar nearly fast trade track eighth straight advance stock clear flat base buy point wednesday volume be average payment network operator last week say buy achiever provider employee recognition reward product ibd stock manhattan associate manh rise new high clear buy point late stage flat base volume be just average supply chain management software maker have post double digit profit sale growth past quarters follow nancy gondo twitter ibd_ngondo
1811,REGN,stock pressed uneven gain early action thursday ride cross current input overseas
1812,REGN,nasdaq power gain climb dow jone industrial average cling advance volume rise nasdaq higher nyse compare action same time wednesday
1813,REGN,attention be scatter stock market today news eurozone regard greece positive weekly jobless claim report open wave heavyweight quarterly earning report federal reserve chair janet yellen senate testimony set begin et take place backdrop nasdaq attempt climb new high
1814,REGN,european central bank vote increase liquidity support greece bank set stage country shutter banking sector reopen week shutdown
1815,REGN,economic news start better expect unemployment claim report open
1816,REGN,philadelphia federal reserve offer less positive view july manufacturing business outlook survey drop read june well estimate price manufacture good hold steady report say raw material cost increase employment be flat
1817,REGN,national association homebuilder be bit more optimistic raise builder confidence index vs read june consensus estimate call read
1818,REGN,big name be motion quarterly report deliver late wednesday thursday morning
1819,REGN,citigroup rise nearly philip morris pm be more taiwan semiconductor tsm be more goldman sachs gs be hold loss
1820,REGN,netflix nflx easily run head nasdaq spiking take fresh high open analyst begin boost stream video service price target follow report late wednesday goldman sachs lift target maintain buy rating suntrust robinson humphrey keep neutral rating lift target
1821,REGN,sherwin william shw tank diving week move average cleveland base paint coating icon report revenue earning expectation management provide soft guidance
1822,REGN,domino pizza dpz slip report better forecast earning revenue growth line consensus view company also announce long time chief financial officer michael lawton retire august be replace treasurer jeffrey lawrence stock have have trouble get lift flat base buy point be trading mark
1823,REGN,ibd stock rise start bell largest gain go vasco datum security vdsi newlink genetic nlnk apiece vasco have be unable regain week move average past week newlink retook day authority end last week be so far month climb right side month deep consolidation
1824,REGN,heavy hour earning calendar include report google googl mattel mat schlumberger slb advanced micro device amd other stock pressed uneven gain early action thursday ride cross current input overseas nasdaq power gain climb dow jone industrial average cling advance volume rise nasdaq higher nyse compare action same time wednesday attention be scatter stock market today news eurozone regard greece positive weekly jobless claim report open wave heavyweight quarterly earning report federal reserve chair janet yellen senate testimony set begin et take place backdrop nasdaq attempt climb new high european central bank vote increase liquidity support greece bank set stage country shutter banking sector reopen week shutdown economic news start better expect unemployment claim report open philadelphia federal reserve offer less positive view july manufacturing business outlook survey drop read june well estimate price manufacture good hold steady report say raw material cost increase employment be flat national association homebuilder be bit more optimistic raise builder confidence index vs read june consensus estimate call read big name be motion quarterly report deliver late wednesday thursday morning citigroup rise nearly philip morris pm be more taiwan semiconductor tsm be more goldman sachs gs be hold loss netflix nflx easily run head nasdaq spiking take fresh high open analyst begin boost stream video service price target follow report late wednesday goldman sachs lift target maintain buy rating suntrust robinson humphrey keep neutral rating lift target sherwin william shw tank diving week move average cleveland base paint coating icon report revenue earning expectation management provide soft guidance domino pizza dpz slip report better forecast earning revenue growth line consensus view company also announce long time chief financial officer michael lawton retire august be replace treasurer jeffrey lawrence stock have have trouble get lift flat base buy point be trading mark ibd stock rise start bell largest gain go vasco datum security vdsi newlink genetic nlnk apiece vasco have be unable regain week move average past week newlink retook day authority end last week be so far month climb right side month deep consolidation heavy hour earning calendar include report google googl mattel mat schlumberger slb advanced micro device amd other
1825,REGN,ibd stock be hit new high stock market today valeant pharmaceutical vrx regeneron pharmaceutical regn netease nte
1826,REGN,goldman sachs report issue thursday include valeant top hedge fund long position actavis act apple aapl facebook fb microsoft msft report say wednesday valeant be advanced talk buy egyptian drugmaker amoun pharma
1827,REGN,valeant climb average volume new time high sixth straight session gain share have be long run cup handle base buy point initially clear dec
1828,REGN,regeneron also enter new high ground gain be session winning streak stock be just buy range cup handle base buy point
1829,REGN,thursday regeneron announce positive result phase study arthritis drug biotech partner sanofi sny expect file fda approval fourth quarter
1830,REGN,netease reach new high well rise buy stock early april cup base share be now more extend buy point mean time take profit haven already
1831,REGN,wednesday chinese gaming site say commerce unit have agree form joint venture focuse internet crowd funding other internet finance business
1832,REGN,follow alissa william twitter ibd_awilliam ibd stock be hit new high stock market today valeant pharmaceutical vrx regeneron pharmaceutical regn netease nte goldman sachs report issue thursday include valeant top hedge fund long position actavis act apple aapl facebook fb microsoft msft report say wednesday valeant be advanced talk buy egyptian drugmaker amoun pharma valeant climb average volume new time high sixth straight session gain share have be long run cup handle base buy point initially clear dec regeneron also enter new high ground gain be session winning streak stock be just buy range cup handle base buy point thursday regeneron announce positive result phase study arthritis drug biotech partner sanofi sny expect file fda approval fourth quarter netease reach new high well rise buy stock early april cup base share be now more extend buy point mean time take profit haven already wednesday chinese gaming site say commerce unit have agree form joint venture focuse internet crowd funding other internet finance business follow alissa william twitter ibd_awilliam
1833,REGN,new product introduction swipe trade secret chipmaker have steal spotlight so far week let not forget biotech stock be highlighted ibd screen day big cap leader semiconductor counterpart large cap biotechs include celgene celg regeneron pharmaceutical regn gilead science gild celgene have
1834,REGN,handful big cap stock be hover buy point regeneron pharmaceutical regn be try clear buy point cup handle base pattern be late stage make risky
1835,REGN,profit revenue growth have picked straight quarters earning latest quarter climb jump sale
1836,REGN,eylea treatment macular degeneration be drive company growth
1837,REGN,well regard fidelity contrafund add holding latest quarter columbia marsico st century fund open new position
1838,REGN,nike nke be approach buy point base base pattern stock accumulation distribution rating indicate rise demand share
1839,REGN,also stock relative strength line be hit new high bullish indicator
1840,REGN,president obama visit athletic apparel maker oregon headquarters friday promote tran pacific partnership trade deal country
1841,REGN,most nike sale currently come north america europe nike make most apparel overseas say pact create job
1842,REGN,abbvie abbv drugmaker have shape cup handle base buy point
1843,REGN,company be spun abbott laboratory be top stock highly rate prescription drug industry group
1844,REGN,profit year be expect rise share follow increase
1845,REGN,abbvie make drug treat rheumatoid arthritis psoriasis other ailment
1846,REGN,present new datum oncology drug pipeline meeting american society clinical oncology june
1847,REGN,anthem antm provider manage health care service be flat base buy point
1848,REGN,company have benefit growth enrollment business customer government program such medicaid
1849,REGN,anthem announce last month profit jump share easily beating wall street estimate revenue climb
1850,REGN,stock have triple past year late base be third stage pattern
1851,REGN,april oppenheimer raise price target anthem number other manage care stock cite continue improvement economy prospect federal reserve interest rate hike boost return investment portfolio
1852,REGN,manage care industry be rank ninth group track ibd monday handful big cap stock be hover buy point regeneron pharmaceutical regn be try clear buy point cup handle base pattern be late stage make risky profit revenue growth have picked straight quarters earning latest quarter climb jump sale eylea treatment macular degeneration be drive company growth well regard fidelity contrafund add holding latest quarter columbia marsico st century fund open new position nike nke be approach buy point base base pattern stock accumulation distribution rating indicate rise demand share also stock relative strength line be hit new high bullish indicator president obama visit athletic apparel maker oregon headquarters friday promote tran pacific partnership trade deal country most nike sale currently come north america europe nike make most apparel overseas say pact create job abbvie abbv drugmaker have shape cup handle base buy point company be spun abbott laboratory be top stock highly rate prescription drug industry group profit year be expect rise share follow increase abbvie make drug treat rheumatoid arthritis psoriasis other ailment present new datum oncology drug pipeline meeting american society clinical oncology june anthem antm provider manage health care service be flat base buy point company have benefit growth enrollment business customer government program such medicaid anthem announce last month profit jump share easily beating wall street estimate revenue climb stock have triple past year late base be third stage pattern april oppenheimer raise price target anthem number other manage care stock cite continue improvement economy prospect federal reserve interest rate hike boost return investment portfolio manage care industry be rank ninth group track ibd monday
1853,REGN,biotech amgen amgn report monday late stage trial cholesterol drug evolocumab meet primary endpoint send amgen stock morning trading stock market today
1854,REGN,trial test potency evolocumab lower ldl bad cholesterol patient homozygous familial rare genetic disorder affect person accord amgen patient evolocumab report significantly lower ldl level placebo group amgen be wait future medical conference report much
1855,REGN,amgen be study evolocumab number different population hope become next blockbuster cholesterol drug belong emerge class call pcsk inhibitor be also be develop pfizer pfe well regeneron regn team sanofi sny
1856,REGN,december report morningstar analyst stefan quenneville estimate person roughly equivalent number person abroad be eligible therapy kind drug lead global market opportunity eventually estimate amgen take expect be first
1857,REGN,nonetheless group also spark worry wall street earlier month come fda be inquiring neurocognitive event related pcsk company involved have deny see kind safety issue trial
1858,REGN,follow amy reeve twitter ibd_areeve biotech amgen amgn report monday late stage trial cholesterol drug evolocumab meet primary endpoint send amgen stock morning trading stock market today trial test potency evolocumab lower ldl bad cholesterol patient homozygous familial rare genetic disorder affect person accord amgen patient evolocumab report significantly lower ldl level placebo group amgen be wait future medical conference report much amgen be study evolocumab number different population hope become next blockbuster cholesterol drug belong emerge class call pcsk inhibitor be also be develop pfizer pfe well regeneron regn team sanofi sny december report morningstar analyst stefan quenneville estimate person roughly equivalent number person abroad be eligible therapy kind drug lead global market opportunity eventually estimate amgen take expect be first nonetheless group also spark worry wall street earlier month come fda be inquiring neurocognitive event related pcsk company involved have deny see kind safety issue trial follow amy reeve twitter ibd_areeve
1859,REGN,amgen amgn stock be afternoon trading stock market today company present study new cholesterol drug weekend result ease safety concern raise earlier month competitor regeneron regn sanofi sny pfizer pfe bristol myer squibb bmy also present datum share be fraction flat
1860,REGN,regeneron pharmaceutical regn beat analyst expectation report tuesday send share early trading stock market today guidance main drug eylea be merely line expectation sale quarter totale year earlier quarter more analyst consensus gaap net income rise
1861,REGN,regeneron pharmaceutical regn rebound more afternoon trading stock market today development partner sanofi sny say regulatory filing raise stake french drug giant move come regeneron superstar eylea treatment age related macular degeneration amd receive european medicine agency endorsement friday expand use other type vision loss company partner several other experimental drug include cholesterol medication have agreement permit sanofi control regeneron regeneron rise intraday move back day move average stock have struggle recent week analyst concern medicare medicaid mandate use roche avastin eylea due concern payment cost sanofi share rise intraday
1862,REGN,stock wobble start gate mixed action wednesday quarterly report power much early action
1863,REGN,dow jone industrial average peck fractional gain nasdaq slump take drop
1864,REGN,volume be also mixed higher nasdaq lower nyse compare trade same time tuesday
1865,REGN,stock market today get roll start earning report general motor gm walt disney help bolster early trade
1866,REGN,early economic news be weak adp report larger expect decline january hire employer
1867,REGN,service sector news be more positive institute supply management january manufacturing index tick be just december upwardly revise tally consensus view also project read
1868,REGN,service purchasing manager index researcher markit rise january december basis point consensus view
1869,REGN,stock sony sne spiked deliver preliminary earning guidance cent share year year well consensus view cent also project revenue consensus cite positive foreign exchange rate gain punch share month high clear correction begin july
1870,REGN,ibd list leader hammer strong gain loss
1871,REGN,manhattan associate manh bolt higher start bell supply chain software developer report tuesday close sale earning consensus expectation management also raise full year earning revenue guidance projection raymond james upgrade stock strong buy outperform move send share new high test support week move average
1872,REGN,china base noah holding noah pop early action asset manager have shape sharp double bottom base fail break yearlong correction december wednesday gain put back week support buy point
1873,REGN,list low end gilead science gild dive report healthy fourth quarter revenue earning drugmaker offer weak sale guidance cite competitive cost pressure
1874,REGN,chipotle grill cmg unraveled diving week move average heavy trade
1875,REGN,fast casual burrito chain report par earning revenue just sliver shy estimate same store sale margin disappoint analyst do guidance full year same store sale growth
1876,REGN,hour schedule hold few name interest growth stock investor nxp semiconductor nxpi reilly automotive orly armour ua expect report quarterly result stock wobble start gate mixed action wednesday quarterly report power much early action dow jone industrial average peck fractional gain nasdaq slump take drop volume be also mixed higher nasdaq lower nyse compare trade same time tuesday stock market today get roll start earning report general motor gm walt disney help bolster early trade early economic news be weak adp report larger expect decline january hire employer service sector news be more positive institute supply management january manufacturing index tick be just december upwardly revise tally consensus view also project read service purchasing manager index researcher markit rise january december basis point consensus view stock sony sne spiked deliver preliminary earning guidance cent share year year well consensus view cent also project revenue consensus cite positive foreign exchange rate gain punch share month high clear correction begin july ibd list leader hammer strong gain loss manhattan associate manh bolt higher start bell supply chain software developer report tuesday close sale earning consensus expectation management also raise full year earning revenue guidance projection raymond james upgrade stock strong buy outperform move send share new high test support week move average china base noah holding noah pop early action asset manager have shape sharp double bottom base fail break yearlong correction december wednesday gain put back week support buy point list low end gilead science gild dive report healthy fourth quarter revenue earning drugmaker offer weak sale guidance cite competitive cost pressure chipotle grill cmg unraveled diving week move average heavy trade fast casual burrito chain report par earning revenue just sliver shy estimate same store sale margin disappoint analyst do guidance full year same store sale growth hour schedule hold few name interest growth stock investor nxp semiconductor nxpi reilly automotive orly armour ua expect report quarterly result
1877,REGN,strong earning growth be most important factor look research stock positive earning surprise be critical factor help buoy stock price thomson reuter report date show sector biggest number firm top view be health care utility service technology
1878,REGN,main stock index make positive price reversal tuesday latest market run mixed signal nasdaq much early close only lower weakness biotech solar technology stock hurt composite nasdaq do close back day move average make reversal more interesting
1879,REGN,be frustrate environment growth stock investor recent breakout have be mixed bag best most big cap leader be hover just just recent buy point best way handle lackluster market be keep exposure modest more breakout prove show decent gain
1880,REGN,cut loss sell signal start appear keep good portion powder dry stock have be able hold recent entry include abbvie abbv cigna ci analog device adi
1881,REGN,abbvie break cup handle base heavy volume share have trade tight remain buy range past buy point
1882,REGN,giant drugmaker report accelerate earning sale most recent quarter
1883,REGN,manage health care provider cigna be still buy range past flat base buy point clear heavy trade
1884,REGN,analog device be pull back heavy volume share be still buy range many chip stock early gain be danger disappear other hand stock nike nke skywork solution swks cognizant technology solution ctsh carmax kmx have slip recent buy point
1885,REGN,be sell signal so far
1886,REGN,nike be testing support week line buy point latest pattern be part base base stretch back november
1887,REGN,nike be expect report profit growth release fiscal fourth quarter result end sale be expect climb
1888,REGN,carmax break cup handle base friday light trade turn lower monday share remain just buy point
1889,REGN,carmax report fiscal result june market open analyst be look earning climb cent share revenue growth
1890,REGN,be used car dealer fifth straight quarter double digit earning sale growth
1891,REGN,decent initial progress skywork solution have return flat base buy point volume have be mostly light stock pull back be positive sign watch see long time leader find support price week move average
1892,REGN,side regeneron regn be act well low volume base be late stage share have gain much buy point remain extend buy range
1893,REGN,stock still base include salesforce com crm facebook fb gilead gild illumina ilmn be frustrate environment growth stock investor recent breakout have be mixed bag best most big cap leader be hover just just recent buy point best way handle lackluster market be keep exposure modest more breakout prove show decent gain cut loss sell signal start appear keep good portion powder dry stock have be able hold recent entry include abbvie abbv cigna ci analog device adi abbvie break cup handle base heavy volume share have trade tight remain buy range past buy point giant drugmaker report accelerate earning sale most recent quarter manage health care provider cigna be still buy range past flat base buy point clear heavy trade analog device be pull back heavy volume share be still buy range many chip stock early gain be danger disappear other hand stock nike nke skywork solution swks cognizant technology solution ctsh carmax kmx have slip recent buy point be sell signal so far nike be testing support week line buy point latest pattern be part base base stretch back november nike be expect report profit growth release fiscal fourth quarter result end sale be expect climb carmax break cup handle base friday light trade turn lower monday share remain just buy point carmax report fiscal result june market open analyst be look earning climb cent share revenue growth be used car dealer fifth straight quarter double digit earning sale growth decent initial progress skywork solution have return flat base buy point volume have be mostly light stock pull back be positive sign watch see long time leader find support price week move average side regeneron regn be act well low volume base be late stage share have gain much buy point remain extend buy range stock still base include salesforce com crm facebook fb gilead gild illumina ilmn
1894,REGN,recent decade high cholesterol have be big pharma gravy train statin oral drug lower bad cholesterol turn best selling drug history pfizer lipitor peak nearly sale
1895,REGN,now however statin have go patent be so pfizer pfe passel other company lead amgen amgn regeneron regn regeneron partner sanofi sny be turn new class cholesterol buster call pcsk inhibitor
1896,REGN,american cardiology conference acc washington saturday monday investor get chance see new drug be do clinical trial
1897,REGN,pcsk be short proprotein convertase subtilisin kexin type enzyme bound liver receptor ldl bad cholesterol target degredation block pcsk company aim boost liver ability eliminate ldl cholesterol blood thus reduce chance heart disease
1898,REGN,pcsk inhibitor mid late stage testing be monoclonal antibody biotechnology already be used best selling cancer immunology drug
1899,REGN,monthly injection
1900,REGN,drug also have be inject once twice month make somewhat more unpleasant take statin partly reason drugmaker be gun subgroup high cholesterol sufferer statin aren adequate
1901,REGN,majority patient program be treat statin normally highest tolerable dose say jay edelberg head sanofi pcsk development launch unit be primarily patient be familial genetic disorder ve have cardiovascular event be diabetic be high risk cardiovascular disease
1902,REGN,then be patient tolerate statin
1903,REGN,morningstar analyst stefan quenneville estimate description cover person expect grow roughly equivalent number potential patient also live abroad estimate
1904,REGN,regeneron sanofi drug alirocumab take most stage time acc meeting presentation detail datum clinical trial be conduct product include study patient genetic high cholesterol patient be take merck mrk zetia abbvie abbv tricor aren well comparison patient zetia alone vs alirocumab alone
1905,REGN,company expect file approval alirocumab early so do amgen be also conduct different late stage clinical trial candidate evolocumab
1906,REGN,amgen be give presentation evolocumab compare zetia statin well effectiveness statin intolerant subject patient kind genetic heterozygous march report study homozygous patient have meet endpoint didn say further detail be reveal
1907,REGN,pfizer be bit regeneron amgen bococizumab just launch phase program october schedule present dose range study patient statin acc
1908,REGN,analyst have be pleased trial result drug so far haven converge favorite way do recent hepatitis race instance hasn be much datum differentiate other say quenneville
1909,REGN,look safety issue
1910,REGN,think trial present acc be go be interesting point drug have be pretty similar quenneville tell ibd look more difference efficacy be anything do safety
1911,REGN,think go be major concern safety signal appear didn see smaller trial waylay specific drug even entire class drug
1912,REGN,safety pcsk come particular scrutiny earlier month word get twitter food drug administration have become aware neurocognitive adverse event pcsk inhibitor class have ask sanofi regeneron make assessment potential neurocognitive adverse event global development program alirocumab especially longer term study accord sanofi annual report
1913,REGN,turn other pcsk player have get same letter deny have find significant safety issue
1914,REGN,analyst however seem have settle evolocumab culprit member cohort osler trial include person report memory impairment amnesia
1915,REGN,isi group analyst mark schoenebaum however point most patient be also statin memory loss have be connect statin so not clear evolocumab be blame
1916,REGN,safety turn be problem quenneville estimate pcsk drug collectively sell more assume alirocumab evolocumab split most market due be first say pfizer yet have something sleeve
1917,REGN,pfizer have imply conference call have more potent pcsk phase discontinue patient person have dramatic lower say ll see not really enough datum tease point recent decade high cholesterol have be big pharma gravy train statin oral drug lower bad cholesterol turn best selling drug history pfizer lipitor peak nearly sale now however statin have go patent be so pfizer pfe passel other company lead amgen amgn regeneron regn regeneron partner sanofi sny be turn new class cholesterol buster call pcsk inhibitor american cardiology conference acc washington saturday monday investor get chance see new drug be do clinical trial pcsk be short proprotein convertase subtilisin kexin type enzyme bound liver receptor ldl bad cholesterol target degredation block pcsk company aim boost liver ability eliminate ldl cholesterol blood thus reduce chance heart disease pcsk inhibitor mid late stage testing be monoclonal antibody biotechnology already be used best selling cancer immunology drug monthly injectionsall drug also have be inject once twice month make somewhat more unpleasant take statin partly reason drugmaker be gun subgroup high cholesterol sufferer statin aren adequate majority patient program be treat statin normally highest tolerable dose say jay edelberg head sanofi pcsk development launch unit be primarily patient be familial genetic disorder ve have cardiovascular event be diabetic be high risk cardiovascular disease then be patient tolerate statin morningstar analyst stefan quenneville estimate description cover person expect grow roughly equivalent number potential patient also live abroad estimate regeneron sanofi drug alirocumab take most stage time acc meeting presentation detail datum clinical trial be conduct product include study patient genetic high cholesterol patient be take merck mrk zetia abbvie abbv tricor aren well comparison patient zetia alone vs alirocumab alone company expect file approval alirocumab early so do amgen be also conduct different late stage clinical trial candidate evolocumab amgen be give presentation evolocumab compare zetia statin well effectiveness statin intolerant subject patient kind genetic heterozygous march report study homozygous patient have meet endpoint didn say further detail be reveal pfizer be bit regeneron amgen bococizumab just launch phase program october schedule present dose range study patient statin acc analyst have be pleased trial result drug so far haven converge favorite way do recent hepatitis race instance hasn be much datum differentiate other say quenneville look safety issue think trial present acc be go be interesting point drug have be pretty similar quenneville tell ibd look more difference efficacy be anything do safety think go be major concern safety signal appear didn see smaller trial waylay specific drug even entire class drug safety pcsk come particular scrutiny earlier month word get twitter food drug administration have become aware neurocognitive adverse event pcsk inhibitor class have ask sanofi regeneron make assessment potential neurocognitive adverse event global development program alirocumab especially longer term study accord sanofi annual report turn other pcsk player have get same letter deny have find significant safety issue analyst however seem have settle evolocumab culprit member cohort osler trial include person report memory impairment amnesia isi group analyst mark schoenebaum however point most patient be also statin memory loss have be connect statin so not clear evolocumab be blame safety turn be problem quenneville estimate pcsk drug collectively sell more assume alirocumab evolocumab split most market due be first say pfizer yet have something sleeve pfizer have imply conference call have more potent pcsk phase discontinue patient person have dramatic lower say ll see not really enough datum tease point
1918,REGN,regeneron pharmaceutical regn plunge friday afternoon trading be briefly halter volatility word get fda be investigate cholesterol drug candidate adverse effect item be bury deep form regeneron big pharma partner sanofi sny file friday discussion firm collaboration alirocumab monoclonal antibody
1919,REGN,stock market close mixed thursday earlier gain vanished afternoon nasdaq fall nearly dow jone industrial average add
1920,REGN,main index negative price reversal be latest instance volatility have plague stock past couple week
1921,REGN,loser top winner nyse side be even nasdaq volume be lower accord early number
1922,REGN,food chip telecom solar stock lead stock market today homebuilder continue show relative strength lgi home lgih make new high wci community wcic climb back buy point industry group have be trend higher rank thursday ibd group
1923,REGN,biotechs airline be leader day earlier rank thursday weakest do discount retailer mining stock
1924,REGN,google googl fall stock continue find support day move average
1925,REGN,ibd be evenly split winner loser outsized loss weigh performance slide discounter sale miss view company issue weak guidance stock promising new issue have be consolidate november
1926,REGN,ambarella amba have be selling deliver quarterly result wednesday guide revenue analyst expectation bearish outlook raise fear demand wearable camera rattle camera maker gopro gpro ambarella supply video chip gopro be week lows stock market close mixed thursday earlier gain vanished afternoon nasdaq fall nearly dow jone industrial average add main index negative price reversal be latest instance volatility have plague stock past couple week loser top winner nyse side be even nasdaq volume be lower accord early number food chip telecom solar stock lead stock market today homebuilder continue show relative strength lgi home lgih make new high wci community wcic climb back buy point industry group have be trend higher rank thursday ibd group biotechs airline be leader day earlier rank thursday weakest do discount retailer mining stock google googl fall stock continue find support day move average ibd be evenly split winner loser outsized loss weigh performance slide discounter sale miss view company issue weak guidance stock promising new issue have be consolidate november ambarella amba have be selling deliver quarterly result wednesday guide revenue analyst expectation bearish outlook raise fear demand wearable camera rattle camera maker gopro gpro ambarella supply video chip gopro be week lows
1927,REGN,biotech regeneron pharmaceutical be shape have eventful year regeneron regn have already become lead stock thank successful launch eylea treatment wet age related macular degeneration type vision loss touch record high monday august product be also expect be approve diabetic macular edema attention however
1928,REGN,stock finished week doubtful note index turn mixed higher volume nasdaq ibd lose edge less volume rise board distribution day count balloon nasdaq index picked distribution day friday drop
1929,REGN,stock be lower early thursday afternoon biotechs face fresh barrage selling ahead friday job report
1930,REGN,selling pressure be muted dow be different story nasdaq tech heavy index lose fuel more weakness biotech stock lose dow jone industrial average give nyse nasdaq volume be tracking lower wednesday pace stock market today
1931,REGN,economic news weekly jobless claim rise slightly more expect datum come ahead friday job report nonfarm payroll be expect rise unemployment rate tick lower february economy create job
1932,REGN,ibd biotech industry group fall nearly group leader biogen idec biib regeneron regn alexion alxn fall anywhere
1933,REGN,google goog be session high meet resistance day move average share still rise new class google stock come market thursday new nonvoting class share trade symbol goog class stock expect trade pretty much lockstep share trade symbol googl
1934,REGN,ibd air lease al be try extend winning streak session share rise company purchase lease commercial jet airline world stock be high extend past buy point
1935,REGN,downside volatile trading continue china growth name include athm share lose be try firm week move average first time ipo base support be question share crumble last week stock close right week line slightly line now
1936,REGN,close watch earning micron technology mu global payment gpn stock be lower early thursday afternoon biotechs face fresh barrage selling ahead friday job report selling pressure be muted dow be different story nasdaq tech heavy index lose fuel more weakness biotech stock lose dow jone industrial average give nyse nasdaq volume be tracking lower wednesday pace stock market today economic news weekly jobless claim rise slightly more expect datum come ahead friday job report nonfarm payroll be expect rise unemployment rate tick lower february economy create job ibd biotech industry group fall nearly group leader biogen idec biib regeneron regn alexion alxn fall anywhere google goog be session high meet resistance day move average share still rise new class google stock come market thursday new nonvoting class share trade symbol goog class stock expect trade pretty much lockstep share trade symbol googl ibd air lease al be try extend winning streak session share rise company purchase lease commercial jet airline world stock be high extend past buy point downside volatile trading continue china growth name include athm share lose be try firm week move average first time ipo base support be question share crumble last week stock close right week line slightly line now close watch earning micron technology mu global payment gpn
1937,REGN,regeneron pharmaceutical regn beat analyst estimate guide year drug sale line view tuesday also say build new facility low tax ireland stock pop new high close regeneron sale quarter totale year earlier quarter more
1938,REGN,stock trade narrow range monday end session high ahead testimony tuesday fed chairwoman janet yellen front house financial service committee nasdaq gain add volume fall friday silly try predict market react yellen have say
1939,REGN,regeneron pharmaceutical regn report more positive trial datum drug eylea day ahead earning report investor be listen closely guidance regeneron partner bayer bayry report patient diabetic macular edema dme continue do well week eylea monthly bimonthly dosing news
1940,REGN,homebuilding gold mining biotech few stock vast retail sector get smack tuesday market decline broadly higher volume nasdaq fall largest decline drop june volume picked nearly nyse turnover intensified greater pace
1941,REGN,many medical stock be picture health several segment post rosy checkup medical biom biotech industry group rank first group track ibd group second straight week list medical ethical drug medical generic be no medical system equipment medical research equipment service rank no mutual fund be throw
1942,REGN,stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high
1943,REGN,nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure
1944,REGN,european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting
1945,REGN,retailer medical apparel stock lead upside datum storage energy steel stock underperform
1946,REGN,nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average
1947,REGN,alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range
1948,REGN,downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting retailer medical apparel stock lead upside datum storage energy steel stock underperform nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report
1949,REGN,stock continue higher be pace finish gain tuesday first time session dow jone industrial average lead gain nasdaq rise respectively turnover be again tracking lower board stock market today alexion pharmaceutical alxn rise bounce back recent slide friday stock slice day line huge volume mark sell signal other lead biotechs drugmaker be also rebound recent weakness spanish drugmaker grifol grfs rally regain day line celgene celg rise actavis act edge elsewhere avnet avt add record high fast trade now past buy point cup handle base clear march market volatility stock have see strong accumulation recent session electronic component maker sale growth accelerate latest quarters downside iii apparel group giii be session low still heavy trading share be much intraday company give disappointing guidance earning sale
1950,REGN,san francisco biotechnology continue take spotlight jpmorgan healthcare conference illumina regeneron offer strong preliminary result former rolled new gene sequence product meanwhile beleaguered robotic surgery firm intuitive surgical stock rebound update beat expectation illumina ilmn ceo jay flatley say revenue rise year earlier
1951,REGN,resilience be operative word monday major average end small gain weak open stock be spook early weak manufacturing datum china clash ukraine weigh nasdaq fall early start rally back first hour trading end gain rally volume
1952,REGN,major average end week clunker friday wall street weigh more corporate earning continue unrest ukraine news wasn good front nasdaq underperform fall meet resistance week move average last week reversed lower finish week small loss lukewarm earning amazon com amzn
1953,REGN,major average suffer setback monday close lows loss close be geopolitical concern unnerved market russia military presence ukraine continue take center stage
1954,REGN,dow jone industrial average lead way fall visa mmm lose nasdaq lose preliminary datum show nyse nasdaq volume come lower friday more so nasdaq
1955,REGN,stock market today list russia stock take heat qiwi qiwi vimpelcom vip yandex yndx lose anywhere market vector russia etf rsx fall
1956,REGN,day gainer china base com wuba add gain soar last week strong earning share rise new high company be provider online advertising service friday company announce third straight quarter accelerate sale growth
1957,REGN,meanwhile large cap oil gas producer concho resource cxo make win row rise early stage week cup base share remain accumulation full year earning be see rise year
1958,REGN,tableau software datum potential emerge leader firm straight loss share rise recent week cup shape base
1959,REGN,biotech group regeneron pharmaceutical regn therapeutic anik bounce back recent weakness rise respectively tuesday open insys therapeutic insy release fourth quarter result company make supportive care product breakthrough cancer pain btcp share rise nearly stock be hold high ahead result
1960,REGN,new york mercantile exchange april gold surge ounce april oil gain barrel
1961,REGN,close watch earning guidewire software gwre vipshop holding vip nuvasive nuva major average suffer setback monday close lows loss close be geopolitical concern unnerved market russia military presence ukraine continue take center stage dow jone industrial average lead way fall visa mmm lose nasdaq lose preliminary datum show nyse nasdaq volume come lower friday more so nasdaq stock market today list russia stock take heat qiwi qiwi vimpelcom vip yandex yndx lose anywhere market vector russia etf rsx fall day gainer china base com wuba add gain soar last week strong earning share rise new high company be provider online advertising service friday company announce third straight quarter accelerate sale growth meanwhile large cap oil gas producer concho resource cxo make win row rise early stage week cup base share remain accumulation full year earning be see rise year tableau software datum potential emerge leader firm straight loss share rise recent week cup shape base biotech group regeneron pharmaceutical regn therapeutic anik bounce back recent weakness rise respectively tuesday open insys therapeutic insy release fourth quarter result company make supportive care product breakthrough cancer pain btcp share rise nearly stock be hold high ahead result new york mercantile exchange april gold surge ounce april oil gain barrel close watch earning guidewire software gwre vipshop holding vip nuvasive nuva
1962,REGN,biotech regeneron pharmaceutical regn beat estimate raise guidance tuesday morning send share stock market
1963,REGN,sale totale year earlier quarter beating analyst consensus pretax income rise analyst have be expect modest decline
1964,REGN,regeneron lead product eylea treatment wet age related macular degeneration vision loss drive growth home abroad company lift full year eylea sale guidance be basically line consensus
1965,REGN,ceo leonard schleifer also announce company have file fda approve drug diabetic macular edema dme roughly year ahead schedule due good clinical trial result
1966,REGN,schleifer say company expect release datum phase trial sarilumab rheumatoid arthritis year end sarilumab be set monoclonal antibody regeneron be develop partnership french pharma giant sanofi sny treat ailment range asthma high cholesterol
1967,REGN,regeneron stock be trading reverse downtrend have be last week email client rbc capital market analyst adnan butt note robust eylea sale reassure wall street
1968,REGN,be important trend expectation be cautious make consensus estimate appear more achievable now write
1969,REGN,analyst be forecasting sale growth next year
1970,REGN,related regeneron sanofi cholesterol drug pass phase trial biotech regeneron pharmaceutical regn beat estimate raise guidance tuesday morning send share stock market sale totale year earlier quarter beating analyst consensus pretax income rise analyst have be expect modest decline regeneron lead product eylea treatment wet age related macular degeneration vision loss drive growth home abroad company lift full year eylea sale guidance be basically line consensus ceo leonard schleifer also announce company have file fda approve drug diabetic macular edema dme roughly year ahead schedule due good clinical trial result schleifer say company expect release datum phase trial sarilumab rheumatoid arthritis year end sarilumab be set monoclonal antibody regeneron be develop partnership french pharma giant sanofi sny treat ailment range asthma high cholesterol regeneron stock be trading reverse downtrend have be last week email client rbc capital market analyst adnan butt note robust eylea sale reassure wall street be important trend expectation be cautious make consensus estimate appear more achievable now write analyst be forecasting sale growth next year related regeneron sanofi cholesterol drug pass phase trial
1971,REGN,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
1972,REGN,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
1973,REGN,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
1974,REGN,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
1975,REGN,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
1976,REGN,share real estate zillow be hour follow result
1977,REGN,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
1978,REGN,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
1979,REGN,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
1980,REGN,stock hold solid gain little more hour left go tuesday session earlier today fed chairwoman janet yellen reassure market fed continue accommodative stance dow jone industrial average lead way rise boee ba goldman sachs gs be strongest perform blue chip more nasdaq gain show noteworthy technical action rise day move average nyse volume be tracking higher monday nasdaq volume rise weren surprise yellen testimony front house financial service committee other thing say economy show more improvement fed continue scale back monthly bond purchase also say recovery labor market be far complete monthly asset purchase be not preset course stock market today regeneron pharmaceutical regn clear long late stage consolidation soar better expect earning tableau software datum flirted time high report strong earning last week share gain now past cup handle buy point group peer splunk splk be poise extend winning streak share rise meanwhile specialty pharmaceutical firm mallinckrodt mnk soar news buy cadence pharmaceutical cadx deal increase mallinckrodt presence hospital cadence key drug be ofirmev intravenous form acetaminophen pain management cadence share gap downside qihoo technology qihu couldn keep market tuesday share fall recent be have hard time get go close watch earning network security firm fireeye feye be show relative strength ahead result not profitable yet company show strong revenue growth recent quarters revenue time be expect rise year online travel firm tripadvisor trip be also schedule report earning share gap friday peer expedia expe report strong earning tripadvisor have be consolidate gain november current pattern have look double bottom potential entry cent jan intraday high
1981,REGN,dow jone industrial average didn move much thursday be different story nasdaq growth stock biotechs particular take heavy hit
1982,REGN,little hour remain session nasdaq lose fall dow ease market be try avoid distribution day nyse nasdaq volume continue track lower wednesday stock market today
1983,REGN,economic news weekly jobless claim rise slightly more expect datum come ahead friday job report nonfarm payroll be expect rise unemployment rate tick lower february economy create job
1984,REGN,ibd biotech industry group take hit fall nearly group leader biogen idec biib regeneron regn alexion alxn drop anywhere
1985,REGN,solar stock be also weak ibd energy solar group fall close
1986,REGN,china growth name pressure thursday include vipshop holding vip yy yy qihoo qihu soufun sfun
1987,REGN,breakout be rare nrg yield nyld be share rise clear buy point company operate contract renewable conventional generation thermal infrastructure asset deliver straight quarters triple digit sale growth yield
1988,REGN,oil gas producer newfield exploration nfx extend gain recent cup handle share rise ub upgrade share buy neutral newfield be now buy point sale growth have be accelerate recent quarters woodland texas base firm
1989,REGN,google goog give back early gain be mostly unchanged new class google stock come market thursday new nonvoting class share trade ticker symbol goog class stock expect trade pretty much lockstep share trade symbol googl
1990,REGN,close watch earning micron technology mu global payment gpn dow jone industrial average didn move much thursday be different story nasdaq growth stock biotechs particular take heavy hit little hour remain session nasdaq lose fall dow ease market be try avoid distribution day nyse nasdaq volume continue track lower wednesday stock market today economic news weekly jobless claim rise slightly more expect datum come ahead friday job report nonfarm payroll be expect rise unemployment rate tick lower february economy create job ibd biotech industry group take hit fall nearly group leader biogen idec biib regeneron regn alexion alxn drop anywhere solar stock be also weak ibd energy solar group fall close china growth name pressure thursday include vipshop holding vip yy yy qihoo qihu soufun sfun breakout be rare nrg yield nyld be share rise clear buy point company operate contract renewable conventional generation thermal infrastructure asset deliver straight quarters triple digit sale growth yield oil gas producer newfield exploration nfx extend gain recent cup handle share rise ub upgrade share buy neutral newfield be now buy point sale growth have be accelerate recent quarters woodland texas base firm google goog give back early gain be mostly unchanged new class google stock come market thursday new nonvoting class share trade ticker symbol goog class stock expect trade pretty much lockstep share trade symbol googl close watch earning micron technology mu global payment gpn
1991,REGN,tech stock outperformed tuesday hit time high intraday basis wall street digest dovish comment monday fed chief janet yellen
1992,REGN,nasdaq rise reclaim day move average dow jone industrial average rise nyse nasdaq volume be tracking higher monday stock market today
1993,REGN,economic news day disappointing read chicago purchasing manufacturer index ism manufacturing index come mostly line expectation
1994,REGN,day gainer former leader intuitive surgical isrg surge regulator approve new version da vinci robotic surgical system stock rise much news be session low hour session
1995,REGN,meanwhile casino operator exposure macau china have good day news gaming revenue region totale march year third highest record melco crown entertainment mpel rise wynn resort wynn la vegas sand lvs gain
1996,REGN,several other china base growth stock score gain heavy volume include athm bitauto bita operate website prospective car buyer china share rise bitauto soar
1997,REGN,qihoo technology qihu be best percentage gainer ibd rise nearly stock plunge day move average last week have be rally mode friday be just day move average early tuesday
1998,REGN,monday move higher ibd biotech group add heavy volume gainer group include gilead science gild celgene celg regeneron pharmaceutical regn biogen idec biib alexion pharmaceutical alxn tech stock outperformed tuesday hit time high intraday basis wall street digest dovish comment monday fed chief janet yellen nasdaq rise reclaim day move average dow jone industrial average rise nyse nasdaq volume be tracking higher monday stock market today economic news day disappointing read chicago purchasing manufacturer index ism manufacturing index come mostly line expectation day gainer former leader intuitive surgical isrg surge regulator approve new version da vinci robotic surgical system stock rise much news be session low hour session meanwhile casino operator exposure macau china have good day news gaming revenue region totale march year third highest record melco crown entertainment mpel rise wynn resort wynn la vegas sand lvs gain several other china base growth stock score gain heavy volume include athm bitauto bita operate website prospective car buyer china share rise bitauto soar qihoo technology qihu be best percentage gainer ibd rise nearly stock plunge day move average last week have be rally mode friday be just day move average early tuesday monday move higher ibd biotech group add heavy volume gainer group include gilead science gild celgene celg regeneron pharmaceutical regn biogen idec biib alexion pharmaceutical alxn
1999,REGN,regeneron regn have be etching flat base past few week also find support week move average biotech sport ibd composite rating best possible reflect many strength company be turnaround play so win find impressive earning history regeneron pharmaceutical have be lose
2000,REGN,biotech stock take beating friday lead gilead science concern grow blockbuster drug sovaldi gilead gild tumble close month low stock be already hit previous friday word congressional inquiry high price sovaldi launch december revolutionary treatment hepatitis
2001,REGN,stock spend day winning territory jump well news budget deal have hit street dow jone industrial average surge nasdaq shot nasdaq end highest september come record best see
2002,REGN,lead manager matthew kamm work market garden variety treat young sprout differently mature produce differently crop ready reap
2003,REGN,approach be work have make artisan mid cap fund top performer largest diversify stock portfolio
2004,REGN,month end jan return top midcap growth peer track morningstar inc average annual gain past year top rival
2005,REGN,kamm year old discuss investment course ibd office milwaukee
2006,REGN,ibd addition mid cap run artisan global opportunity small cap do manage different cap size style fund help
2007,REGN,kamm team include group analyst portfolio manager work collaboratively identify best idea ve be year level tenure trust be important
2008,REGN,look market cap scale globally give broad perspective think re better midcap investor know small cap competitor international emerge market competitor midcap company increasingly face
2009,REGN,ibd divide portfolio type stock advantage
2010,REGN,kamm nomenclature use be garden crop harvest
2011,REGN,garden stock be one believe be just emerge try be early guard risk keep garden position small
2012,REGN,garden position turn right profit growth play allocate more push crop bucket portfolio be largest position fewest position feel profit cycle have be largely risk
2013,REGN,third area be harvest reduce position
2014,REGN,ibd be tweak new buy cope expect slow growth economy
2015,REGN,kamm ve be focuse uniquely position franchise be expose strong growth trend see sign especially economy be get better housing job be example emerge market be struggle grow same rate experience few year
2016,REGN,re focuse durable high quality franchise re less interested high commodity business material business model be very cyclical economy sensitive tend not meet franchise characteristic criterium
2017,REGN,ibd be real world example please latest disclosure
2018,REGN,kamm re focuse innovation health care re year past first sequence human genome now re see benefit novel drug target
2019,REGN,regeneron regn be example have drug call eylea be retinal drug age related macular degeneration lead cause blindness elderly be launch second full year sell strong driver company sale profit
2020,REGN,regeneron also have diverse pipeline additional opportunity extend profit cycle future
2021,REGN,be discover regeneron own lab primarily funded sanofi large french drug company return ability market drug share profit
2022,REGN,ibd chipotle grill cmg recently gap report strong result guidance earning share growth be second straight quarterly acceleration thesis
2023,REGN,kamm think re position growth have very strong brand associate high quality ingredient have significant opportunity grow footprint restaurant ultimately internationally
2024,REGN,re execute well re get customer serve line quicker ve enhance menu re offer office cater re able drive solid same store comp year year make restaurant more profitable higher volume
2025,REGN,ve resist increase price same extent lot restaurant have instead re drive growth higher volume traffic
2026,REGN,ibd alexion pharmaceutical alxn have have great run just gap other day make think still have room run
2027,REGN,kamm fit innovation theme sale profit be drive solaris biologic drug approve ultrarare very serious disease not just globally
2028,REGN,still have room run used solaris still have lot growth ahead still lot opportunity reach more patient
2029,REGN,solaris be also be test additional ultrarare disease early clinical datum be encourage year be additional treatment approval solaris
2030,REGN,also have alpha target certain bone disease tooth loss be expect be approve later year
2031,REGN,ibd be broker dealer lpl financial lpla play grow economy
2032,REGN,kamm re largest independent broker dealer country ve grow attract financial adviser away big bank wire house give independence grow practice way see fit let keep larger percent profit
2033,REGN,continue gain market share market share gainer company outgrow market sustainable way
2034,REGN,also lpl capture float cash balance customer keep float refer earning cash time customer authorize disbursement cash actually leave account rate be low be not so much float capture rate rise economy improve then lpl earning accelerate
2035,REGN,ibd innovation stock athletic wear seller armour ua
2036,REGN,kamm innovation be new material deliver better performance sweat wicking shielding athlete heat cold company armour nike nke adida have be able grow innovate product line drive increase value customer
2037,REGN,armour have great brand athlete especially young athlete be incline spend more re expand other category such footwear cleat translate more traditional ware run shoe
2038,REGN,ve be mostly brand re extend brand internationally drive additional growth outside so think still have long runway re bucket category
2039,REGN,ibd be right think illumina ilmn genomic sequence advance
2040,REGN,kamm gene sequence be technology launch next generation sequence platform cost sequence begin fall lead big growth market launch jan new product hiseq deliver first genome target researcher have be fix year
2041,REGN,so re center action human genetic research have significant growth opportunity make tool even more affordable
2042,REGN,ibd tripadvisor trip have pull back nov high earning share fall most recent quarter aren concern
2043,REGN,kamm re lead review site hotel other travel destination globally ve moved bidding model company bid placement tripadvisor site almost bidding google goog search term earning have decline process be transition re foregoing older advertising measure move customer new bidding system new system start mature profit be lower
2044,REGN,be expect garden investment move get transitional period
2045,REGN,ibd cepheid cphd have uptrended june have show so much volatility quarterly earning
2046,REGN,kamm be crop position make diagnostic system let hospital easily identify molecular marker disease patient used be complex time consume process require highly trained staff cepheid make genexpert automate put blood sample plastic cartridge go instrument get answer so more hospital do molecular testing
2047,REGN,company run manufacturing challenge hurt earning past year ve address issue exit better place term inventory ability provide test cartridge customer have broad pipeline new test ve bring market now have leverage new system do broader range test
2048,REGN,ibd be fortune brand fbhs play housing rebound
2049,REGN,kamm re lead housing product company be crop position
2050,REGN,have lead position fixture kitchen bathroom cabinet faucet lock tend be attractive segment become clear last year housing market be come depth downturn fortune have be gain share key market deliver strong margin expansion margin be still peak last housing cycle so reasonable assume margin continue rise
2051,REGN,ibd rate growth linkedin lnkd earning share have decline quarters ve add stake several recent disclosure game plan
2052,REGN,kamm linkedin have transform recruit hire market main advantage be person update resume profile even re not actively look job person be hire access rich database not just job seeker also person be open right opportunity valuable corporate hr department
2053,REGN,recent year linkedin have be investing improve mobile smartphone tablet tool provide more content more article expert topic be relevant bring person site more frequently higher level engagement translate more advertising dollar linkedin not only grow number recruiter subscribe platform also grow advertising business have long way run
2054,REGN,ibd begin current stake melco crown entertainment mpel september do particular casino stock
2055,REGN,kamm re lead casino operator macau cotai strip macau be well know high growth market noticeably larger la vegas subtle shift market recent year be market be longer drive primarily high roller ultrahigh net worth individual gaming macau be drive mass market today
2056,REGN,melco property be well position serve mass market part market be more profitable high net worth part melco be work open new property expand earning potential
2057,REGN,also transportation macau be improve re see change make more attractive destination travel not just gamble demand
2058,REGN,ibd stake tractor supply tsco have edge
2059,REGN,kamm re lead supply store recreational farm rural lifestyle have store today think have potential least store grow ve do good job increase productivity exist store ve do good job understand business datum
2060,REGN,ve do good job commerce leverage brand outside physical store ve do good job layer private label good store provide different price point help expand own margin driver have potential come year lead manager matthew kamm work market garden variety treat young sprout differently mature produce differently crop ready reap approach be work have make artisan mid cap fund top performer largest diversify stock portfolio month end jan return top midcap growth peer track morningstar inc average annual gain past year top rival kamm year old discuss investment course ibd office milwaukee ibd addition mid cap run artisan global opportunity small cap do manage different cap size style fund help kamm team include group analyst portfolio manager work collaboratively identify best idea ve be year level tenure trust be important look market cap scale globally give broad perspective think re better midcap investor know small cap competitor international emerge market competitor midcap company increasingly face ibd divide portfolio type stock advantage kamm nomenclature use be garden crop harvest garden stock be one believe be just emerge try be early guard risk keep garden position small garden position turn right profit growth play allocate more push crop bucket portfolio be largest position fewest position feel profit cycle have be largely risk third area be harvest reduce position ibd be tweak new buy cope expect slow growth economy kamm ve be focuse uniquely position franchise be expose strong growth trend see sign especially economy be get better housing job be example emerge market be struggle grow same rate experience few year re focuse durable high quality franchise re less interested high commodity business material business model be very cyclical economy sensitive tend not meet franchise characteristic criterium ibd be real world example please latest disclosure kamm re focuse innovation health care re year past first sequence human genome now re see benefit novel drug target regeneron regn be example have drug call eylea be retinal drug age related macular degeneration lead cause blindness elderly be launch second full year sell strong driver company sale profit regeneron also have diverse pipeline additional opportunity extend profit cycle future be discover regeneron own lab primarily funded sanofi large french drug company return ability market drug share profit ibd chipotle grill cmg recently gap report strong result guidance earning share growth be second straight quarterly acceleration thesis kamm think re position growth have very strong brand associate high quality ingredient have significant opportunity grow footprint restaurant ultimately internationally re execute well re get customer serve line quicker ve enhance menu re offer office cater re able drive solid same store comp year year make restaurant more profitable higher volume ve resist increase price same extent lot restaurant have instead re drive growth higher volume traffic ibd alexion pharmaceutical alxn have have great run just gap other day make think still have room run kamm fit innovation theme sale profit be drive solaris biologic drug approve ultrarare very serious disease not just globally still have room run used solaris still have lot growth ahead still lot opportunity reach more patient solaris be also be test additional ultrarare disease early clinical datum be encourage year be additional treatment approval solaris also have alpha target certain bone disease tooth loss be expect be approve later year ibd be broker dealer lpl financial lpla play grow economy kamm re largest independent broker dealer country ve grow attract financial adviser away big bank wire house give independence grow practice way see fit let keep larger percent profit continue gain market share market share gainer company outgrow market sustainable way also lpl capture float cash balance customer keep float refer earning cash time customer authorize disbursement cash actually leave account rate be low be not so much float capture rate rise economy improve then lpl earning accelerate ibd innovation stock athletic wear seller armour ua kamm innovation be new material deliver better performance sweat wicking shielding athlete heat cold company armour nike nke adida have be able grow innovate product line drive increase value customer armour have great brand athlete especially young athlete be incline spend more re expand other category such footwear cleat translate more traditional ware run shoe ve be mostly brand re extend brand internationally drive additional growth outside so think still have long runway re bucket category ibd be right think illumina ilmn genomic sequence advance kamm gene sequence be technology launch next generation sequence platform cost sequence begin fall lead big growth market launch jan new product hiseq deliver first genome target researcher have be fix year so re center action human genetic research have significant growth opportunity make tool even more affordable ibd tripadvisor trip have pull back nov high earning share fall most recent quarter aren concern kamm re lead review site hotel other travel destination globally ve moved bidding model company bid placement tripadvisor site almost bidding google goog search term earning have decline process be transition re foregoing older advertising measure move customer new bidding system new system start mature profit be lower be expect garden investment move get transitional period ibd cepheid cphd have uptrended june have show so much volatility quarterly earning kamm be crop position make diagnostic system let hospital easily identify molecular marker disease patient used be complex time consume process require highly trained staff cepheid make genexpert automate put blood sample plastic cartridge go instrument get answer so more hospital do molecular testing company run manufacturing challenge hurt earning past year ve address issue exit better place term inventory ability provide test cartridge customer have broad pipeline new test ve bring market now have leverage new system do broader range test ibd be fortune brand fbhs play housing rebound kamm re lead housing product company be crop position have lead position fixture kitchen bathroom cabinet faucet lock tend be attractive segment become clear last year housing market be come depth downturn fortune have be gain share key market deliver strong margin expansion margin be still peak last housing cycle so reasonable assume margin continue rise ibd rate growth linkedin lnkd earning share have decline quarters ve add stake several recent disclosure game plan kamm linkedin have transform recruit hire market main advantage be person update resume profile even re not actively look job person be hire access rich database not just job seeker also person be open right opportunity valuable corporate hr department recent year linkedin have be investing improve mobile smartphone tablet tool provide more content more article expert topic be relevant bring person site more frequently higher level engagement translate more advertising dollar linkedin not only grow number recruiter subscribe platform also grow advertising business have long way run ibd begin current stake melco crown entertainment mpel september do particular casino stock kamm re lead casino operator macau cotai strip macau be well know high growth market noticeably larger la vegas subtle shift market recent year be market be longer drive primarily high roller ultrahigh net worth individual gaming macau be drive mass market today melco property be well position serve mass market part market be more profitable high net worth part melco be work open new property expand earning potential also transportation macau be improve re see change make more attractive destination travel not just gamble demand ibd stake tractor supply tsco have edge kamm re lead supply store recreational farm rural lifestyle have store today think have potential least store grow ve do good job increase productivity exist store ve do good job understand business datum ve do good job commerce leverage brand outside physical store ve do good job layer private label good store provide different price point help expand own margin driver have potential come year
2061,REGN,strong performance biotech etfs past year recent market pullback still be room run investor stomach sector high volatility
2062,REGN,course lot depend stock market general direction biotech etfs continue selling monday further progress biotech etfs have market uptrend return
2063,REGN,steven silver equity analyst capital iq say industry success be base pillar
2064,REGN,first be very solid period late stage datum new drug come market say put together think be lot pocket significant progress
2065,REGN,second pillar state be much more accommodative food drug administration be focuse get more drug market last year fda start breakthrough therapy designation provide fast track development review drug serious life threaten condition
2066,REGN,be program have receive designation so far fda be only grant program designation so think long term be really big deal company be receive designation term get drug market faster
2067,REGN,finally sector have prospect increase activity traditionally big pharmas be acquirer smaller biotechs biotechs have grow so large be now market buy smaller firm create more competition market acquisition firm
2068,REGN,biggest biotech etfs be ishare nasdaq biotech ibb spdr biotech xbi be very liquid have reasonable expense ratio asset ibb xbi
2069,REGN,composition be somewhat different ibb hold nasdaq list stock be market cap weight etf be more diversify biotech accounting fund pharma life science
2070,REGN,be market cap weight top holding be large independent biotechs gilead science gild biogen idec biib amgen amgn celgene celg regeneron pharmaceutical regn fund
2071,REGN,comparison xbi be make stock nearly biotechs top holding be intercept pharmaceutical icpt ariad pharmaceutical aria neurocrine bioscience nbix sangamo bioscience sgmo novavax nvax fund be equal weight result bias smaller name meaning more volatility higher turnover
2072,REGN,old school vs new school
2073,REGN,be very different fund say robert goldsborough etf analyst morningstar xbi re go have more early stage biotech firm lot be publicly trade company have drug market yet have profit
2074,REGN,xbi be more year ibb have perform better longer period average annual vs past year vs year
2075,REGN,ibb actually have better risk adjust return long term say goldsborough
2076,REGN,think stock have do very very well base improve growth potential rather investor bidding company just say silver be exciting time do think continue be exciting time strong performance biotech etfs past year recent market pullback still be room run investor stomach sector high volatility course lot depend stock market general direction biotech etfs continue selling monday further progress biotech etfs have market uptrend return steven silver equity analyst capital iq say industry success be base pillar first be very solid period late stage datum new drug come market say put together think be lot pocket significant progress second pillar state be much more accommodative food drug administration be focuse get more drug market last year fda start breakthrough therapy designation provide fast track development review drug serious life threaten condition be program have receive designation so far fda be only grant program designation so think long term be really big deal company be receive designation term get drug market faster finally sector have prospect increase activity traditionally big pharmas be acquirer smaller biotechs biotechs have grow so large be now market buy smaller firm create more competition market acquisition firm biggest biotech etfs be ishare nasdaq biotech ibb spdr biotech xbi be very liquid have reasonable expense ratio asset ibb xbi composition be somewhat different ibb hold nasdaq list stock be market cap weight etf be more diversify biotech accounting fund pharma life science be market cap weight top holding be large independent biotechs gilead science gild biogen idec biib amgen amgn celgene celg regeneron pharmaceutical regn fund comparison xbi be make stock nearly biotechs top holding be intercept pharmaceutical icpt ariad pharmaceutical aria neurocrine bioscience nbix sangamo bioscience sgmo novavax nvax fund be equal weight result bias smaller name meaning more volatility higher turnover old school vs new school be very different fund say robert goldsborough etf analyst morningstar xbi re go have more early stage biotech firm lot be publicly trade company have drug market yet have profit xbi be more year ibb have perform better longer period average annual vs past year vs year ibb actually have better risk adjust return long term say goldsborough think stock have do very very well base improve growth potential rather investor bidding company just say silver be exciting time do think continue be exciting time
2077,REGN,cholesterol drug be develop regeneron pharmaceutical regn sanofi sny succeed cut ldl cholesterol bad cholesterol phase trial company report wednesday
2078,REGN,regeneron stock rise news early trading stock market wednesday
2079,REGN,drug be alirocumab investigational monoclonal antibody
2080,REGN,injectable drug be new class medicine call pcsk inhibitor also be develop amgen amgn other drugmaker analyst call potential blockbuster bring annual sale more reuter report man make antibody block protein prevent body eliminate ldl cholesterol bloodstream offer new way fight buildup artery clog fatty deposit put patient risk heart attack reuter say
2081,REGN,trial drug used meet primary efficacy endpoint regeneron paris base sanofi say news release early wednesday
2082,REGN,be excited finding first phase trial alirocumab dr jay edelberg head pcsk unit sanofi say news release drug also be be test combination other drug monotherapy result be encourage look forward result remain phase trial be investigate alirocumab variety patient population combination different background therapy dose regimen
2083,REGN,result be positive rbc capital market analyst adnan butt write research note early wednesday result show clean safety write say be important good efficacy convenience drug call potential blockbuster
2084,REGN,sanofi regeneron also be work together develop cancer treatment zaltrap well other product tarrytown base regeneron stock rise time high last month sanofi ceo chris reiterate sanofi nearly double stake regeneron present ibd report
2085,REGN,regeneron rank wednesday midweek update ibd get most revenue eye drug eylea treatment wet age related macular degeneration co market bayer bayry cholesterol drug be develop regeneron pharmaceutical regn sanofi sny succeed cut ldl cholesterol bad cholesterol phase trial company report wednesday regeneron stock rise news early trading stock market wednesday drug be alirocumab investigational monoclonal antibody injectable drug be new class medicine call pcsk inhibitor also be develop amgen amgn other drugmaker analyst call potential blockbuster bring annual sale more reuter report man make antibody block protein prevent body eliminate ldl cholesterol bloodstream offer new way fight buildup artery clog fatty deposit put patient risk heart attack reuter say trial drug used meet primary efficacy endpoint regeneron paris base sanofi say news release early wednesday be excited finding first phase trial alirocumab dr jay edelberg head pcsk unit sanofi say news release drug also be be test combination other drug monotherapy result be encourage look forward result remain phase trial be investigate alirocumab variety patient population combination different background therapy dose regimen result be positive rbc capital market analyst adnan butt write research note early wednesday result show clean safety write say be important good efficacy convenience drug call potential blockbuster sanofi regeneron also be work together develop cancer treatment zaltrap well other product tarrytown base regeneron stock rise time high last month sanofi ceo chris reiterate sanofi nearly double stake regeneron present ibd report regeneron rank wednesday midweek update ibd get most revenue eye drug eylea treatment wet age related macular degeneration co market bayer bayry
2086,REGN,regeneron pharmaceutical regn be look do do announce quarterly profit tarrytown base biotech lose money year deliver first ever quarterly profit late april unveil quarterly profit month later regeneron be expect deliver third straight quarterly profit unveil result
2087,REGN,stock turn resilient performance tuesday major average end well session lows logged third distribution day nasdaq fall early end gain lose dow jone industrial average ease ibd index outperformed rise volume rise make
2088,REGN,regeneron pharmaceutical regn prepared release earning open tuesday early sign be look bullish lead product eylea analyst poll thomson reuter be expect total sale year earlier quarter pretax profit be expect decline company general expense
2089,REGN,stock overcome weak open turn mixed tuesday display resilience nasdaq fall early session re-cover nasdaq be now dow jone industrial average be unchanged be just preliminary datum show nyse nasdaq volume tracking higher
2090,REGN,drugmaker regeneron regn have pull back buy range clear cup handle entry follow aug strong volume stock have earlier rise much buy point pull back mostly light volume base show relatively moderate correction pattern show more week
2091,REGN,say big capitalization company make big earning gain third quarter earning season loom nearly half company big cap be expect report profit increase least profit strength be medical sector analyst estimate alexion pharmaceutical alxn post rise earning share
2092,REGN,major average close higher thursday cheer part better expect weekly job claim datum ahead friday employment report
2093,REGN,nasdaq dow jone industrial average rise tack preliminary datum show nyse nasdaq volume come slightly wednesday level
2094,REGN,wall street find comfort better expect weekly jobless datum open claim fall last week april job report be friday et
2095,REGN,oil gas name lag june crude oil settle barrel airline be beneficiary unite continental ual american aal delta dal score gain
2096,REGN,stock market today investor cheer earning tesla motor tsla late wednesday share jolted nearly higher company report narrower expect loss sale jump wall street be still worry company cash burn rate
2097,REGN,meanwhile earning season be minefield several more growth company include epam system epam fleetmatic fltx fall hard early end session high
2098,REGN,selling be less intense regeneron regn rise nearly early regeneron lose report better expect earning second straight quarter accelerate sale growth major average close higher thursday cheer part better expect weekly job claim datum ahead friday employment report nasdaq dow jone industrial average rise tack preliminary datum show nyse nasdaq volume come slightly wednesday level wall street find comfort better expect weekly jobless datum open claim fall last week april job report be friday et oil gas name lag june crude oil settle barrel airline be beneficiary unite continental ual american aal delta dal score gain stock market today investor cheer earning tesla motor tsla late wednesday share jolted nearly higher company report narrower expect loss sale jump wall street be still worry company cash burn rate meanwhile earning season be minefield several more growth company include epam system epam fleetmatic fltx fall hard early end session high selling be less intense regeneron regn rise nearly early regeneron lose report better expect earning second straight quarter accelerate sale growth
2099,REGN,enthusiasm be short live stock market friday better expect job report major average be session lows early strength
2100,REGN,little hour remain session selling be most pronounce nasdaq be hurt partly weakness biotech stock be dow jone industrial average fall less nyse volume be tracking higher thursday nasdaq volume rise
2101,REGN,economic news february employment report come better expect result early cheer nonfarm payroll rise consensus estimate unemployment rate tick higher many thought adverse weather negatively impact datum
2102,REGN,stock market today china base house holding ej rise clear week consolidation buy point be slightly buy point hit intraday high china base real estate service firm report result march
2103,REGN,elsewhere coupon com coup soar first day trading provider digital coupon price propose range stock open be recently trading
2104,REGN,retail related group be day top performer foot locker fl gap strong earning share rise group peer hibbett sport hibb dick sporting good dks be earning next week
2105,REGN,downside institutional money continue flow lead biotech name regeneron pharmaceutical regn sank biogen idec biib give
2106,REGN,medical ethical drug group leaderboard stock valeant pharmaceutical vrx find initial support day move average thursday sharp drop share rise enthusiasm be short live stock market friday better expect job report major average be session lows early strength little hour remain session selling be most pronounce nasdaq be hurt partly weakness biotech stock be dow jone industrial average fall less nyse volume be tracking higher thursday nasdaq volume rise economic news february employment report come better expect result early cheer nonfarm payroll rise consensus estimate unemployment rate tick higher many thought adverse weather negatively impact datum stock market today china base house holding ej rise clear week consolidation buy point be slightly buy point hit intraday high china base real estate service firm report result march elsewhere coupon com coup soar first day trading provider digital coupon price propose range stock open be recently trading retail related group be day top performer foot locker fl gap strong earning share rise group peer hibbett sport hibb dick sporting good dks be earning next week downside institutional money continue flow lead biotech name regeneron pharmaceutical regn sank biogen idec biib give medical ethical drug group leaderboard stock valeant pharmaceutical vrx find initial support day move average thursday sharp drop share rise
2107,REGN,enthusiasm be short live stock market friday better expect job report major average be session lows early strength
2108,REGN,little hour remain session selling be most pronounce nasdaq be hurt partly weakness biotech stock be dow jone industrial average fall less nyse volume be tracking higher thursday nasdaq volume rise
2109,REGN,economic news february employment report come better expect result early cheer nonfarm payroll rise consensus estimate unemployment rate tick higher many thought adverse weather negatively impact datum
2110,REGN,stock market today china base house holding ej rise clear week consolidation buy point be slightly buy point hit intraday high china base real estate service firm report result march
2111,REGN,elsewhere coupon com coup soar first day trading provider digital coupon price propose range stock open be recently trading
2112,REGN,retail related group be day top performer foot locker fl gap strong earning share rise group peer hibbett sport hibb dick sporting good dks be earning next week
2113,REGN,downside institutional money continue flow lead biotech name regeneron pharmaceutical regn sank biogen idec biib give
2114,REGN,medical ethical drug group leaderboard stock valeant pharmaceutical vrx find initial support day move average thursday sharp drop share rise enthusiasm be short live stock market friday better expect job report major average be session lows early strength little hour remain session selling be most pronounce nasdaq be hurt partly weakness biotech stock be dow jone industrial average fall less nyse volume be tracking higher thursday nasdaq volume rise economic news february employment report come better expect result early cheer nonfarm payroll rise consensus estimate unemployment rate tick higher many thought adverse weather negatively impact datum stock market today china base house holding ej rise clear week consolidation buy point be slightly buy point hit intraday high china base real estate service firm report result march elsewhere coupon com coup soar first day trading provider digital coupon price propose range stock open be recently trading retail related group be day top performer foot locker fl gap strong earning share rise group peer hibbett sport hibb dick sporting good dks be earning next week downside institutional money continue flow lead biotech name regeneron pharmaceutical regn sank biogen idec biib give medical ethical drug group leaderboard stock valeant pharmaceutical vrx find initial support day move average thursday sharp drop share rise
2115,REGN,stock market today shift mixed action noon almost evenly split advance decline stock nasdaq turn positive midmorning turn send priceline com pcln more higher dow jone industrial average hold loss be volume remain lower
